



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 139638

TO: Sean McGarry
Location: REM-2D19/2C18
Art Unit: 1635
Monday, December 06, 2004
Case Serial Number: 09/993731

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: (571)272-2527

paul.schulwitz@uspto.gov

Search Notes

Examiner McGarry,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2527



This Page Blank (uspto)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0-alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is ____.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

This Page Blank (uspto)

Schreiber, David

From: McGarry, Sean
Sent: Tuesday, November 30, 2004 3:09 PM
To: Schreiber, David
Subject: score/length 09/993,731

Sean McGarry
AU 1635
REM 02D19 Office
REM 2C18 Mailbox
X20761
09/993,731

David,
Please, a score/length search of 1182-1433 of SEQ ID NO: 10. 8-50. 70%

Thanks

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 6, 2004, 18:12:04 ; Search time 2 Seconds

(without alignments)
2.721 Million cell updates/sec

Title: us-09-993-731-10

Perfect score: 252
Sequence: 1 ctgggcctccagaagccctgt.....gtcctgagcgggcatcatc 252

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 655 seqs, 10796 residues

Total number of hits satisfying chosen parameters: 1310

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Listing first 669 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	16.2	6.4	23	1	ACCESSION:AR3297608
2	16.2	6.3	20	1	ACCESSION:AR307962
3	16.2	6.3	20	1	ACCESSION:AR307963
4	15.8	6.3	17	1	ACCESSION:AR307963
5	15.4	6.1	17	1	ACCESSION:AR307963
6	15.4	6.1	17	1	ACCESSION:AR307963
7	15.4	6.1	20	1	ACCESSION:AR307963
8	15.4	6.1	22	1	ACCESSION:AR307963
9	15.4	6.1	22	1	ACCESSION:AR307963
10	15.4	6.1	22	1	ACCESSION:AR307963
11	15.2	6.0	20	1	ACCESSION:AR307963
12	15.2	6.0	20	1	ACCESSION:AR307963
13	15.2	6.0	20	1	ACCESSION:AR307963
14	15.2	6.0	20	1	ACCESSION:AR307963
15	15.2	6.0	21	1	ACCESSION:AR307963
16	15.2	6.0	21	1	ACCESSION:AR307963
17	15.2	6.0	21	1	ACCESSION:AR307963
18	15.2	6.0	21	1	ACCESSION:AR307963
19	15.2	6.0	21	1	ACCESSION:AR307963
20	15.2	6.0	21	1	ACCESSION:AR307963
21	15.2	6.0	21	1	ACCESSION:AR307963
22	15.2	6.0	21	1	ACCESSION:AR307963
23	15.2	6.0	21	1	ACCESSION:AR307963
24	15.2	6.0	21	1	ACCESSION:AR307963
25	15.2	6.0	21	1	ACCESSION:AR307963
26	15.2	6.0	21	1	ACCESSION:AR307963
27	15.2	6.0	21	1	ACCESSION:AR307963
28	15.2	6.0	21	1	ACCESSION:AR307963
29	15.2	6.0	21	1	ACCESSION:AR307963
30	15.2	6.0	21	1	ACCESSION:AR307963
31	15.2	6.0	21	1	ACCESSION:AR307963
32	15.2	6.0	21	1	ACCESSION:AR307963
33	15.2	6.0	21	1	ACCESSION:AR307963

C 107	13.4	5.3	19	1	AR439726	ACCESSION:AR439726	C 180	12.8	5.1	17	1	AX215097	ACCESSION:AX215097
C 108	13.4	5.3	19	1	AX129116	ACCESSION:AX129116	C 181	12.8	5.1	17	1	AX216736	ACCESSION:AX216736
C 109	13.4	5.3	19	1	AX138469	ACCESSION:AX138469	C 182	12.8	5.1	17	1	AX475650	ACCESSION:AX475650
C 110	13.4	5.3	19	1	AX268963	ACCESSION:AX268963	C 183	12.8	5.1	17	1	AX475651	ACCESSION:AX475651
C 111	13.4	5.3	19	1	AX300829	ACCESSION:AX300829	C 184	12.8	5.1	17	1	AX500510	ACCESSION:AX500510
C 112	13.4	5.3	19	1	AX766706	ACCESSION:AX766706	C 185	12.8	5.1	17	1	AX500511	ACCESSION:AX500511
C 113	13.4	5.3	19	1	BD015637	ACCESSION:BD015637	C 186	12.8	5.1	17	1	AX500513	ACCESSION:AX500513
C 114	13.4	5.3	19	1	BD089497	ACCESSION:BD089497	C 187	12.8	5.1	17	1	AX500514	ACCESSION:AX500514
C 115	13.2	5.2	18	1	AR092795	ACCESSION:AR092795	C 188	12.8	5.1	17	1	AX687751	ACCESSION:AX687751
C 116	13.2	5.2	18	1	AR106959	ACCESSION:AR106959	C 189	12.8	5.1	17	1	AX687752	ACCESSION:AX687752
C 117	13.2	5.2	18	1	AR121134	ACCESSION:AR121134	C 190	12.8	5.1	17	1	AX728108	ACCESSION:AX728108
C 118	13.2	5.2	18	1	AR134068	ACCESSION:AR134068	C 191	12.8	5.1	17	1	AX739146	ACCESSION:AX739146
C 119	13.2	5.2	18	1	AR138066	ACCESSION:AR138066	C 192	12.8	5.1	17	1	AX744246	ACCESSION:AX744246
C 120	13.2	5.2	18	1	BD226617	ACCESSION:BD226617	C 193	12.8	5.1	17	1	AX744247	ACCESSION:AX744247
C 121	13.2	5.2	18	1	BD250522	ACCESSION:BD250522	C 194	12.8	5.1	17	1	AX753820	ACCESSION:AX753820
C 122	13.2	5.2	18	1	AX059438	ACCESSION:AX059438	C 195	12.8	5.1	17	1	AX753821	ACCESSION:AX753821
C 123	13.2	5.2	18	1	AX838288	ACCESSION:AX838288	C 196	12.8	5.1	17	1	AX753822	ACCESSION:AX753822
C 124	13.2	5.2	18	1	AB086471	ACCESSION:AB086471	C 197	12.8	5.1	17	1	AX753823	ACCESSION:AX753823
C 125	13	5.2	17	1	BD266197	ACCESSION:BD266197	C 198	12.8	5.1	18	1	169265	ACCESSION:169265
C 126	13	5.2	17	1	CO617849	ACCESSION:CO617849	C 199	12.8	5.1	18	1	AR253863	ACCESSION:AR253863
C 127	13	5.2	17	1	CO617850	ACCESSION:CO617850	C 200	12.8	5.1	18	1	AR362907	ACCESSION:AR362907
C 128	13	5.2	17	1	CO617851	ACCESSION:CO617851	C 201	12.8	5.1	18	1	AX696918	ACCESSION:AX696918
C 129	13	5.2	17	1	CO617852	ACCESSION:CO617852	C 202	12.8	5.1	18	1	AX753423	ACCESSION:AX753423
C 130	13	5.2	17	1	AR458912	ACCESSION:AR458912	C 203	12.8	5.1	18	1	AX785467	ACCESSION:AX785467
C 131	13	5.2	17	1	AR458913	ACCESSION:AR458913	C 204	12.8	5.1	18	1	BD088350	ACCESSION:BD088350
C 132	13	5.2	17	1	AR458914	ACCESSION:AR458914	C 205	12.8	5.1	18	1	BD088352	ACCESSION:BD088352
C 133	13	5.2	17	1	AR458915	ACCESSION:AR458915	C 206	12.8	5.1	18	1	AB067919	ACCESSION:AB067919
C 134	13	5.2	17	1	AX732608	ACCESSION:AX732608	C 207	12.8	5.1	18	1	AB067921	ACCESSION:AB067921
C 135	13	5.2	17	1	AX759643	ACCESSION:AX759643	C 208	12.8	5.1	20	1	AR307962	ACCESSION:AR307962
C 136	13	5.2	18	1	AR042270	ACCESSION:AR042270	C 209	12.4	4.9	14	1	CO828856	ACCESSION:CO828856
C 137	13	5.2	18	1	AR067089	ACCESSION:AR067089	C 210	12.4	4.9	15	1	A88206	ACCESSION:A88206
C 138	13	5.2	18	1	AR073377	ACCESSION:AR073377	C 211	12.4	4.9	15	1	A90173	ACCESSION:A90173
C 139	13	5.2	18	1	BD250701	ACCESSION:BD250701	C 212	12.4	4.9	15	1	BD065719	ACCESSION:BD065719
C 140	13	5.2	18	1	AR292992	ACCESSION:AR292992	C 213	12.4	4.9	16	1	AX320908	ACCESSION:AX320908
C 141	13	5.2	18	1	AX637698	ACCESSION:AX637698	C 214	12.4	4.9	17	1	AR040189	ACCESSION:AR040189
C 142	12.8	5.1	16	1	AX255757	ACCESSION:AX255757	C 215	12.4	4.9	17	1	AR137298	ACCESSION:AR137298
C 143	12.8	5.1	17	1	BD203087	ACCESSION:BD203087	C 216	12.4	4.9	17	1	AR137304	ACCESSION:AR137304
C 144	12.8	5.1	17	1	BD254885	ACCESSION:BD254885	C 217	12.4	4.9	17	1	BD182368	ACCESSION:BD182368
C 145	12.8	5.1	17	1	CO616186	ACCESSION:CO616186	C 218	12.4	4.9	17	1	BD203088	ACCESSION:BD203088
C 146	12.8	5.1	17	1	CO617222	ACCESSION:CO617222	C 219	12.4	4.9	17	1	BD231281	ACCESSION:BD231281
C 147	12.8	5.1	17	1	CO617223	ACCESSION:CO617223	C 220	12.4	4.9	17	1	BD231287	ACCESSION:BD231287
C 148	12.8	5.1	17	1	CO617854	ACCESSION:CO617854	C 221	12.4	4.9	17	1	BD234595	ACCESSION:BD234595
C 149	12.8	5.1	17	1	CO621870	ACCESSION:CO621870	C 222	12.4	4.9	17	1	CO616192	ACCESSION:CO616192
C 150	12.8	5.1	17	1	CO621873	ACCESSION:CO621873	C 223	12.4	4.9	17	1	CO623568	ACCESSION:CO623568
C 151	12.8	5.1	17	1	CO622606	ACCESSION:CO622606	C 224	12.4	4.9	17	1	CO623569	ACCESSION:CO623569
C 152	12.8	5.1	17	1	CO622607	ACCESSION:CO622607	C 225	12.4	4.9	17	1	CO623570	ACCESSION:CO623570
C 153	12.8	5.1	17	1	CO623057	ACCESSION:CO623057	C 226	12.4	4.9	17	1	CO623571	ACCESSION:CO623571
C 154	12.8	5.1	17	1	CO623058	ACCESSION:CO623058	C 227	12.4	4.9	17	1	CO624036	ACCESSION:CO624036
C 155	12.8	5.1	17	1	CO623907	ACCESSION:CO623907	C 228	12.4	4.9	17	1	CO624037	ACCESSION:CO624037
C 156	12.8	5.1	17	1	CO623909	ACCESSION:CO623909	C 229	12.4	4.9	17	1	CO624038	ACCESSION:CO624038
C 157	12.8	5.1	17	1	CO624606	ACCESSION:CO624606	C 230	12.4	4.9	17	1	CO624039	ACCESSION:CO624039
C 158	12.8	5.1	17	1	CO624607	ACCESSION:CO624607	C 231	12.4	4.9	17	1	AR188354	ACCESSION:AR188354
C 159	12.8	5.1	17	1	AR191764	ACCESSION:AR191764	C 232	12.4	4.9	17	1	AR195710	ACCESSION:AR195710
C 160	12.8	5.1	17	1	AR286077	ACCESSION:AR286077	C 233	12.4	4.9	17	1	AR324207	ACCESSION:AR324207
C 161	12.8	5.1	17	1	AR286131	ACCESSION:AR286131	C 234	12.4	4.9	17	1	AR435294	ACCESSION:AR435294
C 162	12.8	5.1	17	1	AR325659	ACCESSION:AR325659	C 235	12.4	4.9	17	1	AR435295	ACCESSION:AR435295
C 163	12.8	5.1	17	1	AR329056	ACCESSION:AR329056	C 236	12.4	4.9	17	1	AR435296	ACCESSION:AR435296
C 164	12.8	5.1	17	1	AR398067	ACCESSION:AR398067	C 237	12.4	4.9	17	1	AR435297	ACCESSION:AR435297
C 165	12.8	5.1	17	1	AR398121	ACCESSION:AR398121	C 238	12.4	4.9	17	1	AR457255	ACCESSION:AR457255
C 166	12.8	5.1	17	1	AR457249	ACCESSION:AR457249	C 239	12.4	4.9	17	1	AR464631	ACCESSION:AR464631
C 167	12.8	5.1	17	1	AR458285	ACCESSION:AR458285	C 240	12.4	4.9	17	1	AR464632	ACCESSION:AR464632
C 168	12.8	5.1	17	1	AR458286	ACCESSION:AR458286	C 241	12.4	4.9	17	1	AR464633	ACCESSION:AR464633
C 169	12.8	5.1	17	1	AR458917	ACCESSION:AR458917	C 242	12.4	4.9	17	1	AR464634	ACCESSION:AR464634
C 170	12.8	5.1	17	1	AR462933	ACCESSION:AR462933	C 243	12.4	4.9	17	1	AR465099	ACCESSION:AR465099
C 171	12.8	5.1	17	1	AR462936	ACCESSION:AR462936	C 244	12.4	4.9	17	1	AR465100	ACCESSION:AR465100
C 172	12.8	5.1	17	1	AR463669	ACCESSION:AR463669	C 245	12.4	4.9	17	1	AR465101	ACCESSION:AR465101
C 173	12.8	5.1	17	1	AR463670	ACCESSION:AR463670	C 246	12.4	4.9	17	1	AR465102	ACCESSION:AR465102
C 174	12.8	5.1	17	1	AR464120	ACCESSION:AR464120	C 247	12.4	4.9	17	1	AX037420	ACCESSION:AX037420
C 175	12.8	5.1	17	1	AR464121	ACCESSION:AR464121	C 248	12.4	4.9	17	1	AX037426	ACCESSION:AX037426
C 176	12.8	5.1	17	1	AR464970	ACCESSION:AR464970	C 249	12.4	4.9	17	1	AX672037	ACCESSION:AX672037
C 177	12.8	5.1	17	1	AR464972	ACCESSION:AR464972	C 250	12.4	4.9	17	1	AX674680	ACCESSION:AX674680
C 178	12.8	5.1	17	1	AR465669	ACCESSION:AR465669	C 251	12.4	4.9	17	1	AX693513	ACCESSION:AX693513
C 179	12.8	5.1	17	1	AR465670	ACCESSION:AR465670	C 252	12.4	4.9	17	1	AX693514	ACCESSION:AX693514

C 253	12.4	4.9	17	1	AX693315	ACCESSION:AX693315	326	12.2	4.8	17	1	AX372791	ACCESSION:AX372791
C 254	12.4	4.9	17	1	AX693516	ACCESSION:AX693516	C 327	12.2	4.8	17	1	AX372814	ACCESSION:AX372814
C 255	12.4	4.9	17	1	AX729667	ACCESSION:AX729667	C 328	12.2	4.8	17	1	AX729955	ACCESSION:AX729955
C 256	12.4	4.9	17	1	AX730510	ACCESSION:AX730510	C 329	12.2	4.8	17	1	AX317206	ACCESSION:AX317206
C 257	12.4	4.9	17	1	AX733782	ACCESSION:AX733782	C 330	12.2	4.8	17	1	AX325005	ACCESSION:AX325005
C 258	12.4	4.9	17	1	AX760576	ACCESSION:AX760576	C 331	12.2	4.8	17	1	AX325006	ACCESSION:AX325006
C 259	12.4	4.9	17	1	AX762564	ACCESSION:AX762564	C 332	12.2	4.8	17	1	AX325025	ACCESSION:AX325025
C 260	12.4	4.9	17	1	AX782079	ACCESSION:AX782079	C 333	12.2	4.8	17	1	AX325026	ACCESSION:AX325026
C 261	12.4	4.9	17	1	AX782080	ACCESSION:AX782080	C 334	12.2	4.8	17	1	AX423249	ACCESSION:AX423249
C 262	12.4	4.9	17	1	AX782081	ACCESSION:AX782081	C 335	12.2	4.8	17	1	AX423701	ACCESSION:AX423701
C 263	12.4	4.9	17	1	AX782082	ACCESSION:AX782082	C 336	12.2	4.8	17	1	AX475583	ACCESSION:AX475583
C 264	12.4	4.9	17	1	BD075172	ACCESSION:BD075172	C 337	12.2	4.8	17	1	AX475584	ACCESSION:AX475584
C 265	12.4	4.9	17	1	BD075178	ACCESSION:BD075178	C 338	12.2	4.8	17	1	AX499467	ACCESSION:AX499467
C 266	12.2	4.8	17	1	C0623308	ACCESSION:C0623308	C 339	12.2	4.8	17	1	AX499609	ACCESSION:AX499609
C 267	12.2	4.8	17	1	AR464971	ACCESSION:AR464971	C 340	12.2	4.8	17	1	AX500512	ACCESSION:AX500512
C 268	12.2	4.8	17	1	AR039745	ACCESSION:AR039745	C 341	12.2	4.8	17	1	AX530980	ACCESSION:AX530980
C 269	12.2	4.8	17	1	BD204817	ACCESSION:BD204817	C 342	12.2	4.8	17	1	AX578400	ACCESSION:AX578400
C 270	12.2	4.8	17	1	BD241619	ACCESSION:BD241619	C 343	12.2	4.8	17	1	AX579002	ACCESSION:AX579002
C 271	12.2	4.8	17	1	BD254092	ACCESSION:BD254092	C 344	12.2	4.8	17	1	AX579447	ACCESSION:AX579447
C 272	12.2	4.8	17	1	BD259433	ACCESSION:BD259433	C 345	12.2	4.8	17	1	AX649538	ACCESSION:AX649538
C 273	12.2	4.8	17	1	C0616720	ACCESSION:C0616720	C 346	12.2	4.8	17	1	AX687747	ACCESSION:AX687747
C 274	12.2	4.8	17	1	C0617219	ACCESSION:C0617219	C 347	12.2	4.8	17	1	AX687748	ACCESSION:AX687748
C 275	12.2	4.8	17	1	C0617848	ACCESSION:C0617848	C 348	12.2	4.8	17	1	AX687749	ACCESSION:AX687749
C 276	12.2	4.8	17	1	C0622785	ACCESSION:C0622785	C 349	12.2	4.8	17	1	AX687750	ACCESSION:AX687750
C 277	12.2	4.8	17	1	C0623055	ACCESSION:C0623055	C 350	12.2	4.8	17	1	AX688423	ACCESSION:AX688423
C 278	12.2	4.8	17	1	C0623056	ACCESSION:C0623056	C 351	12.2	4.8	17	1	AX688615	ACCESSION:AX688615
C 279	12.2	4.8	17	1	C0623059	ACCESSION:C0623059	C 352	12.2	4.8	17	1	AX690600	ACCESSION:AX690600
C 280	12.2	4.8	17	1	C0623100	ACCESSION:C0623100	C 353	12.2	4.8	17	1	AX690615	ACCESSION:AX690615
C 281	12.2	4.8	17	1	C0623101	ACCESSION:C0623101	C 354	12.2	4.8	17	1	AX690616	ACCESSION:AX690616
C 282	12.2	4.8	17	1	C0623180	ACCESSION:C0623180	C 355	12.2	4.8	17	1	AX693521	ACCESSION:AX693521
C 283	12.2	4.8	17	1	C0623693	ACCESSION:C0623693	C 356	12.2	4.8	17	1	AX693522	ACCESSION:AX693522
C 284	12.2	4.8	17	1	C0623694	ACCESSION:C0623694	C 357	12.2	4.8	17	1	AX722642	ACCESSION:AX722642
C 285	12.2	4.8	17	1	C0623764	ACCESSION:C0623764	C 358	12.2	4.8	17	1	AX722863	ACCESSION:AX722863
C 286	12.2	4.8	17	1	C0623766	ACCESSION:C0623766	C 359	12.2	4.8	17	1	AX724004	ACCESSION:AX724004
C 287	12.2	4.8	17	1	C0623910	ACCESSION:C0623910	C 360	12.2	4.8	17	1	AX727486	ACCESSION:AX727486
C 288	12.2	4.8	17	1	C0623911	ACCESSION:C0623911	C 361	12.2	4.8	17	1	AX728210	ACCESSION:AX728210
C 289	12.2	4.8	17	1	C0624491	ACCESSION:C0624491	C 362	12.2	4.8	17	1	AX738508	ACCESSION:AX738508
C 290	12.2	4.8	17	1	C0624492	ACCESSION:C0624492	C 363	12.2	4.8	17	1	AX744245	ACCESSION:AX744245
C 291	12.2	4.8	17	1	C0624493	ACCESSION:C0624493	C 364	12.2	4.8	17	1	AX751061	ACCESSION:AX751061
C 292	12.2	4.8	17	1	C0624803	ACCESSION:C0624803	C 365	12.2	4.8	17	1	AX751062	ACCESSION:AX751062
C 293	12.2	4.8	17	1	E02988	ACCESSION:E02988	C 366	12.2	4.8	17	1	AX751064	ACCESSION:AX751064
C 294	12.2	4.8	17	1	AR327653	ACCESSION:AR327653	C 367	12.2	4.8	17	1	AX753824	ACCESSION:AX753824
C 295	12.2	4.8	17	1	AR329054	ACCESSION:AR329054	C 368	12.2	4.8	17	1	AX753826	ACCESSION:AX753826
C 296	12.2	4.8	17	1	AR329382	ACCESSION:AR329382	C 369	12.2	4.8	17	1	AX755890	ACCESSION:AX755890
C 297	12.2	4.8	17	1	AR402088	ACCESSION:AR402088	C 370	12.2	4.8	17	1	BD067588	ACCESSION:BD067588
C 298	12.2	4.8	17	1	AR457783	ACCESSION:AR457783	C 371	12.2	4.8	17	1	BD132565	ACCESSION:BD132565
C 299	12.2	4.8	17	1	AR458282	ACCESSION:AR458282	C 372	12	4.8	15	1	161462	ACCESSION:161462
C 300	12.2	4.8	17	1	AR458911	ACCESSION:AR458911	C 373	12	4.8	15	1	AX635877	ACCESSION:AX635877
C 301	12.2	4.8	17	1	AR463848	ACCESSION:AR463848	C 374	12	4.8	17	1	C0624034	ACCESSION:C0624034
C 302	12.2	4.8	17	1	AR464118	ACCESSION:AR464118	C 375	12	4.8	17	1	C0624035	ACCESSION:C0624035
C 303	12.2	4.8	17	1	AR464119	ACCESSION:AR464119	C 376	12	4.8	17	1	C0624486	ACCESSION:C0624486
C 304	12.2	4.8	17	1	AR464122	ACCESSION:AR464122	C 377	12	4.8	17	1	C0624487	ACCESSION:C0624487
C 305	12.2	4.8	17	1	AR464163	ACCESSION:AR464163	C 378	12	4.8	17	1	C0624488	ACCESSION:C0624488
C 306	12.2	4.8	17	1	AR464164	ACCESSION:AR464164	C 379	12	4.8	17	1	C0624489	ACCESSION:C0624489
C 307	12.2	4.8	17	1	AR464243	ACCESSION:AR464243	C 380	12	4.8	17	1	C0624490	ACCESSION:C0624490
C 308	12.2	4.8	17	1	AR464756	ACCESSION:AR464756	C 381	12	4.8	17	1	C0625990	ACCESSION:C0625990
C 309	12.2	4.8	17	1	AR464757	ACCESSION:AR464757	C 382	12	4.8	17	1	C0625991	ACCESSION:C0625991
C 310	12.2	4.8	17	1	AR464827	ACCESSION:AR464827	C 383	12	4.8	17	1	C0625992	ACCESSION:C0625992
C 311	12.2	4.8	17	1	AR464829	ACCESSION:AR464829	C 384	12	4.8	17	1	C0625993	ACCESSION:C0625993
C 312	12.2	4.8	17	1	AR464973	ACCESSION:AR464973	C 385	12	4.8	17	1	C0625994	ACCESSION:C0625994
C 313	12.2	4.8	17	1	AR464974	ACCESSION:AR464974	C 386	12	4.8	17	1	C0625995	ACCESSION:C0625995
C 314	12.2	4.8	17	1	AR465554	ACCESSION:AR465554	C 387	12	4.8	17	1	167733	ACCESSION:167733
C 315	12.2	4.8	17	1	AR465555	ACCESSION:AR465555	C 388	12	4.8	17	1	AR286391	ACCESSION:AR286391
C 316	12.2	4.8	17	1	AR465556	ACCESSION:AR465556	C 389	12	4.8	17	1	AR398381	ACCESSION:AR398381
C 317	12.2	4.8	17	1	AR465866	ACCESSION:AR465866	C 390	12	4.8	17	1	AR465097	ACCESSION:AR465097
C 318	12.2	4.8	17	1	AR483120	ACCESSION:AR483120	C 391	12	4.8	17	1	AR465098	ACCESSION:AR465098
C 319	12.2	4.8	17	1	AX215098	ACCESSION:AX215098	C 392	12	4.8	17	1	AR465549	ACCESSION:AR465549
C 320	12.2	4.8	17	1	AX216210	ACCESSION:AX216210	C 393	12	4.8	17	1	AR465550	ACCESSION:AR465550
C 321	12.2	4.8	17	1	AX216348	ACCESSION:AX216348	C 394	12	4.8	17	1	AR465551	ACCESSION:AR465551
C 322	12.2	4.8	17	1	AX216351	ACCESSION:AX216351	C 395	12	4.8	17	1	AR465552	ACCESSION:AR465552
C 323	12.2	4.8	17	1	AX217079	ACCESSION:AX217079	C 396	12	4.8	17	1	AR465553	ACCESSION:AR465553
C 324	12.2	4.8	17	1	AX265975	ACCESSION:AX265975	C 397	12	4.8	17	1	AR467053	ACCESSION:AR467053
C 325	12.2	4.8	17	1	AX265976	ACCESSION:AX265976	C 398	12	4.8	17	1	AR467054	ACCESSION:AR467054

399	12	4.8	17	1	AR467055	ACCESSION:AR467055	472	11.4	4.5	15	1	AX825243	ACCESSION:AX825243
400	12	4.8	17	1	AR467056	ACCESSION:AR467056	473	11.4	4.5	15	1	BD090530	ACCESSION:BD090530
401	12	4.8	17	1	AR467057	ACCESSION:AR467057	474	11.4	4.5	15	1	BD090534	ACCESSION:BD090534
402	12	4.8	17	1	AR467058	ACCESSION:AR467058	475	11.4	4.5	16	1	A97889	ACCESSION:A97889
403	12	4.8	17	1	AX671989	ACCESSION:AX671989	476	11.4	4.5	16	1	BD222800	ACCESSION:BD222800
404	12	4.8	17	1	AX733574	ACCESSION:AX733574	477	11.4	4.5	16	1	BD222854	ACCESSION:BD222854
405	12	4.8	17	1	AX738099	ACCESSION:AX738099	478	11.4	4.5	16	1	AR254882	ACCESSION:AR254882
406	11.8	4.7	15	1	AR8002	ACCESSION:AR8002	479	11.4	4.5	16	1	AR307515	ACCESSION:AR307515
407	11.8	4.7	15	1	AR8969	ACCESSION:AR8969	480	11.4	4.5	16	1	AX384652	ACCESSION:AX384652
408	11.8	4.7	15	1	AR133621	ACCESSION:AR133621	481	11.4	4.5	16	1	AX428767	ACCESSION:AX428767
409	11.8	4.7	15	1	BD178524	ACCESSION:BD178524	482	11.4	4.5	16	1	AX794569	ACCESSION:AX794569
410	11.8	4.7	15	1	BD182917	ACCESSION:BD182917	483	11.4	4.5	17	1	AX475583	ACCESSION:AX475583
411	11.8	4.7	15	1	BD208752	ACCESSION:BD208752	484	11.4	4.5	17	1	AX475584	ACCESSION:AX475584
412	11.8	4.7	15	1	BD208870	ACCESSION:BD208870	485	11.2	4.4	16	1	A24599	ACCESSION:A24599
413	11.8	4.7	15	1	BD208995	ACCESSION:BD208995	486	11.2	4.4	16	1	A24601	ACCESSION:A24601
414	11.8	4.7	15	1	ES1114	ACCESSION:ES1114	487	11.2	4.4	16	1	A40502	ACCESSION:A40502
415	11.8	4.7	15	1	161469	ACCESSION:161469	488	11.2	4.4	16	1	A89029	ACCESSION:A89029
416	11.8	4.7	15	1	161486	ACCESSION:161486	489	11.2	4.4	16	1	AR175689	ACCESSION:AR175689
417	11.8	4.7	15	1	161638	ACCESSION:161638	490	11.2	4.4	16	1	AR178193	ACCESSION:AR178193
418	11.8	4.7	15	1	AR285792	ACCESSION:AR285792	491	11.2	4.4	16	1	CQ796687	ACCESSION:CQ796687
419	11.8	4.7	15	1	AR322168	ACCESSION:AR322168	492	11.2	4.4	16	1	AR195265	ACCESSION:AR195265
420	11.8	4.7	15	1	AR397783	ACCESSION:AR397783	493	11.2	4.4	16	1	AR204613	ACCESSION:AR204613
421	11.8	4.7	15	1	AX635891	ACCESSION:AX635891	494	11.2	4.4	16	1	AR222347	ACCESSION:AR222347
422	11.8	4.7	15	1	AX635925	ACCESSION:AX635925	495	11.2	4.4	16	1	AR232782	ACCESSION:AR232782
423	11.8	4.7	15	1	AX636028	ACCESSION:AX636028	496	11.2	4.4	16	1	AR241466	ACCESSION:AR241466
424	11.8	4.7	15	1	BD065515	ACCESSION:BD065515	497	11.2	4.4	16	1	AR305485	ACCESSION:AR305485
425	11.8	4.7	16	1	A35651	ACCESSION:A35651	498	11.2	4.4	16	1	AR309589	ACCESSION:AR309589
426	11.8	4.7	16	1	A35684	ACCESSION:A35684	499	11.2	4.4	16	1	AR391435	ACCESSION:AR391435
427	11.8	4.7	16	1	162261	ACCESSION:162261	500	11.2	4.4	16	1	AR391519	ACCESSION:AR391519
428	11.8	4.7	16	1	AR328267	ACCESSION:AR328267	501	11.2	4.4	16	1	AX203198	ACCESSION:AX203198
429	11.8	4.7	16	1	AR329675	ACCESSION:AR329675	502	11.2	4.4	16	1	AX281915	ACCESSION:AX281915
430	11.8	4.7	16	1	AR329710	ACCESSION:AR329710	503	11.2	4.4	16	1	AX281999	ACCESSION:AX281999
431	11.8	4.7	16	1	AX067893	ACCESSION:AX067893	504	11.2	4.4	16	1	AX287202	ACCESSION:AX287202
432	11.8	4.7	16	1	AX357856	ACCESSION:AX357856	505	11.2	4.4	16	1	AX316398	ACCESSION:AX316398
433	11.8	4.7	16	1	AX465582	ACCESSION:AX465582	506	11.2	4.4	16	1	AX572085	ACCESSION:AX572085
434	11.8	4.7	16	1	AX636652	ACCESSION:AX636652	507	11.2	4.4	16	1	AX572177	ACCESSION:AX572177
435	11.8	4.7	16	1	BD104299	ACCESSION:BD104299	508	11.2	4.4	16	1	AX927919	ACCESSION:AX927919
436	11.8	4.7	20	1	AR307963	ACCESSION:AR307963	509	11.2	4.4	16	1	BD014832	ACCESSION:BD014832
437	11.4	4.5	13	1	CO801494	ACCESSION:CO801494	510	11.2	4.4	16	1	BD066542	ACCESSION:BD066542
438	11.4	4.5	15	1	A07515	ACCESSION:A07515	511	11.2	4.4	16	1	BD106396	ACCESSION:BD106396
439	11.4	4.5	15	1	A44395	ACCESSION:A44395	512	11.2	4.4	16	1	DD0269520	ACCESSION:DD0269520
440	11.4	4.5	15	1	A56664	ACCESSION:A56664	513	11.2	4.4	17	1	CQ623907	ACCESSION:CQ623907
441	11.4	4.5	15	1	A80385	ACCESSION:A80385	514	11.2	4.4	17	1	CQ623909	ACCESSION:CQ623909
442	11.4	4.5	15	1	A97824	ACCESSION:A97824	515	11.2	4.4	17	1	AR464970	ACCESSION:AR464970
443	11.4	4.5	15	1	AR011805	ACCESSION:AR011805	516	11.2	4.4	17	1	AR464972	ACCESSION:AR464972
444	11.4	4.5	15	1	AR034503	ACCESSION:AR034503	517	11.2	4.4	17	1	BD241619	ACCESSION:BD241619
445	11.4	4.5	15	1	AR034504	ACCESSION:AR034504	518	11.2	4.4	17	1	AR483120	ACCESSION:AR483120
446	11.4	4.5	15	1	AR048603	ACCESSION:AR048603	519	11.2	4.4	20	1	CQ767554	ACCESSION:CQ767554
447	11.4	4.5	15	1	AR048604	ACCESSION:AR048604	520	11.2	4.4	22	1	E63484	ACCESSION:E63484
448	11.4	4.5	15	1	AR056040	ACCESSION:AR056040	521	11	4.4	11	1	CO833682	ACCESSION:CO833682
449	11.4	4.5	15	1	AR111788	ACCESSION:AR111788	522	11	4.4	11	1	CO833741	ACCESSION:CO833741
450	11.4	4.5	15	1	AR113798	ACCESSION:AR113798	523	11	4.4	11	1	AX471459	ACCESSION:AX471459
451	11.4	4.5	15	1	BD208873	ACCESSION:BD208873	524	11	4.4	11	1	AX624578	ACCESSION:AX624578
452	11.4	4.5	15	1	127821	ACCESSION:127821	525	11	4.4	11	1	AX626768	ACCESSION:AX626768
453	11.4	4.5	15	1	131898	ACCESSION:131898	526	11	4.4	11	1	AX627048	ACCESSION:AX627048
454	11.4	4.5	15	1	135260	ACCESSION:135260	527	11	4.4	11	1	AX628768	ACCESSION:AX628768
455	11.4	4.5	15	1	136660	ACCESSION:136660	528	11	4.4	11	1	AX629280	ACCESSION:AX629280
456	11.4	4.5	15	1	143396	ACCESSION:143396	529	11	4.4	11	1	AX629703	ACCESSION:AX629703
457	11.4	4.5	15	1	143397	ACCESSION:143397	530	11	4.4	11	1	AX631999	ACCESSION:AX631999
458	11.4	4.5	15	1	143407	ACCESSION:143407	531	11	4.4	11	1	AX632783	ACCESSION:AX632783
459	11.4	4.5	15	1	143408	ACCESSION:143408	532	11	4.4	14	1	A88355	ACCESSION:A88355
460	11.4	4.5	15	1	183457	ACCESSION:183457	533	11	4.4	14	1	A90332	ACCESSION:A90332
461	11.4	4.5	15	1	183461	ACCESSION:183461	534	11	4.4	14	1	BD030601	ACCESSION:BD030601
462	11.4	4.5	15	1	AR193521	ACCESSION:AR193521	535	11	4.4	14	1	AR242398	ACCESSION:AR242398
463	11.4	4.5	15	1	AR201242	ACCESSION:AR201242	536	11	4.4	14	1	BD065868	ACCESSION:BD065868
464	11.4	4.5	15	1	AR254817	ACCESSION:AR254817	537	11	4.4	15	1	AR000221	ACCESSION:AR000221
465	11.4	4.5	15	1	AX057554	ACCESSION:AX057554	538	11	4.4	15	1	AR000222	ACCESSION:AR000222
466	11.4	4.5	15	1	AX081340	ACCESSION:AX081340	539	11	4.4	15	1	AR041243	ACCESSION:AR041243
467	11.4	4.5	15	1	AX283170	ACCESSION:AX283170	540	11	4.4	15	1	AR041244	ACCESSION:AR041244
468	11.4	4.5	15	1	AX283299	ACCESSION:AX283299	541	11	4.4	15	1	AR041304	ACCESSION:AR041304
469	11.4	4.5	15	1	AX377091	ACCESSION:AX377091	542	11	4.4	15	1	AR041305	ACCESSION:AR041305
470	11.4	4.5	15	1	AX428702	ACCESSION:AX428702	543	11	4.4	15	1	AR041753	ACCESSION:AR041753
471	11.4	4.5	15	1	AX633061	ACCESSION:AX633061	544	11	4.4	15	1	AR041754	ACCESSION:AR041754

C 545	11	4.4	15	1	AR041831	ACCESSION:AR041831	618	10.8	4.3	15	1	AR132253	ACCESSION:AR132253
C 546	11	4.4	15	1	AR041832	ACCESSION:AR041832	619	10.8	4.3	15	1	AR132254	ACCESSION:AR132254
C 547	11	4.4	15	1	AR132933	ACCESSION:AR132933	620	10.8	4.3	15	1	AR132255	ACCESSION:AR132255
C 548	11	4.4	15	1	183554	ACCESSION:183554	621	10.8	4.3	15	1	AR132372	ACCESSION:AR132372
C 549	11	4.4	15	1	183555	ACCESSION:183555	622	10.8	4.3	15	1	AR132373	ACCESSION:AR132373
C 550	11	4.4	15	1	188922	ACCESSION:188922	C 623	10.8	4.3	15	1	AR132934	ACCESSION:AR132934
C 551	11	4.4	15	1	188923	ACCESSION:188923	C 624	10.8	4.3	15	1	AR133220	ACCESSION:AR133220
C 552	11	4.4	15	1	AR180238	ACCESSION:AR180238	C 625	10.8	4.3	15	1	AR133221	ACCESSION:AR133221
C 553	11	4.4	15	1	AR362086	ACCESSION:AR362086	C 626	10.8	4.3	15	1	AR133222	ACCESSION:AR133222
C 554	11	4.4	15	1	AR362089	ACCESSION:AR362089	C 627	10.8	4.3	15	1	AR133223	ACCESSION:AR133223
C 555	11	4.4	15	1	AR392545	ACCESSION:AR392545	C 628	10.8	4.3	15	1	AR133674	ACCESSION:AR133674
C 556	11	4.4	15	1	AR392546	ACCESSION:AR392546	629	10.8	4.3	15	1	AR133675	ACCESSION:AR133675
C 557	11	4.4	15	1	AR438479	ACCESSION:AR438479	630	10.8	4.3	15	1	AR133870	ACCESSION:AR133870
C 558	11	4.4	15	1	AR489548	ACCESSION:AR489548	C 631	10.8	4.3	15	1	AR176698	ACCESSION:AR176698
C 559	11	4.4	15	1	AR489549	ACCESSION:AR489549	C 632	10.8	4.3	15	1	BD207330	ACCESSION:BD207330
C 560	11	4.4	15	1	AX636718	ACCESSION:AX636718	C 633	10.8	4.3	15	1	BD208434	ACCESSION:BD208434
C 561	11	4.4	15	1	AX636720	ACCESSION:AX636720	C 634	10.8	4.3	15	1	BD208869	ACCESSION:BD208869
C 562	11	4.4	15	1	AX636764	ACCESSION:AX636764	C 635	10.8	4.3	15	1	BD208874	ACCESSION:BD208874
C 563	11	4.4	15	1	AX636766	ACCESSION:AX636766	C 636	10.8	4.3	15	1	BD240722	ACCESSION:BD240722
C 564	11	4.4	15	1	AX637231	ACCESSION:AX637231	C 637	10.8	4.3	15	1	BD260049	ACCESSION:BD260049
C 565	11	4.4	15	1	AX637233	ACCESSION:AX637233	C 638	10.8	4.3	15	1	122060	ACCESSION:122060
C 566	11	4.4	15	1	AX637309	ACCESSION:AX637309	C 639	10.8	4.3	15	1	135259	ACCESSION:135259
C 567	11	4.4	15	1	AX637311	ACCESSION:AX637311	C 640	10.8	4.3	15	1	157826	ACCESSION:157826
C 568	11	4.4	15	1	BD144681	ACCESSION:BD144681	641	10.8	4.3	15	1	161525	ACCESSION:161525
C 569	11	4.4	15	1	BD144682	ACCESSION:BD144682	642	10.8	4.3	15	1	AR179994	ACCESSION:AR179994
C 570	10.8	4.3	14	1	A21765	ACCESSION:A21765	643	10.8	4.3	15	1	AR180035	ACCESSION:AR180035
C 571	10.8	4.3	14	1	A42536	ACCESSION:A42536	644	10.8	4.3	15	1	AR180036	ACCESSION:AR180036
C 572	10.8	4.3	14	1	A45157	ACCESSION:A45157	C 645	10.8	4.3	15	1	AR180082	ACCESSION:AR180082
C 573	10.8	4.3	14	1	A56662	ACCESSION:A56662	C 646	10.8	4.3	15	1	AR180150	ACCESSION:AR180150
C 574	10.8	4.3	14	1	A64229	ACCESSION:A64229	C 647	10.8	4.3	15	1	AR180163	ACCESSION:AR180163
C 575	10.8	4.3	14	1	A64238	ACCESSION:A64238	C 648	10.8	4.3	15	1	AR180373	ACCESSION:AR180373
C 576	10.8	4.3	14	1	AR0383	ACCESSION:AR0383	C 649	10.8	4.3	15	1	AR180497	ACCESSION:AR180497
C 577	10.8	4.3	14	1	AR8727	ACCESSION:AR8727	C 650	10.8	4.3	15	1	AR180506	ACCESSION:AR180506
C 578	10.8	4.3	14	1	AR8918	ACCESSION:AR8918	C 651	10.8	4.3	15	1	AR180765	ACCESSION:AR180765
C 579	10.8	4.3	14	1	AR9394	ACCESSION:AR9394	C 652	10.8	4.3	15	1	AR180787	ACCESSION:AR180787
C 580	10.8	4.3	14	1	AR031534	ACCESSION:AR031534	C 653	10.8	4.3	15	1	AR234463	ACCESSION:AR234463
C 581	10.8	4.3	14	1	AR064269	ACCESSION:AR064269	654	10.8	4.3	15	1	AR262841	ACCESSION:AR262841
C 582	10.8	4.3	14	1	AR102528	ACCESSION:AR102528	655	10.8	4.3	15	1	AR262842	ACCESSION:AR262842
C 583	10.8	4.3	14	1	AR102537	ACCESSION:AR102537	656	10.8	4.3	15	1	AR431511	ACCESSION:AR431511
C 584	10.8	4.3	14	1	AR111786	ACCESSION:AR111786	657	10.8	4.3	15	1	AR490371	ACCESSION:AR490371
C 585	10.8	4.3	14	1	AR118994	ACCESSION:AR118994	658	10.8	4.3	15	1	AR490372	ACCESSION:AR490372
C 586	10.8	4.3	14	1	BD203562	ACCESSION:BD203562	659	10.8	4.3	15	1	AX085054	ACCESSION:AX085054
C 587	10.8	4.3	14	1	BD203570	ACCESSION:BD203570	660	10.8	4.3	15	1	AX108730	ACCESSION:AX108730
C 588	10.8	4.3	14	1	BD209427	ACCESSION:BD209427	C 661	10.8	4.3	15	1	AX297593	ACCESSION:AX297593
C 589	10.8	4.3	14	1	AR202800	ACCESSION:AR202800	C 662	10.8	4.3	15	1	AX455681	ACCESSION:AX455681
C 590	10.8	4.3	14	1	AR262831	ACCESSION:AR262831	C 663	10.8	4.3	15	1	AX632885	ACCESSION:AX632885
C 591	10.8	4.3	14	1	AR262840	ACCESSION:AR262840	C 664	10.8	4.3	15	1	AX632984	ACCESSION:AX632984
C 592	10.8	4.3	14	1	AR490361	ACCESSION:AR490361	C 665	10.8	4.3	15	1	AX633297	ACCESSION:AX633297
C 593	10.8	4.3	14	1	AR490370	ACCESSION:AR490370	666	10.8	4.3	15	1	AX633442	ACCESSION:AX633442
C 594	10.8	4.3	14	1	BD066240	ACCESSION:BD066240	667	10.8	4.3	15	1	AX633489	ACCESSION:AX633489
C 595	10.8	4.3	14	1	BD066431	ACCESSION:BD066431	668	10.8	4.3	15	1	AX636003	ACCESSION:AX636003
C 596	10.8	4.3	14	1	BD066907	ACCESSION:BD066907	669	10.8	4.3	15	1	AX637310	ACCESSION:AX637310
C 597	10.8	4.3	15	1	A35188	ACCESSION:A35188	ALIGNMENTS						
C 598	10.8	4.3	15	1	A64239	ACCESSION:A64239							
C 599	10.8	4.3	15	1	A64240	ACCESSION:A64240	RESULT 1						
C 600	10.8	4.3	15	1	AR033597	ACCESSION:AR033597							
C 601	10.8	4.3	15	1	AR035432	ACCESSION:AR035432	AX297608	23 bp	DNA	linear	PAT 21-NOV-2001		
C 602	10.8	4.3	15	1	AR041880	ACCESSION:AR041880	AX297608	Sequence 9370 from Patent WO0179548.					
C 603	10.8	4.3	15	1	AR055854	ACCESSION:AR055854	DEFINITION						
C 604	10.8	4.3	15	1	AR055904	ACCESSION:AR055904	LOCUS						
C 605	10.8	4.3	15	1	AR056290	ACCESSION:AR056290	ACCESSION						
C 606	10.8	4.3	15	1	AR056391	ACCESSION:AR056391	VERSION						
C 607	10.8	4.3	15	1	AR056485	ACCESSION:AR056485	KEYWORDS						
C 608	10.8	4.3	15	1	AR102538	ACCESSION:AR102538	SOURCE						
C 609	10.8	4.3	15	1	AR102539	ACCESSION:AR102539	ORGANISM						
C 610	10.8	4.3	15	1	AR108946	ACCESSION:AR108946	REFERENCE						
C 611	10.8	4.3	15	1	AR113419	ACCESSION:AR113419	AUTHORS						
C 612	10.8	4.3	15	1	AR113612	ACCESSION:AR113612	TITLE						
C 613	10.8	4.3	15	1	AR113662	ACCESSION:AR113662	JOURNAL						
C 614	10.8	4.3	15	1	AR114048	ACCESSION:AR114048							
C 615	10.8	4.3	15	1	AR114149	ACCESSION:AR114149							
C 616	10.8	4.3	15	1	AR114243	ACCESSION:AR114243							
C 617	10.8	4.3	15	1	AR116342	ACCESSION:AR116342							

Barany, F., Zilvri, M., Gerry, N. P., Favis, R. and Kliman, R.
Method of designing addressable array for detection of nucleic acid
Sequence differences using ligase detection reaction
Patent: WO 0179548-A 9370 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)

RESULT 1
AX297608
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

AX297608 23 bp DNA linear PAT 21-NOV-2001
Sequence 9370 from Patent WO0179548.
DEFINITION
LOCUS
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

Barany,F., Zilvi,M., Gerry,N.P., Favis,R. and Kilman,R.
Method of designing addressable array for detection of nucleic acid
Sequence differences using ligase detection reaction
Patent: WO 0179548-A 9370 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)

FEATURES

```
Location/Qualifiers
1.23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"
```

Query Match	6.4%	Score 16.2;	DB 1;	Length 23;
Best Local Similarity	85.7%;	Pred. No. 51;		
Matches 18; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

OY		1220	TCAGAACCTCCAGCATGTGCT	1240
Dd		3	TCACAACCTCCGTCATGTGCT	23

RESULT	2
AR307962	
LOCUS	AR307962
DEFINITION	Sequence 173 from patent US 6551826.
ACCESSION	AR307962
VERSION	AR307962.1 GI:31698718
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.

```
REFERENCE      1 (bases 1 to 20)
AUTHORS       Matc,A.T.
TITLE         Antisense modulation of rald expression
JOURNAL       Patent: US 6551826-A 173 22-APR-2003;
FEATURES      Location/Qualifiers
               1..20
               /organism="unknown"
               /mol_type="genomic DNA"
```

Query Match	Score 16;	DB 1;	Length 20;
Best Local Similarity	100.0%	Pred. No. 42;	
Matches 16;	Conservative 0;	Mismatches 0;	Indels 0;
Gaps			0;

QY	1227	CTCCGACATGCTCTCG	1242
DB	1	CTCCGACATGCTCTCG	16

RESULT 3			
LOCUS	AR307963	20 bp	DNA
DEFINITION	Sequence 174 from patent US 6551826.		linear
ACCESSION	AR307963		
VERSION	AR307963.1	GI:31698719	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 20)		
TITLE	Watt,A.T.		
JOURNAL	Antisense modulation of raid expression		
FEATURES	Patent: US 6551826-A 174-22-Apr-2003;		
source	Location/Qualifiers		
	1..20		

Query Match	6.3%	Score 16;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred.No. 42;		
Matches 16;	Conservative 0;	Mismatches 0;	Gaps 0;	

QY 1227 CTCGAGCATGTGCTGG 1242
|||||
Db 4 CTCGAGCATGTGCTGG 19

RESULT 4

LOCUS	E63678	20 bp	DNA	linear	PAT 27-AUG-2002
DEFINITION	Method for diagnosing gene of human diabetes.				
ACCESSION	E63678				
VERSION	E63678.1	GI:22556362			
KEYWORDS	UP 2001204476-A/6.				
SOURCE	synthetic construct				

REFERENCE
AUTHORS 1 (bases 1 to 20)
TITLE Hayashizaki, Y. and Bonsumron, D.
JOURNAL Method for diagnosing gene of human diabetes
Patent: JP 2001204476-A 6 31-JUL-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, JAPAN SCIENCE AND
TECHNOLOGY CORP
OS Artificial Sequence
PN JP 2001204476-A/6

CC	Description of Artificial Sequence: Synthetic DNA	Key
FEATURES	Location/Qualifiers.	
SOURCE	Location/Qualifiers	
	1. 20	

Query Match	6.3%	Score 15.8;	DB 1;	length 20;
Best Local Similarity	89.5%	Pred. No. 47;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY 1225 ACCTCCAGCATGTGCTGGC 1243
|||||
Db 1 ACCTCCAGCATGTCTTGC 19

RESULT 5	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE
CO616189	CO616189	Sequence 929 from Patent WO0192524.	CO616189	CO616189.1	GI:41666407	Homo sapiens (human)

REFERENCE
AUTHORS
1. Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 929 06-DEC-2001;
Aeomica, Inc. (US)

Query Match	6.1%	Score 15.4	DB 1	Length 17
Best Local Similarity	94.1%	Pred. No. 40		
Matches 16	Conservative	0	Mismatches 1	Indels 0
			Gaps	0

QY 1264 AGCTGGAAGAGGCTGAG 1280
|||||
Db 1 AGCTGAAGAGGCTGAG 17

RESULT 6

AR457252
LOCUS AR457252 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 929 from patent US 6686188.
ACCESSION AR457252
VERSION AR457252.1 GI:42692309
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
PATENT: US 6686188-A 929 03-FEB-2004;
JOURNAL Location/Qualifiers
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 6.1%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred.No. 40;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1264 AGCTGAGAGAGCTGAG 1280
Db 1 AGCTGAGAGAGCTGAG 17

RESULT 7
LOCUS CQ769232 20 bp DNA linear PAT 04-MAR-2004
DEFINITION Sequence 16 from Patent WO2004007763.
ACCESSION CQ769232
VERSION CQ769232.1 GI:45113030
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE 1
AUTHORS Rocha,B., Veiga-Fernandes,H. and Peixoto,A.
TITLE Method and means for quantitative analysis of the number of
molecules coding for different genes in cells
JOURNAL Patent: WO 2004007763-A 16 22-JAN-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 6.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred.No. 57;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1389 TTGCTGAGCTGCTGGA 1405
Db 4 TTGCTGAGCTGCTGGA 20

RESULT 8
LOCUS E63484 22 bp DNA linear PAT 27-AUG-2002
DEFINITION Non-human animal having modified foreign chromosomal or slice
thereof.
ACCESSION E63484
VERSION E63484.1 GI:22557593
KEYWORDS JP 2001231403-A/16.
SOURCE Synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 22)

AUTHORS Tomizuka,K., Yoshida,H., Ishida,I. and Kuroiwa,Y.
TITLE Non-human animal having modified foreign chromosomal or slice
JOURNAL Patent: JP 2001231403-A 16 28-AUG-2001;
KIRIN BEER KK
COMMENT
OS Artificial Sequence
PN JP 2001231403-A/16
PD 28-AUG-2001
PF 18-FEB-2000 JP 2000042074
PI KAZUMA TOMIZUKA,HITOSHI YOSHIDA,ISAO ISHIDA,YOSHIMI KUROIWA PC
A01K67/027,C12N5/10,C12N15/09//C12N5/10,C12R1:91), (C12N15/09, PC
C12R1:91),
PC C12N5/00,C12N15/00, (C12N5/00,C12R1:91), (C12N15/00,C12R1:91) CC
Description of Artificial Sequence: Primer
FH Key Location/Qualifiers
FEATURES
source 1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred.No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGGAAG 1272
Db 1 GCAGCAACAGCTGGAAG 17

RESULT 9
LOCUS I21430 22 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 6 from patent US 5521295.
ACCESSION I21430
VERSION I21430.1 GI:1601784
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Pacifici,R.E. and Thomason,A.R.
TITLE Nucleic acids encoding hybrid receptor molecules
JOURNAL Patent: US 5521295-A 6 28-MAY-1996;
FEATURES
source Location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred.No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGGAAG 1272
Db 2 GCAGCAACAGCTGGAAG 18

RESULT 10
LOCUS AX544160/c 22 bp DNA linear PAT 23-NOV-2002
DEFINITION Sequence 34 from Patent WO2061109.
ACCESSION AX544160
VERSION AX544160.1 GI:25277690
KEYWORDS
SOURCE Synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Spagnoli,R., Achstetter,T., Cauter,G., Degryse,E., Dumas,B.,
Pompon,D. and Winter,U.
TITLE Yeast strains autonomously producing steroids
JOURNAL Patent: WO 02061109-A 34 08-AUG-2002;
Aventis Pharma S.A. (FR)

FEATURES
source
Location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide C17-5"

Query Match
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1220 TCAGAACTCCGAGCATG 1236
|||||
21 TCAGAACTCCGAGCATG 5

Db

RESULT 11
A86526
LOCUS A86526 20 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 12 from Patent WO9839472.
ACCESSION A86526
VERSION A86526.1 GI:6735125
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Wagener,C.
TITLE METHOD FOR DETECTING MUTATED ALLELS
JOURNAL Patent: WO 9839472-A 12 11-SEP-1998;
WAGENER CHRISTOPH (DE)
FEATURES
source
Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 85.0%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1222 AGAAGCTTCAGCATGTGCTG 1241
|||||
1 ACAAGCTTCGTCATGTGCTG 20

Db

RESULT 12
A8492020/c
LOCUS A8492020 20 bp mRNA linear PAT 15-MAY-2004
DEFINITION Sequence 234 from patent US 6716600.
ACCESSION A8492020
VERSION A8492020.1 GI:47260385
KEYWORDS
SOURCE unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Johnson,E.M., Milbrandt,J.D., Kotzbauer,P.T., Lampe,P.A., Klein,R.
and Desauvage,F.
TITLE Persephin and related growth factors
JOURNAL Patent: US 6716600-A 234 06-APR-2004;
FEATURES
source
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="mRNA"

Query Match
Best Local Similarity 85.0%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1239 CTGGCAGTGTCCGGCTGCA 1258
|||||
20 CTGGCGCTGGCCGGCTGCA 1

Db

RESULT 13
BD070565
LOCUS BD070565 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Method for detecting mutated alleles.
ACCESSION BD070565
VERSION BD070565.1 GI:22616168
KEYWORDS JP 2001514504-A/12.
SOURCE synthetic construct
ORGANISM artificial sequence.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wagener,C.
TITLE Method for detecting mutated alleles
JOURNAL Patent: JP 2001514504-A 12 11-SEP-2001;
CHRISTOPH WAGNER
COMMENT
OS Artificial Sequence
PN JP 2001514504-A/12
PD 11-SEP-2001
PF 04-MAR-1998 JP 1998538071
PR 04-MAR-1997 DE 197 08 758.2
PI CHRISTOPH WAGNER
PC C12Q1/68
CC Description of the Artificial sequence: oligonucleotides FH
Key
FT source
FT 1..20
Location/Qualifiers
/organism='Artificial Sequence'.
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 85.0%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1222 AGAAGCTTCAGCATGTGCTG 1241
|||||
1 ACAAGCTTCGTCATGTGCTG 20

Db

RESULT 14
BD081248/c
LOCUS BD081248 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Persephin and related growth factors.
ACCESSION BD081248
VERSION BD081248.1 GI:22626851
KEYWORDS JP 2001516764-A/126.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 20)
AUTHORS Johnson,E.M., Milbrandt,J.D., Kotzbauer,P.T., Lampe,P.A., Klein,R.
and Desauvage,F.
TITLE Persephin and related growth factors
JOURNAL Patent: JP 2001516764-A 126 02-OCT-2001;
WASHINGTON UNIVERSITY
OS Homo sapiens (human)
PN JP 2001516764-A/126
PD 02-OCT-2001
PF 15-SEP-1998 JP 2000511783
PR 16-SEP-1997 US 08/931858
PI EUGENE M JOHNSON,JEFFREY D MILBRANDT,PAUL
T KOTZBAUER,PATRICIA
PI A LAMPE,
PI ROBERT KLEIN,FRED DESAUVAGE
PC C07K14/475,A61K31/7088,A61K38/00,A61K48/00,C07K16/26,C12N1/21,
PC C12N5/10,
PC C12N15/09,C12P19/34,C12P21/02,C12Q1/68,G01N33/53,A61K37/02, PC
C12N5/00,

```
PC C12N15/00
CC Persephin and related growth factors
FH Key location/Qualifiers
FT source 1..20 /organism='Homo sapiens (human)'
FEATURES
  source
    1..20 location/Qualifiers
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1239 CTGGCAGTGTGCTCCGCTGCA 1258
DB 20 CTGGCGCTGGCCGCGCTGCA 1

RESULT 15
LOCUS CQ754823 21 bp DNA linear PAT 01-MAR-2004
DEFINITION Sequence 39 from Patent EP1378519.
ACCESSION CQ754823
VERSION CQ754823.1 GI:44845858
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
  1 Flegel,W.A. and Wagner,F.F.
  TITLE Sciatama antigens
  JOURNAL Patent: EP 1378519-A 39 07-JAN-2004;
  BIOTEST AG (DE)
FEATURES
  source
    1..21 location/Qualifiers
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"
      /note="Description of Artificial Sequence: primer"

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1360 CAGCTGAGGCTTACCGAGAAG 1379
DB 2 CATCTGAGGCATGCCAGAAG 21

RESULT 16
LOCUS AX468773 21 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 1 from Patent WO0236108.
ACCESSION AX468773
VERSION AX468773.1 GI:21901541
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
  1 Roman,R.J., Harder,D.R., Miyata,N., Sato,M., Kameo,K. and
  Okuyama,S.
  TITLE Use of 20-hete synthesizing enzyme inhibitors as therapy for
  JOURNAL cerebral vascular diseases
  MCW Research Foundation (US) ; Taiho Pharmaceutical Co. Ltd. (JP)
  FEATURES
    source
      1..21 location/Qualifiers
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"

/organism="Oligonucleotide"

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1279 AGGCGAGAGACCTCAGAGGT 1298
DB 2 AGTGAGAGACGCTCATGTGT 21

RESULT 17
LOCUS AX468774 21 bp RNA linear PAT 16-JUL-2002
DEFINITION Sequence 2 from Patent WO0236108.
ACCESSION AX468774
VERSION AX468774.1 GI:21901542
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
  1 Roman,R.J., Harder,D.R., Miyata,N., Sato,M., Kameo,K. and
  Okuyama,S.
  TITLE Use of 20-hete synthesizing enzyme inhibitors as therapy for
  JOURNAL cerebral vascular diseases
  MCW Research Foundation (US) ; Taiho Pharmaceutical Co. Ltd. (JP)
  FEATURES
    source
      1..21 location/Qualifiers
        /organism="synthetic construct"
        /mol_type="unassigned RNA"
        /db_xref="taxon:32630"
        /note="Oligonucleotide"

Query Match
Best Local Similarity 6.0%; Score 15.2; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1279 AGGCGAGAGACCTCAGAGGT 1298
DB 2 AGTGAGAGACGCTCATGTGT 21

RESULT 18
LOCUS BD162134 21 bp DNA linear PAT 17-JAN-2003
DEFINITION Method for assaying nucleic acid of eotaxin, RANTES or
BD162134 anti-inflammatory agent.
ACCESSION BD162134
VERSION BD162134.1 GI:27867892
KEYWORDS JP 2002186485-A/10.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
  1 (bases 1 to 21)
  AUTHORS Shibata,M., Horiya,T. and Ichikawa,H.
  TITLE Method for assaying nucleic acid of eotaxin, RANTES or
  JOURNAL beta-defensin-2 and reagent therefor, and screening method of
  SHISEIDO CO LTD
  OS Artificial Sequence
  PN JP 2002186485-A/10
  PD 02-JUL-2002
  PF 22-DEC-2000 JP 2000391265
  PI MICHIO SHIBATA, TAKESHI HARIYA, HIDEYUKI ICHIKAWA PC
  C12N15/09,A61K45/00,A61P29/00,A61P37/06,C12Q1/68,G01N33/15, PC
  G01N33/50,
  CC GOIN33/53,G01N33/56,C12N15/00
  FH Forward primer for amplification of human gene for beta- CC
  defensin-2 location/Qualifiers
```

FT source 1..21
/organism='Artificial Sequence'.
FEATURES
source location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 6.0%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1257 CAGCAACAGCTGGAAGAGGC 1276
DB 20 CAAAACACCTGGAAGAGGC 1

RESULT 19
LOCUS CQ784154 20 bp DNA linear PAT 17-MAR-2004
DEFINITION Sequence 4294 from Patent EP1396543.
ACCESSION CQ784154
VERSION CQ784154.1 GI:45538642
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
TITLE Primers for synthesizing full length cDNA clones and their use
JOURNAL Patent: EP 1396543-A 4294 10-MAR-2004;
Research Association for Biotechnology (JP)
FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: an artificially
synthesized primer see q uence"

Query Match 6.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1267 TCGAAGAGGCTGAGC 1281
DB 2 TCGAAGAGGCTGAGC 16

RESULT 20
LOCUS BD128078 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD128078
VERSION BD128078.1 GI:23223023
KEYWORDS JP 2002017375-A/3509.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
TITLE Primer for synthesizing full-length cDNA and use thereof
JOURNAL Patent: JP 2002017375-A 3509 22-JAN-2002;
HELIX RESEARCH INSTITUTE
COMMENT OS Unidentified
PN JP 2002017375-A/3509
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO

PI ISHII,
PI YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI,HISASHI KOGA
PC C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/PC
10,
PC C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
Description of Artificial Sequence: an artificially CC
synthesized primer
CC sequence
CC key
FH key
FT source location/Qualifiers
1..20
/organism='unidentified'.
FEATURES
source location/Qualifiers
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 6.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1267 TCGAAGAGGCTGAGC 1281
DB 2 TCGAAGAGGCTGAGC 16

RESULT 21
LOCUS AR078620/C 18 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 46 from patent US 5962672.
ACCESSION AR078620
VERSION AR078620.1 GI:10005366
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Coswert,L.M.
TITLE Antisense modulation of Rhob expression
JOURNAL Patent: US 5962672-A 46 05-OCT-1999;
FEATURES
source location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 CGGCTGCAGCAAGCTG 1268
DB 18 CGGCTGCATCAACTGCTG 1

RESULT 22
LOCUS AR215559/C 18 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 107 from patent US 6410323.
ACCESSION AR215559
VERSION AR215559.1 GI:23313815
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Roberts,M.L. and Coswert,L.M.
TITLE Antisense modulation of human Rho family gene expression
JOURNAL Patent: US 6410323-A 107 25-SEP-2002;
FEATURES
source location/Qualifiers
1..18

```
/organism="unknown"
/mol_type="genomic DNA"

Query Match      5.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1251 CGGCTGACGACAGACAGCTG 1268
        |||||
Db      18 CGGCTGACATCAACTGCTG 1

RESULT 23
HUM045312B/c      18 bp      DNA      linear      STS 29-MAY-2002
LOCUS      A PCR primer for D21S8 locus STS, location 21q22.1, sequence tagged
DEFINITION      site.
ACCESSION      D50246
VERSION      D50246.1 GI:801801
KEYWORDS
SOURCE
ORGANISM      Homo sapiens (human)
                Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS      Tanahashi,H., Ito,T., Hattori,M., Ohira,M., Ohki,M., Tashiro,K. and
                Sakaki,Y.
TITLE      Sixty new STSs (sequence-tagged sites) of human chromosome 21
JOURNAL
MEDLINE      DNA Res. 1 (2), 85-89 (1994)
PUBMED      7584032
REFERENCE
AUTHORS      Sakaki,Y.
TITLE      Direct Submission
JOURNAL      Submitted (28-Apr-1995) Yoshiyuki Sakaki, Institute of Medical
                Science, University of Tokyo, Human Genome Center; 4-6-1
                Shirokanedai Minato-ku, Tokyo 108, Japan
                (E-mail:sakaki@hgc.ims.u-tokyo.ac.jp, Tel:03-5449-5362,
                Fax:03-5449-5445)
COMMENT      Submitted (28-Apr-1995) to DDBJ by:
                Yoshiyuki Sakaki
                Human Genome Center
                Institute of Medical Science
                University of Tokyo
                4-6-1 Shirokanedai Minato-ku
                Tokyo, 108
                Japan
                Phone : 03-5449-5362
                Fax : 03-5449-5445.

FEATURES
    source
        1..18
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
        /chromosome="21"

Query Match      5.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1363 CTGAGCTTACCGAGAC 1380
        |||||
Db      18 CTGAGCTTCCCGAGAC 1

RESULT 24
ARI12917/c      20 bp      DNA      linear      PAT 16-MAY-2001
LOCUS      ARI12917
DEFINITION      Sequence 3 from patent US 6132724.
ACCESSION      ARI12917
VERSION      ARI12917.1 GI:14093239
KEYWORDS
SOURCE
                Unknown.
```

```
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Blum,K.
TITLE      Allelic polymorphism diagnosis of reward deficiency syndrome and
                treatment
JOURNAL      Patent: US 6132724-A 3 17-OCT-2000;
FEATURES
    source
        1..20
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1366 AGGCTTACCGAGACGACG 1383
        |||||
Db      18 AGGCTTAAACGAGACGACG 1

RESULT 25
ARI12943/c      20 bp      DNA      linear      PAT 16-MAY-2001
LOCUS      ARI12943
DEFINITION      Sequence 29 from patent US 6132724.
ACCESSION      ARI12943
VERSION      ARI12943.1 GI:14093265
KEYWORDS
SOURCE
ORGANISM      Unknown.
                Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Blum,K.
TITLE      Allelic polymorphism diagnosis of reward deficiency syndrome and
                treatment
JOURNAL      Patent: US 6132724-A 29 17-OCT-2000;
FEATURES
    source
        1..20
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1366 AGGCTTACCGAGACGACG 1383
        |||||
Db      18 AGGCTTAAACGAGACGACG 1

RESULT 26
CQ767554/c      20 bp      DNA      linear      PAT 04-MAR-2004
LOCUS      CQ767554
DEFINITION      Sequence 21 from Patent EP1386931.
ACCESSION      CQ767554
VERSION      CQ767554.1 GI:45095671
KEYWORDS
SOURCE
ORGANISM      synthetic construct
                synthetic construct
                artificial sequences.
REFERENCE      1
AUTHORS      Wood,W.I., Goddard,A., Gurney,A., Yuan,J., Baker,K.P. and Chen,J.
TITLE      Human neutrotrophin homologue
JOURNAL      Patent: EP 1386931-A 21 04-FEB-2004;
                Genentech, Inc. (US)
FEATURES
    source
        1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Artificial Sequence"

Query Match      5.9%; Score 14.8; DB 1; Length 20;
```

Best Local Similarity 88.9%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1256 GCAGCAGCAGCTGAGA 1273
Db 18 GCAGCAGCAGCTGATGA 1

RESULT 27
AX293370/c 20 bp DNA linear PAT 21-NOV-2001
LOCUS AX293370
DEFINITION Sequence 5132 from Patent WO0179548.
ACCESSION AX293370
VERSION AX293370.1 GI:17055053
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.

REFERENCE
1 Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kliman, R.
AUTHORS Method of designing addressable array for detection of nucleic acid
TITLE sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 5132/25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1242 GCAGTGTCTCCGCTCAG 1259
Db 19 GCAGTGTCTCTCTGCAG 2

RESULT 28
AX297604/c 21 bp DNA linear PAT 21-NOV-2001
LOCUS AX297604
DEFINITION Sequence 9366 from Patent WO0179548.
ACCESSION AX297604
VERSION AX297604.1 GI:17059295
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.

REFERENCE
1 Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kliman, R.
AUTHORS Method of designing addressable array for detection of nucleic acid
TITLE sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 9366/25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 5.9%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 86;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1224 AACCTCCAGCATGTGCTG 1241
Db 20 AACCTCCGTCATGTGCTG 3

RESULT 29

AX297606/c 21 bp DNA linear PAT 21-NOV-2001
LOCUS AX297606
DEFINITION Sequence 9368 from Patent WO0179548.
ACCESSION AX297606
VERSION AX297606.1 GI:17059297
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.

REFERENCE
1 Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kliman, R.
AUTHORS Method of designing addressable array for detection of nucleic acid
TITLE sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 9368/25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 5.9%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 86;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1224 AACCTCCAGCATGTGCTG 1241
Db 20 AACCTCCGTCATGTGCTG 3

RESULT 30
CQ616188 17 bp DNA linear PAT 02-FEB-2004
LOCUS CQ616188
DEFINITION Sequence 928 from Patent WO0192524.
ACCESSION CQ616188
VERSION CQ616188.1 GI:41666406
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1 Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
AUTHORS Shannon, M.B.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 928/06-DEC-2001;
Aeomica, Inc.(US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1264 AGCTGAAGAGGCTGA 1279
Db 2 AGCTGAAGAGGCTGA 17

RESULT 31
CQ616190 17 bp DNA linear PAT 02-FEB-2004
LOCUS CQ616190
DEFINITION Sequence 930 from Patent WO0192524.
ACCESSION CQ616190
VERSION CQ616190.1 GI:41666408
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 930 06-DEC-2001;
Aecomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1265 GCTGAGAGGCTGAG 1280
Db 1 GCTGAAGAGGCTGAG 16
|||||
|||||

RESULT 32
LOCUS AR189954 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5442 from patent US 6346398.
ACCESSION AR189954
VERSION AR189954.1 GI:20235919
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwigen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5442 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1301 CATGTCATCTGTGAG 1316
Db 1 CATGCTCTCTGTGAG 16
|||||
|||||

RESULT 33
LOCUS AR286297 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 669 from patent US 6528640.
ACCESSION AR286297
VERSION AR286297.1 GI:29723893
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgin, A., Beaudry, A., Karpelsky, A.,
Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 669 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1266 CTGAGAGGCTGAG 1281
Db 17 CTGAGAGGCTGAG 2
|||||
|||||

RESULT 34
LOCUS AR324934 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2336 from patent US 6566127.
ACCESSION AR324934
VERSION AR324934.1 GI:33710742
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwigen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2336 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1301 CATGTCATCTGTGAG 1316
Db 1 CATGCTCTCTGTGAG 16
|||||
|||||

RESULT 35
LOCUS AR398287 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 668 from patent US 6617438.
ACCESSION AR398287
VERSION AR398287.1 GI:40135974
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgin, A.B., Beaudry, A., Karpelsky, A.,
Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 668 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1266 CTGAGAGGCTGAG 1281
Db 17 CTGAGAGGCTGAG 2
|||||
|||||

RESULT 36
LOCUS AR457251 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 928 from patent US 6686188.
ACCESSION AR457251
VERSION AR457251.1 GI:42692308
KEYWORDS
SOURCE Unknown.

ORGANISM unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 928 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1264 AGCTGAAGAGGCTGA 1279
DB 2 AGCTGAAGAGGCTGA 17
|||||
|||||

RESULT 37
LOCUS AR457253 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 930 from patent US 6686188.
ACCESSION AR457253
VERSION AR457253.1 GI:42692310
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 930 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1265 GCTGAAGAGGCTGAG 1280
DB 1 GCTGAAGAGGCTGAG 16
|||||
|||||

RESULT 38
LOCUS AX263524 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 915 from Patent WO0173002.
ACCESSION AX263524
VERSION AX263524.1 GI:16512323
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 915 04-OCT-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGAA 1271
DB 2 GCAGCAACAGCTGAA 17
|||||
|||||

RESULT 39
LOCUS AX263525/c 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 916 from Patent WO0173002.
ACCESSION AX263525
VERSION AX263525.1 GI:16512324
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 916 04-OCT-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGAA 1271
DB 16 GCAGCAACAGCTGAA 1
|||||
|||||

RESULT 40
LOCUS AX263532 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 923 from Patent WO0173002.
ACCESSION AX263532
VERSION AX263532.1 GI:16512331
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 923 04-OCT-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGAA 1271
DB 2 GCAGCAACAGCTGAA 17
|||||
|||||

RESULT 41
AX263533/c
LOCUS AX263533 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 924 from Patent WO0173002.
ACCESSION AX263533
VERSION AX263533.1 GI:16512332
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
JOURNAL
TITLE kniec.F.B., Gamper,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 924 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1256 GCAGCAGAGCTGAA 1271
Db 16 GGAGCAGACGCTGAA 1
RESULT 42
AX731832/c
LOCUS AX731832 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3466 from Patent WO03025175.
ACCESSION AX731832
VERSION AX731832.1 GI:3051175
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
JOURNAL
TITLE Telerman,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 3466 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 68;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1383 CTGCGTTTGTCTGAC 1398
Db 16 CTGCGTTTGTCTGATC 1
RESULT 43
AX129117/c
LOCUS AX129117 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 335 from Patent WO0130362.
ACCESSION AX129117
VERSION AX129117.1 GI:14135422

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
TITLE Robbins,J.M. and Tritz,R.
Ribozyme therapy for the treatment of proliferative skin and eye
diseases
Patent: WO 0130362-A 335 03-MAY-2001;
JOURNAL
TITLE IMMUSOL, INC. (US)
FEATURES
source location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Ccd3 ribozyme binding site"
Query Match 5.7%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 85;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1260 CACAGCTGGAAGAG 1275
Db 19 CAGCAGCTGGAAGAG 4
RESULT 44
AR154505/c
LOCUS AR154505 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 12 from patent US 6238915.
ACCESSION AR154505
VERSION AR154505.1 GI:15122558
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS Unclassified.
TITLE Chihara,K.
JOURNAL Mutant human growth hormones and their uses
Patent: US 6238915-A 12 29-MAY-2001;
FEATURES
source location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1356 AGGCGAGCTGAGGCTT 1371
Db 20 AGGCGAGCTGAGGCTT 5
RESULT 45
AR164233
LOCUS AR164233 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 28 from patent US 6271362.
ACCESSION AR164233
VERSION AR164233.1 GI:16235281
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS Unclassified.
TITLE 1 (bases 1 to 20)
JOURNAL Morikawa,M. and Harada,N.
Gene encoding ICG FC region-binding protein
Patent: US 6271362-A 28 07-AUG-2001;
FEATURES
source location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1200 GTGCAGAGGCGGCCA 1215
|||||
DB 3 GTCCGAGGCGGCCA 18

RESULT 46
LOCUS BD244910 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Modulation of gene expression by combination therapy.
ACCESSION BD244910
VERSION BD244910.1 GI:33054680
KEYWORDS JP 2002528391-A/38.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Besterman,J.M., Macleod,A.R. and Siders,W.M.
TITLE Modulation of gene expression by combination therapy
JOURNAL Patent: JP 2002528391-A 38 03-SEP-2002;
METHYLENE INC
OS Artificial Sequence
PN JP 2002528391-A/38
PD 03-SEP-2002
PF 19-OCT-1999 JP 2000576885
PR 19-OCT-1998 US 60/104804
PT JEFFREY M BESTERMAN,ALAN ROBERT MACLEOD,WILLIAM M SIDERS PC
A61K48/00,A61K31/165,A61K31/19,A61K31/513,A61K31/517,A61K31/PC
706,
PC A61K31/7068,A61K31/7088,A61K31/7125,A61K45/00,A61P35/00,C12N15/09//
PC C12N5/10,C12N15/00,C12N5/00
CC antisense
FH Key Location/Qualifiers
FT source 1..20
FT location/Qualifiers
FEATURES
source 1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1281 GGCAGAGACCTCAGG 1296
|||||
DB 5 GACAGAGACCTCAGG 20

RESULT 47
LOCUS CO827154 20 bp DNA linear PAT 29-JUN-2004
DEFINITION Sequence 24 from Patent WO2004050703.
ACCESSION CO827154
VERSION CO827154.1 GI:49455731
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Pagan,R.J., Phelps,C.B., Rodriguez,T.M., Yorke,M. and de Tianl,M.
TITLE Splice variant of the human pituitary growth hormone
JOURNAL Patent: WO 2004050703-A 24 17-JUN-2004;
ARES TRADING S.A. (CH)
FEATURES
source location/Qualifiers
1..20

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1356 AGGCAGCTGAGCCTT 1371
|||||
DB 18 AGGCAGCTGAGCCTT 3

RESULT 48
LOCUS E39194 20 bp DNA linear PAT 18-JUN-2001
DEFINITION DNA encoding novel fused protein and process for producing useful protein mediating the expression thereof.
ACCESSION E39194
VERSION E39194.1 GI:13019268
KEYWORDS JP 1999341991-A/40.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 20)
AUTHORS Seiji,S., Masahiko,H., Toshiyuki,K. and Masaki,K.
TITLE DNA encoding novel fused protein and process for producing useful protein mediating the expression thereof
JOURNAL Patent: JP 1999341991-A 40 14-DEC-1999;
ITO HAM KK,UTZO UDAKA
OS Homo sapiens (human)
PN JP 1999341991-A/40
PD 14-DEC-1999
PF 30-MAR-1999 JP 1999089488
PR SEIJI SATO,MASAHIKO HIGASHIKUJI,TOSHIYUKI KUDO,MASAKI KONDO
PI C12N15/09,C12N1/21,C12P21/02,C12P21/02//C07K14/605,C07K14/62,
PC C07K14/655,
PC C07K19/00,(C12N15/09,C12R1.08),(C12N1/21,C12R1.08),(C12P21/02,
PC C12R1.08)
PC C12N15/00,(C12N15/00,C12R1.08)
CC
FH Key Location/Qualifiers
FT source 1..20
FT location/Qualifiers
FEATURES
source 1..20
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1356 AGGCAGCTGAGCCTT 1371
|||||
DB 20 AGGCAGCTGAGCCTT 5

RESULT 49
LOCUS AR236785 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 5 from patent US 6465247.
ACCESSION AR236785
VERSION AR236785.1 GI:27280978
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Weiseman, I.L., Traver, D.J. and Akashi, K.
TITLE Mammalian myeloid progenitor cell subsets
JOURNAL Patent: US 6465247-A 5 15-OCT-2002;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1389 TTTGCTGAGCTGCTGG 1404
|||||
Db 5 TTGCTGACTGCTGCTG 20

RESULT 50
LOCUS AR241063 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 34 from patent US 6468796.
ACCESSION AR241063
VERSION AR241063.1 GI:27286280
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Walt, A.T.
TITLE Antisense modulation of bifunctional apoptosis regulator expression
JOURNAL Patent: US 6468796-A 34 22-OCT-2002;
FEATURES Location/Qualifiers
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1240 TGGCAGTGTGCGGCT 1255
|||||
Db 19 TGGCAGTGTGCTGCT 4

RESULT 51
LOCUS AR268268 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 60 from patent US 6498035.
ACCESSION AR268268
VERSION AR268268.1 GI:29698543
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt, J.
TITLE Antisense modulation of MEK3 expression
JOURNAL Patent: US 6498035-A 60 24-DEC-2002;
FEATURES Location/Qualifiers
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1356 AGGCAGCTGAGGCTT 1371
|||||
Db 2 AGGCAGCTGAGGATT 17

RESULT 52
LOCUS AR274661 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 45 from patent US 6506555.
ACCESSION AR274661
VERSION AR274661.1 GI:29707195
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sato, S., Higashikuni, N., Kudo, T. and Kondo, M.
TITLE DNAs encoding new fusion proteins and processes for preparing
JOURNAL useful polypeptides through expression of the DNAs
FEATURES Patent: US 6506595-A 45 14-JAN-2003;
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1356 AGGCAGCTGAGGCTT 1371
|||||
Db 20 AGGCAGCTGCTGCTT 5

RESULT 53
LOCUS AR337000 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 61 from patent US 6566132.
ACCESSION AR337000
VERSION AR337000.1 GI:33722854
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Walt, A.T.
TITLE Antisense modulation of Interferon gamma receptor 1 expression
JOURNAL Patent: US 6566132-A 61 20-MAY-2003;
FEATURES Location/Qualifiers
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGA 1271
|||||
Db 1 GCAGCAACACTGGGA 16

RESULT 54
LOCUS AB0991 19 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 43 from Patent EP0918091.
ACCESSION AB0991
VERSION AB0991.1 GI:6731564
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 19)
AUTHORS Kahn, A. and Chelly, J.
TITLE A gene called XUS and the XUS gene product, called doublecortin
JOURNAL and their applications
Patent: EP 0918091-A 43 26-MAY-1999;

FEATURES INST NAT SANTE RECH MED (FR)
source location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No.95;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1323 GGGGACCTTCTTCCAGG 1341
Db 19 GGGGACCGCTACTTCAAG 1

RESULT 55
A95370/c 19 bp DNA linear PAT 26-JAN-2000
LOCUS Sequence 43 from Patent WO9927089.
DEFINITION A95370
ACCESSION A95370.1 GI:6779414
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE Francis, F. and Kahn, A.
AUTHORS A GENE CALLED XLIS AND THE XLIS GENE PRODUCT, CALLED DOUBLECORTIN
TITLE AND THEIR PREPARATIONS
JOURNAL Patent: WO 9927089-A 43 03-JUN-1999;
INST NAT SANTE RECH MED (FR); FRANCIS FIONA (FR)
FEATURES location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No.95;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1323 GGGGACCTTCTTCCAGG 1341
Db 19 GGGGACCGCTACTTCAAG 1

RESULT 56
A80976/c 20 bp DNA linear PAT 21-JAN-2000
LOCUS Sequence 28 from Patent EP0918091.
DEFINITION A80976
ACCESSION A80976
VERSION A80976.1 GI:6731549
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE Kahn, A. and Chelly, J.
AUTHORS A gene called XLIS and the XLIS gene product, called doublecortin
TITLE A gene called XLIS and the XLIS gene product, called doublecortin
JOURNAL Patent: EP 0918091-A 28 26-MAY-1999;
INST NAT SANTE RECH MED (FR)
FEATURES location/Qualifiers
1. .20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.1e+02;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1323 GGGGACCTTCTTCCAGG 1341
Db 19 GGGGACCGCTACTTCAAG 1

RESULT 57
A95355/c 20 bp DNA linear PAT 26-JAN-2000
LOCUS Sequence 28 from Patent WO9927089.
DEFINITION A95355
ACCESSION A95355
VERSION A95355.1 GI:6779399
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE Francis, F. and Kahn, A.
AUTHORS A GENE CALLED XLIS AND THE XLIS GENE PRODUCT, CALLED DOUBLECORTIN
TITLE AND THEIR PREPARATIONS
JOURNAL Patent: WO 9927089-A 28 03-JUN-1999;
INST NAT SANTE RECH MED (FR); FRANCIS FIONA (FR)
FEATURES location/Qualifiers
1. .20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1323 GGGGACCTTCTTCCAGG 1341
Db 19 GGGGACCGCTACTTCAAG 1

RESULT 58
E09681/c 20 bp DNA linear PAT 29-SEP-1997
LOCUS DNA probe for detecting mouse mc26 gene.
DEFINITION E09681
ACCESSION E09681
VERSION E09681.1 GI:22026308
KEYWORDS JP 1995194380-A/6.
SOURCE unidentified
ORGANISM unidentified
REFERENCE Sato, H. and Takao, M.
AUTHORS NEW METHOD FOR PRODUCING SUBSTANCE IN TRANS-GENIC ANIMAL MAMMARY
TITLE GLAND BY USING MC26 GENE MANIFESTATION CONTROL RANGE
JOURNAL Patent: JP 1995194380-A 6 01-AUG-1995;
SUMITOMO METAL IND LTD
OS None
COMMENT
OC Artificial sequences.
PN JP 1995194380-A/6
PD 01-AUG-1995
PF 28-DEC-1993 JP 1993355132
PI SATO HIROYASU, TAKAO MAKOTO
PC C12N1/09.A01K67/027.C12P21/02.C13Q1/68//C12N1/21.C12N5/10, PC
(C12N1/21,
PC C12R1:19);
CC strandedness: Single;
CC topology: linear;
CC hypothetical: No;
CC anti-sense: No;
FH Key location/Qualifiers
FT source 1. .20
FT location/Qualifiers
FEATURES location/Qualifiers
location/Qualifiers

```
source
1. .20
/mol_type="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 5.6%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1349 CTTCCCGAGCGAGCTGAG 1367
Db 19 CTTCCCTGGAGAGCAGAG 1

RESULT 59
E29921
LOCUS E29921 20 bp DNA linear PAT 18-JUN-2001
DEFINITION HIV cofactor inhibitor.
ACCESSION E29921
VERSION E29921.1 GI:13021316
KEYWORDS JP 1999292795-A/75.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Hiroshi,T., Naoki,Y., Toru,K., Kazuyuki,T. and Akira,W.
TITLE HIV cofactor inhibitor
JOURNAL Patent: JP 1999292795-A 75 26-OCT-1999;
YAMANOUCHI PHARMACEUT CO LTD
OS Unidentified
PD JP 1999292795-A/75
PN 26-OCT-1999
PF 02-APR-1998 JP 1998125452
PR
PI HIROSHI TAKAHISA,NAOKI YAMANOTO,TORU KIMURA,KAZUYUKI TAKAI, PI
AKIRA WADA
PC A61K48/00,A61K31/70,A61K31/70,C12N15/09,C12N15/00 CC
FH Key location/Qualifiers
FT source 1. .20
FT /organism='Unidentified'.

FEATURES
source
1. .20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 5.6%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1367 GGCTTACCGAAGCAGCTG 1385
Db 2 GGGTTACCGAAGAACTG 20

RESULT 60
I20578/c
LOCUS I20578 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 13 from patent US 5514600.
ACCESSION I20578
VERSION I20578.1 GI:1600933
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mosey,J., Mishima,K., Nightingale,M.S. and Teuchiya,M.
TITLE Mammalian guanine nucleotide binding protein with an
JOURNAL ADP-ribosylation factor domain
Patent: US 5514600-A 13 07-MAY-1996;
Location/Qualifiers
1. .20
/organism="unknown"
```

```
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 5.6%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1298 TGCCATGCTCATCTGTGAG 1316
Db 20 TGCTATGGCCATCAGTGAG 2

RESULT 61
AR381360/c
LOCUS AR381360 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 71 from patent US 6607916.
ACCESSION AR381360
VERSION AR381360.1 GI:40089179
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Freier,S.W. and Wyatt,J.
TITLE Antisense inhibition of Casein kinase 2-alpha expression
JOURNAL Patent: US 6607916-A 71 19-AUG-2003;
Location/Qualifiers
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 5.6%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1190 CCGAAGCTGTGCGAGAG 1208
Db 19 CCGATGCGCTGAGCAGAG 1

RESULT 62
AX297375
LOCUS AX297375 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 9137 from Patent W00179548.
ACCESSION AX297375
VERSION AX297375.1 GI:17059066
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Barany,F., Zivny,M., Gerry,N.P., Favis,R. and Kilman,R.
TITLE Method of designing addressable array for detection of nucleic acid
JOURNAL Sequence differences using ligase detection reaction
Patent: WO 0179548-A 9137 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)
Location/Qualifiers
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match
Best Local Similarity 5.6%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1318 AGCTAGGAGCCTCTCTC 1336
Db 1 AGCCAGGAGACCTCTCTC 19

RESULT 63
BD088743/c
```

LOCUS BD088743 19 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD088743
VERSION BD088743.1 GI:22634353
KEYWORDS JP 2001321190-A/987.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Soeda, E.
TITLE A method of arraying genome clone
JOURNAL Patent: JP 2001321190-A 987 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
COMMENT GENOTECHS
OS Artificial Sequence
PN JP 2001321190-A/987
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI EITCHI SOEDA
PC C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/53, G01N33/566, PC
C12N15/00,
CC Description of Artificial Sequence: Synthetic DNA FH Key
FT source
FT Location/Qualifiers
1..19
/organism="Artificial Sequence".
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 5.6%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1370 TTACCAAGAGCAGC 1383
DB 16 TTACCAGAGCAGC 3

RESULT 64
LOCUS AX810905 20 bp DNA linear PAT 02-DEC-2003
DEFINITION Sequence 32 from Patent EP133100.
ACCESSION AX810905
VERSION AX810905.1 GI:38635502
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Park, J.G., Kim, I.J., Kang, H.C. and Park, J.H.
TITLE Ret oligonucleotide microchip and method for detecting hereditary
JOURNAL cancer employing same
National Patent: EP 133100-A 32 06-AUG-2003;
National Cancer Center (KR)
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="620M-(W)"

Query Match 5.6%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1184 GGGCTCCAGAGC 1197
DB 18 GGGCTCCAGAGC 5

RESULT 65
LOCUS CQ616187 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 927 from Patent WO0192524.
ACCESSION CQ616187
VERSION CQ616187.1 GI:41666405
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 927 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAGAGGCTG 1278
DB 1 AGAGCTGAGAGGAGCTG 17

RESULT 66
LOCUS CQ617853 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2593 from Patent WO0192524.
ACCESSION CQ617853
VERSION CQ617853.1 GI:41668071
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2593 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1293 CAGGTCGATGTCAT 1309
DB 1 CAGGTCGATGTCAT 17

RESULT 67
LOCUS CQ621871 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6611 from Patent WO0192524.
ACCESSION CQ621871
VERSION CQ621871.1 GI:41672089
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.

1
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 6611 06-DEC-2001;
Aeomica, Inc. (US)
location/Qualifiers

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1222 AGAACCTCCAGCATGTG 1238
||| ||||| |||||
17 AGAGCTCCAGCATGTG 1

RESULT 68
CO621872 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO621872/c
DEFINITION Sequence 6612 from Patent WO0192524.
ACCESSION CO621872
VERSION CO621872.1 GI:41672090
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.

REFERENCE
1
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 6612 06-DEC-2001;
Aeomica, Inc. (US)
location/Qualifiers

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1221 CAGAACCTCCAGCATGT 1237
||| ||||| |||||
17 CAGAGCTCCAGCATGT 1

RESULT 69
CO623908 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO623908
DEFINITION Sequence 8648 from Patent WO0192524.
ACCESSION CO623908
VERSION CO623908.1 GI:41674126
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.

REFERENCE
1
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 8648 06-DEC-2001;
Aeomica, Inc. (US)
location/Qualifiers

FEATURES
location/Qualifiers

source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1254 CTGCAGCAACGCTGTGA 1270
||||| ||||| |||||
1 CTGCAGCTCCAGCTGTGA 17

RESULT 70
AR188352 17 bp DNA linear PAT 20-APR-2002
LOCUS AR188352
DEFINITION Sequence 3840 from patent US 6346398.
ACCESSION AR188352
VERSION AR188352.1 GI:20234317
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
1 (bases 1 to 17)

REFERENCE
Payco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
Patent: US 6346398-A 3840 12-FEB-2002;
location/Qualifiers

FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCCATGTCATCTGTGA 1315
||||| ||||| |||||
1 GCCATGTCCTCTGTGA 17

RESULT 71
AR189953 17 bp DNA linear PAT 20-APR-2002
LOCUS AR189953
DEFINITION Sequence 5441 from patent US 6346398.
ACCESSION AR189953
VERSION AR189953.1 GI:20235918
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
1 (bases 1 to 17)

REFERENCE
Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
Patent: US 6346398-A 5441 12-FEB-2002;
location/Qualifiers

FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCCATGTCATCTGTGA 1315
||||| ||||| |||||
1 GCCATGTCCTCTGTGA 17

RESULT 72

AR286296/c
LOCUS AR286296 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 668 from patent US 6528640.
ACCESSION AR286296
VERSION AR286296.1 GI:29723892
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpelesky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 668 04-MAR-2003;
FEATURES
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1268 GGAAGAGCGCTGAGGCCA 1284
DB 17 GGAAGAGCGCTGAGGTCA 1
RESULT 73
AR324205 AR324205 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR324205
DEFINITION Sequence 1607 from patent US 6566127.
ACCESSION AR324205
VERSION AR324205.1 GI:33710013
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwigen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1607 20-MAY-2003;
FEATURES
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1299 GCCATGCGTCATCTGTGA 1315
DB 1 GGCAATGCTCTTGTGCA 17
RESULT 74
AR398286/c AR398286 17 bp RNA linear PAT 18-DEC-2003
LOCUS AR398286
DEFINITION Sequence 667 from patent US 6617438.
ACCESSION AR398286
VERSION AR398286.1 GI:40135972
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpelesky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 667 09-SEP-2003;
FEATURES
Location/Qualifiers

source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1268 GGAAGAGCGCTGAGGCCA 1284
DB 17 GGAAGAGCGCTGAGGTCA 1
RESULT 75
AR457250 AR457250 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR457250
DEFINITION Sequence 927 from patent US 6686188.
ACCESSION AR457250
VERSION AR457250.1 GI:42692307
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 927 03-FEB-2004;
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1262 ACAGCTGGAGAGGCTG 1278
DB 1 AGAGCTGAAGAGGCTG 17
RESULT 76
AR458916 AR458916 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR458916
DEFINITION Sequence 2593 from patent US 6686188.
ACCESSION AR458916
VERSION AR458916.1 GI:42693973
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2593 03-FEB-2004;
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1293 CAGGTCGCATGTCAT 1309
DB 1 CAGGTCGCATGAGAT 17

RESULT 77
AR462934/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR462934
DEFINITION Sequence 6611 from patent US 6686188.
ACCESSION AR462934
VERSION AR462934.1 GI:42697991
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6611 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1222 AGAAGCTCCAGCATGTG 1238
DB 17 AGAGCTCCAGCATGTG 1

RESULT 78
AR462935/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR462935
DEFINITION Sequence 6612 from patent US 6686188.
ACCESSION AR462935
VERSION AR462935.1 GI:42697992
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6612 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1221 CAGAACCTCCAGCATGT 1237
DB 17 CAGAGCTCCAGCATGT 1

RESULT 79
AR464971 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464971
DEFINITION Sequence 8648 from patent US 6686188.
ACCESSION AR464971
VERSION AR464971.1 GI:42700028
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8648 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1254 CTGCAGCAGCAGCTGGA 1270
DB 1 CTGCAGCTCAGCAGCTGGA 17

RESULT 80
AX263536 17 bp DNA linear PAT 26-OCT-2001
LOCUS AX263536
DEFINITION Sequence 927 from Patent WO0173002.
ACCESSION AX263536
VERSION AX263536.1 GI:16512335
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 927 04-OCT-2001;
FEATURES
LOCATION/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1264 AGCTGGAAGAGCTGAG 1280
DB 1 AGCTGGAAGAGCTGAG 17

RESULT 81
AX263537/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS AX263537
DEFINITION Sequence 928 from Patent WO0173002.
ACCESSION AX263537
VERSION AX263537.1 GI:16512336
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 928 04-OCT-2001;
FEATURES
LOCATION/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1264 AGCTGAGAGGCTGAG 1280

Db 17 AGCTGAGAGGCTGAGG 1

RESULT 82
LOCUS AX674218/c 17 bp DNA linear PAT 27-MAR-2003

DEFINITION Sequence 2663 from Patent WO03004526.

ACCESSION AX674218 GI:29332566

VERSION AX674218.1

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

source

1. 17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match

Best Local Similarity 88.2%; Pred. No. 92;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1210 CAGCCATCTGTCAAGC 1226

Db 17 CAGCCCTGTCTCAGATC 1

RESULT 83
LOCUS AR134167/c 18 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 2592 from patent US 6194150.

ACCESSION AR134167

VERSION AR134167.1 GI:14123072

KEYWORDS

SOURCE

ORGANISM

Unclassified.

1 (bases 1 to 18)

Stinchcomb,D.T., Jarvis,T. and McSwigen,J.

Nucleic acid based inhibition of CD40

Patent: US 6194150-A 2592 27-FEB-2001;

Location/Qualifiers

1. 18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 5.5%; Score 13.8; DB 1; Length 18;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1266 CTGGAAGAGGCTGAGG 1282

Db 18 CTGGGAGGAGCTGAGG 2

RESULT 84

LOCUS BD175415 18 bp DNA linear PAT 18-MAR-2003

DEFINITION Secretary and transmembrane polypeptide and nucleic acid encoding

the same.

BD175415

BD175415.1 GI:29121111

JP 2002253280-A/197.

KEYWORDS

synthetic construct

synthetic construct

artificial sequences.

1 (bases 1 to 18)

Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and

Yuan,J.

Secretory and transmembrane polypeptide and nucleic acid encoding

the same: JP 2002253280-A 197 10-SEP-2002;

Patent: JP 2002253280-A/197

GENENTECH INC

OS Artificial Sequence

PN JP 2002253280-A/197

PD 10-SEP-2002

PF 18-DEC-2001 JP 2001385319

PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR

17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR

17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR

17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR

18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR

17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR

17-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR

24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR

24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR

24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR

27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR

28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR

28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR

28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR

29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR

29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR

29-OCT-1997 US 60/064215,29-OCT-1997 US 60/064375 PR

31-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR

31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR

07-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR

17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR

21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066466 PR

24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR

24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR

WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI

JIAN ZHENG,

PI JEAN YUAN

PC C12N15/09,A61K45/00,A61P1/00,A61P13/12,A61P17/00,A61P17/06, PC

A61P25/00,

PC A61P25/16,A61P25/28,A61P31/12,A61P35/00,C07K14/47,C07K16/18,

PC C07K19/00,

PC C12N1/19,C12N1/21,C12N5/10//A61K38/00,A61K39/395,A61K39/395,

PC A61P43/00,

PC C12P21/08,(C12N1/19,C12R1:645),(C12N1/21,C12R1:19),(C12N5/10,

PC C12R1:91),

PC C12N15/00,C12N5/00,A61K37/02,(C12N5/00,C12R1:91) CC

Description of Artificial Sequence: Synthetic FH Key

Location/Qualifiers

1. 18

FT source

Location/Qualifiers

1. 18

/organism="Artificial Sequence".

source

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match

Best Local Similarity 5.5%; Score 13.8; DB 1; Length 18;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGCTGGCAG 1245

Db 2 CCAGCATGCTGGCAG 18

RESULT 85
BD266206 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Universal arrays.
ACCESSION BD266206
VERSION BD266206.1 GI:33075974
KEYWORDS JP 2002539849-A/206.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Loehart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 206 26-NOV-2002;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFYMETRIX INC
COMMENT OS Artificial Sequence
PN JP 2002539849-A/206
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
PJIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL,KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C1201/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FT Key
FT source
FEATURES
source 1.18
Location/Qualifiers
/organism="Artificial Sequence".
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1258 AGCAGAGCTGGAGAG 1274
Db 1 AGCAGAGCTGGAGAGC 17
RESULT 86
AR188985/C 18 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4473 from patent US 6346398.
ACCESSION AR188985
VERSION AR188985.1 GI:20234950
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
PATENT: US 6346398-A 4473 12-FEB-2002;
FEATURES
source 1.18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1267 TCGAGAGGCTGGAGGC 1283

Db 17 TCGCAGAGGCTGTGGGC 1
RESULT 87
AR324784/C 18 bp RNA linear PAT 17-AUG-2003
LOCUS AR324784
DEFINITION Sequence 2186 from patent US 6566127.
ACCESSION AR324784
VERSION AR324784.1 GI:33710592
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
PATENT: US 6566127-A 2186 20-MAY-2003;
FEATURES
source 1.18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1267 TCGAGAGGCTGGAGGC 1283
Db 17 TCGCAGAGGCTGTGGGC 1
RESULT 88
BD075564 18 bp DNA linear PAT 27-AUG-2002
LOCUS BD075564
DEFINITION Secretory and transmembrane polypeptide and nucleic acid encoding
the same.
ACCESSION BD075564
VERSION BD075564.1 GI:22621167
KEYWORDS JP 2001516580-A/197.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood,W.I., Gueney,A.L., Goddard,A., Penica,D., Chen,J. and Yuan,J.
TITLE Secretory and transmembrane polypeptide and nucleic acid encoding
the same.
JOURNAL Patent: JP 2001516580-A 197 02-OCT-2001;
COMMENT GENENTECH INC
OS Artificial Sequence
PN JP 2001516580-A/197
PD 02-OCT-2001
PF 16-SEP-1998 JP 2000531867
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,18-SEP-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/064103,31-OCT-1997 US 60/063700 PR
03-NOV-1997 US 60/064248,07-NOV-1997 US 60/064809 PR

12-NOV-1997 US 60/065186,17-NOV-1997 US 60/065846 PR
18-NOV-1997 US 60/065693,21-NOV-1997 US 60/066120 PR
21-NOV-1997 US 60/066364,24-NOV-1997 US 60/066772 PR
24-NOV-1997 US 60/066466,24-NOV-1997 US 60/066770 PR
25-NOV-1997 US 60/066511,24-NOV-1997 US 60/066453 PR
25-NOV-1997 US 60/066840
PI WILLIAM I WOOD,AUSTIN L GURNEY,AUDLEY GODDARD,DIANE PENICA, PI
JEAN CHEN,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K14/705,C07K16/18,C07K16/28,C07K19/00,
PC C12N1/19
PC C12N1/21,C12N5/10,C12P21/02,C12P21/08,C12Q1/02//C12P21/08, PC
C12R1:911,
PC C12N15/00,C12N5/00
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1..18 /organism='Artificial Sequence'.
FEATURES
source 1..18 Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGCTGCGCAG 1245
|||||
Db 2 CCAGCATGCTGCGCAG 18

RESULT 89
LOCUS BDI72424 18 bp DNA linear PAT 18-FEB-2003
DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding
the same.
ACCESSION BDI72424
VERSION BDI72424.1 GI:28413724
KEYWORDS JP 2002223786-A/197.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: JP 2002223786-A 197 13-AUG-2002;
COMMENT OS Artificial Sequence
PN JP 2002223786-A/197
PD 13-AUG-2002
PF 18-DEC-2001 JP 2001385135
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/062814,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR

31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
25-NOV-1997 US 60/066840,25-NOV-1997 US 60/066453 PR
WILLIAM I WOOD,AUSTIN L GURNEY,AUDLEY GODDARD,DIANE PENICA, PI
JEAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02//C12P21/08,(C12P21/02,C12R1:19),(C12P21/02,C12R1:911), PC
C12P21/02,C12R1:645),C12N15/00,C12N5/00
CC Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1..18 /organism='Artificial Sequence'.
FEATURES
source 1..18 Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGCTGCGCAG 1245
|||||
Db 2 CCAGCATGCTGCGCAG 18

RESULT 90
LOCUS BDI72743 18 bp DNA linear PAT 18-FEB-2003
DEFINITION Secreted and transmembrane polypeptides and nucleic acids encoding
the same.
ACCESSION BDI72743
VERSION BDI72743.1 GI:28414047
KEYWORDS JP 20022238586-A/197.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: JP 20022238586-A 197 27-AUG-2002;
COMMENT OS Artificial Sequence
PN JP 20022238586-A/197
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385205
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/062814,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR

29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N5/09, C07K14/47, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC
C12N5/10,
PC C12P21/02//C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19),
PC (C12N5/10, C12R1:91), (C12P21/02, C12R1:91), (C12P21/02, C12R1:645), PC
(C12P21/02, C12R1:19), (C12P21/08, C12R1:91), C12N15/00, C12N5/00, PC
Description of Artificial Sequence: Synthetic FH Key
CC Location/Qualifiers
FT source 1.18
Location/Qualifiers
/organism='Artificial Sequence'.
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGCTGCTGCAG 1245
DB 2 CCAGCATGCTGCTGCAG 18
|||||

RESULT 91
BD173062 18 bp DNA linear PAT 18-FEB-2003
LOCUS Secreted and transmembrane polypeptides and nucleic acids encoding
DEFINITION the same.
ACCESSION BD173062.1 GI:28414368
VERSION JP 2002238587-A/197.
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and
Yuan, J.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: JP 2002238587-A 197 27-AUG-2002;
COMMENT OS Artificial Sequence
PN JP 2002238587-A/197
PD 27-AUG-2002
PR 18-DEC-2001 JP 2001385248
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062185 PR
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR

29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/063733 PR
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N5/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/10, PC
C12N15/02,
PC C12P21/02, C12P21/08//C12P21/02, C12R1:91), (C12P21/02, C12R1:19), PC
(C12P21/02, C12R1:645), C12N15/00, C12N5/00, C12N15/00 CC
Description of Artificial Sequence: Synthetic FH Key
CC Location/Qualifiers
FT source 1.18
Location/Qualifiers
/organism='Artificial Sequence'.
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGCTGCTGCAG 1245
DB 2 CCAGCATGCTGCTGCAG 18
|||||

RESULT 92
BD173381 18 bp DNA linear PAT 18-FEB-2003
LOCUS Secreted and transmembrane polypeptides and nucleic acids encoding
DEFINITION the same.
ACCESSION BD173381.1 GI:28414692
VERSION JP 2002238588-A/197.
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and
Yuan, J.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: JP 2002238588-A 197 27-AUG-2002;
COMMENT OS Artificial Sequence
PN JP 2002238588-A/197
PD 27-AUG-2002
PR 18-DEC-2001 JP 2001385315
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062185 PR
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR
27-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR
28-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR

```
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/064735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
07-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N5/09,C07K14/435,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02//C12P21/08,(C12N1/19,C12R1:645),(C12N1/21,C12R1:19),
PC (C12N5/10,C12R1:91),C12N5/00,C12N5/00,(C12N5/00,C12R1:91) CC
Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1..18
/organism='Artificial Sequence'.
Location/Qualifiers
1..18
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1229 CCAGCATGCTGCGCAG 1245
Db 2 CCAGCATGCTGCGCAG 18

RESULT 93
AR075707 19 bp DNA linear PAT 30-AUG-2000
LOCUS AR075707
DEFINITION Sequence 6 from patent US 5958692.
ACCESSION AR075707
VERSION AR075707.1 GI:10002453
KEYWORDS
SOURCE
ORGANISM unknown.
REFERENCE
1 (bases 1 to 19)
Cotton,R.G.H., Youll,R. and Kemper,B.W.
TITLE
Detection of mutation by resolvase cleavage
JOURNAL Patent: US 5958692-A 6 28-SEP-1999;
FEATURES
Location/Qualifiers
1..19
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1245 GTGCTCGGCTGCAGCA 1261
Db 3 GAGTCCGGCTGCAGCA 19

RESULT 94
ARI46546 19 bp DNA linear PAT 08-AUG-2001
LOCUS ARI46546
DEFINITION Sequence 4 from patent US 6218514.
ACCESSION ARI46546
VERSION ARI46546.1 GI:15109735
KEYWORDS
```

```
SOURCE unknown.
ORGANISM unknown.
REFERENCE
1 (bases 1 to 19)
Cotton,R.G.H., Youll,R. and Kemper,B.W.
TITLE
Antibodies specific for soluble truncated integrins
JOURNAL Patent: US 6218514-A 4 17-APR-2001;
FEATURES
Location/Qualifiers
1..19
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1266 CTGAGAGGCTGAGCG 1282
Db 1 CTGAGAGGCTGAGCG 17

RESULT 95
I85585 19 bp DNA linear PAT 10-JUN-1998
LOCUS I85585
DEFINITION Sequence 6 from patent US 5698400.
ACCESSION I85585
VERSION I85585.1 GI:3205303
KEYWORDS
SOURCE
ORGANISM unknown.
REFERENCE
1 (bases 1 to 19)
Cotton,R.G.H., Youll,R. and Kemper,B.W.
TITLE
Detection of mutation by resolvase cleavage
JOURNAL Patent: US 5698400-A 6 16-DEC-1997;
FEATURES
Location/Qualifiers
1..19
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1245 GTGCTCGGCTGCAGCA 1261
Db 3 GAGTCCGGCTGCAGCA 19

RESULT 96
AX131163 19 bp DNA linear PAT 15-MAY-2001
LOCUS AX131163
DEFINITION Sequence 2381 from Patent WO0130362.
ACCESSION AX131163
VERSION AX131163.1 GI:14137468
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
1 (bases 1 to 19)
Robbins,J.M. and Tritz,R.
TITLE
Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 2381 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
Location/Qualifiers
1..19
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'
/note='Cyclin F ribozyme binding site'
```


Query Match 5.3%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGGCGACAG 1287
|||
3 AGAGCTCAGGCGACAG 19

RESULT 97
LOCUS C0616191 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 931 from Patent WO0192524.
ACCESSION C0616191
VERSION C0616191.1 GI:41666409
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 931 06-DEC-2001;
Aeonica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1266 CTGGAAGAGGCTGAG 1280
|||
1 CTGGAAGAGGCTGAG 15

RESULT 98
LOCUS AR188353 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3841 from patent US 6346398.
ACCESSION AR188353
VERSION AR188353.1 GI:20234318
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 3841 12-FEB-2002;
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1301 CATGTCATCTGTGA 1315
|||
1 CATGTCCTCTGTGA 15

RESULT 99
LOCUS AR189955 17 bp DNA linear PAT 20-APR-2002

DEFINITION Sequence 5443 from patent US 6346398.
ACCESSION AR189955
VERSION AR189955.1 GI:20235920
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6346398-A 5443 12-FEB-2002;
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1302 ATGTCATCTGTGAG 1316
|||
1 ATGTCCTCTGTGAG 15

RESULT 100
LOCUS AR324206 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1608 from patent US 6566127.
ACCESSION AR324206
VERSION AR324206.1 GI:33710014
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 1608 20-MAY-2003;
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1301 CATGTCATCTGTGA 1315
|||
1 CATGTCCTCTGTGA 15

RESULT 101
LOCUS AR324935 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2337 from patent US 6566127.
ACCESSION AR324935
VERSION AR324935.1 GI:33710743
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 2337 20-MAY-2003;
location/Qualifiers
1..17
/organism="unknown"

REFERENCE 1 (bases 1 to 18)
AUTHORS Conswert,L.M., Bennett,C.Frank. and O'Malley,B.W.
TITLE Antisense modulation of SRA expression
JOURNAL Patent: US 6107092-A 73 22-AUG-2000;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.3%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1254 CTGCAGCAACAGCTG 1268
Db 17 CTGCAGCCACAGCTG 3

RESULT 107
AR439726/c 19 bp DNA linear PAT 20-FEB-2004
LOCUS AR439726
DEFINITION Sequence 44 from patent US 6664442.
ACCESSION AR439726
VERSION AR439726.1 GI:4265662
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS McConlogue,L.C., Games,K.D., Yednock,T.A., Hua,T., Messersmith,E. and Bard,F.
TITLE Selecting compounds to reduce inflammation associated with Alzheimer's disease
JOURNAL Patent: US 6664442-A 44 16-DEC-2003;
FEATURES Location/Qualifiers
SOURCE 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1286 AGACCTCAGGATGC 1300
Db 16 AGACCTCAGGATGC 2

RESULT 108
AX129116/c 19 bp DNA linear PAT 15-MAY-2001
LOCUS AX129116
DEFINITION Sequence 334 from Patent WO0130362.
ACCESSION AX129116
VERSION AX129116.1 GI:14135421
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 19)
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 334 03-MAY-2001;
FEATURES IMMUSOL, INC. (US)
SOURCE location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cdk3 ribozyme binding site"

Query Match 5.3%; Score 13.4; DB 1; Length 19;

Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1261 AACAGCTGGAAGAGG 1275
Db 19 AGCAGCTGGAAGAGG 5

RESULT 109
AX138469 19 bp RNA linear PAT 30-MAY-2001
LOCUS AX138469
DEFINITION Sequence 30 from Patent EP1097993.
ACCESSION AX138469
VERSION AX138469.1 GI:14274365
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 19)
AUTHORS Takira,K., Warashina,M., Kuwabara,T. and Kawasaki,H.
TITLE Functional ribozyme chimeric molecules capable of sliding
JOURNAL Patent: EP 1097993-A 30 09-MAY-2001;
FEATURES Secretary of Agency of Industrial Science and Technology (JP) ;
SOURCE 1..19
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1326 GACCTCTTCTCCAG 1340
Db 5 GACCTCTTCTCCAG 19

RESULT 110
AX268963/c 19 bp DNA linear PAT 29-OCT-2001
LOCUS AX268963
DEFINITION Sequence 44 from Patent WO0175165.
ACCESSION AX268963
VERSION AX268963.1 GI:16541982
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 19)
AUTHORS McConlogue,L.C., Games,K.D., Yednock,T.A., Hua,T., Messersmith,E. and Bard,F.
TITLE Screening markers and methods for neurodegenerative disorders
JOURNAL Patent: WO 0175165-A 44 11-OCT-2001;
FEATURES Elian Pharmaceuticals, Inc. (US)
SOURCE location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="reverse primer #2-365R"

Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1286 AGACCTCAGGATGC 1300
Db 16 AGACCTCAGGATGC 2

RESULT 111

AX300829/c
LOCUS AX300829 19 bp DNA linear PAT 30-NOV-2001
DEFINITION Sequence 31 from Patent WO0185593.
ACCESSION AX300829
VERSION AX300829.1 GI:17382109
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS 1
TITLE Cooper,D.N., Procter,A.M., Gregory,J.D. and Millar,D.S.
JOURNAL Method for detecting growth hormone variations in humans, the
University of Wales College of Medicine (GB)
FEATURES
source
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1357 GGGCAGCTGAGGCTT 1371
|||||
Db 19 GGGCAGCTGTGGCTT 5
RESULT 112
AX766706/c 19 bp DNA linear PAT 25-JUN-2003
LOCUS AX766706
DEFINITION Sequence 24 from Patent WO03042408.
ACCESSION AX766706
VERSION AX766706.1 GI:32260475
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS 1
TITLE Cooper,D.N., Procter,A.M., Gregory,J. and Millar,D.S.
JOURNAL Sequence variants of the human growth hormone gene and methods for
detection
Patent: WO 03042408-A 24 22-MAY-2003;
University of Wales College of Medicine (GB)
FEATURES
source
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1357 GGGCAGCTGAGGCTT 1371
|||||
Db 19 GGGCAGCTGTGGCTT 5
RESULT 113
BD015637 19 bp RNA linear PAT 27-AUG-2002
LOCUS BD015637
DEFINITION Slidable functional chimeric molecule.
ACCESSION BD015637
VERSION BD015637.1 GI:22556774
KEYWORDS JP 2001190282-A/30.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 19)
TITLE Taira,K., Warashina,M., Kuwabara,T. and Kawasaki,H.
JOURNAL Slidable functional chimeric molecule
Patent: JP 2001190282-A 30 17-JUL-2001;
DIRECTOR GENERAL OF NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL
SCIENCE AND MANBU NAKAJIMA TECHNOLOGY, KAZUNARI TAIRA
OS Homo sapiens (human)
PN JP 2001190282-A/30
PN 17-JUL-2001
PI 02-NOV-2000 JP 2000336082
PI KAZUNARI TAIRA, MASAKI WARASHINA, TOMOKO KUWABARA, HIROAKI PI
KAWASAKI
PC
C12N15/09,A61K31/7105,A61K31/711,A61K38/00,A61K48/00,A61P31/12, PC
A61P43/00,
PC C12N9/22,C12Q1/02,C12Q1/68,G01N33/53,G01N33/566,C12N15/00, PC
A61K37/02
CC Slidable functional chimeric molecule
FH Key Location/Qualifiers
FT source 1. .19
/organism="Homo sapiens (human)".
FEATURES
source
1. .19
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"
Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1326 GACCTCTTCTCCAG 1340
|||||
Db 5 GACCTCTTCTCCAG 19
RESULT 114
BD089497/c 19 bp DNA linear PAT 27-AUG-2002
LOCUS BD089497
DEFINITION A method of arraying genome clone.
ACCESSION BD089497
VERSION BD089497.1 GI:22635107
KEYWORDS JP 2001321190-A/1741.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE
AUTHORS 1 (bases 1 to 19)
TITLE Soeda,E.
JOURNAL A method of arraying genome clone
Patent: JP 2001321190-A 1741 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECNS
OS Artificial Sequence
PN JP 2001321190-A/1741
PN 20-NOV-2001
PI 12-MAR-2001 JP 2001068285
PI EIICHI SOEDA
PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence:Synthetic DNA FH Key
Location/Qualifiers
FT source 1. .19
/organism="Artificial Sequence".
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1199 TGTGACAGGCGAGC 1213
|||||
Db 15 TGTGACAGGCGAGC 1

RESULT 115
AR092795 18 bp DNA linear PAT 08-SEP-2000
LOCUS AR092795 Sequence 10 from patent US 5998206.
ACCESSION AR092795
VERSION AR092795.1 GI:10019547
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
1 (bases 1 to 18)
Cowsett,L.M.
Antisense inhibition of human G-alpha-12 expression
Patent: US 5998206-A 10 07-DEC-1999;
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1264 AGCTGAGAGGCTGAGG 1281
|||||
Db 1 AGCAGCGACGCGCTGAGG 18

RESULT 116
AR106959 18 bp DNA linear PAT 14-FEB-2001
LOCUS AR106959 Sequence 120 from patent US 6107092.
ACCESSION AR106959
VERSION AR106959.1 GI:12821489
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
1 (bases 1 to 18)
Cowsett,L.M., Bennett,C.Frank. and O'Malley,B.W.
Antisense modulation of SRA expression
Patent: US 6107092-A 120 22-AUG-2000;
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1378 AGCAGCTGCGTTTGTGTG 1395
|||||
Db 18 AGCAGCTGCGTTTGTGTG 1

RESULT 117
AR121134 18 bp DNA linear PAT 16-MAY-2001
LOCUS AR121134 Sequence 30 from patent US 6159697.
ACCESSION AR121134
VERSION AR121134.1 GI:14104710
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
1 (bases 1 to 18)
Cowsett,L.M., Bennett,C.Frank. and O'Malley,B.W.
Antisense modulation of SRA expression
Patent: US 6159697-A 30 12-DEC-2000;
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

REFERENCE 1 (bases 1 to 18)
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
1 (bases 1 to 18)
Monta,B.P. and Cowsett,L.M.
Antisense modulation of Smad7 expression
Patent: US 6159697-A 30 12-DEC-2000;
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1405 ACAGACCGGCTGCTGAGC 1422
|||||
Db 18 ACAGACCGGCTGCTGAGC 1

RESULT 118
AR134068 18 bp DNA linear PAT 16-MAY-2001
LOCUS AR134068 Sequence 2493 from patent US 6194150.
ACCESSION AR134068
VERSION AR134068.1 GI:14122973
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
1 (bases 1 to 18)
Stinchcomb,D.T., Jarvik,T. and McSwiggen,J.
Nucleic acid based inhibition of CD40
Patent: US 6194150-A 2493 27-FEB-2001;
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1256 GCAGCACAGCTGGAAGA 1273
|||||
Db 18 GCAGCACAGCTGGAAGA 1

RESULT 119
AR138066 18 bp DNA linear PAT 16-JUN-2001
LOCUS AR138066 Sequence 76 from patent US 6197584.
ACCESSION AR138066
VERSION AR138066.1 GI:14479575
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
SOURCE
1 (bases 1 to 18)
Bennett,C.Frank. and Cowsett,L.M.
Antisense modulation of CD40 expression
Patent: US 6197584-A 76 06-MAR-2001;
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1337 CAGGCGAGAGACTTTC 1354
|||||
Db 18 CAGTGCAGAGAGACTTAC 1

RESULT 120
BD226617/c 18 bp DNA linear PAT 17-JUL-2003
LOCUS BD226617
DEFINITION Antisense modulation of CD40 expression.
ACCESSION BD226617.1 GI:33036387
VERSION BD226617.1
KEYWORDS JP 2002513593-A/76.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 18)
AUTHORS Bennett,C.F. and Cowseert,L.M.
TITLE Antisense modulation of CD40 expression
JOURNAL Patent: JP 2002513593-A 76 14-MAY-2002;
ISIS PHARMACEUTICALS INC
COMMENT OS Unidentified
PN JP 2002513593-A/76
PD 14-MAY-2002
PF 22-APR-1999 JP 2000547271
PI C FRANK BENNETT, LEX M COWSEERT
PC C12N15/09,A61K9/10,A61K45/00,A61K48/00,A61P1/00,A61P11/06, PC
A61P17/06,
PC A61P29/00,A61P35/00,A61P37/02,A61P37/06,A61P43/00,C12P19/34,
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of CD40 expression
FH Key Location/Qualifiers
FT source 1.18
FEATURES
source Location/Qualifiers
1.18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1337 CAGGCAGAGAGCTTCC 1354
DB 18 CAGTCAGAGAGACTTAC 1
RESULT 121
BD250522/c 18 bp DNA linear PAT 17-JUL-2003
LOCUS BD250522
DEFINITION Identification of genetic targets for modulation by
oligonucleotides and generation of oligonucleotides for gene
modulation.
ACCESSION BD250522
VERSION BD250522.1 GI:33060292
KEYWORDS JP 2002511276-A/76.
SOURCE synthetic construct
ORGANISM artificial construct
REFERENCE
1 (bases 1 to 18)
AUTHORS Cowseert,L.M., Baker,B.F., Mcneil,J., Freier,S.M., Sasmor,H.M.,
Brooks,D.G., Ohasi,C., Wyatt,J.R., Borchers,A.H. and Vikkars,T.A.
TITLE Identification of genetic targets for modulation by
oligonucleotides and generation of oligonucleotides for gene
modulation
JOURNAL Patent: JP 2002511276-A 76 16-APR-2002;
ISIS PHARMACEUTICALS INC
COMMENT OS Artificial Sequence
PN JP 2002511276-A/76
PD 16-APR-2002
PF 13-APR-1999 JP 2000543647
PI 13-APR-1998 US 60/081483,28-APR-1998 US 09/067638 PI

LEX M COWSEERT, BRENDA F BAKER, JOHN MCNEIL, SUSAN M FREIER, HENRI PI
M SASMOR,
PI DOUGLAS G BROOKS, CARA OHASI, JACQUELINE R WYATT, ALEXANDER H PI
BORCHERS,
PI TIMOTHY A VIKKARS
PC C12N15/09,C07B61/00,C07B61/00,C12Q1/68,G06F17/30,G06F17/50, PC
C12N15/00
CC Antisense Oligonucleotide
FH Key Location/Qualifiers
FT source 1.18
FEATURES
source Location/Qualifiers
1.18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1337 CAGGCAGAGAGCTTCC 1354
DB 18 CAGTCAGAGAGACTTAC 1
RESULT 122
AX059438 18 bp DNA linear PAT 17-JAN-2001
LOCUS AX059438
DEFINITION Sequence 171 from Patent WO0055325.
ACCESSION AX059438
VERSION AX059438.1 GI:12311543
KEYWORDS
SOURCE
ORGANISM Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosoids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.
REFERENCE
1
AUTHORS Preuss,D., Copenhagen,G. and Keith,K.
TITLE Plant chromosome compositions and methods
JOURNAL Patent: WO 0055325-A 171 21-SEP-2000;
The University of Chicago (US)
FEATURES
source Location/Qualifiers
1.18
/organism="Arabidopsis thaliana"
/mol_type="unassigned DNA"
/db_xref="taxon:3702"
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1279 AGGCGAGAGACCTTCAGG 1296
DB 1 AGGCGAGAGACCTTCAGG 18
RESULT 123
AX838288/c 18 bp DNA linear PAT 15-DEC-2003
LOCUS AX838288
DEFINITION Sequence 5412 from Patent EP1347046.
ACCESSION AX838288
VERSION AX838288.1 GI:39921980
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1
AUTHORS Iisogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S.,
Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R.,
Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and
Masuho,Y.

TITLE Full-length cDNA sequences
JOURNAL Patent: EP 1347046-A 5412 24-SEP-2003;
Research Association for Biotechnology (JP)
FEATURES
 source
 1..18
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"
 /note="Description of Artificial Sequence: an artificially
 synthesized primer se q"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1234 GCACGAGCTGGAAGAGCG 1276
 |||||
 18 GCACGAGCTGGAAGAGCTC 1

RESULT 124
AB086471 18 bp DNA linear SYN 21-MAY-2003
DEFINITION Synthetic construct DNA, forward primer for Japanese flounder
ACCESSION AB086471
VERSION AB086471.1 GI:28804323
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Colibira, M.R.M., Kobayashi, K., Koretsugu, S., Hasegawa, O., Ohara, E.,
Ozaki, A., Sakamoto, T., Naruse, K. and Okamoto, N.
TITLE A genetic linkage map of the Japanese flounder, (*Paralichthys
olivaceus*)
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 18)
AUTHORS Colibira, M.R.M., Kobayashi, K., Koretsugu, S., Hasegawa, O., Ohara, E.,
Ozaki, A., Sakamoto, T., Naruse, K. and Okamoto, N.
TITLE Direct Submission
JOURNAL Submitted (14-JUN-2002) Nobuaki Okamoto, Tokyo University of
Fisheries, Department of Aquatic Biosciences, 4-5-7 Konan,
Minato-ku, Tokyo 108-8477, Japan
(E-mail:nokamoto@okyo-u-fish.ac.jp, Tel:81-3-5463-0547,
Fax:81-3-5463-0552)
FEATURES
 source
 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 1..18
 /note="forward primer for Japanese flounder microsatellite
 sequence Pol149TUF"

Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1234 ATGTCTGCAGTGTCTC 1251
 |||||
 1 ATGAGCTGCAGTCTCTCC 18

RESULT 125
BD266197/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD266197
DEFINITION Universal arrays.
ACCESSION BD266197
VERSION BD266197.1 GI:33075965
KEYWORDS JP 2002539849-A/197.
SOURCE synthetic construct
ORGANISM synthetic construct

artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Fan, J.B., Hirschhorn, J.N., Huang, X., Kaplan, P., Lander, E.S.,
Lockhart, D.J., Ryder, T. and Sklar, P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 197 26-NOV-2002;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, APEWETRIX INC
COMMENT OS Artificial Sequence
PN JP 2002539849-A/197
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PI
JIAN BING FAN, JOEL N HIRSCHHORN, XIAOHUA
HUANG, PAUL KAPLAN, ERIC
PI S LANDER,
PI DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR
PC C1201/68, C12M1/00, C12N15/09, C12N15/09, C12N15/09, G01N33/53, PC
G01N33/566,
PC G01N37/00, C12N15/00, C12N15/00, C12N15/00
CC Primer
FH Key
FT source
FT Location/Qualifiers
 1..17
 /organism="Artificial Sequence".
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1200 GTGCAGAGCGCAG 1212
 |||||
 14 GTGCAGAGCGCAG 2

RESULT 126
CG617849 17 bp DNA linear PAT 02-FEB-2004
LOCUS CG617849
DEFINITION Sequence 2589 from Patent WO0192524.
ACCESSION CG617849
VERSION CG617849.1 GI:41668067
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2589 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGCTGCCATCG 1305
 |||||
 5 CAGGCTGCCATCG 17

RESULT 127
CG617850 17 bp DNA linear PAT 02-FEB-2004
LOCUS CG617850

DEFINITION Sequence 2590 from Patent WO0192524.
ACCESSION CQ617850
VERSION CQ617850.1 GI:41668068
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2590 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCATCG 1305
|||||
|||||
Db 4 CAGGTCATCG 16

RESULT 128
LOCUS CQ617851 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2591 from Patent WO0192524.
ACCESSION CQ617851
VERSION CQ617851.1 GI:41668069
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2591 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCATCG 1305
|||||
|||||
Db 3 CAGGTCATCG 15

RESULT 129
LOCUS CQ617852 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2592 from Patent WO0192524.
ACCESSION CQ617852
VERSION CQ617852.1 GI:41668070
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2592 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCATCG 1305
|||||
|||||
Db 2 CAGGTCATCG 14

RESULT 130
LOCUS AR458912 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2589 from patent US 6686188.
ACCESSION AR458912
VERSION AR458912.1 GI:42693969
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL Patent: US 6686188-A 2589 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGTCATCG 1305
|||||
|||||
Db 5 CAGGTCATCG 17

RESULT 131
LOCUS AR458913 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2590 from patent US 6686188.
ACCESSION AR458913
VERSION AR458913.1 GI:42693970
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL Patent: US 6686188-A 2590 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGGTGCATCG 1305
|||||
Db 4 CAGGGTGCATCG 16

RESULT 132
AR458914 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2591 from patent US 6686188.
ACCESSION AR458914
VERSION AR458914.1 GI:42693971
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.B.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 2591 03-FEB-2004;
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGGTGCATCG 1305
|||||
Db 3 CAGGGTGCATCG 15

RESULT 133
AR458915 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2592 from patent US 6686188.
ACCESSION AR458915
VERSION AR458915.1 GI:42693972
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.B.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 2592 03-FEB-2004;
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 CAGGGTGCATCG 1305
|||||
Db 2 CAGGGTGCATCG 14

RESULT 134
AX732608 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4242 from Patent WO03025175.
ACCESSION AX732608
VERSION AX732608.1 GI:30511951

KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 4242 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
LOCATION/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1215 ATCTGTCAAGACC 1227
|||||
Db 2 ATCTGTCAAGACC 14

RESULT 135
AX759643 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 2964 from Patent WO03040369.
ACCESSION AX759643
VERSION AX759643.1 GI:32254259
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
Patent: WO 03040369-A 2964 15-MAY-2003;
JOURNAL Molecular Engines Laboratories (FR)
LOCATION/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1215 ATCTGTCAAGACC 1227
|||||
Db 2 ATCTGTCAAGACC 14

RESULT 136
AR042270/C 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1060 from patent US 5811300.
ACCESSION AR042270
VERSION AR042270.1 GI:5962766
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 18)
Sullivan,S., Draper,K., Kisch,K., Stinchcomb,D.T. and McSwigen,J.
TITLE TNF-alpha, ribozymes

JOURNAL Patent: US 581300-A 1060 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 GAAGAGCGTGCAG 1281
|||||
Db 15 GAAGAGCGTGCAG 3

RESULT 137
LOCUS AR067089 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 437 from patent US 5851760.
ACCESSION AR067089
VERSION AR067089.1 GI:5998311
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Evans,G.A. and Smith,M.W.
TITLE Method for generation of sequence sampled maps of complex genomes
JOURNAL Patent: US 5851760-A 437 22-DEC-1998;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1200 GTGCAGAGGCGCAG 1212
|||||
Db 18 GTGCAGAGGCGCAG 6

RESULT 138
LOCUS AR073377 18 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 17 from patent US 5951455.
ACCESSION AR073377
VERSION AR073377.1 GI:10000141
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowseert,L.M.
TITLE Antisense modulation of G-alpha-11 expression
JOURNAL Patent: US 5951455-A 17 14-SEP-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1375 AGAAGCAGCTGCG 1387
|||||
Db 18 AGAAGCAGCTGCG 6

RESULT 139
LOCUS BD250701 18 bp DNA linear PAT 17-JUN-2003
DEFINITION Sequence 4727 from patent US 6537751.
ACCESSION AR292992
VERSION AR292992.1 GI:31680276
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 4727 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

LOCUS BD250701 18 bp DNA linear PAT 17-JUN-2003
DEFINITION Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation.
ACCESSION BD250701 GI:33060471
VERSION BD250701.1 GI:33060471
KEYWORDS JP 2002511276-A/255.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowseert,L.M., Baker,B.F., Mcneil,J., Freier,S.M., Saemur,H.M., Brooks,D.G., Ohasi,C., Wyatt,J.R., Borchers,A.H. and Vikkars,T.A.
TITLE Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
JOURNAL Patent: JP 2002511276-A 255 16-APR-2002;
COMMENT ISTS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002511276-A/255
PD 16-APR-2002
PF 13-APR-1999 JP 2000543647
PR 13-APR-1998 US 60/081483 28-APR-1998 US 09/067638 PI
LEX M COMSERT,BRENDA F BAKER,JOHN MCNEIL,SUSAN M FREIER,HENRI PI
M SASMOR,
PI DOUGLAS G BROOKS,CARA OHASI,JACQUELINE R WYATT,ALEXANDER H PI
BORCHERS,
PI TIMOTHY A VIKKARS
PC C12N15/09,C07B61/00,C07B61/00,C12Q1/68,G06F17/30,G06F17/50, PC
C12N15/00
CC Antisense Oligonucleotide
FH Key Location/Qualifiers
FT source 1..18
/organism="Artificial Sequence".
FEATURES Location/Qualifiers
source 1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1375 AGAAGCAGCTGCG 1387
|||||
Db 18 AGAAGCAGCTGCG 6

RESULT 140
LOCUS AR292992 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4727 from patent US 6537751.
ACCESSION AR292992
VERSION AR292992.1 GI:31680276
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 4727 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Qy 1327 ACCTCTCTCCAA 1339
Db 13 ACCTCTCTCCAA 1

RESULT 141
LOCUS AX637698 18 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 4837 from Patent EP1260586.
ACCESSION AX637698
VERSION AX637698.1 GI:28473312
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrita,B., Grimm,S., Dizenzo,A.,
Karpelesky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Swedler,D., Thompson,J.D., Tracz,D., Uzman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes

JOURNAL
PATENT: EP 1260586-A 4837 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
SOURCE 1.18
location/Qualifiers
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 5.1%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1269 GAAAGAGGCTGAGC 1281
Db 15 GAAAGAGGCTGAGC 3

RESULT 142
LOCUS AX255757 16 bp DNA linear PAT 10-OCT-2001
DEFINITION Sequence 178 from Patent WO0170982.
ACCESSION AX255757
VERSION AX255757.1 GI:16074812
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS 1
Beger,C., Barber,J. and Wong-Staal,F.
TITLE Bcr-a-1 regulators and methods of use
JOURNAL Patent: WO 0170982-A 178 27-SEP-2001;
Immunol Incorporated (US); Beger, Carmela (DE)
FEATURES
SOURCE 1.16
location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match 5.1%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1197 CCTGTGACAGGGCAG 1212
Db 16 CCTGCCACAGCGCAG 1

RESULT 143
BD203087

LOCUS BD203087 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD203087
VERSION BD203087.1 GI:33012857
KEYWORDS JP 2002509721-A/6113.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS 1
Bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6113 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/6113
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key location/Qualifiers
FT source 1.17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1220 TCAGACTCCAGCAT 1235
Db 2 TAAGATCTCCAGCAT 17

RESULT 144
BD254885 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254885
VERSION BD254885.1 GI:33064655
KEYWORDS JP 2002541795-A/2678.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1
Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2678 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/2678
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC

C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1.17
/organism='Eukaryote'.
FEATURES
source 1.17
location/Qualifiers
1.17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCAGAGGC 1197
|||
2 CTGGGCTCCAGAGGC 17

RESULT 145
LOCUS C0616186 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 926 from Patent WO0192524.
ACCESSION C0616186
VERSION C0616186.1 GI:41666404
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 926 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAAGAGCT 1277
|||
2 AGAGCTGAAGAGGCT 17

RESULT 146
LOCUS C0617222 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1962 from Patent WO0192524.
ACCESSION C0617222
VERSION C0617222.1 GI:41667440
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1962 06-DEC-2001;
Aeomica, Inc. (US)

FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGTCGACA 1407
|||
2 GCTGAGCTGTCGACA 17

RESULT 147
LOCUS C0617223 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1963 from Patent WO0192524.
ACCESSION C0617223
VERSION C0617223.1 GI:41667441
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1963 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGTCGACA 1407
|||
1 GCTGAGCTGTCGACA 16

RESULT 148
LOCUS C0617854 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2594 from Patent WO0192524.
ACCESSION C0617854
VERSION C0617854.1 GI:41668072
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2594 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 AGGCGCATGTCAT 1309
DB 1 AGGTGTCATGAGAT 16

RESULT 149
LOCUS C0621870 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6610 from Patent WO0192524.
ACCESSION C0621870
VERSION C0621870.1 GI:41672088
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6610 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1223 GAACCTCGAGCATGTG 1238
DB 17 GAGCTCCAGGATGTG 2

RESULT 150
LOCUS C0621873 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6613 from Patent WO0192524.
ACCESSION C0621873
VERSION C0621873.1 GI:41672091
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6613 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 CAGACCTCGAGCATG 1236
DB 16 CAGACCTCGAGCATG 1

RESULT 151
LOCUS C0622606 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 7346 from Patent WO0192524.
ACCESSION C0622606
VERSION C0622606.1 GI:41672824
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7346 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 AACGCTGGAAGAGGC 1276
DB 2 AACGCTGGAAGAGGC 17

RESULT 152
LOCUS C0622607 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7347 from Patent WO0192524.
ACCESSION C0622607
VERSION C0622607.1 GI:41672825
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7347 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1261 AACGCTGGAAGAGGC 1276
DB 1 AACGCTGGAAGAGGC 16

RESULT 153
LOCUS C0623057 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7797 from Patent WO0192524.
ACCESSION C0623057
VERSION C0623057.1 GI:41673275
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 7797 06-DEC-2001;

Acemica, Inc. (US)

FEATURES Location/Qualifiers

source

1..17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1253 GCTGAGCAGACGCTG 1268

Db 2 GCTTCAGCAGCAGCTG 17

RESULT 154

CO623058

LOCUS CQ623058 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 7798 from Patent WO0192524.

ACCESSION CQ623058

VERSION CQ623058.1 GI:41673276

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 7798 06-DEC-2001;

Acemica, Inc. (US)

FEATURES Location/Qualifiers

source

1..17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1253 GCTGAGCAGACGCTG 1268

Db 1 GCTTCAGCAGCAGCTG 16

RESULT 155

CO623907

LOCUS CQ623907 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 8647 from Patent WO0192524.

ACCESSION CQ623907

VERSION CQ623907.1 GI:41674125

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 8647 06-DEC-2001;

Acemica, Inc. (US)

FEATURES Location/Qualifiers

source

1..17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1254 CTGCAGCAACAGCTG 1269

Db 2 CTGCAGCTGCAGCTG 17

RESULT 156

CO623909

LOCUS CQ623909 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 8649 from Patent WO0192524.

ACCESSION CQ623909

VERSION CQ623909.1 GI:41674127

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 8649 06-DEC-2001;

Acemica, Inc. (US)

FEATURES Location/Qualifiers

source

1..17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1255 TGCAGCAACAGCTGGA 1270

Db 1 TGCAAGCTGCAGCTGGA 16

RESULT 157

CO624606

LOCUS CQ624606 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 9346 from Patent WO0192524.

ACCESSION CQ624606

VERSION CQ624606.1 GI:41674824

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 9346 06-DEC-2001;

Acemica, Inc. (US)

FEATURES Location/Qualifiers

source

1..17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1269 GAAGAGCTGAGGCGCA 1284

Db 2 GAAGAGGCTGGGAGCA 17

RESULT 158
LOCUS CQ624607 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9347 from Patent WO0192524.
ACCESSION CQ624607
VERSION CQ624607.1 GI:41674825
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9347 06-DEC-2001;
Aecomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1269 GAAGAGCTGAGGACA 1284
Db 1 GAAGAGCTGAGGACA 16
RESULT 159
LOCUS AR191764 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7252 from patent US 6346398.
ACCESSION AR191764
VERSION AR191764.1 GI:20237729
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7252 12-FEB-2002;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1280 GGGCAGAGACCTCAG 1295
Db 16 GGGCAGAGACCTCAG 1
RESULT 160
LOCUS AR286077 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 449 from patent US 6528640.
ACCESSION AR286077
VERSION AR286077.1 GI:29723673
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
FEATURES
source location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1280 GGGCAGAGACCTCAG 1295
Db 16 GGGCAGAGACCTCAG 1

REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgh,A., Beaudry,A., Karpetsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 449 04-MAR-2003;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1392 GCTGAGCTCTGGACA 1407
Db 1 GCTGAGCTCTGGACA 16
RESULT 161
LOCUS AR286131 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 503 from patent US 6528640.
ACCESSION AR286131
VERSION AR286131.1 GI:29723727
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgh,A., Beaudry,A., Karpetsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 503 04-MAR-2003;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1305 GTCATCTGTGAGCAGC 1320
Db 2 GTCATCTGTGAGCAGC 17
RESULT 162
LOCUS AR325659 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3061 from patent US 6566127.
ACCESSION AR325659
VERSION AR325659.1 GI:33711467
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3061 20-MAY-2003;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1280 GGGCAGAGACCTCAG 1295
Db 16 GGGCAGAGACCTCAG 1

Db 16 GGGCAGAGCCATGAG 1
|||||
RESULT 163
AR329056/c AR329056 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 6458 from patent US 6566127.
DEFINITION AR329056
ACCESSION AR329056
VERSION AR329056.1 GI:33714864
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwigen, J.A., Stinchcomb, D.T. and Sacobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6458 20-MAY-2003;
FEATURES
source
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1267 TCGAGAGCTGAGG 1282
|||||
Db 16 TGGCAGAGCTGTGG 1
|||||
RESULT 164
AR398067 17 bp RNA linear PAT 18-DEC-2003
LOCUS Sequence 448 from patent US 6617438.
DEFINITION AR398067
ACCESSION AR398067
VERSION AR398067.1 GI:40135579
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgin, A.B., Beaudry, A., Karpelsky, A., Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 448 09-SEP-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1392 GCTGAGCTGCTGACA 1407
|||||
Db 1 GCTGCGCTGCTGACA 16
|||||
RESULT 165
AR398121 17 bp RNA linear PAT 18-DEC-2003
LOCUS Sequence 502 from patent US 6617438.
DEFINITION AR398121
ACCESSION AR398121
VERSION AR398121.1 GI:40135671
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)

AUTHORS Beigelman, L., Burgin, A.B., Beaudry, A., Karpelsky, A., Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 502 09-SEP-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1305 GTCATCTGTGAGCAGC 1320
|||||
Db 2 GGCACTCTGTGAGCTGC 17
|||||
RESULT 166
AR457249 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 926 from patent US 6686188.
DEFINITION AR457249
ACCESSION AR457249
VERSION AR457249.1 GI:42692306
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.B.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 926 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1262 ACAGCTGAGAGGCT 1277
|||||
Db 2 AGAGCTGAAGAGGCT 17
|||||
RESULT 167
AR458285 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 1962 from patent US 6686188.
DEFINITION AR458285
ACCESSION AR458285
VERSION AR458285.1 GI:42693342
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.B.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1962 03-FEB-2004;
FEATURES
source
1. .17
/organism="genomic DNA"
/mol_type="genomic DNA"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGGACA 1407
||| ||||| |||||
Db 2 GCTGAGCTGCTGCACA 17

RESULT 168
LOCUS AR458286 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1963 from patent US 6686188.
ACCESSION AR458286
VERSION AR458286.1 GI:42693343
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1963 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGGACA 1407
||| ||||| |||||
Db 1 GCTGAGCTGCTGCACA 16

RESULT 169
LOCUS AR458917 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2594 from patent US 6686188.
ACCESSION AR458917
VERSION AR458917.1 GI:42693974
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2594 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 AGGGTCCATGGTCAT 1309
||| ||||| |||||
Db 1 AGGGTCCATGGAGAT 16

RESULT 170
LOCUS AR462933/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6610 from patent US 6686188.
ACCESSION AR462933
VERSION AR462933.1 GI:42697990
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6610 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1223 GAACTCCAGCATGTG 1238
||| ||||| |||||
Db 17 GAGCTCCAGCATGTG 2

RESULT 171
LOCUS AR462936 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6613 from patent US 6686188.
ACCESSION AR462936
VERSION AR462936.1 GI:42697993
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6613 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 CAGAACTCCAGCATG 1236
||| ||||| |||||
Db 16 CAGAGCTCCAGCATG 1

RESULT 172
LOCUS AR463669 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7346 from patent US 6686188.
ACCESSION AR463669
VERSION AR463669.1 GI:42698726
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7346 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1261 AACAGCTGGAAGAGC 1276
Db 2 AACAGTTGGAAGAGC 17

RESULT 173
LOCUS AR463670 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7347 from patent US 6686188.
ACCESSION AR463670
VERSION AR463670.1 GI:42698727
KEYWORDS
SOURCE .
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7347 03-FEB-2004;
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1261 AACAGCTGGAAGAGC 1276
Db 1 AACAGTTGGAAGAGC 16

RESULT 174
LOCUS AR464120 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7797 from patent US 6686188.
ACCESSION AR464120
VERSION AR464120.1 GI:42699177
KEYWORDS
SOURCE .
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7797 03-FEB-2004;
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1253 GCTGACGACAGCTG 1268
Db 2 GCTTCAGCAGCAGCTG 17

RESULT 175
LOCUS AR464121 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7798 from patent US 6686188.

ACCESSION AR464121
VERSION AR464121.1 GI:42699178
KEYWORDS
SOURCE .
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7798 03-FEB-2004;
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1253 GCTGACGACAGCTG 1268
Db 1 GCTTCAGCAGCAGCTG 16

RESULT 176
LOCUS AR464970 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8647 from patent US 6686188.
ACCESSION AR464970
VERSION AR464970.1 GI:42700027
KEYWORDS
SOURCE .
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8647 03-FEB-2004;
FEATURES
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1254 CTGACGACGACGCTG 1269
Db 2 CTGACGCTGACGCTG 17

RESULT 177
LOCUS AR464972 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8649 from patent US 6686188.
ACCESSION AR464972
VERSION AR464972.1 GI:42700029
KEYWORDS
SOURCE .
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8649 03-FEB-2004;
FEATURES
Location/Qualifiers

```
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1255 TGCAGCAACAGCTGGA 1270
|||||
1 TGCAGCTGAGCTGGA 16

RESULT 178
AR465669
LOCUS AR465669 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9346 from patent US 6686188.
ACCESSION AR465669
VERSION AR465669.1 GI:42700726
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
PATENT: US 6686188-A 9346 03-FEB-2004;
JOURNAL Location/Qualifiers
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1269 GAAGAGCTGAGGGA 1284
|||||
1 GAAGAGCTGGGGA 16

RESULT 179
AR465670
LOCUS AR465670 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9347 from patent US 6686188.
ACCESSION AR465670
VERSION AR465670.1 GI:42700727
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
PATENT: US 6686188-A 9347 03-FEB-2004;
JOURNAL Location/Qualifiers
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1269 GAAGAGCTGAGGGA 1284
|||||
1 GAAGAGCTGGGGA 16
```

```
RESULT 180
AX215097/c
LOCUS AX215097 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 539 from Patent WO0159103.
ACCESSION AX215097
VERSION AX215097.1 GI:15525140
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Blact,L., Mcswigen,J. and Chowitra,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
PATENT: WO 0159103-A 539 16-AUG-2001;
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blact, Lawrence (US) ;
Mcswigen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1263 CAGCTGGAAGAGCTG 1278
|||||
16 CAGCAGGATATGCTG 1

RESULT 181
AX216736/c
LOCUS AX216736 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2178 from Patent WO0159103.
ACCESSION AX216736
VERSION AX216736.1 GI:15526797
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blact,L., Mcswigen,J. and Chowitra,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
PATENT: WO 0159103-A 2178 16-AUG-2001;
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Blact, Lawrence (US) ;
Mcswigen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
Best Local Similarity 5.1%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1188 TCCGAAAGCTGTGC 1203
|||||
17 TCTCAGATCCTGTGC 2

RESULT 182
AX475650
LOCUS AX475650 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 871 from Patent WO0224750.
ACCESSION AX475650
VERSION AX475650.1 GI:22214935
KEYWORDS
```

ORGANISM	Homo sapiens (human)
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE	
JOURNAL	
REFERENCE	1 Zhang,J: Human kidney tumor overexpressed membrane protein 1 Patent: WO 0224750-A 871 28-MAR-2002;
FEATURES	Aeomica, Inc. (US) location/Qualifiers 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
source	
Query Match	5.1%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred.No.1.5e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1353 CCCAGGCGACGCTGAGG 1368 2 CCTAGAGCAGCTGAGG 17
Db	
RESULT 183	
LOCUS	AX475651 17 bp DNA linear PAT 12-AUG-2002
DEFINITION	Sequence 872 from Patent W00224750.
ACCESSION	AX475651
VERSION	AX475651.1 GI:22214936
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	Zhang,J: Human kidney tumor overexpressed membrane protein 1 Patent: WO 0224750-A 872 28-MAR-2002;
TITLE	
JOURNAL	
REFERENCE	1 Aeomica, Inc. (US) location/Qualifiers 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
FEATURES	
source	
Query Match	5.1%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred.No.1.5e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	1353 CCCAGGCGACGCTGAGG 1368 1 CCTAGAGCAGCTGAGG 16
Db	
RESULT 184	
LOCUS	AX500510/c 17 bp DNA linear PAT 27-SEP-2002
DEFINITION	Sequence 1817 from Patent EP1229046.
ACCESSION	AX500510
VERSION	AX500510.1 GI:23382803
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	Zhan,J: Human testis expressed patched like protein Patent: EP 1229046-A 1817 07-AUG-2002;
TITLE	
JOURNAL	
REFERENCE	1 Aeomica, Inc. (US) Location/Qualifiers 1..17
FEATURES	
source	

Query Match	5.1%;	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 1.5e+02;		
Matches 14;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Oy	1300	CCATGTCATCTGTGA	1315	
Db	17	CCATGTCATCTGTGGA	2	
RESULT 185				
AX500511/c		17 bp	DNA	linear
LOCUS				PAT 27-SEP-2002
DEFINITION	Sequence 1818 from Patent EP1229046.			
ACCESSION	AX500511			
VERSION	AX500511.1			
KEYWORDS	GI:23382804			
SOURCE				
ORGANISM	Homo sapiens (human)			
REFERENCE				
AUTHORS	Zhan, J.			
TITLE	Human testis expressed patched like protein			
JOURNAL	Patent: EP 1229046-A 1818 07-AUG-2002;			
FEATURES				
source	location/Qualifiers			
	1..17			
	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
Query Match	5.1%;	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 1.5e+02;		
Matches 14;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Oy	1300	CCATGTCATCTGTGA	1315	
Db	16	CCATGTCATCTGTGGA	1	
RESULT 186				
AX500513/c		17 bp	DNA	linear
LOCUS				PAT 27-SEP-2002
DEFINITION	Sequence 1820 from Patent EP1229046.			
ACCESSION	AX500513			
VERSION	AX500513.1			
KEYWORDS	GI:23382806			
SOURCE				
ORGANISM	Homo sapiens (human)			
REFERENCE				
AUTHORS	Homo sapiens			
TITLE	Eukaryotic; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
JOURNAL	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.			
FEATURES				
source	location/Qualifiers			
	1..17			
	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
Query Match	5.1%;	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 1.5e+02;		
Matches 14;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Oy	1297	GTCGATGTCATCTG	1312	
Db	17	GTCGATGTCATCTG	2	

RESULT 187
AX500514/c 17 bp DNA linear PAT 27-SEP-2002
LOCUS Sequence 1821 from Patent EP1229046.
DEFINITION
ACCESSION AX500514
VERSION AX500514.1 GI:23382807
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Zhan,J
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1821 07-AUG-2002;
Aecmica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1297 GTGCCATGTCATCTG 1312
DB 16 GTTCATGTCATCTG 1
RESULT 188
AX687751/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 483 from Patent EP1281758.
DEFINITION
ACCESSION AX687751
VERSION AX687751.1 GI:29410447
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 483 05-FEB-2003;
Aecmica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1216 TCTGTCAGACCTCCA 1231
DB 17 TCTGTCAGCTCTCCA 2
RESULT 189
AX687752/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS Sequence 484 from Patent EP1281758.
DEFINITION
ACCESSION AX687752
VERSION AX687752.1 GI:29410448
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 484 05-FEB-2003;
Aecmica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1216 TCTGTCAGACCTCCA 1231
DB 16 TCTGTCAGCTCTCCA 1
RESULT 190
AX728108 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 5795 from Patent WO03025176.
DEFINITION
ACCESSION AX728108
VERSION AX728108.1 GI:30507451
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telemann,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 5795 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1234 ATGTGCTGCAGTGGT 1249
DB 2 ATGTGCTGCAGTAGT 17
RESULT 191
AX739146 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 4736 from Patent WO03025177.
DEFINITION
ACCESSION AX739146
VERSION AX739146.1 GI:30518443
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Tejeran,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments

JOURNAL Patent: WO 03025177-A 4736 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1418 TGAGCGGCGCATCATC 1433
DB 16 TGAGAGGCGCATGATC 1

RESULT 192
AX744246 17 bp DNA linear PAT 14-MAY-2003
LOCUS Sequence 211 from Patent WO03031621.
DEFINITION AX744246
ACCESSION AX744246.1 GI:30722913
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 211 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1315 AGCAGCTAGGGGACCT 1330
DB 2 AGCTGTAGGGGACCT 17

RESULT 193
AX744247 17 bp DNA linear PAT 14-MAY-2003
LOCUS Sequence 212 from Patent WO03031621.
DEFINITION AX744247
ACCESSION AX744247.1 GI:30722914
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 212 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1315 AGCAGCTAGGGGACCT 1330
DB 1 AGCTGTAGGGGACCT 16

RESULT 194
AX753820 17 bp DNA linear PAT 23-JUN-2003
LOCUS Sequence 167 from Patent WO03037931.
ACCESSION AX753820
VERSION AX753820.1 GI:32166517
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 167 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1251 CGGCTGAGCAACAGC 1266
DB 1 CAGCAGCAGCAACAGC 16

RESULT 196
AX753822 17 bp DNA linear PAT 23-JUN-2003
LOCUS Sequence 169 from Patent WO03037931.
DEFINITION AX753822
ACCESSION

VERSION AX753822.1 GI:32166519
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 199 08-MAY-2003;
Amerisham Biosciences SV Corp. (US)
location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1253 GCTGCAGCAACAGCTG 1268
DB 2 GCAGCAGCAACAGCAG 17

RESULT 197
AX753823 17 bp DNA linear PAT 23-JUN-2003
LOCUS
DEFINITION Sequence 170 from Patent WO03037931.
AX753823
ACCESSION
VERSION AX753823.1 GI:32166520
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 170 08-MAY-2003;
Amerisham Biosciences SV Corp. (US)
location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1253 GCTGCAGCAACAGCTG 1268
DB 1 GCAGCAGCAACAGCAG 16

RESULT 198
169265/c 18 bp DNA linear PAT 04-FEB-1998
LOCUS
DEFINITION Sequence 535 from patent US 5677149.
169265
ACCESSION
VERSION 169265.1 GI:2831387
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Bauer, S. Christoph, A., Abrams, M. Allen, B., Bradford-Goldberg, S. Ruth, C.,
Caparon, M. Helena, A., Easton, A. Michael, J., Klein, B. R.,
McKearn, J. Patrick, J., Oline, P., Paik, K., Polazzi, J. and
Thomas, J. Warren.
TITLE Interleukin-3 (IL-3) mutant polypeptides and their recombinant

JOURNAL production
Patent: US 5677149-A 535 14-OCT-1997;
location/Qualifiers

FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1337 CAAGCAGAGAGACTTT 1352
DB 17 CATGCAGAGAGATTTT 2

RESULT 199
AR253863 18 bp DNA linear PAT 20-DEC-2002
LOCUS
DEFINITION Sequence 535 from patent US 6479261.
AR253863
ACCESSION
VERSION AR253863.1 GI:27302291
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Bauer, S. C., Abrams, M. A., Bradford-Goldberg, S. R., Caparon, M. H.,
Easton, A. M., Klein, B. K., McKearn, J. P., Oline, P., Paik, K.,
Polazzi, J., and Thomas, J. W.
TITLE Methods of using interleukin-3 (IL-3) mutant polypeptides for
ex-vivo expansion of hematopoietic stem cells
JOURNAL Patent: US 6479261-A 535 12-NOV-2002;
location/Qualifiers

FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1337 CAAGCAGAGAGACTTT 1352
DB 17 CATGCAGAGAGATTTT 2

RESULT 200
AR362907 18 bp DNA linear PAT 03-SEP-2003
LOCUS
DEFINITION Sequence 13 from patent US 5187078.
AR362907
ACCESSION
VERSION AR362907.1 GI:34423447
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Ohya, M., Mizoguchi, J., and Onozawa, T.
TITLE Plasma-type glucathione peroxidase gene and application of the same
JOURNAL Patent: US 5187078-A 13 16-FEB-1993;
location/Qualifiers

FEATURES
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1246 TGATCCGGCTGCAGCA 1261
DB 2 TGGCCCGGCTGCTGCA 17

RESULT 201
AX696918/c
LOCUS AX696918 18 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 535 from Patent EP1283264.
ACCESSION AX696918
VERSION AX696918.1 GI:29420031
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
Bauer, S.C., Abrams, M.A., Braford-Goldberg, S.R., Caparon, M.H.,
Easton, A.M., Klein, B.K., McKearn, J.P., Olins, P.O., Paik, K.,
Polazzi, J.O. and Thomas, J.W.
TITLE
Interleukin-3 (1-3) mutant polypeptides
JOURNAL
Patent: EP 1283264-A 535 12-FEB-2003;
G.D. SEARLE & CO. (US)
FEATURES
source
1..18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1337 CAGGCGAGGAGCTTT 1352
DB 17 CATGGCAGGAGATTTT 2

RESULT 202
AX753423/c
LOCUS AX753423 18 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 11 from Patent WO03037362.
ACCESSION AX753423
VERSION AX753423.1 GI:32166184
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
Steuernagel, A., Bulenberg, K., Broemer, G., Closssek, T., Rudolph, B.,
Rudolph, D., Belgore, F. and Jaekel, S.
TITLE
Mnk kinase homologous proteins involved in the regulation of energy
homeostasis and organelle metabolism
JOURNAL
Patent: WO 03037362-A 11 08-MAY-2003;
Develcoen Aktiengesellschaft fuer entwicklungsbiologische Forschung
(DE)
FEATURES
source
1..18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Mouse Mnk1 Forward Primer"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1280 GGGCAGAGACCTCTCAG 1295
DB 17 GAGCAGAGGCGCTCTCAG 2

RESULT 203
AX785467/c
LOCUS AX785467 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 78 from Patent WO03050301.
ACCESSION AX785467

VERSION AX785467.1 GI:32953087
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
Gurting, H.M.
TITLE
Susceptibility locus for schizophrenia
JOURNAL
Patent: WO 03050301-A 78 19-JUN-2003;
Gurting, Hugh Malcolm Douglas (GB)
FEATURES
source
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1303 TGGTCATCTGTGAGCA 1318
DB 16 TGGTCATCTGTGATCA 1

RESULT 204
BD088350/c
LOCUS BD088350 18 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD088350
VERSION BD088350.1 GI:22633960
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
Soeda, E.
TITLE
A method of arraying genome clone
JOURNAL
Patent: JP 2001321190-A 594 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECs
OS Artificial Sequence
PN JP 2001321190-A/594
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI RIIICHI SOEDA
PC C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/53, G01N33/566, PC
C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence: Synthetic DNA FH Key
Location/Qualifiers
FT source 1..18
Location/Qualifiers
/organism="Artificial Sequence".
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1207 GGGCAGGCACTGTGCA 1222
DB 17 GAGCGGCACTGTGCA 2

RESULT 205
BD088352/c
LOCUS BD088352 18 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.

ACCESSION BD088352
VERSION BD088352.1 GI:22633962
KEYWORDS JP 2001321190-A/596.
SOURCE Synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Soeda, E.
TITLE A method of arraying genome clone
JOURNAL Patent: JP 2001321190-A 596 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECBS
COMMENT OS Artificial Sequence
PN JP 2001321190-A/596
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI EICHI SOEDA
PC C12N15/09, C12N15/00, C12M1/68, G01N33/53, G01N33/566, PC
C12N15/00,
CC C12N15/00
Description of Artificial Sequence: Synthetic DNA FH Key
Location/Qualifiers
1. 18
FT source
FT Location/Qualifiers
1. 18
/organism="Artificial Sequence".
FEATURES
source
1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1207 GGGCAGCCATCTGTCA 1222
DB 17 GAGCGCCATCTGTCA 2
RESULT 206
AB067919/c 18 bp DNA linear SYN 21-MAY-2003
LOCUS Synthetic construct DNA, reverse primer for human STS sts-stsG23084
DEFINITION at 1p36
ACCESSION AB067919
VERSION AB067919.1 GI:15128723
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Chen, Y.Z., Hayashi, Y., Wu, J.G., Takaoka, E., Maekawa, K.,
Watanabe, N., Inazawa, J., Hosoda, F., Arai, Y., Mizushima, H.,
Morohashi, A., Ohira, M., Nakagawara, A., Liu, S., Hoshi, M., Horii, A.
and Soeda, E.
TITLE A BAC-based STS-content map spanning a 35-Mb region of human
JOURNAL Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
Miyagi 980-8575, Japan (E-mail: horii@mail.cc.tohoku.ac.jp,
Tel: 81-22-717-8042, Fax: 81-22-717-8047)
FEATURES
source
1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
misc_feature
1. 18
Location/Qualifiers
1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
misc_feature 1. 18

/note="reverse primer for human STS sts-stsG23084 at 1p36
sts-stsG23084 obtained from clones B313J13, B244M15, Human
BAC library RPT-11"
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1207 GGGCAGCCATCTGTCA 1222
DB 17 GAGCGCCATCTGTCA 2
RESULT 207
AB067921/c 18 bp DNA linear SYN 21-MAY-2003
LOCUS Synthetic construct DNA, reverse primer for human STS sts-AA031909
DEFINITION at 1p36.
ACCESSION AB067921
VERSION AB067921.1 GI:15128725
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Chen, Y.Z., Hayashi, Y., Wu, J.G., Takaoka, E., Maekawa, K.,
Watanabe, N., Inazawa, J., Hosoda, F., Arai, Y., Mizushima, H.,
Morohashi, A., Ohira, M., Nakagawara, A., Liu, S., Hoshi, M., Horii, A.
and Soeda, E.
TITLE A BAC-based STS-content map spanning a 35-Mb region of human
JOURNAL Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
Miyagi 980-8575, Japan (E-mail: horii@mail.cc.tohoku.ac.jp,
Tel: 81-22-717-8042, Fax: 81-22-717-8047)
FEATURES
source
1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
misc_feature
1. 18
/note="reverse primer for human STS sts-AA031909 at 1p36
sts-AA031909 obtained from clones B313J13, B244M15, Human
BAC library RPT-11"
Query Match 5.1%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1207 GGGCAGCCATCTGTCA 1222
DB 17 GAGCGCCATCTGTCA 2
RESULT 208
AR307962/c 20 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 173 from patent US 6551826.
ACCESSION AR307962
VERSION AR307962.1 GI:31698718
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Walt, A.T.
TITLE Antisense modulation of raiid expression

JOURNAL Patent: US 6551826-A 173 22-APR-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 5.1%; Score 12.8; DB 1; Length 20;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1227 CTCGACGATGCTGCG 1242
|||||
18 CTCGACGACATGCTG 3

RESULT 209
LOCUS CQ828856 14 bp DNA linear PAT 05-JUL-2004
DEFINITION Sequence 574 from Patent WO2004053120.
ACCESSION CQ828856
VERSION CQ828856.1 GI:4973239
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Weihe B., Bieller A. and Schaefer M.K.
TITLE Regulatory elements in the 5' region of the vrl gene
JOURNAL Patent: WO 2004053120-A 574 24-JUN-2004;
Gruenthal GmbH (DE)
Location/Qualifiers
source 1..14
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
/note="V\$CEBPP 01"

Query Match 4.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1252 GGCTGCAGCAACAG 1265
|||||
1 GGCTGAGCAACAG 14

RESULT 210
LOCUS A88206 15 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 354 from Patent WO9833904.
ACCESSION A88206
VERSION A88206.1 GI:6736776
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Brysch W. and Schlingensiepen K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 354 06-AUG-1998;
BIOGENOSTIK GES (DE); BRYSCH WOLFGANG (DE)
Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1307 CATCTGTAGAGC 1320
|||||

Db 14 CATCTGTAGAGCTGC 1
|||||

RESULT 211
LOCUS A90173/c 15 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 354 from Patent EP0856579.
ACCESSION A90173
VERSION A90173.1 GI:6738687
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Brysch W.D. and Schlingensiepen K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 354 05-AUG-1998;
BIOGENOSTIK GES (DE)
Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1307 CATCTGTAGAGC 1320
|||||

Db 14 CATCTGTAGAGCTGC 1
|||||

RESULT 212
LOCUS BD065719/c 15 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065719
VERSION BD065719.1 GI:22611322
KEYWORDS JP 2001511000-A/354.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Schlingensiepen K.H. and Brysch W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 354 07-AUG-2001;
BIOGENOSTIK GESELLSCHAFT FUR BIOWOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/354
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
PC C12N15/11.C07H21/04.A61K31/70
CC An antisense oligonucleotide preparation method FH key
Location/Qualifiers
FT source 1..15
/organism="Unknown".
Location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1307 CATCTGTAGAGC 1320
|||||

Db 14 CATCTGTAGAGCTGC 1
|||||

RESULT 213
AX320908 16 bp DNA linear PAT 14-DEC-2001
LOCUS Sequence 29 from Patent WO0179272.
ACCESSION AX320908
VERSION AX320908.1 GI:17902457
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
AUTHORS Tian,H., Schultz,J. and Shan,B.
TITLE Slicesterolemia susceptibility gene (ssg) : compositions and methods
JOURNAL Patent: WO 0179272-A 29 25-OCT-2001;
Tularik Inc. (US)
FEATURES
Location/Qualifiers
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="5' splicing site for exon 6"

Query Match 4.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1237 TGCTGCAGAGTGC 1250
Db 1 TGCTGCAGAGTGC 14

RESULT 214
AR040189 17 bp DNA linear PAT 29-SEP-1999
LOCUS AR040189
DEFINITION Sequence 1037 from patent US 5807743.
ACCESSION AR040189
VERSION AR040189.1 GI:5959552
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 1037 15-SEP-1998;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1285 GAGACCTCAGGCT 1298
Db 1 GAGACCTCAGGCT 14

RESULT 215
AR137298 17 bp DNA linear PAT 16-JUN-2001
LOCUS AR137298
DEFINITION Sequence 45 from patent US 6137505.
ACCESSION AR137298
VERSION AR137298.1 GI:14478807
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Norberg,L.Torbjorn., Andersson,M.Kristina. and
Lindstrom,P.Harry.Rutger.
TITLE Methods for assessing cardiovascular status and compositions for
use thereof
JOURNAL Patent: US 6197505-A 45 06-MAR-2001;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1251 CGGCTGACGACACA 1264
Db 4 CGGCTGACGACACA 17

RESULT 216
AR137304 17 bp DNA linear PAT 16-JUN-2001
LOCUS AR137304
DEFINITION Sequence 51 from patent US 6197505.
ACCESSION AR137304
VERSION AR137304.1 GI:14478813
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Norberg,L.Torbjorn., Andersson,M.Kristina. and
Lindstrom,P.Harry.Rutger.
TITLE Methods for assessing cardiovascular status and compositions for
use thereof
JOURNAL Patent: US 6197505-A 51 06-MAR-2001;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1251 CGGCTGACGACACA 1264
Db 4 CGGCTGACGACACA 17

RESULT 217
BD182368 17 bp DNA linear PAT 15-MAY-2003
LOCUS BD182368/c
DEFINITION Model non-human animals with development disorder of
oligodendroglia.
ACCESSION BD182368
VERSION BD182368.1 GI:30793286
KEYWORDS WO 02091820-A/4.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Takai,T., Aso,H. and Fujiwara,M.
TITLE Model non-human animals with development disorder of
oligodendroglia
JOURNAL Patent: WO 02091820-A 4 21-NOV-2002;
JAPAN SCIENCE AND TECHNOLOGY CORP.,TOSHIYUKI TAKAI,HIROAKI ASO,
MICHIO FUJIWARA
COMMENT OS Artificial Sequence
FN WO 02091820-A/4
PD 21-NOV-2002
PF 02-MAY-2002 WO 2002JP004405
PR 16-MAY-2001 JP 01P 146338

PI TOSHIYUKI TAKAI,HIROAKI ASO,MICHIHIRO FUJIWARA PC A01K67/027
CC Description of Artificial Sequence:P4
FH Location/Qualifiers
FT source 1..17
FT Location/Qualifiers
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1266 CTGGAAGAGGCTGA 1279
Db 14 CTGGCAGAGGCTGA 1

RESULT 218
BD203088 17 bp RNA linear PAT 17-JUL-2003
LOCUS
DEFINITION BD203088 17 bp RNA linear PAT 17-JUL-2003
molecule participating in vasculogenic response.
ACCESSION BD203088.1 GI:33012858
VERSION JP 2002509721-A/6114.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 17)
Pavco, P.A., Roberts, E., Jarvis, T., Coeshott, C. and Mcswigen, J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 6114 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/6114
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P23/00,A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT Location/Qualifiers
/organism='Homo sapiens (human)'.
1..17
location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1222 AGAACCTCCAGCAT 1235
Db 2 AGAATCTCCAGCAT 15

RESULT 219
BD231281

LOCUS BD231281 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Genes for assessing cardiovascular status and compositions for use
thereof.
ACCESSION BD231281
VERSION BD231281.1 GI:33041051
KEYWORDS JP 2002527079-A/45.
SOURCE
ORGANISM
synthetic construct
artificial construct
artificial sequences.
REFERENCE 1 (bases 1 to 17)
Norberg,L.T., Andersson,M.K., Lindstrom,P.H.R. and Jonsson,L.
Genes for assessing cardiovascular status and compositions for use
thereof
Patent: JP 2002527079-A 45 27-AUG-2002;
PAIRSEAKENSINGU AB
JOURNAL
COMMENT
OS Artificial Sequence
PN JP 2002527079-A/45
PD 27-AUG-2002
PF 13-OCT-1999 JP 2000576056
PR 14-OCT-1998 US 60/104286,14-OCT-1998 US 60/104302 PI
LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
RUTGER LINDSTROM,
PI LENA JONSSON
PC C12Q1/68,C12N15/09//G01N33/53,G01N33/566,C12N15/00 CC Genes
for assessing cardiovascular status
and compositions for

Qy 1251 CGGCTGAGCAGACA 1264
Db 4 CGGCGAGCAGACA 17

RESULT 220
BD231287 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION BD231287 17 bp DNA linear PAT 17-JUL-2003
Genes for assessing cardiovascular status and compositions for use
thereof.
ACCESSION BD231287
VERSION BD231287.1 GI:33041057
KEYWORDS JP 2002527079-A/51.
SOURCE
ORGANISM
synthetic construct
artificial construct
artificial sequences.
REFERENCE 1 (bases 1 to 17)
Norberg,L.T., Andersson,M.K., Lindstrom,P.H.R. and Jonsson,L.
Genes for assessing cardiovascular status and compositions for use
thereof
Patent: JP 2002527079-A 51 27-AUG-2002;
PAIRSEAKENSINGU AB
JOURNAL
COMMENT
OS Artificial Sequence
PN JP 2002527079-A/51
PD 27-AUG-2002
PF 13-OCT-1999 JP 2000576056
PR 14-OCT-1998 US 60/104286,14-OCT-1998 US 60/104302 PI
LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
RUTGER LINDSTROM,
PI LENA JONSSON
PC C12Q1/68,C12N15/09//G01N33/53,G01N33/566,C12N15/00 CC Genes
for assessing cardiovascular status
and compositions for

CC use thereof
FH Location/Qualifiers
FT source 1..17
FT /organism='Artificial Sequence'.
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1251 CGGCTGCAGCACCA 1264
DB 4 CGGAGAGAGCACCA 17

RESULT 221
LOCUS BD254595 17 bp DNA linear PAT 17-UTL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254595
VERSION BD254595.1 GI:33064365
KEYWORDS JP 2002541795-A/2388.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blact L., Zwick M., Pavco P. and Mcswiggen J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2388 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/2388
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
FT /organism='Eukaryote'.
FEATURES
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1197 CCTGTGCAGAGGCG 1210
DB 17 CCTTGCAGAGGCG 4

RESULT 222
LOCUS CQ616192 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 932 from Patent WO0192524.
ACCESSION CQ616192
VERSION CQ616192.1 GI:41666410

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu Y., Ji Y., Penn S.G., Hanzel D.K., Rank D.R., Chen W. and
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 932 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1267 TGAAGAGGCTGAG 1280
DB 1 TGAAGAGGCTGAG 14

RESULT 223
LOCUS CQ623568 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8308 from Patent WO0192524.
ACCESSION CQ623568
VERSION CQ623568.1 GI:41673786
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu Y., Ji Y., Penn S.G., Hanzel D.K., Rank D.R., Chen W. and
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8308 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1373 CCAGAGCAGCTGC 1386
DB 17 CCAGAGCAGCTGC 4

RESULT 224
LOCUS CQ623569 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8309 from Patent WO0192524.
ACCESSION CQ623569
VERSION CQ623569.1 GI:41673787
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu Y., Ji Y., Penn S.G., Hanzel D.K., Rank D.R., Chen W. and
TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 8309 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1373 CCAGAAGCAGCTGC 1386
|||||
16 CCAGAAGCAGCTGC 3

RESULT 225
LOCUS C0623570 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8310 from Patent WO0192524.
ACCESSION C0623570
VERSION C0623570.1 GI:41673788
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE
JOURNAL Myosin-like gene expressed in human heart and muscle
Aeomica, Inc. (US)
Patent: WO 0192524-A 8310 06-DEC-2001;

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1373 CCAGAAGCAGCTGC 1386
|||||
15 CCAGAAGCAGCTGC 2

RESULT 226
LOCUS C0623571 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8311 from Patent WO0192524.
ACCESSION C0623571
VERSION C0623571.1 GI:41673789
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE
JOURNAL Myosin-like gene expressed in human heart and muscle
Aeomica, Inc. (US)
Patent: WO 0192524-A 8311 06-DEC-2001;

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;

Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1373 CCAGAAGCAGCTGC 1386
|||||
14 CCAGAAGCAGCTGC 1

RESULT 227
LOCUS C0624036 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8776 from Patent WO0192524.
ACCESSION C0624036
VERSION C0624036.1 GI:41674254
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE
JOURNAL Myosin-like gene expressed in human heart and muscle
Aeomica, Inc. (US)
Patent: WO 0192524-A 8776 06-DEC-2001;

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1304 GGTCTCTGTGACC 1317
|||||
4 GGTCTCTGTGACC 17

RESULT 228
LOCUS C0624037 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8777 from Patent WO0192524.
ACCESSION C0624037
VERSION C0624037.1 GI:41674255
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE
JOURNAL Myosin-like gene expressed in human heart and muscle
Aeomica, Inc. (US)
Patent: WO 0192524-A 8777 06-DEC-2001;

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1304 GGTCTCTGTGACC 1317
|||||
3 GGTCTCTGTGACC 16

RESULT 229

CO624038 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO624038
DEFINITION Sequence 8778 from Patent WO0192524.
ACCESSION CO624038
VERSION CO624038.1 GI:41674256
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS 1
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8778 06-DEC-2001;
Aecomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1304 GGTCTCTGTGTGAC 1317
|||||
Db 2 GGTCTCTGTGTGACC 15
|||||
RESULT 230
CO624039 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO624039
DEFINITION Sequence 8779 from Patent WO0192524.
ACCESSION CO624039
VERSION CO624039.1 GI:41674257
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS 1
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8779 06-DEC-2001;
Aecomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1304 GGTCTCTGTGTGAC 1317
|||||
Db 1 GGTCTCTGTGTGACC 14
|||||
RESULT 231
AR188354 17 bp DNA linear PAT 20-APR-2002
LOCUS AR188354
DEFINITION Sequence 3842 from patent US 6346398.
ACCESSION AR188354
VERSION AR188354.1 GI:20234319
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
Patent: US 6346398-A 3842 12-FEB-2002;
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1302 ATGCTCTCTGTGA 1315
|||||
Db 1 ATGCTCTCTGTGA 14
|||||
RESULT 232
AR195710 17 bp DNA linear PAT 20-APR-2002
LOCUS AR195710
DEFINITION Sequence 175 from patent US 6350934.
ACCESSION AR195710
VERSION AR195710.1 GI:20245147
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P. Ann.Owens.,
Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE Nucleic acid encoding delta-9 desaturase
JOURNAL Patent: US 6350934-A 175 26-FEB-2002;
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1263 CAGCTGAGAGGC 1276
|||||
Db 15 CAGCTGAGATGAGC 2
|||||
RESULT 233
AR324207 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR324207
DEFINITION Sequence 1609 from patent US 6566127.
ACCESSION AR324207
VERSION AR324207.1 GI:33710015
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
Patent: US 6566127-A 1609 20-MAY-2003;
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1302 ATGCTCTCTGTGA 1315
|||||

Db 1 ATGCTCTCTGTGA 14

RESULT 234
LOCUS AR435294 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1717 from patent US 6656700.
ACCESSION AR435294
VERSION AR435294.1 GI:40198137
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 1717 02-DEC-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGG 1269
Db 17 GCAGCAACACTGG 4

RESULT 235
LOCUS AR435295 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1718 from patent US 6656700.
ACCESSION AR435295
VERSION AR435295.1 GI:40198138
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 1718 02-DEC-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGG 1269
Db 16 GCAGCAACACTGG 3

RESULT 236
LOCUS AR435296 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1719 from patent US 6656700.
ACCESSION AR435296
VERSION AR435296.1 GI:40198139
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E

JOURNAL Patent: US 6656700-A 1719 02-DEC-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGG 1269
Db 15 GCAGCAACACTGG 2

RESULT 237
LOCUS AR435297 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1720 from patent US 6656700.
ACCESSION AR435297
VERSION AR435297.1 GI:40198140
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 1720 02-DEC-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGG 1269
Db 14 GCAGCAACACTGG 1

RESULT 238
LOCUS AR457255 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 932 from patent US 6686188.
ACCESSION AR457255
VERSION AR457255.1 GI:42692312
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W., and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 932 03-FEB-2004;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1267 TGAAGAGGCTGAG 1280
Db 1 TGAAGAGGCTGAG 14

RESULT 239
AR464631/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464631
DEFINITION Sequence 8308 from patent US 6686188.
ACCESSION AR464631
VERSION AR464631.1 GI:42699688
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8308 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1373 CCAGAGCAGCTGC 1386
|||||
Db 17 CCAGAGGAGCTGC 4
RESULT 240
AR464632/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464632
DEFINITION Sequence 8309 from patent US 6686188.
ACCESSION AR464632
VERSION AR464632.1 GI:42699689
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8309 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1373 CCAGAGCAGCTGC 1386
|||||
Db 16 CCAGAGGAGCTGC 3
RESULT 241
AR464633/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464633
DEFINITION Sequence 8310 from patent US 6686188.
ACCESSION AR464633
VERSION AR464633.1 GI:42699690
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8310 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1373 CCAGAGCAGCTGC 1386
|||||
Db 15 CCAGAGGAGCTGC 2
RESULT 242
AR464634/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464634
DEFINITION Sequence 8311 from patent US 6686188.
ACCESSION AR464634
VERSION AR464634.1 GI:42699691
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8311 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1373 CCAGAGCAGCTGC 1386
|||||
Db 14 CCAGAGGAGCTGC 1
RESULT 243
AR465099 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR465099
DEFINITION Sequence 8776 from patent US 6686188.
ACCESSION AR465099
VERSION AR465099.1 GI:42700156
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8776 03-FEB-2004;
FEATURES
LOCATION/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1304 GGTGATCTGTGAGC 1317

Db 4 GGTCATCTGTGACC 17

RESULT 244

LOCUS	AR465100	17 bp	DNA	linear	PAT 20-FEB-2004
DEFINITION	Sequence 8777 from patent US 6686188.				
ACCESSION	AR465100				
VERSION	AR465100.1	GI:42700157			
KEYWORDS	Unknown.				
SOURCE					

ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17) Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 8-777 03-FEB-2004;
FEATURES	Location/Qualifiers
SOURCE	1..17

Query Match	4.9%;	Score 12.4;	DB 1;	Length 17;
Best Local Similarity	92.9%;	Pred. No. 1.8e+02;		
Matches 13; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

OY	1304	GGTCATCTGTGAGC	1317	
Db	3	GGTCATCTGTGAGC	16	
RESULT 245				
AR465101				
LOCUS	AR465101	17 bp	DNA	linear
DEFINITION	Sequence 8778 from patent US 6686188.			PAT 20-FEB-2004
ACCESSION	AR465101			
VERSION	AR465101.1	GI:42700158		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	Unclassified.			
AUTHORS	1 (bases 1 to 17)			
	Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and			
	Shannon,M.E.			
TITLE	Poly-nucleotide encoding a human myosin-like polypeptide expressed			
JOURNAL	predominantly in heart and muscle			
FEATURES	Patent: US 6686188-A 8778 03-FEB-2004;			
source	Location/Qualifiers			
	1..17			

```

/organism="unknown"
/mol_type="genomic DNA"

```

Query Match	4.9%	Score 12.4	DB 1	Length 17
Best Local Similarity	92.9%	Pred. No. 1.8e+02		
Matches 13; Conservative	0	Mismatches 1	Indels 0	Gaps 0

REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17)
TITLE	Gu, Y., Uj, Y., Penn, S. G., Hanzel, D. K., Rank, D. R., Chen, W. and Shannon, M. E., Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL	Patent: US 6686188-A 8779 03-FEB-2004;
FEATURES	location/Qualifiers
source	1..17

Query Match	4.9%	Score	12.4	DB	1	length	17
Best local similarity	92.9%	Pred.	No. 1.8e+02				
Matches	13	Conservative	0	Mismatches	1	Indels	0
QY	1304	GGTCATCTGTAGC	1317				
DB	1	GGTCATCTGTAGC	14				

RESULT	247		
AX037420			
LOCUS	AX037420	17 bp	DNA
DEFINITION	Sequence	45 from Patent WO056922.	linear
ACCESSION	AX037420		
VERSION	AX037420.1	GI:11226845	
KEYWORDS			
SOURCE			
ORGANISM	synthetic construct		
	synthetic construct		
	artificial sequences.		

REFERENCE	AUTHORS	TITLE	JOURNAL	FEATURES
1	Norberg,L.T., Olaiasson,E., Jonsson,L., Lindstrom,P.H. and Sanders,R.	Genetic polymorphism and polymorphic pattern for assessing disease status, and compositions for use thereof	Patent: WO 0056922-A 45 28-SEP-2000; NORBERG LEIF TORBJORN (SE) ; OLAISSON ERIK (SE) ; JONSSON LENA (SE) ; GEMINI GENOMICS AB (SE) ; LINDSTROM PER HARRY RUTGER (SE) ; SANDERS RHIANON (SE)	location/Qualifiers 1..17 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="Oligonucleotide primer"

	RESULT	248		
AX037426	LOCUS	AX037426	17 bp	DNA
	DEFINITION	Sequence 51 from Patent WO0056922.		linear
	ACCESSION	AX037426		PAT 16-NOV-2000
	VERSION	AX037426.1		
	KEYWORDS	GI:1126851		
SOURCE		.		
ORGANISM		synthetic construct		
		synthetic construct		
		artificial sequences.		

```
; GEMINI GENOMICS AB (SE) ; LINDSTROM PER HARRY RUTGER (SE) ;
SANDERS RHANNON (SE)
FEATURES
    source          Location/Qualifiers
1..17
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Oligonucleotide primer"
Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1251 CGGCGTGCAGACA 1264
Db      4 CGGCGAGACACACA 17

RESULT 249
AX672037          17 bp DNA linear PAT 27-MAR-2003
DEFINITION      Sequence 482 from Patent WO03004526.
ACCESSION      AX672037
VERSION        AX672037.1 GI:29330385
KEYWORDS
SOURCE
    ORGANISM      Homo sapiens (human)
REFERENCE
    AUTHORS      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    TITLE        Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
    JOURNAL      Telerman, A., Amson, R. and Tuijinder, M.
    SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR
    REVERSION, APOPTOSIS AND/OR RESISTANCE TO VIRUSES AND THEIR USE AS
    MEDICINES
    PATENT: WO 03004526-A 482 16-JAN-2003;
    MOLECULAR ENGINEERS LABORATORIES (FR)
    LOCATION/QUALIFIERS
1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
FEATURES
    source
Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1292 TCAGGTCGCATGG 1305
Db      3 TCAGAGTGCATCG 16

RESULT 250
AX674680          17 bp DNA linear PAT 27-MAR-2003
LOCUS          AX674680
DEFINITION      Sequence 3125 from Patent WO03004526.
ACCESSION      AX674680
VERSION        AX674680.1 GI:29333028
KEYWORDS
SOURCE
    ORGANISM      Homo sapiens (human)
REFERENCE
    AUTHORS      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    TITLE        Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
    JOURNAL      Telerman, A., Amson, R. and Tuijinder, M.
    SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR
    REVERSION, APOPTOSIS AND/OR RESISTANCE TO VIRUSES AND THEIR USE AS
    MEDICINES
    PATENT: WO 03004526-A 3125 16-JAN-2003;
    MOLECULAR ENGINEERS LABORATORIES (FR)
    LOCATION/QUALIFIERS
1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
FEATURES
    source
```

```
/db_xref="taxon:9606"
Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1366 AGGCTTACCAGAG 1379
Db      17 ATGCTTACCAGAG 4

RESULT 251
AX693513          17 bp DNA linear PAT 31-MAR-2003
LOCUS          AX693513
DEFINITION      Sequence 6245 from Patent EP1281758.
ACCESSION      AX693513
VERSION        AX693513.1 GI:29416478
KEYWORDS
SOURCE
    ORGANISM      Homo sapiens (human)
REFERENCE
    AUTHORS      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    TITLE        Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
    JOURNAL      Shannon, M., Gu, Y. and Nguyen, C.T.
    SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR
    REVERSION, APOPTOSIS AND/OR RESISTANCE TO VIRUSES AND THEIR USE AS
    MEDICINES
    PATENT: EP 1281758-A 6245 05-FEB-2003;
    NEOMICA, INC. (US)
    LOCATION/QUALIFIERS
1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
FEATURES
    source
Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1279 AGGGAGAGACCT 1292
Db      4 AGGGAGAGACCT 17

RESULT 252
AX693514          17 bp DNA linear PAT 31-MAR-2003
LOCUS          AX693514
DEFINITION      Sequence 6246 from Patent EP1281758.
ACCESSION      AX693514
VERSION        AX693514.1 GI:29416479
KEYWORDS
SOURCE
    ORGANISM      Homo sapiens (human)
REFERENCE
    AUTHORS      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    TITLE        Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
    JOURNAL      Shannon, M., Gu, Y. and Nguyen, C.T.
    SEQUENCES INVOLVED IN PHENOMENA OF TUMOUR SUPPRESSION, TUMOUR
    REVERSION, APOPTOSIS AND/OR RESISTANCE TO VIRUSES AND THEIR USE AS
    MEDICINES
    PATENT: EP 1281758-A 6246 05-FEB-2003;
    NEOMICA, INC. (US)
    LOCATION/QUALIFIERS
1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
FEATURES
    source
Query Match          4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1279 AGGGAGAGACCT 1292
Db      3 AGGGAGAGACCT 16
```

RESULT 253
AX693515
LOCUS AX693515 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6247 from Patent EP1281758.
ACCESSION AX693515
VERSION AX693515.1 GI:29416480
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6247 05-FEB-2003;
Aecomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1279 AGGCGAGAGACCCT 1292
|||||
|||||
Db 2 AGGCGAGAGACCCT 15

RESULT 254
AX693516
LOCUS AX693516 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6248 from Patent EP1281758.
ACCESSION AX693516
VERSION AX693516.1 GI:29416481
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6248 05-FEB-2003;
Aecomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1279 AGGCGAGAGACCCT 1292
|||||
|||||
Db 1 AGGCGAGAGACCCT 14

RESULT 255
AX729667
LOCUS AX729667 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1301 from Patent WO03025175.
ACCESSION AX729667
VERSION AX729667.1 GI:30509010
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 1301 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1292 TCAGGTCGCATGG 1305
|||||
|||||
Db 3 TCAGAGTCGCATGG 16

RESULT 256
AX730510
LOCUS AX730510 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2144 from Patent WO03025175.
ACCESSION AX730510
VERSION AX730510.1 GI:30509853
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 2144 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1266 CTGGAAGAGGCTGA 1279
|||||
|||||
Db 16 CTGGAAGAGGCGGA 3

RESULT 257
AX733782
LOCUS AX733782 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5416 from Patent WO03025175.
ACCESSION AX733782
VERSION AX733782.1 GI:30513125
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as medicines
Patent: WO 03025175-A 5416 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1264 AGCTGAAGAGGCT 1277
Db 2 ATCTGAAGAGGCT 15

RESULT 258
AX760576/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 3897 from Patent WO03040369.
DEFINITION AX760576
ACCESSION AX760576
VERSION AX760576.1 GI:32255192
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuljander, M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
Patent: WO 03040369-A 3897 15-MAY-2003;
JOURNAL Molecular Engines Laboratories (FR)

FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1257 CAGCAACAGCTGA 1270
Db 16 CAGTAACAGCTGA 3

RESULT 259
AX762564 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 5885 from Patent WO03040369.
DEFINITION AX762564
ACCESSION AX762564
VERSION AX762564.1 GI:32257180
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuljander, M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
Patent: WO 03040369-A 5885 15-MAY-2003;
JOURNAL Molecular Engines Laboratories (FR)

FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1264 AGCTGAAGAGGCT 1277
Db 2 ATCTGAAGAGGCT 15

RESULT 260
AX782079 17 bp DNA linear PAT 17-JUL-2003
LOCUS Sequence 410 from Patent WO03050284.
DEFINITION AX782079
ACCESSION AX782079
VERSION AX782079.1 GI:32949928
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1
Guo, J.
Human prostate cancer candidate protein 1
Patent: WO 03050284-A 410 19-JUN-2003;
JOURNAL Amersham Biosciences (SV) Corp. (US)

FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1318 AGCTAGGGGACCTC 1331
Db 4 AGCAAGGGGACCTC 17

RESULT 261
AX782080 17 bp DNA linear PAT 17-JUL-2003
LOCUS Sequence 411 from Patent WO03050284.
DEFINITION AX782080
ACCESSION AX782080
VERSION AX782080.1 GI:32949929
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1
Guo, J.
Human prostate cancer candidate protein 1
Patent: WO 03050284-A 411 19-JUN-2003;
JOURNAL Amersham Biosciences (SV) Corp. (US)

FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1318 AGCTAGGGGACCTC 1331
Db 3 AGCAAGGGGACCTC 16

RESULT 262
AX782081 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX782081
DEFINITION Sequence 412 from Patent WO03050284.
ACCESSION AX782081
VERSION AX782081.1 GI:32949930
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 412 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
LOCATION/Qualifiers
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1318 AGCTAGGGGACCTC 1331
Db 2 AGCAAGGGGACCTC 15
RESULT 263
AX782082 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX782082
DEFINITION Sequence 413 from Patent WO03050284.
ACCESSION AX782082
VERSION AX782082.1 GI:32949931
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 413 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
LOCATION/Qualifiers
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1318 AGCTAGGGGACCTC 1331
Db 1 AGCAAGGGGACCTC 14
RESULT 264
BD075172 17 bp DNA linear PAT 27-AUG-2002
LOCUS BD075172
DEFINITION Methods for assessing cardiovascular status and compositions for
use thereof.
ACCESSION BD075172
VERSION BD075172.1 GI:22620775
KEYWORDS JP 2001519660-A/45.
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE
AUTHORS Norberg,L.T., Andersson,M.K. and Lindstrom,P.H.R.
TITLE Methods for assessing cardiovascular status and compositions for
use thereof
JOURNAL Patent: JP 2001519660-A 45 23-OCT-2001;
EURONA MEDICAL AB
COMMENT OS Artificial Sequence
PN JP 2001519660-A/45
PD 23-OCT-2001
PF 01-APR-1998 JP 1998542530
PR 04-APR-1997 US 60/042930
PI LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
RUTGER LINDSTROM
PC C1201/68,C07K14/72,C07K14/575,C12N9/48
CC Description of Artificial Sequence: PCR PRIMER FH Key
LOCATION/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 4.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1251 CGGCTGCAGCAACA 1264
Db 4 CGGCAGCAGCAACA 17
RESULT 265
BD075178 17 bp DNA linear PAT 27-AUG-2002
LOCUS BD075178
DEFINITION Methods for assessing cardiovascular status and compositions for
use thereof.
ACCESSION BD075178
VERSION BD075178.1 GI:22620781
KEYWORDS JP 2001519660-A/51.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
AUTHORS Norberg,L.T., Andersson,M.K. and Lindstrom,P.H.R.
TITLE Methods for assessing cardiovascular status and compositions for
use thereof
JOURNAL Patent: JP 2001519660-A 51 23-OCT-2001;
EURONA MEDICAL AB
COMMENT OS Artificial Sequence
PN JP 2001519660-A/51
PD 23-OCT-2001
PF 01-APR-1998 JP 1998542530
PR 04-APR-1997 US 60/042930
PI LEIF TORBJORN NORBERG,MARIA KRISTINA ANDERSSON,PER HARRY PI
RUTGER LINDSTROM
PC C1201/68,C07K14/72,C07K14/575,C12N9/48
CC Description of Artificial Sequence: PCR PRIMER FH Key
LOCATION/Qualifiers
FT source 1..17
/organism='Artificial Sequence'.
FEATURES
source 1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

QY 1251 CCGCTGCAGCAACA 1264
|||||
DB 4 CCGCAGCAGCAACA 17

RESULT 266
LOCUS CQ623908/C 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8648 from Patent WO0192524.
ACCESSION CQ623908
VERSION CQ623908.1 GI:41674126
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8648 06-DEC-2001.
Aeonica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1249 TCCGGCTGCAGCAACAG 1265
|||||
DB 17 TCCAGCTGCAGCTGCAG 1

RESULT 267
LOCUS AR464971/C 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8648 from patent US 6686188.
ACCESSION AR464971
VERSION AR464971.1 GI:42700028
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8648 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1249 TCCGGCTGCAGCAACAG 1265
|||||
DB 17 TCCAGCTGCAGCTGCAG 1

RESULT 268
LOCUS AR039745/C 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 593 from patent US 5807743.
ACCESSION AR039745
VERSION AR039745.1 GI:5959108

KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
JOURNAL Interleukin-2 receptor gamma-chain ribozymes
Patent: US 5807743-A 593 15-SEP-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1369 CTTACGACAGCAGCTG 1385
|||||
DB 17 CTCAGCAGCAGCAGCTG 1

RESULT 269
LOCUS BD204817/C 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Novel human chromosome 16 genes, compositions, methods of making
and using same.
ACCESSION BD204817
VERSION BD204817.1 GI:33014587
KEYWORDS JP 2002514903-A/48.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS Landes,G.W., Burn,T.C., Connors,T.D., Dackowski,W.R., Raay,T.J.V.
and Klinger,K.W.
TITLE Novel human chromosome 16 genes, compositions, methods of making
and using same
JOURNAL Patent: JP 2002514903-A 48 21-MAY-2002;
COMMENT GENZYME CORP
OS Synthetic construct
PN JP 2002514903-A/48
PD 21-MAY-2002
PF 16-JAN-1997 JP 1998502904
PR 17-JUN-1996 US 08/665259, 01-OCT-1996 US 08/720614 PR
09-DEC-1996 US 08/762500
PI GREGORY W LANDES,TIMOTHY C BURN,TIMOTHY D CONNORS,WILLIAM R
PI DACKOWSKI,
PI TERENCE J VAN RAAI,KATHERINE W KLINGER
PC C12N15/12,C12N15/85,C07K14/47,C07K14/475,C07K16/18,A01K67/027
CC Oligonucleotide Primer - Sense Strand
FH Key
FT source Location/Qualifiers
1..17
/organism="Synthetic construct".

FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1243 CAGTGTCCGGCTGCAG 1259
|||||
DB 17 CTGTGTCTGCTGCAG 1

RESULT 270
LOCUS BD241619/C 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Methods and products related to genotyping and DNA analysis.

ACCESSION BD241619
VERSION BD241619.1 GI:33051389
KEYWORDS JP 2002525127-A/566.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J.E., Jordan,B., Housman,D.E. and Charost,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 566 13-AUG-2002;
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT OS Homo sapiens (human)
PN JP 2002525127-A/566
PD 13-AUG-2002
PF 24-SEP-1999 JP 2000572407
PR 25-SEP-1998 US 60/101757
PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
C12N15/09, C12Q1/68, G01N33/53, G01N33/566, G01N33/58, G01N37/00, PC
G01N37/00,
PC C12N15/00
CC Methods and products related to genotyping and DNA analysis FH
Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1377 AAGCAGCTGCGCTTTGC 1393
| | | | | | | | | | | | | | | | | | | |
DB 17 ATGCAGCTGCATCTTGC 1

RESULT 271
BD254092 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254092
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254092
VERSION BD254092.1 GI:33063862
KEYWORDS JP 2002541795-A/1885.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 17)
REFERENCE Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
TITLE Patent: JP 2002541795-A 1885 10-DEC-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/1885
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.

FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1345 GAGACTTCCAGGCA 1361
| | | | | | | | | | | | | | | | | | | |
DB 1 GGGCCTGTCAGGCA 17

RESULT 273
CG616720/c 17 bp DNA linear PAT 02-FEB-2004
LOCUS CG616720
DEFINITION Sequence 1460 from Patent WO0192524.
ACCESSION CG616720
VERSION CG616720.1 GI:41666938
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1345 GAGACTTCCAGGCA 1361
| | | | | | | | | | | | | | | | | | | |
DB 1 GGGCCTGTCAGGCA 17

RESULT 273
CG616720/c 17 bp DNA linear PAT 02-FEB-2004
LOCUS CG616720
DEFINITION Sequence 1460 from Patent WO0192524.
ACCESSION CG616720
VERSION CG616720.1 GI:41666938
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS 1 Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1460 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1369 CTTACGAGAGAGCTG 1385
Db 17 CTTCCGAGAGCTGCTG 1

RESULT 274
LOCUS CQ617219 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1959 from Patent WO0192524.
ACCESSION CQ617219
VERSION CQ617219.1 GI:41667437
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1959 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1376 GAGGAGCTGCTTTG 1392
Db 17 GCAGGAGCTGAGCTTTG 1

RESULT 275
LOCUS CQ617848 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2588 from Patent WO0192524.
ACCESSION CQ617848
VERSION CQ617848.1 GI:4168066
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2588 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1.17

REFERENCE Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS 1 Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1460 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1288 ACCCTGAGGAGGATG 1304
Db 1 AGCTCCAGAGGATG 17

RESULT 276
LOCUS CQ622785 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7525 from Patent WO0192524.
ACCESSION CQ622785
VERSION CQ622785.1 GI:41673003
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7525 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGAGCAACAGCTG 1269
Db 1 GCTGAGCAACAGCTG 17

RESULT 277
LOCUS CQ623055 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7795 from Patent WO0192524.
ACCESSION CQ623055
VERSION CQ623055.1 GI:41673273
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7795 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1250 CCGCTGAGCAACAGC 1266

Db 1 CCAGCTCAGCAGCAGC 17

RESULT 278
LOCUS CQ623056 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7796 from Patent WO0192524.
ACCESSION CQ623056
VERSION CQ623056.1 GI:41673274
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7796 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1251 CGGCTGCAGCAGCAGCT 1267
Db 1 CAGCTTCAGCAGCAGCT 17

RESULT 279
LOCUS CQ623059 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7799 from Patent WO0192524.
ACCESSION CQ623059
VERSION CQ623059.1 GI:41673277
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7799 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGCAGCAGCAGCTGGA 1270
Db 1 CTTGACGACGAGCTGGA 17

RESULT 280
LOCUS CQ623100 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7840 from Patent WO0192524.
ACCESSION CQ623100

VERSION CQ623100.1 GI:41673318
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7840 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAGCAGCTGG 1269
Db 1 GCTGAAGCAGCAGCTGG 17

RESULT 281
LOCUS CQ623101 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7841 from Patent WO0192524.
ACCESSION CQ623101
VERSION CQ623101.1 GI:41673319
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7841 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGCAGCAGCAGCTGGA 1270
Db 1 CTGAAGCAGCAGCTGGA 17

RESULT 282
LOCUS CQ623180 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7920 from Patent WO0192524.
ACCESSION CQ623180
VERSION CQ623180.1 GI:41673398
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7920 06-DEC-2001;
Aeomica, Inc. (US)

Query Match	4.8%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%	Pred. No. 2e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0

RESULT 283			
C0623693/c			
LOCUS	C0623693	17 bp	DNA
DEFINITION	Sequence 8433 from Patent WO0192524.		linear
			PAT 03-FEB-2004

REFERENCE	AUTHORS	TITLE	JOURNAL
1	Gu, Y., Ji, Y., Penn, S. G., Hanzel, D. K., Rank, D. R., Chen, W. and Shannon, M. E.	Myosin-like gene expressed in human heart and muscle	Patent: WO 0192524-A 8433 06-DEC-2001; Aeomica, Inc. (US)

Query Match	4.8%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%	Pred. No. 2e+02;		
Matches 14;	Conservative	0;	Mismatches 3;	Indels 0;
				Gaps 0;
OY	1305	GTGATCTGTGAGCACT	1321	
Db	17	GTCCGCTGTGAGCACT	1	

Query Match	4.8%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 2e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

[illegible]

```

REFERENCE
AUTHORS      1.
              Gu, Y., Ji, Y., Penn, S. G., Hanzel, D. K., Rank, D. R., Chen, W. and
              Shannon, M. E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0132524-A 8504 06-DEC-2001;
              Aeonics, Inc. (US)
FEATURES
source        1.17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

```

Query Match	8.4%;	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 2e+02;		
Matches 1;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
QY	1392	GCTGACGCTGCTGCAGCAG	1408	
Db	1	GATGACAGCGTGTACAG	17	

REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 8506 06-DEC-2001;
FEATURES	Acemica, Inc. (US)
source	Location/Qualifiers 1..17

Query Match	4.8%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 2e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

REFERENCE	1
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.B.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 019252-A 843 06-DDC-2001; Aecomica, Inc. (US)
FEATURES	location/Qualifiers
SOURCE	1..11
	1..organism="Homo sapiens"
	1..mol_type="unassigned DNA"
	/db_xref="taxon:9606"

```

Query Match      4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1394 TGAGCTGCTGGACAGAC 1410
      ||||| ||||| |||||
Db      1 TGAGCAGCTGTACAGGC 17

```

RESULT 287
LOCUS CQ623910 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8650 from Patent WO0192524.
ACCESSION CQ623910
VERSION CQ623910.1 GI:41674128
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8650 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGAAG 1272
|||||
Db 1 GCAGCTGCAGCTGGAAG 17

RESULT 288
LOCUS CQ623911 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8651 from Patent WO0192524.
ACCESSION CQ623911
VERSION CQ623911.1 GI:41674129
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8651 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1257 CAGCAACAGCTGGAAGA 1273
|||||
Db 1 CAGCTGCAGCTGGAAGA 17

RESULT 289
LOCUS CQ624491 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9231 from Patent WO0192524.
ACCESSION CQ624491
VERSION CQ624491.1 GI:41674709
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9231 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 CAGAGGCGAGCCATCTG 1219
|||||
Db 1 CAGAGGCGAGCCTGCAG 17

RESULT 290
LOCUS CQ624492 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9232 from Patent WO0192524.
ACCESSION CQ624492
VERSION CQ624492.1 GI:41674710
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9232 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1204 AGAGGCGAGCCATCTGT 1220
|||||
Db 1 AGAGGCGAGCCTGCAGT 17

RESULT 291
LOCUS CQ624493 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9233 from Patent WO0192524.
ACCESSION CQ624493
VERSION CQ624493.1 GI:41674711
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9233 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers

source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1205 GAGGGCAGCCATCTCTC 1221
|||||
Db 1 GAGGGCAGCCATCTCTC 17

RESULT 292
LOCUS CO624803 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9543 from Patent WO0192524.
ACCESSION CO624803
VERSION CO624803.1 GI:41675021
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.B.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9543 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1192 AGAAGCTGTGCGAGAG 1208
|||||
Db 17 AGAAGCTGTGCGAGAG 1

RESULT 293
LOCUS E02988 17 bp DNA linear PAT 29-SEP-1997
DEFINITION DNA encoding DNA primer for typing DR antigen of human leukocyte
antigen.
ACCESSION E02988
VERSION E02988.1 GI:2171210
KEYWORDS JP 1991164180-A/5.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE
1 (bases 1 to 17)
AUTHORS Kaashiwagi, N., Obata, B. and Abe, A.
TITLE NEW DNA BASE SEQUENCE AND USE THEREOF
JOURNAL Patent: JP 1991164180-A 5 16-JUL-1991;
KASHIWAGI NOBORU, KITASATO INST:THE
OS Artificial gene
OC Artificial sequence; Genes.
PN JP 1991164180-A/5
PD 16-JUL-1991
PR 07-AUG-1990 JP 1990208901
PR 10-AUG-1989 JP 89P 207153
PI KASHIWAGI NOBORU, OBATA BUNYA, ABE AKIO
PC C12N15/12, C12N15/11, C12Q1/68;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;

CC anti-sense: No;
CC *source: clone=PPRS;
FH Key Location/Qualifiers
FH misc_feature 1..17
FT /note="DNA primer for typing DR antigen of FT
FT leukocyte
FT antigen
FT /note="PPRS".
FEATURES
source location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1389 TTGCTGAGCTGCTGGA 1405
|||||
Db 1 TCTGCAGAGCTCTGGA 17

RESULT 294
LOCUS AR327653 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5055 from patent US 6566127.
ACCESSION AR327653
VERSION AR327653.1 GI:33713461
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
PATENT: US 6566127-A 5055 20-MAY-2003;
FEATURES
source location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1376 GAAGCAGCTGCTTTTG 1392
|||||
Db 1 GAGCCAGCTGCTTTTG 17

RESULT 295
LOCUS AR329054 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6456 from patent US 6566127.
ACCESSION AR329054
VERSION AR329054.1 GI:33714862
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
PATENT: US 6566127-A 6456 20-MAY-2003;
FEATURES
source location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGGCGACAG 1287
|||||
17 AGAGCTGTGGCCAAAG 1

Db

RESULT 296
AR329382/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6784 from patent US 6566127.
ACCESSION AR329382
VERSION AR329382.1 GI:33715190
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Unclassified.
TITLES
JOURNAL Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
FEATURES
source 1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1228 TCCAGCATGCTGCTGCA 1244
|||||
17 TCCAGCATGCTGCTGTA 1

Db

RESULT 297
AR402088 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 428 from patent US 6623962.
ACCESSION AR402088
VERSION AR402088.1 GI:40149538
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Feil,P. and McSwigen,J.A.
TITLES Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 428 23-SEP-2003;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1325 GGACCTCTTCTCCAAAG 1341
|||||
1 GGACTTCTTCCCAAG 17

Db

RESULT 298
AR457783/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1460 from patent US 6686188.
ACCESSION AR457783
VERSION AR457783.1 GI:42692840

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Unclassified.
TITLES
JOURNAL Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1369 CTTACGAGAGCAGCTG 1385
|||||
17 CTTCCAGAGAGCTGCTG 1

Db

RESULT 299
AR458282/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1959 from patent US 6666188.
ACCESSION AR458282
VERSION AR458282.1 GI:42693339
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLES Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1959 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1376 GAGCAGCTGCGTTTG 1392
|||||
17 GCAGCAGCTGAGCTTTG 1

Db

RESULT 300
AR458911 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2588 from patent US 6686188.
ACCESSION AR458911
VERSION AR458911.1 GI:42693968
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLES Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2588 03-FEB-2004;
FEATURES
source 1. .17
/organism="unknown"

/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1288 ACCCTCAGGTCGCATG 1304
| | | | | | | | | | | | | | | | | |
1 ACCTCCAGGCTCCATG 17

Db

RESULT 301

AR463848 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR463848
DEFINITION Sequence 7525 from patent US 6686188.
ACCESSION AR463848
VERSION AR463848.1 GI:42698905
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7525 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1253 GCTGCAGCAACAGCTGG 1269
| | | | | | | | | | | | | | | | | |
1 GCTGCAGCAACAGCTTG 17

Db

RESULT 302

AR464118 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464118
DEFINITION Sequence 7795 from patent US 6686188.
ACCESSION AR464118
VERSION AR464118.1 GI:42699175
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7795 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1250 CCGGCTGCAGCAACAGC 1266
| | | | | | | | | | | | | | | | | |
1 CCAGCTTCAGCAGCAGC 17

Db

RESULT 303

AR464119

LOCUS AR464119 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7796 from patent US 6686188.
ACCESSION AR464119
VERSION AR464119.1 GI:42699176
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7796 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1251 CCGGCTGCAGCAACAGCT 1267
| | | | | | | | | | | | | | | | | |
1 CAGCTTCAGCAGCAGCT 17

Db

RESULT 304

AR464122 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464122
DEFINITION Sequence 7799 from patent US 6686188.
ACCESSION AR464122
VERSION AR464122.1 GI:42699179
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7799 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1254 CTGCAGCAACAGCTGGA 1270
| | | | | | | | | | | | | | | | | |
1 CTTGACGACGAGCTGAA 17

Db

RESULT 305

AR464163 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464163
DEFINITION Sequence 7840 from patent US 6686188.
ACCESSION AR464163
VERSION AR464163.1 GI:42699220
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle

JOURNAL Patent: US 6686188-A 7840 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCGACGACGCTGG 1269
DB 1 GCTGAAGCAGCAGCTGG 17
|||||
|||||

RESULT 306
AR464164 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464164
DEFINITION Sequence 7841 from patent US 6686188.
ACCESSION AR464164
VERSION AR464164.1 GI:42699221
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
POLYNUCLEOTIDE encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7841 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGCGACGACGCTGGA 1270
DB 1 CTGAAGCAGCAGCTGGA 17
|||||
|||||

RESULT 307
AR464243 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464243
DEFINITION Sequence 7920 from patent US 6686188.
ACCESSION AR464243
VERSION AR464243.1 GI:42699300
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
POLYNUCLEOTIDE encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7920 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1328 CCTCTTCTCAAGGCAG 1344
DB 17 CCTCTCTTCAAGCCAG 1
|||||
|||||

RESULT 308
AR464756/c 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464756/c
DEFINITION Sequence 8433 from patent US 6686188.
ACCESSION AR464756
VERSION AR464756.1 GI:42699813
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
POLYNUCLEOTIDE encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8433 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1305 GTCATCTGTGACGACT 1321
DB 17 GTCCGCTGTGACGACT 1
|||||
|||||

RESULT 309
AR464757 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464757
DEFINITION Sequence 8434 from patent US 6686188.
ACCESSION AR464757
VERSION AR464757.1 GI:42699814
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
POLYNUCLEOTIDE encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8434 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1304 GGTGATCTGTGAGCAGC 1320
DB 17 GGTCCGCTGTGAGCACC 1
|||||
|||||

RESULT 310
AR464827 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR464827
DEFINITION Sequence 8504 from patent US 6686188.
ACCESSION AR464827
VERSION AR464827.1 GI:42699884
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8504 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1392 GCTGAGCTGCTGACAG 1408
DB 1 GATGAGCAGCTGTACAG 17

RESULT 311
LOCUS AR464829 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8506 from patent US 6686188.
ACCESSION AR464829
VERSION AR464829.1 GI:42699886
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8506 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1394 TGAAGTCTGTCGACAGAC 1410
DB 1 TGAGCAGCTGTACAGC 17

RESULT 312
LOCUS AR464973 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8650 from patent US 6686188.
ACCESSION AR464973
VERSION AR464973.1 GI:42700030
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8650 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAG 1272
DB 1 GCAGCTGACGCTGGAGC 17

RESULT 313
LOCUS AR464974 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8651 from patent US 6686188.
ACCESSION AR464974
VERSION AR464974.1 GI:42700031
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8651 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1257 CAGCAACAGCTGGAAGA 1273
DB 1 CAGCTGACGCTGGAGGA 17

RESULT 314
LOCUS AR465554 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9231 from patent US 6686188.
ACCESSION AR465554
VERSION AR465554.1 GI:42700611
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9231 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 CAGAGGCGAGCATCTG 1219
DB 1 CAGAGGCGAGCTTCAG 17

RESULT 315
LOCUS AR465555 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9232 from patent US 6686188.
ACCESSION AR465555
VERSION AR465555.1 GI:42700612
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9232 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1204 AGAGGCGAGCCATCTGT 1220
|||||
Db 1 AGAGGCGAGCCTGCAGT 17

RESULT 316
AR465556 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR465556
DEFINITION Sequence 9233 from patent US 6686188.
ACCESSION AR465556
VERSION AR465556.1 GI:42700613
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9233 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1205 GAGGCGAGCCATCTGTC 1221
|||||
Db 1 GAGGCGAGCCTGCAGTC 17

RESULT 317
AR465866 17 bp DNA linear PAT 20-FEB-2004
LOCUS AR465866
DEFINITION Sequence 9543 from patent US 6686188.
ACCESSION AR465866
VERSION AR465866.1 GI:42700923
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9543 03-FEB-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1192 AGAGCCTGTGCAGAGG 1208
|||||
Db 17 AGAGCGAGGCGAGAGG 1

RESULT 318
AR483120 17 bp DNA linear PAT 14-MAY-2004
LOCUS AR483120
DEFINITION Sequence 566 from patent US 6703228.
ACCESSION AR483120
VERSION AR483120.1 GI:47245643
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Landers, J., Jordan, B., Housman, D.E. and Charest, A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 566 09-MAR-2004;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1377 AAGCAGCTGCGTTTGC 1393
|||||
Db 17 ATGCAGCTGCATCTTGC 1

RESULT 319
AX215098 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX215098
DEFINITION Sequence 540 from Patent WO0159103.
ACCESSION AX215098
VERSION AX215098.1 GI:15525141
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
1
Blatt, L., McSwiggen, J. and Chowrira, B. M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
TITLE Patent: WO 0159103-A 540 16-AUG-2001;
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1261 AACGCTGGAGAGCGCT 1277
|||||
Db 17 AGCAGCAGGATAGGCT 1

RESULT 320
AX216210/c

LOCUS AX216210 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1652 from Patent WO0159103.
ACCESSION AX216210
VERSION AX216210.1 GI:15526253
KEYWORDS
ORGANISM
SOURCE
REFERENCE
AUTHORS
TITLE
JOURNAL
MCSWIGGEN, James (US) ; Chowitra, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1393 CTGAGCTGCTGACAGA 1409
DB 17 CTGTCTGACAGATAGA 1

RESULT 321
AX216348 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX216348
DEFINITION Sequence 1790 from Patent WO0159103.
ACCESSION AX216348
VERSION AX216348.1 GI:15526409
KEYWORDS
ORGANISM
SOURCE
REFERENCE
AUTHORS
TITLE
JOURNAL
MCSWIGGEN, James (US) ; Chowitra, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1251 CGGCTGACAGCAAGCT 1267
DB 1 CGGCGCGGCGACAGCT 17

RESULT 322
AX216351 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX216351
DEFINITION Sequence 1793 from Patent WO0159103.
ACCESSION AX216351
VERSION AX216351.1 GI:15526412
KEYWORDS
ORGANISM
SOURCE
synthetic construct
synthetic construct

REFERENCE
AUTHORS
TITLE
JOURNAL
MCSWIGGEN, James (US) ; Chowitra, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1251 CGGCTGACAGCAAGCT 1267
DB 1 CAGCTGACAGCATCTCT 17

RESULT 323
AX217079/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX217079/c
DEFINITION Sequence 2521 from Patent WO0159103.
ACCESSION AX217079
VERSION AX217079.1 GI:15527140
KEYWORDS
ORGANISM
SOURCE
REFERENCE
AUTHORS
TITLE
JOURNAL
MCSWIGGEN, James (US) ; Chowitra, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1189 CCCAGAGCCTGTGACAG 1205
DB 17 CTCGAAATCCTGTCTGT 1

RESULT 324
AX265975/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS AX265975/c
DEFINITION Sequence 3366 from Patent WO0173002.
ACCESSION AX265975
VERSION AX265975.1 GI:16514774
KEYWORDS
ORGANISM
SOURCE
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
Kniec, E.B., Gamper, H.B. and Rice, M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3366 04-OCT-2001;

FEATURES
source
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1346 AGACTTCCCGAGGCGAG 1362
Db 17 AAACCTTCCCGAGTGAAG 1

RESULT 325
AX265976 17 bp DNA linear PAT 26-OCT-2001
LOCUS Sequence 3367 from Patent WO0173002.
ACCESSION AX265976
VERSION AX265976.1 GI:16514775
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Knies, E.B., Camper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 3367 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1346 AGACTTCCCGAGGCGAG 1362
Db 17 AAACCTTCCCGAGTGAAG 17

RESULT 326
AX272791 17 bp RNA linear PAT 29-OCT-2001
LOCUS Sequence 360 from Patent WO0162911.
DEFINITION AX272791
ACCESSION AX272791
VERSION AX272791.1 GI:16545528
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Jarvis, T., von Carlwiltz, I., Mcswigen, J.A., Hamblin, P.A. and
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 360 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)

FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1250 CCGGCTGCAGCAACAGC 1266
Db 17 CCTGCAGCAGCAGCAGC 17

RESULT 327
AX272814 17 bp RNA linear PAT 29-OCT-2001
LOCUS Sequence 383 from Patent WO0162911.
DEFINITION AX272814
ACCESSION AX272814
VERSION AX272814.1 GI:16545551
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Jarvis, T., von Carlwiltz, I., Mcswigen, J.A., Hamblin, P.A. and
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 383 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)

FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAACAGCTG 1269
Db 17 GCTGCAGCTGAGCTGCTG 1

RESULT 328
AX272955 17 bp RNA linear PAT 29-OCT-2001
LOCUS Sequence 524 from Patent WO0162911.
DEFINITION AX272955
ACCESSION AX272955
VERSION AX272955.1 GI:16545692
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Jarvis, T., von Carlwiltz, I., Mcswigen, J.A., Hamblin, P.A. and
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 524 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)

FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1252 GGCTGCAGCAACAGCTG 1268
Db 17 GGCTGCAGCTGAGCTGCTG 1

RESULT 329
AX317206

LOCUS AX317206 17 bp DNA linear PAT 14-DEC-2001
DEFINITION Sequence 209 from Patent WO0190337.
ACCESSION AX317206
VERSION AX317206.1 GI:17900195
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 artificial sequences.
AUTHORS
1 Allawi,H., Bartholomay,C.T., Chehak,L., Curtis,M.L., Eis,P.S.,
Hall,J.G., Ip,H.S., Kaiser,M., Kwiatkowski,R.W., Lukowiak,A.A.,
Lyamichnev,V., Ma,W., Olson-Munoz,M.C., Olson,S.M., Schaefer,J.J.,
Skrypczynski,Z., Takova,T.Y., Vedvik,K.L. and Lyamichnev,N.E.
TITLE
Detection of rna
JOURNAL
Patent: WO 0190337-A 209 29-NOV-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1. 17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CACAGCCTGGAGAGGC 1276
Db 1 CTACAACTGAGAGGC 17
|||||
|

RESULT 330
AX325005/c
LOCUS AX325005 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1143 from Patent WO0192512.
ACCESSION AX325005
VERSION AX325005.1 GI:18095760
KEYWORDS
SOURCE Cucumis sativus (cucumber)
ORGANISM Cucumis sativus
REFERENCE
1 Cucurbitaceae; Cucurbitales; Cucurbitaceae; Cucumis.
AUTHORS
1 Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE
Targeted chromosomal genomic alterations in plants using modified
JOURNAL
Patent: WO 0192512-A 1143 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. 17
/organism="Cucumis sativus"
/mol_type="unassigned DNA"
/db_xref="taxon:3659"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1191 CAGAGCCTGTGCAGAG 1207
Db 17 CACAACTATGCAGAG 1
|||||
|

RESULT 331
AX325006
LOCUS AX325006 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1144 from Patent WO0192512.
ACCESSION AX325006
VERSION AX325006.1 GI:18095761
KEYWORDS
SOURCE Cucumis sativus (cucumber)
ORGANISM Cucumis sativus

REFERENCE
1 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; euroside I; Cucurbitales; Cucurbitaceae; Cucumis.
AUTHORS
1 Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
TITLE
Targeted chromosomal genomic alterations in plants using modified
JOURNAL
Patent: WO 0192512-A 1144 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. 17
/organism="Cucumis sativus"
/mol_type="unassigned DNA"
/db_xref="taxon:3659"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1191 CAGAGCCTGTGCAGAG 1207
Db 17 CACAACTATGCAGAG 1
|||||
|

RESULT 332
AX325025/c
LOCUS AX325025 17 bp DNA linear PAT 19-JUN-2002
DEFINITION Sequence 1163 from Patent WO0192512.
ACCESSION AX325025
VERSION AX325025.1 GI:18095780
KEYWORDS
SOURCE Cucurbita sp. WO0192512
ORGANISM Cucurbita sp. WO0192512
REFERENCE
1 Cucurbita sp. WO0192512
AUTHORS
1 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; euroside I; Cucurbitales; Cucurbitaceae; Cucurbita.
TITLE
Targeted chromosomal genomic alterations in plants using modified
JOURNAL
Patent: WO 0192512-A 1163 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. 17
/organism="Cucurbita sp. WO0192512"
/mol_type="unassigned DNA"
/db_xref="taxon:198419"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1191 CAGAGCCTGTGCAGAG 1207
Db 17 CACAACTATGCAGAG 1
|||||
|

RESULT 333
AX325026
LOCUS AX325026 17 bp DNA linear PAT 19-JUN-2002
DEFINITION Sequence 1164 from Patent WO0192512.
ACCESSION AX325026
VERSION AX325026.1 GI:18095781
KEYWORDS
SOURCE Cucurbita sp. WO0192512
ORGANISM Cucurbita sp. WO0192512
REFERENCE
1 Cucurbita sp. WO0192512
AUTHORS
1 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; euroside I; Cucurbitales; Cucurbitaceae; Cucurbita.
TITLE
Targeted chromosomal genomic alterations in plants using modified
JOURNAL
Patent: WO 0192512-A 1164 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)

```

JOURNAL      Patient: WO 0192512-A 1164 06-DEC-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES
SOURCE
1. 17 location/Qualifiers
   /organism="Cucurbita sp. WO0192512
   /mol_type="unassigned DNA"
   /db_xref="taxon:198419"

```

Query Match	4.8%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%	Pred. No. 2e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

QY 1191 CAGAAGCCTGTGCAGAG 1207
||| ||| ||| ||| |||
Db 1 CACAAACCTATGCAGAG 17

RESULT 334			
AX423249			
LOCUS	AX423249	17 bp	RNA
DEFINITION	Sequence 1585 from Patent WO0188124.		linear PAT 18-JUN-2002

Query Match	4.8%;	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 2e+02;		
Matches 14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0

Qy	1217	CTGTCA	AACCTC	CAGC	1233
Db	1	CTGTCT	CAACCC	CAGC	17

RESULT 335			
AX423701			
LOCUS	AX423701	17 bp	RNA
DEFINITION	Sequence 2037 from Patent WO0188124.		linear PAT 18-JUN-2007

Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

RESULT 336	LOCUS	Sequence	804 from Patent WO0224750.	17 bp	DNA	linear	PAT 12-AUG-2002
AX475583/c	AX475583						

TITLE	JOURNAL	FEATURES	source
Human kidney tumor overexpressed membrane protein 1	Patent: WO 0224750-A 804 28-MAR-2002;	Aeomica, Inc. (US)	location/Qualifiers 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"

Query Match	4.8%	Score 12.2	DB 1	Length 17
Best Local Similarity	82.4%	Pred. No. 2e+02		
Matches 14	Conservative 0	Mismatches 3	Indels 0	Gaps 0
QY	1287	GACCTTCAGGAGTCCAT	1303	
db	17	GCCCTCAGGAGTCCAT	1	

UNCLUSTED
 100% bootstrap
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE
 1
 Zhang, J.
 Human kidney tumor overexpressed membrane protein 1
 Patent: WO 0224750-A 805 28-MAR-2002;
 JOURNAL
 Aecomica, Inc. (US)
 FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;

RESULT	338		
AX499467			
LOCUS	17	bp	DNA
AX499467			linear
			PAT 27-SEP-2002

DEFINITION Sequence 774 from Patent EP1229046.
ACCESSION AX499467
VERSION AX499467.1 GI:23381760
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 774 07-AUG-2002;
Aeomica, Inc. (US)

FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1197 CCTGTGACAGGCGCAGC 1213
Db 1 CCTTGCAGAGTACAGC 17

RESULT 339
AX499609 17 bp DNA linear PAT 27-SEP-2002
LOCUS AX499609
DEFINITION Sequence 916 from Patent EP1229046.
ACCESSION AX499609
VERSION AX499609.1 GI:23381902
KEYWORDS
SOURCE Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 916 07-AUG-2002;
Aeomica, Inc. (US)

FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1385 GCGTTTGTGCTGCTGC 1401
Db 17 GCGTTTGTTCACCTGC 1

RESULT 340
AX500512 17 bp DNA linear PAT 27-SEP-2002
LOCUS AX500512
DEFINITION Sequence 1819 from Patent EP1229046.
ACCESSION AX500512
VERSION AX500512.1 GI:23382805
KEYWORDS
SOURCE Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein

JOURNAL Patent: EP 1229046-A 1819 07-AUG-2002;
Aeomica, Inc. (US)

FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1298 TGCCATGTCATCTGTG 1314
Db 17 TTCCATGTCATCTGGG 1

RESULT 341
AX530980 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX530980
DEFINITION Sequence 489 from Patent EP1239051.
ACCESSION AX530980
VERSION AX530980.1 GI:25253747
KEYWORDS
SOURCE Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Shannon, M.
TITLE Human poxh-like protein 1
JOURNAL Patent: EP 1239051-A 489 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
4.8%; Score 12.2; DB 1; Length 17;
Beet Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1275 GCTGAGGCGCAGAGCCC 1291
Db 1 GCTCAGGCGCAGAGCTCC 17

RESULT 342
AX578400 17 bp RNA linear PAT 10-JAN-2003
LOCUS AX578400
DEFINITION Sequence 238 from Patent WO0211674.
ACCESSION AX578400
VERSION AX578400.1 GI:27647602
KEYWORDS
SOURCE Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 238 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)

FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1253 GCTGCAGCAGCAGCTGG 1269
DB 17 GCAGCAGAGAAAGCTGG 1

RESULT 343

AX579002 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 840 from Patent WO0211674.
ACCESSION AX579002
VERSION AX579002.1 GI:27648204
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
TITLE and Grape,A. Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 840 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1370 TTACCAAGACAGCTGC 1386
DB 1 TTACTGCAGCAGCTTC 17

RESULT 344
AX579447 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1285 from Patent WO0211674.
ACCESSION AX579447
VERSION AX579447.1 GI:27648649
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 1285 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1368 GCTTACGAGACAGCT 1384

DB 1 GATTACTGCAGCAGCT 17

RESULT 345
AX649538 17 bp DNA linear PAT 22-MAR-2003
LOCUS AX649538
DEFINITION Sequence 1378 from Patent EP1273660.
ACCESSION AX649538
VERSION AX649538.1 GI:29152356
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1378 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1230 CAGCATGTCTGCAGCT 1246
DB 17 CATCATGTCTGAAGT 1

RESULT 346
AX687747 17 bp DNA linear PAT 31-MAR-2003
LOCUS AX687747
DEFINITION Sequence 479 from Patent EP1281758.
ACCESSION AX687747
VERSION AX687747.1 GI:29410443
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 479 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1220 TCAGACCTCCAGCATG 1236
DB 17 TCAGTCTCTCCACCATG 1

RESULT 347
AX687748 17 bp DNA linear PAT 31-MAR-2003
LOCUS AX687748
DEFINITION Sequence 480 from Patent EP1281758.
ACCESSION AX687748
VERSION AX687748.1 GI:29410444

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 480 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1219 GTCAGAACCTCCAGCAT 1235
Db 17 GTCAGAGCTCTCCACCAT 1
|||||
|||||

RESULT 348
AX687749/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 481 from Patent EP1281758.
ACCESSION AX687749
VERSION AX687749.1 GI:29410445
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 481 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1218 TGTGAGACCTCCAGCA 1234
Db 17 TGTGAGGCTCTCCACCA 1
|||||
|||||

RESULT 349
AX687750/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 482 from Patent EP1281758.
ACCESSION AX687750
VERSION AX687750.1 GI:29410446
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12

JOURNAL Patent: EP 1281758-A 482 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1217 CTGTGAGAACCTCCAGC 1233
Db 17 CTGTGAGGCTCTCCACC 1
|||||
|||||

RESULT 350
AX688423/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 1155 from Patent EP1281758.
ACCESSION AX688423
VERSION AX688423.1 GI:29411125
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 1155 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1371 TACCAGAGACGCTGCG 1387
Db 17 TTCCAGAGGAGGCTGTG 1
|||||
|||||

RESULT 351
AX688615 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 1347 from Patent EP1281758.
ACCESSION AX688615
VERSION AX688615.1 GI:29411317
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 1347 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1255 TGCAGCAGAGCTGGAA 1271
|||||
Db 1 TGCAGCAGAGCTGGAA 17

RESULT 352
AX690600/c
LOCUS AX690600 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3332 from Patent EP1281758.
ACCESSION AX690600
VERSION AX690600.1 GI:29413481
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
Aeomica, Inc. (US)
PATENT: EP 1281758-A 3332 05-FEB-2003;
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1276 CTGAGGCGAGAGCCCT 1292
|||||
Db 17 CTGATGCGCAGAGCTCCT 1

RESULT 353
AX690615
LOCUS AX690615 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3347 from Patent EP1281758.
ACCESSION AX690615
VERSION AX690615.1 GI:29413496
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
Aeomica, Inc. (US)
PATENT: EP 1281758-A 3347 05-FEB-2003;
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1271 AGAGGCTGAGGCGAGG 1287
|||||
Db 1 AGTGCTGAGCAGCAGAG 17

RESULT 354

AX690616
LOCUS AX690616 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3348 from Patent EP1281758.
ACCESSION AX690616
VERSION AX690616.1 GI:29413497
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
Aeomica, Inc. (US)
PATENT: EP 1281758-A 3348 05-FEB-2003;
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1272 GAGGCTGAGGCGAGAGA 1288
|||||
Db 1 GTGCTGAGCAGCAGAGA 17

RESULT 355
AX693521
LOCUS AX693521 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6253 from Patent EP1281758.
ACCESSION AX693521
VERSION AX693521.1 GI:29416486
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y. and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
Aeomica, Inc. (US)
PATENT: EP 1281758-A 6253 05-FEB-2003;
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1284 AGAGCCTCGAGGTGC 1300
|||||
Db 1 AGAGCCTGATGAGTGC 17

RESULT 356
AX693522
LOCUS AX693522 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6254 from Patent EP1281758.
ACCESSION AX693522
VERSION AX693522.1 GI:29416487
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Pour human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6254 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1285 GAGACCTCAGGCTGCC 1301
Db 1 GAGACCTATAGTCTCC 17

RESULT 357
AX722642 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 329 from Patent WO03025176.
DEFINITION AX722642
ACCESSION AX722642.1 GI:30423143
VERSION
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 329 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1223 GAACCTCCAGCATGTGC 1239
Db 1 GATCCTCCTGCTGTGC 17

RESULT 358
AX722863 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 550 from Patent WO03025176.
DEFINITION AX722863
ACCESSION AX722863.1 GI:30423364
VERSION
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 550 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1358 GCGAGCTGAGGCTTACC 1374
Db 1 GGTAGCTGAGGCTGATC 1

RESULT 359
AX724004 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1691 from Patent WO03025176.
DEFINITION AX724004
ACCESSION AX724004.1 GI:30503347
VERSION
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 1691 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1406 CAGACGGGTGCTGAGC 1422
Db 17 CAAACTGGGTCTGATC 1

RESULT 360
AX727486 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 5173 from Patent WO03025176.
DEFINITION AX727486
ACCESSION AX727486.1 GI:30506829
VERSION
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 5173 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 4.8%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1326 GACCTCTTCAGGC 1342
|||
1 GATCTTTTCCAGGC 17

Db

RESULT 361
AX728210 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5897 from Patent WO03025176.
ACCESSION AX728210
VERSION AX728210.1 GI:30507553
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS 1
TITLE Teلمان, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 5897 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1387 GTTGTGAGCTGCTG 1403
|||
1 GATCTGCGAGCTGCTG 17

Db

RESULT 362
AX738508 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4098 from Patent WO03025177.
ACCESSION AX738508
VERSION AX738508.1 GI:30517796
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Teلمان, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 4098 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1210 CAGCATCTGCAGAAC 1226
|||
17 CTGCATCTGCAGATC 1

Db

RESULT 363
AX744245 17 bp DNA linear PAT 14-MAY-2003
LOCUS
DEFINITION Sequence 210 from Patent WO03031621.
ACCESSION AX744245
VERSION AX744245.1 GI:30722912
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Zhang, J.
A human G protein coupled receptor
Patent: WO 03031621-A 210 17-APR-2003;
JOURNAL Amersham Biosciences (SV) Corp. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1313 TGACGAGTGGGAGC 1329
|||
1 TAACTGTAGGGAGC 17

Db

RESULT 364
AX751061 17 bp DNA linear PAT 20-JUN-2003
LOCUS
DEFINITION Sequence 277 from Patent WO03033703.
ACCESSION AX751061
VERSION AX751061.1 GI:32133389
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Human gtp-activator protein for rab-like gtpase
Patent: WO 03033703-A 277 24-APR-2003;
JOURNAL Amersham Biosciences (SV) Corp. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1244 AGTGTCGGCTGCAGC 1260
|||
1 AGGGGTCCCGCTGCAGC 17

Db

RESULT 365
AX751062 17 bp DNA linear PAT 20-JUN-2003
LOCUS
DEFINITION Sequence 278 from Patent WO03033703.
ACCESSION AX751062
VERSION AX751062.1 GI:32133390
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE Human gtp-activator protein for rab-like gtpase
JOURNAL Patent: WO 03033703-A 278 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1245 GTGGTCCGCTGCAGCA 1261
DB 1 GGGGTCCGCTGCAGCA 17

RESULT 366
AX751064 17 bp DNA linear PAT 20-JUN-2003
LOCUS AX751064
DEFINITION Sequence 280 from Patent WO03033703.
ACCESSION AX751064
VERSION AX751064.1 GI:32133392
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE Human gtp-activator protein for rab-like gtpase
JOURNAL Patent: WO 03033703-A 280 24-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1247 GATCCGCTGCAGCAAC 1263
DB 1 GGTCCGCTGCAGCAC 17

RESULT 367
AX753824 17 bp DNA linear PAT 23-JUN-2003
LOCUS AX753824
DEFINITION Sequence 171 from Patent WO03037931.
ACCESSION AX753824
VERSION AX753824.1 GI:32166521
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 171 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1254 CTGCAGCAACAGCTGGA 1270
DB 1 CAGCAGCAACAGCAGCA 17

RESULT 368
AX753826 17 bp DNA linear PAT 23-JUN-2003
LOCUS AX753826
DEFINITION Sequence 173 from Patent WO03037931.
ACCESSION AX753826
VERSION AX753826.1 GI:32166523
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 173 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGGAAG 1272
DB 1 GCAGCAACAGCAGCAG 17

RESULT 369
AX758890 17 bp DNA linear PAT 25-JUN-2003
LOCUS AX758890
DEFINITION Sequence 2211 from Patent WO03040369.
ACCESSION AX758890
VERSION AX758890.1 GI:32253506
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1
AUTHORS Teلمان, A., Amson, R. and Tufjnder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
JOURNAL Patent: WO 03040369-A 2211 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; 3; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1186 GCTCCAGAGCCTGTG 1202
DB 1 GATCCAGTAGCCTGTG 17

RESULT 370
BD067588
LOCUS BD067588 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.
ACCESSION BD067588
VERSION BD067588.1 GI:22613191
KEYWORDS JP 2001511003-A/428.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JOURNAL Patent:JP 2001511003-A 428 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/428
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FT location/Qualifiers
1..17
/organism='Unidentified'.
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 3; Indels 0; Gaps 0;

Qy 1325 GGACCTCTTCCAGG 1341
|||||
1 GGACCTCTTCCAGG 17

Db 1 GGACCTCTTCCAGG 17

RESULT 371
BD132565
LOCUS BD132565 17 bp DNA linear PAT 18-SEP-2002
DEFINITION Anti-alphabeta3 humanized monoclonal antibodies.
ACCESSION BD132565
VERSION BD132565.1 GI:23227510
KEYWORDS JP 2002508656-A/11.
SOURCE Mus sp.
ORGANISM Mus sp.
REFERENCE 1 (bases 1 to 17)
AUTHORS Jonak,Z.L., Johanson,K.O. and Taylor,A.H.
TITLE Anti-alphabeta3 humanized monoclonal antibodies
JOURNAL Patent: JP 2002508656-A 11 19-MAR-2002;
SMITHKLINE BEECHAM CORP
PN JP 2002508656-A/11
PD 19-MAR-2002
PF 12-MAR-1998 JP 1998539860
PI ZDENKA L JONAK,KYUNG O JOHANSON,ALEXANDER H TAYLOR PC
C12N15/13,C07K16/28,C12N5/20,A61K39/395,G01N33/577,G01N33/68 CC
Strandedness: Single;
CC Topology: Unknown;
CC /desc = ' heavy chain decomposition primer'
FH key Location/Qualifiers.

FEATURES
source Location/Qualifiers
1..17
/organism="Mus sp."
/mol_type="genomic DNA"
/db_xref="taxon:10095"

Query Match 4.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2e+02; Mismatches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 1245 GTGTCGGCTGCAGCA 1261
|||||
1 SWRGTCARCTBCARCA 17

Db 1 SWRGTCARCTBCARCA 17

RESULT 372
161462/c
LOCUS 161462 15 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 16 from patent US 5658780.
ACCESSION 161462
VERSION 161462.1 GI:2479410
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE Rel a targeted ribozymes
JOURNAL Patent: US 5658780-A 16 19-AUG-1997;
FEATURES Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1189 CCCAGAGCCTG 1200
|||||
12 CCCAGAGCCTG 1

Db 12 CCCAGAGCCTG 1

RESULT 373
AX635877/c
LOCUS AX635877 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3016 from Patent EP1260586.
ACCESSION AX635877
VERSION AX635877.1 GI:28471491
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.W., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 3016 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.8%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.7e+02; Mismatches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

TITLE Shannon,M.E.
Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9228 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGAGCC 1214
|||||
4 CAGAGGCGAGCC 15

Db

RESULT 379
LOCUS CO624489 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9229 from Patent WO0192524.
ACCESSION CO624489
VERSION CO624489.1 GI:41674707
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9229 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGAGCC 1214
|||||
3 CAGAGGCGAGCC 14

Db

RESULT 380
LOCUS CO624490 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9230 from Patent WO0192524.
ACCESSION CO624490
VERSION CO624490.1 GI:41674708
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9230 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGAGCC 1214
|||||
2 CAGAGGCGAGCC 13

Db

RESULT 381
LOCUS CO625990 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10730 from Patent WO0192524.
ACCESSION CO625990
VERSION CO625990.1 GI:41676208
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10730 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193
|||||
6 CTGGGCTCCGAG 17

Db

RESULT 382
LOCUS CO625991 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10731 from Patent WO0192524.
ACCESSION CO625991
VERSION CO625991.1 GI:41676209
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10731 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193
|||||
5 CTGGGCTCCGAG 16

Db

RESULT 383
LOCUS C0625992 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10732 from Patent WO0192524.
ACCESSION C0625992
VERSION C0625992.1 GI:41676210
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10732 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCGAG 1193
DB 4 CTGGGCTCCGAG 15

RESULT 384
LOCUS C0625993 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10733 from Patent WO0192524.
ACCESSION C0625993
VERSION C0625993.1 GI:41676211
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10733 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCGAG 1193
DB 3 CTGGGCTCCGAG 14

RESULT 385
LOCUS C0625994 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10734 from Patent WO0192524.
ACCESSION C0625994
VERSION C0625994.1 GI:41676212
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10734 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCGAG 1193
DB 2 CTGGGCTCCGAG 13

RESULT 386
LOCUS C0625995 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10735 from Patent WO0192524.
ACCESSION C0625995
VERSION C0625995.1 GI:41676213
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10735 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCGAG 1193
DB 1 CTGGGCTCCGAG 12

RESULT 387
LOCUS I67733 17 bp DNA linear PAT 30-DEC-1997
DEFINITION Sequence 15 from patent US 5672509.
ACCESSION I67733
VERSION I67733.1 GI:2731268
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
TITLE hPDE IV-C: a human phosphodiesterase IV isozyme
JOURNAL Patent: US 5672509-A 15 30-SEP-1997;
FISH, D.A.
FEATURES
SOURCE 1..17
/organism="unknown"

```

/moi_type="unassigned DNA"
Query Match
  4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1204 AGAGGGCAGCCA 1215
        |||||
        2 AGAGGGCAGCCA 13

Db

RESULT 388
AR286391
LOCUS AR286391 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 763 from patent US 6528640.
ACCESSION AR286391
VERSION AR286391.1 GI:29723987
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  Unclassified.
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpelsky,A.,
  Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE Synthetic ribonucleic acids with RNase activity
  JOURNAL Patent: US 6528640-A 763 04-MAR-2003;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match
  4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1182 CTGGGCTCCGAG 1193
        |||||
        5 CTGGGCTCCGAG 16

Db

RESULT 389
AR398381
LOCUS AR398381 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 762 from patent US 6617438.
ACCESSION AR398381
VERSION AR398381.1 GI:40136146
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  Unclassified.
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpelsky,A.,
  Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE Oligoribonucleotides with enzymatic activity
  JOURNAL Patent: US 6617438-A 762 09-SEP-2003;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match
  4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1182 CTGGGCTCCGAG 1193
        |||||
        5 CTGGGCTCCGAG 16

Db

RESULT 390
AR465097
LOCUS AR465097 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8774 from patent US 6686188.
```

```

ACCESSION AR465097
VERSION AR465097.1 GI:42700154
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  Unclassified.
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
  JOURNAL predominantly in heart and muscle
  PATENT: US 6686188-A 8774 03-FEB-2004;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
  4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1304 GGTGATCTGTGA 1315
        |||||
        6 GGTGATCTGTGA 17

Db

RESULT 391
AR465098
LOCUS AR465098 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8775 from patent US 6686188.
ACCESSION AR465098
VERSION AR465098.1 GI:42700155
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  Unclassified.
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
  JOURNAL predominantly in heart and muscle
  PATENT: US 6686188-A 8775 03-FEB-2004;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
  4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1304 GGTGATCTGTGA 1315
        |||||
        5 GGTGATCTGTGA 16

Db

RESULT 392
AR465549
LOCUS AR465549 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9226 from patent US 6686188.
ACCESSION AR465549
VERSION AR465549.1 GI:42700606
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  Unclassified.
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
  JOURNAL predominantly in heart and muscle
  PATENT: US 6686188-A 9226 03-FEB-2004;
  FEATURES
    Location/Qualifiers
```

```
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGCAGCC 1214
|||||
Db 6 CAGAGGCGCAGCC 17

RESULT 393
AR465550 AR465550 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 9227 from patent US 6686188.
ACCESSION AR465550
VERSION AR465550.1 GI:42700607
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 9227 03-FEB-2004;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGCAGCC 1214
|||||
Db 5 CAGAGGCGCAGCC 16

RESULT 394
AR465551 AR465551 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 9228 from patent US 6686188.
ACCESSION AR465551
VERSION AR465551.1 GI:42700608
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 9228 03-FEB-2004;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGCAGCC 1214
|||||
Db 4 CAGAGGCGCAGCC 15
```

```
RESULT 395
AR465552 AR465552 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 9229 from patent US 6686188.
ACCESSION AR465552
VERSION AR465552.1 GI:42700609
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 9229 03-FEB-2004;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGCAGCC 1214
|||||
Db 3 CAGAGGCGCAGCC 14

RESULT 396
AR465553 AR465553 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 9230 from patent US 6686188.
ACCESSION AR465553
VERSION AR465553.1 GI:42700610
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 9230 03-FEB-2004;
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 CAGAGGCGCAGCC 1214
|||||
Db 2 CAGAGGCGCAGCC 13

RESULT 397
AR467053 AR467053 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10730 from patent US 6686188.
ACCESSION AR467053
VERSION AR467053.1 GI:42702110
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Gu.Y., Ji.Y., Penn.S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
```

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
FEATURES Patent: US 6686188-A 10730 03-FEB-2004;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193
|||||
|||||
Db 6 CTGGGCTCCGAG 17

RESULT 398
AR467054 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10731 from patent US 6686188.
DEFINITION AR467054
ACCESSION AR467054
VERSION AR467054.1 GI:42702111
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
JOURNAL Polynucleotide encoding a human myosin-like polypeptide expressed
FEATURES Patent: US 6686188-A 10731 03-FEB-2004;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193
|||||
|||||
Db 5 CTGGGCTCCGAG 16

RESULT 399
AR467055 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10732 from patent US 6686188.
DEFINITION AR467055
ACCESSION AR467055
VERSION AR467055.1 GI:42702112
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
JOURNAL Polynucleotide encoding a human myosin-like polypeptide expressed
FEATURES Patent: US 6686188-A 10732 03-FEB-2004;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193

Db 4 CTGGGCTCCGAG 15
|||||
|||||

RESULT 400
AR467056 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10733 from patent US 6686188.
DEFINITION AR467056
ACCESSION AR467056
VERSION AR467056.1 GI:42702113
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
JOURNAL Polynucleotide encoding a human myosin-like polypeptide expressed
FEATURES Patent: US 6686188-A 10733 03-FEB-2004;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193
|||||
|||||
Db 3 CTGGGCTCCGAG 14

RESULT 401
AR467057 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10734 from patent US 6686188.
DEFINITION AR467057
ACCESSION AR467057
VERSION AR467057.1 GI:42702114
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
TITLE Shannon,M.E.
JOURNAL Polynucleotide encoding a human myosin-like polypeptide expressed
FEATURES Patent: US 6686188-A 10734 03-FEB-2004;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCGAG 1193
|||||
|||||
Db 2 CTGGGCTCCGAG 13

RESULT 402
AR467058 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10735 from patent US 6686188.
DEFINITION AR467058
ACCESSION AR467058
VERSION AR467058.1 GI:42702115
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
1 (bases 1 to 17)
REFERENCE Gu Y., Ji Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
AUTHORS Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 668188-A 10735 03-FEB-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 CTGGGCTCCCG 1193
DB 1 CTGGGCTCCCG 12

RESULT 403
AX671989 17 bp DNA linear PAT 27-MAR-2003
LOCUS AX671989 Sequence 434 from Patent WO03004526.
ACCESSION AX671989
VERSION AX671989.1 GI:29330337
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Telemann, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 434 16-JAN-2003;
FEATURES Molecular Engineering Laboratories (FR)
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1220 TCAGAACTCCA 1231
DB 3 TCAGAACTCCA 14

RESULT 404
AX733574 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX733574 Sequence 5208 from Patent WO03025175.
ACCESSION AX733574
VERSION AX733574.1 GI:30512917
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Telemann, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5208 27-MAR-2003;
FEATURES Molecular Engineering Laboratories (FR)
Location/Qualifiers

source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1220 TCAGAACTCCA 1231
DB 3 TCAGAACTCCA 14

RESULT 405
AX738099 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX738099 Sequence 3689 from Patent WO03025177.
ACCESSION AX738099
VERSION AX738099.1 GI:30517387
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
AUTHORS Telemann, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3689 27-MAR-2003;
FEATURES Molecular Engineering Laboratories (FR)
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.8%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1220 TCAGAACTCCA 1231
DB 3 TCAGAACTCCA 14

RESULT 406
A88002 15 bp DNA linear PAT 22-JAN-2000
LOCUS A88002 Sequence 150 from Patent WO9833904.
ACCESSION A88002
VERSION A88002.1 GI:6736572
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
AUTHORS Brysch, W. and Schillingensiepen, K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 150 06-AUG-1998;
FEATURES BIOLOGISTIK GRS (DE); BRYSCH WOLFGANG (DE)
source
1..15
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1411 CGGGTGTGACGGG 1425

Db 1 ||||| 15
1 CGGGTCCGGCGGG 15

RESULT 407
A89969 15 bp DNA linear PAT 22-JAN-2000
LOCUS Sequence 150 from Patent EP0856579.
ACCESSION A89969
VERSION A89969.1 GI:6738483
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 150 05-AUG-1998;
BIOCHEMISTIK G88 (DE)
FEATURES
source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1411 CGGGTCCGGCGGG 1425
Db 1 CGGGTCCGGCGGG 15

RESULT 408
A813621 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR133621
DEFINITION Sequence 2046 from patent US 6194150.
ACCESSION AR133621
VERSION AR133621.1 GI:14122526
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2046 27-FEB-2001;
FEATURES
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1243 CAGTGCTCCGGCTGC 1257
Db 1 CAGTGCTCCGGCTGC 15

RESULT 409
BD178524 15 bp DNA linear PAT 16-APR-2003
LOCUS BD178524
DEFINITION Method of detecting nucleic acid relating to disease.
ACCESSION BD178524
VERSION BD178524.1 GI:30015790
KEYWORDS WO 02077281-A/30.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE 1 (bases 1 to 15)
AUTHORS Hashimoto,K., Hashimoto,M., Mishiro,S. and Ota,Y.
TITLE Method of detecting nucleic acid relating to disease
JOURNAL Patent: WO 02077281-A 30 03-OCT-2002;
TOSHIBA CORP,KOJI HASHIMOTO,MICHIIE HASHIMOTO,SHUNJI MISHIRO,
YASUHIKO OTA
COMMENT OS Homo sapiens (human)
PN WO 02077281-A/30
PD 03-OCT-2002
PR 05-MAR-2002 WO 2002JP002030
PC 27-MAR-2001 JP 01P 090053,18-SEP-2001 JP 01P 284112 PI
KOJI HASHIMOTO,MICHIIE HASHIMOTO,SHUNJI MISHIRO,YASUHIKO OTA PC
C1201/68,C12N15/09,C12M1/00,G01N33/53,G01N33/566,PC
G01N33/576,
PC G01N37/00
CC Method of detecting nucleic acid relating to disease FH Key
FEATURES
FT source 1..15
Location/Qualifiers
/organism='Homo sapiens (human)'.
1..15
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1249 TCCGGCTGCAGCAAC 1263
Db 15 TCCGGCTGCAGCAAC 1

RESULT 410
BD182917 15 bp DNA linear PAT 17-JUN-2003
LOCUS BD182917/c
DEFINITION Detection of nucleic acid associated with disease.
ACCESSION BD182917
VERSION BD182917.1 GI:11875117
KEYWORDS JP 2002355083-A/30.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 15)
AUTHORS Hashimoto,K., Hashimoto,M., Mishiro,S. and Ota,Y.
TITLE Detection of nucleic acid associated with disease
JOURNAL Patent: JP 2002355083-A 30 10-DEC-2002;
TOSHIBA CORP
COMMENT OS Homo sapiens (human)
PN JP 2002355083-A/30
PD 10-DEC-2002
PR 26-MAR-2002 JP 2002086681
PC KOJI HASHIMOTO,MICHIIE HASHIMOTO,SHUNJI MISHIRO,YASUHIKO OTA PC
C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566,PC
G01N33/566,
PC G01N33/576//C12Q1/68,C12R1/93,C12N15/00,C12N15/00 CC
Detection of nucleic acid associated with disease FH Key
FEATURES
FT source 1..15
Location/Qualifiers
/organism='Homo sapiens (human)'.
1..15
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1249 TCCGGCTGCAGCAAC 1263

Db 15 TCCGGCTGACAAAC 1

|||||

RESULT 411
BD208752/c
LOCUS
DEFINITION BD208752 15 bp RNA linear PAT 17-JUL-2003
Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.

ACCESSION BD208752
VERSION BD208752.1 GI:33018522
KEYWORDS JP 2002512791-A/2342.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt, L., McSwiggen, J.A., Roberts, E., Pavco, P.A. and Macejak, D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Patent: JP 2002512791-A 2342 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC

JOURNAL
COMMENT OS Hepatitis virus (hepatitis C virus)

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1412 GGGTGTGAGCGGC 1426
15 GGGTGTGAGCGGC 1

|||||

RESULT 412
BD20870/c
LOCUS
DEFINITION BD20870 15 bp RNA linear PAT 17-JUL-2003
Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.

ACCESSION BD20870
VERSION BD20870.1 GI:33018640
KEYWORDS JP 2002512791-A/2460.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt, L., McSwiggen, J.A., Roberts, E., Pavco, P.A. and Macejak, D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Patent: JP 2002512791-A 2460 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC

JOURNAL
COMMENT OS Hepatitis virus (hepatitis C virus)

FEATURES
source
1. .15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1. .15
/organism="Hepatitis virus (hepatitis C virus)"
FT

PN JP 2002512791-A/2460
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,
PI DENNIS MACEJAK
PC C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1. .15
/organism="Hepatitis virus (hepatitis C virus)"
FT

FEATURES
source
1. .15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1216 TCTGTGAGACCTCC 1230
15 TCTGTGAGACCAACC 1

|||||

RESULT 413
BD208995
LOCUS
DEFINITION BD208995 15 bp RNA linear PAT 17-JUL-2003
Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.

ACCESSION BD208995
VERSION BD208995.1 GI:33018765
KEYWORDS JP 2002512791-A/2585.
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt, L., McSwiggen, J.A., Roberts, E., Pavco, P.A. and Macejak, D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Patent: JP 2002512791-A 2585 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC

JOURNAL
COMMENT OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2585
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,
PI DENNIS MACEJAK
PC C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1. .15
/organism="Hepatitis virus (hepatitis C virus)"
FT

FEATURES
source
1. .15
/organism="unidentified"
/mol_type="genomic RNA"

```
/db_xref="taxon:32644"
Query Match          4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1261 AACAGCTGGAAGAG 1275
      |||||
Db      1 AACAGCTGMAAAG 15

RESULT 414
E51114      15 bp      DNA      linear      PAT 31-JAN-2002
LOCUS      E51114
DEFINITION Method for detecting virus.
ACCESSION  E51114
VERSION    E51114.1 GI:18622188
KEYWORDS   JP 2000312589-A/18.
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Okamura,K., Kondo,S., Sase,I., Kan,T., Furusawa,I., Mise,K.,
TITLE       Watanabe,Y. and Kawakami,S.
JOURNAL     Method for detecting virus
            Patent: JP 2000312589-A 18 14-NOV-2000;
            BUNSHI BIO HOTONIKUSU KENKYUSHO
COMMENT     OS Artificial Sequence
            PN JP 2000312589-A/18
            PD 14-NOV-2000
            PF 16-JUL-1999 JP 1999203474
            PR
            PI KOJI OKAMURA,SATOSHI KONDO,ICHIRO SASB,TAKAYUKI KAN, PI IMAO
            FUUSAMA,
            PI KAZUYUKI MISE,YUICHIRO WATANABE,SHIGEKI KAWAKAMI PC
            C12N15/09,C12N7/00,C12Q1/70,C12N15/00
            CC

FEATURES
    source             Location/Qualifiers
                        1..15
                        /organism="Artificial Sequence".
                        1..15
                        /organism="synthetic construct"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32630"

Query Match          4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1192 AGAAGCTGTGCAGA 1206
      |||||
Db      1 AGAAGCTTTTCAGA 15

RESULT 415
I61469      15 bp      DNA      linear      PAT 07-OCT-1997
LOCUS      I61469
DEFINITION Sequence 23 from patent US 5658780.
ACCESSION  I61469
VERSION    I61469.1 GI:2479417
KEYWORDS
SOURCE     .
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE       Rel a targeted ribozymes
JOURNAL     Patent: US 5658780-A 23 19-AUG-1997;
            location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

FEATURES
    source
```

```
Query Match          4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1412 GGGTCTGAGCGGC 1426
      |||||
Db      1 GGGCGCTCAGCGGC 15

RESULT 416
I61486/c     15 bp      DNA      linear      PAT 07-OCT-1997
LOCUS      I61486
DEFINITION Sequence 40 from patent US 5658780.
ACCESSION  I61486
VERSION    I61486.1 GI:2479434
KEYWORDS
SOURCE     .
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE       Rel a targeted ribozymes
JOURNAL     Patent: US 5658780-A 40 19-AUG-1997;
            location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match          4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1198 CTGTGCAGAGGCAG 1212
      |||||
Db      15 CTGGCGAGAGGTCAG 1

RESULT 417
I61638/c     15 bp      DNA      linear      PAT 07-OCT-1997
LOCUS      I61638
DEFINITION Sequence 192 from patent US 5658780.
ACCESSION  I61638
VERSION    I61638.1 GI:2479586
KEYWORDS
SOURCE     .
ORGANISM   Unknown.
REFERENCE   1 (bases 1 to 15)
AUTHORS     Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE       Rel a targeted ribozymes
JOURNAL     Patent: US 5658780-A 192 19-AUG-1997;
            location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match          4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1198 CTGTGCAGAGGCAG 1212
      |||||
Db      15 CTGGCGAGAGGTCAG 1

RESULT 418
AR285792     15 bp      RNA      linear      PAT 10-APR-2003
LOCUS      AR285792
DEFINITION Sequence 164 from patent US 6526640.
ACCESSION  AR285792
VERSION    AR285792.1 GI:29723386
KEYWORDS
```


SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 164 04-MAR-2003;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1393 CTGAGCTGCTGGACA 1407
Db 1 CTCGGCTGCTGGACA 15

RESULT 419
AR322168 15 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 19 from patent US 6566061.
DEFINITION AR322168
ACCESSION AR322168
VERSION AR322168.1 GI:33707712
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Philibert,R.A., Gims,E.I. and Delisi,L.
TITLE Identification of polymorphisms in the PCTGA region of xg13
JOURNAL Patent: US 6566061-A 19 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1251 CGGCTGACCAACAG 1265
Db 1 CAGCAGACCAACAG 15

RESULT 420
AR397783 15 bp RNA linear PAT 18-DEC-2003
LOCUS AR397783
DEFINITION Sequence 164 from patent US 6617438.
ACCESSION AR397783
VERSION AR397783.1 GI:40135046
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 164 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1393 CTGAGCTGCTGGACA 1407
Db 1 CTCGGCTGCTGGACA 15

RESULT 421
AX635891 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX635891
DEFINITION Sequence 3030 from Patent EPI260586.
ACCESSION AX635891
VERSION AX635891.1 GI:28471505
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcawiggen,J.A., Modak,A., Payco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3030 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1412 GGGTGTGAGCGGC 1426
Db 1 GGGCGCTGAGCGGC 15

RESULT 422
AX635925 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX635925
DEFINITION Sequence 3064 from Patent EPI260586.
ACCESSION AX635925
VERSION AX635925.1 GI:28471539
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcawiggen,J.A., Modak,A., Payco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3064 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1198 CTGTGACAGGCGC 1212
Db 1 CTGTGACAGGCGC 15

Db 15 CTGGGCGAGGCTCAG 1

RESULT 423
LOCUS AX636028 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3167 from Patent EP1260586.
ACCESSION AX636028
VERSION AX636028.1 GI:28471642
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpelick,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwigen,J.A., Modak,A., Payco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,V.D., Tracz,D., Ueman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 3167 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source location/Qualifiers
1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1198 CTGTGAGAGGCGCAG 1212
Db 15 CTGGCGAGGCTCAG 1

RESULT 424
LOCUS BD065515 15 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065515
VERSION BD065515.1 GI:22611118
KEYWORDS JP 2001511000-A/150.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 15)
AUTHORS Schlengerslepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 150 07-AUG-2001;
BIOLOGIST GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
OS Unknown
PN JP 2001511000-A/150
PD 07-AUG-2001
PF 30-JAN-1998 JP 199832533
PI 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSLEPEN WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1..15
/organism='Unknown'.
FEATURES
source location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.7%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1411 CGGGTGCTGAGCCGG 1425
Db 1 CGGGTGCCGGCGCGG 15

RESULT 425
LOCUS A35651 16 bp DNA linear PAT 02-DEC-1996
DEFINITION Synthetic human IFN-alpha 2 gene oligo.
ACCESSION A35651
VERSION A35651.1 GI:1927033
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 (bases 1 to 16)
AUTHORS Cambie,R. and Edge,M.D.
TITLE Analogous interferon polypeptides, process for their preparation and pharmaceutical compositions containing them
JOURNAL Patent: EP 0194006-A 96 10-SEP-1986;
IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES
source location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGA 1270
Db 1 GCAGCAGCAGCTGCA 15

RESULT 426
LOCUS A35684 16 bp DNA linear PAT 02-DEC-1996
DEFINITION Synthetic human IFN-alpha 2 gene oligo.
ACCESSION A35684
VERSION A35684.1 GI:1927066
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 (bases 1 to 16)
AUTHORS Cambie,R. and Edge,M.D.
TITLE Analogous interferon polypeptides, process for their preparation and pharmaceutical compositions containing them
JOURNAL Patent: EP 0194006-A 129 10-SEP-1986;
IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES
source location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGA 1270
Db 1 GCAGCAGCAGCTGCA 15

RESULT 427
LOCUS I62261/c 16 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 815 from patent US 5658780.
ACCESSION I62261

VERSION 162261.1 GI:2480209
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
JOURNAL Rel a targeted ribozymes
Patent: US 5658780-A 815 19-AUG-1997;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1200 GTGCAGAGGCGAGCC 1214
Db 16 GGGCAGAGGTGAGCC 2
RESULT 428
LOCUS AR328267 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5669 from patent US 6566127.
ACCESSION AR328267
VERSION AR328267.1 GI:33714075
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
JOURNAL Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6566127-A 5669 20-MAY-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1331 CTTCTCAAGCAGC 1345
Db 1 CATCTCAATGACAG 15
RESULT 429
LOCUS AR329675 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 7077 from patent US 6566127.
ACCESSION AR329675
VERSION AR329675.1 GI:33715483
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
JOURNAL Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6566127-A 7077 20-MAY-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1376 GAAGCAGCTGGCTT 1390
Db 2 GAAGCAGTGCCTT 16
RESULT 430
LOCUS AR329710 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 7112 from patent US 6566127.
ACCESSION AR329710
VERSION AR329710.1 GI:33715518
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
JOURNAL Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6566127-A 7112 20-MAY-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1228 TCCAGCATGCTGG 1242
Db 16 TCCAGCATGCTGG 2
RESULT 431
LOCUS AX067893 16 bp DNA linear PAT 19-JAN-2001
DEFINITION Sequence 34 from Patent WO0077205.
ACCESSION AX067893
VERSION AX067893.1 GI:12329750
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Barber,G.N., Saunders,L. and Perkins,D.
TITLE Human nuclear factors associated with derma (nfar)
JOURNAL Patent: WO 0077205-A 34 21-DEC-2000;
JOURNAL Barber, Glen N. (US); Saunders, Laura (US); Perkins, Darren (US)
FEATURES
source
1. .16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1261 AACACCTGGAAGAGC 1275
Db 15 AACACCTGGAAGAGC 1
RESULT 432
LOCUS AX357856 16 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 47 from Patent WO0181916.
ACCESSION AX357856

VERSION AX357856.1 GI:18674669
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Ma,N., Strom,T., Soares,M.C. and Ferran,C.
METHODS Methods of evaluating transplant rejection
PATENT: WO 0181916-A 47 01-NOV-2001;
JOURNAL Beth Israel Deaconess Medical Center, Inc. (US) ; Cornell Research Foundation (US)
FEATURES
source Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="internal sense primer"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1345 GAGACTTCCCGG 1359
DB 1 GAGACTTCACCGG 15
RESULT 433
LOCUS AX465582 16 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 110 from Patent WO0214368.
ACCESSION AX465582
VERSION AX465582.1 GI:21899885
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Zernusen,B.D., Padigaru,M., Spytek,K.A., Spaderna,S.K.,
Ganogoli,E.A., Rastelli,L., Burgess,C.E., Majumder,K., Shimkets,R.,
Mishra,V., Verne,C.A., Szekeres,E.S., Grose,W.M., Alsbrook,J.P.,
Liu,X., Gerlach,V.L., Ellerman,K., Smltson,G., Peyman,J., Stone,D.
and MacDougall,J.
TITLE Proteins and nucleic acids encoding the same
JOURNAL Patent: WO 0214368-A 110 21-FEB-2002;
Curagen Corporation (US)
FEATURES
source Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Ag192 PCR Primer Sequence"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1199 TGTGACGAGGCGAGC 1213
DB 1 TGTGCCGAGGCGCAC 15
RESULT 434
LOCUS AX636652 16 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3791 from Patent EP1260586.
ACCESSION AX636652
VERSION AX636652.1 GI:28472266
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1

AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Marsiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
PATENT: EP 1260586-A 3791 27-NOV-2002;
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1200 GTGCAGAGCGCGCC 1214
DB 16 GGCAGAGGTCAGCC 2
RESULT 435
LOCUS BD104299 16 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104299
VERSION BD104299.1 GI:22649873
KEYWORDS WO 0192572-A/403.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 16)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 403 06-DEC-2001;
NISHINBO INDUSTRIES INC., SYSTEM RESEARCH INC.,HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA
COMMENT OS Artificial Sequence
PN WO 0192572-A/403
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PI 01-JUN-2000 JP 00P 164798
PT HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:primer
FH Key Location/Qualifiers
FT source 1..16
/organism='Artificial Sequence'.
FEATURES
source Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 4.7%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1403 GCACGACCGCGTGC 1417
DB 15 GCACGAGCGCGTGC 1
RESULT 436
LOCUS AR307963 20 bp DNA linear PAT 12-JUN-2003

DEFINITION Sequence 174 from patent US 6551826.
ACCESSION AR307963
VERSION AR307963.1 GI:31698719
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Watt,A.T.
TITLE Antisense modulation of raidd expression
JOURNAL Patent: US 6551826-A 174 22-APR-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.7%; Score 11.8; DB 1; Length 20;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1228 TCCAGCATGTGCTGG 1242
|||||
Db 20 TCCAGCACATGCTGG 6

RESULT 437
LOCUS CO801494 13 bp DNA linear PAT 05-MAY-2004
DEFINITION Sequence 4 from Patent WO2004033723.
ACCESSION CO801494
VERSION CO801494.1 GI:47058088
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Mitchell,J. and de Bellerocche,J.
TITLE Neurodegenerative disease-associated gene
JOURNAL Patent: WO 2004033723-A 4 22-APR-2004;
IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES Location/Qualifiers
source 1..13
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1273 AGGCTGAGGGCAG 1285
|||||
Db 1 AGGCTGGGGGCGAG 13

RESULT 438
LOCUS A07515/c 15 bp DNA linear PAT 27-JUL-1993
DEFINITION primer TG 1290.
ACCESSION A07515
VERSION A07515.1 GI:413623
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS
TITLE
JOURNAL
FEATURES
PROTEINS AND PROCESS FOR PREPARING THEM, DNA SEQUENCES, ANTIBODIES
AND THEIR APPLICATION, POXVIRUS, TRANSFORMED OR INFECTED CELLS AND
PHARMACEUTICAL COMPOSITIONS USEFUL FOR PREVENTING TOXOPLASMOSIS
Patent: WO 890568-A 4 29-JUN-1989;
Location/Qualifiers

source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1284 AGAGCCCTCAGG 1296
|||||
Db 15 AGAGCCACACAGG 3

RESULT 439
LOCUS A44395 15 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 25 from Patent EP0653439.
ACCESSION A44395
VERSION A44395.1 GI:2299224
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 15)
AUTHORS Peyman,A.D., Uhlmann,E.D., Mag,M., Kretzschmar,G.D., Heleberg,M.D.
and Winkler,I.D.
TITLE Stabilized oligonucleotids and the use thereof
JOURNAL Patent: EP 0653439-A 25 17-MAY-1995;
HOECHST AG (DE)
COMMENT Other publication JP 7194385 950801
Other publication CA 2135591 950513
Other publication AU 7779994 950518
Other publication DE 4338704 950518.
FEATURES Location/Qualifiers
source 1..15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

exon 1..15
/note="BFGF TRANSLATION START SITE"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCCATGCTC 1307
|||||
Db 1 GGCTGCCATGCTC 13

RESULT 440
LOCUS A56664 15 bp DNA linear PAT 03-MAR-1998
DEFINITION Sequence 31 from Patent EP0739898.
ACCESSION A56664
VERSION A56664.1 GI:3712709
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Peyman,A.D., Uhlmann,E.D., Breipohl,G.D. and Wallmeier,H.D.
TITLE Phosphonomonoester nucleic acids, methods for their preparation and
their use
JOURNAL Patent: EP 0739898-A 31 30-OCT-1996;
HOECHST AG (DE)
COMMENT Other publication CZ 9600743 961016
Other publication CN 1138588 961225
Other publication PL 313207 960916
Other publication JP 8259579 961008
Other publication NO 961006 960916

Other publication CA 2171589 960914
Other publication AU 4802896 960926
Other publication DE 19508923 960919.
Location/Qualifiers

FEATURES
source
1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCATGTC 1307
Db 1 GGCTGCCATGTC 13

RESULT 441

LOCUS A80385 15 bp DNA linear PAT 20-OCT-1999
DEFINITION Sequence 31 from Patent EP0726274.
ACCESSION A80385
VERSION A80385.1 GI:6093112
KEYWORDS
SOURCE
ORGANISM
unclassified.
1 (bases 1 to 15)

REFERENCE
AUTHORS Peyman,A.D. and Uhlmann,E.D.
TITLE G-CAP STABILIZED OLIGONUCLEOTIDES
JOURNAL Patent: EP 0726274-A 31 14-AUG-1996;
HOECHST AG (DE)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

exon
1..15

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCATGTC 1307
Db 1 GGCTGCCATGTC 13

RESULT 442

LOCUS A97824 15 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 101 from Patent WO9914377.
ACCESSION A97824
VERSION A97824.1 GI:6781062
KEYWORDS
SOURCE
ORGANISM
unclassified.
1 (bases 1 to 15)

REFERENCE
AUTHORS Quint,W. and Klefer,B.
TITLE DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND
TYPE-SPECIFIC REVERSE HYBRIDIZATION
JOURNAL Patent: WO 9914377-A 101 25-MAR-1999;
INNOGENETICS NV (BB); DELFTS DIAGNOSTIC LAB B V (NL)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1232 GCATGTGCTGCA 1244
Db 1 GCATTGCTGCA 13

RESULT 443
AR011805
LOCUS AR011805 15 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 18 from patent US 5763172.
ACCESSION AR011805
VERSION AR011805.1 GI:3969795
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
AUTHORS Magda,D., Seessler,U.L., Wright,M., Miller,R.A. and Dow,W.C.
TITLE Method of phosphate ester hydrolysis
JOURNAL Patent: US 5763172-A 18 09-JUN-1998;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1307 CATCTGTAGCAG 1319
Db 1 CATCTGTAGCGC 13

RESULT 444

LOCUS AR034503 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 6 from patent US 5869462.
ACCESSION AR034503
VERSION AR034503.1 GI:5950108
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
AUTHORS Dzaou,Y.J.
TITLE Inhibition of proliferation of vascular smooth muscle cell
JOURNAL Patent: US 5869462-A 6 09-FEB-1999;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCATGTC 1307
Db 1 GGCTGCCATGTC 13

RESULT 445
AR034504/C
LOCUS AR034504 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 7 from patent US 5869462.
ACCESSION AR034504
VERSION AR034504.1 GI:5950109
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;

REFERENCE 1 (bases 1 to 15)
AUTHORS Dzaou, V.J.
TITLE Inhibition of proliferation of vascular smooth muscle cell
JOURNAL Patent: US 5869462-A 7 09-FEB-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCATGTC 1307
DB 15 GGCTGCCATGTC 3

RESULT 446
AR048603 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR048603
DEFINITION Sequence 6 from patent US 5821234.
ACCESSION AR048603
VERSION AR048603.1 GI:5970946
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Dzaou, V.J.
TITLE Inhibition of proliferation of vascular smooth muscle cell
JOURNAL Patent: US 5821234-A 6 13-OCT-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCATGTC 1307
DB 1 GGCTGCCATGTC 13

RESULT 447
AR048604 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR048604
DEFINITION Sequence 7 from patent US 5821234.
ACCESSION AR048604
VERSION AR048604.1 GI:5970947
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Dzaou, V.J.
TITLE Inhibition of proliferation of vascular smooth muscle cell
JOURNAL Patent: US 5821234-A 7 13-OCT-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCATGTC 1307
DB 15 GGCTGCCATGTC 3

RESULT 448
AR056040/C 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR056040
DEFINITION Sequence 244 from patent US 5837542.
ACCESSION AR056040
VERSION AR056040.1 GI:5981617
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 244 17-NOV-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1278 GAGGCGAGAGACC 1290
DB 15 GAGGCGAGAGACC 3

RESULT 449
AR111788 15 bp DNA linear PAT 14-FEB-2001
LOCUS AR111788
DEFINITION Sequence 31 from patent US 6127346.
ACCESSION AR111788
VERSION AR111788.1 GI:12828636
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Peyman, A., Uhlmann, B., Breipohl, G. and Wallmeier, H.
TITLE Phosphonomonester nucleic acids process for their preparation and their use
JOURNAL Patent: US 6127346-A 31 03-OCT-2000;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCATGTC 1307
DB 1 GGCTGCCATGTC 13

RESULT 450
AR113798 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR113798
DEFINITION Sequence 244 from patent US 6132967.
ACCESSION AR113798
VERSION AR113798.1 GI:14094120
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of

JOURNAL Patent: US 6132967-A 244 17-OCT-2000;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1278 GAGGCGAGAGACC 1290
DB 15 GAGGCGAGAGACC 3

RESULT 451
BD208873/c 15 bp RNA linear PAT 17-JUL-2003
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to hepatitis C virus infection.
ACCESSION BD208873
VERSION BD208873.1 GI:33018643
KEYWORDS JP 2002512791-A/2463.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt, L., McSwiggen, J. A., Roberts, E., Pavco, P. A. and Macejak, D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL Patent: JP 2002512791-A 2463 08-MAY-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PD JP 2002512791-A/2463
PN 08-MAY-2002
PF 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO, DENNIS MACEJAK
PC C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1. .15
FT /organism='Hepatitis virus (hepatitis C FT
virus)'.
FEATURES
source Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1337 CAAGCAGAGAC 1349
DB 15 CAAGCAGAGAC 3

RESULT 452
127821 15 bp DNA linear PAT 06-FEB-1997
LOCUS Sequence 4 from patent US 5567687.
DEFINITION 127821
ACCESSION 127821 GI:1818597
VERSION 127821.1

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Magda, D., Seesler, J. L., Iverson, B., Jansen, P. L., Wright, M.,
Mody, T. D. and Hemmi, G. W.
JOURNAL Texaphyrins and uses thereof
PATENT: US 5567687-A 4 22-OCT-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1307 CATCTGAGCAG 1319
DB 1 CATCTGAGCAG 13

RESULT 453
131898 15 bp DNA linear PAT 06-FEB-1997
LOCUS Sequence 3 from patent US 5583116.
DEFINITION 131898
ACCESSION 131898
VERSION 131898.1 GI:1822689
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Morrison, R. S.
TITLE Method of inhibiting the growth of bFGF-dependent neoplastic cells
JOURNAL Patent: US 5583116-A 3 10-DEC-1996;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGTGCGCATGTC 1307
DB 1 GGTGCGCATGTC 13

RESULT 454
135260 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 228 from patent US 5599706.
DEFINITION 135260
ACCESSION 135260
VERSION 135260.1 GI:2088228
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 15)
TITLE Stinchcomb, D. T., McSwiggen, J., Newton, R. S. and Ramharack, R.
JOURNAL Ribozymes targeted to apo(a) mRNA
PATENT: US 5599706-A 228 04-FEB-1997;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1303 TGGTCATCTGGA 1315
|||||
Db 1 TGGTCATCTATGA 13

RESULT 455
136660 15 bp DNA linear PAT 13-MAY-1997
LOCUS Sequence 4 from patent US 5607924.
ACCESSION 136660
VERSION 136660.1 GI:2086485
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Magda,D., Seesler,J.L., Iverson,B.L., Sansom,P.I. and Wright,M.
TITLE DNA photocleavage using texaphyrins
JOURNAL Patent: US 5607924-A 4 04-MAR-1997;
FEATURES
LOCATION/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1307 CATCTGTGAGCG 1319
|||||
Db 1 CATCTGTAGCGG 13

RESULT 456
143396 15 bp DNA linear PAT 07-OCT-1997
LOCUS Sequence 1 from patent US 5631237.
ACCESSION 143396
VERSION 143396.1 GI:2468640
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Dzaou,V.J. and Kaneda,Y.
TITLE Method for producing in vivo delivery of therapeutic agents via liposomes
JOURNAL Patent: US 5631237-A 1 20-MAY-1997;
FEATURES
LOCATION/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCCATGTC 1307
|||||
Db 1 GGCTGCCATGTC 13

RESULT 457
143397 15 bp DNA linear PAT 07-OCT-1997
LOCUS Sequence 2 from patent US 5631237.
ACCESSION 143397
VERSION 143397.1 GI:2468641
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Dzaou,V.J. and Kaneda,Y.
TITLE Method for producing in vivo delivery of therapeutic agents via liposomes
JOURNAL Patent: US 5631237-A 1 20-MAY-1997;
FEATURES
LOCATION/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

REFERENCE 1 (bases 1 to 15)
AUTHORS Dzaou,V.J. and Kaneda,Y.
TITLE Method for producing in vivo delivery of therapeutic agents via liposomes
JOURNAL Patent: US 5631237-A 2 20-MAY-1997;
FEATURES
LOCATION/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCCATGTC 1307
|||||
Db 1 GGCTGCCATGTC 3

RESULT 458
143407 15 bp DNA linear PAT 07-OCT-1997
LOCUS Sequence 12 from patent US 5631237.
ACCESSION 143407
VERSION 143407.1 GI:2468651
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Dzaou,V.J. and Kaneda,Y.
TITLE Method for producing in vivo delivery of therapeutic agents via liposomes
JOURNAL Patent: US 5631237-A 12 20-MAY-1997;
FEATURES
LOCATION/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCCATGTC 1307
|||||
Db 1 GGCTGCCATGTC 13

RESULT 459
143408 15 bp DNA linear PAT 07-OCT-1997
LOCUS Sequence 13 from patent US 5631237.
ACCESSION 143408
VERSION 143408.1 GI:2468652
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Dzaou,V.J. and Kaneda,Y.
TITLE Method for producing in vivo delivery of therapeutic agents via liposomes
JOURNAL Patent: US 5631237-A 13 20-MAY-1997;
FEATURES
LOCATION/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCCATGTC 1307

Db 15 GCGTGCCATGCTC 3
|||||
|||

RESULT 460
183457 15 bp DNA linear PAT 10-AUG-1998
LOCUS 183457
DEFINITION Sequence 1 from patent US 5714328.
ACCESSION 183457
VERSION 183457.1 GI:3406987
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Magda,D. and Seesler,J.L.
TITLE RNA photocleavage using texaphyrins
JOURNAL Patent: US 5714328-A 1 03-FEB-1998;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1307 CATCTGTGAGCAG 1319
|||||
1 CATCTGTGAGCGC 13

Db 1 CATCTGTGAGCGC 13

RESULT 461
183461 15 bp DNA linear PAT 10-AUG-1998
LOCUS 183461
DEFINITION Sequence 5 from patent US 5714328.
ACCESSION 183461
VERSION 183461.1 GI:3406991
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Magda,D. and Seesler,J.L.
TITLE RNA photocleavage using texaphyrins
JOURNAL Patent: US 5714328-A 5 03-FEB-1998;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1307 CATCTGTGAGCAG 1319
|||||
1 CATCTGTGAGCGC 13

Db 1 CATCTGTGAGCGC 13

RESULT 462
AR193521 15 bp DNA linear PAT 20-APR-2002
LOCUS AR193521
DEFINITION Sequence 25 from patent US 6348312.
ACCESSION AR193521
VERSION AR193521.1 GI:20240113
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Peyman,A., Uhlmann,E., Mag,M., Kretzschmar,G., Helsing,M. and Winkler,I.

TITLE Stabilized oligonucleotides and their use
JOURNAL Patent: US 6348312-A 25 19-FEB-2002;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GCGTGCCATGCTC 1307
|||||
1 GCGTGCCATGCTC 13

Db 1 GCGTGCCATGCTC 13

RESULT 463
AR201242 15 bp DNA linear PAT 20-APR-2002
LOCUS AR201242
DEFINITION Sequence 22 from patent US 6358734.
ACCESSION AR201242
VERSION AR201242.1 GI:20252130
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Delcayre,A.
TITLE Compounds for treatment of infectious and immune system disorders
JOURNAL Patent: US 6358734-A 22 19-MAR-2002;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1359 GCAGCTGAGGCTT 1371
|||||
2 GCAGCTGTGGCTT 14

Db 2 GCAGCTGTGGCTT 14

RESULT 464
AR254817 15 bp DNA linear PAT 20-DEC-2002
LOCUS AR254817
DEFINITION Sequence 101 from patent US 6482588.
ACCESSION AR254817
VERSION AR254817.1 GI:27303865
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Van Doorn,L.-J., Quint,M., Kletter,B. and Terschegget,J.
TITLE Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization
JOURNAL Patent: US 6482588-A 101 19-NOV-2002;
FEATURES
source
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1232 GCATGTGCTGCA 1244
|||||
1 GCATTTGCTGCA 13

Db 1 GCATTTGCTGCA 13

RESULT 465
AX057554
LOCUS AX057554 15 bp DNA linear PAT 17-JAN-2001
DEFINITION Sequence 10 from Patent WO0077259.
ACCESSION AX057554
VERSION AX057554.1 GI:12310282
KEYWORDS
SOURCE Dekkera bruxellensis
ORGANISM Dekkera bruxellensis
Bukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetales; Saccharomycetaceae; Dekkera.

REFERENCE
1 Hydlig-Nielsen,J.J., O'Keefe,H.P. and Stender,H.
AUTHORS Probes, probe sets, methods and kits pertaining to the detection,
TITLE identification and/or enumeration of yeast, particularly in wine
JOURNAL Patent: WO 0077259-A 10 21-DEC-2000;
Boston Probes, Inc. (US)

FEATURES
source
1..15
Location/Qualifiers
/organism="Dekkera bruxellensis"
/mol_type="unassigned DNA"
/db_xref="taxon:5007"
/note="Description of Combined DNA/RNA molecule:PROBING
NUCLEOBASE SEQUENCE"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1185 GGCTCCAGAAC 1197
|||||
Db 3 GGCTCCAGAAC 15

RESULT 466
AX081340
LOCUS AX081340 15 bp DNA linear PAT 27-FEB-2001
DEFINITION Sequence 19 from Patent WO0108707.
ACCESSION AX081340
VERSION AX081340.1 GI:13170182
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Uhlmann,E., Greiner,B., Unger,E., Gothe,G. and Schwerdel,M.
AUTHORS Conjugates and methods for the production thereof, and their use
TITLE for transporting molecules via biological membranes
JOURNAL Patent: WO 0108707-A 19 08-FEB-2001;
Aventis Pharma Deutschland GmbH (DE)

FEATURES
source
1..15
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCCATGGTC 1307
|||||
Db 1 GGCTGCCATGGTC 13

RESULT 467
AX283170
LOCUS AX283170 15 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 8 from Patent WO0179216.
ACCESSION AX283170
VERSION AX283170.1 GI:17044051

KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Uhlmann,E., Breipohl,G. and Will,D.W.
AUTHORS Polyamide nucleic acid derivatives, agents and methods for
TITLE producing them
JOURNAL Patent: WO 0179216-A 8 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)

FEATURES
source
1..15
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen
Sequenz:Oligonukleotide"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCCATGGTC 1307
|||||
Db 1 GGCTGCCATGGTC 13

RESULT 468
AX283299
LOCUS AX283299 15 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 63 from Patent WO0179249.
ACCESSION AX283299
VERSION AX283299.1 GI:17044180
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Uhlmann,E., Breipohl,G. and Will,D.W.
AUTHORS Polyamide nucleic acid derivatives, agents and methods for
TITLE producing the same
JOURNAL Patent: WO 0179249-A 63 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)

FEATURES
source
1..15
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz:
Oligonukleotide"

Query Match 4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1295 GGGTGCCATGGTC 1307
|||||
Db 1 GGCTGCCATGGTC 13

RESULT 469
AX377091/c
LOCUS AX377091 15 bp DNA linear PAT 18-MAR-2002
DEFINITION Sequence 12 from Patent WO0212561.
ACCESSION AX377091
VERSION AX377091.1 GI:19573382
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
1 Kazemi,A., Messer,C. and Tanguay,D.A.

TITLE Haplotypes of the orig1 gene
JOURNAL Patent: WO 0212561-A 12 14-FEB-2002;
Genaisance Pharmaceuticals, Inc. (US)
FEATURES
source
1. .15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 4.5%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1393 CTGAGCTGCTGGACA 1407
DB 15 CTGAGATGCTGTCTCA 1

RESULT 470
AX428702 15 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 101 from Patent EP1201771.
ACCESSION AX428702
VERSION AX428702.1 GI:21538613
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Van Doorn, L.J., Kleter, B. and Ter Schegget, J.
TITLE Detection and identification of human papillomavirus by pcr and
type-specific reverse hybridization
JOURNAL Patent: EP 1201771-A 101 02-MAY-2002;
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 4.5%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1232 GCATGCTGCGCA 1244
DB 1 GCATTGCTGCGCA 13

RESULT 471
AX633061 15 bp RNA linear PAT 21-FEB-2003
LOCUS Sequence 200 from Patent EP1260586.
ACCESSION AX633061
VERSION AX633061.1 GI:28468675
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Dizenzo, A.,
Karpelesky, A., Draper, K.G., Kisch, K., Matulic-Adamic, J.,
Mcswiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Swedler, D., Thompson, J.D., Tracz, D., Uman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 200 27-NOV-2002;
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"

/db_xref="taxon:32644"

Query Match
Best Local Similarity 4.5%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1278 GAGGCGAGAGACC 1290
DB 15 GAGGCGAGAGACC 3

RESULT 472
AX825243 15 bp DNA linear PAT 11-DEC-2003
LOCUS Sequence 52 from Patent WO03072819.
ACCESSION AX825243
VERSION AX825243.1 GI:39750972
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fischer, A.
TITLE Analysis of mixtures of nucleic acid fragments
JOURNAL Patent: WO 03072819-A 52 04-SEP-2003;
FEATURES
source
1. .15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32650"
/note="primer of table 2"

Query Match
Best Local Similarity 4.5%; Score 11.4; DB 1; Length 15;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1247 GGTCCGCGCTGCAG 1259
DB 3 GGTCCGCGCTGCAG 15

RESULT 473
BD090530 15 bp DNA linear PAT 27-AUG-2002
LOCUS Photocleavage of RNA using texaphylline.
ACCESSION BD090530
VERSION BD090530.1 GI:22636140
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Magda, D. and Seesler, J.L.
TITLE Photocleavage of RNA using texaphylline
JOURNAL Patent: JP 2001316270-A 1 13-NOV-2001;
COMMENT PHARMACYCICS INC. BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
OS Artificial Sequence
PN JP 2001316270-A/1
PD 13-NOV-2001
PF 13-MAR-2001 JP 2001071295
PI 07-JUN-1995 US 08/484551
PI DAREN MAGDA, JONATHAN L SESSLER
PC A61K31/7125, A61K31/7135, A61K41/00, A61P35/00//C07H21/00 PC
PC C07H23/00, C12N15/09,
PC C12N15/00
CC Photocleavage of RNA using texaphylline
FH Key Location/Qualifiers
FT source 1. .15
FT Location/Qualifiers
FEATURES
source
1. .15
/organism="synthetic construct"

```
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match      4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1307 CATCTGTGAGCAG 1319
Db      1 CATCTGTGAGCCG 13

RESULT 474
BD090534      15 bp      RNA      linear      PAT 27-AUG-2002
LOCUS      BD090534
DEFINITION      Photocleavage of RNA using texaphylline.
ACCESSION      BD090534
VERSION      BD090534.1 GI:22636144
KEYWORDS      JP 2001316270-A/5.
SOURCE      synthetic construct
ORGANISM      artificial sequences.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Magda, D. and Seesler, J.L.
TITLE      Photocleavage of RNA using texaphylline
JOURNAL      Patent: JP 2001316270-A 5 13-NOV-2001;
              PHARMACEUTICALS INC, BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
COMMENT      OS Artificial Sequence
              PN JP 2001316270-A/5
              PD 13-NOV-2001
              PF 13-MAR-2001 JP 2001071295
              PR 07-JUN-1995 US 08/484551
              PI DARREN MAGDA, JONATHAN L SESSLER
              PC A61K31/7125, A61K31/7135, A61K41/00, A61P35/00//C07H21/00 PC
              PC C12N15/00
              CC Photocleavage of RNA using texaphylline
              FH Key
              FT source
              Location/Qualifiers
                1..15
                  /organism="synthetic construct"
                  /mol_type="genomic RNA"
                  /db_xref="taxon:32630"

Query Match      4.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1307 CATCTGTGAGCAG 1319
Db      1 CATCTGTGAGCCG 13

RESULT 475
A97889      16 bp      DNA      linear      PAT 26-JAN-2000
LOCUS      A97889
DEFINITION      Sequence 166 from Patent WO914377.
ACCESSION      A97889
VERSION      A97889.1 GI:6781127
KEYWORDS
SOURCE      unidentified
ORGANISM      unidentified
REFERENCE      1 (bases 1 to 16)
AUTHORS      Quint, W. and Kleier, B.
TITLE      DIRECTION OF IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND
              TYPE-SPECIFIC REVERSE HYBRIDIZATION
JOURNAL      Patent: WO 9914377-A 166 25-MAR-1999;
              INNOGENETICS NV (BE); DELFTS DIAGNOSTIC LAB B V (NL)
COMMENT      Location/Qualifiers
                1..16
```

```
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match      4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1232 GCATTGCTGGCA 1244
Db      2 GCATTGCTGGCA 14

RESULT 476
BD222800/C      16 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      BD222800
DEFINITION      Quantitative analysis of gene expression using PCR.
ACCESSION      BD222800
VERSION      BD222800.1 GI:33032570
KEYWORDS      JP 2002521035-A/7.
SOURCE      synthetic construct
ORGANISM      artificial sequences.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Carey, J.E.
TITLE      Quantitative analysis of gene expression using PCR
JOURNAL      Patent: JP 2002521035-A 7 16-JUL-2002;
              PHARMAGENE LABORATORIES LTD
COMMENT      OS Artificial Sequence
              PN JP 2002521035-A/7
              PD 16-JUL-2002
              PF 21-JUL-1999 JP 2000561355
              PR 21-JUL-1998 GB 9815799.3
              PI JANET ELLIABETH CAREY
              PC C12N15/09, C12Q1/68, G01N33/50, C12N15/00
              CC Description of Artificial Sequence: oligonucleotide FH
              FT source
              Location/Qualifiers
                1..16
                  /organism="Artificial Sequence".

FEATURES
source
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match      4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1375 AGAGCGAGCTCG 1387
Db      15 AGAGCGAGCTCG 3

RESULT 477
BD223854      16 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      BD223854
DEFINITION      Identification of microorganism causing acute respiratory tract
              infection (ARI).
ACCESSION      BD223854
VERSION      BD223854.1 GI:33033624
KEYWORDS      JP 2002526088-A/29.
SOURCE      synthetic construct
ORGANISM      synthetic construct
REFERENCE      1 (bases 1 to 16)
AUTHORS      Jannes, G. and Schmitt, H.J.
TITLE      Identification of microorganism causing acute respiratory tract
              infection (ARI)
JOURNAL      Patent: JP 2002526088-A 29 20-AUG-2002;
              INNOGENETICS NV
COMMENT      OS Artificial Sequence
              PN JP 2002526088-A/29
```

PD 20-AUG-2002
PF 22-SEP-1999 JP 2000574290
PR 24-SEP-1998 EP 98870203.1
PI GERT JANNES, HEINZ JOSEF SCHMITT
PC C12N15/09, C12Q1/68, C12N15/00
CC Description of Artificial Sequence: oligonucleotide FH Key
FT source 1.16
/organism='Artificial Sequence'.
FEATURES
source location/Qualifiers
1.16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1196 GCCTGTGCAGAG 1208
Db 1 GCCTGTCCAGAG 13
|||||
|||||

RESULT 478
AR254882 16 bp DNA linear PAT 20-DEC-2002
LOCUS Sequence 166 from patent US 6482588.
DEFINITION AR254882
ACCESSION AR254882
VERSION AR254882.1 GI:27303930
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Van Doorn, L.-J., Kleter, W., Kleter, B. and Terschegget, J.
TITLE Detection and identification of human papillomavirus by PCR and
type-specific reverse hybridization
JOURNAL Patent: US 6482588-A 166 19-NOV-2002;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1232 GCATGTGCTGCA 1244
Db 2 GCATTTGCTGCA 14
|||||
|||||

RESULT 479
AR307515 16 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 7 from patent US 6551783.
DEFINITION AR307515
ACCESSION AR307515
VERSION AR307515.1 GI:31698075
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Carey, J.E.
TITLE Quantitative analysis of gene expression using PCR
JOURNAL Patent: US 6551783-A 7 22-APR-2003;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.5%; Score 11.4; DB 1; Length 16;

Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1375 AGAAGCAGTCGC 1387
Db 15 AGAAGCCGTCG 3
|||||
|||||

RESULT 480
AX384652 16 bp DNA linear PAT 19-MAR-2002
LOCUS Sequence 24 from Patent EP182206.
DEFINITION AX384652
ACCESSION AX384652
VERSION AX384652.1 GI:19577847
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Peymann, A., Uhlmann, E., Mag, M., Kretschmar, G., Helsberg, M. and
Winkler, I.
TITLE Stabilized oligonucleotide and the use thereof
JOURNAL Patent: EP 1182206-A 24 27-FEB-2002;
FEATURES HOECHST AKTIBNGBSELISCHAFT (DB)
source Location/Qualifiers
1.16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense Oligonucleotide"

Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1295 GGGTGCATGCTC 1307
Db 1 GGGTGCATGCTC 13
|||||
|||||

RESULT 481
AX428767 16 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 166 from Patent EP1201771.
DEFINITION AX428767
ACCESSION AX428767
VERSION AX428767.1 GI:21538678
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Van Doorn, L.-J., Kleter, B. and Ter Schegget, J.
TITLE Detection and identification of human papillomavirus by pcr and
type-specific reverse hybridization
JOURNAL Patent: EP 1201771-A 166 02-MAY-2002;
FEATURES INNOGENETICS N.V. (BE) ; Delfts Diagnostic laboratory B.V. (NL)
source 1.16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1232 GCATGTGCTGCA 1244
Db 2 GCATTTGCTGCA 14
|||||
|||||

RESULT 482
AX794569

LOCUS AX794569 16 bp DNA linear PAT 04-OCT-2003
DEFINITION Sequence 145 from Patent WO03051917.
ACCESSION AX794569
VERSION AX794569.1 GI:37515508
KEYWORDS
SOURCE
ORGANISM
FEATURES
REFERENCE 1
AUTHORS Giard, J.P., Rousigne, M., Kossida, S. and Amalric, F.
TITLE Novel death associated proteins of the thap family and related par
JOURNAL
patways involved in apoptosis control
Patient: WO 03051917-A 145 26-JUN-2003;
Endocube SAS (FR) ; Centre National De La Recherche
Scientifique-CNRS (FR)
FEATURES
SOURCE
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="DR-5-related sequence"

Query Match 4.5%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1232 GCATGCTGTGCA 1244
Db 3 GCATGCTGTGCA 15

RESULT 483
LOCUS AX475583 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 804 from Patent WO0224750.
ACCESSION AX475583
VERSION AX475583.1 GI:22214868
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL
Patient: WO 0224750-A 804 28-MAR-2002;
Aecomica, Inc. (US)
FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.5%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1285 GAGACCTCTCAGGG 1297
Db 3 GAGACCTCTCAGGG 15

RESULT 484
LOCUS AX475584 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 805 from Patent WO0224750.
ACCESSION AX475584
VERSION AX475584.1 GI:22214869
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL
Patient: WO 0224750-A 805 28-MAR-2002;
Aecomica, Inc. (US)
FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.5%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1285 GAGACCTCTCAGGG 1297
Db 2 GAGACCTCTCAGGG 14

RESULT 485
LOCUS A24599 16 bp DNA linear PAT 02-OCT-1995
DEFINITION Tomato genomic Pet1 fragment.
ACCESSION A24599
VERSION A24599.1 GI:1247304
KEYWORDS
SOURCE
ORGANISM
Lycopersicon esculentum (tomato)
Lycopersicon esculentum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Eukaryota; Viridiplantae; Magnoliophyta; eudicotyledons; core eudicots;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; lamids; Solanales; Solanaceae; Solanum; Lycopersicon.
REFERENCE 1 (bases 1 to 16)
AUTHORS Zabeau, M. and Vos, P.
TITLE Selective restriction fragment amplification : a general method for
JOURNAL
DNA fingerprinting
Patient: EP 0534858-A 9 31-MAR-1993;
KEYGENE N.V.
FEATURES
SOURCE
1. .16
/organism="Lycopersicon esculentum"
/mol_type="unassigned DNA"
/db_xref="taxon:4081"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1227 CTCGACGATGCTGG 1242
Db 16 CTCGACGATGCTGG 1

RESULT 486
LOCUS A24601 16 bp DNA linear PAT 02-OCT-1995
DEFINITION Tomato genomic Pet1 fragment.
ACCESSION A24601
VERSION A24601.1 GI:1247305
KEYWORDS
SOURCE
ORGANISM
Lycopersicon esculentum (tomato)
Lycopersicon esculentum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; lamids; Solanales; Solanaceae; Solanum; Lycopersicon.
REFERENCE 1 (bases 1 to 16)
AUTHORS Zabeau, M. and Vos, P.
TITLE Selective restriction fragment amplification : a general method for
JOURNAL
DNA fingerprinting
Patient: EP 0534858-A 11 31-MAR-1993;
KEYGENE N.V.
FEATURES
SOURCE
1. .16
/organism="Lycopersicon esculentum"

```
/organism="Lycopersicon esculentum"
/mol_type="unassigned DNA"
/db_xref="taxon:4081"

Query Match          4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1244 AGTGTCCGCGCTGCAG 1259
DB 16 AGAGTTGCGCTGCAG 1

RESULT 487
LOCUS A40502 16 bp DNA linear PAT 05-MAR-1997
DEFINITION Sequence 39 from Patent WO9425578.
ACCESSION A40502 GI:2296537
VERSION A40502.1 GI:2296537
KEYWORDS
SOURCE
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS
TITLE ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE
JOURNAL EFFECTS OF TRANSFORMING GROWTH FACTOR--G(b) (TGF--G(b))
BIOLOGIST Patent: WO 9425578-A 39 10-NOV-1994;
DE)
FEATURES
source Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match          4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1254 CTGCAGCAACGCTGG 1269
DB 1 CTGAGCAATGCTGG 16

RESULT 488
LOCUS A89029 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1177 from Patent WO9833904.
ACCESSION A89029
VERSION A89029.1 GI:6737599
KEYWORDS
SOURCE
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1177 06-AUG-1998;
DE)
FEATURES
source Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match          4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1254 CTGCAGCAACGCTGG 1269
DB 1 CTGAGCAATGCTGG 16
```

```
RESULT 489
LOCUS AR175689/c 16 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 89 from patent US 6309853.
ACCESSION AR175689
VERSION AR175689.1 GI:17916988
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Friedman,J.M., Zhang,Y. and Proenca,R.
TITLE Modulators of body weight, corresponding nucleic acids and
JOURNAL proteins, and diagnostic and therapeutic uses thereof
BIOLOGIST Patent: US 6309853-A 89 30-OCT-2001;
DE)
FEATURES
source Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match          4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1209 GCAGCCATCTGTCTAGA 1224
DB 16 GCAGCCAGCAATCAGA 1

RESULT 490
LOCUS AR178193 16 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 12 from patent US 6319494.
ACCESSION AR178193
VERSION AR178193.1 GI:20219331
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Capon,D.J., Weiss,A., Irving,B.A., Roberts,M.R. and Zeebo,K.
TITLE Chimeric chains for receptor-associated signal transduction
JOURNAL pathways
BIOLOGIST Patent: US 6319494-A 12 20-NOV-2001;
DE)
FEATURES
source Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match          4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1240 TGGCAGTGTCTCGGCT 1255
DB 1 TAGCAGAGTCTCAGCT 16

RESULT 491
LOCUS CQ796687 16 bp DNA linear PAT 19-APR-2004
DEFINITION Sequence 59 from Patent WO2004027062.
ACCESSION CQ796687
VERSION CQ796687.1 GI:46408368
KEYWORDS
SOURCE
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Cartaruzza,M. and Hecker,M.
TITLE Functional correction of the sp -786 /sp c/t variance of the human
enos gene
```


JOURNAL Patent: WO 2004027062-A 59 01-APR-2004;
Avontec GmbH (DE)
FEATURES Location/Qualifiers
SOURCE 1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="DNA Oligonucleotide"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1351 TTCCAGGCGAGCTGA 1366
DB 1 TTCCCTGGCCGCTGA 16

RESULT 492
AR195265/c
LOCUS AR195265 16 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 89 from patent US 6350730.
ACCESSION AR195265
VERSION AR195265.1 GI:20244702
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Friedman,J.M., Zhang,Y. and Proenca,R.
TITLE OB polypeptides and modified forms as modulators of body weight
JOURNAL Patent: US 6350730-A 89 26-FEB-2002;
FEATURES Location/Qualifiers
SOURCE 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1209 GCAGCCATCTGTGAGA 1224
DB 16 GCAGCCAGCAATCAGA 1

RESULT 493
AR204613
LOCUS AR204613 16 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 3 from patent US 6368790.
ACCESSION AR204613
VERSION AR204613.1 GI:21501984
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Scott,R.E.
TITLE CDNA encoding P2P proteins and use of P2P cDNA derived antibodies and antisense reagents in determining the proliferative potential of normal, abnormal, and cancer cells in animals and humans
JOURNAL Patent: US 6368790-A 3 09-APR-2002;
FEATURES Location/Qualifiers
SOURCE 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1374 CAGAAGCAGCTGCGTT 1389
DB 1 CAGAAGCAGCTGCTT 1389

DB 1 CAGCAGAGACTGTGTT 16

RESULT 494
AR222347/c
LOCUS AR222347 16 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 89 from patent US 6429290.
ACCESSION AR222347
VERSION AR222347.1 GI:23329832
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Friedman,J.M., Zhang,Y. and Proenca,R.
TITLE OB polypeptides, modified forms and derivatives
JOURNAL Patent: US 6429290-A 89 06-AUG-2002;
FEATURES Location/Qualifiers
SOURCE 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1209 GCAGCCATCTGTGAGA 1224
DB 16 GCAGCCAGCAATCAGA 1

RESULT 495
AR232782
LOCUS AR232782 16 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 39 from patent US 6455689.
ACCESSION AR232782
VERSION AR232782.1 GI:27275120
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiepen,G.-F., Brysch,W., Schlingensiepen,K.-H.,
Schlingensiepen,R. and Bogdahn,U.
TITLE Antisense-oligonucleotides for transforming growth factor-.beta.
(TGF-.beta.)
JOURNAL Patent: US 6455689-A 39 24-SEP-2002;
FEATURES Location/Qualifiers
SOURCE 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGACGACACGCTGG 1265
DB 1 CTGAAGCAATAGTTGG 16

RESULT 496
AR241466/c
LOCUS AR241466 16 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 89 from patent US 6471956.
ACCESSION AR241466
VERSION AR241466.1 GI:27287156
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Friedman,J.M., Zhang,Y. and Proenca,R.

TITLE Ob polypeptides, modified forms and compositions thereto
JOURNAL Patent: US 6471956-A 89 29-OCT-2002;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1209 GCAGCCTCTGTGAGA 1224
|||||
16 GCAGCCGACCAATCAGA 1

Db 16 GCAGCCGACCAATCAGA 1

RESULT 497
AR305485/c 16 bp DNA linear PAT 12-JUN-2003
LOCUS AR305485
DEFINITION Sequence 443 from patent US 6545137.
ACCESSION AR305485
VERSION AR305485.1 GI:31694795
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hees,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.U.
TITLE Receptor
JOURNAL Patent: US 6545137-A 443 08-APR-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1395 GAGCTGCTGGACAGAC 1410
|||||
16 GGGCTGCTGCACAAAGAC 1

Db 16 GGGCTGCTGCACAAAGAC 1

RESULT 498
AR309589/c 16 bp DNA linear PAT 12-JUN-2003
LOCUS AR309589
DEFINITION Sequence 443 from patent US 6555654.
ACCESSION AR309589
VERSION AR309589.1 GI:31701594
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hees,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.U.
TITLE LDL-receptor
JOURNAL Patent: US 6555654-A 443 29-APR-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1395 GAGCTGCTGGACAGAC 1410
|||||
16 GGGCTGCTGCACAAAGAC 1

Db 16 GGGCTGCTGCACAAAGAC 1

RESULT 499
AR391435/c 16 bp DNA linear PAT 18-DEC-2003
LOCUS AR391435
DEFINITION Sequence 47 from patent US 6613520.
ACCESSION AR391435
VERSION AR391435.1 GI:40114927
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ashby,M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: US 6613520-A 47 02-SEP-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1396 AGCTGCTGGACAGACC 1411
|||||
16 AGCTGCGGACACAGAAC 1

Db 16 AGCTGCGGACACAGAAC 1

RESULT 500
AR391519/c 16 bp DNA linear PAT 18-DEC-2003
LOCUS AR391519
DEFINITION Sequence 131 from patent US 6613520.
ACCESSION AR391519
VERSION AR391519.1 GI:40115021
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ashby,M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: US 6613520-A 131 02-SEP-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1396 AGCTGCTGGACAGACC 1411
|||||
16 AGCTGCGGACACAGAAC 1

Db 16 AGCTGCGGACACAGAAC 1

RESULT 501
AX203198 16 bp DNA linear PAT 30-AUG-2001
LOCUS AX203198
DEFINITION Sequence 51 from Patent WO0153529.
ACCESSION AX203198
VERSION AX203198.1 GI:15392564
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Thomann,H.U. and Fitzgerald,M.S.
TITLE Rapid determination of gene structure using cdna sequence
JOURNAL Patent: WO 0153529-A 51 26-JUL-2001;

Genome Therapeutics Corporation (US)
FEATURES
source
1.16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1260 CAACAGCTGAAGAGG 1275
DB 1 CATACCTGAAGAGG 16

RESULT 502
AX281915/c
LOCUS AX281915 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 47 from Patent WO0177392.
ACCESSION AX281915
VERSION AX281915.1 GI:16609166
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 47 18-OCT-2001;
Ashby, Matthew (US)
LOCATION/Qualifiers
1.16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="unidentified soil organism"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1396 AGCTGCTGACGACC 1411
DB 16 AGCTGCGCACGACC 1

RESULT 503
AX281999/c
LOCUS AX281999 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 131 from Patent WO0177392.
ACCESSION AX281999
VERSION AX281999.1 GI:16609250
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 131 18-OCT-2001;
Ashby, Matthew (US)
LOCATION/Qualifiers
1.16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="unidentified soil organism"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1396 AGCTGCTGACGACC 1411
DB 16 AGCTGCGCACGACC 1

RESULT 504
AX287202/c
LOCUS AX287202 16 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 2 from Patent WO0168122.
ACCESSION AX287202
VERSION AX287202.1 GI:17049135
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Schlingensiepen, K.H., Schlingensiepen, R., Apfel, R., Brysch, W., Jachmierz, P. and Bogdahn, U.
TITLE A method for reversing the immunosuppressive effects of the melanoma inhibitory activity mla
JOURNAL Patent: WO 0168122-A 2 20-SEP-2001;
Biogenetik Gesellschaft fuer Biomolekulare Diagnostik mbH (DE)
LOCATION/Qualifiers
1.16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1325 GACCTCTTCTCAAG 1340
DB 16 GTATCTTCTTCCAAG 1

RESULT 505
AX316398
LOCUS AX316398 16 bp DNA linear PAT 14-DEC-2001
DEFINITION Sequence 39 from Patent EP1160319.
ACCESSION AX316398
VERSION AX316398.1 GI:17899571
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Schlingensiepen, G.F., Brysch, W., Schlingensiepen, K.H., Schlingensiepen, R. and Bogdahn, U.
TITLE Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta)
JOURNAL Patent: EP 1160319-A 39 05-DEC-2001;
BIOGENOSTIK GESELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK mbH (DE)
LOCATION/Qualifiers
1.16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Description of unknown: unknown"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGACGACAGCTGG 1269
DB 1 CTGAAGCAATAGTTGG 16

RESULT 506

AX572085
LOCUS AX572085 16 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 125 from Patent WO02055741.
ACCESSION AX572085
VERSION AX572085.1 GI:26004175
KEYWORDS
SOURCE
ORGANISM Human immunodeficiency virus
Virusess; Retroid virusess; Retroviridae; Lentivirus; Primate
lentivirus group.
REFERENCE
1 de Smet,K. and Sruyerer,L.
Method for detection of drug-induced mutations in the hiv reverse
transcriptase gene
Patent: WO 02055741-A 125 18-JUL-2002;
JOURNAL INNOGENETICS N.V. (BE)
FEATURES
source
1.16
/organism="Human immunodeficiency virus"
/mol_type="unassigned DNA"
/db_xref="taxon:12721"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1211 AGCCATCTGTCAGAAC 1226
DB 1 AGTTATCTGTGTCAGTAC 16

RESULT 507
LOCUS AX572177 16 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 217 from Patent WO02055741.
ACCESSION AX572177
VERSION AX572177.1 GI:26004267
KEYWORDS
SOURCE Human immunodeficiency virus
Virusess; Retroid virusess; Retroviridae; Lentivirus; Primate
lentivirus group.
REFERENCE
1 de Smet,K. and Sruyerer,L.
Method for detection of drug-induced mutations in the hiv reverse
transcriptase gene
Patent: WO 02055741-A 217 18-JUL-2002;
JOURNAL INNOGENETICS N.V. (BE)
FEATURES
source
1.16
/organism="Human immunodeficiency virus"
/mol_type="unassigned DNA"
/db_xref="taxon:12721"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1211 AGCCATCTGTCAGAAC 1226
DB 1 AGTCACTATTCAGTAC 16

RESULT 508
LOCUS AX927919 16 bp DNA linear PAT 19-DEC-2003
DEFINITION Sequence 5 from Patent WO03085110.
ACCESSION AX927919
VERSION AX927919.1 GI:40250704
KEYWORDS
SOURCE
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Thru, C.A., h G.A.M. and Kristjansen, P.E.
Oligomeric compounds for the modulation hif-1alpha expression
Patent: WO 03085110-A 5 16-OCT-2003;
JOURNAL Cureon A/S (DK)
FEATURES
source
Location/Qualifiers
1.16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:12630"
/note="Description of Artificial Sequence:antiense
oligonucleotide to human HIF-1a"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1323 GGGAGCCTCTTCCCA 1338
DB 16 GGGAGCCGATTCACCA 1

RESULT 509
LOCUS BD014832 16 bp DNA linear PAT 27-AUG-2002
DEFINITION Modulator of weight, corresponding nucleic acid and protein, and
diagnosis and remedy utilization thereof.
ACCESSION BD014832
VERSION BD014832.1 GI:22555639
KEYWORDS JP 2001157591-A/73.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 16)
Friedman,J.M., Zhang,Y., Proenca,R., Maffei,M., Halaas,J.L.,
Kajiwara,K. and Burley,S.K.
Modulator of weight, corresponding nucleic acid and protein, and
diagnosis and remedy utilization thereof
Patent: JP 2001157591-A 73 12-JUN-2001;
JOURNAL THE ROCKEFELLER UNIVERSITY
COMMENT
OS Homo sapiens (human)
PN JP 2001157591-A/73
PD 12-JUN-2001
PF 29-SEP-2000 JP 2000301496 08/438431 PR
PR 30-NOV-1994 US 08/347563,10-MAY-1995 US 08/438431 PR
PI JEFFRY M FRIEDMAN,YIYING ZHANG,RICARDO PROENCA,MARGHERITA PI
MAFFEI,
PI JEFFRY L HALAAS,KETAN KAJIWARA,STEPHEN K BURLEY PC
C12N15/09,A61K31/711,A61K38/00,A61K39/395,A61K45/00,A61K48/00, PC
A61P3/04,
PC A61P3/06,A61P3/10,A61P9/12,C07K14/47,C07K16/18,C12N1/19,C12N1/
PC 21.C12N5/10,
PC C12N5/10,C12P21/02,C12P21/08,C12Q1/68//C12N1/19,C12R1:72), PC
(C12N1/19,C12R1:85),(C12N1/19,C12R1:19),(C12N1/19,C12R1:07), PC
(C12N1/21,C12R1:465),(C12N1/21,C12R1:38),(C12N5/10,C12R1:91), PC
(C12P21/02,C12R1:19),C12N15/00,A61K37/02,C12N5/00,C12N5/00, PC
(C12N5/00,C12R1:91)
CC Strandedness: Single;
CC Topology: linear;
CC Marker AFM199xh12
FH Key
FT source
1.16
/organism="Homo sapiens (human)".
FEATURES
source
1.16
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;

Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1209 GCAGCATCTGCAGA 1224
|||||||
16 GCAGCCAGCATCAGA 1

Db

RESULT 510
BD066542 16 bp DNA linear PAT 27-AUG-2002
LOCUS An antisense oligonucleotide preparation method.
DEFINITION BD066542
ACCESSION BD066542.1 GI:22612145
VERSION JP 2001511000-A/1177.
KEYWORDS unclassified
SOURCE unclassified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiefen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1177 07-AUG-2001;
BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/1177
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PI 31-JAN-1997 EP 97101531.8
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1..16
Location/Qualifiers
1..16
/organism="Unknown"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 CTGCAGCAACGCTGG 1269
|||||||
1 CTGAGCAATGATTGG 16

Db

RESULT 511
BD106396/c 16 bp DNA linear PAT 18-SEP-2002
LOCUS Novel LDL-receptor.
DEFINITION BD106396
ACCESSION BD106396.1 GI:23201214
VERSION JP 2002501376-A/411.
KEYWORDS Chlamydia sp.
SOURCE Chlamydia sp.
ORGANISM Chlamydia sp.
REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hees,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H. and Hey,P.
TITLE Novel LDL-receptor
JOURNAL Patent: JP 2002501376-A 411 15-JAN-2002;
THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO
INC
COMMENT PN JP 2002501376-A/411
PD 15-JAN-2002
PF 15-APR-1998 JP 1998543635
PI 15-APR-1997 US 60/043553.05-JUN-1997 US 60/048740 PI
JOHN ANDREW TODD,JOHN WILFRED HESS,CHARLES
THOMAS CASKEY,ROGER
PI DAVID COX,
PI DAVID GERHOLD,HOLLY HAMMOND,PATRICIA HEY

PC C12N15/12,C12N15/11,C12Q1/68,C07K14/705,C07K16/28,A61K38/17,
PC A61K39/395,
PC A61K48/00
CC Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers

FEATURES
source 1..16
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match 4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1395 GAGCTGCTGACAGAC 1410
|||||||
16 GGGCTGCTGCAAGAC 1

Db

RESULT 512
D00269S20/c 16 bp DNA linear PRI 21-SEP-2002
LOCUS D00269S20
DEFINITION Homo sapiens gene for tyrosine hydroxylase, exon 13, partial
sequence.
ACCESSION D00269
VERSION D00288.1 GI:220118
KEYWORDS 20 of 24
SEGMENT Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS O'Valley,K.L., Anhalt,M.J., Martin,B.M., Kalsoe,J.R., Winfield,S.L. and Gimms,E.I.
TITLE Isolation and characterization of the human tyrosine hydroxylase
gene: identification of 5' alternative splice sites responsible for
multiple mRNAs
JOURNAL Biochemistry 26 (22), 6910-6914 (1987)
MEDLINE 88107612
PUBMED 2892528
REFERENCE 2 (bases 1 to 16)
AUTHORS Kobayashi,K., Kaneda,N., Ichinose,H., Kishi,F., Nakazawa,A.,
Kurosawa,Y., Fujita,K. and Negatsu,T.
TITLE Structure of the human tyrosine hydroxylase gene: alternative
splicing from a single gene accounts for generation of four mRNA
types
JOURNAL J. Biochem. 103 (6), 907-912 (1988)
MEDLINE 89008200
PUBMED 2902075
COMMENT In [1], they determined the nucleotide sequences of all exons and
their surrounding regions of human TH gene, and the exon/intron
boundaries are shown. The boundaries were determined by comparing
the genomic DNA sequence with the cDNA sequence. The human TH gene
is split into 14 exons. In [1], they concluded that the four types
of human TH mRNA are produced through alternative splicing from a
single gene.

FEATURES
source 1..16
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="about 0.3 kb after segment 19"
<1..7
/number=12
8..>16
/product="tyrosine hydroxylase"
/note="AA 432 at 8"
/number=13
11..13
/citation=[1]

intron
exon
conflict

```
/replace="ctg"

Query Match          4.4%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1230 CAGCATGTGCTGGCAG 1245
        ||| ||||| |||
        16 CAGGACGTGCTGGCAG 1

RESULT 513
LOCUS      CQ623907
DEFINITION Sequence 8647 from Patent WO0192524.
ACCESSION  CQ623907
VERSION     CQ623907.1 GI:41674125
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE    1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
AUTHORS      Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8647 06-DEC-2001;
Aeonica, Inc. (US)
FEATURES
  source      location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match          4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1250 CCGGCTGCAGCAACAG 1265
        ||| ||||| |||
        17 CCAGCTGCAGCTGCAG 2

RESULT 514
LOCUS      CQ623909
DEFINITION Sequence 8649 from Patent WO0192524.
ACCESSION  CQ623909
VERSION     CQ623909.1 GI:41674127
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE    1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
AUTHORS      Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8649 06-DEC-2001;
Aeonica, Inc. (US)
FEATURES
  source      location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match          4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1249 TCCGGCTGCAGCAACA 1264
        ||| ||||| |||
        16 TCCAGCTGCAGCTGCA 1
```

```
RESULT 515
LOCUS      AR464970/c
DEFINITION Sequence 8647 from patent US 6686188.
ACCESSION  AR464970
VERSION     AR464970.1 GI:42700027
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
JOURNAL      Patent: US 6686188-A 8647 03-FEB-2004;
              location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match          4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1250 CCGGCTGCAGCAACAG 1265
        ||| ||||| |||
        17 CCAGCTGCAGCTGCAG 2

RESULT 516
LOCUS      AR464972/c
DEFINITION Sequence 8649 from patent US 6686188.
ACCESSION  AR464972
VERSION     AR464972.1 GI:42700029
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
JOURNAL      Patent: US 6686188-A 8649 03-FEB-2004;
              location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match          4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1249 TCCGGCTGCAGCAACA 1264
        ||| ||||| |||
        16 TCCAGCTGCAGCTGCA 1

RESULT 517
LOCUS      BD241619
DEFINITION Methods and products related to genotyping and DNA analysis.
ACCESSION  BD241619
VERSION     BD241619.1 GI:33051389
KEYWORDS    JP 2002525127-A/566.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE    1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8649 06-DEC-2001;
Aeonica, Inc. (US)
FEATURES
  source      location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match          4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1249 TCCGGCTGCAGCAACA 1264
        ||| ||||| |||
        16 TCCAGCTGCAGCTGCA 1
```

REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
TITLE Methode and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 566 13-AUG-2002;
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT OS Homo sapiens (human)
PN JP 2002525127-A/566
PD 13-AUG-2002
PR 24-SEP-1999 JP 2000572407
PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
C12N15/09, C12Q1/68, G01N33/53, G01N33/566, G01N33/58, G01N37/00, PC
G01N37/00,
PC C12N15/00
CC Methods and products related to genotyping and DNA analysis FH
Key Location/Qualifiers
FT source 1..17
FT Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

FEATURES
source
1..17
Location/Qualifiers
1..17
/organism="Homo sapiens (human)".

Query Match 4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1373 CCAGAGCAGCTGCGT 1388
Db 2 CAAGATGCAGCTGCAT 17

RESULT 518
AR483120
LOCUS AR483120 17 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 566 from patent US 6703228.
ACCESSION AR483120
VERSION AR483120.1 GI:47245643
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.
TITLE Methode and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 566 09-MAR-2004;
FEATURES
source
1..17
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1373 CCAGAGCAGCTGCGT 1388
Db 2 CAAGATGCAGCTGCAT 17

RESULT 519
CQ767554
LOCUS CQ767554 20 bp DNA linear PAT 04-MAR-2004
DEFINITION Sequence 21 from Patent EP1386931.
ACCESSION CQ767554
VERSION CQ767554.1 GI:45095671
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Wood,W.I., Goddard,A., Gurney,A., Yuan,J., Baker,K.P. and Chen,J.

TITLE Human neutrotrimin homologue
JOURNAL Patent: EP 1386931-A 21 04-FEB-2004;
Genentech, Inc. (US)
FEATURES
source
1..20
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Artificial Sequence"

Query Match 4.4%; Score 11.2; DB 1; Length 20;
Best Local Similarity 81.2%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1226 CCTCAGCATGTCGT 1241
Db 2 CATCCAGCTGATGCTG 17

RESULT 520
E63484/c
LOCUS E63484/c 22 bp DNA linear PAT 27-AUG-2002
DEFINITION Non-human animal having modified foreign chromosomal or slice
thereof.
ACCESSION E63484
VERSION E63484.1 GI:22557593
KEYWORDS JP 2001231403-A/16.
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 22)
AUTHORS Tomizuka,K., Yoshida,H., Ishida,I. and Kuroiwa,Y.
TITLE Non-human animal having modified foreign chromosomal or slice
JOURNAL Patent: JP 2001231403-A 16 28-AUG-2001;
KIRIN BEER KK
OS Artificial Sequence
PN JP 2001231403-A/16
PD 28-AUG-2001
PI 18-FEB-2000 JP 2000042074
PI KAZUMA TOMIZUKA, HITOSHI YOSHIDA, ISNO ISHIDA, YOSHIMI KUROIWA PC
A01K67/027, C12N5/10, C12N15/09// (C12N5/10, C12R1:91), (C12N15/09, PC
C12R1:91),
PC C12N5/00, C12N15/00, (C12N5/00, C12R1:91), (C12N15/00, C12R1:91) CC
Description of Artificial Sequence: Primer
FH Key Location/Qualifiers
1..22
Location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

FEATURES
source
1..22
Location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 4.4%; Score 11.2; DB 1; Length 22;
Best Local Similarity 81.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1205 GAGGCGAGCCATCTGT 1220
Db 22 GAGGCGCTTCATCTGT 7

RESULT 521
CQ832682/c
LOCUS CQ832682/c 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 53 from Patent WO2004059002.
ACCESSION CQ832682
VERSION CQ832682.1 GI:50832289
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Peterohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,

TITLE Conradt,M. and Hofmann,K.
JOURNAL Method for determining the homeostasis of hairy skin
Patent: WO 2004059002-A 53 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
SOURCE 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1353 CCCAGGCGCAGC 1363
|||||
Db 11 CCCAGGCGCAGC 1

RESULT 522
LOCUS CQ833741 11 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 1112 from Patent WO2004059002.
ACCESSION CQ833741
VERSION CQ833741.1 GI:50833348
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Schlotmann,K., Gassenmeier,T., Holtkoetter,O.,
Conradt,M. and Hofmann,K.
TITLE Method for determining the homeostasis of hairy skin
JOURNAL Patent: WO 2004059002-A 1112 15-JUL-2004;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
SOURCE 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1270 AAGAGGCTGAG 1280
|||||
Db 1 AAGAGGCTGAG 1

RESULT 523
LOCUS AX471459 11 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 1036 from Patent WO02053773.
ACCESSION AX471459
VERSION AX471459.1 GI:22206584
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 1036 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES Location/Qualifiers
SOURCE 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1307 CATCTGAGC 1317
|||||
Db 1 CATCTGAGC 11

RESULT 524
LOCUS AX624578/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1619 from Patent WO02053774.
ACCESSION AX624578
VERSION AX624578.1 GI:28452519
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 1619 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
SOURCE 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1202 GCAGAGGCGAG 1212
|||||
Db 11 GCAGAGGCGAG 1

RESULT 525
LOCUS AX626768 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 3809 from Patent WO02053774.
ACCESSION AX626768
VERSION AX626768.1 GI:28454806
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 3809 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers
SOURCE 1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1281 GGCAGAGACCC 1291
|||||
Db 1 GGCAGAGACCC 11

RESULT 526
LOCUS AX627048/c

LOCUS AX627048 11 bp DNA 11 linear PAT 21-FEB-2003
DEFINITION Sequence 4089 from Patent WO02053774.
ACCESSION AX627048
VERSION AX627048.1 GI:28455086
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 Petersohn, D., Conrad, M. and Hofmann, K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 4089 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1271 AGAGGCTGAGC 1281
Db 11 AGAGGCTGAGC 1
RESULT 527
LOCUS AX628768 11 bp DNA 11 linear PAT 21-FEB-2003
DEFINITION Sequence 5809 from Patent WO02053774.
ACCESSION AX628768
VERSION AX628768.1 GI:28456806
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 Petersohn, D., Conrad, M. and Hofmann, K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 5809 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1352 TCCGAGGGCAG 1362
Db 11 TCCGAGGGCAG 1
RESULT 528
LOCUS AX629280 11 bp DNA 11 linear PAT 21-FEB-2003
DEFINITION Sequence 6321 from Patent WO02053774.
ACCESSION AX629280
VERSION AX629280.1 GI:28457318
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 Petersohn, D., Conrad, M. and Hofmann, K.
AUTHORS

TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6321 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1261 AACAGCTGAA 1271
Db 1 AACAGCTGAA 1
RESULT 529
LOCUS AX629703 11 bp DNA 11 linear PAT 21-FEB-2003
DEFINITION Sequence 6744 from Patent WO02053774.
ACCESSION AX629703
VERSION AX629703.1 GI:28457741
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 Petersohn, D., Conrad, M. and Hofmann, K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 6744 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1307 CATCTGTGAGC 1317
Db 1 CATCTGTGAGC 1
RESULT 530
LOCUS AX631999 11 bp DNA 11 linear PAT 21-FEB-2003
DEFINITION Sequence 9041 from Patent WO02053774.
ACCESSION AX631999
VERSION AX631999.1 GI:28467614
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
1 Petersohn, D., Conrad, M. and Hofmann, K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 9041 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1307 CATCTGTGAGC 1317
Db 1 CATCTGTGAGC 1

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1202 GCAGAGGCAG 1212
|||||
Db 11 GCAGAGGCAG 1

RESULT 531
AX632783/C
LOCUS
DEFINITION Sequence 9825 from Patent WO02053774.
ACCESSION AX632783
VERSION AX632783.1 GI:28468398
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 9825 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1353 CCCAGGCGAGC 1363
|||||
Db 11 CCCAGGCGAGC 1

RESULT 532
A88355
LOCUS
DEFINITION Sequence 503 from Patent WO9833904.
ACCESSION A88355
VERSION A88355.1 GI:6736925
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 503 06-AUG-1998;
BIOGENOSTIK GES (DE); BRSCH WOLFGANG (DE)
FEATURES
source
1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.4%; Score 11; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1198 CTGTGCAGAGG 1208
|||||
Db 4 CTGTGCAGAGG 14

RESULT 533
A90322
LOCUS
DEFINITION Sequence 503 from Patent EP0856579.
ACCESSION A90322

VERSION A90322.1 GI:6738836
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 503 05-AUG-1998;
BIOGENOSTIK GES (DE)
FEATURES
source
1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.4%; Score 11; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1198 CTGTGCAGAGG 1208
|||||
Db 4 CTGTGCAGAGG 14

RESULT 534
BD203601/C
LOCUS
DEFINITION Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD203601
VERSION BD203601.1 GI:33013371
KEYWORDS JP 2002509721-A/6627.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6627 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/6627
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI FAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P9/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH key location/Qualifiers
FT source 1. .14
FT location/Qualifiers
1. .14
/organism="Homo sapiens (human)".
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 4.4%; Score 11; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1352 TCCGAGGCGAG 1362
|||||

Db 14 TCCAGGCGCAG 4

RESULT 535
LOCUS AR242398/c 14 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 2 from patent US 6472209.
ACCESSION AR242398
VERSION AR242398.1 GI:27288354
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Richelson E., Tyler B.M., McCormick D.J., Cusack B.M.,
Hoshall C.V., Douglas C.L. and Jansen K.
TITLE Using polyamide nucleic acid oligomers to engender a biological
response
JOURNAL Patent: US 6472209-A 2 29-OCT-2002;
FEATURES
source Location/Qualifiers
1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1268 GGAAGAGCGCTG 1278
DB 11 GGAAGAGCGCTG 1

RESULT 536
LOCUS BD065868 14 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065868
VERSION BD065868.1 GI:22611471
KEYWORDS JP 2001511000-A/503.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingensiefen K.H. and Brysch W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 503 07-AUG-2001;
BIOCHEMISTRIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/503
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PI 31-JAN-1997 EP 97101531.8
PC KARL HERMANN SCHLINGENSIEFEN WOLFGANG BRYSCH
PC C12N15/11.C07H21/04.A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1..14
/organism="unknown".
1..14
Location/Qualifiers

FEATURES
source 1..14
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.4%; Score 11; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1198 CTGTGACAGG 1208
DB 4 CTGTGACAGG 14

RESULT 537
LOCUS AR000221/c 15 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 19 from patent US 5736336.
ACCESSION AR000221
VERSION AR000221.1 GI:3962752
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Buchardt O., deceased, Buchardt B., Dorte, representative, Egholm M.,
Nielsen P., Bigil, and Berg R., Henrik.
TITLE Peptide nucleic acids having enhanced binding affinity, sequence
specificity and solubility
JOURNAL Patent: US 5736336-A 19 07-APR-1998;
FEATURES
source Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1284 AGAGACCTCA 1294
DB 12 AGAGACCTCA 2

RESULT 538
LOCUS AR000222/c 15 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 20 from patent US 5736336.
ACCESSION AR000222
VERSION AR000222.1 GI:3962753
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Buchardt O., deceased, Buchardt B., Dorte, representative, Egholm M.,
Nielsen P., Bigil, and Berg R., Henrik.
TITLE Peptide nucleic acids having enhanced binding affinity, sequence
specificity and solubility
JOURNAL Patent: US 5736336-A 20 07-APR-1998;
FEATURES
source Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1284 AGAGACCTCA 1294
DB 12 AGAGACCTCA 2

RESULT 539
LOCUS AR041243/c 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 33 from patent US 5811300.
ACCESSION AR041243
VERSION AR041243.1 GI:5961739
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan S., Draper K., Kisch K., Stinchcomb D.T. and McSwigen J.

TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 33 22-SEP-1998;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGG 1281
|||||
Db 15 AGAGGCTGAGG 5

RESULT 540
AR041244/c AR041244 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 34 from patent US 5811300.
DEFINITION AR041244
ACCESSION AR041244
VERSION AR041244.1 GI:5961740
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 34 22-SEP-1998;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 GAAGAGGCTGA 1279
|||||
Db 11 GAAGAGGCTGA 1

RESULT 541
AR041304/c AR041304 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 94 from patent US 5811300.
DEFINITION AR041304
ACCESSION AR041304
VERSION AR041304.1 GI:5961800
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 94 22-SEP-1998;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 CAGCTGAGAGA 1273
|||||
Db 15 CAGCTGAGAGA 5

RESULT 542

AR041305/c AR041305 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 95 from patent US 5811300.
DEFINITION AR041305
ACCESSION AR041305
VERSION AR041305.1 GI:5961801
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 95 22-SEP-1998;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 CAGCTGAGAGA 1273
|||||
Db 14 CAGCTGAGAGA 4

RESULT 543
AR041753/c AR041753 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 543 from patent US 5811300.
DEFINITION AR041753
ACCESSION AR041753
VERSION AR041753.1 GI:5962249
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 543 22-SEP-1998;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 GAAGAGGCTGA 1279
|||||
Db 11 GAAGAGGCTGA 1

RESULT 544
AR041754/c AR041754 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 544 from patent US 5811300.
DEFINITION AR041754
ACCESSION AR041754
VERSION AR041754.1 GI:5962250
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 544 22-SEP-1998;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1263 CAGAGCGCTGA 1279
Db 11 CAGAGCGCTGA 1

RESULT 545
AR041831/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR041831
DEFINITION Sequence 621 from patent US 5811300.
ACCESSION AR041831
VERSION AR041831.1 GI:5962327
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kieich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 621 22-SEP-1998;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1263 CAGCTGAAGA 1273
Db 15 CAGCTGAAGA 5

RESULT 546
AR041832 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR041832
DEFINITION Sequence 622 from patent US 5811300.
ACCESSION AR041832
VERSION AR041832.1 GI:5962328
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kieich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 622 22-SEP-1998;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1263 CAGCTGAAGA 1273
Db 14 CAGCTGAAGA 4

RESULT 547
AR132933/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR132933
DEFINITION Sequence 1358 from patent US 6194150.
ACCESSION AR132933
VERSION AR132933.1 GI:14121838
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 1358 27-FEB-2001;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1272 GAGGCTGAGG 1282
Db 14 GAGGCTGAGG 4

RESULT 548
183554/c 15 bp DNA linear PAT 10-AUG-1998
LOCUS 183554
DEFINITION Sequence 19 from patent US 5714331.
ACCESSION 183554
VERSION 183554.1 GI:3407084
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Buchardt,O. deceased, Buchardt,b.Dorte. representative, Egholm,M.,
Nielsen,P.Bigil. and Berg,R.Henrik.
TITLE Peptide nucleic acids having enhanced binding affinity, sequence
JOURNAL Patent: US 5714331-A 19 03-FEB-1998;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1284 AGAGACCTCA 1294
Db 12 AGAGACCTCA 2

RESULT 549
183555/c 15 bp DNA linear PAT 10-AUG-1998
LOCUS 183555
DEFINITION Sequence 20 from patent US 5714331.
ACCESSION 183555
VERSION 183555.1 GI:3407085
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Buchardt,O. deceased, Buchardt,b.Dorte. representative, Egholm,M.,
Nielsen,P.Bigil. and Berg,R.Henrik.
TITLE Peptide nucleic acids having enhanced binding affinity, sequence
JOURNAL Patent: US 5714331-A 20 03-FEB-1998;
FEATURES
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1284 AGAGACCTCA 1294
Db 12 AGAGACCTCA 2

RESULT 550
188922/c 188922 15 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 19 from patent US 5719262.
ACCESSION 188922
VERSION 188922.1 GI:3408862
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
Buchardt,O. deceased, Buchardt,b.Dorte, legalrepresentative,
Egholm,M., Nielsen,P.,Eigil. and Berg,R.Henrik.
TITLE Peptide nucleic acids having amino acid side chains
JOURNAL Patent: US 5719262-A 19 17-FEB-1998;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1284 AGAGACCTCA 1294
Db 12 AGAGACCTCA 2

RESULT 551
188923/c 188923 15 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 20 from patent US 5719262.
ACCESSION 188923
VERSION 188923.1 GI:3408863
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
Buchardt,O. deceased, Buchardt,b.Dorte, legalrepresentative,
Egholm,M., Nielsen,P.,Eigil. and Berg,R.Henrik.
TITLE Peptide nucleic acids having amino acid side chains
JOURNAL Patent: US 5719262-A 20 17-FEB-1998;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1284 AGAGACCTCA 1294
Db 12 AGAGACCTCA 2

RESULT 552
ARI80238 15 bp DNA linear PAT 20-APR-2002
LOCUS ARI80238/c
DEFINITION Sequence 306 from patent US 6333152.
ACCESSION ARI80238
VERSION ARI80238.1 GI:20222271
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 306 25-DEC-2001;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1206 AGGCGAGCCAT 1216
Db 12 AGGCGAGCCAT 2

RESULT 553
AR362086 15 bp DNA linear PAT 17-AUG-2003
LOCUS AR362086
DEFINITION Sequence 3 from patent US 6600028.
ACCESSION AR362086
VERSION AR362086.1 GI:33770242
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
Brown,D., Loakes,D., Williams,D., Hill,F., Kumar,S., Nampalli,S.,
McDougall,M., Hamilton,A., Smith,C., Simmonds,A.C., Cummins,W.J.
and Finn,P.
TITLE Tricyclic base analogues
JOURNAL Patent: US 6600028-A 3 29-JUL-2003;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1232 GCATGTGCTGG 1242
Db 2 GCATGTGCTGG 12

RESULT 554
AR362089 15 bp DNA linear PAT 17-AUG-2003
LOCUS AR362089
DEFINITION Sequence 6 from patent US 6600028.
ACCESSION AR362089
VERSION AR362089.1 GI:33770245
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 15)
Brown,D., Loakes,D., Williams,D., Hill,F., Kumar,S., Nampalli,S.,
McDougall,M., Hamilton,A., Smith,C., Simmonds,A.C., Cummins,W.J.
and Finn,P.
TITLE Tricyclic base analogues
JOURNAL Patent: US 6600028-A 6 29-JUL-2003;
FEATURES
source
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1232 GCATGTGCTGG 1242
|||||
Db 2 GCATGTGCTGG 12

RESULT 555
AR392545/c 15 bp DNA linear PAT 18-DEC-2003

LOCUS AR392545 Sequence 32 from patent US 6613873.

DEFINITION AR392545

ACCESSION AR392545

VERSION AR392545.1 GI:40116601

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.

TITLE Peptide nucleic acids having 2,6-diaminopurine nucleobases

JOURNAL Patent: US 6613873-A 32 02-SEP-2003;

FEATURES Location/Qualifiers

1..15

/organism="unknown"

/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1284 AGAGACCTCA 1294
|||||
Db 12 AGAGACCTCA 2

RESULT 556

AR392546/c

LOCUS AR392546 15 bp DNA linear PAT 18-DEC-2003

DEFINITION Sequence 33 from patent US 6613873.

ACCESSION AR392546

VERSION AR392546.1 GI:40116602

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.

TITLE Peptide nucleic acids having 2,6-diaminopurine nucleobases

JOURNAL Patent: US 6613873-A 33 02-SEP-2003;

FEATURES Location/Qualifiers

1..15

/organism="unknown"

/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1284 AGAGACCTCA 1294
|||||
Db 12 AGAGACCTCA 2

RESULT 557

AR438479

LOCUS AR438479 15 bp DNA linear PAT 20-FEB-2004

DEFINITION Sequence 1 from patent US 6664058.

ACCESSION AR438479

VERSION AR438479.1 GI:42663344

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 15)

AUTHORS Kumar,S., Nampalli,S., Neagu,C., McDougall,M., Lookes,D. and

Brown,D.

TITLE Base analogues

JOURNAL Patent: US 6664058-A 1 16-DEC-2003;

FEATURES Location/Qualifiers

1..15

/organism="unknown"

/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1232 GCATGTGCTGG 1242
|||||
Db 2 GCATGTGCTGG 12

RESULT 558

AR489548/c

LOCUS AR489548 15 bp DNA linear PAT 15-MAY-2004

DEFINITION Sequence 19 from patent US 6710164.

ACCESSION AR489548

VERSION AR489548.1 GI:47256573

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Nielsen,P.E., Egholm,M., Berg,R.H., Buchardt,O. and Buchardt,D.

TITLE Peptide nucleic acids having enhanced binding affinity, sequence

JOURNAL Patent: US 6710164-A 19 23-MAR-2004;

FEATURES Location/Qualifiers

1..15

/organism="unknown"

/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1284 AGAGACCTCA 1294
|||||
Db 12 AGAGACCTCA 2

RESULT 559

AR489549/c

LOCUS AR489549 15 bp DNA linear PAT 15-MAY-2004

DEFINITION Sequence 20 from patent US 6710164.

ACCESSION AR489549

VERSION AR489549.1 GI:47256574

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Nielsen,P.E., Egholm,M., Berg,R.H., Buchardt,O. and Buchardt,D.

TITLE Peptide nucleic acids having enhanced binding affinity, sequence

JOURNAL Patent: US 6710164-A 20 23-MAR-2004;

FEATURES Location/Qualifiers

1..15

/organism="unknown"

/mol_type="genomic DNA"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1284 AGAGACCTCA 1294
DB 12 AGAGACCTCA 2

RESULT 560
LOCUS AX636718 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3857 from Patent EP1260586.
ACCESSION AX636718
VERSION AX636718.1 GI:28472332
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related
genes

JOURNAL Patent: EP 1260586-A 3857 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGG 1281
DB 15 AGAGCTGAGG 5

RESULT 561
LOCUS AX636720 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3859 from Patent EP1260586.
ACCESSION AX636720
VERSION AX636720.1 GI:28472334
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related
genes

JOURNAL Patent: EP 1260586-A 3859 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 GAAGAGGCTGA 1279
DB 11 GAAGAGGCTGA 1

RESULT 562
LOCUS AX636764 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3903 from Patent EP1260586.
ACCESSION AX636764
VERSION AX636764.1 GI:28472378
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related
genes

JOURNAL Patent: EP 1260586-A 3903 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 CAGCTGAGGA 1273
DB 14 CAGCTGAGGA 4

RESULT 563
LOCUS AX636766 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3905 from Patent EP1260586.
ACCESSION AX636766
VERSION AX636766.1 GI:28472380
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related
genes

JOURNAL Patent: EP 1260586-A 3905 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 CAGCTGAGGA 1273
DB 14 CAGCTGAGGA 4

RESULT 564

AX637231/c
LOCUS AX637231 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 4370 from Patent EP1260586.
ACCESSION AX637231
VERSION AX637231.1 GI:28472845
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 4370 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 GAAGAGGCTGA 1279
DB 11 GAAGAGGCTGA 1

RESULT 565
AX637233/c
LOCUS AX637233 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 4372 from Patent EP1260586.
ACCESSION AX637233
VERSION AX637233.1 GI:28472847
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 4372 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 GAAGAGGCTGA 1279
DB 11 GAAGAGGCTGA 1

RESULT 566
AX637309/c
LOCUS AX637309 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 4448 from Patent EP1260586.

ACCESSION AX637309
VERSION AX637309.1 GI:28472923
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 4448 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 CAGCTGGAAGA 1273
DB 14 CAGCTGGAAGA 4

RESULT 567
AX637311/c
LOCUS AX637311 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 4450 from Patent EP1260586.
ACCESSION AX637311
VERSION AX637311.1 GI:28472925
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 4450 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 CAGCTGGAAGA 1273
DB 14 CAGCTGGAAGA 4

RESULT 568
BD144681/c
LOCUS BD144681 15 bp DNA linear PAT 17-JAN-2003
DEFINITION Peptide nucleic acid having elevated binding affinity, sequence specificity and solubility.
ACCESSION BD144681
VERSION BD144681.1 GI:27850439

KEYWORDS JP 2002105059-A/19.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 15)
AUTHORS Buchardt,O., Nielsen,P.A., Einhorn,M. and Berg,R.H.
TITLE Peptide nucleic acid having elevated binding affinity, sequence specificity and solubility
JOURNAL Patent: JP 2002105059-A 19 10-APR-2002;
DORTE BUCHARDT,PETER A NIELSEN,MICHAEL EINHORN,ROLF HO BERG

COMMENT OS Unidentified
PN JP 2002105059-A/19
PD 10-APR-2002
PF 23-JUL-2001 JP 2001222248
PR 24-JUL-1996 US 08/685484,24-JUL-1996 US 08/686116 PR
24-JUL-1996 US 08/686114,24-JUL-1996 US 08/686113 PR
29-MAY-1997 US 60/051002
PI OLE BUCHARDT,PETER A NIELSEN,MICHAEL EINHORN,ROLF HO BERG PC
C07D233/64,C12N15/09,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Fluorescein conjugated
CC thymine attached to aminoethyl-lysine backbone CC thymine attached to aminoethyl-lysine backbone CC thymine attached to aminoethyl-lysine backbone CC thymine attached to aminoethyl-lysine backbone FH Key Location/Qualifiers
FT source 1..15 /organism='Unidentified'.
location/Qualifiers
1..15 /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1284 AGAGACCCCTCA 1294
DB 12 AGAGACCCCTCA 2

RESULT 569
BD144682/c 15 bp DNA linear PAT 17-JAN-2003
LOCUS BD144682
DEFINITION Peptide nucleic acid having elevated binding affinity, sequence specificity and solubility.
ACCESSION BD144682
VERSION BD144682.1 GI:27850440
KEYWORDS JP 2002105059-A/20.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Buchardt,O., Nielsen,P.A., Einhorn,M. and Berg,R.H.
TITLE Peptide nucleic acid having elevated binding affinity, sequence specificity and solubility
JOURNAL Patent: JP 2002105059-A 20 10-APR-2002;
DORTE BUCHARDT,PETER A NIELSEN,MICHAEL EINHORN,ROLF HO BERG

COMMENT OS Unidentified
PN JP 2002105059-A/20
PD 10-APR-2002
PF 23-JUL-2001 JP 2001222248
PR 24-JUL-1996 US 08/685484,24-JUL-1996 US 08/686116 PR
24-JUL-1996 US 08/686114,24-JUL-1996 US 08/686113 PR
29-MAY-1997 US 60/051002
PI OLE BUCHARDT,PETER A NIELSEN,MICHAEL EINHORN,ROLF HO BERG PC
C07D233/64,C12N15/09,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC conjugated with fluorescent dye
CC thymine attached to aminoethyl-lysine backbone CC thymine

attached to aminoethyl-lysine backbone CC thymine attached to aminoethyl-lysine backbone CC thymine attached to aminoethyl-lysine backbone FH Key Location/Qualifiers
FT source 1..15 /organism='Unidentified'.
location/Qualifiers
1..15 /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES source
location/Qualifiers
1..15 /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 4.4%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1284 AGAGACCCCTCA 1294
DB 12 AGAGACCCCTCA 2

RESULT 570
A21765/c 14 bp DNA linear PAT 07-JUL-1994
LOCUS A21765
DEFINITION oligonucleotide.
ACCESSION A21765
VERSION A21765.1 GI:579060
KEYWORDS
SOURCE
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 14)
AUTHORS
TITLE MUCIN NUCLEOTIDES
JOURNAL Patent: WO 9109867-A 1 11-JUL-1991;
DORTE

COMMENT OS Unidentified
PN JP 2002105059-A/19
PD 10-APR-2002
PF 23-JUL-2001 JP 2001222248
PR 24-JUL-1996 US 08/685484,24-JUL-1996 US 08/686116 PR
24-JUL-1996 US 08/686114,24-JUL-1996 US 08/686113 PR
29-MAY-1997 US 60/051002
PI OLE BUCHARDT,PETER A NIELSEN,MICHAEL EINHORN,ROLF HO BERG PC
C07D233/64,C12N15/09,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC conjugated with fluorescent dye
CC thymine attached to aminoethyl-lysine backbone CC thymine

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1231 AGCATGCTGCGCA 1244

DB 1 AGCATGCTGCGCA 14

RESULT 572
A45157/c 14 bp DNA linear PAT 07-MAR-1997

LOCUS Sequence 34 from Patent WO9517507.
DEFINITION A45157
ACCESSION A45157
VERSION A45157.1 GI:2299652

KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.

REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W., Schlingensiepen,K., Schlingensiepen,R. and
TITLE ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF
JOURNAL DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
BIOCHEMISTRIK GEB (DE)
Patent: WO 9517507-A 34 29-JUN-1995;

COMMENT Other publication AU 1313095 950710.

FEATURES

source
1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 AGGTCGCATGCTC 1307

DB 14 AGTGTCTATGCTC 1

RESULT 573

A56662 14 bp DNA linear PAT 03-MAR-1998
LOCUS A56662
DEFINITION Sequence 29 from Patent EP0739898.

ACCESSION A56662
VERSION A56662.1 GI:3712707

KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.

REFERENCE 1
AUTHORS Peyman,A.D., Uhlmann,B.D., Breipohl,G.D. and Wallmeier,H.D.
TITLE Phosphonomonoester nucleic acids, methods for their preparation and
JOURNAL their use
HOECHST AG (DE)
Patent: EP 0739898-A 29 30-OCT-1996;

COMMENT

Other publication CZ 9600743 961016
Other publication CN 1138588 961235
Other publication PL 313207 960916
Other publication JP 8259579 961008
Other publication NO 961006 960916
Other publication CA 2171589 960914
Other publication AU 4802896 960926
Other publication DE 19508923 960919.

FEATURES

source
1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1268 CGAAGAGGCTGAGC 1281

DB 1 CGAGATCTGTGAGC 14

RESULT 574

A64229 14 bp DNA linear PAT 29-MAR-1999
LOCUS A64229
DEFINITION Sequence 17 from Patent WO9727332.

ACCESSION A64229
VERSION A64229.1 GI:3717660

KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.

REFERENCE 1
AUTHORS Stuyver,L., Louwagie,J. and Roseau,R.
TITLE METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
JOURNAL TRANSCRIPTASE GENE
Patent: WO 9727332-A 17 31-JUL-1997;

COMMENT Other publication AU 1444397 19970820.

FEATURES

source
1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAAGAGC 1275

DB 1 AGAGCTGGAAGAGC 14

RESULT 575

A64238 14 bp DNA linear PAT 29-MAR-1999
LOCUS A64238
DEFINITION Sequence 26 from Patent WO9727332.

ACCESSION A64238
VERSION A64238.1 GI:3717669

KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.

REFERENCE 1
AUTHORS Stuyver,L., Louwagie,J. and Roseau,R.
TITLE METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
JOURNAL TRANSCRIPTASE GENE
Patent: WO 9727332-A 26 31-JUL-1997;

COMMENT Other publication AU 1444397 19970820.

FEATURES

source
1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAAGAGC 1275

DB 1 AGAAGCTGGAAGAGC 14

RESULT 576
A80383 14 bp DNA linear PAT 20-OCT-1999
LOCUS Sequence 29 from Patent EP0726274.
ACCESSION A80383
VERSION A80383.1 GI:6093110
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Peyman,A.D. and Uhlmann,E.D.
JOURNAL G-CAP STABILIZED OLIGONUCLEOTIDES
HOECHST AG (DE)
Patent: EP 0726274-A 29 14-AUG-1996;
FEATURES
source location/Qualifiers
1..14 /organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
exon 1..14
Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1268 GGAGAGGCTGAGG 1281
Db 1 GGAGATGCTGANG 14
A88727 14 bp DNA linear PAT 22-JAN-2000
LOCUS Sequence 875 from Patent WO9833904.
ACCESSION A88727
VERSION A88727.1 GI:6737297
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Brysch,W. and Schlingensiepen,K.
JOURNAL AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
Patent: WO 9833904-A 875 06-AUG-1998;
BIOLOGISTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source location/Qualifiers
1..14 /organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1231 AGCATGCTGGCA 1244
Db 1 AGCATGAGTGGCA 14
A88918 14 bp DNA linear PAT 22-JAN-2000
LOCUS Sequence 1066 from Patent WO9833904.
ACCESSION A88918
VERSION A88918.1 GI:6737488
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Brysch,W. and Schlingensiepen,K.
JOURNAL AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
Patent: WO 9833904-A 1066 06-AUG-1998;
BIOLOGISTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source location/Qualifiers
1..14 /organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1066 06-AUG-1998;
BIOLOGISTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source location/Qualifiers
1..14 /organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Qy 1294 AGGTCGCATGCTC 1307
Db 14 AGTGTGCTATGCTC 1
A89394 14 bp DNA linear PAT 22-JAN-2000
LOCUS Sequence 1542 from Patent WO9833904.
ACCESSION A89394
VERSION A89394.1 GI:6737964
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Brysch,W. and Schlingensiepen,K.
JOURNAL AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
Patent: WO 9833904-A 1542 06-AUG-1998;
BIOLOGISTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source location/Qualifiers
1..14 /organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1189 CCCAGAACCTGTG 1202
Db 1 CCCACATGCTGTG 14
A8031534 14 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 6 from patent US 5866372.
ACCESSION A8031534
VERSION A8031534.1 GI:5945823
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Stein,H., Durkop,H. and Latza,U.
JOURNAL Nucleic acids encoding lymphoid CD30 antigen
Patent: US 5866372-A 6 02-FEB-1999;
FEATURES
source location/Qualifiers
1..14 /organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1369 CTTACGAGACGACG 1382
Db 1 CTTACGAGACGACG 1382

Db 14 CTTTCAGAGCAG 1

RESULT 581

LOCUS AR064269 14 bp DNA linear PAT 29-FEB-1999

DEFINITION Sequence 10 from patent US 5846823.

ACCESSION AR064269

VERSION AR064269.1 GI:5993577

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

FEATURES

Unclassified.

REFERENCE 1 (bases 1 to 14)

AUTHORS Owojabi,J., Rampersad,V. and Kamboj,R.

TITLE Expression of human D4 dopamine receptors in stable cell lines

JOURNAL Patent: US 5846823-A 10 08-DEC-1998;

FEATURES

Location/Qualifiers

1..14

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 2.7e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1415 TGCTGAGCGGCGCA 1428

Db 1 TGCTGAGCGGCGCA 14

RESULT 582

LOCUS AR102528 14 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 17 from patent US 6087093.

ACCESSION AR102528

VERSION AR102528.1 GI:12814116

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)

AUTHORS Lieven,S., Joost,L. and Rudi,R.

TITLE Method for detection of drug-induced mutations in the reverse

JOURNAL Patent: US 6087093-A 17 11-JUL-2000;

FEATURES

Location/Qualifiers

1..14

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 2.7e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAAGG 1275

Db 1 AGAGCTGGAAGG 14

RESULT 583

LOCUS AR102537 14 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 26 from patent US 6087093.

ACCESSION AR102537

VERSION AR102537.1 GI:12814125

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)

AUTHORS Lieven,S., Joost,L. and Rudi,R.

TITLE Method for detection of drug-induced mutations in the reverse

transcriptase gene

JOURNAL Patent: US 6087093-A 26 11-JUL-2000;

FEATURES

Location/Qualifiers

1..14

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 2.7e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAAGG 1275

Db 1 AGAGCTGGAAGG 14

RESULT 584

LOCUS AR111786 14 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 29 from patent US 6127346.

ACCESSION AR111786

VERSION AR111786.1 GI:12828634

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)

AUTHORS Peyman,A., Uhlmann,E., Breipohl,G. and Wallmeier,H.

TITLE Phosphonomonester nucleic acids process for their preparation and their use

JOURNAL Patent: US 6127346-A 29 03-OCT-2000;

FEATURES

Location/Qualifiers

1..14

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 2.7e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1268 GGAAGAGGCTGAGG 1281

Db 1 GGAAGAGGCTGAGG 14

RESULT 585

LOCUS AR118994 14 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 120 from patent US 6150092.

ACCESSION AR118994

VERSION AR118994.1 GI:14100904

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)

AUTHORS Uchida,K., Uchida,T., Tanaka,Y., Matsuda,Y. and Kondo,S.

TITLE Antisense nucleic acid compound targeted to VEGF

JOURNAL Patent: US 6150092-A 120 21-NOV-2000;

FEATURES

Location/Qualifiers

1..14

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 2.7e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1273 AGGCTGAGGCGAGA 1286

Db 1 AGGAGAGGCGAGA 1

RESULT 586
BD203562/C
LOCUS BD203562 14 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD203562.1 GI:33013332
VERSION BD203562.1
KEYWORDS JP 2002509721-A/6588.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 14)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6588 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/6588
PD 02-APR-2002
PR 24-MAR-1999 JP 2000541291
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT, JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..14
FT Location/Qualifiers
FT /organism='Homo sapiens (human)'.
1..14
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1352 TCCGAGGCACTG 1365
DB 14 TCCTGGGCACTG 1
RESULT 587
BD203570
LOCUS BD203570 14 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD203570
VERSION BD203570.1 GI:33013340
KEYWORDS JP 2002509721-A/6596.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 14)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6596 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/6596
PD 02-APR-2002
PR 24-MAR-1999 JP 2000541291

PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT, JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..14
FT Location/Qualifiers
FT /organism='Homo sapiens (human)'.
1..14
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1328 CCTCTCTCCAGG 1341
DB 1 CCTCTCTCCAGG 14
RESULT 588
BD209427/C
LOCUS BD209427 14 bp RNA linear PAT 17-JUL-2003
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD209427
VERSION BD209427.1 GI:33019197
KEYWORDS JP 2002512791-A/3017.
SOURCE unclassified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL Patent: JP 2002512791-A 3017 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/3017
PD 08-MAY-2002
PR 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR 25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A PAVCO,
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09, PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..14
FT /organism='Hepatitis virus (hepatitis C virus)'.
1..14
/organism='unclassified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'
Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1334 CTCGACGACGAG 1347
Db 14 CGCCAGGCGAAG 1

RESULT 589
AR202800/c AR202800 14 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 34 from patent US 6365345.
ACCESSION AR202800
VERSION AR202800.1 GI:21499022
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch, W., Schlingensiepen, K.-H., Schlingensiepen, R. and
TITLE Antisense nucleic acids for the prevention and treatment of
JOURNAL disorders in which expression of c-erbB plays a role
FEATURES
source 1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 AGGGTCCATGTC 1307
Db 14 AGTGTCTATGTC 1

RESULT 590
AR262831 AR262831 14 bp DNA linear PAT 29-JAN-2003
LOCUS Sequence 17 from patent US 6331389.
ACCESSION AR262831
VERSION AR262831.1 GI:28074534
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Lieven, S., Joost, L. and Rudi, R.
TITLE Method for detection of drug-induced mutations in the reverse
JOURNAL transcriptase gene
FEATURES Patent: US 6331389-A 17 18-DEC-2001;
source 1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAGAG 1275
Db 1 AGAGCTGGAAAAG 14

RESULT 591
AR262840 AR262840 14 bp DNA linear PAT 29-JAN-2003
LOCUS Sequence 26 from patent US 6331389.
ACCESSION AR262840
VERSION AR262840.1 GI:28074543
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Lieven, S., Joost, L. and Rudi, R.
TITLE Method for detection of drug-induced mutations in the reverse
JOURNAL transcriptase gene
FEATURES Patent: US 6331389-A 26 18-DEC-2001;
source 1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAGAG 1275
Db 1 AGAGCTGGAAAAG 14

RESULT 592
AR490361 AR490361 14 bp DNA linear PAT 15-MAY-2004
LOCUS Sequence 17 from patent US 6713251.
ACCESSION AR490361
VERSION AR490361.1 GI:47257742
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Stuyver, L., Louwaghe, J. and Rossau, R.
TITLE Method for detection of drug-induced mutations in the reverse
JOURNAL transcriptase gene
FEATURES Patent: US 6713251-A 17 30-MAR-2004;
source 1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGGAGAG 1275
Db 1 AGAGCTGGAAAAG 14

RESULT 593
AR490370 AR490370 14 bp DNA linear PAT 15-MAY-2004
LOCUS Sequence 26 from patent US 6713251.
ACCESSION AR490370
VERSION AR490370.1 GI:47257751
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)
AUTHORS Stuyver, L., Louwaghe, J. and Rossau, R.
TITLE Method for detection of drug-induced mutations in the reverse
JOURNAL transcriptase gene
FEATURES Patent: US 6713251-A 26 30-MAR-2004;
source 1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1262 ACAGCTGAGAGG 1275
| | | | | | | | | |
Db 1 AGACTGAGAGG 14

RESULT 594
BD066240 14 bp DNA linear PAT 27-AUG-2002
LOCUS An antisense oligonucleotide preparation method.
DEFINITION BD066240
ACCESSION BD066240.1 GI:22611843
VERSION JP 2001511000-A/875.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingsiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 875 07-AUG-2001;
BIOLOGIST GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT OS Unknown
PN JP 2001511000-A/875
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers

FEATURES
source 1. .14
/organism="Unknown".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1231 AGCATGCTGSCA 1244
| | | | | | | | | |
Db 1 AGCATGAGTGGCA 14

RESULT 595
BD066431 14 bp DNA linear PAT 27-AUG-2002
LOCUS An antisense oligonucleotide preparation method.
DEFINITION BD066431
ACCESSION BD066431.1 GI:22612034
VERSION JP 2001511000-A/1066.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingsiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1066 07-AUG-2001;
BIOLOGIST GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT OS Unknown
PN JP 2001511000-A/1066
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers

FT source 1. .14

FEATURES
source 1. .14
/organism="Unknown".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1294 AGGTGCCATGTC 1307
| | | | | | | | | |
Db 14 AGTGCTATGTC 1

RESULT 596
BD066907 14 bp DNA linear PAT 27-AUG-2002
LOCUS An antisense oligonucleotide preparation method.
DEFINITION BD066907
ACCESSION BD066907.1 GI:22612510
VERSION JP 2001511000-A/1542.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingsiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1542 07-AUG-2001;
BIOLOGIST GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT OS Unknown
PN JP 2001511000-A/1542
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers

FEATURES
source 1. .14
/organism="Unknown".
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1189 CCCAGAGCCCTGTG 1202
| | | | | | | | | |
Db 1 CCCACATGCTGTG 14

RESULT 597
A35188 15 bp DNA linear PAT 10-MAY-1996
LOCUS Synthetic crystalline silk gene 5' extension.
DEFINITION A35188
ACCESSION A35188.1 GI:1568384
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Edwards,R.M., Light,J.A. and Nicholson,K.
TITLE Improvements in or relating to structural proteins
JOURNAL Patent: EP 0294979-A 12 14-DEC-1988;
PA Consulting Services Limited
Location/Qualifiers

FEATURES
source 1. .14

source 1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1254 CTGCAGCAGCAGCT 1267
Db 15 CTGCAGCAGCAGAT 2

RESULT 598
A64239 15 bp DNA linear PAT 29-MAR-1999
LOCUS A64239 Sequence 27 from Patent WO9727332.
ACCESSION A64239
VERSION A64239.1 GI:3717670
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stuyver, L., Louwagie, J. and Rossau, R.
TITLE METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
JOURNAL TRANSCRIPTASE GENE
PATENT: WO 9727332-A 27 31-JUL-1997;
INNOGENETICS NV (BE)
COMMENT Other publication AU 1444397 19970820.
FEATURES
source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1262 ACAGCTGAGAGG 1275
Db 2 AGAAGTGGAGAGG 15

RESULT 599
A64240 15 bp DNA linear PAT 29-MAR-1999
LOCUS A64240 Sequence 28 from Patent WO9727332.
ACCESSION A64240
VERSION A64240.1 GI:3717671
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stuyver, L., Louwagie, J. and Rossau, R.
TITLE METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
JOURNAL TRANSCRIPTASE GENE
PATENT: WO 9727332-A 28 31-JUL-1997;
INNOGENETICS NV (BE)
COMMENT Other publication AU 1444397 19970820.
FEATURES
source 1..15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1262 ACAGCTGAGAGG 1275
Db 1 AGAAGTGGAGAGG 14

RESULT 600
AR033597 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR033597/C
DEFINITION Sequence 363 from patent US 5869253.
ACCESSION AR033597
VERSION AR033597.1 GI:5949202
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Draper, K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 5869253-A 363 09-FEB-1999;
FEATURES
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1278 GAGGCGAGAGACC 1291
Db 15 GAGGCGGAGAGACC 2

RESULT 601
AR035432 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR035432
DEFINITION Sequence 4 from patent US 5871902.
ACCESSION AR035432
VERSION AR035432.1 GI:5952100
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Weininger, S. and Weininger, A.M.
TITLE Sequence-specific detection of nucleic acid hybrids using a
DNA-binding molecule or assembly capable of discriminating perfect
JOURNAL hybrids from non-perfect hybrids
PATENT: US 5871902-A 4 16-FEB-1999;
FEATURES
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1341 GCAGGAGACTTCC 1354
Db 1 GCTGGGAGACTTCC 14

RESULT 602
AR041880 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR041880
DEFINITION Sequence 670 from patent US 5811300.
ACCESSION AR041880
VERSION AR041880.1 GI:5962376
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1
AUTHORS
TITLE
JOURNAL
PATENT:
COMMENT
FEATURES
source 1..15
/organism="unassigned DNA"
/mol_type="unassigned DNA"

REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- α ribozymes
JOURNAL Patent: US 5811300-A 670 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1244 AGTGTCGCGCTGC 1257
|||||
DB 2 AGTGTCAGGTTGC 15

RESULT 603
AR055854/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR055854 Sequence 58 from patent US 5837542.
DEFINITION AR055854
ACCESSION AR055854
VERSION AR055854.1 GI:5981431
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 58 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CCATGTCATCTGT 1313
|||||
DB 15 CCATGTCATCTCT 2

RESULT 604
AR055904/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR055904 Sequence 108 from patent US 5837542.
DEFINITION AR055904
ACCESSION AR055904
VERSION AR055904.1 GI:5981481
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 108 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1374 CAGAGCAGCTCGG 1387
|||||

DB 14 CAGAGGAAGCTGCG 1

RESULT 605
AR056290 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR056290 Sequence 494 from patent US 5837542.
DEFINITION AR056290
ACCESSION AR056290
VERSION AR056290.1 GI:5981867
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 494 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCAGCTAGGCGACC 1329
|||||
DB 2 GCAGCTAGCGGACC 15

RESULT 606
AR056391/c 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR056391 Sequence 595 from patent US 5837542.
DEFINITION AR056391
ACCESSION AR056391
VERSION AR056391.1 GI:5981968
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 595 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGGGCA 1284
|||||
DB 15 AGTGCTGAGGGTA 2

RESULT 607
AR056485 15 bp DNA linear PAT 29-SEP-1999
LOCUS AR056485 Sequence 689 from patent US 5837542.
DEFINITION AR056485
ACCESSION AR056485
VERSION AR056485.1 GI:5982062
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and

Draper,K.G.
TITLE Interellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 689 17-NOV-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1316 GCAGCTAGGAGCC 1329
Db 2 GGAGCTAGCGGACC 15

RESULT 608
LOCUS AR102538 15 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 27 from patent US 6087093.
ACCESSION AR102538
VERSION AR102538.1 GI:12814126
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lieven,S., Joost,L. and Rudi,R.
TITLE Method for detection of drug-induced mutations in the reverse
transcriptase gene
JOURNAL Patent: US 6087093-A 27 11-JUL-2000;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1262 ACAGCTGGAAGAG 1275
Db 2 AGAAGTGAAGAGG 15

RESULT 609
LOCUS AR102539 15 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 28 from patent US 6087093.
ACCESSION AR102539
VERSION AR102539.1 GI:12814127
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lieven,S., Joost,L. and Rudi,R.
TITLE Method for detection of drug-induced mutations in the reverse
transcriptase gene
JOURNAL Patent: US 6087093-A 28 11-JUL-2000;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1262 ACAGCTGGAAGAG 1275
Db 1 AGAAGTGAAGAGG 14

RESULT 610
LOCUS AR108946/c 15 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6113913.
ACCESSION AR108946
VERSION AR108946.1 GI:12825222
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Brough,D.E. and Kovacs,I.
TITLE Recombinant adenovirus
JOURNAL Patent: US 6113913-A 1 05-SEP-2000;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1268 GGAAGAGGCTGAGG 1281
Db 15 GGAGAGAGTGAAGG 2

RESULT 611
LOCUS AR113419/c 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 363 from patent US 6132966.
ACCESSION AR113419
VERSION AR113419.1 GI:14093741
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Draper,K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 6132966-A 363 17-OCT-2000;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1278 GAGGCGAGAGACC 1291
Db 15 GAGGCGAGAGACC 2

RESULT 612
LOCUS AR113612/c 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 58 from patent US 6132967.
ACCESSION AR113612
VERSION AR113612.1 GI:14093934
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of
intercellular adhesion molecule-1 (ICAM-1)

JOURNAL Patent: US 6132967-A 58 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CCATGTCATCTCGT 1313
|||||
Db 15 CCATGTCATCTCT 2

RESULT 613
AR113662/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR113662 Sequence 108 from patent US 6132967.
DEFINITION AR113662
ACCESSION AR113662
VERSION AR113662.1 GI:14093984
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 108 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1374 CAGAGCAGCTCGC 1387
|||||
Db 14 CAGAGAGACTCGC 1

RESULT 614
AR114048 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR114048 Sequence 494 from patent US 6132967.
DEFINITION AR114048
ACCESSION AR114048
VERSION AR114048.1 GI:14094370
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 494 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCAGCTAGGGGACC 1329
|||||
Db 2 GGAGCTAGCGGACC 15

RESULT 615
AR114149 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR114149 Sequence 595 from patent US 6132967.
DEFINITION AR114149
ACCESSION AR114149
VERSION AR114149.1 GI:14094471
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 595 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1271 AGAGCTGAGGGCA 1284
|||||
Db 15 AGTGGCTGAGGGTA 2

RESULT 616
AR114243 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR114243 Sequence 689 from patent US 6132967.
DEFINITION AR114243
ACCESSION AR114243
VERSION AR114243.1 GI:14094565
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 689 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 GCAGCTAGGGGACC 1329
|||||
Db 2 GGAGCTAGCGGACC 15

RESULT 617
AR116342 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR116342 Sequence 30 from patent US 6133031.
DEFINITION AR116342
ACCESSION AR116342
VERSION AR116342.1 GI:14096664
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)

AUTHORS Monia,B.P. and Gaarde,W.A.
TITLE Antisense inhibition of focal adhesion kinase expression
JOURNAL Patent: US 6133031-A 30 17-OCT-2000;
FEATURES Location/Qualifiers
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1377 AAGCAGTCGCTTT 1390
| | | | | | | | | |
2 AAGCAGTCGCTT 15

RESULT 618
AR132253 15 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 678 from patent US 6194150.
ACCESSION AR132253
VERSION AR132253.1 GI:14121158
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 678 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1330 TCTTCTCCAGGCA 1343
| | | | | | | | | |
2 TGTCTCCAAAGCA 15

RESULT 619
AR132254 15 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 679 from patent US 6194150.
ACCESSION AR132254
VERSION AR132254.1 GI:14121159
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 679 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1330 TCTTCTCCAGGCA 1343
| | | | | | | | | |
2 TGTCTCCAAAGCA 15

RESULT 620
AR132255 15 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 680 from patent US 6194150.
ACCESSION AR132255
VERSION AR132255.1 GI:14121160
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 680 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1330 TCTTCTCCAGGCA 1343
| | | | | | | | | |
2 TGTCTCCAAAGCA 15

RESULT 621
AR132372 15 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 797 from patent US 6194150.
ACCESSION AR132372
VERSION AR132372.1 GI:14121277
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 797 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1345 GAGACTTCCAGG 1358
| | | | | | | | | |
2 GACAATTTCCAGG 15

RESULT 622
AR132373 15 bp DNA linear PAT 16-MAY-2001
LOCUS
DEFINITION Sequence 798 from patent US 6194150.
ACCESSION AR132373
VERSION AR132373.1 GI:14121278
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 798 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"

```

      /mol_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1345 GAGACTTCCCGAG 1358
      ||| ||| ||| ||| |||
Db      1 GACATTTCCCGAG 14

RESULT 623
ARI32934/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      ARI32934
DEFINITION Sequence 1359 from patent US 6194150.
ACCESSION ARI32934
VERSION ARI32934.1 GI:14121839
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 1359 27-FEB-2001;
FEATURES
      Location/Qualifiers
      1..15
      /organism="unknown"
      /mol_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1266 CTGGAAGAGGCTGA 1279
      ||| ||| ||| ||| |||
Db      14 CTGGGGGAGGCTGA 1

RESULT 624
ARI33220/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      ARI33220
DEFINITION Sequence 1645 from patent US 6194150.
ACCESSION ARI33220
VERSION ARI33220.1 GI:14122125
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 1645 27-FEB-2001;
FEATURES
      Location/Qualifiers
      1..15
      /organism="unknown"
      /mol_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1307 CATCTGTGAGCAGC 1320
      ||| ||| ||| ||| |||
Db      15 CATCTGAGATCAGC 2

RESULT 625
ARI33221/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      ARI33221
DEFINITION Sequence 1646 from patent US 6194150.
ACCESSION ARI33221
VERSION ARI33221.1 GI:14122126
```

```

      .
      KEYWORDS
      SOURCE Unknown.
      ORGANISM Unknown.
      REFERENCE 1 (bases 1 to 15)
      AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
      TITLE Nucleic acid based inhibition of CD40
      JOURNAL Patent: US 6194150-A 1646 27-FEB-2001;
      FEATURES
      Location/Qualifiers
      1..15
      /organism="unknown"
      /mol_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1307 CATCTGTGAGCAGC 1320
      ||| ||| ||| ||| |||
Db      15 CATCTGAGATCAGC 2

RESULT 626
ARI33222/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      ARI33222
DEFINITION Sequence 1647 from patent US 6194150.
ACCESSION ARI33222
VERSION ARI33222.1 GI:14122127
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 1647 27-FEB-2001;
FEATURES
      Location/Qualifiers
      1..15
      /organism="unknown"
      /mol_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1307 CATCTGTGAGCAGC 1320
      ||| ||| ||| ||| |||
Db      15 CATCTGAGATCAGC 2

RESULT 627
ARI33223/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      ARI33223
DEFINITION Sequence 1648 from patent US 6194150.
ACCESSION ARI33223
VERSION ARI33223.1 GI:14122128
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 1648 27-FEB-2001;
FEATURES
      Location/Qualifiers
      1..15
      /organism="unknown"
      /mol_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 1307 CATCTGTGAGCACC 1320
|||||
Db 15 CATCTGAGATCAGC 2

RESULT 628
ARI133674 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 2099 from patent US 6194150.
DEFINITION ARI133674
ACCESSION ARI133674.1 GI:14122579
VERSION ARI133674.1 GI:14122579
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2099 27-FEB-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1326 GACCTCTTCTCCAA 1339
|||||
Db 1 GGCTTCTTCTCCAA 14

RESULT 629
ARI133675 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 2100 from patent US 6194150.
DEFINITION ARI133675
ACCESSION ARI133675.1 GI:14122580
VERSION ARI133675.1 GI:14122580
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2100 27-FEB-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1328 CCTCTTCTCCAAAG 1341
|||||
Db 2 CTTCTTCTCCAAATG 15

RESULT 630
ARI133870 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 2295 from patent US 6194150.
DEFINITION ARI133870
ACCESSION ARI133870
VERSION ARI133870.1 GI:14122775
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.

TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2295 27-FEB-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1326 GACCTCTTCTCCAA 1339
|||||
Db 1 GGCTTCTTCTCCAA 14

RESULT 631
ARI176698 15 bp DNA linear PAT 17-DEC-2001
LOCUS Sequence 29 from patent US 6312894.
DEFINITION ARI176698
ACCESSION ARI176698.1 GI:17919053
VERSION ARI176698.1 GI:17919053
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Hedgpeth,J., Afonina,I.A., Kutayavin,I.V., Lukhtanov,E.A.,
Belousov,E.S. and Meyer,R.B. Jr.
TITLE Hybridization and mismatch discrimination using oligonucleotides
JOURNAL Patent: US 6312894-A 29 06-NOV-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1316 GCAGCTAGCGGAGCC 1329
|||||
Db 15 GCAGCTCGGAGACC 2

RESULT 632
BD207330 15 bp RNA linear PAT 17-JUL-2003
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to hepatitis C virus infection.
ACCESSION BD207330
BD207330.1 GI:33017100
VERSION JP 2002512791-A/920.
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 15)
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL Patent: JP 2002512791-A 920 08-MAY-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Hepatitis C virus (hepatitis C virus)
PN JP 2002512791-A/920
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PAVCO,
DENNIS MACEJAK
PI C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,

PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT /organism='Hepatitis virus (hepatitis C FT
virus)';
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1278 GAGGCGAGAGACCC 1291
DB 15 GAGGCGAGAGACCC 2

RESULT 633
BD208434/c
LOCUS BD208434
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.
ACCESSION BD208434
VERSION BD208434.1 GI:33018204
KEYWORDS JP 2002512791-A/2024.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 15)
REFERENCE
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Parent: JP 2002512791-A 2024 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT /organism='Hepatitis virus (hepatitis C FT
virus)';
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1402 TGGACAGACCGGCT 1415
DB 14 TGGACAGACCGGCT 1

RESULT 634
BD208869/c
LOCUS BD208869
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.
ACCESSION BD208869
VERSION BD208869.1 GI:33018639
KEYWORDS JP 2002512791-A/2459.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 15)
REFERENCE
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Parent: JP 2002512791-A 2459 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT /organism='Hepatitis virus (hepatitis C FT
virus)';
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1217 CTGTCAAGACCTCC 1230
DB 15 CTGTCAAGACCAACC 2

RESULT 635
BD208874/c
LOCUS BD208874
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.
ACCESSION BD208874
VERSION BD208874.1 GI:33018644
KEYWORDS JP 2002512791-A/2464.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 15)
REFERENCE
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Parent: JP 2002512791-A 2464 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT /organism='Hepatitis virus (hepatitis C FT
virus)';
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1217 CTGTCAAGACCTCC 1230
DB 15 CTGTCAAGACCAACC 2

RESULT 635
BD208874/c
LOCUS BD208874
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection.
ACCESSION BD208874
VERSION BD208874.1 GI:33018644
KEYWORDS JP 2002512791-A/2464.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 15)
REFERENCE
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to hepatitis C virus infection
Parent: JP 2002512791-A 2464 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT /organism='Hepatitis virus (hepatitis C FT
virus)';
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

PF 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PACCO,
PI DENNIS MACEJAK
PC C12N9/00, A61K31/7105, A61K48/00, A61P31/12, C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1.15
/organism='Hepatitis virus (hepatitis C FT
virus)'.
Location/Qualifiers
1.15
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1331 CTTCTCCAGGAGC 1344
Db 15 CTCGCCAGGAGC 2

RESULT 636
BD240722/c 15 bp DNA linear PAT 17-JUL-2003
LOCUS Replication-deficient recombinant adenovirus having mutation major
DEFINITION late promoter.
ACCESSION BD240722
VERSION BD240722.1 GI:33050492
KEYWORDS JP 2002519036-A/1.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 15)
AUTHORS Brough, D.E. and Kovsed, I.
TITLE Replication-deficient recombinant adenovirus having mutation major
JOURNAL late promoter
PATENT: JP 2002519036-A 1 02-JUL-2002;
COMMENT GENEVEC INC
OS Human adenovirus serotype 5
PN JP 2002519036-A/1
PD 02-JUL-2002
PF 24-JUN-1999 JP 2000557381
PR 26-JUN-1998 US 09/105515
PI DOUGLAS E BROUGH, IMRE KOVSEDI
PC C12N15/09, C12N15/10, C12N7/00//A61K35/76, A61K39/235, A61K48/00,
PC C12N15/00,
PC C12N5/00
CC Replication-deficient recombinant adenovirus having mutation
CC major late
CC promoter
FH Key Location/Qualifiers
FT source 1.15
/organism='Human adenovirus serotype 5'.
Location/Qualifiers
1.15
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

FEATURES
source

Qy 1268 GGAAGAGCTGAGC 1281
Db 15 GGAAGAGCTGAGC 2

RESULT 637
BD260049/c 15 bp DNA linear PAT 17-JUL-2003
LOCUS Hybridization and mismatch discrimination using oligonucleotides
DEFINITION conjugated to minor groove binders.
ACCESSION BD260049
VERSION BD260049.1 GI:33069819
KEYWORDS JP 2002527040-A/29.
SOURCE Escherichia coli
ORGANISM Escherichia coli
Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
Enterobacteriaceae; Escherichia.
REFERENCE 1 (bases 1 to 15)
AUTHORS Hedgpeth, J., Afonina, I.A., Kutlyavin, I.V., Lukhtanov, E.A.,
Belousov, E.S. and Jr, R.B.M.
TITLE Hybridization and mismatch discrimination using oligonucleotides
JOURNAL conjugated to minor groove binders
PATENT: JP 2002527040-A 29 27-AUG-2002;
COMMENT EPOCH BIOSCIENCES INC
OS Escherichia coli
PN JP 2002527040-A/29
PD 27-AUG-2002
PF 05-APR-1999 JP 2000542342
PR 03-APR-1998 US 09/054832
PI JOEL HEDGPETH, IRINA A AFONINA, IGOR V KUTYAVIN, EUGENY A PI
LUKHTANOV,
PI EVGENIY S BELOUSOV, RICH B MEYER JR
PC C12N15/09, C12N15/09, C07H21/02, C07H21/04, C12Q1/68, G01N21/78, PC
G01N33/483,
PC G01N33/53, G01N33/566, C12N15/00, C12N15/00
CC Hybridization and mismatch discrimination using CC
oligonucleotides
CC conjugated to minor groove binders
FH Key Location/Qualifiers
FT source 1.15
/organism='Escherichia coli'.
Location/Qualifiers
1.15
/organism='Escherichia coli'
/mol_type='genomic DNA'
/db_xref='taxon:562'

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1316 GCAGCTAGGGAGCC 1329
Db 15 GCAGCTCGGAGACC 2

RESULT 638
122060/c 15 bp DNA linear PAT 07-OCT-1996
LOCUS Sequence 3 from patent US 5525714.
DEFINITION 122060
ACCESSION 122060
VERSION 122060.1 GI:1602414
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Van Broeckhoven, C., Martin, J.-J., Hendriks, L. and Cras, P.
TITLE Mutated form of the beta-amyloid precursor protein gene
JOURNAL Patent: US 5525714-A 3 11-JUN-1996;
FEATURES Location/Qualifiers
1.15
/organism='unknown'

```

/moi_type="unassigned DNA"
Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1330 TCTTCTCCAGGCA 1343
      |||||
Db      14 TCTTCTCCAGGAA 1

RESULT 639
LOCUS      135259      15 bp      DNA      linear      PAT 13-MAY-1997
DEFINITION      Sequence 227 from patent US 5599706.
ACCESSION      135259
VERSION      135259.1 GI:2088227
KEYWORDS
SOURCE
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
TITLE      Ribozymes targeted to apo(a) mRNA
JOURNAL      Patent: US 5599706-A 227 04-FEB-1997;
FEATURES
SOURCE
/organism="Unknown"
/moi_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1301 CATGTCATCTCTG 1314
      |||||
Db      2 CTGTGTCATCTATG 15

RESULT 640
LOCUS      157826/c      15 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION      Sequence 363 from patent US 5610054.
ACCESSION      157826
VERSION      157826.1 GI:2482890
KEYWORDS
SOURCE
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Draper,K.G.
TITLE      Enzymatic RNA molecule targeted against Hepatitis C virus
JOURNAL      Patent: US 5610054-A 363 11-MAR-1997;
FEATURES
SOURCE
/organism="Unknown"
/moi_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1278 GAGGGCAGAGCCC 1291
      |||||
Db      15 GAGGGGAGAGCCC 2

RESULT 641
LOCUS      161525      15 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION      Sequence 79 from patent US 5658780.
ACCESSION      161525
VERSION      161525.1 GI:2479473
```

```

KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.
TITLE      Rel a targeted ribozymes
JOURNAL      Patent: US 5658780-A 79 19-AUG-1997;
FEATURES
SOURCE
/organism="Unknown"
/moi_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1385 GCGTTTGTGAGC 1398
      |||||
Db      2 GCGTATGCTGTGC 15

RESULT 642
LOCUS      AR179994      15 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 62 from patent US 6333152.
ACCESSION      AR179994
VERSION      AR179994.1 GI:20222027
KEYWORDS
SOURCE
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE      Gene expression profiles in normal and cancer cells
JOURNAL      Patent: US 6333152-A 62 25-DEC-2001;
FEATURES
SOURCE
/organism="Unknown"
/moi_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1206 AGGCGAGCATCTG 1219
      |||||
Db      2 ATGGCAGCATCCG 15

RESULT 643
LOCUS      AR180035      15 bp      DNA      linear      PAT 20-APR-2002
DEFINITION      Sequence 103 from patent US 6333152.
ACCESSION      AR180035
VERSION      AR180035.1 GI:20222068
KEYWORDS
SOURCE
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE      Gene expression profiles in normal and cancer cells
JOURNAL      Patent: US 6333152-A 103 25-DEC-2001;
FEATURES
SOURCE
/organism="Unknown"
/moi_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 1233 CATGTGTCGCAGT 1246
| | | | |
| | | | |
Db 1 CATGTGTCGCCTGT 14

RESULT 644
ARI80036

LOCUS ARI80036 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 104 from patent US 6333152.
ACCESSION ARI80036
VERSION ARI80036.1 GI:20222069
KEYWORDS
SOURCE
ORGANISM
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 104 25-DEC-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1273 AGGCTGAGCGCAGA 1286
| | | | |
| | | | |
Db 2 ATGCTGATGCGCAGA 15

RESULT 645
ARI80082/c

LOCUS ARI80082 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 150 from patent US 6333152.
ACCESSION ARI80082
VERSION ARI80082.1 GI:20222115
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 150 25-DEC-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GCTGAGCGCGCCAT 1429
| | | | |
| | | | |
Db 15 GCTGGGCTGGCCAT 2

RESULT 646
ARI80150/c

LOCUS ARI80150 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 218 from patent US 6333152.
ACCESSION ARI80150
VERSION ARI80150.1 GI:20222183
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.

TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 218 25-DEC-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1291 CTCAGGTCGCATG 1304
| | | | |
| | | | |
Db 14 CCACAGGTTCCATG 1

RESULT 647
ARI80163/c
LOCUS ARI80163 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 231 from patent US 6333152.
ACCESSION ARI80163
VERSION ARI80163.1 GI:20222196
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 231 25-DEC-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1223 GACCTCCAGCATG 1236
| | | | |
| | | | |
Db 14 GCACCTCCACCATG 1

RESULT 648
ARI80373/c
LOCUS ARI80373 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 441 from patent US 6333152.
ACCESSION ARI80373
VERSION ARI80373.1 GI:20222406
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE
1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 441 25-DEC-2001;
FEATURES
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1296 GGTGCATGTCAT 1309
| | | | |
| | | | |
Db 15 GGTGCATCATCAT 2

RESULT 649

```
AR180497/c      15 bp      DNA      linear      PAT 20-APR-2002
LOCUS           AR180497
DEFINITION      Sequence 565 from patent US 6333152.
ACCESSION       AR180497
VERSION         AR180497.1 GI:20222530
KEYWORDS
SOURCE          .
ORGANISM        Unknown.
REFERENCE       1 (bases 1 to 15)
                Unclassified.
AUTHORS         Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE           Gene expression profiles in normal and cancer cells
JOURNAL         Patent: US 6333152-A 565 25-DEC-2001;
                Location/Qualifiers
FEATURES
                source
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
                Best Local Similarity 85.7%; Pred.No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1291 CTCAGGGGCCATG 1304
Db      14 CACAGGGTTCATG 1

RESULT 650
AR180506/c      15 bp      DNA      linear      PAT 20-APR-2002
LOCUS           AR180506
DEFINITION      Sequence 574 from patent US 6333152.
ACCESSION       AR180506
VERSION         AR180506.1 GI:20222539
KEYWORDS
SOURCE          .
ORGANISM        Unknown.
REFERENCE       1 (bases 1 to 15)
                Unclassified.
AUTHORS         Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE           Gene expression profiles in normal and cancer cells
JOURNAL         Patent: US 6333152-A 574 25-DEC-2001;
                Location/Qualifiers
FEATURES
                source
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
                Best Local Similarity 85.7%; Pred.No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1203 CAGAGCGCAGCCAT 1216
Db      15 CAGCGCGCAGTCAT 2

RESULT 651
AR180765        15 bp      DNA      linear      PAT 20-APR-2002
LOCUS           AR180765
DEFINITION      Sequence 833 from patent US 6333152.
ACCESSION       AR180765
VERSION         AR180765.1 GI:20222798
KEYWORDS
SOURCE          .
ORGANISM        Unknown.
REFERENCE       1 (bases 1 to 15)
                Unclassified.
AUTHORS         Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE           Gene expression profiles in normal and cancer cells
JOURNAL         Patent: US 6333152-A 833 25-DEC-2001;
                Location/Qualifiers
FEATURES
                source
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
                Best Local Similarity 85.7%; Pred.No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1206 AGGCACGCATCTG 1219
Db      2 ATGGCAGCCATCCG 15

RESULT 652
AR180787/c      15 bp      DNA      linear      PAT 20-APR-2002
LOCUS           AR180787
DEFINITION      Sequence 855 from patent US 6333152.
ACCESSION       AR180787
VERSION         AR180787.1 GI:20222820
KEYWORDS
SOURCE          .
ORGANISM        Unknown.
REFERENCE       1 (bases 1 to 15)
                Unclassified.
AUTHORS         Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE           Gene expression profiles in normal and cancer cells
JOURNAL         Patent: US 6333152-A 855 25-DEC-2001;
                Location/Qualifiers
FEATURES
                source
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
                Best Local Similarity 85.7%; Pred.No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1291 CTCAGGGGCCATG 1304
Db      14 CCCAGGTTCCATG 1

RESULT 653
AR234463/c      15 bp      DNA      linear      PAT 20-DEC-2002
LOCUS           AR234463
DEFINITION      Sequence 1 from patent US 6458578.
ACCESSION       AR234463
VERSION         AR234463.1 GI:27277165
KEYWORDS
SOURCE          .
ORGANISM        Unknown.
REFERENCE       1 (bases 1 to 15)
                Unclassified.
AUTHORS         Brough,D.B. and Kovesdi,I.
TITLE           Recombinant cell line produces adenoviral gene products E1 and
                DEFA, and/or DEFB
JOURNAL         Patent: US 6458578-A 1 01-OCT-2002;
                Location/Qualifiers
FEATURES
                source
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      4.3%; Score 10.8; DB 1; Length 15;
                Best Local Similarity 85.7%; Pred.No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1268 GGAAGAGCTGAGG 1281
Db      15 GGAAGAGAGTGAGG 2

RESULT 654
AR262841        15 bp      DNA      linear      PAT 29-JAN-2003
LOCUS           AR262841
DEFINITION      Sequence 27 from patent US 6331389.
ACCESSION       AR262841
VERSION         AR262841.1 GI:28074544
```

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lieven,S., Joost,L. and Rudi,R.
TITLE Method for detection of drug-induced mutations in the reverse
transcriptase gene
JOURNAL Patent: US 6331389-A 27 18-DEC-2001;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1262 ACAGCTGGAGAGG 1275
| | | | | | | | | | | | | | |
Db 2 AGAAGTGGAGAGG 15

RESULT 655
AR262842 15 bp DNA linear PAT 29-JAN-2003
LOCUS AR262842
DEFINITION Sequence 28 from patent US 6331389.
ACCESSION AR262842
VERSION AR262842.1 GI:28074545
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lieven,S., Joost,L. and Rudi,R.
TITLE Method for detection of drug-induced mutations in the reverse
transcriptase gene
JOURNAL Patent: US 6331389-A 28 18-DEC-2001;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1262 ACAGCTGGAGAGG 1275
| | | | | | | | | | | | | | |
Db 1 AGAAGTGGAGAGG 14

RESULT 656
AR431511 15 bp DNA linear PAT 18-DEC-2003
LOCUS AR431511
DEFINITION Sequence 21 from patent US 6653069.
ACCESSION AR431511
VERSION AR431511.1 GI:40193615
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Gomi,Y., Sunamachi,H., Takahashi,M. and Yamanishi,K.
TITLE Method for quality control of an attenuated varicella live vaccine
JOURNAL Patent: US 6653069-A 21 25-NOV-2003;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1268 GGAGAGGCTGAGG 1281
| | | | | | | | | | | | | | |
Db 1 GGAGAGGCGGAGG 14

RESULT 657
AR490371 15 bp DNA linear PAT 15-MAY-2004
LOCUS AR490371
DEFINITION Sequence 27 from patent US 6713251.
ACCESSION AR490371
VERSION AR490371.1 GI:47257752
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stuyver,L., Louvagle,J. and Rossau,R.
TITLE Method for detection of drug-induced mutations in the reverse
transcriptase gene
JOURNAL Patent: US 6713251-A 27 30-MAR-2004;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1262 ACAGCTGGAGAGG 1275
| | | | | | | | | | | | | | |
Db 2 AGAAGTGGAGAGG 15

RESULT 658
AR490372 15 bp DNA linear PAT 15-MAY-2004
LOCUS AR490372
DEFINITION Sequence 28 from patent US 6713251.
ACCESSION AR490372
VERSION AR490372.1 GI:47257753
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stuyver,L., Louvagle,J. and Rossau,R.
TITLE Method for detection of drug-induced mutations in the reverse
transcriptase gene
JOURNAL Patent: US 6713251-A 28 30-MAR-2004;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1262 ACAGCTGGAGAGG 1275
| | | | | | | | | | | | | | |
Db 1 AGAAGTGGAGAGG 14

RESULT 659
AX085054 15 bp DNA linear PAT 09-MAR-2001
LOCUS AX085054
DEFINITION Sequence 231 from Patent WO0113117.
ACCESSION AX085054
VERSION AX085054.1 GI:13275202
KEYWORDS
SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Herath,H.M.
TITLE Proteins, genes and their use for diagnosis and treatment of breast cancer

JOURNAL Patent: WO 0113117-A 231 22-FEB-2001;
Oxford Glycosciences (UK) Limited (GB)

FEATURES
source 1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Probe"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1312 GTGAGCAGCTAGGG 1325
|||||
1 GTGAGCATCCAGCG 14

Db

RESULT 660
AX108730 15 bp DNA linear PAT 30-APR-2001
LOCUS AX108730
DEFINITION Sequence 34 from Patent WO0123543.
ACCESSION AX108730
VERSION AX108730.1 GI:13923930
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Reini,S.J., Lindbo,J.A. and Turpen,T.
TITLE Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
JOURNAL Patent: WO 0123543-A 34 05-APR-2001;
Large Scale Biology Corporation (US)

FEATURES
source 1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="linker region nucleotide sequence"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1236 GTGCTGGCAGTGGT 1249
|||||
2 GTGCTGTGTGTGT 15

Db

RESULT 661
AX297593/C 15 bp DNA linear PAT 21-NOV-2001
LOCUS AX297593
DEFINITION Sequence 9355 from Patent WO0199548.
ACCESSION AX297593
VERSION AX297593.1 GI:17059284
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Barany,F., Zivvi,M., Gerry,N.P., Favis,R. and Kliman,R.
TITLE Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 9355 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)

FEATURES
location/Qualifiers

source 1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 GTGCCATGTCATC 1310
|||||
14 GCGCCATGCGCATC 1

Db

RESULT 662
AX455681/C 15 bp DNA linear PAT 06-JUL-2002
LOCUS AX455681
DEFINITION Sequence 158 from Patent WO0222809.
ACCESSION AX455681
VERSION AX455681.1 GI:21714741
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Bauer,S., Lipford,G. and Wagner,H.
TITLE Process for high throughput screening of cpq-based immuno-agonist/antagonist
JOURNAL Patent: WO 0222809-A 158 21-MAR-2002;
Coley Pharmaceutical GmbH (DE)

FEATURES
source 1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1270 AAGAGCTGAGGCC 1283
|||||
14 AAGATGCTGAGGCC 1

Db

RESULT 663
AX632885/C 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX632885
DEFINITION Sequence 24 from Patent EP1260586.
ACCESSION AX632885
VERSION AX632885.1 GI:28468499
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A., Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswiggen,J.A., Modak,A., Pavco,F., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 24 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

FEATURES
source 1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1300 CCATGTCATCTGT 1313
Db 15 CCATGTCATCTCT 2

RESULT 664
AX632984/c 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX632984
DEFINITION Sequence 123 from Patent EP1260586.
ACCESSION AX632984
VERSION AX632984.1 GI:28468598
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelesky,A., Draper,K.G., Klisch,K., Matulic-Adamic,J.,
Mcawiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 123 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1374 CAGAGCAGCTGCG 1387
Db 14 CAGAGAGAGCTGCG 1

RESULT 665
AX633297/c 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX633297
DEFINITION Sequence 436 from Patent EP1260586.
ACCESSION AX633297
VERSION AX633297.1 GI:28468911
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 unidentified
unidentified
unclassified.

Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelesky,A., Draper,K.G., Klisch,K., Matulic-Adamic,J.,
Mcawiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 436 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1271 AGAGCTGAGGCA 1284
Db 15 AGTGCTGAGGCTA 2

RESULT 666
AX633442 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX633442
DEFINITION Sequence 581 from Patent EP1260586.
ACCESSION AX633442
VERSION AX633442.1 GI:28469056
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelesky,A., Draper,K.G., Klisch,K., Matulic-Adamic,J.,
Mcawiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 581 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1316 GCAGCTAGGGACC 1329
Db 2 GCAGCTAGCGGACC 15

RESULT 667
AX633489 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX633489
DEFINITION Sequence 628 from Patent EP1260586.
ACCESSION AX633489
VERSION AX633489.1 GI:28469103
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 unidentified
unidentified
unclassified.

Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelesky,A., Draper,K.G., Klisch,K., Matulic-Adamic,J.,
Mcawiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 628 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1316 GCAGCTAGGGACC 1329
Db 1316 GCAGCTAGGGACC 1329

Db 2 GGAGCTACGGAGCC 15

RESULT 668

AX636003 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX636003
DEFINITION Sequence 3142 from Patent EP1260586.
ACCESSION AX636003
VERSION AX636003.1 GI:28471617
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpelisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes

TITLE Patent: EP 1260586-A 3142 27-NOV-2002;
JOURNML RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1385 GCGTTTGTGTGAGC 1398
Db 2 GCGTATGCTGTGC 15

RESULT 669
AX637310 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX637310
DEFINITION Sequence 4449 from Patent EP1260586.
ACCESSION AX637310
VERSION AX637310.1 GI:28472924
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpelisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related
genes

TITLE Patent: EP 1260586-A 4449 27-NOV-2002;
JOURNML RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 4.3%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1244 AGTGTCCGGCTGC 1257
Db 2 AGTGTCAAGTTGC 15

Search completed: December 6, 2004, 18:12:08
Job time : 4 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 6, 2004, 18:15:40 ; Search time 2 Seconds
(without alignments)
3.316 Million cell updates/sec

Title: us-09-993-731-10

Perfect score: 252
Sequence: 1 ctggcgcccccagaagcctgt.....gtcgtagcgcgccatcctc 252

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 751 seqs, 13160 residues

Total number of hits satisfying chosen parameters: 1502

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 759 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20	7.9	20	1	AA161563 Human inhibitor-ka
2	20	7.9	20	1	AA161564 Human inhibitor-ka
3	20	7.9	20	1	AA161561 Human inhibitor-ka
4	20	7.9	20	1	AA161564 Human inhibitor-ka
5	20	7.9	20	1	AA161562 Human inhibitor-ka
6	20	7.9	20	1	AA161555 Human inhibitor-ka
7	20	7.9	20	1	AA161566 Human inhibitor-ka
8	20	7.9	20	1	AA161567 Human inhibitor-ka
9	20	7.9	20	1	AA161552 Human inhibitor-ka
10	20	7.9	20	1	AA161553 Human inhibitor-ka
11	20	7.9	20	1	AA161556 Human inhibitor-ka
12	20	7.9	20	1	AA161559 Human inhibitor-ka
13	20	7.9	20	1	AA161560 Human inhibitor-ka
14	20	7.9	20	1	AA161557 Human inhibitor-ka
15	20	7.9	20	1	AA161568 Human inhibitor-ka
16	20	7.9	20	1	AA161558 Human inhibitor-ka
17	20	7.9	20	1	AA161565 Human inhibitor-ka
18	20	7.9	20	1	AA161569 Human inhibitor-ka
19	18.6	7.4	25	1	AC136127 Human microarray D
20	18.4	7.3	23	1	AAQ10661 HLA Class II locus
21	17.4	6.9	20	1	AA221462 Human BURB1 PCR pr
22	16.6	6.6	23	1	AD149166 Human NOV protein-
23	16.4	6.5	20	1	AD138636 Human LIM domain k
24	16.4	6.5	20	1	AD138636 Human LIM domain k
25	16.2	6.4	21	1	AB860230 Human polymorphism
26	16.2	6.4	21	1	AB860229 Human polymorphism
27	16.2	6.4	21	1	AB860227 Human polymorphism
28	16.2	6.4	21	1	AB860228 Human polymorphism
29	16.2	6.4	22	1	AD26392 NOV protein-relate
30	16.2	6.4	23	1	AB182182 p53 mutation detec
31	16	6.3	20	1	ABK99821 Mouse RAID antise
32	16	6.3	20	1	ABK99820 Mouse RAID antise
33	15.8	6.3	19	1	AD84437 Human ABL1-targete

C	34	15.8	6.3	19	1	AD844756 Human ABL1-targete
C	35	15.8	6.3	20	1	ABA01022 Human ZAC/PLAG1 ge
C	36	15.8	6.3	20	1	AB293426 Human oligonucleot
C	37	15.8	6.3	20	1	ABD29656 AA626698-derived o
C	38	15.8	6.3	21	1	AB851235 Human CAPPKL DNA 8
C	39	15.4	6.1	17	1	ABN00937 Human GDM/P-1-17-m
C	40	15.4	6.1	17	1	AD898963 LRP5 mutagenic PCR
C	41	15.4	6.1	19	1	AD830113 Mitogen activated
C	42	15.4	6.1	19	1	AD830113 Mitogen activated
C	43	15.4	6.1	20	1	AD830113 Mitogen activated
C	44	15.4	6.1	20	1	AD830113 Mitogen activated
C	45	15.4	6.1	20	1	AD830113 Mitogen activated
C	46	15.4	6.1	22	1	AAQ75970 Antisense DNA Olig
C	47	15.4	6.1	22	1	AAQ75970 Antisense DNA Olig
C	48	15.4	6.1	22	1	AAQ75970 Antisense DNA Olig
C	49	15.4	6.1	22	1	AAQ75970 Antisense DNA Olig
C	50	15.2	6.0	20	1	AAV59166 Antisense DNA Olig
C	51	15.2	6.0	20	1	AAV59166 Antisense DNA Olig
C	52	15.2	6.0	20	1	AAV59166 Antisense DNA Olig
C	53	15.2	6.0	20	1	AAV59166 Antisense DNA Olig
C	54	15.2	6.0	20	1	AAV59166 Antisense DNA Olig
C	55	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	56	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	57	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	58	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	59	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	60	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	61	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	62	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	63	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	64	15.2	6.0	21	1	AAQ85727 Antisense DNA Olig
C	65	14.8	5.9	18	1	AA222430 Antisense oligonuc
C	66	14.8	5.9	18	1	AA222430 Antisense oligonuc
C	67	14.8	5.9	18	1	AA222430 Antisense oligonuc
C	68	14.8	5.9	18	1	AA222430 Antisense oligonuc
C	69	14.8	5.9	19	1	AD014748 Antisense oligonuc
C	70	14.8	5.9	19	1	AD014748 Antisense oligonuc
C	71	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	72	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	73	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	74	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	75	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	76	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	77	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	78	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	79	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	80	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	81	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	82	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	83	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	84	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	85	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	86	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	87	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	88	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	89	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	90	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	91	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	92	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	93	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	94	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	95	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	96	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	97	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	98	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	99	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	100	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	101	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	102	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	103	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	104	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	105	14.8	5.9	20	1	AAV72821 Antisense oligonuc
C	106	14.8	5.9	20	1	AAV72821 Antisense oligonuc

C 107	14.8	5.9	20	1	ADP46861	Human PRO 300 PCR	C 180	14.2	5.6	20	1	AAT00877	Murine mc26 struct
C 108	14.8	5.9	20	1	ADG52618	Human PRO 300 PCR	181	14.2	5.6	20	1	AAZ03138	CXCR4 gene inhibit
C 109	14.8	5.9	20	1	ADG59938	Human PRO 300 PCR	182	14.2	5.6	20	1	AAZ06182	PCR primer used for
C 110	14.8	5.9	20	1	AD160698	Human PRO 300 PCR	C 183	14.2	5.6	20	1	AA336856	Human X1S gene fr
C 111	14.8	5.9	20	1	AD142441	Novel human secret	C 184	14.2	5.6	20	1	AA286920	Probe for mouse mc
C 112	14.8	5.9	20	1	ADB48355	Human PRO 300 PCR	C 185	14.2	5.6	20	1	ABN74835	Human and mouse ca
C 113	14.8	5.9	20	1	ADBF89456	Human PRO 300 PCR	C 186	14.2	5.6	20	1	AB567687	Casein Kinase-2 an
C 114	14.8	5.9	20	1	ADBF61096	Human PRO 300 PCR	187	14.2	5.6	20	1	AB197417	Capture oligonucle
C 115	14.8	5.9	20	1	ADP39788	Human PRO 300 PCR	C 188	14.2	5.6	20	1	ABX97662	Novel human protei
C 116	14.8	5.9	20	1	ADP45584	Human PRO 300 PCR	189	14.2	5.6	20	1	AB223825	EGFR mRNA inhibiti
C 117	14.8	5.9	20	1	ADP23980	Human PRO 300 PCR	C 190	14.2	5.6	20	1	AB222817	Salmonella s1pB-si
C 118	14.8	5.9	20	1	ADP40412	Human PRO 300 PCR	191	14.2	5.6	20	1	AL62392	Human ABC transpor
C 119	14.8	5.9	20	1	ADP23356	Human PRO 300 PCR	192	14.2	5.6	20	1	AA61584	Human inhibitor-ka
C 120	14.8	5.9	20	1	ADP33339	Human PRO 300 PCR	C 193	14.2	5.6	20	1	ADP87711	Single nucleotide
C 121	14.8	5.9	20	1	ADP26806	Human PRO 300 PCR	C 194	14.2	5.6	20	1	ADH93689	Human gene PCR pri
C 122	14.8	5.9	20	1	ADP27442	Human PRO 300 PCR	C 195	14.2	5.6	20	1	AB290979	Human oligonucleot
C 123	14.8	5.9	20	1	ADP41036	Human PRO 300 PCR	C 196	14.2	5.6	20	1	AB285937	Human oligonucleot
C 124	14.8	5.9	20	1	ADP32715	Human PRO 300 PCR	197	14.2	5.6	20	1	ABD22167	Human stemlocalci
C 125	14.8	5.9	20	1	ADP25081	Human PRO 300 PCR	C 198	14.2	5.6	20	1	ABD27209	AA180912-derived o
C 126	14.8	5.9	20	1	ADP26182	Human PRO 300 PCR	C 199	14.2	5.6	20	1	ADG72227	Human SREBP-1 targ
C 127	14.8	5.9	20	1	ADP33971	Human PRO 300 PCR	C 200	14.2	5.6	20	1	ADG72098	Human SREBP-1 anti
C 128	14.8	5.9	20	1	ADP46208	Human PRO 300 PCR	C 201	14.2	5.6	20	1	ADN03131	Human P1M-1 DNA an
C 129	14.8	5.9	20	1	ADG50194	Human PRO 300 PCR	C 202	14.2	5.6	20	1	ADN03059	Human H1P-1 DNA an
C 130	14.8	5.9	20	1	ADG49570	Human PRO 300 PCR	C 203	14.2	5.6	20	1	AD048125	Human H1P-1 target
C 131	14.8	5.9	20	1	ADG51442	Human PRO 300 PCR	C 204	14.2	5.6	20	1	AD048059	Human H1P-1 antise
C 132	14.8	5.9	20	1	ADG48946	Human PRO 300 PCR	C 205	14	5.6	15	1	AAFS2821	IGF-1 oligonucleot
C 133	14.8	5.9	20	1	ADG48322	Human PRO 300 PCR	C 206	14	5.6	15	1	AAFS2823	IGF-1 oligonucleot
C 134	14.8	5.9	20	1	ADG50818	Human PRO 300 PCR	C 207	14	5.6	18	1	AB298178	Human CD23 -deriv
C 135	14.8	5.9	20	1	ADG58762	Human PRO 300 PCR	C 208	14	5.6	18	1	ABD31209	Human CD23 -deriv
C 136	14.8	5.9	20	1	ADG62218	Human PRO 300 PCR	C 209	14	5.6	18	1	ADU60043	Oligonucleotide as
C 137	14.8	5.9	20	1	ADH25243	Human neurotrophin	C 210	14	5.6	18	1	AD045533	Human oligonucleot
C 138	14.8	5.9	20	1	ADH17020	Human PRO 300 PCR	C 211	14	5.6	19	1	AB143943	Human chromosome 1
C 139	14.8	5.9	20	1	ADL06854	Human PRO 300 PCR	C 212	14	5.6	19	1	ADF31546	Human IGF-1R trans
C 140	14.8	5.9	20	1	ADP68735	Mouse PPAR-alpha a	C 213	14	5.6	20	1	ADF31823	Human IGF-1R siNA
C 141	14.8	5.9	20	1	ADP68836	Mouse PPAR-alpha a	C 214	14	5.6	20	1	ABX17840	Mouse urokinase pl
C 142	14.8	5.9	21	1	AB182180	p53 mutation detec	C 215	14	5.6	20	1	ADU66929	RET oligonucleotid
C 143	14.8	5.9	21	1	AB182177	p53 mutation detec	C 216	14	5.6	20	1	ADK95533	Primer of the inve
C 144	14.8	5.9	21	1	AB182179	p53 mutation detec	C 217	14	5.6	20	1	ADK94306	Mouse flk-1 VEGF r
C 145	14.8	5.9	21	1	AB182176	p53 mutation detec	C 218	13.8	5.5	17	1	AAAX72691	Human KDR VEGF rec
C 146	14.4	5.7	17	1	AAAX72692	Mouse flk-1 VEGF r	C 219	13.8	5.5	17	1	AAAX71090	Human KDR VEGF rec
C 147	14.4	5.7	17	1	ABA78077	BRCAl mutation cor	C 220	13.8	5.5	17	1	ABA78082	BRCAl mutation cor
C 148	14.4	5.7	17	1	ABA78078	BRCAl mutation cor	C 221	13.8	5.5	17	1	ABA78081	BRCAl mutation cor
C 149	14.4	5.7	17	1	ABA78070	BRCAl mutation cor	C 222	13.8	5.5	17	1	ABN06620	Human GDM1P-1 17-m
C 150	14.4	5.7	17	1	ABN06619	Human GDM1P-1 17-m	C 223	13.8	5.5	17	1	ABN06619	Human GDM1P-1 17-m
C 151	14.4	5.7	17	1	ABN00936	Human GDM1P-1 17-m	C 224	13.8	5.5	17	1	ABN06619	Human GDM1P-1 17-m
C 152	14.4	5.7	17	1	ABN00938	Human GDM1P-1 17-m	C 225	13.8	5.5	17	1	ABN08656	Human GDM1P-1 17-m
C 153	14.4	5.7	17	1	ABT37829	Tumour suppression	C 226	13.8	5.5	17	1	ABN00935	Human HER2 DNAzyme
C 154	14.4	5.7	17	1	ABZ64881	Human HER2 DNAzyme	C 227	13.8	5.5	17	1	ABZ64880	Human HER2 DNAzyme
C 155	14.4	5.7	19	1	AAA82749	cdk3 ribozyme bind	C 228	13.8	5.5	17	1	ACC58685	Human ADAMTS14 gen
C 156	14.4	5.7	19	1	AAH57911	Cell-cycle depende	C 229	13.8	5.5	17	1	ACC53896	Human tumour suppr
C 157	14.4	5.7	19	1	ADP87815	Single nucleotide	C 230	13.8	5.5	17	1	ADL48354	Human IKK-gamma su
C 158	14.4	5.7	20	1	AAAT61090	Reverse primer GS4	C 231	13.8	5.5	18	1	AAAX67092	Human B7-2 hairpin
C 159	14.4	5.7	20	1	AAAT95825	Primer used in gro	C 232	13.8	5.5	18	1	AAAX71723	Human KDR VEGF rec
C 160	14.4	5.7	20	1	AAZ59203	First strand cDNA	C 233	13.8	5.5	18	1	AAAX5424	Forward PCR primer
C 161	14.4	5.7	20	1	AAAF28588	HPRT PCR primer #1	C 234	13.8	5.5	18	1	AAAS2844	Human CQ44 antisen
C 162	14.4	5.7	20	1	AAAD34772	Human MEKK3 cDNA t	C 235	13.8	5.5	18	1	AAAC73261	Forward primer #48
C 163	14.4	5.7	20	1	ADG17896	Primer of the inve	C 236	13.8	5.5	18	1	ADCT8694	Human PRO polypept
C 164	14.4	5.7	20	1	ABX78217	Human bifunctional	C 237	13.8	5.5	18	1	AAAF72582	Human PRO polypept
C 165	14.4	5.7	20	1	AAAD52223	Human IFNGR1 antis	C 238	13.8	5.5	18	1	ADH59543	Human secreted/tra
C 166	14.4	5.7	20	1	ADG72147	Mouse SREBP-1 anti	C 239	13.8	5.5	18	1	ADU138322	Human secreted/tra
C 167	14.4	5.7	20	1	ADN01787	Human H1P1 antisen	C 240	13.8	5.5	18	1	ADU26590	Human secreted/tra
C 168	14.4	5.7	20	1	ADN01865	Human H1P1 antisen	C 241	13.8	5.5	18	1	ADDE9693	Human secreted/tra
C 169	14.4	5.7	20	1	ADN31465	Mouse forehead box	C 242	13.8	5.5	18	1	ADDE96813	Human secreted/tra
C 170	14.4	5.7	20	1	ADP43312	Human pituitary gr	C 243	13.8	5.5	18	1	ADDE99240	Human secreted/tra
C 171	14.4	5.7	20	1	AQ080813	Porcine Ig(H19-RL2	C 244	13.8	5.5	18	1	ADG40710	Human secreted/tra
C 172	14.2	5.6	19	1	AA336871	Human X1S gene fr	C 245	13.8	5.5	18	1	ADG92523	Human secreted/tra
C 173	14.2	5.6	19	1	ADH16361	Human BACE transcr	C 246	13.8	5.5	18	1	ADG92950	Human secreted/tra
C 174	14.2	5.6	19	1	ADH16686	Human BACE siNA 1o	C 247	13.8	5.5	18	1	ADH20739	Human secreted/tra
C 175	14.2	5.6	19	1	ADL79691	Human HER1 (EGFR)	C 248	13.8	5.5	18	1	ADH07594	Human secreted/tra
C 176	14.2	5.6	19	1	ADH79384	Human HER1 (EGFR)	C 249	13.8	5.5	18	1	ADH60139	Human secreted/tra
C 177	14.2	5.6	19	1	AD005557	Rhizobium meliloti	C 250	13.8	5.5	18	1	ADH07167	Human secreted/tra
C 178	14.2	5.6	19	1	AD060387	Anti-Cyclophilin s	C 251	13.8	5.5	18	1	ADU18909	Human secreted/tra
C 179	14.2	5.6	20	1	AAQ79338	Oligo HARP4-codAR	C 252	13.8	5.5	18	1	ADI65629	Human secreted/tra

253	13.8	5.5	18	1	ADI37888	Human secreted/tra	326	12.8	5.1	17	1	AAA22887	Integrin subunit b
254	13.8	5.5	18	1	ADI97658	Human secreted/tra	327	12.8	5.1	17	1	AAV91009	Human C-raif target
255	13.8	5.5	18	1	ADI66056	Human secreted/tra	328	12.8	5.1	17	1	AAV02687	Hammerhead ribozym
256	13.8	5.5	18	1	ADM25390	Human secreted/tra	329	12.8	5.1	17	1	ABK00539	Human NOGO Hammeth
257	13.8	5.5	18	1	ADM30140	Human secreted/tra	330	12.8	5.1	17	1	ABK02178	Human NOGO DNAAzyme
258	13.8	5.5	18	1	AD006462	Human PRO PCR prim	331	12.8	5.1	17	1	ABN01971	Human GDMLP-1 17-m
259	13.8	5.5	19	1	AA700610	21-hydroxylase B g	332	12.8	5.1	17	1	ABN06618	Human GDMLP-1 17-m
260	13.8	5.5	19	1	AA11965	Human truncated pl	333	12.8	5.1	17	1	ABN07805	Human GDMLP-1 17-m
261	13.8	5.5	19	1	AA84795	Cyclin F ribozyme	334	12.8	5.1	17	1	ABN01970	Human GDMLP-1 17-m
262	13.8	5.5	19	1	AA77488	Sense PCR primer s	335	12.8	5.1	17	1	ABN07355	Human GDMLP-1 17-m
263	13.8	5.5	19	1	AAH5957	Cyclin F ribozyme	336	12.8	5.1	17	1	ABN06621	Human GDMLP-1 17-m
264	13.8	5.5	19	1	ADFS3941	Human GAB2 short 1	337	12.8	5.1	17	1	ABN07806	Human GDMLP-1 17-m
265	13.8	5.5	19	1	ADFS4277	Human GAB2 short 1	338	12.8	5.1	17	1	ABN08655	Human GDMLP-1 17-m
266	13.8	5.5	19	1	ADH16704	Human BACE sRNA 10	339	12.8	5.1	17	1	ABN07354	Human GDMLP-1 17-m
267	13.8	5.5	19	1	ADH16379	Human BACE sRNA 10	340	12.8	5.1	17	1	ABN06657	Human GDMLP-1 17-m
268	13.8	5.5	19	1	ADH16638	Human BACE transcr	341	12.8	5.1	17	1	ABN09355	Human GDMLP-1 17-m
269	13.8	5.5	19	1	ADH16313	Human BACE transcr	342	12.8	5.1	17	1	ABN02602	Human GDMLP-1 17-m
270	13.8	5.5	19	1	AD043664	PCR primer used to	343	12.8	5.1	17	1	ABN09354	Human GDMLP-1 17-m
271	13.4	5.3	15	1	AB266523	Human HER2 synthet	344	12.8	5.1	17	1	ABN00934	Human GDMLP-1 17-m
272	13.4	5.3	15	1	ACD82534	Nucleic acid cloni	345	12.8	5.1	17	1	ABO64096	Human KTOm1a porti
273	13.4	5.3	17	1	AA771091	Human KDR VEGF rec	346	12.8	5.1	17	1	ABV80574	Human HTPU scannin
274	13.4	5.3	17	1	AA772693	Mouse flk-1 VEGF r	347	12.8	5.1	17	1	ABV80575	Human HTPU scannin
275	13.4	5.3	17	1	ABN00939	Human GDMLP-1 17-m	348	12.8	5.1	17	1	ABV80571	Human HTPU scannin
276	13.4	5.3	17	1	ACD59616	HCV DNAAzyme subet	349	12.8	5.1	17	1	ABV80572	Human HTPU scannin
277	13.4	5.3	17	1	AD150114	Human tumour suppr	350	12.8	5.1	17	1	ACN04605	WNV minus strand D
278	13.4	5.3	17	1	ACCS3109	HCV DNAAzyme subet	351	12.8	5.1	17	1	ACN13660	WNV minus strand D
279	13.4	5.3	18	1	AD184172	Human tumour suppr	352	12.8	5.1	17	1	ACN12442	WNV minus strand I
280	13.4	5.3	18	1	AA244760	Human FADD primer	353	12.8	5.1	17	1	ACN09390	WNV minus strand H
281	13.4	5.3	19	1	AA92573	Antisense oligonuc	354	12.8	5.1	17	1	ACN05546	WNV Ambexzyme subs
282	13.4	5.3	19	1	AA82748	cdk3 ribozyme blind	355	12.8	5.1	17	1	ACN05545	WNV Ambexzyme subs
283	13.4	5.3	19	1	AA590372	Human PADD mRNA ta	356	12.8	5.1	17	1	ACN05545	G-protein coupled
284	13.4	5.3	19	1	AA515082	Mouse IL-10 PCR pr	357	12.8	5.1	17	1	ACA99694	G-protein coupled
285	13.4	5.3	19	1	AAH57910	Cell-cycle depende	358	12.8	5.1	17	1	ADA99495	Human MD23 scannin
286	13.4	5.3	19	1	AA518881	Growth hormone 1 g	359	12.8	5.1	17	1	ADA99495	Human MD23 scannin
287	13.4	5.3	19	1	ABL44697	Human chromosome 1	360	12.8	5.1	17	1	ADA99494	Human MD23 scannin
288	13.4	5.3	19	1	ADC61330	Human Growth Hormo	361	12.8	5.1	17	1	AB264765	Human HER2 DNAAzyme
289	13.4	5.3	19	1	ADK5577	Primer of the inve	362	12.8	5.1	17	1	AB265195	Human HER2 DNAAzyme
290	13.2	5.2	18	1	AA057975	Sequence of portio	363	12.8	5.1	17	1	ACD62279	HCV minus strand D
291	13.2	5.2	18	1	AA66982	Human B7 hairpin r	364	12.8	5.1	17	1	ACD60646	HCV DNAAzyme subet
292	13.2	5.2	18	1	AA240927	Human CD40 phospho	365	12.8	5.1	17	1	ACD61199	HCV DNAAzyme subet
293	13.2	5.2	18	1	AA542898	Human CD44 antisen	366	12.8	5.1	17	1	ACD61470	HCV minus strand D
294	13.2	5.2	18	1	AA247760	Human CD40 antisen	367	12.8	5.1	17	1	ACD60390	HCV DNAAzyme subet
295	13.2	5.2	18	1	AA257670	Human G-alpha-12 a	368	12.8	5.1	17	1	ACC68548	Human HER2 DNAAzyme
296	13.2	5.2	18	1	AA22265	Arbidiopsis thalia	369	12.8	5.1	17	1	ACC58691	HCV minus strand D
297	13.2	5.2	18	1	AA92620	Antisense oligonuc	370	12.8	5.1	17	1	ADC37821	Human ADAMTS14 gen
298	13.2	5.2	18	1	AA26687	Human Smad7 phosph	371	12.8	5.1	17	1	ADC37818	Human ADAMPLA scann
299	13.2	5.2	18	1	AAH63040	Shrimp white spot	372	12.8	5.1	17	1	ADC37819	Human ADAMPLA scann
300	13.2	5.2	18	1	AB281780	Huntington's disea	373	12.8	5.1	17	1	ADC37820	Human ADAMPLA scann
301	13.2	5.2	18	1	AB281779	Huntington's disea	374	12.8	5.1	17	1	AD152233	Human tumour suppr
302	13.2	5.2	18	1	ADM06727	Human PCR primer S	375	12.8	5.1	17	1	AD146982	Human NOGO recepto
303	13.2	5.2	18	1	ADK96112	IGF-I oligonucleot	376	12.8	5.1	17	1	ADM09619	Human NOGO recepto
304	13.2	5.2	15	1	AA52824	IGF-I oligonucleot	377	12.8	5.1	17	1	AD184554	HCV DNAAzyme subet
305	13.2	5.2	15	1	AA52820	IGF-I oligonucleot	378	12.8	5.1	17	1	AD184971	HCV DNAAzyme subet
306	13.2	5.2	17	1	AAFC73225	Forward primer #39	379	12.8	5.1	17	1	AD185092	HCV DNAAzyme subet
307	13.2	5.2	17	1	ABN02597	Human GDMLP-1 17-m	380	12.8	5.1	17	1	AD185509	HCV DNAAzyme subet
308	13.2	5.2	17	1	ABN02598	Human GDMLP-1 17-m	381	12.8	5.1	17	1	AD184698	HCV DNAAzyme subet
309	13.2	5.2	17	1	ABN02599	Human GDMLP-1 17-m	382	12.8	5.1	17	1	AA750738	Rabbit CERP hairpi
310	13.2	5.2	17	1	ABN02600	Human GDMLP-1 17-m	383	12.8	5.1	17	1	AAH91892	Human inflammatory
311	13.2	5.2	17	1	ABR38605	Tumour suppression	384	12.8	5.1	17	1	ABL43550	Human chromosome 1
312	13.2	5.2	17	1	ADB42641	Tumour suppression	385	12.8	5.1	17	1	ABL43552	Human chromosome 1
313	13.2	5.2	18	1	AA082437	Chromosome 11 (loc	386	12.8	5.1	17	1	ADC03075	Ex vivo stem-cell
314	13.2	5.2	18	1	AA756700	Human TNF-alpha ha	387	12.8	5.1	17	1	ADFI1027	Human PCM1 exon 34
315	13.2	5.2	18	1	AA750730	Rabbit CERP hairpi	388	12.8	5.1	17	1	ACC57596	Mouse MAP kinase-i
316	13.2	5.2	18	1	AA741106	Human G-alpha-11 p	389	12.8	5.1	17	1	ADM57496	M. tuberculosis PC
317	13.2	5.2	18	1	AA719477	Human G-alpha-11 p	390	12.8	5.1	17	1	ADP92301	Human cyclokeratin
318	13.2	5.2	18	1	AA770371	Human biallelic ma	391	12.8	5.1	17	1	AD158750	Human interleukin
319	13.2	5.2	18	1	AA289196	Human riboprotein	392	12.8	5.1	17	1	ADL32584	Human beclin rever
320	13.2	5.2	18	1	AA289196	Human riboprotein	393	12.8	5.1	17	1	ABK99820	Mouse RAIDD antis
321	12.8	5.1	16	1	AA209676	Human biallelic po	394	12.6	5.0	20	1	ABX97662	Novel human protei
322	12.8	5.1	16	1	AA565903	Validation ribozym	395	12.4	4.9	14	1	AAV97210	Mouse RAIDD antis
323	12.8	5.1	16	1	AB598338	Human multidrug re	396	12.4	4.9	14	1	ADQ030281	Potato citrate id
324	12.8	5.1	17	1	AA744502	Mouse flt-1 VEGF r	397	12.4	4.9	15	1	AAV48765	ETB-2 gene antise
325	12.8	5.1	17	1	AAV96518	Potato citrate syn	398	12.4	4.9	15	1	AAV49271	IGF-I oligonucleot

399	12.4	4.9	15	1	AAFS0722	IGF-I oligonucleot	472	12.4	4.9	17	1	AD185892	HCV DNAzyme subestr
400	12.4	4.9	15	1	AAF49272	IGF-I oligonucleot	473	12.4	4.9	17	1	AD185891	HCV DNAzyme subestr
401	12.4	4.9	15	1	AAF49377	IGF-I oligonucleot	474	12.2	4.8	17	1	ABN08656	Human GDMLP-1 17-m
402	12.4	4.9	15	1	AAF49376	IGF-I oligonucleot	475	12.2	4.8	17	1	AAV97648	Human EGF-R target
403	12.4	4.9	15	1	AAFS0723	IGF-I oligonucleot	476	12.2	4.8	17	1	AAV16349	Primer used to clo
404	12.4	4.9	15	1	AAFA5157	Antisense oligonuc	477	12.2	4.8	17	1	AAV94867	Mouse IL-2 recepto
405	12.4	4.9	15	1	AAH18762	Human IL4 allele-s	478	12.2	4.8	17	1	AAV71807	Wirtine IgG1 heavy
406	12.4	4.9	15	1	ABK96641	Interleukin-3 (IL-	479	12.2	4.8	17	1	AAA36507	Human genomic SNP
407	12.4	4.9	16	1	AAD22032	Human sitosterolae	480	12.2	4.8	17	1	AAA25058	Oestrogen receptor
408	12.4	4.9	17	1	AAT06918	Chromosomal locus	481	12.2	4.8	17	1	AAAF01894	Hammerhead ribozym
409	12.4	4.9	17	1	AAV71092	Human KDR VEGF rec	482	12.2	4.8	17	1	AAAF0235	Hammerhead ribozym
410	12.4	4.9	17	1	AAV64712	Primer E15 for map	483	12.2	4.8	17	1	ABK00540	Human NOGO Hammeth
411	12.4	4.9	17	1	AAK62300	Granule Bound scar	484	12.2	4.8	17	1	ABK02521	Human NOGO Ambetzy
412	12.4	4.9	17	1	AAV95089	Canine IL-2 recept	485	12.2	4.8	17	1	ABK01652	Human NOGO G-Cleav
413	12.4	4.9	17	1	AAV08617	Primer ACP/8RB for	486	12.2	4.8	17	1	ABK01790	Human NOGO Zinzyne
414	12.4	4.9	17	1	AAV08623	Primer ACP/16RT fo	487	12.2	4.8	17	1	ABK01793	Human NOGO Zinzyne
415	12.4	4.9	17	1	AAV22888	Integrin subunit b	488	12.2	4.8	17	1	ABA90520	MSH6 mutation corr
416	12.4	4.9	17	1	AAV91008	Human C-raf target	489	12.2	4.8	17	1	ABA80521	MSH6 mutation corr
417	12.4	4.9	17	1	AAA38251	Human ACE regulato	490	12.2	4.8	17	1	ABL46727	Human GRID NCH rib
418	12.4	4.9	17	1	AAA38245	Human ACE regulato	491	12.2	4.8	17	1	ABL46891	Human GRID G-cleav
419	12.4	4.9	17	1	AAC61251	Human ACE, AGT and	492	12.2	4.8	17	1	ABL46750	Human GRID NCH rib
420	12.4	4.9	17	1	AAC61245	Human ACE, AGT and	493	12.2	4.8	17	1	ABN07803	Human GDMLP-1 17-m
421	12.4	4.9	17	1	AAF02397	Hammerhead ribozym	494	12.2	4.8	17	1	ABN08659	Human GDMLP-1 17-m
422	12.4	4.9	17	1	ABN08787	Human GDMLP-1 17-m	495	12.2	4.8	17	1	ABN01468	Human GDMLP-1 17-m
423	12.4	4.9	17	1	ABN08784	Human GDMLP-1 17-m	496	12.2	4.8	17	1	ABN07848	Human GDMLP-1 17-m
424	12.4	4.9	17	1	ABN08786	Human GDMLP-1 17-m	497	12.2	4.8	17	1	ABN07928	Human GDMLP-1 17-m
425	12.4	4.9	17	1	ABN08316	Human GDMLP-1 17-m	498	12.2	4.8	17	1	ABN07807	Human GDMLP-1 17-m
426	12.4	4.9	17	1	ABN08317	Human GDMLP-1 17-m	499	12.2	4.8	17	1	ABN08514	Human GDMLP-1 17-m
427	12.4	4.9	17	1	ABN08319	Human GDMLP-1 17-m	500	12.2	4.8	17	1	ABN08658	Human GDMLP-1 17-m
428	12.4	4.9	17	1	ABN00940	Human GDMLP-1 17-m	501	12.2	4.8	17	1	ABN02596	Human GDMLP-1 17-m
429	12.4	4.9	17	1	ABN08318	Human GDMLP-1 17-m	502	12.2	4.8	17	1	ABN09241	Human GDMLP-1 17-m
430	12.4	4.9	17	1	ABN08785	Human GDMLP-1 17-m	503	12.2	4.8	17	1	ABN09239	Human GDMLP-1 17-m
431	12.4	4.9	17	1	ABA02327	Human hepatoma-ase	504	12.2	4.8	17	1	ABN07533	Human GDMLP-1 17-m
432	12.4	4.9	17	1	ABF76194	Human PAP-EB asso	505	12.2	4.8	17	1	ABN07804	Human GDMLP-1 17-m
433	12.4	4.9	17	1	ABF76191	Human PAP-EB asso	506	12.2	4.8	17	1	ABN08441	Human GDMLP-1 17-m
434	12.4	4.9	17	1	ABF76193	Human PAP-EB asso	507	12.2	4.8	17	1	ABN09551	Human GDMLP-1 17-m
435	12.4	4.9	17	1	ABF76192	Human PAP-EB asso	508	12.2	4.8	17	1	ABN07849	Human GDMLP-1 17-m
436	12.4	4.9	17	1	ACN11988	WNV minus strand I	509	12.2	4.8	17	1	ABN09240	Human GDMLP-1 17-m
437	12.4	4.9	17	1	ACN09283	WNV minus strand H	510	12.2	4.8	17	1	ABN08512	Human GDMLP-1 17-m
438	12.4	4.9	17	1	ACN05643	WNV Amberyzme subs	511	12.2	4.8	17	1	ABN08442	Human GDMLP-1 17-m
439	12.4	4.9	17	1	ACN05644	WNV Amberyzme subs	512	12.2	4.8	17	1	ABN01967	Human GDMLP-1 17-m
440	12.4	4.9	17	1	ACN01507	WNV Itozyme subestr	513	12.2	4.8	17	1	ABQ64028	Human KROM1a porti
441	12.4	4.9	17	1	ACN11990	WNV minus strand I	514	12.2	4.8	17	1	ABQ64029	Human KROM1a porti
442	12.4	4.9	17	1	ACN11989	WNV minus strand I	515	12.2	4.8	17	1	ABK25804	Stress tolerance c
443	12.4	4.9	17	1	ACN12143	WNV minus strand I	516	12.2	4.8	17	1	ABK25783	Stress tolerance c
444	12.4	4.9	17	1	ACN01611	WNV Itozyme subestr	517	12.2	4.8	17	1	ABK25803	Stress tolerance c
445	12.4	4.9	17	1	ACN13555	WNV minus strand Z	518	12.2	4.8	17	1	ABK25784	Stress tolerance c
446	12.4	4.9	17	1	ABT35664	Tumour suppression	519	12.2	4.8	17	1	ABV79670	Human HTP1L scannin
447	12.4	4.9	17	1	ABT35657	Tumour suppression	520	12.2	4.8	17	1	ABV80573	Human HTP1L scannin
448	12.4	4.9	17	1	ABT39779	Tumour suppression	521	12.2	4.8	17	1	ABV79528	Human HTP1L scannin
449	12.4	4.9	17	1	ACA07728	NFKB sub-unit modu	522	12.2	4.8	17	1	ABK19390	Human ERG Amberyzm
450	12.4	4.9	17	1	ACA06453	NFKB sub-unit modu	523	12.2	4.8	17	1	ABK18938	Human ERG DNAzyme
451	12.4	4.9	17	1	ACB085259	Human MD212 scanni	524	12.2	4.8	17	1	ABV89776	Human POSH1L scann
452	12.4	4.9	17	1	ACB085260	Human MD212 scanni	525	12.2	4.8	17	1	ABK55867	Human CLCA1 gene e
453	12.4	4.9	17	1	ADB05262	Human MD212 scanni	526	12.2	4.8	17	1	ABK56469	Human CLCA1 gene e
454	12.4	4.9	17	1	ADB05261	Human MD212 scanni	527	12.2	4.8	17	1	ABK56914	Human CLCA1 gene e
455	12.4	4.9	17	1	ACD63053	HCV minus strand D	528	12.2	4.8	17	1	ACN02632	WNV Itozyme subestr
456	12.4	4.9	17	1	ACD63054	HCV minus strand D	529	12.2	4.8	17	1	ACN05723	WNV Amberyzme subs
457	12.4	4.9	17	1	AA151462	Oligodendrocyte de	530	12.2	4.8	17	1	ACN08403	WNV minus strand H
458	12.4	4.9	17	1	ADB43574	Tumour suppression	531	12.2	4.8	17	1	ACN10812	WNV minus strand I
459	12.4	4.9	17	1	ADB45562	Tumour suppression	532	12.2	4.8	17	1	ACN13459	WNV minus strand Z
460	12.4	4.9	17	1	ADC66185	Human CFTR related	533	12.2	4.8	17	1	ACN05182	WNV DNAzyme subestr
461	12.4	4.9	17	1	ADC66186	Human CFTR related	534	12.2	4.8	17	1	ACN10625	WNV minus strand I
462	12.4	4.9	17	1	ADP62509	Human PCCP1 DNA fr	535	12.2	4.8	17	1	ACN11869	WNV minus strand I
463	12.4	4.9	17	1	ADP62506	Human PCCP1 DNA fr	536	12.2	4.8	17	1	ACN13498	WNV minus strand Z
464	12.4	4.9	17	1	ADP62508	Human PCCP1 DNA fr	537	12.2	4.8	17	1	ACN12792	WNV minus strand Z
465	12.4	4.9	17	1	ADP62507	Human PCCP1 DNA fr	538	12.2	4.8	17	1	ACA99693	G-protein coupled
466	12.4	4.9	17	1	ACCS1715	Human tumour suppr	539	12.2	4.8	17	1	ACA06589	NFKB sub-unit modu
467	12.4	4.9	17	1	ACCS4358	Human tumour suppr	540	12.2	4.8	17	1	ACA07774	NFKB sub-unit modu
468	12.4	4.9	17	1	AD148389	Human IKK-gamma su	541	12.2	4.8	17	1	ACA06584	NFKB sub-unit modu
469	12.4	4.9	17	1	AD147853	Human IKK-gamma su	542	12.2	4.8	17	1	ACA06585	NFKB sub-unit modu
470	12.4	4.9	17	1	AD147854	Human IKK-gamma su	543	12.2	4.8	17	1	ADB02361	Human MD23 scannin
471	12.4	4.9	17	1	ADK13157	Human glioma endot	544	12.2	4.8	17	1	ADA99492	Human MD23 scannin

C 545	12.2	4.8	17	1	ADA99490	Human MD23 scannin	618	12	4.8	17	1	ABZ65158	Human HER2 DNAzyme
546	12.2	4.8	17	1	ADB05268	Human MD212 scanni	619	12	4.8	17	1	ADB98935	LRP5 mutagenic PCR
C 547	12.2	4.8	17	1	ADA99493	Human MD23 scannin	620	12	4.8	17	1	ADI51186	Human tumour suppress
548	12.2	4.8	17	1	ADB02362	Human MD24 scannin	621	12	4.8	17	1	ACC51667	Human tumour suppress
C 549	12.2	4.8	17	1	ADA99491	Human MD23 scannin	622	12	4.8	17	1	ADP92499	Human cyclokeratin
C 550	12.2	4.8	17	1	ADB00169	Human MD23 scannin	623	12	4.8	17	1	ADL82354	Human ER+ breast c
C 551	12.2	4.8	17	1	ADB05267	Human MD212 scanni	624	12	4.8	20	1	AAI61584	Human inhibitor-ka
C 552	12.2	4.8	17	1	ADB02346	Human MD24 scannin	625	11.8	4.7	15	1	AAT54830	Mouse reia hammarh
553	12.2	4.8	17	1	ADB00361	Human MD23 scannin	626	11.8	4.7	15	1	AAT54967	Mouse reia hammarh
554	12.2	4.8	17	1	ACD63387	HCV minus strand D	627	11.8	4.7	15	1	AAT54864	Mouse reia hammarh
C 555	12.2	4.8	17	1	ACC64444	Murine oligonucleo	628	11.8	4.7	15	1	AAK65552	Human CD40 hammarh
556	12.2	4.8	17	1	ACC63082	Murine oligonucleo	629	11.8	4.7	15	1	AAV48561	p53 gene antisense
557	12.2	4.8	17	1	ACC67926	Murine oligonucleo	630	11.8	4.7	15	1	AAZ64417	Substrate for ham
C 558	12.2	4.8	17	1	ACC68650	Murine oligonucleo	631	11.8	4.7	15	1	AAZ64174	Substrate for ham
C 559	12.2	4.8	17	1	ACC63303	Murine oligonucleo	632	11.8	4.7	15	1	AAZ64292	Substrate for ham
560	12.2	4.8	17	1	ADB41888	Tumour suppression	633	11.8	4.7	15	1	AAF45848	ICBP2 oligonucleo
C 561	12.2	4.8	17	1	ADC04891	Human Na/H exchang	634	11.8	4.7	15	1	AAF49371	ICG-I oligonucleot
562	12.2	4.8	17	1	ADC37824	Human AMLP1a scann	635	11.8	4.7	15	1	AAF49374	ICG-I oligonucleot
563	12.2	4.8	17	1	ADC37822	Human AMLP1a scann	636	11.8	4.7	15	1	AAF52764	ICG-I oligonucleot
564	12.2	4.8	17	1	ADD21021	Human GAP N DNA 17	637	11.8	4.7	15	1	AAF50260	ICG-I oligonucleot
565	12.2	4.8	17	1	ADD21022	Human GAP N DNA 17	638	11.8	4.7	15	1	AAF50724	ICG-I oligonucleot
566	12.2	4.8	17	1	ADD21024	Human GAP N DNA 17	639	11.8	4.7	15	1	AAF48295	ICBP3 oligonucleo
C 567	12.2	4.8	17	1	AD151595	Human tumour suppl	640	11.8	4.7	15	1	AAF50719	ICG-I oligonucleot
C 568	12.2	4.8	17	1	ADM09584	Human NOGO recepto	641	11.8	4.7	15	1	AAF45849	ICBP2 oligonucleo
569	12.2	4.8	17	1	ADM09561	Human NOGO recepto	642	11.8	4.7	15	1	AAF49273	ICG-I oligonucleot
570	12.2	4.8	17	1	AD149613	Human PKR substrat	643	11.8	4.7	15	1	AAF49375	ICG-I oligonucleot
C 571	12.2	4.8	17	1	AD146693	Human NOGO recepto	644	11.8	4.7	15	1	AAZ64697	Target virus detec
C 572	12.2	4.8	17	1	AD149927	Human PKR substrat	645	11.8	4.7	15	1	AAZ20690	ASO probe #9 used
C 573	12.2	4.8	17	1	AD150179	Human PKR substrat	646	11.8	4.7	15	1	AAZ16939	Probing nucleobase
C 574	12.2	4.8	17	1	ADM09496	Human NOGO recepto	647	11.8	4.7	15	1	AAI45923	Murine dystrophin
C 575	12.2	4.8	17	1	ADM09585	Human NOGO recepto	648	11.8	4.7	15	1	ABL52290	Human CCR6 allele
C 576	12.2	4.8	17	1	ADM09586	Human NOGO recepto	649	11.8	4.7	15	1	ABX01470	Hepatitis C virus
C 577	12.2	4.8	17	1	ADM55922	Human GRID mRNA bu	650	11.8	4.7	15	1	ABX01227	Hepatitis C virus
C 578	12.2	4.8	17	1	ADM54085	Human GRID mRNA bu	651	11.8	4.7	15	1	ABX01345	Hepatitis C virus
C 579	12.2	4.8	17	1	ADM54108	Human GRID mRNA bu	652	11.8	4.7	15	1	ABK85835	Myotonic dystrophy
580	12.2	4.8	17	1	AD186057	HCV DNAzyme subste	653	11.8	4.7	15	1	ACD40395	Human A1P1 cDNA f
581	12.2	4.8	17	1	ADN44475	Mutant cell identi	654	11.8	4.7	15	1	ACD66351	Anti-HCV nucleic a
C 582	12.2	4.8	17	1	ADN44474	Mutant cell identi	655	11.8	4.7	15	1	ACD66421	Anti-HCV enzymatic
C 583	12.2	4.8	17	1	ADN44474	Mutant cell identi	656	11.8	4.7	15	1	ABZ81747	Oligonucleotide HD
584	12.2	4.8	17	1	ADN44495	Mutant cell identi	657	11.8	4.7	15	1	ACD82576	Nucleic acid cloni
C 585	12.2	4.8	14	1	AD61809	Rat IGFBP-3 gene I	658	11.8	4.7	15	1	ACD82304	Nucleic acid cloni
C 586	12.2	4.8	15	1	AAT54816	Mouse rela hammarh	659	11.8	4.7	15	1	ACD82546	Nucleic acid cloni
587	12.2	4.8	15	1	AAC69826	E. coli mred RNAMO	660	11.8	4.7	15	1	ABX08696	Pathogenic organis
588	12.2	4.8	15	1	AAT52825	IGF-I oligonucleot	661	11.8	4.7	15	1	ADP92298	Human cyclokeratin
589	12.2	4.8	15	1	AAT50721	IGF-I oligonucleot	662	11.8	4.7	15	1	ADH50189	Bacterial DNA hylr
590	12.2	4.8	15	1	AAT50720	IGF-I oligonucleot	663	11.8	4.7	15	1	ADK67644	Oligonucleotide HD
591	12.2	4.8	15	1	AAT52819	IGF-I oligonucleot	664	11.8	4.7	15	1	ADL72196	Human nucleotide s
592	12.2	4.8	15	1	AAT518274	ASO primer #21 to	665	11.8	4.7	15	1	ADM88705	Human nucleotide s
593	12.2	4.8	15	1	AAL41773	Human MC2R gene AS	666	11.8	4.7	15	1	AD187738	Anti-HCV molecule
594	12.2	4.8	15	1	ABK34186	Human interleukin	667	11.8	4.7	15	1	ADO49413	H. pylori strain J
C 595	12.2	4.8	15	1	ABT05303	Human N-acetylgluta	668	11.8	4.7	15	1	ADO49413	H. pylori strain J
596	12.2	4.8	15	1	ABT05330	Human N-acetylgluta	669	11.8	4.7	15	1	AAT55606	Mouse reia hairpin
C 597	12.2	4.8	15	1	AB864223	Tachykinin recepto	670	11.8	4.7	16	1	AAF24333	Human NPAR-
C 598	12.2	4.8	15	1	ACD82535	Nucleic acid cloni	671	11.8	4.7	16	1	ABA02928	Human cyclophilin
C 599	12.2	4.8	16	1	AAQ97769	Bovine prostagland	672	11.8	4.7	16	1	ABK48424	Human MEGF/Fibryl
600	12.2	4.8	16	1	AAV43468	HIV-1 beta-chemoki	673	11.8	4.7	16	1	ABL30914	Human HLA genotypi
601	12.2	4.8	16	1	AAF73460	HGF nucleic acid I	674	11.8	4.7	16	1	ABX56490	Human epidermal gr
602	12.2	4.8	17	1	AAT90963	Gene-specific inel	675	11.8	4.7	16	1	ADP92303	Human cyclokeratin
603	12.2	4.8	17	1	AAT93233	Primer GSI for hum	676	11.8	4.7	16	1	AD192405	Anti-HCV enzymatic
604	12.2	4.8	17	1	ABN10742	Human GDMPLP-1 17-m	677	11.8	4.6	20	1	ABK99821	Mouse RAIDD antisense
609	12.2	4.8	17	1	ABN08783	Human GDMPLP-1 17-m	678	11.6	4.6	15	1	ABL52157	Human PER1 allele
610	12.2	4.8	17	1	ABN09234	Human GDMPLP-1 17-m	683	11.6	4.6	18	1	ABZ81779	Human ribozyme tar
611	12.2	4.8	17	1	ABN09235	Human GDMPLP-1 17-m	684	11.4	4.5	13	1	AAV11036	Human ribozyme tar
612	12.2	4.8	17	1	ABN08782	Human GDMPLP-1 17-m	685	11.4	4.5	14	1	ABZ72854	VEGFR2 R21 ribozyme
613	12.2	4.8	17	1	ABN09236	Human GDMPLP-1 17-m	686	11.4	4.5	14	1	AAV95593	Human c-fos target
614	12.2	4.8	17	1	ABN09238	Human GDMPLP-1 17-m	687	11.4	4.5	15	1	AAQ75046	Human bFGF antisense
615	12.2	4.8	17	1	ABN10741	Human GDMPLP-1 17-m	688	11.4	4.5	15	1	AAQ75047	Human bFGF PCR pri
616	12.2	4.8	17	1	ABN10743	Human GDMPLP-1 17-m	689	11.4	4.5	15	1	AAT05414	AS-FGF (antisense
617	12.2	4.8	17	1	ABT39571	Tumour suppression	690	11.4	4.5	15	1	AAQ88737	Human bFGF transla

C 691	11.4	4.5	15	1	AA252000	Human ICAM hammerhead
C 692	11.4	4.5	15	1	AA097664	Bioinactivated anti- bFGF antisense com
C 693	11.4	4.5	15	1	AA744260	bFGF antisense com
C 694	11.4	4.5	15	1	AA737759	Ap(α) mRNA (nc. p
C 695	11.4	4.5	15	1	AA333920	bFGF expression in
C 696	11.4	4.5	15	1	AA789133	Lutealium texaphryl
C 697	11.4	4.5	15	1	AA734531	Human Fas antigen
C 698	11.4	4.5	15	1	AA734533	Human Fas antigen
C 699	11.4	4.5	15	1	AA734231	Phosphononoxester
C 700	11.4	4.5	15	1	AA763286	Human basic fibrob
C 701	11.4	4.5	15	1	AAV07304	Metallotexaphryn- Type-specific HPV
C 703	11.4	4.5	15	1	AA261949	Human basic fibrob
C 704	11.4	4.5	15	1	AA289335	Substrate for ham
C 705	11.4	4.5	15	1	AA264235	E. coli yfca RNAMO
C 706	11.4	4.5	15	1	AA502955	Human CMV1 allele
C 707	11.4	4.5	15	1	AA660910	Anti-bFGF oligonuc
C 708	11.4	4.5	15	1	AA494249	IGF-I oligonucleot
C 710	11.4	4.5	15	1	AA494270	IGF-I oligonucleot
C 711	11.4	4.5	15	1	AA550261	IGF-I oligonucleot
C 712	11.4	4.5	15	1	AA550262	IGF-I oligonucleot
C 713	11.4	4.5	15	1	AA494937	IGF-I oligonucleot
C 714	11.4	4.5	15	1	AA494941	IGF-I oligonucleot
C 715	11.4	4.5	15	1	AA494940	IGF-I oligonucleot
C 716	11.4	4.5	15	1	AA474749	IGFBP3 oligonucleo
C 717	11.4	4.5	15	1	AA474749	IGFBP3 oligonucleo
C 718	11.4	4.5	15	1	AA474749	IGFBP3 oligonucleo
C 719	11.4	4.5	15	1	AA428575	Human interleukin- Dekkera bruxellens
C 720	11.4	4.5	15	1	AA428663	Human IL4 allele-s
C 721	11.4	4.5	15	1	AA418764	Human IL4 allele-s
C 722	11.4	4.5	15	1	AA669368	Human IL4 allele-s
C 723	11.4	4.5	15	1	AA449215	Anti-bFGF oligonuc
C 724	11.4	4.5	15	1	AA250088	PCR primer for M.
C 725	11.4	4.5	15	1	AB101602	bFGF targeted anti
C 726	11.4	4.5	15	1	ABK93748	Human LCAT gene po
C 727	11.4	4.5	15	1	AA138345	ASO probe for dete
C 728	11.4	4.5	15	1	AB160175	Human MUC1 PCR pri
C 729	11.4	4.5	15	1	AB497515	BFGF targeted anti
C 730	11.4	4.5	15	1	AA324242	Human ORIG1 gene p
C 731	11.4	4.5	15	1	AB152248	Human PHK3 allele
C 732	11.4	4.5	15	1	ABN80600	Human P450/cytochr
C 733	11.4	4.5	15	1	ABK12188	Human Tachykinin R
C 734	11.4	4.5	15	1	AB145861	Human EDG6 gene al
C 735	11.4	4.5	15	1	AB191823	Human LIPG gene al
C 736	11.4	4.5	15	1	AA146751	BFGF antisense oli
C 737	11.4	4.5	15	1	AAK98549	Human enolase 3 ge
C 738	11.4	4.5	15	1	ABK72656	Human enolase B4 rec
C 739	11.4	4.5	15	1	ABX01368	Hepatitis C virus
C 740	11.4	4.5	15	1	ACN15239	WNV minus enzymati
C 741	11.4	4.5	15	1	ACN8258	Nucleic acid cloni
C 742	11.4	4.5	15	1	ACD82516	Nucleic acid cloni
C 743	11.4	4.5	15	1	ACD82570	Nucleic acid cloni
C 744	11.4	4.5	15	1	ACD82510	Nucleic acid cloni
C 745	11.4	4.5	15	1	ACD82522	Nucleic acid cloni
C 746	11.4	4.5	15	1	AD666131	Nucleic acid cloni
C 747	11.4	4.5	15	1	AD744540	Human CTRR exon 19
C 748	11.4	4.5	15	1	AD744552	Allele-specific ol
C 749	11.4	4.5	15	1	ACF57607	Human CERP gene al
C 750	11.4	4.5	16	1	AA662014	Human ALDOB gene a
C 751	11.4	4.5	16	1	AA260085	HPV type-specific
C 752	11.4	4.5	16	1	AA414189	PCR primer used to
C 753	11.4	4.5	16	1	ACN37058	B. pertussis 16S-2</

ALIGNMENTS

XX	RESULT 1
AC	AAL61563/c
XX	AAL61563 standard; DNA; 20 BP.
XX	AAL61563;
D7	22-SEP-2003 (first entry)
XX	Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130488.
DE	
XX	Human, inhibitor-kappa B-R; I-kappaB; IKK; I-kappa-B-related; NFKBIL2;
KW	Ikkapb r; antisense; immune response; infection; inflammation; therapy;
KW	tumour; prophylaxis; phosphorothioate; ss.
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	1..20
FT	/+tag= a
FT	/mod_base= OTHER
FT	/note= "phosphorothioate backbone; All cytidine residues
FT	are 5-methylcytidines"
FT	1..5
FT	modified_base
FT	1..5
FT	/+tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	16..20
FT	/+tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN	WO2003042360-A2.
XX	
PB	22-MAY-2003.
XX	
PF	05-NOV-2002; 2002MO-US035597.
XX	
PR	13-NOV-2001; 2001US-00993731.
XX	
PA	(ISIS-) ISIS PHARM INC.
PI	Monia BP, Watt AT;
XX	
DR	WPI; 2003-468635/44.
XX	
PT	New antisense oligonucleotides targeted to nucleic acids encoding
PT	inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT	associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT	immune response or infection.
XX	
PS	Claim 3; Page 74; 108bp; English.
XX	
CC	The invention relates to antisense compounds targetted to a nucleic acid
CC	molecule encoding human inhibitor-kappa B-R (also known as I-kappabR,
CC	IKK; I-kappa-B-related, Ikappab r, nuclear factor of kappa light
CC	polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC	inhibit its expression. Antisense compounds of the invention are useful
CC	for treating diseases or conditions associated with the expression of
CC	inhibitor-kappa B-R such as a heightened immune response involving
CC	increased cytokine expression, or a result of infection (e.g. bacterial,
CC	viral or parasitic). They are useful for diagnostics, therapeutics,
CC	prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC	formation, as research reagents and kits and in distinguishing between
CC	functions of various members of a biological pathway. They are also
CC	useful in antisense therapy. The present sequence is an oligonucleotide
CC	targetted to human inhibitor-kappa B-R DNA
XQ	Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1323 GGGGACCTCTTCCAGGC 1342
DB 20 GGGGACCTCTTCCAGGC 1
RESULT 2
AAL61554/C
ID AAL61554 standard; DNA; 20 BP.
AC AAL61554;
XX
XX 22-SEP-2003 (first entry)
DT
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130479.
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKK; I-kappa-B-related; NFKB1L2;
KW ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
FH
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT modified_base
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Watt AT;
XX
XX WPI; 2003-468635/44.
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Claim 3; Page 74; 108bp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKK, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKB1L2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide

CC targeted to human inhibitor-kappa B-R DNA
XX
XX Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
SQ Query Match 7.9%; Score 20; DB 1; Length 20;
Best local similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1213 CCATCTGTCAGACCTCCAG 1232
DB 20 CCATCTGTCAGACCTCCAG 1
RESULT 3
AAL61561/C
ID AAL61561 standard; DNA; 20 BP.
AC AAL61561;
XX
XX 22-SEP-2003 (first entry)
DT
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130486.
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKK; I-kappa-B-related; NFKB1L2;
KW ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
FH
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT modified_base
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Watt AT;
XX
XX WPI; 2003-468635/44.
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Claim 3; Page 74; 108bp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKK, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKB1L2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving

CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
CC
XX

SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 7.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 16;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1300 CCATGTCATCTGTGAGCAG 1319

DB 20 CCATGTCATCTGTGAGCAG 1

RESULT 4

AL61564/C

ID AL61564 standard; DNA; 20 BP.

XX AL61564;

DT 22-SEP-2003 (first entry)

DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130489.

XX Human; inhibitor-kappa B-R; I-kappaB; IKK α ; I-kappa-B-related; NFKB1L2;

KM Ikappab r; antisense; immune response; infection; inflammation; therapy;

KW tumour; prophylaxis; phosphorothioate; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base

FT 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone; All cytidine residues

FT are 5-methylcytidines"

FT 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT 16..20

FT /*tag= C

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003042360-A2.

PD 22-MAY-2003.

XX 05-NOV-2002; 2002WO-US035597.

XX 13-NOV-2001; 2001US-00993731.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Walt AT;

XX WPI; 2003-468635/44.

XX New antisense oligonucleotides targeted to nucleic acids encoding

PT inhibitor-kappa B-R, useful for diagnosing or creating diseases

PT associated with expression of inhibitor-kappa B-R, e.g., a heightened

PT immune response or infection.

XX Claim 3; Page 74; 108pp; English.

XX The invention relates to antisense compounds targeted to a nucleic acid

CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKK α , I-kappa-B-related, Ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKB1L2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
CC
XX

SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 7.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 16;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1328 CCTCTCTCCAGGACAGAG 1347

DB 20 CCTCTCTCCAGGACAGAG 1

RESULT 5

AL61562/C

ID AL61562 standard; DNA; 20 BP.

XX AL61562;

DT 22-SEP-2003 (first entry)

DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130487.

XX Human; inhibitor-kappa B-R; I-kappaB; IKK α ; I-kappa-B-related; NFKB1L2;

KM Ikappab r; antisense; immune response; infection; inflammation; therapy;

KW tumour; prophylaxis; phosphorothioate; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base

FT 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone; All cytidine residues

FT are 5-methylcytidines"

FT 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT 16..20

FT /*tag= C

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003042360-A2.

PD 22-MAY-2003.

XX 05-NOV-2002; 2002WO-US035597.

XX 13-NOV-2001; 2001US-00993731.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Walt AT;

XX WPI; 2003-468635/44.

XX New antisense oligonucleotides targeted to nucleic acids encoding

PT inhibitor-kappa B-R, useful for diagnosing or creating diseases

PT	associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT	immune response or infection.
XX	
PS	Claim 3, Page 74, 108pp, English.
XX	
CC	The invention relates to antisense compounds targetted to a nucleic acid
CC	molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC	IKB β , I-kappa-B-related, I-kappa β , nuclear factor of kappa light
CC	polypeptides gene enhancer in B-cells inhibitor-like 2 and NF κ BIL2) to
CC	inhibit its expression. Antisense compounds of the invention are useful
CC	for treating diseases or conditions associated with the expression of
CC	inhibitor-kappa B-R such as a heightened immune response involving
CC	increased cytokine expression, or a result of infection (e.g. bacterial,
CC	viral or parasitic). They are useful for diagnostics, therapeutics,
CC	prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC	formation, as research reagents and kits and in distinguishing between
CC	functions of various members of a biological pathway. They are also
CC	useful in antisense therapy. The present sequence is an oligonucleotide
CC	targetted to human inhibitor-kappa B-R DNA
XX	
SQ	Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
	Query Match 7.9%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 16;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
OY	1310 CTGTGAGCAGCTAGGGAGAC 1329
DB	20 CTGTGAGCAGCTAGGGAGAC 1
RESULT 6	
AA161555/c	
ID	AA161555 standard; DNA; 20 BP.
XX	
AC	AA161555;
XX	
DT	22-SEP-2003 (first entry)
XX	
DE	Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130480.
XX	
KW	Human; inhibitor-kappa B-R; I-kappaB β ; I-kappa-B-related; NF κ BIL2;
KW	I-kappa β ; antisense; immune response; infection; inflammation; therapy;
KW	tumour; prophylaxis; phosphorothioate; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
XX	
FH	Key
FH	Location/Qualifiers
FT	modified_base
FT	1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone; All cytidine residues
FT	are 5-methylcytidines"
FT	1..5
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX	
PN	WO2003042360-A2.
XX	
PD	22-MAY-2003.
XX	
PF	05-NOV-2002; 2002WO-US035597.
XX	
PR	13-NOV-2001; 2001US-00993731.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	

PI	Monia BP, Walt AT;
XX	
DR	WPI; 2003-468635/44.
XX	
PT	New antisense oligonucleotides targeted to nucleic acids encoding
PT	inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT	associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT	immune response or infection.
XX	
PS	Claim 3; Page 74; 108pp; English.
XX	
CC	The invention relates to antisense compounds targetted to a nucleic acid
CC	molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC	IKB β , I-kappa-B-related, Ikappab τ , nuclear factor of kappa light
CC	polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC	inhibit its expression. Antisense compounds of the invention are useful
CC	for treating diseases or conditions associated with the expression of
CC	inhibitor-kappa B-R such as a heightened immune response involving
CC	increased cytokine expression, or a result of infection (e.g. bacterial,
CC	viral or parasitic). They are useful for diagnostics, therapeutics,
CC	prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC	formation, as research reagents and kits and in distinguishing between
CC	functions of various members of a biological pathway. They are also
CC	useful in antisense therapy. The present sequence is an oligonucleotide
CC	targetted to human inhibitor-kappa B-R DNA
XX	
SO	Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match	7.9%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 16;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1223 GAACCTCCAGCATGTGCTGG 1242
DB	20 GAACCTCCAGCATGTGCTGG 1
RESULT 7	
AA161566/c	
ID	AA161566 standard; DNA; 20 BP.
XX	
AC	AA161566;
XX	
DT	22-SEP-2003 (first entry)
XX	
DE	Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130491.
XX	
XX	Human, inhibitor-kappa B-R, I-kappaB; IKB β , I-kappa-B-related; NFkBIL2;
KW	Ikappab τ ; antisense; immune response; infection; inflammation; therapy;
KW	tumour; prophylaxis; phosphorothioate; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key
FT	Location/Qualifiers
FT	1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone; All cytidine residues
FT	are 5-methylcytidines"
FT	1..15
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX	
PN	WO2003042360-A2.
XX	
XX	22-MAY-2003.
XX	

```
PF 05-NOV-2002; 2002MO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Walt AT;
XX
XX WPI; 2003-468635/44.
XX
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX
XX Example 15; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKBR, I-kappa-B-related, Ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
XX
XX
XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1347 GACTTCCAGGCGAGCTGA 1366
DB 20 GACTTCCAGGCGAGCTGA 1
RESULT 8
ID AAL61567/c
XX AAL61567 standard; DNA; 20 BP.
XX
XX AAL61567;
XX
XX 22-SEP-2003 (first entry)
XX
XX Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130492.
DE
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKBR; I-kappa-B-related; NFkBIL2;
KW Ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5 /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20 /*tag= c
FT /mod_base= OTHER
```

```
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002MO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Walt AT;
XX
XX WPI; 2003-468635/44.
XX
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX
XX Example 15; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKBR, I-kappa-B-related, Ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
XX
XX
XX Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1373 CCAGAGCAGCTGCGCTTTG 1392
DB 20 CCAGAGCAGCTGCGCTTTG 1
RESULT 9
ID AAL61552/c
XX AAL61552 standard; DNA; 20 BP.
XX
XX AAL61552;
XX
XX 22-SEP-2003 (first entry)
XX
XX Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130477.
DE
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKBR; I-kappa-B-related; NFkBIL2;
KW Ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
```

```
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT      16..20
FT      modified_base
FT      /tag= c
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX      WO2003042360-A2.
XX
XX      22-MAY-2003.
XX
XX      05-NOV-2002; 2002WO-US035597.
XX
XX      13-NOV-2001; 2001US-00993731.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Montia BP, Watt AT;
XX
XX      WPI; 2003-468635/44.
XX
XX      New antisense oligonucleotides targeted to nucleic acids encoding
XX      inhibitor-kappa B-R, useful for diagnosing or treating diseases
XX      associated with expression of inhibitor-kappa B-R, e.g., a heightened
XX      immune response or infection.
XX
XX      Claim 3, Page 74; 108pp; English.
XX
XX      The invention relates to antisense compounds targeted to a nucleic acid
XX      molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
XX      IKBP, I-kappa-B-related, ikappab r, nuclear factor of kappa light
XX      polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
XX      inhibit its expression. Antisense compounds of the invention are useful
XX      for treating diseases or conditions associated with the expression of
XX      inhibitor-kappa B-R such as a heightened immune response involving
XX      increased cytokine expression, or a result of infection (e.g. bacterial,
XX      viral or parasitic). They are useful for diagnostics, therapeutics,
XX      prophylaxis e.g. to prevent or delay infection, inflammation or tumour
XX      formation, as research reagents and kits and in distinguishing between
XX      functions of various members of a biological pathway. They are also
XX      useful in antisense therapy. The present sequence is an oligonucleotide
XX      targeted to human inhibitor-kappa B-R DNA
XX
XX      Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match          7.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 16;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1182 CTGGGCTCCGAGAGCTGT 1201
XX      |||||
XX      DB      20 CTGGGCTCCGAGAGCTGT 1
XX
XX      RESULT 10
XX      AAL61553/c
XX      ID      AAL61553 standard; DNA; 20 BP.
XX
XX      AAL61553;
XX
XX      22-SEP-2003 (first entry)
XX
XX      Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130478.
XX
XX      Human; inhibitor-kappa B-R; I-kappaB; IKBP; I-kappa-B-related; NFkBIL2;
XX      ikappab r; antisense; immune response; infection; inflammation; therapy;
XX      tumour; prophylaxis; phosphorothioate; ss.
XX
XX      Homo sapiens.
XX      OS
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
```

```
FT      modified_base 1..20
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "Phosphorothioate backbone; All cytidine residues
FT      are 5-methylcytidines"
FT      1..5
FT      modified_base
FT      /tag= b
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT      16..20
FT      modified_base
FT      /tag= c
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX      WO2003042360-A2.
XX
XX      22-MAY-2003.
XX
XX      05-NOV-2002; 2002WO-US035597.
XX
XX      13-NOV-2001; 2001US-00993731.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Montia BP, Watt AT;
XX
XX      WPI; 2003-468635/44.
XX
XX      New antisense oligonucleotides targeted to nucleic acids encoding
XX      inhibitor-kappa B-R, useful for diagnosing or treating diseases
XX      associated with expression of inhibitor-kappa B-R, e.g., a heightened
XX      immune response or infection.
XX
XX      Claim 3, Page 74; 108pp; English.
XX
XX      The invention relates to antisense compounds targeted to a nucleic acid
XX      molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
XX      IKBP, I-kappa-B-related, ikappab r, nuclear factor of kappa light
XX      polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
XX      inhibit its expression. Antisense compounds of the invention are useful
XX      for treating diseases or conditions associated with the expression of
XX      inhibitor-kappa B-R such as a heightened immune response involving
XX      increased cytokine expression, or a result of infection (e.g. bacterial,
XX      viral or parasitic). They are useful for diagnostics, therapeutics,
XX      prophylaxis e.g. to prevent or delay infection, inflammation or tumour
XX      formation, as research reagents and kits and in distinguishing between
XX      functions of various members of a biological pathway. They are also
XX      useful in antisense therapy. The present sequence is an oligonucleotide
XX      targeted to human inhibitor-kappa B-R DNA
XX
XX      Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX      Query Match          7.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 16;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1194 AAGCTGTGACAGGCGCAGC 1213
XX      |||||
XX      DB      20 AAGCTGTGACAGGCGCAGC 1
XX
XX      RESULT 11
XX      AAL61556/c
XX      ID      AAL61556 standard; DNA; 20 BP.
XX
XX      AAL61556;
XX
XX      22-SEP-2003 (first entry)
XX
XX      Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130481.
XX
XX      Human; inhibitor-kappa B-R; I-kappaB; IKBP; I-kappa-B-related; NFkBIL2;
XX      ikappab r; antisense; immune response; infection; inflammation; therapy;
XX
```

KW tumour; prophylaxis; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Walt AT;
XX
XX WPI; 2003-468635/44.
XX
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX
XX Claim 3; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
CC
SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1234 ATGTCTGCGAGTGTGCGG 1253
DB 20 ATGTCTGCGAGTGTGCGG 1

DT 22-SEP-2003 (first entry)
XX
XX Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130484.
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKBR; I-kappa-B-related; NFkBIL2;
KW ikappab r; antisense; immune response; infection; inflammation; therapy;
XX tumour; prophylaxis; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Walt AT;
XX
XX WPI; 2003-468635/44.
XX
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX
XX Claim 3; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
CC
SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1289 CCTCAGGTCGATGTCA 1308
DB 20 CCTCAGGTCGATGTCA 1

```
RESULT 13
AAL61560/c
ID AAL61560 standard; DNA; 20 BP.
XX
AC AAL61560;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130485.
XX
KW Human; inhibitor-kappa B-R; I-kappaB; IKK; I-kappa-B-related; NFkBIL2;
KW Ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT 1..20 /*tag= a
FT /*mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /*mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /*mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Matt AT;
XX
XX WPI; 2003-468635/44.
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
XX inhibitor-kappa B-R, useful for diagnosing or treating diseases
XX associated with expression of inhibitor-kappa B-R, e.g., a heightened
XX immune response or infection.
XX
XX Claim 3; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
XX IKK, I-kappa-B-related, ikappab r, nuclear factor of kappa light
XX polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
XX inhibit its expression. Antisense compounds of the invention are useful
XX for treating diseases or conditions associated with the expression of
XX inhibitor-kappa B-R such as a heightened immune response involving
XX increased cytokine expression, or a result of infection (e.g. bacterial,
XX viral or parasitic). They are useful for diagnostics, therapeutics,
XX prophylaxis e.g. to prevent or delay infection, inflammation or tumour
XX formation, as research reagents and kits and in distinguishing between
XX functions of various members of a biological pathway. They are also
XX useful in antisense therapy. The present sequence is an oligonucleotide
XX targeted to human inhibitor-kappa B-R DNA
XX
XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

1297 GTGCCATGTCATCTGTGAG 1316
OY |||||||
20 GTGCCATGTCATCTGTGAG 1

RESULT 14
AAL61557/c
ID AAL61557 standard; DNA; 20 BP.
XX
AC AAL61557;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130482.
XX
KW Human; inhibitor-kappa B-R; I-kappaB; IKK; I-kappa-B-related; NFkBIL2;
KW Ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT 1..20 /*tag= a
FT /*mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /*mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /*mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003042360-A2.
XX
XX 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Matt AT;
XX
XX WPI; 2003-468635/44.
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
XX inhibitor-kappa B-R, useful for diagnosing or treating diseases
XX associated with expression of inhibitor-kappa B-R, e.g., a heightened
XX immune response or infection.
XX
XX Claim 3; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
XX IKK, I-kappa-B-related, ikappab r, nuclear factor of kappa light
XX polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
XX inhibit its expression. Antisense compounds of the invention are useful
XX for treating diseases or conditions associated with the expression of
XX inhibitor-kappa B-R such as a heightened immune response involving
XX increased cytokine expression, or a result of infection (e.g. bacterial,
XX viral or parasitic). They are useful for diagnostics, therapeutics,
XX prophylaxis e.g. to prevent or delay infection, inflammation or tumour
XX formation, as research reagents and kits and in distinguishing between
XX functions of various members of a biological pathway. They are also
XX useful in antisense therapy. The present sequence is an oligonucleotide
XX targeted to human inhibitor-kappa B-R DNA
XX
```

```
XX Sequence 20 BP; 4 A; 9 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1238 GCTGACAGTGGTCCGGCTGC 1257
Db 20 GCTGACAGTGGTCCGGCTGC 1

RESULT 15
AAL61568/c
ID AAL61568 standard; DNA; 20 BP.
AC AAL61568;
DT 22-SEP-2003 (first entry)
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130493.
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKK $\beta$ ; I-kappa-B-related; NFKB1L2;
KM ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
PD 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Watt AT;
XX
XX MPI, 2003-468635/44.
DR
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Claim 3; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
CC IKK $\beta$ , I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKB1L2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
```

```
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
Oy 1392 GCTGAGCTGCTGCAGACACC 1411
Db 20 GCTGAGCTGCTGCAGACACC 1

RESULT 16
AAL61558/c
ID AAL61558 standard; DNA; 20 BP.
AC AAL61558;
DT 22-SEP-2003 (first entry)
DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130483.
XX
XX Human; inhibitor-kappa B-R; I-kappaB; IKK $\beta$ ; I-kappa-B-related; NFKB1L2;
KM ikappab r; antisense; immune response; infection; inflammation; therapy;
KW tumour; prophylaxis; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003042360-A2.
PD 22-MAY-2003.
XX
XX 05-NOV-2002; 2002WO-US035597.
XX
XX 13-NOV-2001; 2001US-00993731.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Watt AT;
XX
XX MPI, 2003-468635/44.
DR
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Example 15; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,
```

CC	IKR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC	polypeptide gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC	inhibit its expression. Antisense compounds of the invention are useful
CC	for treating diseases or conditions associated with the expression of
CC	inhibitor-kappa B-R such as a heightened immune response involving
CC	increased cytokine expression, or a result of infection (e.g. bacterial,
CC	viral or parasitic). They are useful for diagnostic, therapeutics,
CC	prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC	formation, as research reagents and kits and in distinguishing between
CC	functions of various members of a biological pathway. They are also
CC	useful in antisense therapy. The present sequence is an oligonucleotide
CC	targeted to human inhibitor-kappa B-R DNA
CC	
SO	Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
SO	
Query Match	7.9%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 16;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps
Oy	1258 AGCAACAGCTGGAAAGAGCT 1277
Db	20 AGCAACAGCTGGAAAGAGCT 1
RESULT 17	
ID	AL61565/c
XX	AL61565 standard; DNA; 20 BP.
AC	AL61565;
DT	22-SEP-2003 (first entry)
XX	
DE	Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130490.
XX	
KW	Human; inhibitor-kappa B-R; I-kappabR; IKR; I-kappa-B-related; NFkBIL2;
KW	ikappab r; antisense; immune response; infection; inflammation; therapy;;
KW	tkunour; r; phosphorothioate; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
EH	Key
EH	Location/Qualifiers
FT	1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone; All cytidine residues
FT	are 5-methylcytidines"
FT	1..5
FT	modified_base
FT	1..5
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	16..20
FT	modified_base
FT	16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX	
PN	WO2003042360-A2.
XX	
PD	22-MAY-2003.
XX	
PF	05-NOV-2002; 2002WO-US035597.
XX	
PR	13-NOV-2001; 2001US-00993731.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Monia BP, Watt AT;
XX	
DR	WPI, 2003-468635/44.
XX	
PT	New antisense oligonucleotides targeted to nucleic acids encoding
PT	inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT	associated with expression of inhibitor-kappa B-R, e.g., a heightened

PT		immune response or infection.
XX		
PS	Claim 3; Page 74; 108bp; English.	
CC		
XX	The invention relates to antisense compounds targetted to a nucleic acid	
CC	molecule encoding human inhibitor-kappa B-R (also known as I-kappaB,	
CC	IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light	
CC	polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to	
CC	inhibit its expression. Antisense compounds of the invention are useful	
CC	for treating diseases or conditions associated with the expression of	
CC	inhibitor-kappa B-R such as a heightened immune response involving	
CC	increased cytokine expression, or a result of infection (e.g. bacterial,	
CC	viral or parasitic). They are useful for diagnostics, therapeutics,	
CC	prophylaxis e.g. to prevent or delay infection, inflammation or tumour	
CC	formation, as research reagents and kits and in distinguishing between	
CC	functions of various members of a biological pathway. They are also	
CC	useful in antisense therapy. The present sequence is an oligonucleotide	
CC	targeted to human inhibitor-kappa B-R DNA	
XX		
SQ	Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;	
	Query Match	7.9%; Score 20; DB 1; Length 20;
	Best Local Similarity	100.0%; Pred. No. 16;
	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1342 CAGGAGACTTTCCCGAGGCCA 1361	
DB	20 CAGGAGACTTTCCCGAGGCCA 1	
RESULT 18		
AAL61569/C		
ID	AAL61569 standard; DNA; 20 BP.	
XX		
AC	AAL61569;	
DT	22-SEP-2003 (first entry)	
XX		
DE	Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130494.	
XX		
KW	Human; inhibitor-kappa B-R; I-kappaB; IKBR; I-kappa-B-related; NFKBIL2;	
KM	ikappab r; antisense; immune response; infection; inflammation; therapy;	
XX	tumour; prophylaxis; phosphorothioate; ss.	
XX		
OS	Homo sapiens.	
OS	Synthetic.	
XX		
FH	Location/Qualifiers	
FT	1..20	
FT	/*tag= a	
FT	/mod_base= OTHER	
FT	/note= "Phosphorothioate backbone; All cytidine residues	
FT	are 5-methylcytidines"	
FT	1..5	
FT	modified_base	
FT	/*tag= b	
FT	/mod_base= OTHER	
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"	
FT	16..20	
FT	/*tag= c	
FT	/mod_base= OTHER	
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"	
PN	WO2003042360-A2.	
XX		
PD	22-MAY-2003.	
PP	05-NOV-2002; 2002WO-USO355597.	
XX		
PR	13-NOV-2001; 2001US-00993731.	
XX		
PA	(ISIS-) ISIS PHARM INC.	
XX		
PI	Monia BP, Walt AT;	

XX WPI; 2003-468635/44.
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Example 15; Page 74; 108pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB
CC IKAR, I-kappa-B-related, I-kappaB T, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFkBIL2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targeted to human inhibitor-kappa B-R DNA
XX
XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 7.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1414 GTGCTAGCGGGCCATCATC 1433
DB |||||
20 GTGCTAGCGGGCCATCATC 1
RESULT 19
ID AC136127
AC136127 standard; DNA; 25 BP.
XX
XX AC136127;
XX
DT 13-OCT-2003 (first entry)
XX
DE Human microarray DNA oligonucleotide SEQ ID NO 36118.
XX
KM EST, ss; probe; expressed sequence tag; microarray; gene expression;
KM genetic variation; diallelic marker; polymorphism; human;
KM cross-species comparison.
XX
OS Homo sapiens.
XX
XX US2003104410-A1.
XX
XX 05-JUN-2003.
XX
XX 15-MAR-2002; 2002US-00098263.
XX
XX 16-MAR-2001; 2001US-0276759P.
XX
XX (APFY-) AFFYMETRIX INC.
XX
XX Mitmann MP;
XX
XX WPI; 2003-567953/53.
XX
XX New array of nucleic acid probes, useful for in situ hybridization, in
PT Southern, Northern or dot-blot hybridization to identify or detect the
PT sequence or specific mutations of any gene.
XX
XX Claim 1; SEQ ID NO 36118; 9pp; English.
XX
XX The invention discloses a microarray comprising a plurality of nucleic

CC acid probes including one of 2,018,500 fully defined sequences, or its
CC perfect match, perfect mismatch, antisense match or antisense mismatch.
CC Also disclosed is a method of gene expression analysis. The array is used
CC in monitoring gene expression levels by hybridisation to a DNA library,
CC in analysis of genetic variation or in hybridisation of tag-labelled
CC compounds. The nucleic acid probes are specifically designed for analysis
CC of at least one target sequence. The method of analysis comprises
CC hybridising at least one or more nucleic acids to at least two or more
CC nucleic acid probes and detecting the hybridisation. The nucleic acid
CC probes are attached to a solid support. The analysis comprises monitoring
CC gene expression levels, identifying diallelic markers or polymorphisms,
CC or family members of a gene and a cross-species comparison. Each of the
CC nucleic acids further comprises a tag sequence. The array of nucleic acid
CC probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC blot hybridisation to identify or detect the sequence or specific
CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC primer extensions or in screening cDNA or genomic libraries or subclones
CC for additional subclones containing segments of DNA that have been
CC isolated and previously sequenced. The sequence presented is one of the
CC nucleic acid probes incorporated in the microarray. Note: The sequence
CC data for this patent can also be obtained in electronic format directly
CC from USPTO at seqdata.uspto.gov/sequence.html
XX
XX Sequence 25 BP; 5 A; 9 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 7.4%; Score 18.6; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 59;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 1393 CTGAGCTGCTGACAGACCGGCTGC 1417
DB |||||
1 CGGAGTCTCTAGACAGACCGGCTGC 25
RESULT 20
ID AAQ10661
AAQ10661 standard; DNA; 23 BP.
XX
XX AAQ10661;
XX
DT 25-MAR-2003 (revised)
DT 29-APR-1991 (first entry)
XX
DE HLA Class II locus-specific primer DQB E1.
XX
KM Human leukocyte antigen; major histocompatibility complex; MHC;
KM restriction fragment length polymorphic analysis; RFLP; tissue typing;
KM allele; PCR; ss.
XX
OS Synthetic.
XX
XX EP414469-A.
XX
XX 27-FEB-1991.
XX
XX 20-AUG-1990; 90EP-00309107.
XX
XX 25-AUG-1989; 89US-00398217.
XX 11-SEP-1989; 89US-00405499.
XX 16-JAN-1990; 90US-00465863.
XX 11-JUN-1990; 90US-00551239.
XX
XX (GENE-) GENETYPAGE AG.
XX (JEAN-) GENETYPAGE AG.
XX (SIMO/) SIMONS M J.
XX
XX Simons MJ;
XX
XX WPI; 1991-059664/09.
XX
XX Detection of adjacent and non-adjacent locus, e.g. HLA alleles - by
PT amplifying genomic DNA, for direct determination of haplotype.
XX

PT New isolated NOVX polypeptides and polynucleotides, useful for
PT preventing, diagnosing or treating NOVX-associated disorders, e.g.
PT osteoarthritis, obesity, atherosclerosis, cancer, Parkinson's disease,
PT asthma, or infections.

XX
XX Example C; Page 247; 311pp; English.

CC The present invention relates to novel NOV proteins and their coding
CC sequences (ADP49028-ADP49131). The proteins and coding sequences are
CC useful in the manufacture of a medicament for treating a syndrome
CC associated with a human disease, preferably a NOV-associated disorder
CC such as metabolic disorders, diabetes, obesity, infectious diseases
CC (viral, bacterial, fungal, helminthic, and protozoal), anorexia, cancer,
CC cardiovascular diseases (hypertension, atherosclerosis),
CC neurodegenerative disorders (Alzheimer's disease, Parkinson's disease,
CC inflammatory skin disorders, asthma and various dyslipidemias. The coding
CC sequences and proteins may also be used as targets for the identification
CC of small molecules that modulate or inhibit e.g. neurogenesis, cell
CC differentiation, cell proliferation, haematopoiesis, wound healing and
CC angiogenesis, in gene therapy, in generation of antibodies that bind
CC immunospecifically to NOV substances for use in therapeutic or diagnostic
CC methods. The present sequence is a probe which was used in an example
CC from the invention. This sequence is labelled at the 5' end with TET and
CC at the 3' end with TAMRA.

XX
XX Sequence 23 BP; 7 A; 10 C; 4 G; 2 T; 0 U; 0 Other;

SQ

Query Match 6.6%; Score 16.6; DB 1; Length 23;
Best Local Similarity 82.6%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1234 ATGTGCTGCGACGTGTCGCGCTG 1256
DB 23 ATGTGCTGCGACGTGTCGCGCTG 1

RESULT 23
AD13836
ID AD13836 standard; DNA; 20 BP.

XX
XX AD13836;

DT 22-APR-2004 (first entry)

XX
XX Human LIM domain kinase 1 antisense oligonucleotide #120.

DE
XX
XX neuroprotective; LIM domain kinase 1; developmental disorder;
KW neurological disorder; diagnostic; prophylaxis; human; ss.

OS
XX
XX Homo sapiens.

PH
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone. All cytidines
FT are 5-methylcytidines"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004014047-A1.
XX
XX 22-JAN-2004.
XX
XX 18-JUL-2002; 2002US-00199199.

PR 18-JUL-2002; 2002US-00199199.

XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowser LM, Dobie KW;
XX
XX WPI; 2004-121553/12.

DR
XX
XX New antisense oligonucleotides for modulating LIM domain kinase 1
PT expression, useful for diagnosing, preventing or treating conditions
PT associated with the kinase, e.g. neurological or developmental disorders.

XX
XX Example 15; SEQ ID NO 135; 81pp; English.

PS
XX
XX The invention describes a compound 8-80 nucleobases in length targeted to
CC a nucleic acid molecule encoding LIM domain kinase 1. The compound
CC specifically hybridises with the nucleic acid molecule encoding LIM
CC domain kinase 1 and inhibits the expression of LIM domain kinase 1. It
CC specifically hybridises with at least an 8-nucleobase portion of a
CC preferred target region on the nucleic acid molecule encoding LIM domain
CC kinase 1. The antisense oligonucleotide is useful for modulating the
CC expression of LIM domain kinase 1 in cells or tissues to treat diseases
CC associated with their expression, such as a developmental disorder or a
CC neurological disorder. In addition, the compound is used for diagnostics,
CC prophylaxis, or as research reagents or kits. This sequence represents a
CC human LIM domain kinase 1 antisense oligonucleotide.

XX
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

SQ

Query Match 6.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1251 CGGCTGCGACGACGCTG 1268
DB 2 CGGCTGCGACGACGCTG 19

RESULT 24
AD138771/c
ID AD138771 standard; DNA; 20 BP.

XX
XX AD138771;

DT 22-APR-2004 (first entry)

XX
XX Human LIM domain kinase 1 antisense oligonucleotide #55.

DE
XX
XX neuroprotective; LIM domain kinase 1; developmental disorder;
KW neurological disorder; diagnostic; prophylaxis; human; ss.

OS
XX
XX Homo sapiens.

PH
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone. All cytidines
FT are 5-methylcytidines"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004014047-A1.
XX
XX 22-JAN-2004.
XX
XX 18-JUL-2002; 2002US-00199199.

```
XX 18-JUL-2002; 2002US-00199199.
XX (ISIS-) ISIS PHARM INC.
XX Cowert LM, Dobie KW;
XX WPI, 2004-121553/12.
XX
XX New antisense oligonucleotides for modulating LIM domain kinase 1
XX expression, useful for diagnosing, preventing or creating conditions
XX associated with the kinase, e.g. neurological or developmental disorders.
XX
XX Example 15; SEQ ID NO 70; 81pp; English.
XX
XX The invention describes a compound 8-80 nucleobases in length targeted to
XX a nucleic acid molecule encoding LIM domain kinase 1. The compound
XX specifically hybridises with the nucleic acid molecule encoding LIM
XX domain kinase 1 and inhibits the expression of LIM domain kinase 1. It
XX specifically hybridises with at least an 8-nucleobase portion of a
XX preferred target region on the nucleic acid molecule encoding LIM domain
XX kinase 1. The antisense oligonucleotide is useful for modulating the
XX expression of LIM domain kinase 1 in cells or tissues to treat diseases
XX associated with their expression, such as a developmental disorder or a
XX neurological disorder. In addition, the compound is used for diagnostics,
XX prophylaxis, or as research reagents or kits. This sequence represents a
XX human LIM domain kinase 1 antisense oligonucleotide.
XX
XX Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 6.5%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 80;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1251 CGGCTGACGACACAGCTG 1268
XX |||||
XX 19 CGGCTGACGACAGCTG 2
XX
XX RESULT 25
XX ABS60230
XX ID ABS60230 standard; DNA; 21 BP.
XX
XX AC ABS60230;
XX
XX DT 05-NOV-2002 (first entry)
XX
XX DE Human polymorphism associated DNA sequence #124.
XX
XX KW Aminopeptidase P, XPNP2; bradykinin receptor B1; ds; BDKRB1;
XX tachykinin receptor B1; TACK1; CI esterase inhibitor; C1NH; kallikrein 1;
XX KLIK; bradykinin receptor B2; BDKRB2; gene therapy;
XX angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;
XX polymorphisms; haemangioma; tumour; sarcoma; Crohn's disease; trichoma;
XX cardiovascular disease; angina pectoris; hypertension; heart failure;
XX myocardial infarction; ventricular hypertrophy; vascular disease;
XX aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
XX arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
XX autoimmune disease; inflammatory arthritis; cancer; wound;
XX viral infection; bacterial infection; fungal infection; COPD;
XX Chronic obstructive pulmonary disease; enterocolitis.
XX
XX OS Homo sapiens.
XX
XX PN WO200261131-A2.
XX
XX PD 08-AUG-2002.
XX
XX PF 03-DEC-2001; 2001WO-US047235.
XX
XX PR 04-DEC-2000; 2000US-0251015P.
XX PR 23-JAN-2001; 2001US-0263678P.
XX PR 02-MAR-2001; 2001US-0273037P.
```

```
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX (TSUC/) TSUCHIHASHI Z.
XX (HUI/) HUI L.
XX
XX Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
XX Swanson BN, Powell JR;
XX WPI, 2002-619265/66.
XX
XX New isolated nucleic acid with at least one polymorphic position, useful
XX for detecting, diagnosing and treating disorders such as angioedema,
XX cancer, viral, bacterial or fungal infection, cardiovascular and
XX autoimmune diseases.
XX
XX Disclosure; Page 718; 977pp; English.
XX
XX The invention relates to an isolated nucleic acid from a human gene
XX encoding aminopeptidase P (XPNP2), bradykinin receptor B1 (BDKRB1),
XX tachykinin receptor B1 (TACK1), CI esterase inhibitor (C1NH), kallikrein
XX 1 (KLIK), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
XX 2 (ACE2) or protease inhibitor 4 (P14), comprising at least one
XX polymorphic position. Also included are (1) a probe that hybridises to a
XX polymorphic position as provided in the detailed summary of single
XX nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
XX sequence; (2) analysing (M1) at least one nucleic acid sample comprising
XX obtaining the sample from one or more individuals and determining the
XX nucleic acid sequence at one or more polymorphic positions in a gene
XX encoding a protein selected from the group above; (3) constructing (M2)
XX haplotypes using the genes comprising grouping at least two nucleic acids
XX (4) identifying (M3) an individual at risk of developing a disorder
XX upon administration of an ACE inhibitor and/or vasopressinase inhibitor
XX using the polymorphic data; (5) a library of nucleic acids, each of which
XX comprises one or more polymorphic positions within a gene encoding a
XX human protein selected from the group above; and (6) genotyping (M4) an
XX individual comprising obtaining a nucleic acid sample, determining the
XX nucleotide present in at least one polymorphic position, and comparing at
XX least one position with a known data set. The genes, (M1, M2, M3 and M4)
XX and compositions are useful for detecting, diagnosing, treating,
XX preventing various disorders such as angioedema and diseases which
XX involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
XX disease, trichomas, and cardiovascular diseases like angina pectoris,
XX hypertension, heart failure, myocardial infarction, ventricular
XX hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
XX artery disease, arteriosclerosis and/or atherosclerosis, and
XX hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
XX arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
XX obstructive pulmonary disease (COPD) and enterocolitis (many other
XX diseases and disorders are listed in the specification). The
XX polymorphisms are also useful for chromosome identification. Antibodies
XX against the proteins may be utilised for immunophenotyping of cell lines
XX and biological samples. The present sequence is included in the sequence
XX listing but is not referred to anywhere else in the specification
XX
XX Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 6.4%; Score 16.2; DB 1; Length 21;
XX Best Local Similarity 85.7%; Pred. No. 1e+02;
XX Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1186 GCTCCAGAGCGCTGTCAG 1206
XX |||||
XX 1 GCTCTCAGAGCCAGTTCAG 21
XX
XX RESULT 26
XX ABS60229
XX ID ABS60229 standard; DNA; 21 BP.
XX
XX AC ABS60229;
XX
XX DT 05-NOV-2002 (first entry)
XX
```

DE Human polymorphism associated DNA sequence #122.

XX Aminopeptidase P; XPNP2; bradykinin receptor B1; ds; BDKRB1;

KW tachykinin receptor B1; TACB1; C1 esterase inhibitor; C1NH; kallikrein 1;

XX KLU1; bradykinin receptor B2; BDKRB2; gene therapy;

KW angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;

KW polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;

KW cardiovascular disease; angina pectoris; hypertension; heart failure;

KW myocardial infarction; ventricular hypertrophy; vascular disease;

KW aneurysm; embolism; thrombosis; coronary artery disease; angioedema;

KW arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;

KW autoimmune disease; inflammatory arthritis; cancer; wound;

KW viral infection; bacterial infection; fungal infection; COPD;

KM Chronic obstructive pulmonary disease; enterocolitis.

XX

OS Homo sapiens.

XX

XX WO200261131-A2.

XX

XX 08-AUG-2002.

XX

XX 03-DEC-2001; 2001WO-US047235.

XX

XX 04-DEC-2000; 2000US-0251015P.

XX 23-JAN-2001; 2001US-0263678P.

XX 02-MAR-2001; 2001US-0273037P.

XX

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

PA (TSUC.) TSUCHIHASHI Z.

PA (HUI/L.) HUI L.

XX

XX Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone ME;

P1 Swanson BN, Powell JR;

XX WPI; 2002-619265/66.

DR

XX

XX New isolated nucleic acid with at least one polymorphic position, useful

PT for detecting, diagnosing and treating disorders such as angioedema,

PT cancer, viral, bacterial or fungal infection, cardiovascular and

PT autoimmune diseases.

XX

XX Disclosure; Page 718; 977pp; English.

XX

XX The invention relates to an isolated nucleic acid from a human gene

CC encoding aminopeptidase P (XPNP2), bradykinin receptor B1 (BDKRB1),

CC tachykinin receptor B1 (TACB1), C1 esterase inhibitor (C1NH), kallikrein

CC 1 (KLU1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme

CC 2 (ACE2) or protease inhibitor 4 (P14), comprising at least one

CC polymorphic position. Also included are (1) a probe that hybridises to a

CC polymorphic position as provided in the detailed summary of single

CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic

CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising

CC obtaining the sample from one or more individuals and determining the

CC nucleic acid sequence at one or more polymorphic positions in a gene

CC encoding a protein selected from the group above; (3) constructing (M2)

CC haplotypes using the genes comprising grouping at least two nucleic acids

CC (4) identifying (M3) an individual at risk of developing a disorder

CC upon administration of an ACE inhibitor and/or vasopressinase inhibitor

CC using the polymorphic data; (5) a library of nucleic acids, each of which

CC comprises one or more polymorphic positions within a gene encoding a

CC human protein selected from the group above; and (6) genotyping (M4) an

CC individual comprising obtaining a nucleic acid sample, determining the

CC nucleotide present in at least one polymorphic position, and comparing at

CC least one position with a known data set. The genes, (M1, M2, M3 and M4)

CC and compositions are useful for detecting, diagnosing, treating,

CC preventing various disorders such as angioedema and diseases which

CC involve angioedemas like haemangiomas, tumours, sarcomas, Crohn's

CC disease, trachomas, and cardiovascular diseases like angina pectoris,

CC hypertension, heart failure, myocardial infarction, ventricular

CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary

CC artery disease, arteriosclerosis and/or atherosclerosis, and

CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory

CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic

CC

CC	obstructive pulmonary disease (COPD) and enterocolitis (many other
CC	diseases and disorders are listed in the specification). The
CC	polynucleotides are also useful for chromosome identification. Antibodies
CC	against the proteins may be utilised for immunophenotyping of cell lines
CC	and biological samples. The present sequence is included in the sequence
CC	listing but is not referred to anywhere else in the specification
XX	
SO	Sequence 21 BP, 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
	Query Match 6.4%; Score 16.2; DB 1; Length 21;
	Best Local Similarity 85.7%; Pred. No. 1e+02;
	Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0
OY	1186 GCTCCGAGAGCCTGTGCAGA 1206
	1 GCTCTCAGAGCCAGTTCAGA 21
Db	
RESULT 27	
AB560227	
ID	AB560227 standard; DNA; 21 BP.
XX	
AC	AB560227;
XX	
DT	05-NOV-2002 (first entry)
XX	
DE	Human polymorphism associated DNA sequence #121.
XX	
KW	Aminopeptidase P; XPNBP2; bradykinin receptor B1; ds; BDKRB1;
KW	teachykinin receptor B1; TACR1; Cl esterase inhibitor; C1NH; kallikrein 1;
KW	KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
KW	angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;
KW	polymorphisms; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
KW	cardiovascular disease; angina pectoris; hypertension; heart failure;
KW	myocardial infarction; ventricular hypertrophy; vascular disease;
KW	aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
KW	arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
KW	autoimmune disease; inflammatory arthritis; cancer; wound;
KW	viral infection; bacterial infection; fungal infection; COPD;
KW	Chronic obstructive pulmonary disease; enterocolitis.
XX	
OS	Homo sapiens.
XX	
PN	WO200261131-A2.
PD	08-AUG-2002.
XX	
PF	03-DEC-2001; 2001WO-US047235.
XX	
PR	04-DEC-2000; 2000US-0251015P.
PR	23-JAN-2001; 2001US-0263678P.
PR	02-MAR-2001; 2001US-0273037P.
XX	
PA	(BRIM) BRISTOL-MYERS SQUIBB CO.
PA	(TSUC/) TSUCHIHASHI Z.
PA	(HUI/) HUI L.
XX	
PI	Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
PI	Swanson BN, Powell JR;
DR	WPI; 2002-619265/66.
XX	
PT	New isolated nucleic acid with at least one polymorphic position, useful
PT	for detecting, diagnosing and treating disorders such as angioedema,
PT	cancer, viral, bacterial or fungal infection, cardiovascular and
PT	autoimmune diseases.
XX	
PS	Disclosure; Page 718; 977pp; English.
XX	
CC	The invention relates to an isolated nucleic acid from a human gene
CC	encoding aminopeptidase P (XPNBP2), bradykinin receptor B1 (BDKRB1),
CC	teachykinin receptor B1 (TACR1), Cl esterase inhibitor (C1NH), kallikrein
CC	1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme

CC 2 (ACE2) or protease inhibitor 4 (PI4), comprising at least one
CC polymorphic position. Also included are (1) a probe that hybridises to a
CC polymorphic position as provided in the detailed summary of single
CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising
CC obtaining the sample from one or more individuals and determining the
CC nucleic acid sequence at one or more polymorphic positions in a gene
CC encoding a protein selected from the group above; (3) constructing (M2)
CC haplotypes using the genes comprising grouping at least two nucleic acids
CC; (4) identifying (M3) an individual at risk of developing a disorder
CC upon administration of an ACE inhibitor and/or vasopeptidase inhibitor
CC using the polymorphic data; (5) a library of nucleic acids, each of which
CC comprises one or more polymorphic positions within a gene encoding a
CC human protein selected from the group above; and (6) genotyping (M4) an
CC individual comprising obtaining a nucleic acid sample, determining the
CC nucleotide present in at least one polymorphic position, and comparing at
CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
CC and compositions are useful for detecting, diagnosing, treating,
CC preventing various disorders such as angioedema and diseases which
CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
CC disease, trachomas, and cardiovascular diseases like angina pectoris,
CC hypertension, heart failure, myocardial infarction, ventricular
CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
CC artery disease, arteriosclerosis and/or atherosclerosis, and
CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
CC obstructive pulmonary disease (COPD) and enterocolitis (many other
CC diseases and disorders are listed in the specification). The
CC polymorphisms are also useful for chromosome identification. Antibodies
CC against the proteins may be utilised for immunophenotyping of cell lines
CC and biological samples. The present sequence is included in the sequence
CC listing but is not referred to anywhere else in the specification
XX

Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 6.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1186 GCTCCAGAGCCTGTGCAGA 1206
DB 1 GCTCTCAGAGCCAGTTCAGA 21

RESULT 28
ABS60228
ID ABS60228 standard; DNA; 21 BP.

XX AC ABS60228;

XX DT 05-NOV-2002 (first entry)

XX XX Human polymorphism associated DNA sequence #122.

KM Amino peptidase P; XPNBP2; bradykinin receptor B1; ds; BDKRB1;
KM tachykinin receptor B1; TACR1; C1 esterase inhibitor; C1NH; kallikrein 1;
KM KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
KM angiotensin converting enzyme 2; ACE2; protease inhibitor 4; PI4;
KM polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
KM cardiovascular disease; angina pectoris; hypertension; heart failure;
KM myocardial infarction; ventricular hypertrophy; vascular disease;
KM aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
KM arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
KM autoimmune disease; inflammatory arthritis; cancer; wound;
KM viral infection; bacterial infection; fungal infection; COPD;
KM Chronic obstructive pulmonary disease; enterocolitis.

XX OS Homo sapiens.

XX PN WO200261131-A2.

XX PD 08-AUG-2002.

XX XX

PF 03-DEC-2001; 2001WO-US047235.
XX 04-DEC-2000; 2000US-0251015P.
PR 23-JAN-2001; 2001US-0263678P.
PR 02-MAR-2001; 2001US-0273037P.
XX
PA (BRIM) BRISTOL-MYERS SQUIBB CO.
PA (TSUC)/ TSUCHIHASHI Z.
PA (HUI/L) HUI L.
XX
PI Tsuchiashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
PI Swanson BN, Powell JR;
XX WPI; 2002-619265/66.
XX
PT New isolated nucleic acid with at least one polymorphic position, useful
PT for detecting, diagnosing and treating disorders such as angioedema,
PT cancer, viral, bacterial or fungal infection, cardiovascular and
PT autoimmune diseases.
XX
PS Disclosure; Page 718; 977pp; English.

XX The invention relates to an isolated nucleic acid from a human gene
CC encoding aminopeptidase P (XPNBP2), bradykinin receptor B1 (BDKRB1),
CC tachykinin receptor B1 (TACR1), C1 esterase inhibitor (C1NH), kallikrein
CC 1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
CC 2 (ACE2) or protease inhibitor 4 (PI4), comprising at least one
CC polymorphic position. Also included are (1) a probe that hybridises to a
CC polymorphic position as provided in the detailed summary of single
CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising
CC obtaining the sample from one or more individuals and determining the
CC nucleic acid sequence at one or more polymorphic positions in a gene
CC encoding a protein selected from the group above; (3) constructing (M2)
CC haplotypes using the genes comprising grouping at least two nucleic acids
CC; (4) identifying (M3) an individual at risk of developing a disorder
CC upon administration of an ACE inhibitor and/or vasopeptidase inhibitor
CC using the polymorphic data; (5) a library of nucleic acids, each of which
CC comprises one or more polymorphic positions within a gene encoding a
CC human protein selected from the group above; and (6) genotyping (M4) an
CC individual comprising obtaining a nucleic acid sample, determining the
CC nucleotide present in at least one polymorphic position, and comparing at
CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
CC and compositions are useful for detecting, diagnosing, treating,
CC preventing various disorders such as angioedema and diseases which
CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
CC disease, trachomas, and cardiovascular diseases like angina pectoris,
CC hypertension, heart failure, myocardial infarction, ventricular
CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
CC artery disease, arteriosclerosis and/or atherosclerosis, and
CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
CC obstructive pulmonary disease (COPD) and enterocolitis (many other
CC diseases and disorders are listed in the specification). The
CC polymorphisms are also useful for chromosome identification. Antibodies
CC against the proteins may be utilised for immunophenotyping of cell lines
CC and biological samples. The present sequence is included in the sequence
CC listing but is not referred to anywhere else in the specification
XX

Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 6.4%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1186 GCTCCAGAGCCTGTGCAGA 1206
DB 1 GCTCTCAGAGCCAGTTCAGA 21

RESULT 29
ADC26392/C
ID ADC26392 standard; DNA; 22 BP.

XX AC ADC26392;
XX DT 18-DEC-2003 (first entry)
XX DE NOV protein-related forward PCR primer SEQ ID 217.
XX NO
XX NOV; cytostatic; metabolic disorder; immune; neurodegenerative;
XX circulatory; haemopoietic; wasting; cancer; gene therapy; vaccine;
XX transgenic; human; ss; PCR; primer.
XX Homo sapiens.
XX WO2003004687-A2.
XX PN 16-JAN-2003.
XX PD 03-JUL-2002; 2002WO-US021361.
XX PF 05-JUL-2001; 2001US-0303046P.
XX PR 09-JUL-2001; 2001US-0303828P.
XX PR 09-JUL-2001; 2001US-0304016P.
XX PR 11-JUL-2001; 2001US-0304502P.
XX PR 13-JUL-2001; 2001US-0305262P.
XX PR 16-JUL-2001; 2001US-0305673P.
XX PR 17-JUL-2001; 2001US-0306085P.
XX PR 24-JUL-2001; 2001US-0307536P.
XX PR 27-JUL-2001; 2001US-0308228P.
XX PR 30-JUL-2001; 2001US-0308877P.
XX PR 01-AUG-2001; 2001US-0309255P.
XX PR 17-AUG-2001; 2001US-0313328P.
XX PR 12-SEP-2001; 2001US-0318711P.
XX PR 19-SEP-2001; 2001US-0323380P.
XX PR 21-SEP-2001; 2001US-0323969P.
XX PR 04-JAN-2002; 2002US-0345022P.
XX PR 04-JAN-2002; 2002US-0345038P.
XX PR 28-FEB-2002; 2002US-0361172P.
XX PR 01-MAR-2002; 2002US-0360814P.
XX PR 01-MAR-2002; 2002US-0360830P.
XX PR 01-MAR-2002; 2002US-0361133P.
XX PR 01-MAR-2002; 2002US-0361147P.
XX PR 05-MAR-2002; 2002US-0361677P.
XX PR 02-APR-2002; 2002US-0363637P.
XX PR 12-APR-2002; 2002US-0372326P.
XX PR 16-APR-2002; 2002US-0372990P.
XX PR 19-APR-2002; 2002US-0373881P.
XX PR 19-APR-2002; 2002US-0373921P.
XX PR 02-JUL-2002; 2002US-00188186.
XX PA (CURA-) CURAGEN CORP.
XX PI Anderson DM, Bergs C, Boldog FL, Burgess CE, Casman SJ;
XX PI Catereron E, Edinger S, Eissen AJ, Ellerman K, Gerlach V, Gorman L;
XX PI Guo X, Jeffers M, Kekda R, Li L, Malyanar UM, Miller CE;
XX PI Padigaru M, Paturajan M, Pena CBA, Rastelli L, Shenoy S;
XX PI Shukers RA, Spaerana SK, Spytek KA, Stone DJ, Taupier RJ;
XX PI Vernet CAM, Voss EZ, Zhong M;
XX DR WPI; 2003-221607/21.
XX PT New isolated NOV polypeptide, useful for determining the presence of, or
XX PT predisposition to, a disease associated with altered levels of expression
XX PT of the polypeptide, and for treating or preventing cancer.
XX PS Example C; SEQ ID NO 217; 478pp; English.
XX CC The invention relates to a novel isolated NOV polypeptide. The
XX CC polypeptide of the invention demonstrates cytostatic activity and may be
XX CC used for determining the presence of, or predisposition to, a disease
XX CC associated with altered levels of expression of the polypeptide,
XX CC including metabolic disorders, immune disorders, neurodegenerative
XX CC disorders, circulatory diseases, haemopoietic disorders, wasting diseases
XX CC and cancer. The polypeptide may also be utilised during gene therapy

CC procedures, vaccine development and transgenic animal production. The
CC current sequence is that of the PCR primer of the invention which was
CC used to analyse human NOV DNA.
XX SQ Sequence 22 BP; 2 A; 9 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 6.4%; Score 16.2; DB 1; Length 22;
XX Best Local Similarity 85.7%; Pred. No. 1.2e+02;
XX Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1192 AGAGCCTGTGACAGGACAG 1212
DB 22 AGAGCCTATGAGAGACAG 2
RESULT 30
ABI82182
ID ABI82182 standard; DNA; 23 BP.
XX AC ABI82182;
XX DT 15-FEB-2002 (first entry)
XX DE p53 mutation detection primer/probe #61.
XX Human; K-ras; PCR primer; probe; capture probe; mutation detection;
XX ligase detection reaction; LDR; p53; BRCA1, BRCA2; infectious disease;
XX infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
XX oncogene; tumour suppressor; human papillomavirus; forensic;
XX environmental monitoring; food industry; feed industry; ss.
XX Homo sapiens.
OS Synthetic.
XX WO200179548-A2.
XX PD 25-OCT-2001.
XX PF 04-APR-2001; 2001WO-US010958.
XX PR 14-APR-2000; 2000US-0197271P.
XX PA (CORR) CORNELL RES FOUND INC.
XX Barany F, Zivri M, Gerry NP, Favis R, Kliman R;
XX WPI; 2002-034366/04.
XX PT Designing capture oligonucleotide probes for use on a support to which
XX PT complementary oligonucleotides hybridize with little mismatch.
XX PS Example 3; Page 64; 300pp; English.
XX CC The present invention describes a method (M1) for designing capture
XX CC oligonucleotide probes (I) for use on a support to which complementary
XX CC oligonucleotide probes (II) will hybridize with little mismatch, where
XX CC (I) have melting temperatures within a narrow range. The method is useful
XX CC for detecting infectious diseases caused by bacterial infectious agents
XX CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
XX CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
XX CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
XX CC Epstein-Barr virus and polio virus, and parasitic infectious agents
XX CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
XX CC medinensis. The method is also useful for detecting genetic diseases such
XX CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
XX CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
XX CC involved in DNA amplification, replication, recombination or repair, the
XX CC cancer is specifically associated with a gene selected from BRCA1 gene,
XX CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
XX CC method is also used for environmental monitoring, forensics and the food
XX CC and feed industry, detecting comprises scanning (using e.g. a scanning
XX CC electron microscope and infrared microscope) the support at the
XX CC particular sites and identifying if ligation of the oligonucleotide probe

CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB187546 represent oligonucleotide sequences used in the exemplification
CC of the present invention
XX
SQ Sequence 23 BP; 4 A; 10 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 6.4%; Score 16.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1220 CTCAGACCTCCAGCATGTGCT 1240
DB 3 CTCAGACCTCCAGCATGTGCT 23
RESULT 31
ABK99821
ID ABK99821 standard; DNA; 20 BP.
XX
AC ABK99821;
XX
DT 21-OCT-2002 (first entry)
XX
DE Mouse RAID antisense oligonucleotide #75.
XX
KM Antisense gene therapy; RAID; death domain; caspase recruitment domain;
KM CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KM metabolic disorder; infection; inflammation; tumour formation;
KM RIP associated ICH-1/CBD-3-homologous protein with death domain;
KM receptor interacting protein; antisense oligonucleotide; ss.
XX
OS Mus musculus.
XX
PN WO200248314-A2.
XX
PD 20-JUN-2002.
XX
PF 29-OCT-2001; 2001WO-US050914.
XX
PR 01-NOV-2000; 2000US-00705267.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Zhang H, Freier SM, Watt AT;
XX
DR WPI; 2002-583496/62.
XX
PT Novel antisense compound that hybridizes and inhibits nucleic acid
PT encoding RAID which is an adaptor molecule containing both death domain
PT and caspase recruitment domains, for treating hyperproliferative
PT disorder.
XX
PS Example 16; Page 96; 144pp; English.
XX
CC The invention describes a compound (I) 8-50 nucleobases in length
CC targeted to a nucleic acid molecule (II) encoding RAID which is an
CC adaptor molecule containing both death domain (DD) and caspase
CC recruitment domains (CARD), where (I) specifically hybridizes with and
CC inhibits expression of RAID, or specifically hybridizes with at least an
CC 8-nucleobase portion of an active site on (II). (I) is useful for
CC inhibiting the expression of RAID (Receptor interacting protein (RIP)
CC associated ICH-1/CBD-3-homologous protein with death domain) in cells or
CC tissues, and for treating an animal having a disease or condition
CC associated with RAID, where the disease or condition is a
CC hyperproliferative disorder such as cancer, or a growth or metabolic
CC disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC as research reagents and kits, for distinguishing functions of various
CC members of a biological pathway, and in antisense gene therapy. (I) is
CC also useful prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. This sequence represents a mouse RAID
CC antisense oligonucleotide used to control expression of the RAID protein
XX

SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 6.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1227 CTCAGCATGTGCTGG 1242
DB 4 CTCAGCATGTGCTGG 19
RESULT 32
ABK99820
ID ABK99820 standard; DNA; 20 BP.
XX
AC ABK99820;
XX
DT 21-OCT-2002 (first entry)
XX
DE Mouse RAID antisense oligonucleotide #74.
XX
KM Antisense gene therapy; RAID; death domain; caspase recruitment domain;
KM CARD; hyperproliferative disorder; cancer; growth disorder; mouse;
KM metabolic disorder; infection; inflammation; tumour formation;
KM RIP associated ICH-1/CBD-3-homologous protein with death domain;
KM receptor interacting protein; antisense oligonucleotide; ss.
XX
OS Mus musculus.
XX
PN WO200248314-A2.
XX
PD 20-JUN-2002.
XX
PF 29-OCT-2001; 2001WO-US050914.
XX
PR 01-NOV-2000; 2000US-00705267.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Zhang H, Freier SM, Watt AT;
XX
DR WPI; 2002-583496/62.
XX
PT Novel antisense compound that hybridizes and inhibits nucleic acid
PT encoding RAID which is an adaptor molecule containing both death domain
PT and caspase recruitment domains, for treating hyperproliferative
PT disorder.
XX
PS Claim 3; Page 95; 144pp; English.
XX
CC The invention describes a compound (I) 8-50 nucleobases in length
CC targeted to a nucleic acid molecule (II) encoding RAID which is an
CC adaptor molecule containing both death domain (DD) and caspase
CC recruitment domains (CARD), where (I) specifically hybridizes with and
CC inhibits expression of RAID, or specifically hybridizes with at least an
CC 8-nucleobase portion of an active site on (II). (I) is useful for
CC inhibiting the expression of RAID (Receptor interacting protein (RIP)
CC associated ICH-1/CBD-3-homologous protein with death domain) in cells or
CC tissues, and for treating an animal having a disease or condition
CC associated with RAID, where the disease or condition is a
CC hyperproliferative disorder such as cancer, or a growth or metabolic
CC disorder. (I) is also useful for diagnostics, therapeutics, prophylaxis,
CC as research reagents and kits, for distinguishing functions of various
CC members of a biological pathway, and in antisense gene therapy. (I) is
CC also useful prophylactically, e.g. to prevent or delay infection,
CC inflammation or tumour formation. This sequence represents a mouse RAID
CC antisense oligonucleotide used to control expression of the RAID protein
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 6.3%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1227 CTCGACATGTGCTG3 1242
|||
DB 1 CTCGACATGTGCTG3 16

RESULT 33

ADP84437
ID ADP84437 standard; RNA; 19 BP.

AC ADP84437;

DT 26-FEB-2004 (first entry)

DE Human ABL1-targeted siRNA - SEQ ID 731.

KM short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.

OS Homo sapiens.

PN WO2003070972-A2.

PD 28-AUG-2003.

PF 20-FEB-2003; 2003WO-US005234.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PR 15-AUG-2002; 2002US-0404039P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 14-JAN-2003; 2003US-0439922P.

PR 15-JAN-2003; 2003US-0440129P.

PA (RIBO-) RIBOZYME PHARM INC.

PI Mcswiggen J, Beigelman L, Chowrira B;

DR WPI; 2003-679889/64.

PT New double-stranded interfering nucleic acid, useful e.g. for treatment
and diagnosis of leukemia and lymphoma, downregulates the breakpoint
cluster region-Abelson (BCR-ABL) gene.
CC activity and may be useful for modulating expression of the BCR-ABL gene,
as well as for treating leukemia or lymphoma and in diagnosis, drug
screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
the human ABL1-targeted siRNA of the invention.

PS Example 7; SEQ ID NO 731; 197pp; English.

CC The invention relates to a novel double-stranded short interfering
nucleic acid (siNA) that downregulates expression of the breakpoint
cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
(BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
activity and may be useful for modulating expression of the BCR-ABL gene,
as well as for treating leukemia or lymphoma and in diagnosis, drug
screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
the human ABL1-targeted siRNA of the invention.

CC Sequence 19 BP; 2 A; 6 C; 9 G; 0 T; 2 U; 0 Other;

QY 1239 CTGGCAGTGTCCGGCTGC 1257

DB 1 CAGGCAGTGTCCGGCGGC 19

RESULT 34
ADP84756/c

ID ADP84756 standard; RNA; 19 BP.

AC ADP84756;

DT 26-FEB-2004 (first entry)

DE Human ABL1-targeted siRNA - SEQ ID 1050.

KM short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.

OS Homo sapiens.

PN WO2003070972-A2.

PD 28-AUG-2003.

PF 20-FEB-2003; 2003WO-US005234.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PR 15-AUG-2002; 2002US-0404039P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 14-JAN-2003; 2003US-0439922P.

PR 15-JAN-2003; 2003US-0440129P.

PA (RIBO-) RIBOZYME PHARM INC.

PI Mcswiggen J, Beigelman L, Chowrira B;

DR WPI; 2003-679889/64.

PT New double-stranded interfering nucleic acid, useful e.g. for treatment
and diagnosis of leukemia and lymphoma, downregulates the breakpoint
cluster region-Abelson (BCR-ABL) gene.
CC activity and may be useful for modulating expression of the BCR-ABL gene,
as well as for treating leukemia or lymphoma and in diagnosis, drug
screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
the human ABL1-targeted siRNA of the invention.

PS Example 7; SEQ ID NO 1050; 197pp; English.

CC The invention relates to a novel double-stranded short interfering
nucleic acid (siNA) that downregulates expression of the breakpoint
cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
(BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
activity and may be useful for modulating expression of the BCR-ABL gene,
as well as for treating leukemia or lymphoma and in diagnosis, drug
screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
the human ABL1-targeted siRNA of the invention.

CC Sequence 19 BP; 2 A; 9 C; 6 G; 0 T; 2 U; 0 Other;

QY 1239 CTGGCAGTGTCCGGCTGC 1257

DB 1 CAGGCAGTGTCCGGCGGC 1

RESULT 35

ABAO1022
ID ABAO1022 standard; DNA; 20 BP.

AC ABAO1022;

DT 22-JAN-2002 (first entry)

DE Human ZAC/PLAG1 gene PCR primer PLAG1ex1b1.

XX

KW Human; transient neonatal diabetes mellitus; TNDM; genetic imprinting;
XX ZAC/PLAGL1; PCR primer; ss.
OS Homo sapiens.
XX JP2001204476-A.
XX 31-JUL-2001.
XX 28-JAN-2000; 2000JP-00020067.
XX 28-JAN-2000; 2000JP-00020067.
XX (RIKA) RIKAKAKU KENKYUSHO.
XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX WPI; 2001-629476/73.
XX Genetic diagnosis of human diabetes mellitus.
XX Example 5; Page 7; 17pp; Japanese.
XX The invention relates to the identification of an imprinted gene relating
CC to transient neonatal diabetes mellitus (TNDM). It relates to the
CC diagnosis of human diabetes, particularly TNDM, by analysis of the
CC ZAC/PLAGL1 gene. It is useful for the diagnosis of diabetes mellitus
CC showing high expression of ZAC/PLAGL1, especially diabetes caused by de-
CC methylation of the GC rich region of the ZAC/PLAGL1 gene. The method is
CC useful for genetic diagnosis, prevention and/or treatment of diabetes
CC mellitus, and for screening drugs for the prevention and/or treatment of
CC TNDM. The present sequence is a primer used in an example illustrating
CC the invention
XX
SQ Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 6.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1225 ACCTCCAGCATGTGCTGC 1243
DB 1 ACCTCCAGCATGTGCTGC 19

RESULT 36

AB293426
ID AB293426 standard; DNA; 20 BP.

XX AC AB293426;

XX DT 17-OCT-2003 (first entry)

XX DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antidiabetic gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX

PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX

PS Disclosure; SEQ ID NO 8668; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 6.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1366 AGGCTTACCAAGCAGCT 1384
DB 2 AGGCTTACCAAGCAGCAGCT 20

RESULT 37

ABD29656
ID ABD29656 standard; DNA; 20 BP.

XX AC ABD29656;

XX DT 29-JUL-2004 (first entry)

XX DE AA626698-derived oligonucleotide SEQ ID 8668.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX

PA (EPIG-) EPIGENESIS PHARM INC.
XX NYce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
PS Claim 15; SEQ ID NO 8668; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 6.3%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1366 AGGCTTACCAAGAGCCT 1384
DB 2 AGGCTTACCAAGAGCCT 20
RESULT 38
ABS51235
ID ABS51235 standard; DNA; 21 BP.
XX
XX ABS51235;
AC
XX
XX 21-OCT-2002 (first entry)
DT
XX
XX Human CADPKL DNA single nucleotide polymorphism flanking sequence #2.
DE
XX
XX Human; calcium/calmodulin-dependent protein kinase-like gene; CADPKL; ds;
KM SNP; neuropsychiatric disorder; attention deficit disorder; ADD;
KM schizoaffective disorder; bipolar disorder; unipolar affective disorder;
KM schizophrenia; adolescent conduct disorder; pharmacogenomics;
KM fingerprinting; paternity testing; antidepressant; neuroleptic;
KM single nucleotide polymorphism.
XX

OS Homo sapiens.
XX
XX WO200254939-A2.
XX
XX 18-JUL-2002.
XX
XX 07-JAN-2002; 2002WO-US000367.
XX
XX 09-JAN-2001; 2001US-00757300.
PR 23-AUG-2001; 2001US-00935464.
XX
XX (MILL-) MILLENNIUM PHARM INC.
PA
XX
XX Meyer JM, Barrington-Martin R, Parker A;
PI WPI; 2002-590643/63.
DR
XX
XX New variants of calcium/calmodulin-dependent protein kinase-like nucleic
PT acids and polypeptides, useful for diagnosing and treating
PT neuropsychiatric disorders, e.g. schizophrenia, schizoaffective disorder,
PT and bipolar disorder.
XX
XX Claim 5; Page 11; 223pp; English.
XX
XX The invention relates to a nucleic acid comprising a polymorphic region
CC of a Calcium/Calmodulin-dependent protein kinase-like gene (CADPKL)
CC allelic variant, and the polypeptide it encodes. CADPKL allelic variants
CC are useful in determining whether a subject has or is at risk of
CC developing a neuropsychiatric disorder, such as schizophrenia, attention
CC deficit disorder (ADD), schizoaffective disorder, bipolar disorder,
CC unipolar affective disorder and adolescent conduct disorder. The CADPKL
CC polypeptides, polynucleotides, antibodies and modulators of the CADPKL
CC allelic variants are useful for diagnosing or treating these
CC neuropsychiatric disorders. The polypeptides may be used to raise
CC antibodies to a CADPKL polypeptide. The nucleic acids may be used as
CC probes or primers, in pharmacogenomics for designing therapies for the
CC disorders, and in fingerprinting for detection of different individuals
CC with the same species (e.g. paternity testing). This sequence represents
CC a human CADPKL genomic DNA single nucleotide polymorphism (SNP) flanking
CC sequence of the invention
XX
SQ Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 6.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1327 ACCCTCTCTCCAGGACAG 1345
DB 1 ACCCTCTCTCCAGGACCTGG 19
RESULT 39
ABN00937
ID ABN00937 standard; DNA; 17 BP.
XX
XX ABN00937;
AC
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMUP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:929.
DE
XX
XX Human; genome-derived myosin-like protein 1; GDMUP-1; hGDMUP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF

XX 26-MAY-2000; 2000US-0207455P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0234635P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 929; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 6.1%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 77;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1264 AGCTGGAAGAGGCTGAG 1280
XX |||||
XX DB 1 AGCTGAAGAGGCTGAG 17
XX
XX RESULT 40
XX ADB98963/c
XX ID ADB98963 standard; DNA; 17 BP.
XX
XX AC ADB98963;
XX
XX 04-DEC-2003 (first entry)
XX
XX LRP5 mutagenic PCR primer #82.
XX
XX

KW Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW bone mass modulation; osteoporosis; PCR; primer; ss.
XX
XX Synthetic.
XX
XX WO200292000-A2.
XX
XX 21-NOV-2002.
XX
XX 13-MAY-2002; 2002WO-US014877.
XX
XX 11-MAY-2001; 2001US-0290071P.
XX 17-MAY-2001; 2001US-0291311P.
XX 01-FEB-2002; 2002US-0353058P.
XX 04-MAR-2002; 2002US-0361293P.
XX
XX (GENO-) GENOME THERAPEUTICS CORP.
XX (AMAP) WYETH.
XX
XX Allen K, Antkowiak A, Graham JR, Morales A, Yaworsky PJ, Liu W;
XX WPI; 2003-129214/12.
XX
XX New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT diagnosing a HBM-like phenotype in a subject and for preparing a
PT composition for modulating bone mass and/or lipid levels in a subject
PT suffering from e.g. osteoporosis.
XX
XX Disclosure; Page 53; 629pp; English.
XX
XX The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC level modulation. The invention is useful for diagnosing a HBM-like
CC phenotype in a subject and for preparing a composition for modulating
CC bone mass and/or lipid levels in a subject suffering from e.g.
CC osteoporosis. The present sequence was used to illustrate the invention.
XX
XX SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 6.1%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 77;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1349 CTTTCCGAGGCGAGCTG 1365
XX |||||
XX DB 17 CTTTCCGAGGCGAGCTG 1
XX
XX RESULT 41
XX ADB30113/c
XX ID ADB30113 standard; RNA; 19 BP.
XX
XX ADB30113;
XX
XX 29-JAN-2004 (first entry)
XX
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:735.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytoskeletal; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antineumatic; antiarthritic;
KW antiproliferative; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
XX Synthetic.
XX
XX WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
XX

```
XX 28-JAN-2003; 2003WO-US002510.
PF 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA Mcswiggen J, Beigelman L, Usman N, Haerberl P, Chowrira B;
PI WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX Example 3; SEQ ID NO 735; 164pp; English.
PS
XX CC The present invention describes a short interfering nucleic acid (siNA)
XX CC that downregulates expression of a mitogen-activated protein kinase
XX CC (MAPK) genes by RNA interference. Also described: (1) a method for
XX CC modulating expression of MAPK genes in cells, tissue explants or
XX CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
XX CC vectors that express siNA and cells containing these vectors. MAPK siNAs
XX CC have cytostatic, anorectic, antidiabetic, antibacterial, antiinflammatory,
XX CC antiaesthetic, immunosuppressive, antibacterial, antirheumatic,
XX CC antiarthritic, antipsoiatic and gastrointestinal activities. The MAPK
XX CC siNAs can be used to modulate the expression of MAPK genes, in cells,
XX CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
XX CC and II; a wide range of tumours, and inflammatory diseases (asthma,
XX CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
XX CC disease). They can also be used for drug screening; diagnosis; target
XX CC identification and validation; genetic engineering; pharmacogenomics;
XX CC studying gene function and gene mapping (e.g. of single-nucleotide
XX CC polymorphisms). The present sequence represents a MAPK siNA which is used
XX CC in the exemplification of the present invention.
XX
XX SQ Sequence 19 BP; 7 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
SQ
XX Query Match 6.1%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 1.1e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1301 CATGTCATCTGTGAGC 1317
DB 19 CATGTCATCTGTAGC 3

```

```
OS Synthetic.
XX
XX PN WO2003072590-A1.
XX
XX PD 04-SEP-2003.
XX
XX PF 28-JAN-2003; 2003WO-US002510.
XX
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Mcswiggen J, Beigelman L, Usman N, Haerberl P, Chowrira B;
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX Example 3; SEQ ID NO 944; 164pp; English.
PS
XX CC The present invention describes a short interfering nucleic acid (siNA)
XX CC that downregulates expression of a mitogen-activated protein kinase
XX CC (MAPK) genes by RNA interference. Also described: (1) a method for
XX CC modulating expression of MAPK genes in cells, tissue explants or
XX CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
XX CC vectors that express siNA and cells containing these vectors. MAPK siNAs
XX CC have cytostatic, anorectic, antidiabetic, antibacterial, antiinflammatory,
XX CC antiaesthetic, immunosuppressive, antibacterial, antirheumatic,
XX CC antiarthritic, antipsoiatic and gastrointestinal activities. The MAPK
XX CC siNAs can be used to modulate the expression of MAPK genes, in cells,
XX CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
XX CC and II; a wide range of tumours, and inflammatory diseases (asthma,
XX CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
XX CC disease). They can also be used for drug screening; diagnosis; target
XX CC identification and validation; genetic engineering; pharmacogenomics;
XX CC studying gene function and gene mapping (e.g. of single-nucleotide
XX CC polymorphisms). The present sequence represents a MAPK siNA which is used
XX CC in the exemplification of the present invention.
XX
XX SQ Sequence 19 BP; 4 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
SQ
XX Query Match 6.1%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 64.7%; Pred. No. 1.1e+02;
XX Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
OY 1301 CATGTCATCTGTGAGC 1317
DB 1 CAUGGUCACUCGUNAAGC 17

```

XX	Homo sapiens.
OS	
XX	US2002055479-A1.
PN	
XX	
PD	09-MAY-2002.
XX	
PF	14-MAY-2001; 2001US-00854883.
PR	18-JAN-2000; 2000US-00487368.
PR	31-JUL-2000; 2000US-00629644.
XX	
PA	(COMS/) COMSERT L M.
PA	(WYAT/) WYATT J. M.
PA	(FREI/) FREIER S. M.
PA	(MONI/) MONIA B. P.
PA	(BUTL/) BUTLER M. M.
PA	(MCKA/) MCKAY R.
PI	Cowseert LM, Wyatt J, Freier SM, Monia BP, Butler MM, Mckay R;
XX	
DR	WPI; 2002-462914/49.
PT	
PT	Compound for inhibiting the expression of protein phosphatase 1B (PTP1B)
PT	and for treating diabetes, cancer, or obesity, comprises an antisense
PT	oligonucleotide targeted to nucleic acid encoding PTP1B.
PS	
PS	Claim 3; Page 28; 133pp; English.
XX	
CC	The invention relates to a compound of 8-50 nucleobases in length
CC	targeted to a nucleic acid encoding protein phosphatase 1B (PTP1B), where
CC	the compound specifically hybridizes with and inhibits the expression of
CC	PTP1B (e.g. an antisense oligonucleotide). Also included are (1) a
CC	compound of 8-50 nucleobases in length which specifically hybridizes with
CC	an 8 nucleobase portion of an active site on a nucleic acid encoding
CC	PTP1B; (2) inhibiting the expression of PTP1B in cells or tissues
CC	comprising contacting the cells or tissues with the compound; treating an
CC	animal having or suspected of having a disease or condition associated
CC	with PTP1B comprising administering the compound; (4) decreasing blood
CC	sugar levels in an animal comprising administering the compound; (5)
CC	preventing or delaying the onset of a disease or condition associated
CC	with PTP1B in an animal comprising administering the compound; and (6)
CC	preventing or delaying the onset of an increase in blood glucose levels
CC	in an animal comprising administering the compound. The compound is used
CC	to inhibit the expression of PTP1B in cells or tissues, to treat or
CC	prevent or delay the onset of a disease or condition associated with
CC	PTP1B, such as type 2 diabetes, obesity, cancer (especially ovarian
CC	cancer, chronic myeloid leukaemia and hyperproliferative diseases in an
CC	animal having or suspected of having the disease or condition, and for
CC	decreasing blood sugar levels or preventing or delaying the onset of an
CC	increase in blood glucose levels in an animal. The compound is also used
CC	in diagnostics, therapeutics, prophylaxis, and in research reagents and
CC	kits. The present sequence is an antisense compound of the invention
CC	targeting human PTP1B
XX	
SQ	Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
XX	
Query Match	6.1%; Score 15.4; DB 1; Length 20;
Beet Local Similarity	94.1%; Pred. No. 1.2e+02;
Matches 16; Conservative	0; Mismatches 1; Indels 0; Gaps 0
QY	1328 CCTCTTCTCCAGGCAG 1344
DB	2 CCTCTTCTCCAGGCAG 18
RESULT 44	
AD180530	
ID	AD180530 standard; DNA; 20 BP.
XX	
AC	AD180530;
XX	
DT	22-APR-2004 (first entry)

XX		Quantitative gene analysis-related mouse PCR primer SeqID16.
DE		
XX	KM	quantitative analysis; gene quantification; simultaneous comparison;
KW	KM	medical monitoring; mouse; murine; PCR; primer; ss.
OS	Mus sp.	
PN	WO200400763-A2.	
PD	22-JAN-2004.	
PF	09-JUL-2003; 2003WO-FR002130.	
PR	09-JUL-2002; 2002FR-00008593.	
PA	(NECK-) INST NECKER.	
PI	Rocha B, Veiga-Fernandes H, Peixoto A;	
XX	WPI. 2004-122980/12.	
DR		
PT	Quantitative analysis of nucleic acid, useful for simultaneous	
PT	determination of many genes, e.g. for diagnosis, by two-stage polymerase	
XX	chain reaction, applied to one or a few cells.	
PS	Claim 15; SEQ ID NO 16; 49pp; French.	
XX		
CC	This invention relates to a novel method for quantitative analysis, in	
CC	vitro and/or ex vivo, of the number of molecules of nucleic acid encoding	
CC	different genes, expressed in the cells of a living organism, using a	
CC	small number of cells or a single cell. The method is used for	
CC	quantification of genes, particularly for simultaneous comparison and	
CC	quantitative evaluation of many genes at the level of individual cells	
CC	(or a few cells), for example for diagnosis, treatment and/or medical	
CC	monitoring. The method provides absolute quantification of the number of	
CC	mRNA molecules derived from particular genes, even in a single cell. The	
CC	present sequence is that of a mouse-derived PCR primer which was used in	
CC	the method of the invention.	
SQ	Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;	
OY	Query Match 6.1%; Score 15.4; DB 1; Length 20; Best Local Similarity 94.1%; Pred. No. 1.2e+02; Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
DB	1389 TTTCGTGAGCTGCTCGA 1405 4 TTTCGTGACTGCTCGA 20	
RESULT 45		
ID	AD114060	
XX	AD114060 standard; DNA; 20 BP.	
AC	AD114060;	
DT	22-APR-2004 (first entry)	
DE	Antisense DNA oligo to target human PTP1B DNA SeqID 313.	
XX		
KW	human; ss; antisense; PTP1B; protein phosphatase 1B; PTPN1;	
KW	phosphotrichlate backbone; hyperproliferative condition; cancer;	
KW	cytostatic; antidiabetic; anorectic; type 2 diabetes; obesity.	
OS	Homo sapiens.	
OS	Synthetic.	
XX		
FH	Key Location/Qualifiers	
FT	modified_base 1..20	
FT	/tag= b	
FT	/mod_base= OTHER	
FT	/note= "OTHER= phosphotrichlate backbone"	

```
FT modified_base 1. .5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT nucleobases are 5' methylcytidine."
FT 16. .20
FT /*tag= C
FT /mod_base= OTHER
FT /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT nucleobases are 5' methylcytidine."
XX
XX US2003220282-A1.
XX
XX 27-NOV-2003.
XX
XX 07-FEB-2003; 2003US-00360510.
XX
XX 18-JAN-2000; 2000US-00487368.
XX 31-JUL-2000; 2000US-00629644.
XX 14-MAY-2001; 2001US-00854883.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bhanot S, Cowsett LM, Wyatt JR, Monia BP, Butler MM, McKay R,
XX Freter SM;
XX WPI; 2004-051719/05.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding PTP1B, useful for treating a disease/condition
XX associated with PTP1B, such as cancer, diabetes or obesity.
XX
XX Claim 3; SEQ ID NO 313; 143bp; English.
XX
XX This invention relates to novel compositions and methods for modulating
XX the expression of PTP1B (also known as protein phosphatase 1B and PTPN1).
XX Specifically, it refers to antisense compounds that can target and
XX hybridise with a nucleic acid molecule encoding PTP1B, as well as splice
XX variants thereof and inhibit expression accordingly. PTP1B is a tyrosine
XX phosphatase that plays an essential regulatory role in signalling
XX mediated by the insulin receptor and as such is useful for treating
XX diseases such as type 2 diabetes and obesity. Furthermore, PTP1B can
XX suppress transformation of oncogenic genes, such that compositions of
XX this invention can also be used to treat hyperproliferative conditions
XX including cancer. Accordingly, these compounds can be described as having
XX cytosstatic, antidiabetic and anorectic activities. This oligonucleotide
XX sequence is an antisense DNA oligo that targets human PTP1B DNA, and
XX which has a phosphorothioate backbone and 2'-O-methoxyethyl wings, used
XX in an exemplification of the invention.
XX
XX Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 6.1%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1328 CCTCTTCCAAAGCAG 1344
DB 2 CCTCTTCCAAAGCAG 18
RESULT 46
AAQ75970
ID AAQ75970 standard; DNA; 22 BP.
AC AAQ75970;
XX
XX 25-MAR-2003 (revised)
DT 24-AUG-1995 (first entry)
XX
XX EPOR primer D, binds downstream of the unique BglII site of EGFR.
DE
XX Probe; isolation; epidermal growth factor receptor; EGFR; human;
```

```
KW placenta; cDNA library; pSPORT vector; erythropoietin receptor; EPOR;
KW BECA; BECB; extracellular; domain; transmembrane; cytoplasmic; murine;
XX primer; amplify; PCR; ss.
XX
XX Synthetic.
XX
XX W09429458-A1.
XX
XX 22-DEC-1994.
XX
XX 03-JUN-1994; 94WO-US006280.
XX
XX 07-JUN-1993; 93US-00073196.
XX
XX (AMGE-) AMGEN INC.
XX
XX Pacifici RE, Thomason AR, Chang M;
XX WPI; 1995-036485/05.
XX
XX New biologically active hybrid receptors - comprising a domain derived
XX from the haematopoietic cytokine receptor family and a heterologous
XX receptor domain.
XX
XX Example 1; Page 25; 34pp; English.
XX
XX The sequences given in AAQ75965-66 are probes which were used in the
XX isolation of the epidermal growth factor receptor (EGFR) cDNA from a
XX human placenta library prepared in the pSPORT vector. The isolated
XX sequence was used in the production of a EGFR/erythropoietin receptor
XX (EPOR) construct, BECA, which contains the extracellular domain of EGFR
XX (residues -24 to 620) and the transmembrane and cytoplasmic domain of
XX murine EPOR. The primer sequences given in AAQ75967-68 are primers which
XX were used to link the EGFR extracellular domain to a portion of EPOR. To
XX obtain the appropriate portion of EPOR intracellular domain cDNA the
XX primers given in AAQ75969-70 were used. (Updated on 25-MAR-2003 to
XX correct EN field.)
XX
XX Sequence 22 BP; 7 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1256 GCAGCAACAGCTGGAAG 1272
DB 2 GCAGCAACAGCTGGAAG 18
RESULT 47
AAAI0003
ID AAAI0003 standard; DNA; 22 BP.
AC AAAI0003;
XX
XX 05-JUN-2000 (first entry)
DT
XX
XX Primer CDPuro-1 for human CD8a gene.
DE
XX Foreign chromosome; microcell fusion; homologous recombination; antibody;
KW targeting vector; transgenic animal; disease model; knockout animal;
KW PCR primer; human; ss.
XX
XX Homo sapiens.
XX
XX W0200010383-A1.
XX
XX 02-MAR-2000.
XX
XX 23-AUG-1999; 99WO-JP004518.
XX
XX 21-AUG-1998; 98JP-00236169.
XX
```

PA (KIRI) KIRIN BEER KK.
XX Tomizuka K, Yoshida H, Hanacka K, Oshimura M, Ishida I;
PI Kuroiwa Y;
XX WPI; 2000-246479/21.
XX
XX
XX Producing a cell containing modified foreign chromosomes, useful for the
PT generation of transgenic animals.
XX
XX
XX Example 95; Page 179; 316pp; Japanese.
XX
XX The invention relates to a novel method of producing cells containing a
CC modified foreign chromosome or chromosome fragment. The method comprises:
CC (a) fusing a microcell comprising the foreign chromosome or chromosome
CC fragment, with a cell having a high efficiency for homologous
CC recombination; (b) marking the desired site of insertion of the foreign
CC chromosome using a targeting vector; and (c) inducing deletion or
CC translocation at the marked site. Transgenic animals produced by the
CC method are useful to provide disease models and knockout animals, and in
CC the production of human proteins, particularly human antibodies. This
CC sequence is used in the method of the invention
XX
XX Sequence 22 BP; 7 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
SQ

Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCACAGCTGAG 1272
|||
1 GCAGCACAGCTGAG 17

Db

RESULT 48
AA171716
ID AA171716 standard; DNA; 22 BP.
XX
XX AA171716;
AC
XX 15-JAN-2002 (first entry)
DT
XX
XX PCR primer CDPuro-1.
DE
XX
XX PCR primer; chimeric mouse; chromosome 14; chromosome 22;
KM antibody heavy chain gene; light chain lambda gene; ss.
XX
XX Synthetic.
OS
XX JP2001231403-A.
PN
XX 28-AUG-2001.
PD
XX
XX 18-FEB-2000; 2000JP-00042074.
PF
XX
XX 18-FEB-2000; 2000JP-00042074.
PR
XX
XX (KIRI) KIRIN BREWERY KK.
PA
XX
XX WPI; 2001-609926/70.
DR
XX
XX Non-human animals maintaining a modified alien chromosome or its
PT fragment.
XX
XX Example 9; Page 17; 43pp; Japanese.
PS
XX
XX The present invention relates to a chimeric mouse which carries fragments
CC of human chromosomes 14 and 22. The chimeric mouse carries the complete
CC human antibody heavy chain gene from chromosome 14 and the light chain
CC lambda gene from chromosome 22. The present sequence is a PCR primer,
CC which was used in an example from the present invention
XX
XX Sequence 22 BP; 7 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1256 GCAGCACAGCTGAG 1272
|||
1 GCAGCACAGCTGAG 17

Db

RESULT 49
AB11871/C
ID AB11871 standard; DNA; 22 BP.
XX
XX AB11871;
AC
XX 19-DEC-2002 (first entry)
DT
XX
XX Autonomously steroid producing yeast strain related oligo SEQ ID No 35.
DE
XX
XX Genetically modified yeast strain; autotomous; metabolism of cholesterol;
KM 17alpha-hydroxypregnenolone; steroid; cortisol; cortisone;
KM 17alpha-hydroxypregnenolone; ds.
XX
XX Unidentified.
OS
XX
XX WO200261109-A2.
PN
XX
XX 08-AUG-2002.
PD
XX
XX 29-JAN-2002; 2002WO-FR000348.
PF
XX
XX 31-JAN-2001; 2001FR-00001294.
PR
XX
XX (AVET) AVENTIS PHARMA SA.
PA
XX
XX Spagnoli R, Acheteux T, Caulet G, Degryse E, Dumas B, Pompon D;
PI Winter J;
XX WPI; 2002-723143/78.
DR
XX
XX New genetically modified yeast, useful for producing therapeutic steroids
PT from simple carbon source, provide high yields at low cost.
XX
XX Example 12; Page 75; 79pp; French.
PS
XX
XX The invention relates to a genetically modified yeast strain that
CC produces, autonomously from a simple carbon source, a steroid, or its
CC derivative, formed by metabolism of cholesterol. The steroid is 17alpha-
CC hydroxypregnenolone; cortisol; cortisone or 17alpha-
CC hydroxypregnenolone. The genetically modified yeast strain is used to
CC produce therapeutic useful steroids, and can itself be used as a
CC pharmaceutical. This polynucleotide sequence represents an
CC oligonucleotide relating to the steroid producing genetically modified
CC yeast strain of the invention
XX
XX Sequence 22 BP; 4 A; 4 C; 8 G; 6 T; 0 U; 0 Other;
SQ

Query Match 6.1%; Score 15.4; DB 1; Length 22;
Best Local Similarity 94.1%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1220 TCAGACTCCAGCATG 1236
|||
21 TCAGACTCCAGCATG 5

Db

RESULT 50
AAV59166
ID AAV59166 standard; DNA; 20 BP.
XX
XX AAV59166;
AC
XX

```
DT 14-DEC-1998 (first entry)
XX
XX p53 immobilisation oligonucleotide 7.
XX
XX ss; mutant allele; carrier; cancer.
XX
XX Synthetic.
XX
XX WO9839472-A2.
XX
XX 11-SEP-1998.
XX
XX 04-MAR-1998; 98WO-DE000676.
XX
XX 04-MAR-1997; 97DE-01008758.
XX
XX (WAGE/) WAGENER C.
XX
XX Wagener C;
XX
XX WPI, 1998-495865/42.
XX
XX Detecting mutated alleles in presence of excess wild-type allele - by
XX separation of wild-type on support carrying specific oligonucleotides,
XX used to detect mutation(s), particularly for cancer diagnosis.
XX
XX Disclosure; Fig 1; 17pp; German.
XX
XX The p53 immobilisation oligonucleotides AAV59160-V59168 were used to
XX detect a point mutation in a p53 gene as an example of the method of the
XX invention to detect mutant alleles among an excess of wild-type alleles.
XX This is carried out by separating the wild type alleles using a carrier
XX on which are bound one or more oligonucleotides complementary to the wild
XX type. The method is used to detect mutants having one or more point
XX mutations, deletions, inversions, insertions and/or substitutions of
XX small or large genetic regions, particularly to detect genetic
XX abnormalities for cancer diagnosis. The method can detect cancer cells in
XX faeces, sputum, bronchial lavage, urine or tissue biopsies. Rare alleles
XX can be detected, making the method suitable for detecting heterozygous or
XX homozygous mutations or polymorphisms of any origin
XX
XX Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 6.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1222 AGAACCTCCAGCATGTGCTG 1241
DB 1 ACMACTCCGTCATGTGCTG 20
RESULT 51
AAK60530/C
ID AAK60530 standard; DNA; 20 BP.
XX
XX AAK60530;
XX
XX 17-AUG-1999 (first entry)
XX
XX WO9914235 Seq ID No: 234.
XX
XX Growth factor; GF; persephin; neuron growth; cellular degeneration;
XX peripheral neuropathy; amyotrophic lateral sclerosis; ischemic stroke;
XX Alzheimer's disease; Parkinson's disease; Huntington's disease; trauma;
XX brain injury; spinal cord injury; nervous system tumour; infection;
XX multiple sclerosis; cardiac muscle degeneration; injury; neurotoxin;
XX metabolic disease; diabetes; renal dysfunction; neuriturin; ss.
XX
XX Synthetic.
XX
XX WO9914235-A1.
XX
```

```
PD 25-MAR-1999.
XX
XX 15-SEP-1998; 98WO-US019163.
XX
XX 16-SEP-1997; 97US-00931858.
XX
XX (UNIW ) UNIV WASHINGTON.
XX
XX Johnson EM, Milbrandt JD, Kotzbauer PT, Lampe PA, Klein R;
XX Desauvage F;
XX
XX WPI: 1999-244023/20.
XX
XX New isolated persephin growth factor nucleic acids used to, e.g. promote
XX neuronal growth.
XX
XX Example 15; Page 209; 222pp; English.
XX
XX The invention relates to a novel isolated and purified growth factor (GF)
XX that comprises persephin or a fragment or a conservatively substituted
XX variant. The persephin GF polypeptides can promote the survival and
XX growth of neurons and non-neuronal cells. The persephin GF polypeptides
XX or polynucleotides can be used for preventing or treating cellular
XX degeneration or insufficiency, e.g. neuronal degeneration resulting from
XX peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's
XX disease, Parkinson's disease, Huntington's disease, ischemic stroke,
XX acute brain injury, acute spinal cord injury, nervous system tumours,
XX multiple sclerosis, or infection, hematopoietic cell degeneration or
XX insufficiency resulting from eosinopenia, anemias, thrombocytopenia, or
XX stem-cell insufficiencies, cardiac muscle degeneration or insufficiency
XX resulting from cardiomyopathy or congestive heart failure. They can also
XX be used for treating e.g. peripheral nerve trauma or injury, exposure to
XX neurotoxins, metabolic diseases such as diabetes or renal dysfunctions
XX and damage caused by infectious agents. The GF can also be used for
XX promoting the growth and/or differentiation of a cell in a culture
XX medium. The antisense polynucleotides can be used for treating a disease
XX condition mediated by expression of persephin by a population of cells.
XX The products can also be used for detection and diagnosis
XX
XX Sequence 20 BP; 3 A; 8 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 6.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1239 CTGGCAGTGTCCGGCTGCA 1258
DB 20 CTGGCGCTGGCGCCGGCTGCA 1
RESULT 52
AAL60984/C
ID AAL60984 standard; DNA; 20 BP.
XX
XX AAL60984;
XX
XX 22-SEP-2003 (first entry)
XX
XX Human MyD88 antisense oligonucleotide, ISIS #190981.
XX
XX Antisense; human; myeloid differentiation primary response gene 88;
XX MyD88; Alzheimer's disease; neurodegenerative disease; schizophrenia;
XX gene therapy; Down's syndrome; phosphorothioate; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone; All cytidine residues
XX are 5-methylcytidines"
XX
```



```
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003046132-A2.
XX
XX 05-JUN-2003.
XX
XX 20-NOV-2002; 2002MO-US037411.
XX
XX 23-NOV-2001; 2001US-00021707.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Karraas JG, Dobie K;
XX
XX WPI; 2003-505193/47.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding MYD88, useful for preparing a composition for treating
XX neurodegenerative disease, e.g. Alzheimer's disease.
XX
XX Claim 3; Page 76; 106pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
XX encoding human MYD88 (myeloid differentiation primary response gene 88)
XX to inhibit its expression. Antisense compounds of the invention are
XX useful for preparing a composition for treating neurodegenerative disease
XX e.g. Alzheimer's disease, Down's syndrome or schizophrenia. The invention
XX is also useful in gene therapy. The present sequence is an antisense
XX oligonucleotide targeted to human MYD88 DNA
XX
XX Sequence 20 BP; 1 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 6.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1258 AGCAACAGCTGGAGAGGCT 1277
DB 20 AGCAGCAGCAGAGGAGGCT 1
RESULT 53
AB282681/C
ID AB282681 standard; DNA; 20 BP.
XX
XX AB282681;
XX
XX 14-MAY-2003 (first entry)
XX
XX Human HSL chimeric phosphorothioate oligonucleotide SEQ ID NO:70.
XX
XX Hormone-sensitive lipase; antisense oligonucleotide; inhibitor; obesity;
XX phosphorothioate; antidiabetic; anorectic; cytosolic; antisense therapy;
XX abnormal metabolic condition; hyperlipidemia; type 2 diabetes; cancer;
XX hyperproliferative disorder; human; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages"
XX modified_base 1..5
XX /tag= b
```

```
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyl (2'-MOE) wing"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyl (2'-MOE) wing"
XX
XX WO2003010139-A2.
XX
XX 06-FEB-2003.
XX
XX 15-JUL-2002; 2002MO-US022672.
XX
XX 26-JUL-2001; 2001US-00915814.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Butler MM, Watt AT, Freier SM, Wyatt JR;
XX
XX WPI; 2003-239411/23.
XX
XX New antisense oligonucleotides targeted against nucleic acids encoding
XX hormone-sensitive lipase, useful for treating abnormal metabolic
XX condition, e.g. hyperlipidemia and obesity, or a hyperproliferative
XX disorder, e.g. cancer.
XX
XX Claim 3; Page 88; 167pp; English.
XX
XX The present invention describes a compound (I) 8-50 nucleobases in length
XX targeted to a nucleic acid molecule encoding a hormone-sensitive lipase
XX (HSL) or a splice variant of HSL. The compound specifically hybridises
XX with and inhibits the expression of HSL or a splice variant of HSL, or
XX specifically hybridises with at least an 8-nucleobase portion of an
XX active site on a nucleic acid molecule encoding HSL. (I) have anorectic,
XX antidiabetic and cytosolic activities, and can be used in antisense
XX therapy. (I) is useful for treating an animal, particularly human,
XX suspected of having an abnormal metabolic condition such as obesity,
XX hyperlipidaemia, type 2 diabetes, a hyperproliferative disorder such as
XX cancer (e.g. pituitary, colorectal, breast, testicular, pulmonary or
XX epithelial cancer). (I) is also useful in modulating blood glucose
XX levels, particularly plasma or serum glucose levels, in a diabetic
XX animal. The present sequence represents a human hormone-sensitive lipase
XX chimeric phosphorothioate antisense oligonucleotide, which is used in an
XX example from the present invention
XX
XX Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;
SQ
Query Match 6.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1269 GAAGAGGCTGAGGCGAGACA 1288
DB 20 GAAGAGGCTGAGGCCAAAAA 1
RESULT 54
AB558313
ID AB558313 standard; DNA; 20 BP.
XX
XX AB558313;
XX
XX 21-FEB-2003 (first entry)
XX
XX Silkworm spider dragline silk gene (MasP1) specific PCR primer #1.
XX
XX Silkworm; primer; ss; spider drag-line; silk; fibroin; PCR; light chain;
XX l chain; MasP1.
XX
XX Bombyx mori.
XX
XX US2002137211-A1.
XX
```

PD 26-SEP-2002.
 XX 04-OCT-2001; 2001US-00969852.
 PF
 XX 02-JAN-2001; 2001CN-00106406.
 PR
 XX (UNSI-) UNIV SICHUAN TIANYOU BIOLOGIC ENG CO LTD.
 PA
 XX Liu T, Liu H, Li W, Zhao L;
 PI
 XX WPI; 2003-110604/10.
 DR
 XX Establishing expression systems of spider drag-line silk genes in
 PT silkworms, by fusing silkworm fibroin L-chain cDNA and its promoter
 PT upstream of spider drag-line silk gene cDNA to direct drag-line protein
 PT expression and secretion.
 PR
 XX Example 1; Page 2; 19pp; English.
 PS
 XX This invention relates to a novel method for establishing an expression
 CC system of spider drag-line silk genes in silkworm by fusing the silkworm
 CC fibroin L-chain cDNA and its promoter upstream of the spider drag-line
 CC silk gene cDNA, ligating the fused gene with a reporter gene and
 CC inserting into a transposon to obtain a recombinant transposon which can
 CC be used to transform a silkworm egg. The method of the invention is
 CC useful for establishing an expression system of spider drag-line silk
 CC gene in B. mori. The spider dragline silk gene product accounts for 30%
 CC of total silk proteins. This method provides a rate of transformation of
 CC about 0.5-1%. The present sequence represents a PCR primer used to
 CC amplify the silkworm spider dragline silk gene (Maspi) sequence used in
 CC the method of the invention
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 QY
 Query Match 6.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1253 GCTGCGAACAAGCTGAG 1272
 |||||
 1 GCAGCAGCAGCAGCTGAG 20
 DB
 RESULT 55
 AAQ85727
 ID AAQ85727 standard; DNA; 21 BP.
 AC AAQ85727;
 XX
 XX 25-MAR-2003 (revised)
 DT 04-OCT-1995 (first entry)
 XX
 DE Sense PCR primer no. 3354 for Wilson's disease gene exon 11.
 XX
 KM Wilson's disease; chromosome 13; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 PN MO9506714-A1.
 PD 09-MAR-1995.
 XX
 PF 01-SEP-1994; 94WO-US009851.
 XX
 PR 01-SEP-1993; 93US-00118441.
 XX
 PA (UYCO) UNIV COLUMBIA NEW YORK.
 XX (GEHO) GEN HOSPITAL CORP.
 PI Gilliam TC, Tanzi RB;
 XX WPI; 1995-115430/15.
 DR
 XX

PT Isolated Wilson's disease nucleic acid mol., - also probes, vectors, etc.,
 PT useful for diagnosis and gene therapy of Wilson's disease.
 XX
 XX Example; Page 73; 175pp; English.
 PS
 CC The reverse transcription reaction for Wilson's disease cDNA was
 CC performed using first strand cDNA synthesis kit (clontech), random
 CC hexamers as primers, and poly(A+)-RNA from human brain, liver, placenta,
 CC and kidney (Clontech). The reverse transcriptase cDNA mixture was
 CC subjected to 30 amplification cycles. Sense primers used in the
 CC amplification were AAQ85726-Q85728. Anti-sense primers were AAQ85729-
 CC Q85731. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
 QY
 Query Match 6.0%; Score 15.2; DB 1; Length 21;
 Best Local Similarity 85.0%; Pred. No. 1.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1261 AACAGCTGGAAGAGCTGAG 1280
 |||||
 2 AACGTGTGGAAGAGCTCAG 21
 DB
 RESULT 56
 AAD15161
 ID AAD15161 standard; DNA; 21 BP.
 XX
 XX AAD15161;
 AC
 DT 01-NOV-2001 (first entry)
 XX
 DE 3' RT-PCR primer for rabbit RECU_1 clone.
 XX
 KM Fatty lesion development; atherosclerosis; Alzheimer's disease;
 KM nervous system disorder; Parkinson's disease; immune system disorder;
 KM ischaemia; lymphopoenia; leukocyte adhesion deficiency syndrome;
 KM haemoglobinuria; anaemia; hyperproliferative disorder; Gaucher's disease;
 KM coagulation disorder; blood platelet disorder; autoimmune disorder;
 KM dermatitis; herpes simplex; Addison's disease; rheumatoid arthritis;
 KM Grave's disease; gene therapy; antiarteriosclerotic; immunostimulant;
 KM cardiovascular; antiviral; RT-PCR primer; rabbit; ss.
 KM
 OS Oryctolagus cuniculus.
 OS
 PN MO200154651-A2.
 XX
 XX 02-AUG-2001.
 PD
 XX 25-JAN-2001; 2001WO-US002439.
 PF
 XX 25-JAN-2000; 2000US-0177963P.
 PR
 XX (DIGIT-) DIGITAL GENE TECHNOLOGIES INC.
 PA
 XX Leonardi A, Sartani A, Glaes JR, Sutcliffe JG, Hasel KM;
 PI WPI; 2001-514526/56.
 DR
 XX New polynucleotides regulated by fatty lesion development and their
 PT encoded polypeptides, useful for preventing, creating or ameliorating
 PT atherosclerosis, as well as for immune or hyperproliferative disorders.
 XX
 PS Example 2; Page 124; 188pp; English.
 XX
 CC The present invention relates to an isolated nucleic acid regulated by
 CC fatty lesion development, which comprises any of 55 polynucleotide
 CC sequences from Oryctolagus cuniculus. The polynucleotide, polypeptide or
 CC antibody is useful for preventing, creating, modulating or ameliorating a
 CC medical condition, particularly atherosclerosis. The invention is used as
 CC a marker or detector of nervous system disorder or disease (e.g.
 CC Parkinson's disease, Alzheimer's disease, ischaemia, dementia). The
 CC invention may also be useful for treating deficiencies or disorders of

CC the immune system (e.g. lymphopenia, leukocyte adhesion deficiency
CC syndrome or haemoglobinuria, anaemia), hyperproliferative disorders
CC (e.g. Gaucher's disease), infectious disease (e.g. herpes simplex),
CC coagulation disorders, blood platelet disorders and autoimmune disorders
CC (Addison's disease, rheumatoid arthritis, dermatitis, Grave's disease).
CC The polynucleotide sequence is also used in gene therapy. The present
CC sequence is a 3' RT-PCR primer for rabbit RECL_1 clone
XX
SQ Sequence 21 BP; 7 A; 3 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 6.0%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1256 GCAGCAACGCTGGAAGAGC 1275
DB 1 GCAGCAACGAGGAGAGAGC 20

RESULT 57
ABK89666/c
ID ABK89666 standard; DNA; 21 BP.

AC ABK89666;
XX
XX 21-OCT-2002 (first entry)
DT
XX Human beta-defensin-2 forward PCR primer.
DE
XX Human; eotaxin; RANTES; beta-defensin-2; anti-inflammatory;
KW atopic dermatitis; PCR; primer; ss.
XX
XX Homo sapiens.

OS
XX JP2002186485-A.
PN
XX 02-JUL-2002.

XX 22-DEC-2000; 2000JP-00391265.
XX
XX 22-DEC-2000; 2000JP-00391265.

XX (SHS) SHISEIDO CO LTD.
XX
XX WPI; 2002-579943/62.

DR
XX Measuring mRNA or cDNA of eotaxin, RANTES or beta-defensin-2, a reagent
PT for it and screening of an anti-inflammatory agent, a kit for the
PT measurement of mRNA or cDNA, an anti-inflammatory agent.

PS Claim 3; Page 2; 17pp; Japanese.

XX The invention relates to a method of measuring mRNA or cDNA of eotaxin,
CC RANTES or beta-defensin-2 by carrying out a polymerase chain reaction
CC (PCR) by a DNA polymerase having 5' to 3' exonuclease activity using a
CC probe having a forward primer, a reverse primer, a reporter and a
CC quencher and hybridizing with a template nucleic acid in the region
CC placed between the both primers. The method is useful for screening an
CC anti-inflammatory agent or an agent for treating atopic dermatitis. The
CC present sequence represents a PCR primer used to isolate the coding
CC sequence of human beta-defensin-2
XX
XX

SQ Sequence 21 BP; 1 A; 5 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 6.0%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1257 CAGCAACGCTGGAAGAGC 1276
DB 20 CAAAAACACCTGGAAGAGC 1

RESULT 58
AAD36482
ID AAD36482 standard; DNA; 21 BP.

AC AAD36482;

DT 27-AUG-2002 (first entry)

XX Rat CYP4A1 antisense oligonucleotide.

XX Cerebral vascular disease; 20-hydroxyicosetetraenoic acid; infection;
KW 20-HETE; occlusive stroke; neurological disease; Alzheimer's disease;
KW subarachnoid haemorrhage; migraine headache; haemorrhagic stroke; CV;
KW cerebrovasospasm; SAH; Parkinson's disease; Huntington's disease; rat;
KW injury; dementia; therapy; antisense; rat; ss.

XX Rattus sp.

OS WO200236108-A2.

XX 10-MAY-2002.

XX 06-SEP-2001; 2001WO-US027605.

XX 03-NOV-2000; 2000US-0245638P.

XX (MCLR-) MCM RES FOUND INC.

XX (TAIS) TAISHO PHARM CO LTD.

XX Roman RJ, Harder DR, Miyata N, Sato M, Kameo K, Okuyama S;

XX WPI; 2002-426665/45.

XX Treatment of cerebral vascular disease e.g. occlusive stroke in animals
PT involves reducing 20-hydroxyicosetetraenoic acid (20-HETE) synthesizing
PT enzyme activity in animal.

XX Claim 30; Page 9; 38pp; English.

XX The invention relates to a method for treating cerebral vascular disease
CC in human or non-human animal. The method involves reducing 20-
CC hydroxyicosetetraenoic acid (20-HETE) synthesizing enzyme activity to
CC increase or prevent a decrease in cerebral blood flow in the animal. The
CC method is used in the treatment of cerebral vascular disease e.g.
CC occlusive strokes, infections, migraine headaches, hemorrhagic strokes,
CC cerebrovasospasm (CV) after subarachnoid hemorrhage (SAH), conditions
CC caused by traumatic head and brain injury or chronic neurological
CC diseases associated with reduced blood flow such as Alzheimer's disease,
CC dementia, Parkinson's disease and Huntington disease. The present
CC sequence is an antisense DNA targeted to rat cytochrome P450 (CYP4A1) to
CC inhibit its expression. CYP4A1 serves as hydroxyicosetetraenoic acid (20
CC -HETE) synthesizing enzyme
XX
XX

SQ Sequence 21 BP; 5 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 6.0%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1279 AGGCAAGACCTTCAGAGC 1298
DB 2 AGTGCAGACGCTCATGT 21

RESULT 59

AAD36483
ID AAD36483 standard; RNA; 21 BP.

XX AAD36483;

XX 27-AUG-2002 (first entry)

XX Rat CYP4A1 antisense RNA.

XX Cerebral vascular disease; 20-hydroxyelicosetetraenoic acid; infection;
KW 20-HETE; occlusive stroke; neurological disease; Alzheimer's disease;
KW subarachnoid haemorrhage; migraine headache; haemorrhagic stroke; CV;
KW cerebrovasospasm; SAH; Parkinson's disease; Huntington's disease; rat;
KW injury; dementia; therapy; antisense; rat; ss.
XX
OS Rattus sp.
XX
PN WO200236108-AZ.
XX
PD 10-MAY-2002.
XX
PF 06-SEP-2001; 2001WO-US027605.
XX
PR 03-NOV-2000; 2000US-0245638P.
XX
PA (MCLR-) MCM RES FOUND INC.
PI (TAIS) TAISHO PHARM CO LTD.
XX
PI Roman RJ, Harder DR, Miyata N, Sato M, Kameo K, Okuyama S;
XX
DR WPI; 2002-426665/45.
XX
PT Treatment of cerebral vascular disease e.g. occlusive stroke in animals
PT involves reducing 20-hydroxyelicosetetraenoic acid (20-HETE) synthesizing
PT enzyme activity in animal.
XX
PS Claim 33; Page 9; 38pp; English.
XX
CC The invention relates to a method for treating cerebral vascular disease
CC in human or non-human animal. The method involves reducing 20-
CC hydroxyelicosetetraenoic acid (20-HETE) synthesising enzyme activity to
CC increase or prevent a decrease in cerebral blood flow in the animal. The
CC method is used in the treatment of cerebral vascular disease e.g.
CC occlusive strokes, infections, migraine headaches, haemorrhagic strokes,
CC cerebrovasospasm (CV) after subarachnoid haemorrhage (SAH), conditions
CC caused by traumatic head and brain injury or chronic neurological
CC diseases associated with reduced blood flow such as Alzheimer's disease,
CC dementia, Parkinson's disease and Huntington disease. The present
CC sequence is an antisense RNA targeted to rat cytochrome P450 (CYP) 4A1 to
CC inhibit its expression. CYP4A1 serves as hydroxyelicosetetraenoic acid (20
CC -HETE) synthesising enzyme
XX
SQ Sequence 21 BP; 5 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
XX
Query Match 6.0%; Score 15.2; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
OY 1279 AGGCGAGACCCCTCAGGAT 1298
DB ||||| :||| :
2 AGGCGAGACCGCUCAGUGU 21
XX
RESULT 60
ID AAF52822
XX ADI03754 standard; DNA; 21 BP.
XX
AC ADI03754;
XX
DT 22-APR-2004 (first entry)
XX
DE Human ERMAP gene fragment amplifying primer ev4a.
KW ERMAP; erythroid membrane-associated protein; Sciana antigen; Sc;
KW Radin antigen; Rd; red cell adhesion protein; human; PCR; primer; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
PN EPI378519-AI.
XX

PD 07-JAN-2004.
XX
XX 05-JUN-2002; 2002EP-00014908.
PF
XX 05-JUN-2002; 2002EP-00014908.
PR
XX (BIOT-) BIOTEST AG.
PA
PI Flegel WA, Wagner FF;
XX
XX WPI; 2004-101299/11.
DR
XX
XX
PT New polynucleotides encoding a human erythroid membrane-associated
PT protein (ERMAP) having at least one mutation compared to a wild type
PT ERMAP, useful for detecting Sciana antigen or determining Sciana
PT antigen type.
XX
PS Disclosure; SEQ ID NO 39; 58pp; English.
XX
XX The invention relates to a polynucleotide (I) encoding human erythroid
CC membrane-associated protein (ERMAP), its fragment or variant, carrying at
CC least one mutation as compared to the nucleotide sequence (SEQ ID NO: 1).
CC Substitution in (I) is a missense mutation causing an amino acid
CC substitution in the extracellular portion of the ERMAP protein.
CC Specifically causing an amino acid substitution in position 26, 57 and/or
CC 60 of the amino acid sequence of ERMAP. The mutation may also be a
CC deletion causing a shift in the reading frame of the ERMAP gene, where
CC the mutation occurs in nucleotide position 54, 76, 169, 178, 307 and/or
CC 308. The mutation is a silent mutation in nucleotide position 54 from C
CC to T, or a missense mutation in position 76 from C to T, a G to A in
CC position 169, and/or a C to G in position 178. The mutation may be a
CC deletion of nucleotide position 307 and 308 of the ERMAP gene (SEQ ID NO:
CC 1). The polynucleotide, oligonucleotide, antibody, aptamer or phage is
CC useful for the detection of a Sciana antigen and/or for the
CC determination of the Sciana antigen (Sc) type. The cells from a proband,
CC preferably red blood cells, are useful for a serologic test. The
CC polynucleotide may also be used in the characterisation of monoclonal and
CC polyclonal antibodies for Sciana antigen determination, and for the
CC assessment of affinity, avidity, sensitivity, specificity and/or
CC reactivity of anti-Sc antibodies. Sequences ADI03727-ADI03763 represent
CC PCR primers for amplifying the eleven exon fragments and parts of
CC promoter of the human ERMAP gene.
XX
SQ Sequence 21 BP; 6 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 6.0%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1360 CAGCTGAGGCTTACCAGAG 1379
DB ||||| :||| :
2 CATCTGAGCATGCCAGAG 21
XX
RESULT 61
ID AAF52822
XX AAF52822 standard; DNA; 15 BP.
XX
AC AAF52822;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #3782.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antiposrotic;
KW cyrostatic; dermatological; cardiant; virocid; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; plarais;
KW growth factor mediated cell proliferation; ichthyosis; seroporiosis; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX

OS Homo sapiens.
 XX
 PN WO20078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 8; Page 85; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3) which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation.
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 SQ Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 6.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 63;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1232 GCATGTGCTGGCAGT 1246
 Db 1 GCATGTGCTGGCAGT 15
 RESULT 62
 AAK95049
 ID AAK95049 standard; DNA; 20 BP.
 XX
 AC AAK95049;
 XX
 DT 06-NOV-2001 (first entry)
 XX
 DE Human cDNA clone-specific primer, SEQ ID NO: 4294.
 XX
 KM Human; full length cDNA; cDNA synthesis; oligo-capping; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1130094-A2.
 XX
 PD 05-SEP-2001.
 XX
 PF 07-JUL-2000; 2000EP-00114089.
 XX
 PR 08-JUL-1999; 99JP-00194486.
 PR 11-JAN-2000; 2000JP-00118774.
 PR 02-MAY-2000; 2000JP-00183765.

XX
 PA (HELI-) HELIX RES INST.
 XX
 PI Ota T, Nishikawa T, Isogai T, Hayaishi K, Ichii S, Kawai Y;
 PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
 XX
 DR WPI; 2001-524255/58.
 XX
 PT 830 Primers useful for synthesizing full length cDNA clones and their use
 PT in genetic manipulation.
 XX
 PS Example 18; Page 129; 1380pp + Sequence Listing; English.
 XX
 CC The invention relates to primers for synthesizing full length cDNA
 CC clones. 830 cDNA molecules encoding a human protein have been isolated
 CC and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
 CC been determined. Primers for synthesizing the full length cDNA are useful
 CC for clarifying the function of the protein encoded by the cDNA. The full
 CC length clones were obtained by construction of full length enriched cDNA
 CC libraries that were synthesised by the oligo-capping method. The primers
 CC enable the production of the full length cDNA easily without any special
 CC methods. The present sequence is a primer used to amplify a human cDNA
 CC clone provided in the invention
 CC
 SQ Sequence 20 BP; 8 A; 2 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 6.0%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1267 TGGAAAGGCTGAGG 1281
 Db 2 TGGAAAGGCTGAGG 16
 RESULT 63
 ABX17337
 ID ABX17337 standard; DNA; 20 BP.
 XX
 AC ABX17337;
 XX
 DT 04-FEB-2003 (first entry)
 XX
 DE Human cancer promoting protein PE7879 PCR primer #2.
 XX
 KM Human; primer; ss; cancer; cancer promoting; PCR.
 XX
 OS Homo sapiens.
 XX
 PN CN1351082-A.
 XX
 PD 29-MAY-2002.
 XX
 PF 31-OCT-2000; 2000CN-00127103.
 XX
 PR 31-OCT-2000; 2000CN-00127103.
 XX
 PA (SHAN-) SHANGHAI INST ONCOLOGY.
 XX
 PI Gu J;
 XX
 DR WPI; 2002-609438/66.
 XX
 PT New human protein with cancer cell growth promoting function and a
 PT polynucleotide encoding it, for treating diseases, such as cancer.
 XX
 PS Example 2; Page 12 (disclosure); 35pp; Chinese.
 XX
 CC This invention relates to the cDNA and protein sequences of a novel human
 CC protein with the function of promoting cancer cell growth. The invention
 CC also discloses a method for preparing the polypeptide by recombination
 CC and application of the polypeptide in treating diseases such as cancer,
 CC etc. An antagonist of the polypeptide and its medical action, and

CC application of the polynucleotide are disclosed. The present sequence
CC represents a PCR primer used to amplify a cancer promoting protein cDNA
CC of the invention

XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 6.0%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1216 TCTGTCAGACCTCC 1230

DB 4 TCTGTCAGACCTCC 18

RESULT 64

ADL32261
ID ADL32261 standard; DNA; 20 BP.

AC ADL32261;

XX 20-MAY-2004 (first entry)

DE Clone specific PCR primer to amplify human full length cDNA SeqID 4294.

XX human; medicine; signal transduction; glycoprotein; transcription;

KW oligo-capping method; ss; PCR; primer.

XX Homo sapiens.

XX EPI396543-A2.

XX 10-MAR-2004.

XX 07-JUL-2000; 2003EP-00025638.

XX 08-JUL-1999; 99JP-00194486.

PR 11-JAN-2000; 2000JP-0018774.

PR 02-MAY-2000; 2000JP-00183865.

PR 07-JUL-2000; 2000EP-00114089.

XX (REAS-) RES ASSOC BIOTECHNOLOGY.

XX Ota T, Nishikawa T, Isegai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;

DR WPI; 2004-204755/20.

XX New oligonucleotide primers (830 CDNAs) useful for synthesizing full
PT length human cDNAs.

PS Example 18; SEQ ID NO 4294; 1340bp; English.

XX This invention relates to a novel primers useful for synthesizing full
CC length cDNA molecules that encode human proteins. Specifically, it refers
CC to secretory or membrane proteins that are potential therapeutic agents/
CC target molecules in the field of medicine, and in particular genes
CC encoding proteins that are associated with signal transduction,
CC glycoproteins and transcription. The present invention describes a method
CC for efficiently cloning a full length human cDNA from both the 5' and 3'
CC ends using the oligo-capping method. This oligonucleotide sequence is a
CC human clone specific PCR primer used in an exemplification of the
CC invention.

XX Sequence 20 BP; 8 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 6.0%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1267 TGGAGAGGCTGAGG 1281

DB 2 TGGAGAGGCTGAGG 16

RESULT 65

AAZ22430/C
ID AAZ22430 standard; DNA; 18 BP.

XX AAZ22430;

XX 25-NOV-1999 (first entry)

DE Antisense oligonucleotide directed against human Rhob mRNA.

XX Human; Rhob protein; antisense oligonucleotide; disease; Rhob expression;
KW breast cancer; primer; phosphorothioate; ss.

XX Synthetic.

OS Homo sapiens.

XX US5962672-A.

XX 05-OCT-1999.

XX 18-SEP-1998; 98US-00156979.

XX 18-SEP-1998; 98US-00156979.

XX (ISIS-) ISIS PHARM INC.

XX Coswert LM;

XX WPI; 1999-571296/48.

XX Antisense inhibition of the gene encoding Rhob, useful for treating
PT diseases associated with Rhob expression e.g. breast cancer.

XX Claim 3; Col 28; 24pp; English.

XX AA222392-222431 represent antisense oligonucleotides, which are 8-30
CC nucleotides in length, and are targeted to the gene encoding human Rhob.

CC The antisense oligonucleotides may be useful for treating diseases
CC associated with the expression of Rhob, such as breast cancer. They may
CC also have research and diagnostic applications

XX Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

XX Query Match 5.9%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1251 CGGCTGCAGCAACAGCTG 1268

DB 18 CGGCTGCATCACTGCTG 1

XX 1251 CGGCTGCAGCAACAGCTG 1268

XX 18 CGGCTGCATCACTGCTG 1

RESULT 66

AAF94683/C
ID AAF94683 standard; DNA; 18 BP.

XX AAF94683;

XX 23-MAY-2001 (first entry)

DE Rho B antisense phosphorothioate oligonucleotide SEQ ID 107.

XX Rho; GTP binding protein; phosphorothioate antisense oligonucleotide;
KW Rhob; Rhob; Rhoc; Rhog; Rac 1; cdc42; hyperproliferative condition;
KW cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation;
KW ss.

XX Homo sapiens.

XX WO200115739-A1.

XX

XX

XX

PD 08-MAR-2001.
XX
XX 18-AUG-2000; 2000MO-US022808.
XX
XX 31-AUG-1999; 99US-00387341.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Roberts ML, Cowart LM;
XX
XX WPI; 2001-191677/19.
XX
XX An antisense compound targeted to a nucleic acid molecule encoding a
PT member of the human Rho family of small GTP binding proteins useful for
PT treating e.g. cancer and ischemia.
XX
XX Example 13; Page 65; 156pp; English.
XX
XX This invention relates to an antisense compound targeted to a nucleic
CC acid molecule encoding a member of the human Rho family of small GTP
CC binding proteins, where the antisense compound inhibits the expression of
CC the member of the human Rho family. The invention includes antisense
CC oligonucleotides AAF94580 - AAF94637 which target a RhoA nucleotide
CC sequence, AAF94645 - AAF94684 which target a RhoB nucleotide sequence,
CC AAF94686 - AAF94725 which target a RhoC nucleotide sequence, AAF94727 -
CC AAF94766 which target RhoG nucleotide sequence, AAF94769 - AAF94790 which
CC target a Rac1 nucleotide sequence and AAF94795 - AAF94809 which target
CC cdc42 nucleotide sequence. The antisense compound is useful for treating
CC hyperproliferative conditions, especially cancer, abnormal wound healing
CC or clotting conditions and ischemia/reperfusion or reoxygenation injury.
CC The compound may also be used to diagnose the above conditions
XX
SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1251 CGGCTGCAGCAACAGCTG 1268
DB 18 CGGCTGCATCAACTGCTG 1
RESULT 67
ADK94829
ID ADK94829 standard; DNA; 18 BP.
XX
XX ADK94829;
XX
XX 06-MAY-2004 (first entry)
XX
XX Primer of the invention #549.
XX
XX human; single nucleotide polymorphism; SNP; ss; primer.
XX
XX Synthetic.
XX
XX JP2003259875-A.
XX
XX 16-SEP-2003.
XX
XX 08-MAR-2002; 2002JP-00064373.
XX
XX 08-MAR-2002; 2002JP-00064373.
XX
XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
XX
XX WPI; 2004-093977/10.
XX
XX Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX

PS Claim 2; SEQ ID NO 3858; 2627pp; Japanese.
XX
XX The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
SQ Sequence 18 BP; 0 A; 4 C; 7 G; 7 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1383 CTGCTTTTGTGCTGAGCTG 1400
DB 1 CTGCTGTGCTGTGCTG 18
RESULT 68
AD014748/C
ID AD014748 standard; RNA; 19 BP.
XX
XX AD014748;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human PDGFR-targeted siNA upper strand SEQ ID NO:179.
XX
XX cytosolic; vasotropic; nephrotropic; cerebroprotective;
XX treating leukemia; solid tumors; restenosis; polycystic kidney disease;
XX bronchiolitis; glomerulonephritis; stroke; RNA interference;
XX short interfering nucleic acid; siNA; short interfering RNA; siRNA;
XX double-stranded RNA; micro-RNA; mRNA; short hairpin RNA; shRNA;
XX expression modulation; gene therapy; drug screening; diagnosis;
XX therapeutic target identification; pharmacogenomics;
XX gene function analysis; gene mapping; human;
XX platelet derived growth factor receptor; PDGFR; ss.
XX
XX Homo sapiens.
XX
XX WO2003072704-A2.
XX
XX 04-SEP-2003.
XX
XX 05-FEB-2003; 2003WO-US003473.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 06-JUN-2002; 2002US-0386783P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcwiggan J, Beigelman L, Chowrira B;
XX
XX WPI; 2003-731605/69.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX
XX Example 3; SEQ ID NO 179; 148pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFR) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
XX

PS Example 4; SEQ ID NO 8; 29pp; Chinese.
XX
CC The invention relates to an isolated Rho polypeptide containing an amino
CC acid sequence of 827 amino acids, as defined in the specification. The
CC invention further comprises: an isolated polynucleotide containing a
CC polynucleotide selected from: a polynucleotide that encodes a polypeptide
CC with a sequence of 827 amino acids, or a complementary polynucleotide; a
CC vector containing the polynucleotide; a host cell for genetic engineering
CC that contains the vector; a process for producing the Rho protein by
CC culturing the host cells to express such protein for isolation from the
CC cultured material; a reagent kit for detecting baldness susceptibility
CC comprising a primer for specific the amplification of the Rho gene or
CC transcrip; and compositions containing a safe and effective dose of the
CC polypeptide and pharmaceutically-acceptable carrier. The Rho polypeptide
CC has dermatological activity. The polynucleotides, polypeptides and their
CC recombinant versions are useful in diagnosis and treatment of baldness.
CC This polynucleotide sequence represents a primer used in the
CC exemplification of the invention.
XX
SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1270 AAGAGCTGAGGCGCAG 1287
Db 19 AAGCGCTGAGAGCAGCAG 2
RESULT 71
AAV72821/C
ID AAV72821 standard; DNA; 20 BP.
XX
AC AAV72821;
XX
DT 22-FEB-1999 (first entry)
XX
DE Cannabinoid receptor gene PCR primer #1.
XX
XX Human; cryptophan 2,3-dioxygenase; TDO2; allelic polygene diagnosis;
XX reward deficiency syndrome; RDS; obesity; alcohol; tobacco; drug use;
XX Tourette syndrome; attention deficit hyperactivity disorder; ADHD;
XX schizoid/avoidant behaviour; aggression; premenstrual syndrome; violence;
XX hostility; mania; depression; anxiety; sleep problem; autism;
XX osteoporosis; binge eating; craving; inhibition; PCR primer; ss.
XX
OS Synthetic.
XX
PN MO9848785-A2.
XX
PD 05-NOV-1998.
XX
PF 29-APR-1998; 98WO-US008684.
XX
PR 29-APR-1997; 97US-0044394P.
XX
XX (BLUM-) BLUM INC KENNETH.
XX (TEXA-) UNIV TEXAS SYSTEM.
XX (CITY) CITY OF HOPE NAT MEDICAL CENT.
XX
XX Blum K, Comings DE, Ivy JL;
XX
XX WPI; 1998-610008/51.
XX
XX Composition for treating reward deficiency syndrome behaviour, attention
XX deficit disorders or controlling weight - contains inhibitor of opiate
XX peptide destruction, neurotransmitter precursor and chromium.
XX
XX Example 19; Page 399; 663pp; English.
XX
XX A composition (A) has been developed for: (i) treating a reward
XX deficiency syndrome (RDS) behaviour; or (ii) preventing or treating

XX unwanted weight gain. (A) comprises: (a) an agent (1), i.e. amino acid or
XX peptide, or their analogues or derivatives, that inhibits enzymatic
XX destruction of a neurotransmitter opiate; (b) a neurotransmitter precursor
XX (11) to promote neurotransmitter synthesis, i.e. L-Tyr, L-Phe or L-dopa
XX (dopamine precursors) L-Trp or 5-hydroxytryptophan (serotonin precursors)
XX or L-Glu (or its salt) or L-Gln (gamma-aminobutyric acid precursors); and
XX (c) chromium picolinate or nicotinate to increase the level of Trp.
XX Typical of many behaviours that can be treated with (A) include:
XX substance use disorder; obesity; alcohol, tobacco or other drug use;
XX Tourette syndrome; attention deficit hyperactivity disorder (ADHD);
XX schizoid/avoidant behaviour; aggression; premenstrual syndrome; violence;
XX hostility; mania; depression; anxiety; sleep problems; autism. Methods
XX given in the invention can be applied for diagnosis of RDS or e.g.
XX elevated levels of low density lipoprotein (LDL) or cholesterol, (A)
XX longevity, lack of ADHD, osteoporosis. In treatment of obesity, (A)
XX inhibits binge eating and craving. The present sequence represents a PCR
XX primer used in an example from the present invention
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1366 AGGCTTACGAGACGAC 1383
Db 18 AGGTTACGAGACGAC 1
RESULT 72
AAV72827/C
ID AAV72827 standard; DNA; 20 BP.
XX
AC AAV72827;
XX
DT 22-FEB-1999 (first entry)
XX
DE Cannabinoid receptor gene PCR primer #1.
XX
XX Human; cryptophan 2,3-dioxygenase; TDO2; allelic polygene diagnosis;
XX reward deficiency syndrome; RDS; obesity; alcohol; tobacco; drug use;
XX Tourette syndrome; attention deficit hyperactivity disorder; ADHD;
XX schizoid/avoidant behaviour; aggression; premenstrual syndrome; violence;
XX hostility; mania; depression; anxiety; sleep problem; autism;
XX osteoporosis; binge eating; craving; inhibition; PCR primer; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN MO9848785-A2.
XX
PD 05-NOV-1998.
XX
PF 29-APR-1998; 98WO-US008684.
XX
PR 29-APR-1997; 97US-0044394P.
XX
XX (BLUM-) BLUM INC KENNETH.
XX (TEXA-) UNIV TEXAS SYSTEM.
XX (CITY) CITY OF HOPE NAT MEDICAL CENT.
XX
XX Blum K, Comings DE, Ivy JL;
XX
XX WPI; 1998-610008/51.
XX
XX Composition for treating reward deficiency syndrome behaviour, attention
XX deficit disorders or controlling weight - contains inhibitor of opiate
XX peptide destruction, neurotransmitter precursor and chromium.
XX
XX Example 4; Page 197; 663pp; English.
XX
XX A composition (A) has been developed for: (i) treating a reward
XX deficiency syndrome (RDS) behaviour; or (ii) preventing or treating

CC unwanted weight gain. (A) comprises: (a) an agent (I), i.e. amino acid or
CC peptide, or their analogues or derivatives, that inhibits enzymatic
CC destruction of a neurotransmitter precursor; (b) a neurotransmitter precursor
CC (II) to promote neurotransmitter synthesis, i.e. L-Tyr, L-Phe or L-dopa
CC (dopamine precursors) L-Tyr or 5-hydroxytryptophan (serotonin precursors)
CC or L-Glu (or its salt) or L-Gln (gamma-aminobutyric acid precursors); and
CC (c) chromium picolinate or nicotinate to increase the level of Tyr.
CC Typical of many behaviours that can be treated with (A) include:
CC Substance use disorders; obesity; alcohol, tobacco or other drug use;
CC Tourette syndrome; attention deficit hyperactivity disorder (ADHD);
CC schizoid/avoidant behaviour; aggression; premenstrual syndrome; violence;
CC hostility; mania; depression; anxiety; sleep problems; autism. Methods
CC given in the invention can be applied for diagnosis of RDS or e.g.
CC elevated levels of low density lipoprotein (LDL) or cholesterol.
CC longevity, lack of ADHD, osteoporosis. In treatment of obesity, (A)
CC inhibits binge eating and craving. The present sequence represents a PCR
CC primer used in an example from the present invention
CC
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1366 AGGCTTACCAGAGCAGC 1363
DB 18 AGGGTTAACAGAACGAGC 1
|||||
|||

RESULT 73
AAZ06139/c
ID AAZ06139 standard; DNA; 20 BP.
XX
AC AAZ06139;
XX
DT 07-OCT-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; peritphalitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartolinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS Synthetic.
XX Chlamydia trachomatis.
XX
XX WO9928475-A2.
XX
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
XX
XX 28-NOV-1997; 97FR-000150A1.
XX 17-DEC-1997; 97FR-00016034.
XX 04-NOV-1998; 98US-0107077P.
XX
XX (BEST) GENSET.
XX
XX Griffais R;
XX
XX WPI; 1999-371125/31.
XX
XX Genome sequence of Chlamydia trachomatis.
XX
XX Disclosure; Page 1828; 1755pp; English.
XX
XX PCR primers AAZ01426-206209 were used to amplify open reading frames
CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as

CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis;
CC epididymitis, cervicitis, salpingitis, peritphalitis, bartolinitis;
CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
CC
SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1337 CAAGGACAGAGACTTCC 1354
DB 20 CAAGGATGAGACTTCC 3
|||||
|||

RESULT 74
AAZ33908/c
ID AAZ33908 standard; DNA; 20 BP.
XX
XX AAZ33908;
XX
XX 07-DEC-1999 (first entry)
XX
XX Human PRO300 PCR forward primer 2.
XX
XX Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;
KW probe; blood coagulation disorder; cancer; cellular adhesion disorder;
KW secreted protein; transmembrane protein; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9946281-A2.
XX
XX 16-SEP-1999.
XX
XX 08-MAR-1999; 99WO-US005028.
XX
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040020.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079234P.
XX 26-MAR-1998; 98US-0079653P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.

PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081833P.
PR 15-APR-1998; 98US-0081955P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082566P.
PR 21-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082767P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083323P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
XX (GETH) GENENTECH INC.
XX
XX Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;
XX WPI, 1999-551358/46.
XX
XX New secreted and transmembrane polypeptides and their polynucleotides,
XX useful for treating blood coagulation disorders, cancers and cellular
XX adhesion disorders.
XX
XX Example 5, Page 184; 530pp; English.
XX
XX The present invention describes secreted and transmembrane polypeptides
XX and their polynucleotides. The nucleotide sequences are useful as sources
XX of probes, primers, for chromosome mapping, and for generation of
XX antisense sequences. They can also be used to create transgenic animals.

CC The proteins can be used to treat a variety of diseases and disorders,
CC depending on their function. Diseases that may be treated include blood
CC coagulation disorders, cancers and cellular adhesion disorders. They may
CC also be used to raise antibodies. AA233891 to AA234338, and AA41655 to
CC AA41774 represent polynucleotide and polypeptide sequence given in the
CC exemplification of the present invention
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1256 GCACCAACGCTGGAAGA 1273
Db 18 GCACCAACGCTGGAAGA 1
RESULT 75
AAC65364/C
ID AAC65364 standard; DNA; 20 BP.
XX AAC65364;
AC AAC65364;
XX
DT 12-FEB-2001 (first entry)
XX
XX Human cannabinoid receptor gene PCR primer #1.
XX Human; anti-ADD; anti-ADHD; opiate destruction inhibitor;
XX neurotransmitter synthesis promoter; tryptophan-concentration enhancing;
XX allelic polygene diagnosis; reward deficiency syndrome; RDS; obesity;
XX smoking; Tourette's syndrome; schizoid avoidant behaviour; aggression;
XX post-traumatic stress syndrome; pre-menstrual syndrome;
XX cannabinoid receptor gene; dopamine DRDA receptor;
XX tryptophan 2,3-dioxygenase; TDO2; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX US6132724-A.
XX
XX 17-OCT-2000.
XX
XX 29-APR-1998; 98US-00069886.
XX
XX 29-APR-1998; 98US-00069886.
XX
XX (CITY) CITY OF HOPE NAT MEDICAL CENT.
XX (TEXA) UNIV TEXAS SYSTEM.
XX
XX Blum K;
XX
XX WPI; 2000-678662/66.
XX
XX
XX Compositions used to treat attention deficit (hyperactivity) disorder
XX have of neuroleptidyl opiate enzymatic destruction inhibitor,
XX neurotransmitter, mineral compound and Rhodiola extract or huperzine.
XX
XX Example 19; Col 233; 207pp; English.
XX
XX The present sequence is used in a method for the allelic polygene
XX diagnosis of reward deficiency syndrome. Compositions are disclosed which
XX comprise at least one substance that inhibits the enzymatic destruction
XX of a neuroleptidyl opiate, at least one neurotransmitter, a tryptophan
XX concentration-enhancing amount of a mineral compound; and at least one
XX substance chosen from Rhodiola extract and huperzine. The compositions
XX are used to treat ADD and ADHD. They are used to treat reward deficiency
XX syndrome (RDS) behaviours including obesity, smoking, Tourette's
XX syndrome, schizoid avoidant behaviour, aggression, post-traumatic stress
XX syndrome, pre-menstrual syndrome or tobacco use. The presence of
XX encephalin releasers dramatically improves the patient's response to
XX treatment
XX
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCAACGCTGGAGA 1273
DB 18 GCAGCACCGCTGGATGA 1

RESULT 78
ABI93412/C
ID ABI93412 standard; DNA, 20 BP.

XX AC ABI93412;
XX
DT 15-FEB-2002 (first entry)
XX

XX Capture oligonucleotide Zip ID#499 oligo #9.

XX Human; K-ras; PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
KW oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.

XX Synthetic.

XX WO200179548-A2.

XX 25-OCT-2001.

XX 04-APR-2001; 2001WO-US010958.

XX 14-APR-2000; 2000US-0197271P.

XX (CORR) CORNELL RES FOUND INC.

XX Barany F, Zilvri M, Gerry NP, Favie R, Kilman R;

XX WPI; 2002-034366/04.

XX Designing capture oligonucleotide probes for use on a support to which
XX complementary oligonucleotides hybridize with little mismatch.

PS Example 5; Fig 29; 300pp; English.

XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridise with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. ABI82074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
CC of the present invention

XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

XX Query Match 5.9%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1242 GCAGTGGTCCGGCTGCAG 1259
DB 19 GCAATGGTCTGCTGCAG 2

RESULT 79
ACA63476/C
ID ACA63476 standard; DNA, 20 BP.

XX AC ACA63476;
XX

DT 16-JUN-2003 (first entry)
XX

XX Novel human secreted and transmembrane protein related primer #10.

XX Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cycostatic;
KW antidiabetic; gene therapy; inflammatory disease; organ failure;
KW atherosclerosis; cardiac injury; infertility; birth defect;
KW premature aging; AIDS; cancer; diabetic complication; chromosome mapping;
KW gene mapping; pharmaceutical; diagnostic; biosensor; bioreactor;
KW tissue typing; PCR; primer; ss.

XX Homo sapiens.

XX US2002192706-A1.

XX 19-DEC-2002.

XX 24-OCT-2001; 2001US-00999832.

XX 17-OCT-1997; 97US-0062250P.

XX 03-NOV-1997; 97US-0064249P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066364P.

XX 10-MAR-1998; 98US-0077450P.

XX 11-MAR-1998; 98US-0077632P.

XX 11-MAR-1998; 98US-0077641P.

XX 12-MAR-1998; 98US-0077791P.

XX 13-MAR-1998; 98US-0078004P.

XX 17-MAR-1998; 98US-00040220.

XX 20-MAR-1998; 98US-0078886P.

XX 20-MAR-1998; 98US-0078910P.

XX 20-MAR-1998; 98US-0078936P.

XX 20-MAR-1998; 98US-0078939P.

XX 25-MAR-1998; 98US-0079284P.

XX 26-MAR-1998; 98US-0079656P.

XX 27-MAR-1998; 98US-0079663P.

XX 27-MAR-1998; 98US-0079664P.

XX 27-MAR-1998; 98US-0079689P.

XX 27-MAR-1998; 98US-0079728P.

XX 30-MAR-1998; 98US-0079786P.

XX 30-MAR-1998; 98US-0079920P.

XX 30-MAR-1998; 98US-0079932P.

XX 31-MAR-1998; 98US-0080107P.

XX 31-MAR-1998; 98US-0080157P.

XX 31-MAR-1998; 98US-0080165P.

XX 31-MAR-1998; 98US-0080194P.

XX 01-APR-1998; 98US-0080327P.

XX 01-APR-1998; 98US-0080328P.

XX 01-APR-1998; 98US-0080338P.

XX 01-APR-1998; 98US-0080343P.

XX 08-APR-1998; 98US-0081049P.

XX 08-APR-1998; 98US-0081070P.

XX 08-APR-1998; 98US-0081071P.

XX 09-APR-1998; 98US-0081195P.

XX 09-APR-1998; 98US-0081203P.

XX 15-APR-1998; 98US-0081229P.

XX 15-APR-1998; 98US-0081817P.

PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082795P.
PR 07-OCT-1998; 98MO-US021141.
PR 20-NOV-1998; 98MO-US024855.
PR 05-JAN-1999; 99MO-US000106.
PR 08-MAR-1999; 99MO-US005028.
PR 10-MAR-1999; 99MO-US005190.
PR 14-MAY-1999; 99MO-US010733.
PR 02-JUN-1999; 99MO-US012252.
PR 30-NOV-1999; 99MO-US028313.
PR 02-DEC-1999; 99MO-US028551.
PR 16-DEC-1999; 99MO-US030095.
PR 30-DEC-1999; 99MO-US031243.
PR 30-DEC-1999; 99MO-US031274.
PR 05-JAN-2000; 2000MO-US000219.
PR 06-JAN-2000; 2000MO-US000277.
PR 11-FEB-2000; 2000MO-US003565.
PR 18-FEB-2000; 2000MO-US004341.
PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 10-MAR-2000; 2000MO-US006319.
PR 21-MAR-2000; 2000MO-US007532.
PR 30-MAR-2000; 2000MO-US008439.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 28-JUL-2000; 2000MO-US020710.
PR 24-AUG-2000; 2000MO-US023328.
PR 01-DEC-2000; 2000MO-US032678.
PR 20-DEC-2000; 2000MO-US034956.
PR 28-FEB-2001; 2001MO-US006520.
PR 22-MAR-2001; 2001MO-US009552.
PR 25-MAY-2001; 2001MO-US017092.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
XX
XX (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Filvarolf E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PM, Wood WI,
XX
XX WPI; 2003-328860/31.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,
XX cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.
XX
XX Example 5; Page 126, 453pp; English.
XX
XX The invention describes an isolated nucleic acid (1) comprising, or which
XX is at least 80 % sequence identity to, or the full-length coding sequence
XX of, any of 118 300-2100 nucleotide sequences, which encodes its
XX corresponding PRO polypeptide selected from 118 100-700 amino acid
XX sequences, all given in the specification. The nucleic acids and
XX polypeptides are useful for treating inflammatory diseases, organ

CC failure, atherosclerosis, cardiac injury, infertility, birth defects,
CC premature aging, AIDS, cancer, or diabetic complications. The nucleic
CC acids are useful as hybridisation probes, in chromosome and gene mapping,
CC and in generating antisense RNA or DNA. The polypeptides are useful as
CC pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful
CC in tissue typing. This sequence represents a novel human secreted and
CC transmembrane PRO polypeptide associated primer
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1256 GCAGCAACAGCTGGAGCA 1273
Db 18 GCAGCAACAGCTGGATCA 1
RESULT 80
ID ACA71640 standard; DNA; 20 BP.
AC ACA71640;
XX
XX 11-AUG-2003 (first entry)
XX
XX Human PRO polypeptide associated oligonucleotide SEQ ID NO 21.
DE
XX Human; ds; thrombolytic agent; interferon; interleukin; cytokine;
KW erythropoietin; colony stimulating factor; cancer; colorectal carcinoma;
KW apoptosis related condition; AIDS; amyotrophic lateral sclerosis;
KW inflammatory disease; asthma; atherosclerosis; neurodegenerative disease;
KW gastrointestinal disorder; Alzheimer's disease; Parkinson's disease;
KW hypertension; myocardial ischaemia; kidney disease; carcinogenesis;
KW glomerulonephritis; lung disease; pulmonary hypertension; preeclampsia;
KW bronchial asthma; gastric ulcer; renal failure; cardiovascular disease;
KW inflammatory bowel disease; reproductive disorder; premature labour.
OS Homo sapiens.
XX
XX US2002177553-A1.
XX
XX 28-NOV-2002.
XX
XX 15-OCT-2001; 2001US-00978192.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040320.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 26-JUN-1998; 98US-00105413.
XX 07-OCT-1998; 98US-00168978.

PR	1-MAR-1998	98US-00775322
PR	11-MAR-1998	98US-00776419
PR	11-MAR-1998	98US-0077649P
PR	12-MAR-1998	98US-0077791P
PR	13-MAR-1998	98US-0078004P
PR	17-MAR-1998	98US-00004820
PR	17-MAR-1998	98US-00788860
PR	20-MAR-1998	98US-0078910P
PR	20-MAR-1998	98US-0078936P
PR	20-MAR-1998	98US-0078939P
PR	25-MAR-1998	98US-0079254P
PR	26-MAR-1998	98US-0079656P
PR	27-MAR-1998	98US-0079663P
PR	27-MAR-1998	98US-0079669P
PR	27-MAR-1998	98US-0079788P
PR	27-MAR-1998	98US-0079786P
PR	30-MAR-1998	98US-00799230P
PR	30-MAR-1998	98US-00799320P
PR	26-JUN-1998	98US-00105413
PR	07-OCT-1998	98US-00166978P
PR	07-OCT-1998	98US-0021144.1
PR	02-NOV-1998	98US-00184236
PR	06-NOV-1998	98US-00184236P
PR	20-NOV-1998	98US-00524855
PR	07-DEC-1998	98US-00202054
PR	22-DEC-1998	98US-00216517P
PR	05-JAN-1999	99US-005000106P
PR	05-MAR-1999	99US-0025456P
PR	08-MAR-1999	99US-00256088
PR	10-MAR-1999	99US-00265686
PR	10-MAR-1999	99US-00505190
PR	12-APR-1999	99US-00284829P
PR	14-MAY-1999	99US-0031832.2
PR	02-JUN-1999	99US-005012523
PR	25-AUG-1999	99US-00380137
PR	25-AUG-1999	99US-00380138
PR	25-AUG-1999	99US-00380142P
PR	30-NOV-1999	99US-00283313
PR	02-DEC-1999	99US-005028551
PR	02-DEC-1999	99US-00502855
PR	16-DEC-1999	99US-00503025
PR	30-DEC-1999	99US-005031993
PR	05-JAN-2000	99US-00501274
PR	06-JAN-2000	2000US-005000219
PR	06-JAN-2000	2000US-005000277
PR	11-FEB-2000	2000US-00500365
PR	18-FEB-2000	2000US-0050434.1
PR	24-FEB-2000	2000US-00505004
PR	02-MAR-2000	2000US-00505841
PR	10-MAR-2000	2000US-00506319
PR	21-MAR-2000	2000US-00507532
PR	30-MAR-2000	2000US-00508439
PR	17-MAY-2000	2000US-00501305
PR	22-MAY-2000	2000US-005014042
PR	30-MAY-2000	2000US-00501941.1
PR	02-JUN-2000	2000US-005051264
PR	28-JUN-2000	2000US-005020710
PR	24-AUG-2000	2000US-005023328
PR	08-NOV-2000	2000US-00709238
PR	27-NOV-2000	2000US-00723749
PR	01-DEC-2000	2000US-00503678
PR	20-DEC-2000	2000US-00747259
PR	20-DEC-2000	2000US-005034956
PR	28-FEB-2001	2001US-00506520
PR	22-MAR-2001	2001US-00816744
PR	22-MAR-2001	2001US-00816920
PR	10-MAY-2001	2001US-00845952
PR	10-MAY-2001	2001US-00845208
PR	15-MAY-2001	2001US-00854280
PR	25-MAY-2001	2001US-005017092.2

```

PR 01-JUN-2001; 2001WO-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 01-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH ) GENENTECH INC.
XX
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton D;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi UC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoi NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams FW, Wood WI;
XX Stewart TA, Tumas D, Williams FW, Wood WI;
XX WPI; 2003-288163/28.
XX
XX Novel secreted and transmembrane polypeptides and polynucleotides
XX encoding them useful for treating cancer, kidney diseases, bone,
XX cartilage disorders and immune deficiencies.
XX
XX Example 5; Page 126; 459pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
XX polypeptides, and the polynucleotide sequences encoding them. The PRO
XX polypeptides are secreted and transmembrane proteins. The PRO
XX polypeptides are useful for detecting other PRO polypeptides, for linking
XX bioactive molecules to cells expressing PRO polypeptides, and for for
XX biological activities of cells expressing PRO polypeptides, and for for
XX identifying agonists or antagonists. The bioactive molecule maybe a
XX toxin, radiolabel or antibody, and causes apoptosis or death of the cell.
XX The PRO polypeptides are useful for treating immune disorders, diabetes
XX or hyper or hypo-insulinaemia, cardiac insufficiency, nervous system
XX disorders, kidney disorders, bone and cartilage disorders or arthritis,
XX tumours, and wound healing. The polynucleotide sequences encoding PRO
XX polypeptides are useful as hybridisation probes, in chromosome and gene
XX mapping, in the generation of antisense RNA and DNA, in the preparation
XX of PRO polypeptides, for generating transgenic animals or knockout
XX animals, for the genetic analysis of individuals with genetic disorders,
XX and in gene therapy. The present sequence represents a PCR primer used in
XX the examples of the present invention. Note: The sequence data for this
XX patent was obtained in electronic format directly from the USPTO web site
XX at seqdata.uspto.gov/psipdbIDntry.html
XX
XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 5.9%; Score 14.8; DB 1; Length 20;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0
XX
XX 1256 GCAGCAACAGCTGGAGCA 1273
XX ||||| ||||| ||||| |||||
XX 18 GCAGCACCAAGCTGGATGA 1
XX
XX RESULT 82
XX ACA66021/c
XX ID ACA66021 standard; DNA; 20 BP.
XX
XX ACA66021;
XX
XX 24-JUN-2003 (first entry)
XX
XX Human secreted/transmembrane protein PRO300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; primer;
XX malignancy; cancer; ovarian cancer; colorectal cancer; sarcoma;
XX leukaemia; lymphoma; inflammatory disease; necrosis; atherosclerosis;
XX infertility; premature aging; psoriasis; inflammatory disease;
XX renal disease; arthritis; immune-mediated alopecia; stroke; encephalitis;

```


KM hepatitis; multiple sclerosis; gene therapy.
 XX
 OS Homo sapiens.
 XX US2003004102-A1.
 PD 02-JAN-2003.
 XX
 PE 15-OCT-2001; 2001US-00978189.
 XX
 PR 17-OCT-1997; 97US-0062250P.
 PR 03-NOV-1997; 97US-0064249P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 21-NOV-1997; 97US-0066364P.
 PR 10-MAR-1998; 98US-0077450P.
 PR 11-MAR-1998; 98US-0077632P.
 PR 11-MAR-1998; 98US-0077641P.
 PR 11-MAR-1998; 98US-0077649P.
 PR 12-MAR-1998; 98US-0077791P.
 PR 13-MAR-1998; 98US-0078004P.
 PR 17-MAR-1998; 98US-00040220.
 PR 20-MAR-1998; 98US-0078886P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 20-MAR-1998; 98US-0078936P.
 PR 20-MAR-1998; 98US-0078939P.
 PR 25-MAR-1998; 98US-0079294P.
 PR 26-MAR-1998; 98US-0079656P.
 PR 27-MAR-1998; 98US-0079663P.
 PR 27-MAR-1998; 98US-0079664P.
 PR 27-MAR-1998; 98US-0079689P.
 PR 27-MAR-1998; 98US-0079728P.
 PR 27-MAR-1998; 98US-0079786P.
 PR 30-MAR-1998; 98US-0079920P.
 PR 30-MAR-1998; 98US-0079923P.
 PR 26-JUN-1998; 98US-00105413.
 PR 07-OCT-1998; 98US-00168978.
 PR 07-OCT-1998; 98US-00184216.
 PR 02-NOV-1998; 98US-00184216.
 PR 06-NOV-1998; 98US-00187358.
 PR 20-NOV-1998; 98US-00204855.
 PR 07-DEC-1998; 98US-00202054.
 PR 22-DEC-1998; 98US-00218517.
 PR 05-JAN-1999; 99US-00254465.
 PR 05-MAR-1999; 99US-00254465.
 PR 08-MAR-1999; 99US-00254465.
 PR 10-MAR-1999; 99US-00254465.
 PR 12-MAR-1999; 99US-00254465.
 PR 12-APR-1999; 99US-00284291.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99US-00311832.
 PR 02-JUN-1999; 99US-0031252.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-NOV-1999; 99US-00380142.
 PR 02-DEC-1999; 99US-00380142.
 PR 02-DEC-1999; 99US-00380142.
 PR 02-DEC-1999; 99US-00380142.
 PR 16-DEC-1999; 99US-00380142.
 PR 30-DEC-1999; 99US-00380142.
 PR 30-DEC-1999; 99US-00380142.
 PR 05-JAN-2000; 2000US-00380142.
 PR 06-JAN-2000; 2000US-00380142.
 PR 06-JAN-2000; 2000US-00380142.
 PR 11-FEB-2000; 2000US-00380142.
 PR 18-FEB-2000; 2000US-00380142.
 PR 24-FEB-2000; 2000US-00380142.
 PR 01-MAR-2000; 2000US-00380142.
 PR 02-MAR-2000; 2000US-00380142.
 PR 10-MAR-2000; 2000US-00380142.
 PR 21-MAR-2000; 2000US-00380142.
 PR 30-MAR-2000; 2000US-00380142.
 PR 17-MAY-2000; 2000US-00380142.

PR 22-MAY-2000; 2000US-00380142.
 PR 30-MAY-2000; 2000US-00380142.
 PR 02-JUN-2000; 2000US-00380142.
 PR 28-JUL-2000; 2000US-00380142.
 PR 24-AUG-2000; 2000US-00380142.
 PR 08-NOV-2000; 2000US-00380142.
 PR 10-NOV-2000; 2000US-00380142.
 PR 27-NOV-2000; 2000US-00380142.
 PR 01-DEC-2000; 2000US-00380142.
 PR 20-DEC-2000; 2000US-00380142.
 PR 20-DEC-2000; 2000US-00380142.
 PR 28-FEB-2001; 2001US-00380142.
 PR 22-MAR-2001; 2001US-00380142.
 PR 22-MAR-2001; 2001US-00380142.
 PR 10-MAY-2001; 2001US-00380142.
 PR 10-MAY-2001; 2001US-00380142.
 PR 25-MAY-2001; 2001US-00380142.
 PR 01-JUN-2001; 2001US-00380142.
 PR 01-JUN-2001; 2001US-00380142.
 PR 05-JUN-2001; 2001US-00380142.
 PR 14-JUN-2001; 2001US-00380142.
 PR 19-JUN-2001; 2001US-00380142.
 PR 20-JUN-2001; 2001US-00380142.
 PR 29-JUN-2001; 2001US-00380142.
 PR 09-JUL-2001; 2001US-00380142.
 PR 30-JUL-2001; 2001US-00380142.
 PR
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrarini N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gueney AL, Hillan KJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 DR WPI, 2003-341189/32.
 XX
 PT New genes and secreted and transmembrane polypeptides (e.g. PRO337 or
 PT PRO1359), useful for treating or diagnosing e.g. cancers,
 PT atherosclerosis, infertility, stroke, encephalitis, hepatitis or multiple
 PT sclerosis in mammals.
 XX
 PS Example 5; Page 122; 460pp; English.
 XX
 CC The invention relates to a new isolated nucleic acid molecule comprising a
 CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
 CC 94 PRO polypeptides whose sequences are fully defined in the
 CC specification; or (b) any of 94 nucleotide sequences fully defined in the
 CC specification; or the full length coding sequence of any these 94
 CC nucleotide sequences. Also included are an isolated PRO polypeptide
 CC scoring at least 80% positives when compared to any of the PRO
 CC polypeptide sequences cited above (or an isolated PRO polypeptide having
 CC at least 80% amino acid sequence identity to: (a) an amino acid sequence
 CC encoded by the nucleotide deposited with ATCC numbers listed in the
 CC specification; (b) the PRO polypeptide, lacking its associated signal
 CC peptide; or (c) an extracellular domain of the PRO polypeptide, with or
 CC lacking its associated signal peptide), a vector comprising the nucleic
 CC acid molecule, a host cell comprising the vector (and producing a PRO
 CC polypeptide), a chimeric molecule comprising the PRO polypeptide fused
 CC to a heterologous amino acid sequence and an anti-PRO antibody. The PRO
 CC polypeptides or polynucleotides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. These are particularly useful for
 CC detecting or treating e.g. malignancies or cancers (e.g. ovarian cancer,
 CC colorectal cancer, sarcoma, leukaemia or lymphoma), inflammatory disease,
 CC necrosis, atherosclerosis, infertility, premature aging, psoriasis,
 CC inflammatory disease, renal disease, arthritis, immune-mediated alopecia,
 CC stroke, encephalitis, hepatitis, or multiple sclerosis in mammals. The
 CC PRO polypeptides are useful in drug screening, particularly as targets
 CC for therapeutic intervention in these diseases, and in the diagnostic
 CC determination of the presence of these diseases. The PRO polypeptides are
 CC also useful as molecular weight markers, or for chromosome
 CC identification. The PRO genes are useful as hybridisation probes, or for

CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence is a PCR primer used in the isolation of a
CC cDNA encoding a pro polypeptide

XX
XQ Sequence 20 BP, 2 A, 7 C, 5 G, 6 T, 0 U, 0 Other;

Query Match	5.9%	Score 14.8	DB 1	Length 20
Best Local Similarity	88.9%	Pred. No. 1.6e+02		
Matches 16	Conservative 0	Mismatches 2	Indels 0	Gaps 0

```

QY      1256 GCAGCACAGCTGGAAGA 1273
          |||||
Db      18 GCAGCACAGCTGATGA 1

```

RESULT 83
AAD57607
ID AAD57607 standard; DNA, 20 BP.
XX
XX AAD57607;
AC
XX
DT 20-NOV-2003 (first entry)
XX
XX Hunan PLSCR3 antisense oligonucleotide, ISIS #196419.
DE

Human, phospholipid scramblase 3, gene therapy, HuPLSCR3, MuPLSCR3
 PLSCR3, neurodegenerative disease, hyperproliferative disorder;
 autoimmune disorder, neuroprotective, immunosuppressive; antisense
 phosphorothioate backbone, 86.

OS Homo sapiens.
OS Synthetic.

	Key	Location/Qualifiers
FH	modified base	1. .20
FT		

```

14 /csg= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"

```

```

1      /cag= 0
FT      /mod_base= OTHER
FT      /note= "2.-methoxyethyl nucleotides"
FT
FT      modified_base
FT      16..20
FT      /*tag= C
FT      /mod_base= OTHER
FT      /note= "2.-methoxyethyl nucleotides"

```

PN WO2003048324-A2.

PD 12-JUN-2003

PF 04-DEC-2002; 2002WO-US038521.

PR 04-DEC-2001; 2001US-00006972.

PA (ISIS-) ISIS PHARM INC.

PI Dobie KW;

DR WPI; 2003-569053/53.

PT New compound, useful.

PT to a nucleic acid encoding human phospholipid scramblase 3.

PS Example 15; Page 79; 107pp; English.

CC The present invention is directed to compounds, particularly antisense
CC oligonucleotides, which are targeted to a nucleic acid encoding human
CC phospholipid scramblase 3 (also known as PLSCR3, HuPLSCR3 and MUPPLSCR3
CC and which modulates the expression of phospholipid scramblase 3. The

CC compounds of the invention are useful for preparing compositions for
 CC treating neurodegenerative diseases e.g. hyperproliferative or autoimmune
 CC disorders. The invention is also used in gene therapy. The present
 CC sequence is an antisense oligonucleotide targeted to human PLSCR3 DNA
 XX Sequence 20 BP, 4 A, 6 C, 5 G, 5 T, 0 U, 0 Other;

Query Match	5.9%	Score	14.8	DB 1	Length	20			
Best Local Similarity	88.9%	Pred. NO.	1.6e+02						
Matches	16	Conservative	0	Mismatches	2	Indels	0	Gaps	0

```

QY      1290 CCTCAGGTCGCATGGTC 1307
          ||||| } ||||| |||||
Db      1 CCTCAAGTGCCATGGTC 18

```

RESULT 84	ADA24560/c
ID	ADA24560 standard; DNA; 20 BP.
XX	
AC	ADA24560;
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Secreted and transmembrane PRO

KW Human, secreted and transmembrane protein; PRO, tissue typing;
KW chromosome identification; vaccine; cancer; retinal disorder;
KW sports-related joint disorder; osteoarthritis; rheumatoid arthritis;
KW wound healing; obesity; diabetes; hearing loss;

KW	haemoglobin a
XX	

XX US2003050241-A1.
PN

PD 13-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00978564.

PR 03-NOV-1997; 97US-0064249P
PR 13-NOV-1997; 97US-0065311P
PR 21-NOV-1997; 97US-0066364P
PR 10-MAR-1998; 98US-0077450P
PR 11-MAR-1998; 98US-0077632P
PR 11-MAR-1998; 98US-0077641P

PR 12-MAR-1998;

PR 20-MAR-1998;

PR 20-MAR-1998;

PR 25-MAR-1998;

PR 27-MAR-1998;

PR 27-MAR-1998;

PR 27-MAR-1998;

PR 30-MAR-1998;

PR 31-MAR-1998;

PR 31-MAR-1998;

PR 01-APR-1998; 98US-0080328P
PR 01-APR-1998; 98US-0080333P
PR 01-APR-1998; 98US-0080334P
PR 08-APR-1998; 98US-0081049P

PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0083466P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084411P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-01093048.
PR 20-NOV-1998; 98WO-US020485.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 03-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005018.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.

PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142688P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028555.
PR 02-DEC-1999; 99WO-US028555.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003365.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAR-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;
PI Kijavlin IO, Kuo SS, Napier MA, Pan J, Faont NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX WPI, 2003-521814/49.
XX
XX New isolated PRO polypeptides for example extracellular, secreted and
XX membrane bound proteins, useful for modulating the biological activities
XX of cells and for treating, for example diabetes, cancer, rheumatoid
XX arthritis, and hearing loss.
XX
XX Example 5; Page 133; 461pp; English.
XX
XX The invention describes an isolated secreted and transmembrane (PRO)
XX polypeptide (I). PRO337 polypeptide is useful for detecting PRO4993
XX polypeptide in a sample, and vice versa. PRO725, PRO700 and PRO739 are
XX useful for detecting PRO1559 polypeptide in a sample, and PRO1559 is
XX useful for detecting PRO725, PRO700 and PRO739 in a sample. PRO4993 is
XX useful for linking a bioactive molecule to a cell expressing a PRO337
XX polypeptide, and PRO337 is useful for linking a bioactive molecule to a
XX cell expressing a PRO4993 polypeptide. PRO1559 is useful for linking a
XX bioactive molecule to a cell expressing a PRO735, PRO700 and PRO739
XX polypeptide, and PRO735, PRO700 and PRO739 polypeptides are useful for

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCACGCTGGAGCA 1273
Db 18 GCAGCACGCTGGATGA 1

RESULT 85
ACD29622/c
ID ACD29622 standard; DNA; 20 BP.
XX
AC ACD29622;
XX
DT 08-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein related primer #10.
XX
KW Human; secreted and transmembrane protein; PRO; cell death; neuropathy;
KW peripheral neuropathy; diabetic peripheral neuropathy;
KW AIDS-associated neuropathy; Charcot-Marie-Tooth disease;
KW Refsum's disease; Abetalipoproteinemia; Tangier disease;
KW Krabbe's disease; Metachromatic leukodystrophy; Fabry's disease;
KW Dejerine-Sottas syndrome; chromosome mapping; gene mapping; gene therapy;
KW PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003050240-A1.
XX
PD 13-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00978403.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 13-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.

PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-008269P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086032P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086466P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0080863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0133957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.

PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-014037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014041.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Peoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tunas D, Williams FM, Wood WL;
XX
DR WPI; 2003-503575/47.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Example 5; Page 126; 459p; English.
XX
CC The invention describes an isolated, secreted and transmembrane
CC polypeptide, termed PRO polypeptide (I). (I) is useful for detecting
CC PRO4937, PRO337, PRO159, PRO725, PRO700 or PRO739 polypeptide, and for
CC linking a bioactive molecule to a cell expressing the above polypeptides.
CC The bioactive molecule is a toxin, radiolabel or an antibody and causes
CC cell death. (I) is useful as therapeutic agent, in medical and industrial
CC applications e.g. for treating neuropathy, especially peripheral
CC neuropathy, diabetic peripheral neuropathy, AIDS-associated neuropathy,
CC Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinemia,
CC Tangier disease, Krabbe's disease, Metachromatic leukodystrophy, Fabry's

RESULT 86
ID ADA12221/c
ADA12221 standard; DNA; 20 BP.
XX
AC ADA12221;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane polypeptide PRO300 primer #2.
XX
KW primer; ss; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS; cancer;
KW diabetic complication; tissue typing; human; PCR.
XX
OS Homo sapiens.
XX
PN US2003055216-A1.
XX
PD 20-MAR-2003.
XX
PF 17-OCT-2001; 2001US-00978824.
XX
XX 21-MAY-1996; 96US-0018049P.
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 12-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040220.
XX 20-MAR-1998; 98US-0007886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
XX 15-APR-1998; 98US-0081838P.
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082796P.
 PR 27-APR-1998; 98US-0083336P.
 PR 28-APR-1998; 98US-0083322P.
 PR 29-APR-1998; 98US-0083392P.
 PR 29-APR-1998; 98US-0083496P.
 PR 29-APR-1998; 98US-0083499P.
 PR 29-APR-1998; 98US-0083500P.
 PR 29-APR-1998; 98US-0083554P.
 PR 29-APR-1998; 98US-0083555P.
 PR 29-APR-1998; 98US-0083555P.
 PR 30-APR-1998; 98US-0083742P.
 PR 05-MAY-1998; 98US-0084366P.
 PR 06-MAY-1998; 98US-0084414P.
 PR 06-MAY-1998; 98US-0084441P.
 PR 07-MAY-1998; 98US-0084598P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 07-MAY-1998; 98US-0084627P.
 PR 07-MAY-1998; 98US-0084637P.
 PR 07-MAY-1998; 98US-0084639P.
 PR 07-MAY-1998; 98US-0084640P.
 PR 07-MAY-1998; 98US-0084643P.
 PR 13-MAY-1998; 98US-0085323P.
 PR 13-MAY-1998; 98US-0085338P.
 PR 13-MAY-1998; 98US-0085339P.
 PR 15-MAY-1998; 98US-0085573P.
 PR 15-MAY-1998; 98US-0085579P.
 PR 15-MAY-1998; 98US-0085580P.
 PR 15-MAY-1998; 98US-0085582P.
 PR 15-MAY-1998; 98US-0085689P.
 PR 15-MAY-1998; 98US-0085697P.
 PR 15-MAY-1998; 98US-0085700P.
 PR 18-MAY-1998; 98US-0085704P.
 PR 22-MAY-1998; 98US-0086023P.
 PR 22-MAY-1998; 98US-0086392P.
 PR 22-MAY-1998; 98US-0086414P.
 PR 22-MAY-1998; 98US-0086430P.
 PR 22-MAY-1998; 98US-0086486P.
 PR 28-MAY-1998; 98US-0087098P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 28-MAY-1998; 98US-0087208P.
 PR 26-JUN-1998; 98US-00105413.
 PR 26-JUN-1998; 98US-0090863P.
 PR 26-JUN-1998; 98US-0091010P.
 PR 01-JUL-1998; 98US-0091359P.
 PR 30-JUL-1998; 98US-0096651P.
 PR 11-SEP-1998; 98US-0100038P.
 PR 07-OCT-1998; 98US-00168978.
 PR 07-OCT-1998; 98WO-US021141.
 PR 02-NOV-1998; 98US-00184216.
 PR 06-NOV-1998; 98US-00187368.
 PR 20-NOV-1998; 98US-0109304P.
 PR 20-NOV-1998; 98WO-US024855.
 PR 07-DEC-1998; 98US-00202054.
 PR 22-DEC-1998; 98US-00218517.
 PR 23-DEC-1998; 98US-0113296P.
 PR 23-DEC-1998; 98US-0113621P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 05-MAR-1999; 99US-00254465.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99US-00265686.
 PR 12-MAR-1999; 99WO-US005190.
 PR 12-MAR-1999; 99US-00267213.
 PR 29-MAR-1999; 99US-0123957P.
 PR 12-APR-1999; 99US-0126773P.
 PR 21-APR-1999; 99US-00284291.
 PR 26-APR-1999; 99US-0130232P.
 PR 26-APR-1999; 99US-0131022P.
 PR 14-MAY-1999; 99US-0031445P.
 PR 14-MAY-1999; 99US-0031832P.
 PR 14-MAY-1999; 99US-0134287P.
 PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.
 PR 16-JUN-1999; 99US-0139557P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 07-JUL-1999; 99US-0142680P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380139.
 PR 25-AUG-1999; 99US-00380142.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028511.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 30-DEC-1999; 99WO-US031243.
 PR 05-JAN-2000; 99WO-US031274.
 PR 06-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000US-00709238.
 PR 27-NOV-2000; 2000US-00723749.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 22-MAR-2001; 2001US-00816920.
 PR 22-MAR-2001; 2001WO-US009552.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 21-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882536.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 30-JUL-2001; 2001US-00918585.
 XX (GERTH) GENENTECH INC.
 PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
 PI Pi Ferrera N, Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME;
 Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 86.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 1256 GCAGCACAGCTGGAGA 1273
 Db 18 GCAGCACAGCTGGATGA 1
 RESULT 87
 ACD29037/c
 ID ACD29037 standard; DNA; 20 BP.
 XX
 AC ACD29037;

XX 27-AUG-2003 (first entry)
XX Novel human secreted and transmembrane protein related primer #10.
DE Human; secreted and transmembrane protein; PRO; viral infection;
XX tumour growth; retinal disorder; injury; sight loss;
XX retinitis pigmentosa; age-related macular degeneration;
XX sport-related joint problem; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; wound healing; obesity; diabetes; nephropathy;
XX kidney disorder; mesangial cell function; Berger disease;
XX celiac disease; dermatitis; Crohn disease; neuropathy;
XX cardiac insufficiency disorder; peripheral neuropathy;
XX diabetic peripheral neuropathy; autonomic neuropathy;
XX reduced motility of the gastrointestinal tract;
XX atony of the urinary bladder; post polio syndrome; Krabbe's disease;
XX Charcot-Marie-Tooth disease; Fabry's disease; Tangier disease;
XX Refsum's disease; PCR; primer; ss.
XX Homo sapiens.
XX US2003049633-A1.
XX 13-MAR-2003.
XX 16-OCT-2001; 2001US-00978585.
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-007450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-00040220.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081953P.
XX 15-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082700P.

PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0083296P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083459P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086032P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.

PR	14-MAY-1999;	99US-00311832.
PR	14-MAY-1999;	99US-0134287P.
PR	14-MAY-1999;	99WO-US010733.
PR	02-JUN-1999;	99WO-US012252.
PR	16-JUN-1999;	99US-0139557P.
PR	23-JUN-1999;	99US-0141037P.
PR	07-JUL-1999;	99US-0142680P.
PR	26-JUL-1999;	99US-0145698P.
PR	28-JUL-1999;	99US-0146222P.
PR	25-AUG-1999;	99US-00380137.
PR	25-AUG-1999;	99US-00380138.
PR	25-AUG-1999;	99US-00380142.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000US-00709238.
PR	27-NOV-2000;	2000US-00723749.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	22-MAR-2001;	2001US-00816920.
PR	22-MAR-2001;	2001WO-US009552.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.

```

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0.

Oy      1256 GCAGCAACAGCTGAGAGA 1273
      ||||| ||||| |||
Db      18 GCAGCACCAGCTGGATGA 1

RESULT 88
ADB73527/c
ID      ADB73527 standard; DNA; 20 BP.
XX      ADB73527;
XX      AC
XX      AC
XX      04-DEC-2003 (first entry)
XX      DE
XX      Human PRO DNA PCR primer #10.
XX      Human; PRO polypeptide; secreted protein; transmembrane protein;
KW      cell death; neuropathy; neuropathy related disease;

```

KW	Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW	Chromosome mapping; gene mapping; genetic disorder; septic shock;
KW	antibacterial; immunosuppressive; neuroprotective; PCR; primer; ss
XX	
OS	Homo sapiens.
XX	
PN	US2003045462-A1.
XX	
PD	06-MAR-2003.
XX	
PF	16-OCT-2001; 2001US-00978608.
XX	
PR	17-OCT-1997; 97US-0062250P.
PR	03-NOV-1997; 97US-0064249P.
PR	13-NOV-1997; 97US-0065311P.
PR	21-NOV-1997; 97US-0066364P.
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077741P.
PR	11-MAR-1998; 98US-0077649P.
PR	12-MAR-1998; 98US-0077791P.
PR	13-MAR-1998; 98US-0078004P.
PR	17-MAR-1998; 98US-00040220.
PR	20-MAR-1998; 98US-0078886P.
PR	20-MAR-1998; 98US-0078910P.
PR	20-MAR-1998; 98US-0078936P.
PR	20-MAR-1998; 98US-0078939P.
PR	25-MAR-1998; 98US-0079294P.
PR	26-MAR-1998; 98US-0079656P.
PR	27-MAR-1998; 98US-0079663P.
PR	27-MAR-1998; 98US-0079664P.
PR	27-MAR-1998; 98US-0079689P.
PR	27-MAR-1998; 98US-0079728P.
PR	27-MAR-1998; 98US-0079786P.
PR	30-MAR-1998; 98US-0079920P.
PR	30-MAR-1998; 98US-0079923P.
PR	31-MAR-1998; 98US-0080105P.
PR	31-MAR-1998; 98US-0080107P.
PR	31-MAR-1998; 98US-0080165P.
PR	31-MAR-1998; 98US-0080194P.
PR	01-APR-1998; 98US-0080327P.
PR	01-APR-1998; 98US-0080328P.
PR	01-APR-1998; 98US-0080333P.
PR	01-APR-1998; 98US-0080334P.
PR	08-APR-1998; 98US-0081049P.
PR	08-APR-1998; 98US-0081070P.
PR	08-APR-1998; 98US-0081071P.
PR	09-APR-1998; 98US-0081195P.
PR	09-APR-1998; 98US-0081203P.
PR	09-APR-1998; 98US-0081229P.
PR	15-APR-1998; 98US-0081817P.
PR	15-APR-1998; 98US-0081819P.
PR	15-APR-1998; 98US-0081838P.
PR	15-APR-1998; 98US-0081952P.
PR	15-APR-1998; 98US-0081955P.
PR	21-APR-1998; 98US-008268P.
PR	21-APR-1998; 98US-008269P.
PR	22-APR-1998; 98US-0082700P.
PR	22-APR-1998; 98US-0082704P.
PR	22-APR-1998; 98US-0082797P.
PR	22-APR-1998; 98US-0082804P.
PR	23-APR-1998; 98US-0082796P.
PR	27-APR-1998; 98US-0083336P.
PR	28-APR-1998; 98US-0083322P.
PR	29-APR-1998; 98US-0083392P.
PR	29-APR-1998; 98US-0083495P.
PR	29-APR-1998; 98US-0083496P.
PR	29-APR-1998; 98US-0083499P.
PR	29-APR-1998; 98US-0083500P.
PR	29-APR-1998; 98US-0083545P.
PR	29-APR-1998; 98US-0083554P.
PR	29-APR-1998; 98US-008358P.
PR	29-APR-1998; 98US-0083559P.

PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 30-JUL-1998; 98US-0091359P.
PR 11-SEP-1998; 98US-0094651P.
PR 07-OCT-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0016897P.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-00254406.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 98US-00254465.
PR 10-MAR-1999; 98US-00265686.
PR 10-MAR-1999; 98US-00265686.
PR 12-MAR-1999; 98US-00267213.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 12-APR-1999; 98US-00284291.
PR 21-APR-1999; 98US-0130233P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-00314832.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98US-00310733.
PR 02-JUN-1999; 98US-00312525.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 25-AUG-1999; 98US-00380137.
PR 25-AUG-1999; 98US-00380138.
PR 25-AUG-1999; 98US-00380142.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98US-0028313.
PR 02-DEC-1999; 98US-0028551.

PR 02-DEC-1999; 98US-0028565.
PR 16-DEC-1999; 98US-0030095.
PR 30-DEC-1999; 98US-0031243.
PR 30-DEC-1999; 98US-0031274.
PR 05-JAN-2000; 98US-0030219.
PR 06-JAN-2000; 98US-0030277.
PR 06-JAN-2000; 98US-0030376.
PR 11-FEB-2000; 98US-0030565.
PR 18-FEB-2000; 98US-00304341.
PR 24-FEB-2000; 98US-00305004.
PR 02-MAR-2000; 98US-00305841.
PR 10-MAR-2000; 98US-00306319.
PR 21-MAR-2000; 98US-00307532.
PR 30-MAR-2000; 98US-00308439.
PR 17-MAY-2000; 98US-00313705.
PR 22-MAY-2000; 98US-00314042.
PR 30-MAY-2000; 98US-00314941.
PR 02-JUN-2000; 98US-00315264.
PR 28-JUL-2000; 98US-00320710.
PR 24-AUG-2000; 98US-00323388.
PR 08-NOV-2000; 98US-00709238.
PR 27-NOV-2000; 98US-00723749.
PR 01-DEC-2000; 98US-00732678.
PR 20-DEC-2000; 98US-00747259.
PR 20-DEC-2000; 98US-0074956.
PR 28-FEB-2001; 98US-00806520.
PR 22-MAR-2001; 98US-00816744.
PR 22-MAR-2001; 98US-00816920.
PR 22-MAR-2001; 98US-00819552.
PR 10-MAY-2001; 98US-00854208.
PR 10-MAY-2001; 98US-00854280.
PR 25-MAY-2001; 98US-008547092.
PR 01-JUN-2001; 98US-00872035.
PR 01-JUN-2001; 98US-00872800.
PR 05-JUN-2001; 98US-00874503.
PR 14-JUN-2001; 98US-00882636.
PR 19-JUN-2001; 98US-00886342.
PR 20-JUN-2001; 98US-00919692.
PR 29-JUN-2001; 98US-00921066.
PR 09-JUL-2001; 98US-00921735.
PR 30-JUL-2001; 98US-00918585.
PR XX
PR PA (GETH) GENENTECH INC.
PR XX
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Ct 1256 GCAGCAGCAGCTGGAGG 1273
Db 18 GCAGCAGCAGCTGGATGA 1
RESULT 89
ID ADB76243/C
XX ADB76243 standard; DNA, 20 BP.
AC ADB76243;
DT 04-DEC-2003 (first entry)
XX
DB Human PRO DNA PCR primer #10.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW Chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; PCR; primer; ss.
OS Homo sapiens.
XX
XX US2003083248-A1.
PN

XX	01-MAY-2003.		PR	07-MAY-1998;	98US-0084640P.
PD			PR	07-MAY-1998;	98US-0084643P.
XX			PR	13-MAY-1998;	98US-0085323P.
PR	16-OCT-2001; 2001US-00978757.		PR	13-MAY-1998;	98US-0085338P.
XX			PR	13-MAY-1998;	98US-0085339P.
PR	17-OCT-1997;	97US-0062250P.	PR	15-MAY-1998;	98US-0085573P.
PR	03-NOV-1997;	97US-0064249P.	PR	15-MAY-1998;	98US-0085579P.
PR	13-NOV-1997;	97US-0065311P.	PR	15-MAY-1998;	98US-0085580P.
PR	21-NOV-1997;	97US-0066364P.	PR	15-MAY-1998;	98US-0085582P.
PR	10-MAR-1998;	98US-0077450P.	PR	15-MAY-1998;	98US-0085689P.
PR	11-MAR-1998;	98US-0077632P.	PR	15-MAY-1998;	98US-0085697P.
PR	11-MAR-1998;	98US-0077641P.	PR	15-MAY-1998;	98US-0085700P.
PR	11-MAR-1998;	98US-0077649P.	PR	15-MAY-1998;	98US-0085704P.
PR	12-MAR-1998;	98US-0077791P.	PR	18-MAY-1998;	98US-0086023P.
PR	13-MAR-1998;	98US-0078004P.	PR	22-MAY-1998;	98US-0086332P.
PR	20-MAR-1998;	98US-0078886P.	PR	22-MAY-1998;	98US-0086414P.
PR	20-MAR-1998;	98US-0078910P.	PR	22-MAY-1998;	98US-0086430P.
PR	20-MAR-1998;	98US-0078936P.	PR	22-MAY-1998;	98US-0086486P.
PR	20-MAR-1998;	98US-0078939P.	PR	28-MAY-1998;	98US-0087098P.
PR	25-MAR-1998;	98US-0079294P.	PR	28-MAY-1998;	98US-0087106P.
PR	26-MAR-1998;	98US-0079656P.	PR	28-MAY-1998;	98US-0087208P.
PR	27-MAR-1998;	98US-0079663P.	PR	26-JUN-1998;	98US-0090863P.
PR	27-MAR-1998;	98US-0079664P.	PR	26-JUN-1998;	98US-0091010P.
PR	27-MAR-1998;	98US-0079689P.	PR	01-JUL-1998;	98US-0091359P.
PR	27-MAR-1998;	98US-0079728P.	PR	30-JUL-1998;	98US-0094651P.
PR	30-MAR-1998;	98US-0079920P.	PR	11-SEP-1998;	98US-0100038P.
PR	30-MAR-1998;	98US-0079923P.	PR	07-OCT-1998;	98WO-US021141.
PR	31-MAR-1998;	98US-0080105P.	PR	20-NOV-1998;	98WO-US024855.
PR	31-MAR-1998;	98US-0080165P.	PR	22-DEC-1998;	98US-0113266P.
PR	31-MAR-1998;	98US-0080174P.	PR	23-DEC-1998;	98US-0113621P.
PR	01-APR-1998;	98US-0080327P.	PR	05-JAN-1999;	99WO-US000106.
PR	01-APR-1998;	98US-0080328P.	PR	08-MAR-1999;	99WO-US005028.
PR	01-APR-1998;	98US-0080333P.	PR	10-MAR-1999;	99WO-US005190.
PR	01-APR-1998;	98US-0080334P.	PR	12-MAR-1999;	99US-0123957P.
PR	08-APR-1998;	98US-0081049P.	PR	29-MAR-1999;	99US-0126773P.
PR	08-APR-1998;	98US-0081070P.	PR	21-APR-1999;	99US-0130232P.
PR	08-APR-1998;	98US-0081071P.	PR	26-APR-1999;	99US-0131022P.
PR	09-APR-1998;	98US-0081195P.	PR	28-APR-1999;	99US-0131445P.
PR	09-APR-1998;	98US-0081203P.	PR	14-MAY-1999;	99US-0134287P.
PR	09-APR-1998;	98US-0081222P.	PR	14-MAY-1999;	99WO-US010733.
PR	15-APR-1998;	98US-0081817P.	PR	02-JUN-1999;	99WO-US012252.
PR	15-APR-1998;	98US-0081819P.	PR	16-JUN-1999;	99US-0139557P.
PR	15-APR-1998;	98US-0081838P.	PR	23-JUN-1999;	99US-0141037P.
PR	15-APR-1998;	98US-0081952P.	PR	07-JUL-1999;	99US-0142680P.
PR	15-APR-1998;	98US-0081955P.	PR	26-JUL-1999;	99US-0145698P.
PR	21-APR-1998;	98US-0082568P.	PR	28-JUL-1999;	99US-0146222P.
PR	21-APR-1998;	98US-0082569P.	PR	29-OCT-1999;	99US-0162506P.
PR	22-APR-1998;	98US-0082700P.	PR	30-NOV-1999;	99WO-US028313.
PR	22-APR-1998;	98US-0082704P.	PR	02-DEC-1999;	99WO-US028551.
PR	22-APR-1998;	98US-0082797P.	PR	02-DEC-1999;	99WO-US028565.
PR	22-APR-1998;	98US-0082804P.	PR	16-DEC-1999;	99WO-US030095.
PR	23-APR-1998;	98US-0082796P.	PR	30-DEC-1999;	99WO-US031243.
PR	27-APR-1998;	98US-0083336P.	PR	30-DEC-1999;	99WO-US031774.
PR	28-APR-1998;	98US-0083322P.	PR	05-JAN-2000;	2000WO-US000219.
PR	29-APR-1998;	98US-0083392P.	PR	06-JAN-2000;	2000WO-US000277.
PR	29-APR-1998;	98US-0083495P.	PR	11-FEB-2000;	2000WO-US000376.
PR	29-APR-1998;	98US-0083496P.	PR	11-FEB-2000;	2000WO-US000365.
PR	29-APR-1998;	98US-0083499P.	PR	18-FEB-2000;	2000WO-US004341.
PR	29-APR-1998;	98US-0083500P.	PR	24-FEB-2000;	2000WO-US005004.
PR	29-APR-1998;	98US-0083545P.	PR	02-MAR-2000;	2000WO-US005841.
PR	29-APR-1998;	98US-0083554P.	PR	10-MAR-2000;	2000WO-US006319.
PR	29-APR-1998;	98US-0083558P.	PR	21-MAR-2000;	2000WO-US007532.
PR	29-APR-1998;	98US-0083559P.	PR	30-MAR-2000;	2000WO-US008439.
PR	30-APR-1998;	98US-0083742P.	PR	17-MAY-2000;	2000WO-US013705.
PR	05-MAY-1998;	98US-0084366P.	PR	22-MAY-2000;	2000WO-US014042.
PR	06-MAY-1998;	98US-0084414P.	PR	30-MAY-2000;	2000WO-US014941.
PR	06-MAY-1998;	98US-0084441P.	PR	02-JUN-2000;	2000WO-US015264.
PR	07-MAY-1998;	98US-0084598P.	PR	28-JUL-2000;	2000WO-US020710.
PR	07-MAY-1998;	98US-0084600P.	PR	24-AUG-2000;	2000WO-US023328.
PR	07-MAY-1998;	98US-0084627P.	PR	01-DEC-2000;	2000WO-US032678.
PR	07-MAY-1998;	98US-0084637P.	PR	20-DEC-2000;	2000WO-US034956.
PR	07-MAY-1998;	98US-0084639P.	PR	28-FEB-2001;	2001WO-US006520.

PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US01692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GENTH) GENEINTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Nessler MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PW, Wood WL;
XX WPI; 2003-755118/71.
XX
PT New PRO polypeptides useful for treating peripheral neuropathy,
PT neuropathies associated with systemic disease such as post-polio syndrome
PT or AIDS-associated syndrome.
XX
PS Example 5; Page 126; 425pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The bioactive molecule maybe a
CC toxin, radiolabel or antibody, and cause cell death. The PRO polypeptides
CC are useful for treating neuropathy and neuropathy related diseases such
CC as Charcot-Marie-Tooth disorder, Refsum's disease, and Krabbe's disease.
CC The polynucleotide sequences encoding PRO polypeptides are useful as
CC hybridisation probes, in chromosome and gene mapping, in the generation
CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCACGCTGAGAGA 1273
DB 18 GCAGCACGCTGAGAGA 1

RESULT 90
ADCA3669/C
ID ADCA3669 standard; DNA; 20 BP.
XX
AC ADCA3669;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytoskeletal;
KW ophthalmological; antiarthritic; osteopathic; antineumatic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003054986-A1.
XX
PD 20-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00981915.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078933P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080331P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081047P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081203P.
PR 15-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082804P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083544P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0083466P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.

PR 15-MAY-1998; 98US-0085573P.
 PR 15-MAY-1998; 98US-0085579P.
 PR 15-MAY-1998; 98US-0085580P.
 PR 15-MAY-1998; 98US-0085582P.
 PR 15-MAY-1998; 98US-0085688P.
 PR 15-MAY-1998; 98US-0085697P.
 PR 15-MAY-1998; 98US-0085700P.
 PR 15-MAY-1998; 98US-0085704P.
 PR 18-MAY-1998; 98US-0086023P.
 PR 22-MAY-1998; 98US-0086392P.
 PR 22-MAY-1998; 98US-0086414P.
 PR 22-MAY-1998; 98US-0086430P.
 PR 22-MAY-1998; 98US-0086486P.
 PR 28-MAY-1998; 98US-0087098P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 28-MAY-1998; 98US-0087208P.
 PR 26-JUN-1998; 98US-00105413.
 PR 26-JUN-1998; 98US-0090863P.
 PR 26-JUN-1998; 98US-0091010P.
 PR 01-JUL-1998; 98US-0091359P.
 PR 30-JUL-1998; 98US-0094651P.
 PR 11-SEP-1998; 98US-0100038P.
 PR 07-OCT-1998; 98US-00168978.
 PR 07-OCT-1998; 98WO-US021141.
 PR 02-NOV-1998; 98US-00184216.
 PR 06-NOV-1998; 98US-00187368.
 PR 20-NOV-1998; 98US-0109304P.
 PR 20-NOV-1998; 98WO-US024855.
 PR 07-DEC-1998; 98US-00202054.
 PR 22-DEC-1998; 98US-00218517.
 PR 22-DEC-1998; 98US-0113296P.
 PR 23-DEC-1998; 98US-0113621P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 05-JAN-1999; 99US-00254465.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99US-00265686.
 PR 10-MAR-1999; 99WO-US005190.
 PR 12-MAR-1999; 99US-00267213.
 PR 12-MAR-1999; 99US-0123957P.
 PR 29-MAR-1999; 99US-0126773P.
 PR 12-APR-1999; 99US-00284291.
 PR 21-APR-1999; 99US-0130232P.
 PR 26-APR-1999; 99US-0131022P.
 PR 28-APR-1999; 99US-0131445P.
 PR 14-MAY-1999; 99US-00311832.
 PR 14-MAY-1999; 99US-0134287P.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 16-JUN-1999; 99US-0139557P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 07-JUL-1999; 99US-0142680P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0145222P.
 PR 25-AUG-1999; 99US-00380137.
 PR 25-AUG-1999; 99US-00380138.
 PR 25-AUG-1999; 99US-00380142.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 24-FEB-2000; 2000WO-US005804.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US00631P.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUN-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000US-00709238.
 PR 27-NOV-2000; 2000US-00723749.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 22-MAR-2001; 2001US-00816920.
 PR 22-MAR-2001; 2001WO-US009552.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GETH) GENENTECH INC.
 XX

Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1256 GCAGCAGCAGCTGCAGACA 1273
 Db 18 GCAGCAGCAGCTGCATGA 1

RESULT 91
 ADC61429/c
 ID ADC61429 standard; DNA; 20 BP.
 XX
 AC ADC61429;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human PRO 300 PCR primer #2.
 XX
 KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosstatic;
 KW optalmological; antiarthritic; osteopathic; antirheumatic; vulnary;
 KW auditory; tumour growth; retinal disorder; sports-related joint problem;
 KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
 KW wound healing; hearing loss; primer.
 XX
 OS Homo sapiens.
 XX
 PN US2003049684-A1.
 PD 13-MAR-2003.
 XX
 PF 24-OCT-2001; 2001US-00017081.
 XX
 PR 17-OCT-1997; 97US-0062250P.
 PR 03-NOV-1997; 97US-0064249P.
 PR 21-NOV-1997; 97US-0065311P.
 PR 11-MAR-1998; 98US-0077450P.
 PR 11-MAR-1998; 98US-0077450P.
 PR 11-MAR-1998; 98US-0077643P.
 PR 11-MAR-1998; 98US-0077644P.
 PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079688P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0080349P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.

PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0030863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 98US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010773.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028555.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004314.
PR 24-FEB-2000; 2000WO-US0050041.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023338.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.

PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98WO-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010773.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028555.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
XX
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Flivarov E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI: 2003-596568/56.
XX
XX Novel secreted and transmembrane polypeptides and polynucleotides
XX encoding them, useful for treating wound healing, tissue growth and
XX muscle generation and regeneration, amyotrophic lateral sclerosis or
XX neuropathy.
XX
XX Example 5; SEQ ID NO 21; 472pp; English.
XX
XX

CC The invention describes an isolated secreted and transmembrane PRO
CC polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
CC is useful in biotechnological and medical research, as well as in various
CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
CC PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853,
CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
CC therapeutically in vivo for lessening the effects of viral infection.
CC PRO200 is useful for the treatment of wound healing, tissue growth and
CC muscle generation and regeneration. PRO337 is useful for treating
CC amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
CC diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
CC useful for generating transgenic animals or knockout animals which are
CC useful in the development and screening of therapeutically useful
CC reagents, as probes for generating a pool of sequences for identifying
CC related PRO coding sequences, and to construct hybridisation probes for
CC mapping the gene which encodes the PRO and for the genetic analysis of
CC individuals with genetic disorders, for recombinantly expressing (I) and
CC for chromosome identification. (I) is useful as molecular marker for
CC protein electrophoresis purposes, and as therapeutic agents. (I) is also
CC useful for screening compounds to identify those that mimic the PRO
CC polypeptide (agonists) or prevent the effect of the PRO polypeptide
CC (antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
CC are useful for immunohistochemical staining and/or assay of sample
CC fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence represents a human secreted and transmembrane PRO
CC protein associated primer.
XX
XX

XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGGAAGA 1273

DB 18 GCAGCACCAGCTGGATGA 1

RESULT 94
AD68617/c
ID AD68617 standard; DNA; 20 BP.

XX AD68617;

DT 18-DEC-2003 (first entry)

XX Human PRO 300 PCR primer #2.

XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
XX opththomologic; antiarthritic; osteopathic; antirheumatic; vlnary;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX
XX US2003064407-A1.
XX 03-APR-2003.

XX 24-OCT-2001; 2001US-00999834.
PF 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079565P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083548P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086418P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00103413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091010P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US0000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-0026568P.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130233P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 16-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US049556.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001WO-US017092.
PR 25-MAY-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
PA
PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACGCTGAGAGA 1273
Db 18 GCAGCACGAGCTGATGA 1

RESULT 95
AD62677/C
ID AD62677 standard; DNA; 20 BP.
XX
XX

AC AD62677;

DT 18-DEC-2003 (first entry)

DE Human PRO 300 PCR primer #2.

XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolatic;
XX ophthalmologic; antiarthritic; osteopathic; antithematic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.

XX Homo sapiens.

OS US2003068648-A1.

PN 10-APR-2003.

PF 25-OCT-2001; 2001US-00013921.

XX 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066364P.

PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079669P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079932P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 15-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084588P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085860P.
PR 15-MAY-1998; 98US-0085862P.

PR 15-MAY-1998; 98US-0085689P.
PI 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0102114P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113621P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-0500010P.
PR 08-MAR-1999; 99US-0500502P.
PR 10-MAR-1999; 99US-0500519P.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0125773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-0501073P.
PR 02-JUN-1999; 99US-0501225P.
PR 16-JUN-1999; 99US-0139577P.
PR 30-NOV-1999; 99US-0139577P.
PR 02-DEC-1999; 99US-05028551.
PR 02-DEC-1999; 99US-05028551.
PR 16-DEC-1999; 99US-05030095.
PR 30-DEC-1999; 99US-05031243.
PR 30-DEC-1999; 99US-05031274.
PR 05-JAN-2000; 2000US-05000219.
PR 06-JAN-2000; 2000US-05000277.
PR 06-JAN-2000; 2000US-05000376.
PR 11-FEB-2000; 2000US-05003565.
PR 18-FEB-2000; 2000US-05004341.
PR 24-FEB-2000; 2000US-05005004.
PR 02-MAR-2000; 2000US-05005841.
PR 10-MAR-2000; 2000US-05006319.
PR 21-MAR-2000; 2000US-05007532.
PR 17-MAY-2000; 2000US-05008439.
PR 12-MAY-2000; 2000US-05013705.
PR 22-MAY-2000; 2000US-05014042.
PR 30-MAY-2000; 2000US-05015264.
PR 02-JUN-2000; 2000US-05015264.
PR 28-JUL-2000; 2000US-05020710.
PR 24-AUG-2000; 2000US-05023328.
PR 01-DEC-2000; 2000US-05032678.
PR 20-DEC-2000; 2000US-05034956.
PR 28-FEB-2001; 2001US-05006520.
PR 22-MAR-2001; 2001US-05009552.
PR 25-MAY-2001; 2001US-05017092.
PR 01-JUN-2001; 2001US-05017800.
PR 20-JUN-2001; 2001US-05019692.
PR 29-JUN-2001; 2001US-05021066.
PR 09-JUL-2001; 2001US-05021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;

PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI-2003-695924/66.
DR
XX
XX
PT New isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Example 5; SEQ ID NO 21; 467pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCACACGCTGATGA 1273
DB 18 GCAGCACACGCTGATGA 1
ADCG7742C
ID ADG67742 standard; DNA; 20 BP.
XX
AC ADG67742;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
XX US2003069178-A1.
XX
PD 10-APR-2003.
XX
PF 16-OCT-2001; 2001US-00978423.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 10-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079686P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080332P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083555P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.

PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US01073P.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005804.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Fexteraiz N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Guirney AL, Hillan KJ;
PI Klavavin IY, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tunas D, Williams PM, Wood WI;
XX
DR WPI; 2003-657582/62.

XX Novel secreted and transmembrane polypeptides, designated PRO
PT polypeptides, and polynucleotides encoding them useful for treating
PT kidney diseases, bone, cartilage and retinal disorders.
XX
PS Example 5; SEQ ID NO 21; 468bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide), a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO317 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO317
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGGAGA 1273
Db 18 GCAGCAGCAGCTGGATGA 1

RESULT 97
ADCA1062/C
ID ADCA1062 standard; DNA; 20 BP.
XX
AC ADCA1062;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
XX Homo sapiens.
OS
XX
PN US2003072745-A1.
XX
PD 17-APR-2003.
XX
PF 25-OCT-2001; 2001US-00013929.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-006511P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 13-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081932P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083329P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083549P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085882P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087096P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0112966P.
PR 23-DEC-1998; 98US-011621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005150.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US004341.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers J, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Garber H, Gerltsen ME,
PI Goddard A, Goddowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Napiet MA, Pan J, Pironi NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PW, Wood WL;
XX
DR WPI; 2003-743806/70.
XX
PT Novel isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX

PS Example 5; SEQ ID NO 21; 466pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGAGAGA 1273
Db 18 GCAGCACCAGCTGATGA 1
||||| ||||| |||

RESULT 98
AD67117/c
ID AD67117 standard; DNA; 20 BP.
XX
AC AD67117;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW vulnereary; virinude; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inhibitor; PRO; viral infection; wound healing;
KW secreted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003073131-A1.
XX
PD 17-APR-2003.
XX
PF 25-OCT-2001; 2001US-00016177.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079766P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.

PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081223P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081833P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083559P.
PR 29-APR-1998; 98US-0083742P.
PR 30-APR-1998; 98US-0083743P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084419P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.

PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US030095.
PR 16-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023238.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

(GETH) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Klavlin ID, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PM, Wood WI,
XX WPI; 2003-743810/70.

DR Novel isolated secreted and transmembrane PRO polypeptides, useful in the
XX preparation of a medicament for treating a condition responsive to the
XX polypeptide, and as therapeutic agents e.g. vaccines.

PS Example 5; SEQ ID NO 21; 464p; English.

XX The invention describes an isolated secreted and transmembrane PRO
CC polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
CC is useful in biotechnological and medical research, as well as in various

CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
CC PRO708, PRO320, PRO351, PRO352, PRO615, PRO618, PRO772, PRO853,
CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
CC therapeutically in vivo for lessening the effects of viral infection.
CC PRO200 is useful for the treatment of wound healing, tissue growth and
CC muscle generation and regeneration. PRO337 is useful for treating
CC amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACAGCTGGAGA 1273
Db 18 GCAGCACAGCTGGATGA 1
|||||
|||

RESULT 99
ADCC62053/c
ID ADCC62053 standard; DNA; 20 BP.
XX
XX ADCC62053;
AC
XX
DT 18-DEC-2003 (first entry)
XX
XX Human PRO 300 PCR primer #2.
DE
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolatic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vlnetary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
XX Homo sapiens.
OS
XX US2003073624-A1.
PN
XX 17-APR-2003.
PD
XX
XX 15-OCT-2001; 2001US-00978193.
PF
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0065364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083352P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084411P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086466P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00116898P.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US0204855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.

PR	23-DEC-1998	99US-0113621P
PR	05-JAN-1999	99MO-US000101C
PR	05-MAR-1999	99US-00234465
PR	08-MAR-1999	99MO-US0050528
PR	10-MAR-1999	99US-00265686
PR	10-MAR-1999	99MO-US0051190
PR	12-MAR-1999	99US-00262713
PR	12-MAR-1999	99US-01235357P
PR	12-MAR-1999	99US-01235357P
PR	29-MAR-1999	99US-01267473P
PR	12-APR-1999	99US-002848291
PR	21-APR-1999	99US-01030232P
PR	26-JUL-1999	99US-0131022P
PR	28-APR-1999	99US-00311832
PR	14-MAY-1999	99US-00311832
PR	14-MAY-1999	99US-0134287P
PR	14-MAY-1999	99MO-US010733
PR	02-JUN-1999	99MO-US010733
PR	02-DEC-1999	99MO-US012252
PR	16-DEC-1999	99US-0139557P
PR	23-JUN-1999	99US-0141037P
PR	07-JUL-1999	99US-0142680P
PR	26-JUL-1999	99US-0145568P
PR	28-JUL-1999	99US-0145622P
PR	25-AUG-1999	99US-00380137
PR	25-AUG-1999	99US-00380138
PR	25-AUG-1999	99US-00380138
PR	25-AUG-1999	99US-00380142
PR	29-OCT-1999	99US-0162506P
PR	05-JAN-2000	99MO-US028313
PR	06-JAN-2000	2000MO-US0002027
PR	06-JAN-2000	2000MO-US000376
PR	04-FEB-2000	2000US-0180165P
PR	11-FEB-2000	2000MO-US003565
PR	18-FEB-2000	2000MO-US004341
PR	14-FEB-2000	2000MO-US005004
PR	02-MAR-2000	2000MO-US005841
PR	10-MAR-2000	2000MO-US0066319
PR	21-MAR-2000	2000MO-US007532
PR	30-MAR-2000	2000MO-US008435
PR	17-MAY-2000	2000MO-US013705
PR	22-MAY-2000	2000MO-US014042
PR	30-MAY-2000	2000MO-US014941
PR	02-JUN-2000	2000MO-US015264
PR	28-JUL-2000	2000MO-US020710
PR	24-AUG-2000	2000MO-US023328
PR	27-NOV-2000	2000US-00709238
PR	27-NOV-2000	2000US-00723749
PR	01-DEC-2000	2000MO-US03768
PR	20-DEC-2000	2000US-00747259
PR	20-DEC-2000	2000MO-US034956
PR	28-FEB-2001	2001MO-US006520
PR	28-FEB-2001	2001MO-US016744
PR	22-MAR-2001	2001US-00816920
PR	22-MAR-2001	2001MO-US009552
PR	10-MAY-2001	2001US-00854208
PR	15-MAY-2001	2001MO-US017092
PR	01-JUN-2001	2001US-00870335
PR	01-JUN-2001	2001MO-US017800
PR	05-JUN-2001	2001US-00874503
PR	14-JUN-2001	2001US-00886363
PR	19-JUN-2001	2001US-00885342
PR	20-JUN-2001	2001MO-US019692
PR	29-JUN-2001	2001MO-US021066
PR	09-JUL-2001	2001MO-US021735
XX	30-JUL-2001	2001US-00915855
XX		
XX	(GETH) GENENTECH INC.	

Query Match	Similarity	5.9%	Score 14.8	DB 1	Length 20
Best Local	Similarity	88.9%	Pred. No. 1.6e+02		
Matches	16	Conservative	0	Mismatches	2
				Indels	0
				Gaps	0
OY	1256	GCAGCAACAGCTGGAGA	1273		
DB	18	GCAGCACCAGCTGATGA	1		
	RESULT 100				
	ADCC41686/c				
XX	ADCC41686	standard; DNA; 20 BP.			
XX					
AC	ADCC41686;				
XX					
DT	18-DEC-2003	(first entry)			
XX					
DE	Human PRO 300	PCR primer #2.			
XX					
KW	Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;				
KW	ophthalmological; antiarthritic; osteopathic; anti-rheumatic; vulnary;				
KW	auditory; tumour growth; retinal disorder; sports-related joint problem;				
KW	articular cartilage defects; osteoarthritis; rheumatoid arthritis;				
KW	wound healing; hearing loss; primer.				
XX					
OS	Homo sapiens.				
XX					
PN	US2003104998-A1.				
XX					
PD	05-JUN-2003.				
XX					
XX					
PF	16-OCT-2001; 2001US-00978643.				
XX					
PR	17-OCT-1997;	97US-0062250P.			
PR	03-NOV-1997;	97US-0064249P.			
PR	13-NOV-1997;	97US-0065311P.			
PR	21-NOV-1997;	97US-0066364P.			
PR	10-MAR-1998;	98US-0077450P.			
PR	11-MAR-1998;	98US-0077632P.			
PR	11-MAR-1998;	98US-0077641P.			
PR	11-MAR-1998;	98US-0077649P.			
PR	12-MAR-1998;	98US-0077791P.			
PR	13-MAR-1998;	98US-0078004P.			
PR	17-MAR-1998;	98US-00040220.			
PR	20-MAR-1998;	98US-0078886P.			
PR	20-MAR-1998;	98US-0078910P.			
PR	20-MAR-1998;	98US-0078936P.			
PR	20-MAR-1998;	98US-0078939P.			
PR	25-MAR-1998;	98US-0079294P.			
PR	26-MAR-1998;	98US-0079656P.			
PR	27-MAR-1998;	98US-0079663P.			
PR	27-MAR-1998;	98US-0079664P.			
PR	27-MAR-1998;	98US-0079689P.			
PR	27-MAR-1998;	98US-0079728P.			
PR	27-MAR-1998;	98US-0079786P.			
PR	30-MAR-1998;	98US-0079920P.			
PR	30-MAR-1998;	98US-0079923P.			
PR	31-MAR-1998;	98US-0080105P.			
PR	31-MAR-1998;	98US-0080107P.			
PR	31-MAR-1998;	98US-0080165P.			
PR	31-MAR-1998;	98US-0080194P.			
PR	01-APR-1998;	98US-0080327P.			
PR	01-APR-1998;	98US-0080338P.			
PR	01-APR-1998;	98US-0080333P.			
PR	01-APR-1998;	98US-0080334P.			
PR	08-APR-1998;	98US-0081049P.			
PR	08-APR-1998;	98US-0081070P.			
PR	08-APR-1998;	98US-0081071P.			
PR	08-APR-1998;	98US-0081195P.			
PR	09-APR-1998;	98US-0081203P.			
PR	09-APR-1998;	98US-0081229P.			
PR	15-APR-1998;	98US-0081817P.			

PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0083366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084459P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085572P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 30-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00158979.
PR 07-OCT-1998; 98WO-US011141.
PR 02-NOV-1998; 98US-00164216.
PR 06-NOV-1998; 98US-01093368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.

PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284491.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US030095.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019592.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

XX
PA (GETH) GENENTECH INC.

Query Match 5.9%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1256 GCAGCAACGCTGAGACA 1273

||||| ||||||| ||

DB 18 GCAGCACCAGCTGATGA 1
RESULT 101
ADE49055/C
ID ADE49055 standard; DNA; 20 BP.
XX ADE49055;
AC
XX 29-JAN-2004 (first entry)
DT
XX
DE Human PRO 300 PCR primer #2.
XX
XX Human, SS; PCR; secreted protein; transmembrane protein; PRO; cytostatic;
XX ophthalmological; aneurysmal; osteopathic; antineoplastic; vulvar; urinary;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX
XX US2003096744-A1.
XX
XX 22-MAY-2003.
XX
XX 28-JAN-2002; 2002US-00978187.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-0004022P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
XX 15-APR-1998; 98US-0081838P.
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082700P.
XX 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082966P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US020485.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113261P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-JAN-1999; 98US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00285686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-MAR-1999; 98US-0126773P.
PR 12-MAR-1999; 98US-00284231.
PR 12-MAR-1999; 98US-0130232P.
PR 21-APR-1999; 99US-0131022P.
PR 26-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.

PR	14-MAY-1999;	99US-0134287P.
PR	14-MAY-1999;	99WO-US010733.
PR	02-JUN-1999;	99WO-US012252.
PR	16-JUN-1999;	99US-0139557P.
PR	23-JUN-1999;	99US-0141037P.
PR	07-JUL-1999;	99US-0142680P.
PR	26-JUL-1999;	99US-0145698P.
PR	28-JUL-1999;	99US-0146222P.
PR	25-AUG-1999;	99US-00380137.
PR	25-AUG-1999;	99US-00380138.
PR	25-AUG-1999;	99US-00380142.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	16-DEC-1999;	99WO-US030095.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000US-00709238.
PR	27-NOV-2000;	2000US-00723749.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001US-00816744.
PR	22-MAR-2001;	2001US-00816920.
PR	22-MAR-2001;	2001WO-US009552.
PR	10-MAY-2001;	2001US-00854208.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001US-00872036.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019632.
PR	29-JUN-2001;	2001WO-US021056.
PR	09-JUL-2001;	2001WO-US021735.
PR	30-JUL-2001;	2001US-00918585.
XX		
XX		
PA	(GETH) GENENTECH INC.	
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;	
Query Match	5.9%; Score 14.8; DB 1;	
Best Local Similarity	88.9%; Pred. No. 1.6e+02;	
Matches	16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
OY	1256 GCAGCAACGCTCGAGAGA 1273	
Db	18 GCAGCACCAAGCTGATGA 1	
RESULT 102		
ADE35109/c		
ID	ADE35109 standard; DNA; 20 BP.	
XX		

AC	ADE35109;
XX	
DT	29-JAN-2004 (first entry)
XX	
DE	Human PRO 300 PCR primer #2.
XX	
KW	Human; sex; PCR; secreted protein; transmembrane protein; PRO; cytosstatic; ophtalmological; antiarthritis; osteopathic; antineumatic; vlnuery; auditory; tumour growth; retinal disorder; sports-related joint problem; articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW	wound healing; hearing loss; primer.
XX	
OS	Homo sapiens.
XX	
PN	US2003203434-A1.
XX	
PD	30-OCT-2003.
XX	
PF	18-OCT-2001; 2001US-00145088.
XX	
XX	15-MAY-1998; 98US-0085689P.
PR	08-MAR-1999; 99WO-US005028.
PR	28-APR-1999; 99US-0131445P.
PR	25-AUG-1999; 99US-00380138.
PR	18-FEB-2000; 2000WO-US004341.
PR	30-JUL-2001; 2001US-00918585.
XX	
PA	(GETH) GENENTECH INC.
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI	Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI	Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI	Klajavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI	Stewart TA, Tumas D, Williams PM, Wood WI;
XX	
DR	WPI; 2003-875641/81.
XX	
PT	New genes, and its encoded secreted and transmembrane polypeptides,
PT	useful for treating e.g. lung or breast tumors, osteoarthritis,
PT	rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT	hypoinsulinemia or wounds.
XX	
PS	Example 5; SEQ ID NO 21; 462pp; English.
XX	
CC	The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide), a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide. PRO337 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559
CC	

CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1256 GCAGCAACGCTGGAGA 1273
Db 18 GCAGCACGCGTGATGA 1
|||||
RESULT 103
AD72838/c
ID ADE16223 standard; DNA; 20 BP.
XX
AC ADE16223;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vlnetary;
KW audiotory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003203435-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145092.
XX
PR 30-APR-1998; 98US-0083742P.
PR 08-MAR-1999; 99WO-US005028.
PR 23-JUN-1999; 99US-0141037P.
PR 25-AUG-1999; 99US-0038013P.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GERTH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Baton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillen KJ;
PI Kilaavon IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumes D, Williams PW, Wood WI;
XX
XX MPI; 2003-875642/81.
XX
PT New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for treating e.g. lung or breast tumors, osteoarthritis,
PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT hypoinulinemia or wounds.
XX
PS Example 5; SEQ ID NO 21; 452pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal

CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody; PRO337 polypeptide is useful for detecting a PRO493
CC polypeptide in a sample suspected of containing PRO493 polypeptide.
CC Similarly, PRO493 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO493 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO493 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO493 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO493 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO493 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1256 GCAGCAACGCTGGAGA 1273
Db 18 GCAGCACGCGTGATGA 1
|||||
RESULT 104
ADD72838/c
ID ADD72838 standard; DNA; 20 BP.
XX
AC ADD72838;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vlnetary;
KW audiotory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003203436-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145129.
XX
PR 22-MAY-1998; 98US-0086414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99US-00284291.
PR 12-APR-1999; 99US-00284291.

PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-875643/81.
XX
XX New PRO genes and encoded secreted and transmembrane polypeptides, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT wounds.
XX
PS Example 5; SEQ ID NO 21; 453bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX
AC ADD72196;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antiinematic; vulnerary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003194781-A1.
XX
PD 16-OCT-2003.
XX
XX 19-OCT-2001; 2001US-00164929.
XX
XX 30-MAR-1998; 98US-0079920P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 15-APR-1999; 99WO-US008313.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380138.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US014964.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032478.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
XX Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
XX Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-852598/79.
XX

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for stimulating the release of tumor necrosis factor alpha from human
PT blood and stimulating the proliferation of differentiation of chondrocyte
PT cells.

PS Example 5; SEQ ID NO 21; 462pp; English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeraic molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of the cell expressing PRO725, PRO700 or PRO739 polypeptide. The polypeptides are useful for inhibiting tumour growth, retinal disorders, sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in mammals. The present sequence is a PCR primer used to isolate nucleic acid encoding a PRO protein.

SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match	5.9%	Score 14.8	DB 1	Length 20
Best Local Similarity	88.9%	Pred. NO. 1.6e+02		
Matches 16	Conservative	0	Mismatches 2	Indels 0
				Gaps 0

```

QY      1256 GCAGCACAGCTGGAAGA 1273
          ||||| ||||| ||
Db      18 GCAGCACAGCTGATGA 1

```

RESULT 106
ADE16847/c
ID ADE16847 standard; DNA; 20 BP.

KW Human; PCP; secreted protein; transmembrane protein; PRO; cytosolic;
 KW ophthalmological, ankyrathritic; osteopathic, anfrneumatic; vulnery;
 KW auditory; tumour growth; retinal disorder; sports-related joint problem;
 KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
 KW wound healing; hearing loss; primer.

OS Homo sapiens.

PN US2003203433-A1.

PD 30-OCT-2003.

PF 18-OCT-2001; 2001US-00145016.

PR 06-MAY-1998; 98US-0084414P.

PR 05-JAN-1999; 99WO-US000106.

PR 12-APR-1999; 99US-00284291.

PR 18-FEB-2000; 2000WO-US004341.
PR 30-TH-2001; 2001WE-00919E9E

XX
PA (GETH) GENENTECH INC

XX Ashkenazi AT. Baker KP. Bot

PI Ferrara N, Fivallott E, Goddard A, Godowski PJ, Gri

PI	Stewart TA,	Thomas D,	Willie
FI	Kavanaugh,	Kuo SS,	Napier

WPI; 2003-875640/81.

PT New genes, and its encoded secreted and transmembrane polypeptide

PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,

XX

XX

transmembrane prote

CC in the specification

Example 5; SEQ ID NO 21; 459pp; English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide. PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of the cell expressing PRO725, PRO700 or PRO739 polypeptide. The polypeptides are useful for inhibiting tumour growth, retinal disorders, sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in mammals. The present sequence is a PCR primer used to isolate nucleic acid encoding a PRO protein.

Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

```
Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1256 GCAGCACAAGCTGGAGAGA 1273
      |||||
      18 GCAGCACCAGCTGGATGA 1

RESULT 107
ADF46861/c
ID      ADF46861 standard; DNA; 20 BP.
XX
XX      ADF46861;
AC
XX      12-FEB-2004 (first entry)
DT
XX
XX      Human PRO 300 PCR primer #2.
DE
XX
XX      Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosstatic;
XX      ophthalmological; antiarthritic; osteoparhic; antirheumatic; vulnetary;
XX      auditory; tumour growth; retinal disorder; sports-related joint problem;
XX      articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX      wound healing; hearing loss; primer.
OS
XX      Homo sapiens.
XX
XX      US2003195333-A1.
XX
XX      16-OCT-2003.
PD
XX
XX      15-OCT-2001; 2001US-00978194.
PF
XX
XX      17-OCT-1997; 97US-0062250P.
PR      03-NOV-1997; 97US-0064249P.
PR      13-NOV-1997; 97US-0065311P.
PR      21-NOV-1997; 97US-0065364P.
PR      10-MAR-1998; 98US-0077450P.
PR      11-MAR-1998; 98US-0077632P.
PR      11-MAR-1998; 98US-0077641P.
PR      11-MAR-1998; 98US-0077649P.
PR      12-MAR-1998; 98US-0077791P.
PR      13-MAR-1998; 98US-0078004P.
PR      17-MAR-1998; 98US-00040220.
PR      17-MAR-1998; 98US-0078886P.
PR      20-MAR-1998; 98US-0078910P.
PR      20-MAR-1998; 98US-0078936P.
PR      20-MAR-1998; 98US-0078939P.
PR      25-MAR-1998; 98US-0079294P.
PR      26-MAR-1998; 98US-0079656P.
PR      27-MAR-1998; 98US-0079663P.
PR      27-MAR-1998; 98US-0079664P.
PR      27-MAR-1998; 98US-0079689P.
PR      27-MAR-1998; 98US-0079728P.
PR      27-MAR-1998; 98US-0079786P.
PR      30-MAR-1998; 98US-0079920P.
PR      30-MAR-1998; 98US-0079923P.
PR      31-MAR-1998; 98US-0080105P.
PR      31-MAR-1998; 98US-0080107P.
PR      31-MAR-1998; 98US-0080165P.
PR      31-MAR-1998; 98US-0080194P.
PR      01-APR-1998; 98US-0080327P.
PR      01-APR-1998; 98US-0080328P.
PR      01-APR-1998; 98US-0080333P.
PR      01-APR-1998; 98US-0080334P.
PR      08-APR-1998; 98US-0081049P.
PR      08-APR-1998; 98US-0081070P.
PR      08-APR-1998; 98US-0081071P.
PR      09-APR-1998; 98US-0081203P.
PR      09-APR-1998; 98US-0081229P.
PR      15-APR-1998; 98US-0081817P.
```

```
PR      15-APR-1998; 98US-0081819P.
PR      15-APR-1998; 98US-0081838P.
PR      15-APR-1998; 98US-0081952P.
PR      15-APR-1998; 98US-0081955P.
PR      21-APR-1998; 98US-0082568P.
PR      21-APR-1998; 98US-0082569P.
PR      22-APR-1998; 98US-0082700P.
PR      22-APR-1998; 98US-0082704P.
PR      22-APR-1998; 98US-0082797P.
PR      22-APR-1998; 98US-0082804P.
PR      23-APR-1998; 98US-0082798P.
PR      27-APR-1998; 98US-0083336P.
PR      28-APR-1998; 98US-0083332P.
PR      29-APR-1998; 98US-0083392P.
PR      29-APR-1998; 98US-0083495P.
PR      29-APR-1998; 98US-0083496P.
PR      29-APR-1998; 98US-0083499P.
PR      29-APR-1998; 98US-0083500P.
PR      29-APR-1998; 98US-0083545P.
PR      29-APR-1998; 98US-0083554P.
PR      29-APR-1998; 98US-0083558P.
PR      29-APR-1998; 98US-0083559P.
PR      30-APR-1998; 98US-0083742P.
PR      05-MAY-1998; 98US-0084366P.
PR      06-MAY-1998; 98US-0084414P.
PR      07-MAY-1998; 98US-0084598P.
PR      07-MAY-1998; 98US-0084600P.
PR      07-MAY-1998; 98US-0084627P.
PR      07-MAY-1998; 98US-0084637P.
PR      07-MAY-1998; 98US-0084639P.
PR      07-MAY-1998; 98US-0084640P.
PR      07-MAY-1998; 98US-0084643P.
PR      13-MAY-1998; 98US-0085323P.
PR      13-MAY-1998; 98US-0085338P.
PR      13-MAY-1998; 98US-0085339P.
PR      15-MAY-1998; 98US-0085573P.
PR      15-MAY-1998; 98US-0085579P.
PR      15-MAY-1998; 98US-0085580P.
PR      15-MAY-1998; 98US-0085582P.
PR      15-MAY-1998; 98US-0085689P.
PR      15-MAY-1998; 98US-0085697P.
PR      15-MAY-1998; 98US-0085700P.
PR      15-MAY-1998; 98US-0085704P.
PR      18-MAY-1998; 98US-0086023P.
PR      22-MAY-1998; 98US-0086392P.
PR      22-MAY-1998; 98US-0086414P.
PR      22-MAY-1998; 98US-0086430P.
PR      22-MAY-1998; 98US-0086486P.
PR      28-MAY-1998; 98US-0087098P.
PR      28-MAY-1998; 98US-0087106P.
PR      28-MAY-1998; 98US-0094651P.
PR      26-JUN-1998; 98US-00105413.
PR      26-JUN-1998; 98US-0090863P.
PR      26-JUN-1998; 98US-0091010P.
PR      01-JUL-1998; 98US-0091359P.
PR      30-JUL-1998; 98US-0094651P.
PR      11-SEP-1998; 98US-0100038P.
PR      07-OCT-1998; 98US-00168978.
PR      07-OCT-1998; 98WO-US021141.
PR      02-NOV-1998; 98US-00184216.
PR      06-NOV-1998; 98US-00187368.
PR      20-NOV-1998; 98US-0109304P.
PR      20-NOV-1998; 98WO-US024855.
PR      07-DEC-1998; 98US-00202054.
PR      22-DEC-1998; 98US-00218517.
PR      22-DEC-1998; 98US-0113216P.
PR      23-DEC-1998; 98US-0113621P.
PR      05-JAN-1999; 99WO-US000106.
PR      05-MAR-1999; 99US-00254465.
PR      08-MAR-1999; 99WO-US005028.
PR      10-MAR-1999; 99US-00265866.
PR      10-MAR-1999; 99WO-US005190.
```


PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284231.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00380137.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 24-AUG-2000; 2000WO-US020710.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001WO-US084280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH) GENENTECH INC.
XX
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCACGCTGATGA 1273
||||| |||||||

DB 18 GCAGCACGCTGATGA 1
RESULT 108.4
ADG52618/c
ADG52618 standard; DNA; 20 BP.
XX
AC ADG52618;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
FN US2003216561-A1.
XX
PD 20-NOV-2003.
XX
PF 25-OCT-2001; 2001US-00013927.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079229P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 30-MAR-1998; 98US-0080103P.
PR 31-MAR-1998; 98US-0080194P.
PR 31-MAR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081103P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 09-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082569P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0100211P.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0109248P.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-0113621P.
PR 08-MAR-1999; 98US-0113621P.
PR 10-MAR-1999; 98US-0113621P.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130233P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98US-0134287P.
PR 02-JUN-1999; 98US-0139557P.
PR 16-JUN-1999; 98US-0141037P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98US-0162506P.
PR 02-DEC-1999; 98US-0162506P.
PR 02-DEC-1999; 98US-0162506P.
PR 16-DEC-1999; 98US-0162506P.

PR 30-DEC-1999; 98US-0162506P.
PR 30-DEC-1999; 98US-0162506P.
PR 05-JAN-2000; 98US-0162506P.
PR 06-JAN-2000; 98US-0162506P.
PR 11-FEB-2000; 98US-0162506P.
PR 18-FEB-2000; 98US-0162506P.
PR 24-FEB-2000; 98US-0162506P.
PR 02-MAR-2000; 98US-0162506P.
PR 10-MAR-2000; 98US-0162506P.
PR 21-MAR-2000; 98US-0162506P.
PR 30-MAR-2000; 98US-0162506P.
PR 17-MAY-2000; 98US-0162506P.
PR 22-MAY-2000; 98US-0162506P.
PR 30-MAY-2000; 98US-0162506P.
PR 02-JUN-2000; 98US-0162506P.
PR 28-JUN-2000; 98US-0162506P.
PR 24-AUG-2000; 98US-0162506P.
PR 01-DEC-2000; 98US-0162506P.
PR 20-DEC-2000; 98US-0162506P.
PR 28-FEB-2001; 98US-0162506P.
PR 22-MAR-2001; 98US-0162506P.
PR 25-MAY-2001; 98US-0162506P.
PR 01-JUN-2001; 98US-0162506P.
PR 20-JUN-2001; 98US-0162506P.
PR 29-JUN-2001; 98US-0162506P.
PR 09-JUL-2001; 98US-0162506P.
PR 30-JUL-2001; 98US-0162506P.
PA (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL,
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gertltsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kijavrin IJ, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PM, Wood WI,
XX WPI; 2003-902053/82.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
XX Example 5; SEQ ID NO 21; 457pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO493
CC polypeptide in a sample suspected of containing PRO493 polypeptide.
CC Similarly, PRO493 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO493 polypeptide is useful for linking a

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCACCAGCTGGAGA 1273
DB 18 GCAGCACCAGCTGGATGA 1

RESULT 109
ADG59938/c
ID ADG59938 standard; DNA; 20 BP.
XX

AC ADG59938;
XX 11-MAR-2004 (first entry)
XX Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX US2003206915-A1.
XX 06-NOV-2003.
XX 25-OCT-2001; 2001US-00013916.
XX 29-APR-1998; 98US-0083554P.
XX 08-MAR-1999; 99WO-US005028.
XX 28-APR-1999; 99US-0131445P.
XX 25-AUG-1999; 99US-00380138.
XX 18-FEB-2000; 2000WO-US004341.
XX 30-JUL-2001; 2001US-00918585.
XX
XX (GENTH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Garber H, Gerritsen ME;
XX Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Klabavin IJ, Kuo SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
XX Stewart TA, Tumas D, Williams PM, Wood WJ;
XX WPI, 2003-901034/82.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy for treating obesity or diabetes, in chromosome and gene
XX mapping, and as chromosome markers in tissue typing.
XX
XX Example 5; SEQ ID NO 21; 520pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
XX Similarly, PRO4993 polypeptide is useful for detecting PRO337
XX polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
XX PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
XX PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
XX bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
XX molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
XX causes death of the cell. PRO337 polypeptide is useful for linking a
XX bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
XX PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
XX to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
XX useful for linking a bioactive molecule to a cell expressing PRO725,
XX PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
XX polypeptide is useful for modulating at least one biological activity of
XX the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
XX polypeptide or anti-PRO4993 polypeptide is useful for modulating the
XX biological activity of the cell expressing PRO4993 polypeptide; PRO725,
XX PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
XX modulating the biological activity of the cell expressing PRO1559
XX polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-

CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1256 GCAGCACGCTGGAGAA 1273
DB 18 GCAGCACGCTGGATGA 1
XX
RESULT 110
AD160698/C
ID AD160698 standard; DNA; 20 BP.
XX
AC AD160698;
XX
DT 22-APR-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX
XX US2003077700-A1.
XX
XX 24-APR-2003.
XX
XX 24-OCT-2001; 2001US-00999830.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 20-MAR-1998; 98US-0078866P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078933P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.

PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081107P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083509P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US02485P.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.

PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005841.
PR 02-MAR-2000; 2000WO-US006319.
PR 10-MAR-2000; 2000WO-US007532.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

PA (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski P, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX WPI; 2003-765401/72.
DR
XX
XX New isolated PRO polypeptide e.g. PRO200, PRO322, PRO540, PRO846 or
PT PRO617 polypeptide, useful for treating sight loss due to retinitis
PT pigmentosum by enhancing retinal neural cells survival.
XX
XX
XX Example 5; SEQ ID NO 21; 465pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular/intracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993

CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.6e+02; Mismatches 2; Indels 0; Gaps 0;

1256 GCAGCAGACGTGTGAGA 1273
18 GCAGCAGCAGCTGTGTA 1

RESULT 111
ACD42441/C
ID ACD42441 standard; DNA; 20 BP.

AC ACD42441;

DT 09-SEP-2003 (first entry)

DE Novel human secreted and transmembrane protein related primer #10.

KM Human; secreted and transmembrane protein; PRO; virucide; gene therapy;

KM cell death; growth induction cascade; blood coagulation cascade;

KM viral infection; PCR; primer; ss.

OS Homo sapiens.

PN US2003050239-A1.

PD 13-MAR-2003.

PE 15-OCT-2001; 2001US-00978191.

PR 17-OCT-1997; 97US-0062250P.

PR 13-NOV-1997; 97US-0064249P.

PR 21-NOV-1997; 97US-0066311P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 17-MAR-1998; 98US-00040220.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078931P.

PR 25-MAR-1998; 98US-0079294P.

PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.

PR 30-MAR-1998; 98US-0079920P.

PR 31-MAR-1998; 98US-0080105P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080165P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080328P.

PR 01-APR-1998; 98US-0080333P.

PR 01-APR-1998; 98US-0080344P.

PR 08-APR-1998; 98US-0081070P.

PR 08-APR-1998; 98US-0081071P.

PR 09-APR-1998; 98US-0081195P.

PR 09-APR-1998; 98US-0081203P.

PR 09-APR-1998; 98US-0081229P.

PR 15-APR-1998; 98US-0081817P.

PR 15-APR-1998; 98US-0081819P.

PR 15-APR-1998; 98US-0081830P.

PR 15-APR-1998; 98US-0081952P.

PR 15-APR-1998; 98US-0081955P.

PR 21-APR-1998; 98US-0082568P.

PR 22-APR-1998; 98US-0082700P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082796P.

PR 27-APR-1998; 98US-0083336P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083392P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083500P.

PR 29-APR-1998; 98US-0083545P.

PR 29-APR-1998; 98US-0083554P.

PR 29-APR-1998; 98US-0083558P.

PR 30-APR-1998; 98US-0083742P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 06-MAY-1998; 98US-0084441P.

PR 07-MAY-1998; 98US-0084598P.

PR 07-MAY-1998; 98US-0084600P.

PR 07-MAY-1998; 98US-0084627P.

PR 07-MAY-1998; 98US-0084637P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 13-MAY-1998; 98US-0085323P.

PR 13-MAY-1998; 98US-0085338P.

PR 15-MAY-1998; 98US-0085573P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085697P.

PR 15-MAY-1998; 98US-0085700P.

PR 15-MAY-1998; 98US-0085704P.

PR 18-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086332P.

PR 22-MAY-1998; 98US-0086414P.

PR 22-MAY-1998; 98US-0086430P.

PR 22-MAY-1998; 98US-0086466P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087106P.

PR 28-MAY-1998; 98US-0087208P.

PR 26-JUN-1998; 98US-00105413.

PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.

PR 30-JUL-1998; 98US-0094651P.

PR 11-SEP-1998; 98US-0100038P.

PR 07-OCT-1998; 98US-00168978.

PR 02-NOV-1998; 98WO-US021141.

PR 06-NOV-1998; 98US-00184216.

PR 20-NOV-1998; 98US-00187368.

PR 20-NOV-1998; 98US-0109304P.

PR 20-NOV-1998; 98WO-US024855.

PR 07-DEC-1998; 98US-00202054.

PR 22-DEC-1998; 98US-00218517.

PR 23-DEC-1998; 98US-0113296P.

PR 05-JAN-1999; 98US-0113621P.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99US-00254465.

PR 10-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99US-00265686.

PR 10-MAR-1999; 99WO-US005190.

PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0146680P.
PR 26-JUL-1999; 99US-0146223P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US02678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US044956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US081674.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
PA (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1256 GCAGCAACAGCTGAGGA 1273
Db 18 GCAGCACCAGCTGATGA 1

RESULT 112

ADBE48355/c
ID ADBE48355 standard; DNA; 20 BP.

XX
AC ADBE48355;

XX
XX 29-JAN-2004 (first entry)

DE Human PRO 300 PCR primer #2.

XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosstatic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnerrary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.

XX OS Homo sapiens.

XX EN US2003104536-A1.

XX PD 05-JUN-2003.

XX PF 19-OCT-2001; 2001US-00166709.

XX 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
PA (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;


```
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084643P.
PR 07-MAY-1998; 98US-0084644P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-011621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131023P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-013445P.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-014568P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

XX
PA (ASHK/) ASHKENAZI A J.
PA (BAKE/) BAKER K P.
PA (BOTS/) BOTSTEIN D.
PA (DESN/) DESNOYERS L.
PA (EATO/) EATON D L.
PA (FERR/) FERRARA N.
PA (FLIV/) FLIVAROFF E.
PA (FONG/) FONG S.
PA (GAOW/) GAO W.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GIRM/) GIRMALDI J C.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLMAN K J.
PA (KLJA/) KLJAVIN I J.
PA (KHOS/) KUO S S.
PA (NAPI/) NAPIER M A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (ROYM/) ROY M A.
PA (SHEL/) SHELTON D L.
PA (STEM/) STEWART T A.
PA (TUMA/) TUMAS D.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.

XX

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGGAGA 1273
DB 18 GCAGCACAGCTGGATGA 1

RESULT 114
ADFF61096/c
ID ADF61096 standard; DNA; 20 BP.
XX
AC ADF61096;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW Ophthalmological; ankyratic; osteopathic; antirheumatic; vulnary;
KW auctory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
OS Homo sapiens.
XX
PN US2003195345-A1.
```


XX 16-OCT-2003.
PD
XX 21-OCT-2001; 2001US-00013922.
PF
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0065364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 30-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 31-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0080344P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083323P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083546P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084416P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085709P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130233P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010773.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145688P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023338.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gether H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tunas D, Williams PM, Wood WT;
XX WPI; 2004-021097/02.
DR
XX New PRO nucleic acid, useful for treating e.g. lung or breast tumors,
PT osteoarthritis, rheumatoid arthritis, obesity, diabetes,
PT hyperinsulinemia, hypoinsulinemia or wounds.
XX
XX Example 5; SEQ ID NO 21; 464bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO493
CC polypeptide in a sample suspected of containing PRO493 polypeptide.
CC Similarly, PRO493 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGAGAGA 1273
DB 18 GCAGCAGCAGCTGATGA 1

RESULT 115
ADP39788/C
ID ADF39788 standard; DNA; 20 BP.
XX
XX ADF39788;
XX AC
XX 12-FEB-2004 (first entry)
DT
XX
XX Human PRO 300 PCR primer #2.
DE
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytotostatic;
KW ophthalmological; antiarthritis; osteopathic; antirheumatic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX OS
XX US2003198994-A1.
XX
XX 23-OCT-2003.
XX PD
XX 24-OCT-2001; 2001US-00020445.
XX PE
XX 17-OCT-1997; 97US-0062250P.
XX PR 03-NOV-1997; 97US-0064249P.
XX PR

PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0080004P.
PR 17-MAR-1998; 98US-00804020.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079254P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081955P.
PR 15-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 22-APR-1998; 98US-0082796P.
PR 23-APR-1998; 98US-0083336P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083742P.
PR 30-APR-1998; 98US-0084336P.
PR 05-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.

```
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0010541P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0016897P.
PR 07-OCT-1998; 98US-0021141P.
PR 02-NOV-1998; 98US-0018421P.
PR 06-NOV-1998; 98US-0018736P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0024855P.
PR 07-DEC-1998; 98US-0020205P.
PR 22-DEC-1998; 98US-0021851P.
PR 23-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99US-0025445P.
PR 08-MAR-1999; 99US-0026566P.
PR 10-MAR-1999; 99US-0026566P.
PR 12-MAR-1999; 99US-0026721P.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-0028429P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0031183P.
PR 14-MAY-1999; 99US-0036013P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99US-0031252P.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-0038013P.
PR 25-AUG-1999; 99US-0038014P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0028313P.
PR 02-DEC-1999; 99US-0028551P.
PR 16-DEC-1999; 99US-0028565P.
PR 30-DEC-1999; 99US-0030095P.
PR 30-DEC-1999; 99US-0031124P.
PR 05-JAN-2000; 99US-0031274P.
PR 06-JAN-2000; 2000US-0000219P.
PR 06-JAN-2000; 2000US-0000277P.
PR 11-FEB-2000; 2000US-0000376P.
PR 18-FEB-2000; 2000US-0004341P.
PR 24-FEB-2000; 2000US-0005004P.
PR 02-MAR-2000; 2000US-0005841P.
PR 10-MAR-2000; 2000US-0006319P.
PR 21-MAR-2000; 2000US-0007532P.
PR 30-MAR-2000; 2000US-0008439P.

PR 17-MAY-2000; 2000US-0013705P.
PR 22-MAY-2000; 2000US-0014042P.
PR 30-MAY-2000; 2000US-0014941P.
PR 02-JUN-2000; 2000US-0015254P.
PR 28-JUN-2000; 2000US-0020710P.
PR 24-AUG-2000; 2000US-0023328P.
PR 08-NOV-2000; 2000US-0070923P.
PR 27-NOV-2000; 2000US-0072374P.
PR 01-DEC-2000; 2000US-0032678P.
PR 20-DEC-2000; 2000US-0074725P.
PR 20-DEC-2000; 2000US-0034956P.
PR 28-FEB-2001; 2001US-0006520P.
PR 22-MAR-2001; 2001US-0081674P.
PR 22-MAR-2001; 2001US-0081692P.
PR 10-MAY-2001; 2001US-0085420P.
PR 25-MAY-2001; 2001US-0085428P.
PR 01-JUN-2001; 2001US-0087203P.
PR 05-JUN-2001; 2001US-0087450P.
PR 14-JUN-2001; 2001US-0088263P.
PR 19-JUN-2001; 2001US-0088634P.
PR 20-JUN-2001; 2001US-0019692P.
PR 29-JUN-2001; 2001US-0021066P.
PR 09-JUL-2001; 2001US-0021735P.
PR 30-JUL-2001; 2001US-0091858P.

XX (GETH ) GENENTECH INC.
XX

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Beet Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CY 1256 GCAGCACGCTGAGAGA 1273
DB 18 GCAGCACGCTGAGATGA 1

RESULT 116
ADP45584/C
ID ADP45584 standard; DNA; 20 BP.
XX
AC ADP45584;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vlnetary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
OS Homo sapiens.
XX
PN US2003195148-A1.
XX
PD 16-OCT-2003.
XX
PF 16-OCT-2001; 2001US-00978681.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
```

PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 01-APR-1998; 98US-0080349P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081071P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.

PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113286P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284491.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00380137.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 25-AUG-1999; 99US-0162506P.
PR 29-OCT-1999; 99WO-US028313.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 28-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.

PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US0747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001WO-US009520.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1256 GCAGCAGCTGGAAGA 1273
DB 18 GCAGCAGCTGATGA 1
RESULT 117
ADP23980/c
ID ADF23980 standard; DNA; 20 BP.
XX
AC ADF23980;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
ophthalmological; aneurismatic; osteopathic; antineumatic; vulnery;
auditory; tumor growth; retinal disorder; sports-related joint problem;
articular cartilage defects; osteoarthritis; rheumatoid arthritis;
wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX OS
PN US2003204055-A1.
XX
PD 30-OCT-2003.
XX
PE 24-OCT-2001; 2001US-00017085.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
XX

PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079669P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081079P.
PR 08-APR-1998; 98US-0081077P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083332P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 30-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX

BA	(GENE) GENENTECH INC.
XX	
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnovers I., Eaton DL,
PI	Ferrara N, Flivarov E, Fong S, Gerber H, Gerritsen ME;
PI	Goddard A, Godowski PJ, Grunwald JC, Gurney AL, Hillan KJ;
PI	Klavavin IJ, Kuo SS, Napier MA, Pan J, Pooni NF, Roy MA, Shelton DL;
PI	Stewart TA, Tunas D, Williams PM, Wood WJ;
DR	WPI; 2004-04194/04.
XX	
PT	New PRO polypeptide useful for treating peripheral neuropathy, or
PT	neuropathies associated with systemic disease such as post-polio syndrome
PT	or acquired immunodeficiency syndrome-associated syndrome.
PS	
XX	
XX	Example 5; SEQ ID NO 21; 459pp; English.
CC	The invention relates to an isolated PRO polypeptide (secreted or
CC	transmembrane protein) having at least 80% amino acid sequence identity
CC	to an amino acid sequence chosen from 94 fully defined sequences as given
CC	in the specification (including PRO lacking its associated signal
CC	peptide), a PRO extracellular domain with or without its associated signal
CC	peptide). Also included are nucleic acids encoding the PRO proteins
CC	mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC	comprising the vector and producing PRO, a chimeric molecule comprising
CC	PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC	antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC	polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC	Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC	polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC	PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC	PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC	bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC	molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC	causes death of the cell. PRO337 polypeptide is useful for linking a
CC	bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC	PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC	to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC	useful for linking a bioactive molecule to a cell expressing PRO725,
CC	PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC	polypeptide is useful for modulating at least one biological activity of
CC	the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC	polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC	biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC	PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC	modulating the biological activity of the cell expressing PRO1559
CC	polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC	PRO739 polypeptide is useful for modulating the biological activity of
CC	the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC	polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC	sports-related joint problems, articular cartilage defects,
CC	osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC	mammals. The present sequence is a PCR primer used to isolate nucleic
CC	acid encoding a PRO protein.
XX	
SQ	Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX	
Query Match	5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity	88.9%; Pred No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0	
OY	1256 GCAGCAACAGCTGAGA 1273
DB	18 GCAGCACAGCTGATGA 1
RESULT 118	
ADF40412/C	
ID	ADF40412 standard; DNA; 20 BP.
XX	
ADP40412;	
XX	
DT	12-FEB-2004 (first entry)

DE Human PRO 300 PCR primer #2.

XX Human, ss; PCR: secreted protein; transmembrane protein, PRO; cytosolic;

KW opththlmo logical; antarthritic; osteopathic; antirheumatic; vulnary;

KW auditory; tumour growth; retinal disorder; sports-related joint problem;

KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;

KW wound healing; hearing loss; primer.

XX

OS Homo sapiens.

XX

PN US2003199021-A1.

XX

XX 23-OCT-2003.

PD

XX 25-OCT-2001; 2001US-00013924.

PF

XX 30-JUL-2001; 2001US-00918585.

PR

XX (GENTH) GENENTECH INC.

PA

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

XX Ferrera N, Filvaroff E, Fong S, Gao W, Gether H, Gerlitsen ME;

PI Goddard A, Gadowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;

PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;

PI Stewart TA, Tumas D, Williams PM, Wood MI;

XX WPI; 2004-041351/04.

DR

XX New nucleic acid encoding a secreted and transmembrane polypeptide,

PT useful for treating e.g. lung or breast tumors, osteoarthritis,

PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,

PT hypoinulinemia or wounds.

XX

PS Example 5; SEQ ID NO 21; 461pp; English.

XX

CC The invention relates to an isolated PRO polypeptide (secreted or

CC transmembrane protein) having at least 80% amino acid sequence identity

CC to an amino acid sequence chosen from 94 fully defined sequences as given

CC in the specification (including PRO lacking its associated signal

CC peptide, a PRO extracellular domain with or without its associated signal

CC peptide). Also included are nucleic acids encoding the PRO proteins

CC mentioned above, a vector comprising a PRO nucleic acid, a host cell

CC comprising the vector and producing PRO, a chimeric molecule comprising

CC PRO fused to a heterologous amino acid sequence, and an anti-PRO

CC antibody. PRO337 polypeptide is useful for detecting a PRO4993

CC polypeptide in a sample suspected of containing PRO4993 polypeptide.

CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting

CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting

CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a

CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive

CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

CC causes death of the cell. PRO337 polypeptide is useful for linking a

CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,

CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule

CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is

CC useful for linking a bioactive molecule to a cell expressing PRO725,

CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337

CC polypeptide is useful for modulating at least one biological activity of

CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337

CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the

CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,

CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for

CC modulating the biological activity of the cell expressing PRO1559

CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of

CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The

CC polypeptides are useful for inhibiting tumour growth, retinal disorders,

CC sports-related joint problems, articular cartilage defects,

CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in

CC mammals. The present sequence is a PCR primer used to isolate nucleic

CC acid encoding a PRO protein.

XX

```

SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1256 GCAGCACAGCTGATGA 1273
Db 18 GCAGCACAGCTGATGA 1

RESULT 119
ADP23356/C
ID ADP23356 standard; DNA; 20 BP.
XX
XX ADF23356;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human PRO 300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
XX Ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX
XX OS
XX US2003203402-A1.
XX
XX 30-OCT-2003.
XX
XX 24-OCT-2001; 2001US-00017084.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 17-MAR-1998; 98US-0040220.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 15-MAY-1998; 98US-0086023P.
PR 18-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086466P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091355P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0016897P.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 03-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
```

PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00380137.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010723.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001WO-US016920.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCAACGCTGAAGA 1273

Db 18 GCAGCAACGCTGAAGA 1
|||||
RESULT 120
ADF33339/c
ID ADF33339 standard; DNA; 20 BP.
XX
XX ADF33339;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antiinflammatory; vulnary;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003194780-A1.
XX
PD 16-OCT-2003.
XX
PF 19-OCT-2001; 2001US-00164829.
XX

XX 29-APR-1998; 98US-0083392P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US024855.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 15-APR-1999; 99WO-US008313.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380138.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Ferrara N, Fljvartoff E, Fong S, Gao W, Gether H, Gerritsen ME;
PI Goddard A, Godowski RJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini J, Kuo SS, Napier MA, Pan J, Peoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI, 2004-021078/02.
XX
XX
XX New secreted and transmembrane nucleic acid useful for treating
XX inflammation, organ failure, atherosclerosis, cardiac injury,
XX infertility, birth defects, premature aging, acquired immunodeficiency
XX syndrome, or cancer.
XX
XX Example 5; SEQ ID NO 21; 463pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
XX Similarly, PRO4993 polypeptide is useful for detecting PRO337
XX polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
XX PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
XX PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
XX bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
XX molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
XX causes death of the cell. PRO337 polypeptide is useful for linking a
XX bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
XX PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
XX to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
XX useful for linking a bioactive molecule to a cell expressing PRO725,
XX PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
XX polypeptide is useful for modulating at least one biological activity of
XX the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
XX polypeptide or anti-PRO4993 polypeptide is useful for modulating the
XX biological activity of the cell expressing PRO4993 polypeptide; PRO725,
XX PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
XX modulating the biological activity of the cell expressing PRO1559
XX polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
XX PRO739 polypeptide is useful for modulating the biological activity of
XX the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
XX polypeptides are useful for inhibiting tumour growth, retinal disorders,
XX sports-related joint problems, articular cartilage defects,
XX osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
XX mammals. The present sequence is a PCR primer used to isolate nucleic
XX acid encoding a PRO protein.
XX
XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 5.9%; Score 14.8; DB 1; Length 20;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1256 GCAGCACGCTGAGGA 1273
XX 18 GCAGCACGCTGATGA 1
XX
XX RESULT 121
XX ADF26806/C
XX ADF26806 standard; DNA; 20 BP.
XX
XX ADF26806;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human PRO 300 PCR primer #2.

XX
XX Human; seq. PCR; secreted protein; transmembrane protein; PRO; cytosolic;
XX ophthalmological; antiarthritic; osteopathic; vulnervary;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX
XX US2003199436-A1.
XX
XX 23-OCT-2003.
XX
XX 16-OCT-2001; 2001US-00978544.
XX
XX 17-OCT-1997; 97US-0062250P.
XX PR 03-NOV-1997; 97US-0064249P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 21-NOV-1997; 97US-0066364P.
XX PR 10-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 11-MAR-1998; 98US-0077641P.
XX PR 11-MAR-1998; 98US-0077649P.
XX PR 12-MAR-1998; 98US-0077791P.
XX PR 13-MAR-1998; 98US-0078004P.
XX PR 20-MAR-1998; 98US-0078886P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 20-MAR-1998; 98US-0078936P.
XX PR 20-MAR-1998; 98US-0078939P.
XX PR 25-MAR-1998; 98US-0079294P.
XX PR 26-MAR-1998; 98US-0079656P.
XX PR 27-MAR-1998; 98US-0079663P.
XX PR 27-MAR-1998; 98US-0079664P.
XX PR 27-MAR-1998; 98US-0079689P.
XX PR 27-MAR-1998; 98US-0079728P.
XX PR 27-MAR-1998; 98US-0079786P.
XX PR 30-MAR-1998; 98US-0079920P.
XX PR 30-MAR-1998; 98US-0079923P.
XX PR 31-MAR-1998; 98US-0080105P.
XX PR 31-MAR-1998; 98US-0080107P.
XX PR 31-MAR-1998; 98US-0080165P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 01-APR-1998; 98US-0080327P.
XX PR 01-APR-1998; 98US-0080328P.
XX PR 01-APR-1998; 98US-0080333P.
XX PR 01-APR-1998; 98US-0080334P.
XX PR 08-APR-1998; 98US-0081049P.
XX PR 08-APR-1998; 98US-0081070P.
XX PR 08-APR-1998; 98US-0081071P.
XX PR 09-APR-1998; 98US-0081105P.
XX PR 09-APR-1998; 98US-0081203P.
XX PR 09-APR-1998; 98US-0081229P.
XX PR 15-APR-1998; 98US-0081817P.
XX PR 15-APR-1998; 98US-0081819P.
XX PR 15-APR-1998; 98US-0081838P.
XX PR 15-APR-1998; 98US-0081952P.
XX PR 15-APR-1998; 98US-0081953P.
XX PR 21-APR-1998; 98US-0082568P.
XX PR 21-APR-1998; 98US-0082569P.
XX PR 22-APR-1998; 98US-0082700P.
XX PR 22-APR-1998; 98US-0082704P.
XX PR 22-APR-1998; 98US-0082797P.
XX PR 22-APR-1998; 98US-0082804P.
XX PR 23-APR-1998; 98US-0082796P.
XX PR 27-APR-1998; 98US-0083336P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 29-APR-1998; 98US-0083392P.
XX PR 29-APR-1998; 98US-0083435P.
XX PR 29-APR-1998; 98US-0083436P.
XX PR 29-APR-1998; 98US-0083499P.
XX PR 29-APR-1998; 98US-0083500P.
XX PR 29-APR-1998; 98US-0083545P.
XX PR 29-APR-1998; 98US-0083546P.

PR	29-APR-1998	98US-00835588
PR	29-APR-1998	98US-00835599
PR	30-APR-1998	98US-00837422
PR	05-MAY-1998	98US-00843661
PR	06-MAY-1998	98US-0084416P
PR	06-MAY-1998	98US-00844416P
PR	07-MAY-1998	98US-00844416P
PR	07-MAY-1998	98US-0084598P
PR	07-MAY-1998	98US-00846027P
PR	07-MAY-1998	98US-0084637P
PR	07-MAY-1998	98US-00846439P
PR	07-MAY-1998	98US-00846439P
PR	07-MAY-1998	98US-00846439P
PR	13-MAY-1998	98US-0085232P
PR	13-MAY-1998	98US-0085338P
PR	13-MAY-1998	98US-0085338P
PR	15-MAY-1998	98US-0085573P
PR	15-MAY-1998	98US-0085573P
PR	15-MAY-1998	98US-0085573P
PR	15-MAY-1998	98US-0085580P
PR	15-MAY-1998	98US-0085582P
PR	15-MAY-1998	98US-0085582P
PR	15-MAY-1998	98US-0085697P
PR	15-MAY-1998	98US-0085700P
PR	15-MAY-1998	98US-0085704P
PR	18-MAY-1998	98US-0086032P
PR	22-MAY-1998	98US-0086292P
PR	22-MAY-1998	98US-0086431P
PR	22-MAY-1998	98US-0086431P
PR	22-MAY-1998	98US-0086486P
PR	28-MAY-1998	98US-0087098P
PR	28-MAY-1998	98US-0087106P
PR	28-MAY-1998	98US-0087208P
PR	26-JUN-1998	98US-0090863P
PR	26-JUN-1998	98US-0091015P
PR	30-JUL-1998	98US-0094651P
PR	30-JUL-1998	98US-0094651P
PR	11-SEP-1998	98US-0100038P
PR	07-OCT-1998	98US-05021141.1
PR	20-NOV-1998	98US-0109304P
PR	20-NOV-1998	98US-0109304P
PR	22-DEC-1998	98US-0113366P
PR	23-DEC-1998	98US-0113621P
PR	05-JAN-1999	98MO-US0000106
PR	08-MAR-1999	98MO-US0050128
PR	10-MAR-1999	98MO-US0050190
PR	12-MAR-1999	98US-0123577P
PR	29-MAR-1999	98US-0126773P
PR	21-APR-1999	98US-0130232P
PR	26-APR-1999	98US-0131022P
PR	28-APR-1999	98US-0131445P
PR	14-MAY-1999	98US-0134287P
PR	14-MAY-1999	98US-0134287P
PR	16-JUN-1999	98MO-US012252.2
PR	16-JUN-1999	98US-0139557P
PR	02-DEC-1999	98MO-US028613.3
PR	02-DEC-1999	98MO-US028613.3
PR	16-DEC-1999	98MO-US030095.5
PR	30-DEC-1999	98MO-US031243.3
PR	30-DEC-1999	98MO-US0300129.4
PR	05-JAN-2000	2000MO-US000219.7
PR	06-JAN-2000	2000MO-US000277.7
PR	11-FEB-2000	2000MO-US000303.6
PR	11-FEB-2000	2000MO-US003565.5
PR	18-FEB-2000	2000MO-US004041.4
PR	24-FEB-2000	2000MO-US005034.0
PR	10-MAR-2000	2000MO-US005058.41
PR	10-MAR-2000	2000MO-US006619.9

PR	21-MAR-2000	2000OW-US007532
PR	30-MAR-2000	2000OW-US000839
PR	17-MAY-2000	2000OW-US013705
PR	32-MAY-2000	2000OW-US014042
PR	30-MAY-2000	2000OW-US014941
PR	02-JUN-2000	2000OW-US015264
PR	28-JUL-2000	2000OW-US020710
PR	24-DEC-2000	2000OW-US023328
PR	01-DEC-2000	2000OW-US032678
PR	20-DEC-2000	2000OW-US034956
PR	28-FEB-2001	2001OW-US006520
PR	22-MAR-2001	2001OW-US009552
PR	25-MAY-2001	2001OW-US017922
PR	01-JUN-2001	2001OW-US017800
PR	20-JUN-2001	2001OW-US019692
PR	29-JUL-2001	2001OW-US021066
PR	09-JUL-2001	2001OW-US021735
PR	30-JUL-2001	2001OW-US018585
XX		
(GENTH) GENENTECH INC.		

(GETH) GENENTECH INC

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrera N, Filyavov E, Fong S, Garber H, Gerltsen ME;
 PI Gaddara N, Godawari FU, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Klayvan TJ, Kuo SS, Napier MA, Pan J, Seoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tunnas D, Williams PM, Wood WL;
 DR WPI; 2004-041374/04.

PT neuropathy.
PT arthritis, cardiac insufficiency disorders, treating peripheral
PT (Berger disease, celiac disease), pericyte-associated tumors, anemia
PT Novel PRO polypeptides useful for treating diabetes, kidney disorders
PT

Example 5; SEQ ID NO 21; 457pp; English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 84 amino acid sequence identity to an amino acid sequence chosen from 90 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO373 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide.

Query Match	5.9%	Score 14.8;	DB 1;	Length 20;
Best Local Similarity	88.9%	Pred. No. 1.6e+02;		
Matches 16; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY	1256	GCAGCAACAGCTGGAAGA	1273
Db	18	GCAGCACCACTGATGA	1

RESULT	122
ADF27442/c	
ID	ADF27442 standard; DNA; 20 BP.

AC ADF27442;

DT 12-FEB-2004 (first entry)

Human PRO 300 PCR primer #2.

Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
auditory; tumour growth; retinal disorder; sports-related joint problem;
articular cartilage defects; osteoarthritis; rheumatoid arthritis;
wound healing; hearing loss; primer.

OS	Homo sapiens.		
XX	US2003199437-A1.		
XX	23-OCT-2003.		
PD	16-OCT-2001; 2001US-00978665.		
XX			
PR	17-OCT-1997; 97US-0062250P.	PR	07-MAY-1998; 98US-0084600P.
PR	03-NOV-1997; 97US-0064249P.	PR	07-MAY-1998; 98US-0084627P.
PR	13-NOV-1997; 97US-0065311P.	PR	07-MAY-1998; 98US-0084637P.
PR	21-NOV-1997; 97US-0066364P.	PR	07-MAY-1998; 98US-0084639P.
PR	10-MAR-1998; 98US-0077450P.	PR	07-MAY-1998; 98US-0084640P.
PR	11-MAR-1998; 98US-0077632P.	PR	07-MAY-1998; 98US-0084643P.
PR	11-MAR-1998; 98US-0077641P.	PR	13-MAY-1998; 98US-0085323P.
PR	11-MAR-1998; 98US-0077649P.	PR	13-MAY-1998; 98US-0085338P.
PR	12-MAR-1998; 98US-0077791P.	PR	13-MAY-1998; 98US-0085339P.
PR	13-MAR-1998; 98US-0078004P.	PR	15-MAY-1998; 98US-0085573P.
PR	17-MAR-1998; 98US-0080422P.	PR	15-MAY-1998; 98US-0085579P.
PR	20-MAR-1998; 98US-0080886P.	PR	15-MAY-1998; 98US-0085580P.
PR	20-MAR-1998; 98US-0078910P.	PR	15-MAY-1998; 98US-008582P.
PR	20-MAR-1998; 98US-0078936P.	PR	15-MAY-1998; 98US-0085689P.
PR	20-MAR-1998; 98US-0078939P.	PR	15-MAY-1998; 98US-0085700P.
PR	25-MAR-1998; 98US-0079294P.	PR	15-MAY-1998; 98US-0085704P.
PR	26-MAR-1998; 98US-0079656P.	PR	18-MAY-1998; 98US-0086023P.
PR	27-MAR-1998; 98US-0079663P.	PR	22-MAY-1998; 98US-0086392P.
PR	27-MAR-1998; 98US-0079664P.	PR	22-MAY-1998; 98US-0086414P.
PR	27-MAR-1998; 98US-0079689P.	PR	22-MAY-1998; 98US-0086430P.
PR	27-MAR-1998; 98US-0079728P.	PR	22-MAY-1998; 98US-0086486P.
PR	27-MAR-1998; 98US-0079786P.	PR	28-MAY-1998; 98US-0087098P.
PR	30-MAR-1998; 98US-0079920P.	PR	28-MAY-1998; 98US-0087106P.
PR	30-MAR-1998; 98US-0079923P.	PR	28-MAY-1998; 98US-0087208P.
PR	31-MAR-1998; 98US-0080105P.	PR	26-JUN-1998; 98US-0090863P.
PR	31-MAR-1998; 98US-0080165P.	PR	26-JUN-1998; 98US-0091010P.
PR	31-MAR-1998; 98US-0080194P.	PR	01-JUL-1998; 98US-0091359P.
PR	01-APR-1998; 98US-0080327P.	PR	30-JUL-1998; 98US-0094651P.
PR	01-APR-1998; 98US-0080328P.	PR	11-SEP-1998; 98US-0100038P.
PR	01-APR-1998; 98US-0080333P.	PR	07-OCT-1998; 98US-0016897P.
PR	01-APR-1998; 98US-0080334P.	PR	02-OCT-1998; 98WO-US021141.
PR	08-APR-1998; 98US-0081049P.	PR	06-NOV-1998; 98US-00184216.
PR	08-APR-1998; 98US-0081070P.	PR	20-NOV-1998; 98US-00187368.
PR	08-APR-1998; 98US-0081071P.	PR	20-NOV-1998; 98WO-US024855.
PR	09-APR-1998; 98US-0081195P.	PR	07-DEC-1998; 98US-00202054.
PR	09-APR-1998; 98US-0081203P.	PR	22-DEC-1998; 98US-00218517.
PR	09-APR-1998; 98US-0081229P.	PR	22-DEC-1998; 98US-0113266P.
PR	15-APR-1998; 98US-0081817P.	PR	23-DEC-1998; 98US-0113621P.
PR	15-APR-1998; 98US-0081819P.	PR	05-JAN-1999; 99WO-US000106.
PR	15-APR-1998; 98US-0081838P.	PR	05-MAR-1999; 99US-00254465.
PR	15-APR-1998; 98US-0081952P.	PR	08-MAR-1999; 99WO-US005028.
PR	15-APR-1998; 98US-0081955P.	PR	10-MAR-1999; 98US-00265686.
PR	21-APR-1998; 98US-0082568P.	PR	12-MAR-1999; 99WO-US005190.
PR	21-APR-1998; 98US-0082569P.	PR	12-MAR-1999; 99US-00267213.
PR	22-APR-1998; 98US-0082700P.	PR	12-MAR-1999; 99US-0123957P.
PR	22-APR-1998; 98US-0082704P.	PR	29-MAR-1999; 99US-0126773P.
PR	22-APR-1998; 98US-0082797P.	PR	12-APR-1999; 98US-00284291.
PR	22-APR-1998; 98US-0082804P.	PR	21-APR-1999; 98US-0130232P.
PR	23-APR-1998; 98US-0082796P.	PR	26-APR-1999; 99US-0131022P.
PR	27-APR-1998; 98US-0083336P.	PR	28-APR-1999; 99US-0031445P.
PR	28-APR-1998; 98US-0083322P.	PR	14-MAY-1999; 99US-00311832.
PR	29-APR-1998; 98US-0083392P.	PR	14-MAY-1999; 99US-00380137.
PR	29-APR-1998; 98US-0083495P.	PR	14-MAY-1999; 98US-0134287P.
PR	29-APR-1998; 98US-0083496P.	PR	14-MAY-1999; 98WO-US010733.
PR	29-APR-1998; 98US-0083499P.	PR	02-JUN-1999; 99WO-US012252.
PR	29-APR-1998; 98US-0083500P.	PR	16-JUN-1999; 99US-0139557P.
PR	29-APR-1998; 98US-0083545P.	PR	07-JUL-1999; 99US-0141037P.
PR	29-APR-1998; 98US-0083554P.	PR	26-JUL-1999; 99US-0145698P.
PR	29-APR-1998; 98US-0083558P.	PR	28-JUL-1999; 98US-0146222P.
PR	29-APR-1998; 98US-0083559P.	PR	25-AUG-1999; 99US-00380138.
PR	29-APR-1998; 98US-0083554P.	PR	30-NOV-1999; 99US-00380142.
PR	29-APR-1998; 98US-0083558P.	PR	02-DEC-1999; 99WO-US028551.
PR	30-APR-1998; 98US-0083742P.	PR	16-DEC-1999; 99WO-US030095.
PR	05-MAY-1998; 98US-0084366P.	PR	30-DEC-1999; 99WO-US031243.
PR	06-MAY-1998; 98US-0084414P.	PR	05-JAN-2000; 2000WO-US000219.
PR	07-MAY-1998; 98US-0084598P.	PR	06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 16-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021725.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Petrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCAACGCTGGAGCA 1273
Db 18 GCAGCACGACGCTGATGA 1
RESULT 123
ADFA1036/C
ID ADFA1036 standard; DNA; 20 BP.
XX
AC ADFA1036;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW optithalmo; antiarthritic; osteopathic; antirheumatic; vulneryay;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX OS
XX US2003199435-A1.
XX PN
XX PD 23-OCT-2003.
XX
PF 15-OCT-2001; 2001US-00978299.

XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079224P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080377P.
PR 01-APR-1998; 98US-0080382P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080343P.
PR 08-APR-1998; 98US-0081043P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084538P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.

PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98MO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98MO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99MO-US0040106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99MO-US0050128.
PR 12-MAR-1999; 99MO-US0051090.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00380137.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99MO-US010733.
PR 02-JUN-1999; 99MO-US01252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99MO-US028313.
PR 02-DEC-1999; 99MO-US028551.
PR 02-DEC-1999; 99MO-US028565.
PR 16-DEC-1999; 99MO-US030095.
PR 30-DEC-1999; 99MO-US031243.
PR 30-DEC-1999; 99MO-US031274.
PR 05-JAN-2000; 2000MO-US000219.
PR 06-JAN-2000; 2000MO-US000277.
PR 06-JAN-2000; 2000MO-US000376.
PR 11-FEB-2000; 2000MO-US003565.
PR 18-FEB-2000; 2000MO-US004341.
PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 10-MAR-2000; 2000MO-US006319.
PR 21-MAR-2000; 2000MO-US007532.
PR 30-MAR-2000; 2000MO-US008439.

PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 28-JUL-2000; 2000MO-US020710.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000MO-US032678.
PR 20-DEC-2000; 2000MO-US0747259.
PR 20-DEC-2000; 2000MO-US034956.
PR 28-FEB-2001; 2000MO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001MO-US0016920.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001MO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001MO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 30-JUL-2001; 2001US-00918585.
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerltzen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1256 GCAGCAACGCTGGAGG 1273
Db 18 GCAGCAACGCTGGATGA 1
RESULT 124
ADP32715/C
ID ADP32715 standard; DNA; 20 BP.
XX
AC ADP32715;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW opthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
KW atrophy; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003211091-A1.
XX
PD 13-NOV-2003.
XX
PF 25-OCT-2001; 2001US-00013918.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
DR WPI, 2004-021571/02.
XX
XX
XX Novel PRO polypeptides useful for treating peripheral neuropathy,
PT neuropathies associated with systemic disease such as post-polio syndrome
PT or AIDS-associated syndrome.
XX
XX
XX Example 5; SEQ ID NO 21; 465bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide), a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAGCAGCTGAGAGA 1273
Db 18 GCAGCAGCAGCTGAGTGA 1

RESULT 125
ADP25081/C
ID ADP25081 standard; DNA; 20 BP.
XX
XX ADF25081;
AC
XX 12-FEB-2004 (first entry)
DT
XX Human PRO 300 PCR primer #2.
DE
XX Human; 8S; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
KW auditory; tumor growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
XX Homo sapiens.
OS
XX US2003211092-A1.
PN
XX 13-NOV-2003.
PD
XX 19-OCT-2001; 2001US-00162521.
PF
XX
XX 17-MAR-1998; 98US-00040220.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-00182114.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-00248554.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99US-00254465.
PR 05-MAR-1999; 99WO-002500106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00256586.
PR

PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-00380137.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
PA
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
DR WPI, 2004-021572/02.
XX
XX New nucleic acid encoded a secreted and transmembrane polypeptide, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT wounds.
XX
XX Example 5; SEQ ID NO 21; 465bp; English.
PS
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given

in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid), a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of the cell expressing PRO725, PRO700 or PRO739 polypeptide. The polypeptides are useful for inhibiting tumour growth, retinal disorders, sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in mammals. The present sequence is a PCR primer used to isolate nucleic acid encoding a PRO protein.

Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match	5.9%	Score 14.8	DB 1	Length 20
Best Local Similarity	88.9%	Pred. No. 1.6e+02		
Matches 16; Conservative	0	Mismatches 2	Indels 0	Gaps 0

```

Oy      1256 GCAGCACAGCTGGAAGA 1273
          ||||| ||||| ||
Db      18 GCAGCACCAGCTGGATGA 1

```

RESULT 126
AD26182/c
ID AD26182 standard; DNA; 20 BP.

AC ADF26182;

DT 12-FEB-2004 (first entry)

Human PRO 300 PCR primer #2.

KM Human, sb; P&R, secreted protein; transmembrane protein, PRO, cytosolic;
KM ophthalmological, anarthritic; osteopathic, antihaematic; vulnery;
KM auditory; tumour growth; retinal disorder; sports-related joint problem;
KM articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KM wound healing; hearing loss; primer.

OS Homo sapiens.

PN US2003199674-A1.

PD 23-OCT-2003 .

PF 16-OCT-2001; 2001US-00978802.

PR 17-OCT-1997; 97US-0062250P.

PR 13-NOV-1997; 97US-0065311P.

PR	11-NOV-1997	9.7U5-006636340
PR	10-MAR-1998	98U5-00774540P
PR	11-MAR-1998	98U5-00776332P
PR	11-MAR-1998	98U5-00776641P
PR	11-MAR-1998	98U5-00776649P
PR	12-MAR-1998	98U5-00777919P
PR	13-MAR-1998	98U5-00780004P
PR	20-MAR-1998	98U5-00788866P
PR	20-MAR-1998	98U5-00789110P
PR	20-MAR-1998	98U5-00789366P
PR	20-MAR-1998	98U5-00789393P
PR	25-MAR-1998	98U5-00792924P
PR	26-MAR-1998	98U5-00796566P
PR	27-MAR-1998	98U5-00796634P
PR	27-MAR-1998	98U5-00796646P
PR	27-MAR-1998	98U5-00796689P
PR	27-MAR-1998	98U5-00797288P
PR	27-MAR-1998	98U5-00797866P
PR	30-MAR-1998	98U5-00799200P
PR	30-MAR-1998	98U5-00799320P
PR	31-MAR-1998	98U5-00801050P
PR	31-MAR-1998	98U5-00801070P
PR	31-MAR-1998	98U5-00801344P
PR	31-MAR-1998	98U5-00801365P
PR	01-MAR-1998	98U5-00801946P
PR	01-APR-1998	98U5-00803272P
PR	01-APR-1998	98U5-00803328P
PR	01-APR-1998	98U5-00803333P
PR	01-APR-1998	98U5-00803434P
PR	01-APR-1998	98U5-00804033P
PR	08-APR-1998	98U5-00810494P
PR	08-APR-1998	98U5-00810700P
PR	08-APR-1998	98U5-00810710P
PR	09-APR-1998	98U5-00811017P
PR	09-APR-1998	98U5-00811956P
PR	09-APR-1998	98U5-00812033P
PR	09-APR-1998	98U5-00812292P
PR	15-APR-1998	98U5-00818117P
PR	15-APR-1998	98U5-00818191P
PR	15-APR-1998	98U5-00818318P
PR	15-APR-1998	98U5-00819522P
PR	15-APR-1998	98U5-00819565P
PR	21-APR-1998	98U5-00825686P
PR	21-APR-1998	98U5-00825699P
PR	22-APR-1998	98U5-00827000P
PR	22-APR-1998	98U5-00827044P
PR	22-APR-1998	98U5-00827977P
PR	22-APR-1998	98U5-00828044P
PR	23-APR-1998	98U5-00827966P
PR	23-APR-1998	98U5-00833336P
PR	27-APR-1998	98U5-00833322P
PR	28-APR-1998	98U5-00833522P
PR	28-APR-1998	98U5-00833592P
PR	29-APR-1998	98U5-00834956P
PR	29-APR-1998	98U5-00834966P
PR	29-APR-1998	98U5-00834999P
PR	29-APR-1998	98U5-00835000P
PR	29-APR-1998	98U5-00835454P
PR	29-APR-1998	98U5-00835544P
PR	29-APR-1998	98U5-00835586P
PR	29-APR-1998	98U5-00835592P
PR	30-APR-1998	98U5-00837422P
PR	05-MAY-1998	98U5-00843366P
PR	06-MAY-1998	98U5-00844414P
PR	06-MAY-1998	98U5-00844419P
PR	07-MAY-1998	98U5-00845980P
PR	07-MAY-1998	98U5-00846000P
PR	07-MAY-1998	98U5-00846527P
PR	07-MAY-1998	98U5-00846577P
PR	07-MAY-1998	98U5-00846596P
PR	07-MAY-1998	98U5-00846640P
PR	13-MAY-1998	98U5-00853332P
PR	13-MAY-1998	98U5-00853380P
PR	13-MAY-1998	98U5-00853396P
PR	15-MAY-1998	98U5-00855797P

PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085688P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-0113621P.
PR 08-MAR-1999; 99US-0113621P.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99US-0139557P.
PR 16-JUN-1999; 99US-0141037P.
PR 23-JUN-1999; 99US-0142680P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 30-DEC-1999; 99US-0162506P.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000219.
PR 11-FEB-2000; 2000US-0000376.
PR 18-FEB-2000; 2000US-0000376.
PR 24-FEB-2000; 2000US-0000376.
PR 02-MAR-2000; 2000US-0000376.
PR 10-MAR-2000; 2000US-0000376.
PR 21-MAR-2000; 2000US-0000376.
PR 30-MAR-2000; 2000US-0000376.
PR 17-MAY-2000; 2000US-0000376.
PR 22-MAY-2000; 2000US-0000376.
PR 30-MAY-2000; 2000US-0000376.
PR 02-JUN-2000; 2000US-0000376.
PR 28-JUN-2000; 2000US-0000376.
PR 24-AUG-2000; 2000US-0000376.
PR 01-DEC-2000; 2000US-0000376.
PR 20-DEC-2000; 2000US-0000376.
PR 28-FEB-2001; 2001US-0000376.
PR 22-MAR-2001; 2001US-0000376.
PR 25-MAY-2001; 2001US-0000376.
PR 01-JUN-2001; 2001US-0000376.
PR 20-JUN-2001; 2001US-0000376.
PR 29-JUL-2001; 2001US-0000376.
PR 30-JUL-2001; 2001US-0000376.

XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gether H, Gerlitsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AU, Hillan KJ;
PI K11avin ID, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tamas D, Williams PM, Wood WI;
XX WPI; 2004-041393/04.
XX
XX New PRO polypeptides PRO200, PRO322, PRO540, PRO846 and PRO617 that
PT enhance the survival/proliferation of rod photoreceptor cells, useful for
PT treating retinal disorders or injuries e.g., sight loss in mammals.
XX
XX Example 5; SEQ ID NO 21; 464bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Beat Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1256 GCAGCAACAGCTGAGAG 1273
DB 18 GCAGCACCAGCTGATGA 1
|||||
|||

RESULT 127
ADP33971/C
ID ADP33971 standard; DNA; 20 BP.
XX
XX ADP33971;
XX
XX 12-FEB-2004 (first entry)
DT
XX
DE Human PRO 300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
XX ophthalmological; antirheumatic; osteopathic; antirheumatic; vlnetary;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
XX US2003194410-A1.
XX
XX 16-OCT-2003.
PD
XX
XX 18-OCT-2001; 2001US-00145087.
PP
XX
XX 18-FEB-2000; 2000US-00004341.
PR
XX 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
PA
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gether H, Gerlitsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AU, Hillan KJ;
PI K11avin ID, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tamas D, Williams PM, Wood WI;


```
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0100211P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0112968P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-0113621P.
PR 08-MAR-1999; 99US-0113621P.
PR 10-MAR-1999; 99US-0113621P.
PR 12-MAR-1999; 99US-0113621P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131455P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99US-0134287P.
PR 16-JUN-1999; 99US-0134287P.
PR 23-JUN-1999; 99US-0134287P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0142680P.
PR 28-JUL-1999; 99US-0142680P.
PR 29-OCT-1999; 99US-0142680P.
PR 30-NOV-1999; 99US-0142680P.
PR 02-DEC-1999; 99US-0142680P.
PR 16-DEC-1999; 99US-0142680P.
PR 30-DEC-1999; 99US-0142680P.
PR 05-JAN-2000; 2000US-0142680P.
PR 06-JAN-2000; 2000US-0142680P.
PR 11-FEB-2000; 2000US-0142680P.
PR 18-FEB-2000; 2000US-0142680P.
PR 24-FEB-2000; 2000US-0142680P.
PR 02-MAR-2000; 2000US-0142680P.
PR 10-MAR-2000; 2000US-0142680P.
PR 21-MAR-2000; 2000US-0142680P.
PR 30-MAR-2000; 2000US-0142680P.
PR 17-MAY-2000; 2000US-0142680P.
PR 22-MAY-2000; 2000US-0142680P.
PR 30-MAY-2000; 2000US-0142680P.
PR 02-JUN-2000; 2000US-0142680P.

PR 28-JUL-2000; 2000US-0202710.
PR 24-AUG-2000; 2000US-0202710.
PR 01-DEC-2000; 2000US-0202710.
PR 20-DEC-2000; 2000US-0202710.
PR 28-FEB-2001; 2001US-0202710.
PR 22-MAR-2001; 2001US-0202710.
PR 25-MAY-2001; 2001US-0202710.
PR 01-JUN-2001; 2001US-0202710.
PR 20-JUN-2001; 2001US-0202710.
PR 29-JUN-2001; 2001US-0202710.
PR 09-JUL-2001; 2001US-0202710.
PR 30-JUL-2001; 2001US-0202710.

PA (GETH ) GENENTECH INC.
XX
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Flivartoff E, Fong S, Gao W, Getz H, Gerritsen ME;
XX Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;
XX Klevavich ID, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
XX Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX WPI; 2004-021096/02.
XX
XX New nucleic acid encoding a secreted and transmembrane polypeptide,
XX useful for treating e.g. lung or breast tumors, osteoarthritis,
XX rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
XX hypoinulinemia or wounds.
XX
XX Example 5; SEQ ID NO 21; 460bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide), a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO37 polypeptide is useful for detecting a PRO493
XX polypeptide in a sample suspected of containing PRO493 polypeptide.

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACGCTGGAAGA 1273
DB 18 GCAGCAACGCTGGAAGA 1

RESULT 129
ADG50194/C
ID ADG50194 standard; DNA; 20 BP.
XX
XX AC ADG50194;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human PRO 300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
XX ophthalmological; antiarthritic; osteoporotic; antirheumatic; vlnary;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX
XX Homo sapiens.
XX
XX US2003207803-A1.
XX
XX 06-NOV-2003.
XX
```

PX	19-OCT-2001; 2001US-00143026.
FR	28-MAY-1998; 98US-0087106P.
PR	30-JUL-1998; 98US-0094651P.
PR	08-MAR-1999; 98WO-US005028.
PR	25-AUG-1999; 99US-00380138.
PR	18-FEB-2000; 2000MO-US004341.
PR	30-JUL-2001; 2001US-00918585.
XX	
PA	(GENTH) GENENTECH INC.
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL,
PI	Ferrara N, Flivieroff E, Fong S, Gao W, Gerber H, Gerritsen MB,
PI	Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI	Klitvin IJ, Kuo SS, Nabner MA, Pan J, Peoni NF, Roy MA, Shelton DL;
PI	Stewart TA, Tumas D, Williams PM, Wood WT;
DR	WPI; 2004-021515/02.
XX	
PT	New genes and encoded secreted and transmembrane polypeptides, useful for
PT	treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT	arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT	wounds.
PS	
XX	Example 5; SEQ ID NO 21; 463pp; English.
XX	
CC	The invention relates to an isolated PRO polypeptide (secreted or
CC	transmembrane protein) having at least 80% amino acid sequence identity
CC	to an amino acid sequence chosen from 94 fully defined sequences as given
CC	in the specification (including PRO lacking its associated signal
CC	peptide, a PRO extracellular domain with or without its associated signal
CC	peptide). Also included are nucleic acids encoding the PRO proteins
CC	mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC	comprising the vector and producing PRO, a chimeric molecule comprising
CC	PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC	antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC	polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC	Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC	polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC	PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC	PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC	bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC	molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC	causes death of the cell. PRO337 polypeptide is useful for linking a
CC	bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC	PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC	to a cell expressing PRO1559 polypeptide, and PRO1559 polypeptide is
CC	useful for linking a bioactive molecule to a cell expressing PRO725,
CC	PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC	polypeptide is useful for modulating at least one biological activity of
CC	the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC	polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC	biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC	PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC	modulating the biological activity of the cell expressing PRO1559
CC	polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC	PRO739 polypeptide is useful for modulating the biological activity of
CC	the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC	polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC	sports-related joint problems, articular cartilage defects,
CC	osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC	mammals. The present sequence is a PCR primer used to isolate nucleic
CC	acid encoding a PRO protein.
SQ	Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX	
Query Match	5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity	88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0	
OY	1256 GCAGCAACGCTGGAGA 1273
DB	18 GCAGCACCGAGCTGGATGA 1

RESULT 130	ADG49570/c	ADG49570 standard; DNA; 20 BP.
XX	ID	ADG49570
XX	AC	ADG49570;
XX	DT	11-MAR-2004 (f1ret entry)
XX	DE	Human PRO 300 PCR primer #2.
XX	KM	Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KM	KM	ophthalmological; antiarthritis; osteopathic; antirheumatic; vitreary;
KM	KM	auditory; tumour growth; retinal disorder; sports-related joint problem;
KM	KM	articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KM	KM	wound healing; hearing loss; primer.
XX	OS	Homo sapiens.
XX	PN	US2003215905-A1.
XX	PD	20-NOV-2003.
XX	PF	25-OCT-2001; 2001US-00013928.
XX	PR	07-OCT-1998; 98WO-US021141.
PR	PR	20-NOV-1998; 98WO-US024855.
PR	PR	05-JAN-1999; 99WO-US000106.
PR	PR	08-MAR-1999; 99WO-US005028.
PR	PR	10-MAR-1999; 99WO-US005190.
PR	PR	28-APR-1999; 99US-0131445P.
PR	PR	14-MAY-1999; 99WO-US010733.
PR	PR	02-JUN-1999; 99WO-US012252.
PR	PR	25-AUG-1999; 99US-00380138.
PR	PR	30-NOV-1999; 99WO-US028313.
PR	PR	02-DEC-1999; 99WO-US028551.
PR	PR	02-DEC-1999; 99WO-US028565.
PR	PR	16-DEC-1999; 99WO-US030095.
PR	PR	30-DEC-1999; 99WO-US031243.
PR	PR	30-DEC-1999; 99WO-US031274.
PR	PR	05-JAN-2000; 2000WO-US000219.
PR	PR	06-JAN-2000; 2000WO-US000277.
PR	PR	06-JAN-2000; 2000WO-US000376.
PR	PR	11-FEB-2000; 2000WO-US003565.
PR	PR	18-FEB-2000; 2000WO-US004341.
PR	PR	24-FEB-2000; 2000WO-US005004.
PR	PR	02-MAR-2000; 2000WO-US005841.
PR	PR	10-MAR-2000; 2000WO-US006319.
PR	PR	21-MAR-2000; 2000WO-US007532.
PR	PR	30-MAR-2000; 2000WO-US008439.
PR	PR	17-MAY-2000; 2000WO-US013705.
PR	PR	22-MAY-2000; 2000WO-US014042.
PR	PR	30-MAY-2000; 2000WO-US014941.
PR	PR	02-JUN-2000; 2000WO-US012664.
PR	PR	28-JUN-2000; 2000WO-US020710.
PR	PR	24-AUG-2000; 2000WO-US023328.
PR	PR	01-DEC-2000; 2000WO-US032678.
PR	PR	20-DEC-2000; 2000WO-US034956.
PR	PR	28-FEB-2001; 2001WO-US006520.
PR	PR	22-MAR-2001; 2001WO-US009552.
PR	PR	25-MAY-2001; 2001WO-US017092.
PR	PR	01-JUN-2001; 2001WO-US017800.
PR	PR	20-JUN-2001; 2001WO-US016992.
PR	PR	29-JUN-2001; 2001WO-US021066.
PR	PR	09-JUL-2001; 2001WO-US021735.
XX	XX	30-JUL-2001; 2001US-00918585.
PA	(GETH)	GENENTECH INC.
XX	XX	
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,	
PI	Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,	
PI	Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;	

PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2004-060683/08.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
XX Example 5; SEQ ID NO 21; 454bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumor growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1256 GCAGCAGAGCTGGAAGA 1273
Db 18 GCAGCAGCAGCTGGAATGA 1
AC
XX ADG51442 standard; DNA; 20 BP.
XX
XX ADG51442;
AC
XX 11-MAR-2004 (first entry)
DT
XX
XX Human PRO 300 PCR primer #2.
DE
XX
XX Human, 89; PCR, secreted protein, transmembrane protein, PRO, cytosstatic,
KM ophthalmological, antiarthritic, osteopamchic, antirheumatic, vulnery;
KM auditory, tumor growth, retinal disorder, sports-related joint problem;
KM articular cartilage defects, osteoarthritis, rheumatoid arthritis;

KM wound healing; hearing loss; primer.
XX
XX Home sapiens.
OS
XX US2003215908-A1.
XX
XX 20-NOV-2003.
XX
XX 19-OCT-2001; 2001US-00162522.
XX
XX 06-MAY-1998; 98US-0084441P.
XX
XX 08-MAR-1999; 99WO-US005028.
XX
XX 25-AUG-1999; 99US-00380138.
XX
XX 30-NOV-1999; 99WO-US028313.
XX
XX 18-FEB-2000; 2000WO-US004341.
XX
XX 30-JUL-2001; 2001US-00918585.
XX
XX (GENTH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2004-021841/02.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
XX Example 5; SEQ ID NO 21; 453bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumor growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 5.9%; Score 14.8; DB 1; Length 20;

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-01462506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

(GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Flivartoff E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumes D, Williams PM, Wood WJ;
XX
DR WPI; 2004-033145/03.
XX
XX
PT New secreted and transmembrane PRO polypeptide useful as a molecular
PT weight marker and for treating arthritis, thalassemia, diabetes, or
PT cardiac insufficiency disorders.
XX
XX
PS Example 5; SEQ ID NO 21; 456bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1256 GCAGCAACAGCTGAGA 1273
DB 18 GCAGCAACAGCTGATGA 1

RESULT 133
ADG48322/Cv standard; DNA, 20 BP.
ID ADG48322 standard; DNA, 20 BP.
XX
XX ADG48322;
AC
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2003216560-A1.
XX
PD 20-NOV-2003.
XX
PF 25-OCT-2001; 2001US-00013925.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079669P.
PR 27-MAR-1998; 98US-0079688P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080339P.
PR 08-APR-1998; 98US-0080349P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081222P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084643P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 30-JUL-1998; 98US-0091359P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0100211P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130233P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-013145P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 16-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023128.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

(GERTH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tunas D, Williams PM, Wood WI;

WPI; 2004-031149/03.

PT New PRO polypeptide useful for treating peripheral neuropathy,
PT neuropathies associated with systemic disease such as post-polio syndrome
PT or acquired immunodeficiency syndrome-associated syndrome.

Example 5; SEQ ID NO 21; 454pp; English.

CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide), a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1256 GCAGCAACAGCTGGAGA 1273
||| ||| ||| ||| ||| |||
Db 18 GCAGCACCACTGATGA 1

RESULT 134

ID ADG50818 standard; DNA; 20 BP.

XX ADG50818;

XX

DT 25-MAR-2004 (first entry)
 XX
 DE Human PRO 300 PCR primer #2.
 XX
 KW Human, ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
 KW ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnary;
 KW auditory; tumour growth; retinal disorder; sports-related joint problem;
 KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
 KW wound healing; hearing loss; primer.
 XX
 OS Homo sapiens.
 XX
 PN US2004005312-A1.
 XX
 PD 08-JAN-2004.
 XX
 PF 18-OCT-2001; 2001US-00145093.
 XX
 PR 15-APR-1998; 98US-0081952P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 30-NOV-1999; 99WO-US028313.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GENTH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tunas D, Williams PM, Wood WI;
 XX
 DR WPI; 2004-081694/08.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy for treating obesity or diabetes, in chromosome and gene
 PT mapping, as chromosome markers, in tissue typing, and in identifying
 PT chromosome.
 XX
 PS Example 5; SEQ ID NO 21; 463bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 94 fully defined sequences as given
 CC in the specification (including PRO lacking its associated signal
 CC peptide, a PRO extracellular domain with or without its associated signal
 CC peptide). Also included are nucleic acids encoding the PRO proteins
 CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
 CC comprising the vector and producing PRO, a chimeric molecule comprising
 CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
 CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
 CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
 CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
 CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
 CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
 CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
 CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
 CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
 CC causes death of the cell. PRO337 polypeptide is useful for linking a
 CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
 CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
 CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
 CC useful for linking a bioactive molecule to a cell expressing PRO725,
 CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
 CC polypeptide is useful for modulating at least one biological activity of
 CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
 CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
 CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
 CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
 CC modulating the biological activity of the cell expressing PRO1559
 CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
 CC PRO739 polypeptide is useful for modulating the biological activity of

CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
 CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
 CC sports-related joint problems, articular cartilage defects,
 CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
 CC mammals. The present sequence is a PCR primer used to isolate nucleic
 CC acid encoding a PRO protein.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
 XX
 Query Match 5.9%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 1256 GCAGCAACGCTGGAAGA 1273
 DB 18 GCAGCACCAGCTGGAATCA 1
 XX
 RESULT 135
 ADG58762/C
 ID ADG58762 standard; DNA; 20 BP.
 XX
 AC ADG58762;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human PRO 300 PCR primer #2.
 XX
 PI Human, ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
 PI ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnary;
 PI auditory; tumour growth; retinal disorder; sports-related joint problem;
 PI articular cartilage defects; osteoarthritis; rheumatoid arthritis;
 KW wound healing; hearing loss; primer.
 KW
 OS Homo sapiens.
 XX
 PN US2004005657-A1.
 XX
 PD 08-JAN-2004.
 XX
 PF 25-OCT-2001; 2001US-00013919.
 XX
 PR 15-APR-1998; 98US-0081952P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 30-NOV-1999; 99WO-US028313.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GENTH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tunas D, Williams PM, Wood WI;
 XX
 DR WPI; 2004-081722/08.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acid
 PT molecules, useful in gene therapy, or for diagnosing and treating
 PT neoplastic cell growth and proliferation, diabetes or cardiac
 PT insufficiency disorders in mammals.
 XX
 PS Example 5; SEQ ID NO 21; 463bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 94 fully defined sequences as given
 CC in the specification (including PRO lacking its associated signal
 CC peptide, a PRO extracellular domain with or without its associated signal
 CC peptide). Also included are nucleic acids encoding the PRO proteins
 CC mentioned above, a vector comprising a PRO nucleic acid, a host cell

CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO493
CC polypeptide in a sample suspected of containing PRO493 polypeptide.
CC Similarly, PRO493 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO493 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO493 polypeptide. PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO493 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO493 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO493 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.

CC
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1256 GCAGCAGCCTGAGAGA 1273
|||
Db 18 GCAGCAGCAGCTGATGA 1

RESULT 136
ADG62218/C
ID ADG62218 standard; DNA; 20 BP.

XX AC ADG62218;

XX DT 25-MAR-2004 (first entry)

XX DE Human PRO 300 PCR primer #2.

XX Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiallergic; osteopathic; antirheumatic; vulnery;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.

XX Homo sapiens.

XX US2004006219-A1.

XX PD 08-JAN-2004.

XX PF 25-OCT-2001; 2001US-00013920.

XX PR 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066364P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078959P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079669P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085699P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 15-MAY-1998; 98US-0086023P.
PR 18-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.

PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
XX Ferrara N, Flivartoff E, Fong S, Gao W, Gerber H, Gertlesen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TN, Tumas D, Williams PM, Wood WI;
XX WPI; 2004-090107/09.
XX
XX Novel secreted and transmembrane PRO polypeptides useful for treating
PT diabetes, kidney disorders (Berger disease, celiac disease), pericyte-
XX associated tumors, arthritis and cardiac insufficiency disorders.
XX
XX Example 5; SEQ ID NO 21; 458bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide, a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
XX Similarly, PRO4993 polypeptide is useful for detecting PRO337
XX polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
XX PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting

CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articulating cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1256 GCAGCAACAGCTGGAAGA 1273
DB 18 GCAGCAACAGCTGGAATCA 1
|||||
ADH25243/C
ID ADH25243 standard; DNA; 20 BP.
XX
XX ADH25243;
XX
XX 22-APR-2004 (first entry)
XX
XX Human neurotrophin homologue related nucleotide sequence SEQ ID NO:21.
XX
XX human neurotrophin homologue; human; neurotrophin; neuroprotective;
XX muscular; nephrotropic; gene therapy; PRO337; neural dysfunction;
XX amyotrophic lateral sclerosis; Bell's palsy; paralysis;
XX spinal muscular atrophy; dementia; trauma; neuropathy;
XX AIDS-associated neuropathy; Charcot-Marie-Tooth disease;
XX Reiter's disease; Tangle disease; Krabbe's disease; Fabry's disease;
XX Dejerie-Sottas syndrome; PCR primer; probe; ss.
XX
XX Homo sapiens.
XX
XX EP386931-A1.
XX
XX 04-FEB-2004.
XX
XX 08-MAR-1999; 2003EP-00006440.
XX
XX 25-MAR-1998; 98US-0079294P.
XX
XX (GETH) GENENTECH INC.
XX
XX Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;
XX WPI; 2004-124994/13.
XX
XX New human neurotrophin homologue (PRO337) polypeptides and nucleic acids,
XX useful for treating diseases characterized by neural dysfunction, e.g.,
XX amyotrophic lateral sclerosis, Bell's palsy, and paralysis.
XX

PS Disclosure; SEQ ID NO 21; 40bp; English.
XX
CC The present invention describes an isolated human neurotrophin homologue
CC nucleic acid (1) having: (a) at least 80% sequence identity to a
CC nucleotide sequence encoding a polypeptide comprising a sequence of 344
CC amino acids (SEQ ID NO:523; ADH25745); or (b) a sequence encoding SEQ ID
CC NO: 523. Also described: (1) a vector comprising (1); (2) a host cell
CC comprising the vector; (3) a process for producing a polypeptide by
CC culturing the host cell of (2) for the expression of the polypeptide, and
CC recovering the polypeptide from the cell culture; (4) an isolated
CC polypeptide comprising: (a) a sequence having at least 80% sequence
CC identity to SEQ ID NO: 523; (b) a sequence having at least 80% sequence
CC identity to the amino acid sequence encoding the nucleotide deposited
CC under accession number ATCC 209487; (c) SEQ ID NO: 523; or (d) a sequence
CC having the amino acid sequence encoding the nucleotide deposited under
CC accession number ATCC 209487; (5) a chimeric molecule comprising a
CC polypeptide of (4); (6) an antibody which specifically binds to a
CC polypeptide of (4); and (7) a composition comprising the antibody in
CC admixture with a pharmaceutical carrier. (1) has neuroprotective,
CC muscular and nephroprotective activities, and can be used in gene therapy.
CC (1) is useful as a hybridisation probe, in chromosome and gene mapping,
CC in generating antisense RNA and DNA, and in generating transgenic
CC animals. The human neurotrophin homologue PRO337 polypeptide may be used
CC in assays to identify its ligands, or in treating diseases characterised
CC by neural dysfunction, e.g. amyotrophic lateral sclerosis, Bell's palsy,
CC paralysis, and various conditions involving spinal muscular atrophy.
CC PRO337 polypeptide may also be used as a cognitive enhancer, to enhance
CC learning particularly in dementia or trauma, or to treat neuropathies
CC (e.g. AIDS-associated neuropathy, Charcot-Marie-Tooth disease, Refsum's
CC disease, Tangier disease, Krabbe's disease, Fabry's disease or Dejerine-
CC Sottas syndrome. The present sequence is used in the exemplification of
CC the present invention.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. NO. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1256 GCAGCAACGCTGGAAGA 1273
Db 18 GCAGCACCACTGGATGA 1
RESULT 139
ADN17020/C
ID ADN17020 standard; DNA; 20 BP.
XX
AC ADN17020;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human PRO 300 PCR primer #2.
XX
KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
KW ophthalmological; antiarthritic; osteopathic; anti-rheumatic; vulvar;
KW auditory; tumour growth; retinal disorder; sports-related joint problem;
KW articular cartilage defects; osteoarthritis; rheumatoid arthritis;
KW wound healing; hearing loss; primer.
XX
OS Homo sapiens.
XX
PN US2004048332-A1.
XX
PD 11-MAR-2004.
XX
PE 24-OCT-2001; 2001US-00999831.
XX
PF 29-APR-1998; 98US-0083545P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00360138.
PR 29-OCT-1999; 99US-0162506P.
PR 02-DEC-1999; 99WO-US028551.

PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GERTH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Borstein D, Denoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Geber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
PI Kijavrin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI: 2004-238493/22.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acid
PT molecules, useful in gene therapy, or for diagnosing and treating
PT neoplastic cell growth and proliferation, diabetes or cardiac
PT insufficiency disorders in mammals.
XX
PS Example 5; SEQ ID NO 21; 461bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO337
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC PRO1559 polypeptide, and PRO700 or PRO739 polypeptide is useful for detecting
CC PRO725. PRO700 or PRO739 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence is a PCR primer used to isolate nucleic
CC acid encoding a PRO protein.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. NO. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1256 GCAGCAACGCTGGAAGA 1273
Db 18 GCAGCACCACTGGATGA 1
RESULT 139
ADL06854/C
ID ADL06854 standard; DNA; 20 BP.
XX

AC ADL06854;
XX 17-JUN-2004 (first entry)
XX Human PRO 300 PCR primer #2.
XX
XX Human, ss; PCR; secreted protein; transmembrane protein; PRO; cytosolic;
XX ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery;
XX auditory; tumour growth; retinal disorder; sports-related joint problem;
XX articular cartilage defects; osteoarthritis; rheumatoid arthritis;
XX wound healing; hearing loss; primer.
XX Homo sapiens.
XX
XX US2004063921-A1.
XX 01-APR-2004.
XX 25-OCT-2001; 2001US-00013917.
XX
XX 17-MAR-1998; 98US-00040220.
XX 26-JUN-1998; 98US-00105413.
XX 07-OCT-1998; 98US-00168978.
XX 07-OCT-1998; 98WO-US021141.
XX 02-NOV-1998; 98US-00184216.
XX 06-NOV-1998; 98US-00187368.
XX 20-NOV-1998; 98WO-US024855.
XX 07-DEC-1998; 98US-00202054.
XX 22-DEC-1998; 98US-00218517.
XX 05-JAN-1999; 99WO-US000106.
XX 05-MAR-1999; 99US-00254465.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99US-00265686.
XX 10-MAR-1999; 99WO-US005130.
XX 12-MAR-1999; 99US-00267213.
XX 12-APR-1999; 99US-00284291.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99US-00380137.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99US-00380148.
XX 25-AUG-1999; 99US-00380142.
XX 30-NOV-1999; 99WO-US028513.
XX 02-DEC-1999; 99WO-US028513.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 30-DEC-1999; 99WO-US031243.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 24-FEB-2000; 2000WO-US005004.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015254.
XX 28-JUL-2000; 2000WO-US020710.
XX 24-AUG-2000; 2000WO-US023348.
XX 08-NOV-2000; 2000US-00709238.
XX 27-NOV-2000; 2000US-00723749.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 22-MAR-2001; 2001US-00816920.
XX 22-MAR-2001; 2001WO-US009552.

PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017892.
PR 01-JUN-2001; 2001US-00872835.
PR 01-JUN-2001; 2001US-00872835.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME,
XX Goddard A, Godowski PJ, Grimaldi JC, Gueney AL, Hillan KJ,
XX Klavins LJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL,
XX Stewart TA, Tumas D, Williams PM, Wood WI,
XX
XX WPI; 2004-282524/26.
XX
XX New PRO polynucleotides and polypeptides, used as molecular weight
XX markers and are useful in chromosome mapping and tissue typing and in
XX treating tumors.
XX
XX Example 5; SEQ ID NO 21; 464pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 94 fully defined sequences as given
XX in the specification (including PRO lacking its associated signal
XX peptide), a PRO extracellular domain with or without its associated signal
XX peptide). Also included are nucleic acids encoding the PRO proteins
XX mentioned above, a vector comprising a PRO nucleic acid, a host cell
XX comprising the vector and producing PRO, a chimeric molecule comprising
XX PRO fused to a heterologous amino acid sequence, and an anti-PRO
XX antibody. PRO337 polypeptide is useful for detecting a PRO4993
XX polypeptide in a sample suspected of containing PRO4993 polypeptide.
XX Similarly, PRO4993 polypeptide is useful for detecting PRO337
XX polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
XX PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
XX PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
XX bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
XX molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
XX causes death of the cell. PRO337 polypeptide is useful for linking a
XX bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
XX PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
XX to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
XX useful for linking a bioactive molecule to a cell expressing PRO725,
XX PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
XX polypeptide is useful for modulating at least one biological activity of
XX the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
XX polypeptide or anti-PRO4993 polypeptide is useful for modulating the
XX biological activity of the cell expressing PRO4993 polypeptide; PRO725,
XX PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
XX modulating the biological activity of the cell expressing PRO1559
XX polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
XX PRO739 polypeptide is useful for modulating the biological activity of
XX the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
XX polypeptides are useful for inhibiting tumour growth, retinal disorders,
XX sports-related joint problems, articular cartilage defects,
XX osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
XX mammals. The present sequence is a PCR primer used to isolate nucleic
XX acid encoding a PRO protein.
XX
XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY      1256 GCAGCACGCTGGAAGA 1273
      ||||| ||||| |||||
Db      18 GCAGCACGCTGGATGA 1

RESULT 140
ADPe8735
ID      ADPe8735 standard; DNA; 20 BP.
XX
XX      ADPe8735;
AC
XX      09-SEP-2004 (first entry)
DT
XX
XX      Mouse PPAR-alpha antisense oligonucleotide seqid 171.
DE
XX
XX      cyrostatic; gene therapy; PPAR-alpha;
KW      peroxisome proliferator-activated receptor-alpha; PPAR-alpha modulator;
KW      PPAR-alpha associated disorder; hyperproliferative disorder; mouse;
KW      antisense oligonucleotide; antisense technology; ss.
XX
XX      Mus musculus.
OS
XX      US2004115637-A1.
PN
XX      17-JUN-2004.
PD
XX      11-DEC-2002; 2002US-00317500.
PF
XX      11-DEC-2002; 2002US-00317500.
PR
XX      11-DEC-2002; 2002US-00317500.
XX
XX      (ISIS-) ISIS PHARM INC.
PA
XX      McKay R, Dobie KW;
XX      WPI; 2004-449378/42.
XX
XX      New oligonucleotide compound that inhibits expression of PPAR-alpha,
PT      useful for preparing a composition for treating hyperproliferative
PT      disorders, e.g. cancer.
XX
XX      Example 16; SEQ ID NO 171; 121bp; English.
PS
XX
XX      The invention describes a compound, having a sequence comprising 8-80 bp
CC      targeted to a nucleic acid encoding PPAR-alpha (peroxisome proliferator-
CC      activated receptor-alpha), that specifically hybridises with the nucleic
CC      acid encoding PPAR-alpha comprising 86001-bp sequence and inhibits
CC      expression of PPAR-alpha. Also described are: a method of inhibiting the
CC      expression of PPAR-alpha in cells or tissues; a method of screening for a
CC      modulator of PPAR-alpha; a diagnostic method for identifying a disease
CC      state; a kit or assay device comprising the compound; and a method of
CC      treating an animal having a disease or condition associated with PPAR-
CC      alpha. The oligonucleotide compound is useful for preparing a composition
CC      for treating hyperproliferative disorder e.g. cancer. This sequence
CC      represents a mouse peroxisome proliferator-activated receptor-alpha (PPAR
CC      -alpha) antisense oligonucleotide.
CC
SQ      Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1353 CCCAGGCGAGCTGAGGCT 1370
      ||||| ||||| |||||
Db      1 CCTGGGCACTTGAGGCT 18

RESULT 141
ADPe8836/C
ID      ADPe8836 standard; DNA; 20 BP.
XX
XX      ADPe8836;
AC
XX
```

```
DT      09-SEP-2004 (first entry)
XX
XX      Mouse PPAR-alpha antisense oligonucleotide seqid 272.
DE
XX
XX      cyrostatic; gene therapy; PPAR-alpha;
KW      peroxisome proliferator-activated receptor-alpha; PPAR-alpha modulator;
KW      PPAR-alpha associated disorder; hyperproliferative disorder; mouse;
KW      antisense oligonucleotide; antisense technology; ss.
XX
XX      Homo sapiens.
OS
XX      US2004115637-A1.
PN
XX      17-JUN-2004.
PD
XX      11-DEC-2002; 2002US-00317500.
PF
XX      11-DEC-2002; 2002US-00317500.
PR
XX      11-DEC-2002; 2002US-00317500.
XX
XX      (ISIS-) ISIS PHARM INC.
PA
XX      McKay R, Dobie KW;
XX      WPI; 2004-449378/42.
XX
XX      New oligonucleotide compound that inhibits expression of PPAR-alpha,
PT      useful for preparing a composition for treating hyperproliferative
PT      disorders, e.g. cancer.
XX
XX      Example 16; SEQ ID NO 272; 121bp; English.
PS
XX
XX      The invention describes a compound, having a sequence comprising 8-80 bp
CC      targeted to a nucleic acid encoding PPAR-alpha (peroxisome proliferator-
CC      activated receptor-alpha), that specifically hybridises with the nucleic
CC      acid encoding PPAR-alpha comprising 86001-bp sequence and inhibits
CC      expression of PPAR-alpha. Also described are: a method of inhibiting the
CC      expression of PPAR-alpha in cells or tissues; a method of screening for a
CC      modulator of PPAR-alpha; a diagnostic method for identifying a disease
CC      state; a kit or assay device comprising the compound; and a method of
CC      treating an animal having a disease or condition associated with PPAR-
CC      alpha. The oligonucleotide compound is useful for preparing a composition
CC      for treating hyperproliferative disorder e.g. cancer. This sequence
CC      represents a mouse peroxisome proliferator-activated receptor-alpha (PPAR
CC      -alpha) antisense oligonucleotide.
CC
SQ      Sequence 20 BP; 3 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

Query Match      5.9%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1353 CCCAGGCGAGCTGAGGCT 1370
      ||||| ||||| |||||
Db      20 CCTGGGCACTTGAGGCT 3

RESULT 142
AB182180/C
ID      AB182180 standard; DNA; 21 BP.
XX
XX      AB182180;
AC
XX      15-FEB-2002 (first entry)
DT
XX
XX      p53 mutation detection primer/probe #59.
DE
XX
XX      Human; K-ras; PCR primer; probe; capture probe; mutation detection;
KW      ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW      infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
KW      oncogene; tumour suppressor; human papillomavirus; forensic;
KW      environmental monitoring; food industry; feed industry; ss.
XX
XX      Homo sapiens.
OS
```

```

OS Synthetic.
XX WO200179548-A2.
XX
XX 25-OCT-2001.
XX
XX 04-APR-2001; 2001WO-US010958.
XX
XX 14-APR-2000; 2000US-01972721P.
XX
XX (CORR ) CORNELL RES FOUND INC.
XX
XX Barany F, Zilvri M, Gerry NP, Favis R, Kliman R;
XX WPI; 2002-034366/04.
XX
XX Designing capture oligonucleotide probes for use on a support to which
XX complementary oligonucleotides hybridize with little mismatch.
XX
XX Example 3; Page 64; 300pp; English.
XX
XX The present invention describes a method (M1) for designing capture
XX oligonucleotide probes (I) for use on a support to which complementary
XX oligonucleotide probes (II) will hybridize with little mismatch, where
XX (I) have melting temperatures within a narrow range. The method is useful
XX for detecting infectious diseases caused by bacterial infectious agents
XX e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
XX infectious agents e.g. Cryptococcus neoformans, Candida albicans and
XX Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
XX Epstein-Barr virus and polio virus, and parasitic infectious agents
XX selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
XX medineis. The method is also useful for detecting genetic diseases such
XX as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
XX Detecting cancer involving oncogenes, tumour suppressor genes, or genes
XX involved in DNA amplification, replication, recombination or repair, the
XX cancer is specifically associated with a gene selected from BRCA1 gene,
XX p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
XX method is also used for environmental monitoring, forensics and the food
XX and feed industry, detecting comprises scanning (using e.g. a scanning
XX electron microscope and infrared microscope) the support at the
XX particular sites and identifying if ligation of the oligonucleotide probe
XX sets occurred and correlating (using a computer) identified ligation to a
XX presence or absence of the target nucleotide sequences. AB182074 to
XX AB197546 represent oligonucleotide sequences used in the exemplification
XX of the present invention
XX
XX Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 5.9%; Score 14.8; DB 1; Length 21;
XX Best Local Similarity 88.9%; Pred. No. 1.9e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1224 AACCTCCAGCATGTGCTG 1241
XX ||||| ||||| |||||
XX 20 AACCTCCGTCATGTGCTG 3
XX
XX RESULT 143
XX AB182177/C
XX ID AB182177 standard; DNA; 21 BP.
XX
XX AC AB182177;
XX
XX 15-FEB-2002 (first entry)
XX
XX p53 mutation detection primer/probe #56.
XX
XX Human, K-ras; PCR primer; probe; capture probe; mutation detection;
XX ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
XX infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
XX oncogene; tumour suppressor; human papillomavirus; forensic;
XX environmental monitoring; food industry; feed industry; ss.

```

```

OS Homo sapiens.
OS Synthetic.
XX WO200179548-A2.
XX
XX 25-OCT-2001.
XX
XX 04-APR-2001; 2001WO-US010958.
XX
XX 14-APR-2000; 2000US-01972721P.
XX
XX (CORR ) CORNELL RES FOUND INC.
XX
XX Barany F, Zilvri M, Gerry NP, Favis R, Kliman R;
XX WPI; 2002-034366/04.
XX
XX Designing capture oligonucleotide probes for use on a support to which
XX complementary oligonucleotides hybridize with little mismatch.
XX
XX Example 3; Page 64; 300pp; English.
XX
XX The present invention describes a method (M1) for designing capture
XX oligonucleotide probes (I) for use on a support to which complementary
XX oligonucleotide probes (II) will hybridize with little mismatch, where
XX (I) have melting temperatures within a narrow range. The method is useful
XX for detecting infectious diseases caused by bacterial infectious agents
XX e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
XX infectious agents e.g. Cryptococcus neoformans, Candida albicans and
XX Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
XX Epstein-Barr virus and polio virus, and parasitic infectious agents
XX selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
XX medineis. The method is also useful for detecting genetic diseases such
XX as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
XX Detecting cancer involving oncogenes, tumour suppressor genes, or genes
XX involved in DNA amplification, replication, recombination or repair, the
XX cancer is specifically associated with a gene selected from BRCA1 gene,
XX p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
XX method is also used for environmental monitoring, forensics and the food
XX and feed industry, detecting comprises scanning (using e.g. a scanning
XX electron microscope and infrared microscope) the support at the
XX particular sites and identifying if ligation of the oligonucleotide probe
XX sets occurred and correlating (using a computer) identified ligation to a
XX presence or absence of the target nucleotide sequences. AB182074 to
XX AB197546 represent oligonucleotide sequences used in the exemplification
XX of the present invention
XX
XX Sequence 21 BP; 7 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 5.9%; Score 14.8; DB 1; Length 21;
XX Best Local Similarity 88.9%; Pred. No. 1.9e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1224 AACCTCCAGCATGTGCTG 1241
XX ||||| ||||| |||||
XX 20 AACCTCCGTCATGTGCTG 3
XX
XX RESULT 144
XX AB182179/C
XX ID AB182179 standard; DNA; 21 BP.
XX
XX AC AB182179;
XX
XX 15-FEB-2002 (first entry)
XX
XX p53 mutation detection primer/probe #58.
XX
XX Human, K-ras; PCR primer; probe; capture probe; mutation detection;
XX ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
XX infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
XX oncogene; tumour suppressor; human papillomavirus; forensic;
XX environmental monitoring; food industry; feed industry; ss.

```


KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 PN WO9715662-A2.
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US017480.
 PE
 XX 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 PI WPI, 1997-259017/23.
 XX
 DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 XX
 PS Claim 4; Page 126; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (Flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
 XX
 Query Match 5.7%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 1.2e+02;
 Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
 QY 1301 CATGCTCATCTGTGAG 1316
 Db 1 CAUGGUCUCUCUGAG 16
 XX
 RESULT 147
 ABA78078/c
 ID ABA78078 standard; DNA; 17 BP.
 XX
 XX ABA78078;
 AC
 XX
 XX 24-JAN-2002 (first entry)
 DT
 XX
 XX BRCA1 mutation correcting oligonucleotide SEQ ID NO: 924.
 DE
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytoskeletal; antisticking; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 PN WO200173002-A2.

XX
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gampier HB, Rice MC;
 PI WPI, 2001-639230/73.
 XX
 DR Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX
 PS Claim 7; Page 100; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 5.7%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1256 GCAGCAACAGCTGGA 1271
 Db 16 GGAGCAACAGCTGGA 1
 XX
 RESULT 148
 ABA78077
 ID ABA78077 standard; DNA; 17 BP.
 XX
 XX ABA78077;
 AC
 XX
 XX 24-JAN-2002 (first entry)
 DT
 XX
 XX BRCA1 mutation correcting oligonucleotide SEQ ID NO: 923.
 DE
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytoskeletal; antisticking; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 XX Homo sapiens.
 OS
 XX

PN WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX Claim 7; Page 100; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1256 GCAGCAACAGCTGGA 1271
Db 2 GGAGCAACAGCTGGA 17
RESULT 149
ABA78070/c
ID ABA78070 standard; DNA; 17 BP.
XX
XX ABA78070;
XX
XX 24-JAN-2002 (first entry)
XX
XX BRCA1 mutation correcting oligonucleotide SEQ ID NO: 916.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cyrostatic; antisticking; antianaemic; haemostatic;
KW antilipemic; ss.
XX
XX Homo sapiens.
OS

XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX Claim 7; Page 99; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1256 GCAGCAACAGCTGGA 1271
Db 16 GGAGCAACAGCTGGA 1
RESULT 150
ABA78069
ID ABA78069 standard; DNA; 17 BP.
XX
XX ABA78069;
XX
XX 24-JAN-2002 (first entry)
XX
XX BRCA1 mutation correcting oligonucleotide SEQ ID NO: 915.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cyrostatic; antisticking; antianaemic; haemostatic;
KW antilipemic; ss.
XX
XX Homo sapiens.
OS

```
OS Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192179P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAMARE.
XX
XX kmiec EB, Gampier HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 99; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MTH1, MSH2, MSH6, MSH3,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 5.7%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.2e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Oy 1256 GCAGCAACAGCTGGA 1271
XX | | | | | | | | | | | | | | | |
XX Db 2 GCAGCAACAGCTGGA 17
XX
XX RESULT 151
XX ABN00936
XX ID ABN00936 standard; DNA; 17 BP.
XX
XX AC ABN00936;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPL-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:928.
XX
XX Human; genome-derived myosin-like protein 1; GDMPL-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
```

```
PF 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPL-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPL-1.
XX
XX Disclosure; SEQ ID NO 928; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPL-1). The protein and polynucleotide sequences of hGDMPL-
XX 1 can be used in gene therapy and vaccine production. The hGDMPL-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPL-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPL-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the protein. The hGDMPL-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPL
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPL proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPL-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPL-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPL-1, in particular heart
XX and skeletal muscle disorders. hGDMPL-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPL-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 5.7%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.2e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Oy 1264 AGCTGAAGAGGCTGA 1279
XX | | | | | | | | | | | | | | | |
XX Db 2 AGCTGAAGAGGCTGA 17
XX
XX RESULT 152
XX ABN00938
XX ID ABN00938 standard; DNA; 17 BP.
XX
XX AC ABN00938;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPL-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:930.
XX
```

XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI, 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 930; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence for this patent did not form part of the present
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1265 GCTGAAGAAGGCTGAG 1280
|||
Db 1 GCTGAAGAAGGCTGAG 16

RESULT 153
ABT37829/C
ID ABT37829 standard; DNA, 17 BP.
XX
XX
AC ABT37829;
XX
XX 12-JUN-2003 (first entry)
DT
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3466.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KM human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
PE
XX
XX 17-SEP-2001; 2001FR-00011978.
PR
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
PI WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; Page 439; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optional
CC alignment, at least 80 % identity to the 17 mer sequence, or the complement
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 5.7%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1383 CTGCGTTTGGCTGAGC 1398
|||||
Db 16 CTGCGTTTGGCTGATC 1

```
RESULT 154
AB264881/C
XX ID AB264881 standard; RNA; 17 BP.
XX AC AB264881;
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNAzyme substrate #338.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US016840.
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcsw19gen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX PS Claim 4; Page 139; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
XX CC rheumatic activity. The nucleic acid molecules are useful for reducing
XX CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX CC also useful for treating breast, ovarian, colorectal, lung, prostate,
XX CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX CC shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524,
XX CC AB266530 - AB266585 represent substrate/target sequences for the human
XX CC ribozymes of the invention
XX SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 5.7%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.2e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Oy 1266 CTGGAAGAGCTGAGG 1281
XX |||||||
XX |||||||
XX |||||||
XX |||||||
XX |||||||
XX Db 17 CTGGAAGAGCTGAGG 2
XX
XX RESULT 155
XX AA82749/C
XX ID AA82749 standard; DNA; 19 BP.
XX AC AA82749;
XX DT 04-DEC-2000 (first entry)
XX DE cdk3 ribozyme binding site #34.
XX KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
```

```
XX OS Mammalia.
XX KW cdk3 ribozyme;
XX PN WO200032765-A2.
XX PD 08-JUN-2000.
XX PF 06-DEC-1999; 99WO-US028772.
XX PR 04-DEC-1998; 98US-0110954P.
XX PA (IMMU-) IMMUSOL INC.
XX PI Tritz R, Welch PJ, Barber JR, Robbins JW;
XX DR WPI; 2000-412314/35.
XX PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PT PCNA and Cyclin B1.
XX PS Disclosure; Page 51; 109pp; English.
XX CC The present invention relates to a hairpin or hammerhead ribozyme,
XX CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX CC Representative examples of ribozyme recognition sites are given in
XX CC AA82415 to AA86787. The ribozyme of the invention is useful for
XX CC inhibiting restenosis by introduction of the ribozyme into cells. The
XX CC ribozyme is resistant to endonuclease activity and hence is efficient in
XX CC restenosis treatment
XX SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 5.7%; Score 14.4; DB 1; Length 19;
XX Best Local Similarity 93.8%; Pred. No. 1.7e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Oy 1260 CAACAGCTGGAAGAG 1275
XX |||||||
XX |||||||
XX |||||||
XX |||||||
XX |||||||
XX Db 19 CAGCAGCTGGAAGAG 4
XX
XX RESULT 156
XX AAH57911/C
XX ID AAH57911 standard; DNA; 19 BP.
XX AC AAH57911;
XX DT 10-SEP-2001 (first entry)
XX DE Cell-cycle dependent kinase cdk3 ribozyme binding site SEQ ID NO:335.
XX KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX KW recognition site; target; ribozyme binding site; eye disease; vulnery;
XX KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX KW matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;
XX KW antiproliferative; dermatological; anti-leukemic; antidiabetic; virucide;
XX KW anticlotting; ophthalmological; keratolytic; gene therapy; viral wart;
XX KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX KW basal cell carcinoma; sebaceous wart; vitreoretinopathy; scar;
XX KW sickle cell retinopathy; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200130362-A2.
XX PD 03-MAY-2001.
XX PR 26-OCT-2000; 2000WO-US029500.
XX
```

PR 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX WPI; 2001-300427/31.
DR
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 96; 408pp; English.
PS
XX The present invention describes a method for treating a proliferative
XX skin or eye disease and scarring. The method involves administering a
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX dependent kinase, growth factor or a reductase, or administering a
XX nucleic acid molecule (II) comprising a promoter operably linked to a
XX nucleic acid segment encoding (I). (I) can have antiproliferative,
XX dermatological, cytostatic, antineoplastic, antidiabetic, antisticking,
XX ophthalmological, vulvetary, keratolytic and virucide activities, and
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX in gene therapy. (I) and (II) are useful for treating proliferative skin
XX diseases such as psoriasis, atopic dermatitis, actinic keratosis,
XX squamous or basal cell carcinoma and viral or seboretic wart. They can
XX also be used for treating proliferative eye diseases such as diabetic
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX prematurity and retinal detachment, and for treating and preventing
XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
XX scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention
SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
QY Query Match 5.7%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DB 1260 CAACGCTGCAAGAGG 1275
19 CAGCAGCTGCAAGAGG 4
OY
RESULT 157
ADP87815/C
ID ADP87815 standard; DNA; 19 BP.
XX
XX ADP87815;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Single nucleotide polymorphism detection primer, SEQ ID No 1398.
DB
XX human; single nucleotide polymorphism; microarray; side effect; ss;
KW primer; PCR.
XX
XX Synthetic.
OS Homo sapiens.
OS
XX JP2003235571-A.
PN
XX
XX 26-AUG-2003.
PD
XX 12-FEB-2002; 2002JP-00034717.
PF
XX 12-FEB-2002; 2002JP-00034717.
PR
XX (KAGA-) KAGAKU GIJUTSU SHIKO JIGYODAN.
PA
XX WPI; 2003-820454/77.
DR
XX

PT Novel polynucleotide useful for detecting single nucleotide polymorphisms
PT in human gene.
XX
XX Claim 2; SEQ ID NO 1398; 704pp; Japanese.
PS
XX The invention relates to a novel polynucleotide isolated and purified
CC from a human gene having any one of 935 fully defined sequences as given
CC in specification, or a sequence having a base substitution. The invention
CC further relates to: an oligonucleotide containing single nucleotide
CC polymorphisms; a PCR primer set chosen from the combination of two DNA
CC fragments from any one of 1220 fully defined sequences as given in
CC specification; a labelling probe containing the SNP containing oligo; and
CC a microarray equipped with the SNP containing oligo. The isolated human
CC gene of the invention is useful for detecting the single nucleotide
CC polymorphisms in human gene. The isolated human gene is also useful for
CC diagnosis of disease and determination of side effect to a medical agent.
CC The isolated human gene is also effective in detecting single nucleotide
CC polymorphisms in a human gene. This polynucleotide sequence represents
CC one of the PCR primers used in the single nucleotide polymorphism
CC detection method of the invention.
SQ Sequence 19 BP; 2 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
QY Query Match 5.7%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
DB 1195 AGCCTGTGCAAGAGG 1210
16 AGCCTGTGCAAGAGG 1
OY
RESULT 158
AAT63090
ID AAT63090 standard; cDNA; 20 BP.
AC
XX AAT63090;
AC
XX 13-MAY-1997 (first entry)
DT
XX
XX Reverse primer GS4 amplifies Fc-gamma-BP cDNA.
DE
XX
XX Fragment 13; pNV11-ST; IgG-Fc binding protein; immunoglobulin; K17;
KW human; colonic epithelium; monoclonal antibody; K9; probe; primer; ss.
XX
XX Synthetic.
OS
XX WO9527057-A1.
PN
XX
XX 12-OCT-1995.
PD
XX
XX 03-APR-1995; 95WO-JP000638.
PF
XX
XX 01-APR-1994; 94JP-00129487.
PR
XX 24-AUG-1994; 94JP-00222547.
PR
XX 30-MAR-1995; 95JP-00109927.
XX
XX (CHUS) CHUGAI SEIYAKU KK.
PA
XX
XX Morikawa M, Harada N;
PI
XX WPI; 1995-358632/46.
DR
XX
XX DNA derived from colonic epithelium encoding IgG-Fc binding protein -
PT used in the mapping and analysis of IgG-Fc binding protein mRNA.
PT
XX
XX Example 20; Page 54; 132pp; Japanese.
PS
XX The sequences given in AAT63086-91 are primers which were used in the
CC amplification of the cDNA encoding the IgG-Fc binding protein of human
CC colonic epithelium (Fc-gamma-BP). mRNA isolated from human colonic
CC epithelial tissue was used to prepare a cDNA library. This library was
CC screened using monoclonal antibodies K9 and K17 which bind to the large

CC and small components of the binding protein. Active clones, see also
CC AAT3077-81, were used to derive probes for screening a second DNA
CC library from human colonic epithelial tissue
XX
SO Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1200 GTGCAGAGGCGACCA 1215
DB 3 GTGCCGAGGCGACCA 18
RESULT 159
AAT95825/C
ID AAT95825 standard; DNA; 20 BP.
XX
XX AAT95825;
XX
XX 19-MAR-1998 (first entry)
XX
XX Primer used in growth hormone mutant preparation.
XX
XX Mutant; human growth hormone; hGH; treatment; gigantism; acromegaly;
XX gene therapy; PCR primer; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX EP790305-A1.
XX
XX 20-AUG-1997.
XX
XX 12-FEB-1997; 97EP-00300902.
XX
XX 13-FEB-1996; 96JP-00050940.
XX
XX 18-JUN-1996; 96JP-00178643.
XX
XX (JCRP-) JCR PHARM CO LTD.
XX
XX Chihara K;
XX
XX WPI; 1997-404732/38.
XX
XX
XX Mutant human growth hormone proteins - with increased receptor affinity
XX and reduced hormone activity.
XX
XX Example 1; Page 15; 28pp; English.
XX
XX The present sequence was used in the preparation of a mutant human growth
XX hormone (hGH), which can be used to treat gigantism or acromegaly, while
XX its DNA can be used for gene therapy. The mutant has a higher affinity
XX for hGH receptor than wild-type hGH, can inhibit binding of hGH to its
XX receptor and has a lower activity than wild-type hGH
XX
XX Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
SO
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1356 AGGCGAGCTGAGGCTT 1371
DB 20 AGGCGAGCTGAGGCTT 5
RESULT 160
AAZ59203/C
ID AAZ59203 standard; DNA; 20 BP.
XX
XX AAZ59203;
AC

XX
XX 20-APR-2000 (first entry)
DT
XX
XX First strand cDNA synthesis primer for human growth hormone gene.
DE
XX
XX Fusion protein; Bacillus; cell wall protein; promoter; cleavage site;
XX TEV protease; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX JP11341991-A.
XX
XX 14-DEC-1999.
XX
XX 30-MAR-1999; 99JP-00089488.
XX
XX 31-MAR-1998; 98JP-00087339.
XX
XX (ITOH-) ITOHAM FOODS INC.
XX PA (UDAK/) UDAKA S.
XX
XX Sato S, Higashikuni N, Kudo T, Kondo M;
PI
XX
XX WPI; 2000-101697/09.
DR
XX
XX A DNA coding a new fused protein and preparation of a useful peptide
PT through its expression.
PT
XX
XX Example 9; Page 16; 43pp; Japanese.
XX
XX The invention relates to a DNA construct encoding a fusion protein
XX comprising a Bacillus species cell wall protein fused to a cleavage
XX peptide and a heterologous protein. The fusion construct is placed
XX downstream of a Bacillus species promoter sequence. An example of the
XX construct is construct MWPBP-MWPp20-TEV-GH, which comprises the Bacillus
XX brevis middle wall protein mp20 linked to the human growth hormone
XX protein via a TEV protease cleavable linker sequence. This sequence
XX represents a primer for the synthesis of the first cDNA strand of the
XX human growth hormone (GH) gene from purified mRNA
XX
XX Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
SO
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1356 AGGCGAGCTGAGGCTT 1371
DB 20 AGGCGAGCTGAGGCTT 5
RESULT 161
AAF28588
ID AAF28588 standard; DNA; 20 BP.
XX
XX AAF28588;
XX
XX 02-APR-2001 (first entry)
DT
XX
XX HPRT PCR primer #1.
DE
XX
XX Human; myeloid progenitor cell; transplantation; PCR primer; c-kit;
XX CD117; IL-7Ra1pha; interleukin-7 receptor alpha; HPRT; ss.
XX
XX Homo sapiens.
XX
XX WO200100019-A1.
XX
XX 04-JAN-2001.
XX
XX 29-JUN-2000; 2000WO-US018047.
XX
XX 29-JUN-1999; 99US-0141421P.
XX
XX

XX	(STRD) UNIV LELAND STANFORD JUNIOR.
PA	Weissman IL, Traver DJ, Akashi K;
PI	WPI; 2001-122949/13.
DR	Mammalian myeloid progenitor cell composition, useful for lineage and
XX	transplantation, experimental evaluation and as a source of lineage and
PT	cell specific products.
PS	Example 1; Page 24; 35pp; English.
XX	The present invention relates to a composition of mammalian myeloid
CC	progenitor cells, where at least 95% of the cells are characterised as C-
CC	-kit (CD117 protein), IL-7Ralpha+ (interleukin-7 receptor alpha) and lin ⁻
CC	- (lineage negative). The composition is useful in transplantation,
CC	experimental evaluation, and as a source of lineage and cell specific
CC	products, including mRNA species useful in identifying genes specifically
CC	expressed in these cells, and as targets for the discovery of factors or
CC	molecules that can affect them. The present sequence is a PCR primer used
CC	in the present invention
SQ	Sequence 20 BP; 1 A; 5 C; 6 G; 8 T; 0 U; 0 Other;
QY	Query Match 5.7%; Score 14.4; DB 1; Length 20;
	Best Local Similarity 93.8%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db	1389 TTTCGCTGAGCTGCTGG 1404 5 TTTCGCTGAGCTGCTGG 20
RESULT 162	
AAD34772	
ID	AAD34772 standard; DNA; 20 BP.
AC	AAD34772;
XX	
DT	16-JUL-2002 (first entry)
XX	
DE	Human MEK3 cDNA targetted antisense oligonucleotide ISIS #123024.
XX	
KM	Human; MAP/ERK kinase kinase 3; MEK3; mitogen activated protein kinase;
KW	MAP; ERK; extracellular signal regulated kinase; infection; cytostatic;
KV	antisense therapy; tumour formation; phosphorothioate backbone;
KW	inflammation; antisense; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	Location/Qualifiers
FT	1..20
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone"
FT	1..5
FT	/tag= b
FT	/mod_base= OTHER
FT	/note= "Methoxyethyl residues"
FT	6
FT	/tag= d
FT	/mod_base= m5c
FT	9
FT	/tag= e
FT	/mod_base= m5c
FT	16..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "Methoxyethyl residues"
PN	WO200220550-A1.

```

XX 14-MAR-2002.
PD
XX PF 07-SEP-2001; 2001WO-US028118.
XX PR 08-SEP-2000; 2000US-00658688.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Ward DT, Gaarde WA, Monia BP, Wyatt JR;
XX DR WPI; 2002-329863/36.
XX PT New antisense oligonucleotides targeted to nucleic acid encoding MAP/ERK
XX PS kinase kinase 3 (MEKK3), useful for inhibiting the expression of MEKK3
XX PS and for treating a disease or condition associated with the expression of
XX PS MEKK3.
XX PS Claim 3; Page 90; 116pp; English.
XX
XX The invention relates to antisense oligonucleotides targeted to nucleic
XX acids encoding mitogen activated protein kinase (MAP)/extracellular
XX signal regulated (ERK) kinase kinase 3 (MEKK3) or a splice variant of
XX MEKK3. MEKK3 is an ubiquitously expressed serine-threonine kinase and
XX activates only the ERK and JNK/SAPK pathways. The antisense compound is
XX useful for inhibiting the expression of MEKK3. These may also be
XX or condition associated with the expression of MEKK3. These may also be
XX used as research reagents and diagnostics, to distinguish between
XX functions of various members of a biological pathway, and in the
XX treatment of a disease or disorder, which can be treated by modulating
XX the expression of MEKK3. The antisense compounds are further useful
XX prophylactically, e.g. to prevent or delay infection, inflammation or
XX tumour formation, and as probes or primers. The present sequence is an
XX antisense oligonucleotide targetted towards human MEKK3 cDNA
XX
SQ Sequence 20 BP; 4 A; 2 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1356 AGGCGAGCTGAGGCTT 1371
DB |||||||||
2 AGGCGAGCTGAGGATT 17
RESULT 163
ADGI7896/C
ID ADGI7896 standard; DNA; 20 BP.
XX ADGI7896;
XX
XX 26-FEB-2004 (first entry)
XX DT
XX DE Primer of the invention #5.
XX cell-wall protein; CWP; enzymatic cleavage; primer; ss.
XX OS Synthetic.
XX PN JP2003079379-A.
XX PD 18-MAR-2003.
XX PF 13-SEP-2001; 2001JP-00278534.
XX PR 13-SEP-2001; 2001JP-00278534.
XX PA (ITOH-) ITO HAM KK.
XX PA (UTAKA/) UTAKA S.
XX DR WPI; 2003-816982/77.
XX
```


PT New DNA for producing phytamin, encodes a fusion protein comprising a
PT leader peptide having amino acids from a Bacillus cell-wall protein, a
PT growth hormone sequence for enzymatic cleavage, and the phytamin amino
PT acid sequence.
XX
XX Example 1; SEQ ID NO 11, 38pp; Japanese.
XX
CC The present invention relates to DNA encoding a fusion protein comprising
CC a leader peptide having a sequence comprising one or more amino acid
CC residues from N-terminus of the cell-wall protein (CWP) of Bacillus, an
CC amino acid sequence of growth hormone for enzymatic cleavage, and a
CC phytamin amino acid sequence or its fragment, variant or analog,
CC connected in order. The DNA is useful in the production of phytamin or
CC its functional fragment, variant or analog. The present sequence a primer
CC of the invention.
XX
SQ Sequence 20 BP; 5 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred.No.1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1356 AGGCGAGCTGAGGCTT 1371
DB 20 AGGCGAGCTGAGGCTT 5
RESULT 164
ABX78217/C
ID ABX78217 standard; DNA; 20 BP.
XX
AC ABX78217;
XX
DT 17-APR-2003 (first entry)
XX
DE Human bifunctional apoptosis regulator antisense oligo ISIS NO 143748.
XX
KW Human bifunctional apoptosis regulator; antisense; phosphorothioate;
KW cytoskeletal; antiinflammatory; inhibitor; infection; inflammation; tumour;
KW 88.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone, nucleotides 1-5 and 16
FT -20 are 2'-methoxyethoxy (MOE) nucleotides, nucleotides 7
FT -14 are 2'-deoxy- nucleotides, all C nucleotides are 5-
FT methyl cytosines"
XX
XX US6468796-B1.
XX
XX 22-OCT-2002.
XX
PD 27-APR-2001; 2001US-00844525.
XX
PR 27-APR-2001; 2001US-00844525.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Wate AT;
XX
XX WPI; 2003-196749/19.
XX
DR New antisense compounds targeted to nucleic acids encoding human
PT bifunctional apoptosis regulator, for modulating expression of the
PT regulator and treating diseases associated with expression of the
PT regulator in humans.
XX
PS Example 15; COL 45-46; 42pp; English.
XX

CC This invention describes a novel compound, 17-50 nucleobases in length
CC which specifically hybridizes with a nucleic acid encoding human
CC bifunctional apoptosis regulator (BAR) and inhibits the expression of
CC human BAR. The products of the invention have cytoskeletal and
CC antiinflammatory activity and can be used to inhibit human BAR expression
CC during antisense therapy, useful for inhibiting the expression of human
CC BAR in cells or tissues and for treating diseases associated with
CC expression of BAR in an animal, particularly a human suspected of having
CC or being prone to a disease or condition associated with expression of
CC human BAR. In addition the antisense oligonucleotides are useful for
CC diagnostics, therapeutics and as research reagent, e.g. prophylactically
CC to prevent or delay infection, inflammation or tumor formation. The
CC oligonucleotides described in the invention have 2'-methoxyethyl (2'-MOE)
CC wings and a deoxy gap. This sequence represents a human BAR antisense
CC oligonucleotide described in the disclosure of the invention
XX
SQ Sequence 20 BP; 6 A; 8 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred.No.1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1240 TGGCAGTGTCGCGCT 1255
DB 19 TGGCAGTGTCGCTGCT 4
RESULT 165
AAD52223
ID AAD52223 standard; DNA; 20 BP.
XX
AC AAD52223;
XX
DT 02-MAY-2003 (first entry)
XX
DE Human IFNGR1 antisense oligonucleotide, ISIS 147639.
XX
XX
KW Human; interferon gamma receptor 1; IFNGR1; autoimmune disorder; cancer;
KW diabetes; autoimmune thyroiditis; multiple sclerosis; immunosuppressive;
KW infection; neuroprotective; inflammation; cytoskeletal; antisense therapy;
KW autoimmune arthritis; autoimmune insulinitis; Crohn's disease; tumour;
KW receptor; antisense; phosphorothioate backbone; 88.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
XX
XX WO200288162-A1.
XX
XX 07-NOV-2002.
XX
PD 16-APR-2002; 2002WO-US012006.
XX
PR 26-APR-2001; 2001US-00843376.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Wate AT;
XX

DR WPI; 2003-156687/15.
XX
XX New antisense oligonucleotides targeted to a nucleic acid molecule
PT encoding interferon gamma receptor 1, useful for treating an autoimmune
PT disorder, e.g. diabetes, multiple sclerosis or Crohn's disease, or
PT cancer.
XX
XX
XX Claim 3; Page 85; 124pp; English.
XX
XX The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of interferon gamma receptor 1 (IFNGR1).
CC The compositions comprise antisense compounds, particularly antisense
CC oligonucleotides, targeted to nucleic acids encoding IFNGR1. The
CC antisense compound is useful for treating a disease or condition
CC associated with IFNGR1, such as an autoimmune disorder (e.g. diabetes,
CC autoimmune thyroiditis, multiple sclerosis, autoimmune arthritis,
CC autoimmune insulinitis or Crohn's disease), cancer or a disease or
CC condition caused by aberrant apoptosis. It is also used for inhibiting
CC the expression of IFNGR1, as research reagents and diagnostics, to
CC distinguish between functions of various members of a biological pathway,
CC as prophylactic agents (e.g. to prevent or delay infection, inflammation
CC or tumor formation), and as probes or primers. It is also used in
CC antisense therapy. The present sequence is an antisense oligonucleotide
CC targeted to human IFNGR1 DNA. This sequence is used in the
CC exemplification of the invention
XX
XX Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1256 GCAGCAGCAGCTGGAA 1271
Db 1 GCAGCAGCAGCTGGAA 16
RESULT 166
ADG72147
ID ADG72147 standard; DNA; 20 BP.
AC ADG72147;
XX
XX
DT 11-MAR-2004 (first entry)
XX
XX Mouse SREBP-1 antisense oligonucleotide ISIS 219692.
DE
XX Sterol regulatory element-binding protein-1; SREBP-1; ss; mouse;
KW antisense gene therapy;
KW sterol regulatory element-binding transcription factor; SREBF;
KW metabolic disorder; diabetes; cardiovascular disorder; atherosclerosis;
KW hyperlipidaemia.
XX
XX Mus musculus.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytidines are 5-
methylycytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residues"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residues"
XX
XX US2003224515-A1.
PN
XX
XX 04-DEC-2003.
PD

XX
XX 04-JUN-2002; 2002US-00161996.
PF
XX
XX 04-JUN-2002; 2002US-00161996.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Freier SM, Baker BF, Dobie KW;
PI WPI; 2004-022079/02.
XX
XX
XX New compound, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding sterol regulatory element-binding protein-1, useful
PT for treating diabetes, atherosclerosis or hyperlipidaemia.
XX
XX Example 16; SEQ ID NO 142; 112pp; English.
PS
XX The invention relates to a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridises with a nucleic acid molecule
CC encoding sterol regulatory element-binding protein-1 (SREBP-1, also known
CC as sterol regulatory element-binding transcription factor, SREBF), and
CC inhibits the expression of SREBP-1, i.e. is an antisense oligonucleotide.
CC Also included are a compound 8-80 nucleobases in length that specifically
CC hybridises with at least an 8-nucleobase portion of an active site on a
CC nucleic acid molecule encoding sterol regulatory element-binding protein-
CC 1, a composition comprising the compound and a carrier or diluent,
CC inhibiting the expression of sterol regulatory element-binding protein-1
CC in cells or tissues (by contacting the cells or tissues with the compound
CC so that expression of sterol regulatory element-binding protein-1 is
CC inhibited) and treating an animal having a disease or condition
CC associated with sterol regulatory element-binding protein-1 by
CC administering to the animal a therapeutic or prophylactic amount of the
CC compound so that expression of sterol regulatory element-binding protein-
CC 1 is inhibited. The antisense oligonucleotide comprises at least one
CC modified internucleoside linkage (preferably 2'-O-methoxyethyl sugar
CC at least one modified sugar moiety (preferably 2'-O-methoxyethyl sugar
CC moiety) or at least one modified nucleobase (preferably 5-
CC methylcytosine). The compound, composition and methods are useful for
CC treating a disease or condition associated with sterol regulatory element
CC binding protein-1, such as a metabolic disorder e.g. diabetes, or a
CC cardiovascular disorder, e.g. atherosclerosis or hyperlipidaemia. They
CC are also useful in research and diagnostics for modulating the expression
CC of sterol regulatory element-binding protein-1. The present sequence is
CC an antisense oligonucleotide targeting mouse SREBP-1.
XX
XX Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 5.7%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1231 AGCATGCTGGCAGT 1246
Db 5 AGCATGCTGGCAGT 20
RESULT 167
ADN01787/C
ID ADN01787 standard; DNA; 20 BP.
AC ADN01787;
XX
XX
DT 29-JUL-2004 (first entry)
XX
XX Human HIP1 antisense oligonucleotide ISIS251592.
DE
XX Human, antisense; ss; Huntington interacting protein 1; HIP1;
KW cellular apoptosis; Huntington's disease; chromosome 7q11.23.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT

```
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "Phosphorothioate linkages and all cyridines are 5
FT      -methylcyridines"
FT      modified_base
FT      1..5
FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl residues"
FT      16..20
FT      /*tag= C
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl residues"
XX      US2004092465-A1.
XX      13-MAY-2004.
XX      11-NOV-2002; 2002US-00293864.
XX      11-NOV-2002; 2002US-00293864.
XX      (ISIS-) ISIS PHARM INC.
XX      (ISIS-) ISIS PHARM INC.
XX      Dobie KM;
XX      WPI; 2004-374983/35.
XX      New compound that modulates huntingtin interacting protein 1 expression,
XX      useful in treating an animal having a disease or condition involving
XX      dysregulation of cellular apoptosis.
XX      Example 15; SEQ ID NO 25; 85pp; English.
XX      The invention relates to a compound targeted to a nucleic acid molecule
XX      encoding huntingtin interacting protein 1, HIP1. The compound, 8-80
XX      nucleobases in length, is an antisense oligonucleotide, where the
XX      compound specifically hybridises with the nucleic acid molecule encoding
XX      huntingtin interacting protein 1 comprising a sequence appearing as
XX      ADN01766 and inhibits the expression of huntingtin interacting protein 1.
XX      Also included are inhibiting the expression of huntingtin interacting
XX      protein 1 in cells or tissues, screening for a modulator of huntingtin
XX      interacting protein 1, a diagnostic method for identifying a disease
XX      state, a kit or assay device comprising the compound and treating an
XX      animal having a disease or condition associated with huntingtin
XX      interacting protein 1 compound so that expression of huntingtin
XX      interacting protein 1 is inhibited. The compound and the methods are
XX      useful in treating an animal having a disease or condition involving
XX      dysregulation of cellular apoptosis e.g. Huntington's disease. The HIP1
XX      gene is located on chromosome 7q11.23. The present sequence is an
XX      antisense oligonucleotide of the invention.
XX      Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
XX      Query Match 5.7%; Score 14.4; DB 1; Length 20;
XX      Best Local Similarity 93.8%; Pred. No. 1.9e+02;
XX      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX      1263 CAGCTGGAAGAGGCTG 1278
XX      18 CAGCTGACGAGGCTG 3
XX      RESULT 168
XX      ADN01865
XX      ADN01865 standard; cDNA; 20 BP.
XX      AC ADN01865;
XX      DT 29-JUL-2004 (first entry)
XX      DE Human HIP1 antisense target sequence ISIS168108.
XX      KW Human; antisense; ss; Huntingtin interacting protein 1; HIP1;
```

```
KW      cellular apoptosis; Huntington's disease; chromosome 7q11.23.
XX      Homo sapiens.
XX      US2004092465-A1.
XX      13-MAY-2004.
XX      11-NOV-2002; 2002US-00293864.
XX      11-NOV-2002; 2002US-00293864.
XX      (ISIS-) ISIS PHARM INC.
XX      (ISIS-) ISIS PHARM INC.
XX      Dobie KM;
XX      WPI; 2004-374983/35.
XX      New compound that modulates huntingtin interacting protein 1 expression,
XX      useful in treating an animal having a disease or condition involving
XX      dysregulation of cellular apoptosis.
XX      Example 15; SEQ ID NO 103; 85pp; English.
XX      The invention relates to a compound targeted to a nucleic acid molecule
XX      encoding huntingtin interacting protein 1, HIP1. The compound, 8-80
XX      nucleobases in length, is an antisense oligonucleotide, where the
XX      compound specifically hybridises with the nucleic acid molecule encoding
XX      huntingtin interacting protein 1 comprising a sequence appearing as
XX      ADN01766 and inhibits the expression of huntingtin interacting protein 1.
XX      Also included are inhibiting the expression of huntingtin interacting
XX      protein 1 in cells or tissues, screening for a modulator of huntingtin
XX      interacting protein 1, a diagnostic method for identifying a disease
XX      state, a kit or assay device comprising the compound and treating an
XX      animal having a disease or condition associated with huntingtin
XX      interacting protein 1 compound so that expression of huntingtin
XX      interacting protein 1 is inhibited. The compound and the methods are
XX      useful in treating an animal having a disease or condition involving
XX      dysregulation of cellular apoptosis e.g. Huntington's disease. The HIP1
XX      gene is located on chromosome 7q11.23. The present sequence is an
XX      antisense target region from the HIP1 cDNA.
XX      Sequence 20 BP; 4 A; 5 C; 9 G; 2 T; 0 U; 0 Other;
XX      Query Match 5.7%; Score 14.4; DB 1; Length 20;
XX      Best Local Similarity 93.8%; Pred. No. 1.9e+02;
XX      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX      1263 CAGCTGGAAGAGGCTG 1278
XX      3 CAGCTGACGAGGCTG 18
XX      RESULT 169
XX      ADN31465
XX      ADN31465 standard; DNA; 20 BP.
XX      AC ADN31465;
XX      DT 12-AUG-2004 (first entry)
XX      DE Mouse forehead box C2 antisense oligonucleotide ISIS207317.
XX      KW Mouse; ss; antisense; forehead box C2; developmental disorder;
XX      lymphoedema; lymphoedema-distichiasis; dysgenesis; iridocorneal angle;
XX      Axenfeld-Rieger anomaly; congenital glaucoma.
XX      OS Mus musculus.
XX      Key Location/Qualifiers
XX      FH modified_base 1..20
XX      FT /*tag= b
XX      FT /mod_base= OTHER
```

FT FT /note= "Phosphorochioate backbone and all cytidines are 5
FT modified_base 1..5
FT -methyletylidines"
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue"
XX
XX US2004102621-A1.
XX
XX PD 27-MAY-2004.
XX
XX PF 21-NOV-2002; 2002US-00303635.
XX
XX PR 21-NOV-2002; 2002US-00303635.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Dobie KM;
XX WPI; 2004-399740/37.
XX
XX DR WPI; 2004-399740/37.
XX
XX PT New compound targeted to a nucleic acid molecule encoding forkhead box
XX C2, useful in diagnosing and treating developmental disorder.
XX
XX PS Example 16; SEQ ID NO 130; 80pp; English.
XX
XX CC The invention relates to a new compound 8-80 nucleobases in length (an
XX antisense oligonucleotide) targeted to a nucleic acid molecule encoding
XX forkhead box C2, where the compound specifically hybridizes with the
XX nucleic acid molecule encoding human forkhead box C2 appearing as
XX ADN3139 and inhibits the expression of forkhead box C2. Also included
XX are inhibiting the expression of forkhead box C2 in cells or tissues,
XX screening for a modulator of forkhead box C2, a diagnostic method for
XX identifying a disease state, a kit or assay device comprising the
XX compound and treating an animal having a disease or condition associated
XX with forkhead box C2. The compound and methods are useful in diagnosing
XX and treating developmental disorders e.g. lymphedemas such as lymphedema-
XX distichiasis, dysgeneses of the mouse iridocorneal angle similar to those
XX seen in human Axenfeld-Rieger anomaly and congenital glaucoma. The
XX present sequence is an antisense oligonucleotide targeting forkhead box
XX C2.
XX
XX SQ Sequence 20 BP; 1 A; 5 C; 6 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 5.7%; Score 14.4; DB 1; Length 20;
XX Best Local Similarity 93.8%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1386 CGTTTGCTGAGCTGC 1401
DB 2 CGTTTGCTGAGCTGC 17
XX
XX RESULT 170
XX ADP43312/C
XX ID ADP43312 standard; DNA; 20 BP.
XX
XX AC ADP43312;
XX
XX DT 09-SEP-2004 (first entry)
XX
XX DE Human pituitary growth hormone variant INSP101 gene primerINSP101-CP2.
XX
XX ss; primer; gynecological; cytosstatic; anti-HIV; osteopathic; endocrine;
XX antiangiogenic; immunosuppressive; antiinflammatory; cardiovascular;
XX neuroprotective; analgesic; antidiabetic; anorectic; immunomodulator;
XX nephroretropic; virucide; fungicide; antibacterial; antiparasitic;
XX neurotropic; vaccine; INSP101; reproductive disorder; pregnancy disorder;
XX gestational trophoblastic disease; developmental disorder;

KW Silver-Russell syndrome; growth disorder; growth hormone deficiency;
KW Cushing's disease; endocrine disorder; cell proliferative disorder;
KW neoplasm; carcinoma; pituitary tumor; ovary tumor; melanoma;
KW placental site trophoblastic tumor; adenocarcinoma; choriocarcinoma;
KW osteosarcoma; angiogenesis; myeloproliferative disorder;
KW autoimmune disorder; inflammatory disorder; cardiovascular disorder;
KW neurological disorder; pain; metabolic disorder; diabetes mellitus;
KW osteoporosis; obesity; cachexia; AIDS; renal disease; lung injury; aging.
XX
XX OS Homo sapiens.
XX
XX PN WO2004050703-A1.
XX
XX PD 17-JUN-2004.
XX
XX PF 05-DEC-2003; 2003WO-GB005295.
XX
XX PR 05-DEC-2002; 2002GB-00028441.
XX
XX PA (ARBS-) ARBS TRADING SA.
XX
XX PI Fagan RJ, Phelps CB, Rodrigues TM, Yorke M, De Tiani M;
XX WPI; 2004-450722/42.
XX
XX DR WPI; 2004-450722/42.
XX
XX PT Novel INSP101 polypeptides or fragments useful for treating Cushing's
XX disease, endocrine disorders, cell proliferative disorders, cachexia,
XX bacterial and parasitic infections.
XX
XX PS Example 2; Page 56; 83pp; English.
XX
XX CC The invention relates to a polypeptide (I) comprising a fully defined
XX INSP101 sequence of 199 or 173 amino acids (S1), its fragment functioning
XX as a growth hormone, or having an antigenic determinant in common with
XX (I) having (S1), or the functional equivalent of (S1) or its fragment.
XX (I) is useful for diagnosing a disease in a patient, which involves
XX assessing the level of expression of a natural gene encoding (I), or
XX assessing the activity of (I), in tissue from the patient and comparing
XX the level of expression or activity to a control level, where a level
XX that is different to the control level is indicative of disease, where
XX the method is carried out in vitro. The disease includes, but is not
XX limited to reproductive disorders, pregnancy disorder, such as
XX gestational trophoblastic disease, developmental disorders such as Silver
XX -Russell syndrome, growth disorders, growth hormone deficiency, Cushing's
XX disease, endocrine disorders, cell proliferative disorders, including
XX neoplasm, carcinoma, pituitary tumor, ovary tumor, melanoma, lung,
XX colorectal, breast, pancreas, head and neck, placental site trophoblastic
XX tumor, adenocarcinoma, choriocarcinoma, osteosarcoma and other solid
XX tumors, angiogenesis, myeloproliferative disorders,
XX autoimmune/inflammatory disorders, cardiovascular disorders, neurological
XX disorders, pain, metabolic disorders including diabetes mellitus,
XX osteoporosis, and obesity, cachexia, AIDS, renal disease, lung injury,
XX aging, infections including viral infection, bacterial infection, fungal
XX infection and parasitic infection and other pathological conditions,
XX where the disease is a disease in which growth hormone proteins are
XX implicated. (I) is useful as a growth hormone or as a modulator of growth
XX hormone activity. (I) or (II) is useful for monitoring the therapeutic
XX treatment of disease in a patient, which involves monitoring over a
XX period of time the level of expression or activity of (I), or the level
XX of expression of (II) in tissue from the patient, where altering the
XX level of expression or activity over the period of time towards a control
XX level is indicative of regression of the disease. The INSP101 gene is
XX generated from 5 exon spliced together. This sequence corresponds to a
XX PCR primer to amplify and clone the DNA sequence encoding a new pituitary
XX growth hormone INSP101.
XX
XX SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 5.7%; Score 14.4; DB 1; Length 20;
XX Best Local Similarity 93.8%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1356 AGGGCAAGCTGAGCTT 1371

Db 18 AGGCGAGCTGTGGCTT 3

RESULT 171

ID ADQ80813 standard; DNA; 20 BP.

AC ADQ80813;

DT 23-SEP-2004 (first entry)

DE Porcine IG(H19-RL23mp)D UP-primer.

XX Anorectic; Antidiabetic; Muscular; Gene Therapy; Cpg island;

KM IGF2 gene intron 3; muscle mass; fat deposition; test number; obesity;

KM muscle deficiency; diabetes; PCR; primer; ss; pig.

OS Sue scrofa.

PN EP1437418-A1.

PD 14-JUL-2004.

PE 10-JAN-2003; 2003EP-00075091.

PR 10-JAN-2003; 2003EP-00075091.

XX (UPLI-) UNIV LIEGE.

PA (MELI-) MELICA HB.

PA (GENT-) GENTEC BV.

PI Andersson L, Andersson G, Georges M, Buys N;

DR WPI; 2004-501307/48.

XX WPI; 2004-501307/48.

PT Selecting an animal for desired genotypic or potential phenotypic

PT properties such as muscle mass and/or fat deposition, comprises testing

PT for a single nucleotide polymorphism in intron 3 of the IGF2 gene.

XX Example 1; Page 22; 38pp; English.

XX The present invention relates to a method (M1) for selecting an animal

CC for having desired genotypic or potential phenotypic properties. (M1)

CC comprises testing the animal for the presence of a nucleic acid

CC modification affecting the activity of an evolutionary conserved Cpg

CC island located in intron 3 of an IGF2 gene; and/or binding of a nuclear

CC factor to an IGF2 gene. The nuclear factor is capable of binding to a

CC stretch of nucleotides which in the wild type pig, mouse or human IGF2

CC gene is part of an evolutionary conserved Cpg island, located in intron 3

CC of the IGF2 gene. The stretch is functionally equivalent to (ADQ80709).

CC The nucleic acid modification in ADQ80709 comprises a G to A transition

CC at IGF2-intron3-nt3072. (M1) is useful for selecting an animal with

CC properties related to muscle mass, fat deposition, and/or test number.

CC Also claimed is a method (M2) for modulating mRNA transcription of an

CC IGF2 gene by modulating the activity of an evolutionarily conserved Cpg

CC island located in intron 3 of an IGF2 gene and/or modulating binding of a

CC nuclear factor to an IGF2 gene. Also claimed is a method (M3) for

CC identifying a compound capable of modulating mRNA transcription of an

CC IGF2 gene and a method (M4) for identifying a compound capable of

CC modulating binding of a nuclear factor to an IGF2 gene. (M2) is useful

CC for modulating mRNA transcription of an IGF2 gene in a cell or organism.

CC (M3) and (M4) are useful for identifying compounds capable of modulating

CC mRNA transcription of an IGF2 gene and/or modulating binding of a nuclear

CC factor to an IGF2 gene. Compounds identified are potentially useful for

CC treating obesity, muscle deficiencies and diabetes. The present sequence

CC is a primer which was used to produce porcine sequence tagged sites (STS)

CC in an example from the invention.

CC Sequence 20 BP; 6 A; 2 C; 12 G; 0 T; 0 U; 0 Other;

XX SQ

Query Match 5.7%; Score 14.4; DB 1; Length 20;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1273 AGGCTAGGCGAGCA 1288
Db 1 AGGCGAGGCGAGCA 16

RESULT 172

ID AAX36871/c standard; DNA; 19 BP.

AC AAX36871;

DT 14-JUL-1999 (first entry)

DE Human XLIS gene fragment PCR primer Flm3.

XX XLIS gene; human; detection; diagnosis; prenatal diagnosis; therapy;

KM lissencephaly; LIS; agyria-pachygyria; subcortical laminar heterotopia;

KM SCH; cortical dysgenesis; cryptogenic epilepsy; neurological disorder;

KM neurodegenerative disease; Alzheimer's disease; X-linked disorder;

KM genetic counselling; PCR primer; ss.

OS Synthetic.

OS Homo sapiens.

PN EP918091-A1.

PD 26-MAY-1999.

PE 21-NOV-1997; 97EP-00402811.

PR 21-NOV-1997; 97EP-00402811.

XX (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

PA Chelly J, Kahn A, Des Portes V, Pinard J;

DR WPI; 1999-290318/25.

XX WPI; 1999-290318/25.

PT New gene and its gene product expressed in the brain, useful for

PT diagnosing and treating disorders such as lissencephaly and subcortical

PT laminar heterotopia.

XX Claim 9; Page 44; 71pp; English.

XX This sequence is a primer for the human XLIS gene of the invention. The

CC XLIS fragments may be used to detect abnormalities in the expression of

CC the XLIS gene transcripts or to compare their sequence with that of the

CC XLIS transcripts from patients for in vitro especially prenatal diagnosis

CC of lissencephaly (LIS) (or agyria-pachygyria), subcortical laminar

CC heterotopia (SCH), cortical dysgenesis, cryptogenic epilepsies or

CC neurodegenerative diseases such as Alzheimer's disease. These disorders

CC mainly affect females as the XLIS gene is X-linked. The XLIS fragments

CC may also be used to administer to patients to prevent or treat the above

CC disorders and may be used as a tool in genetic counselling.

CC Oligonucleotides which bind to the fragments may be used to amplify the

CC XLIS gene from a sample for comparison to normal samples in the in vitro

CC diagnosis regime. This may also be performed by amplifying XLIS cDNA from

CC the mRNA in the sample. Antibodies to XLIS may be used to detect XLIS in

CC a biological sample or can be administered to patients to prevent or

CC treat the above disorders. They may also be used to purify XLIS from a

CC biological sample. XLIS may also be administered to patients to prevent

CC or treat the above neurological disorders. In addition XLIS may be used

CC as a marker of neuronal cells at an early stage of development; its

CC discovery increases understanding of both the neuronal movement; its

CC leads to development of the cortical region of the brain and of the

CC pathogenesis of the group of neuronal disorders mentioned above

XX SQ

Query Match 5.6%; Score 14.2; DB 1; Length 19;

Best Local Similarity 84.2%; Pred. No. 1.8e+02;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1323 GGGGACCTCTCTCCACAG 1341
|||||
Db 19 GGGGACCGCTACTTCACAG 1
|||||
RESULT 173
ADH16361/C
ID ADH16361 standard; RNA; 19 BP.
XX
AC ADH16361;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE transcript target sequence/siNA upper strand, SEQ ID NO:151.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW beta-secretase; BACE; human; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwigggen J, Beigelman L;
XX
DR WPI, 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 151; 144pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised.
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA, conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the BACE gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating Alzheimer's disease or other degenerative conditions such as
CC dementia and stroke/cardiovascular accident. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene

CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human BACE-targeted
CC double-stranded siNA, which is identical to the BACE transcript target
CC sequence.
XX
SQ Sequence 19 BP; 3 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1246 TGGTCCGCTGCACACACA 1264
|||||
Db 19 TGGTCAGCTGCACACACA 1
|||||
RESULT 174
ADH16686
ID ADH16686 standard; RNA; 19 BP.
XX
AC ADH16686;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE siNA lower strand, SEQ ID NO:476.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW beta-secretase; BACE; human; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwigggen J, Beigelman L;
XX
DR WPI, 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 476; 144pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also

PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwigen J, Pavco P, Beigelman L, Fosnaugh K, Jamison S;
XX
XX WPI; 2003-697612/66.
DR
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the epidermal growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 549; 171pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of one or more human epidermal growth factor
CC receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of EGFR genes in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating a wide range of cancers such as breast and ovarian cancer. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human HER1 (EGFR)-targeted double-stranded siNA, which is identical to
CC the HER1 transcript target sequence.
XX
XX
SQ Sequence 19 BP; 3 A; 8 C; 7 G; 0 T; 1 U; 0 Other;
XX
XX
Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1187 CTCCGAGAGCCTGCGAG 1205
DB 19 CTCCGGGGGGCTGTGCGAG 1
XX
XX
RESULT 177
AD005557
ID AD005557 standard; DNA; 19 BP.
XX
AC AD005557;
XX
DT 01-JUL-2004 (first entry)
XX
XX Rhizobium meliloti anthranilate synthase PCR primer Rhizo R8, SEQ.139.
DE
XX Anthranilate synthase; AS; EC 4.1.3.27; tryptophan biosynthesis;
KW transgenic plant; tryptophan content; animal feed; foodstuff; anabolic;
KW tryptophan supplement; PCR; primer; ss.
XX
XX Sinorhizobium meliloti.
OS
XX WO2003092363-A2.
PN
XX 13-NOV-2003.
PD
XX 05-MAY-2003; 2003WO-US013944.
PP
XX 03-MAY-2002; 2002US-0377727P.
PR 05-MAY-2003; 2003US-00430011.
XX

XX
XX (MONS) MONSANTO TECHNOLOGY LLC.
PA
XX
XX Weaver LM, Oulmassov TN, Vaduva G, Liang J, Varagona MJ;
PI Venkatesh TV;
XX
XX WPI; 2004-108245/11.
DR
XX
XX Isolated anthranilate synthase DNA molecules useful for producing plants
PT with altered tryptophan content, useful in human foods and animal feeds.
PT
XX
XX Example 11; SEQ ID NO 139; 162pp; English.
XX
XX The invention relates to a DNA encoding a protein substantially
CC homologous to one of 7 plant anthranilate synthases (AD005484, AD005526-
CC AD005529, AD005551 and AD005555). Anthranilate synthase (AS; EC 4.1.3.27)
CC is a key enzyme in the tryptophan biosynthetic pathway in plants, fungi
CC and bacteria. The most common form of AS is a heterotetrameric enzyme
CC consisting of 2 alpha (TTPS) subunits and 2 beta (TTPG) subunits,
CC although monomeric forms, where a single polypeptide chain has the
CC activities of both alpha and beta subunits, have been discovered
CC (however, the enzymatically active form of such "monomeric" AS is
CC typically a homodimer of the monomeric polypeptides). The invention also
CC relates to DNA constructs comprising either a monomeric AS expression
CC cassette, or both an AS alpha subunit expression cassette and an AS beta
CC subunit expression cassette; a method for altering the tryptophan content
CC of a plant by the production of a transgenic plant comprising the DNA
CC construct of the invention; the transgenic plant produced; and an animal
CC feed or human food produced using a transgenic plant of the invention. AS
CC -encoding genes and constructs containing them may be used in the
CC production of transgenic plants with altered, preferably increased
CC tryptophan content. The plants may be used in the production of human and
CC animal food. The present sequence represents a PCR primer used to amplify
CC the Rhizobium meliloti anthranilate synthase gene in an example of the
CC invention.
XX
XX
SQ Sequence 19 BP; 1 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX
Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1292 TCAGGCTGCCATGTCATC 1310
DB 1 TCAGGCTGCCCTTGCTTTC 19
XX
XX
RESULT 178
AD060387
ID AD060387 standard; RNA; 19 BP.
XX
AC AD060387;
XX
DT 09-SEP-2004 (first entry)
XX
XX Anti-Cyclophilin siRNA Cyclo 55 SEQ ID NO.86.
DE
XX ss: siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference; cyclophilin.
XX
XX Synthetic.
OS
XX WO2004045543-A2.
PN
XX 03-JUN-2004.
PD
XX 14-NOV-2003; 2003WO-US036787.
PP
XX 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
XX (DHAR-) DHARMACON INC.
PA
XX

PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
XX WPI; 2004-420527/39.
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
XX Example 1; SEQ ID NO 86; 199pp; English.
XX
XX The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUAGUAGAU; GAAGUACUCCAUUUAAG;
CC GUAGCAACCGGAGAU; AGAUAGUAGUAGUAGAU; UGAAGUCCUCCAGU;
CC CAUGCGCCUCCUUGUA; UGCGCCUCCUUGAUU; GAGAUAGUAGUAGUAGAU.
CC GGAUGUAGUAGUAGAU; and GAAGUCCUCCAGU. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention.
XX
SQ Sequence 19 BP; 5 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.8e+02;
Matches 14; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
QY 1344 GGAAGCTTTCCCGAGGAG 1362
Db 1 GGAGCUCUCCACGAGGAG 19
RESULT 179
AAQ79338/C
ID AAQ79338 standard; cDNA; 20 BP.
XX
XX AAQ79338;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1995 (first entry)
XX
XX Oligo HARP4-codAR which is complementary to bases 396-415 of rat and
DE human ARF 4 cDNA.
XX
XX ADP-ribosylation factor; ARF; ARD 1; oligo; ss.
KM
XX
XX Synthetic.
OS
XX MO9424283-A2.
PN
XX 27-OCT-1994.
PD
XX 15-APR-1994; 94WO-US004190.
PF
XX 16-APR-1993; 93US-00049252.
PR 19-APR-1993; 93US-00049473.
XX
XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
PA
XX Moss J, Mishima K, Nightingale M, Tsuchiya M;
PI

DR WPI; 1994-341862/42.
XX
XX GTP-binding protein ARD1 with ADP-ribosylation factor domain - useful as
PT biochemical and diagnostic reagent.
PT
XX
XX Example; Table III, Page 16; 52pp; English.
XX
XX A novel ARD 1 protein includes an 18 kDa region that exhibits significant
CC homology to known ADP-ribosylation factors (ARFs) and is called ARD 1 for
CC ARF domain. Human fetal brain cDNA and rat brain cDNA lambda ZAP library
CC were analysed for ARD 1 using the oligos in Table II (AAQ79328-Q79336)
CC and Table III (AAQ29337-Q79351) in order to isolate ARD 1 from human and
CC rat See AAQ79326/R66033 (human) and AAQ79327/R66034 (rat) for the cDNA
CC and deduced AA sequences. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1298 TGCATGCTCATCTGTGAG 1316
Db 20 TGCTATGCTCATCTGTGAG 2
RESULT 180
AAT00877/C
ID AAT00877 standard; DNA; 20 BP.
XX
XX AAT00877;
AC
XX
XX 27-MAR-1996 (first entry)
DT
XX
XX Murine mC26 structural gene probe.
DE
XX
XX Mouse; Balb/c; mC26; mammary; transgenic; gene expression control; ss.
KM
XX
XX Mus musculus.
OS
XX
XX JP07194380-A.
PN
XX
XX 01-AUG-1995.
PD
XX
XX 28-DEC-1993; 93JP-00355132.
PF
XX
XX 28-DEC-1993; 93JP-00355132.
PR
XX
XX (SUMO) SUMITOMO METAL IND LTD.
PA
XX
XX WPI; 1995-298147/39.
DR
XX
XX Use of mC26 gene expression control regions for prepn. of a substance -
PT in the mammary gland of a transgenic animal, other than a human.
PT
XX
XX Claim 2; Page 33; 20pp; Japanese.
PS
XX
XX AAT00874-T00877 are probes for the new murine mC26 structural gene. The
CC gene expression control regions from this gene can be linearised and used
CC in an expression vector to produce a transgenic animal by introducing the
CC vector into an embryonic cell of a mammal. The mammary gland is excellent
CC for the prodn. of transgene products in large quantities. This is due to
CC the ease of removal of the product from milk produced which can itself be
CC very easily obtained
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1349 CTTCCGAGGAGCACTGAG 1367
|||

Db 19 CTTTCCTGGAGACGAG 1

RESULT 181
AAZ31318
ID AAZ31318 standard; DNA; 20 BP.
XX
AC AAZ31318;
XX
DT 24-JAN-2000 (first entry)
XX
DE CXCR4 gene inhibiting antisense oligo AS(s)-75.
XX
KW HIV cofactor inhibitor; HIV infection; CXCR4 gene; CCR5 gene;
KW drug composition; antisense; ss.
XX
OS Synthetic.
XX
PN WO9951751-A1.
XX
PD 14-OCT-1999.
XX
PF 01-APR-1999; 99WO-JP001722.
XX
PR 02-APR-1998; 98JP-00125452.
XX
PA (MARI-) MARINE BIO CO LTD.
XX
PI Takaku H, Yamamoto N, Kimura T, Takai K, Wada A;
DR WPI; 1999-620207/53.
XX
PT Antisense oligonucleotide-based HIV cofactor inhibitors, as drug
PT compositions for treatment of HIV infection.
XX
PS Claim 6; Page 17; 59pp; Japanese.
XX
SS The invention provides HIV cofactor inhibitors that contain
CC oligonucleotides with a base sequence complementary to the CXCR4 or CCR5
CC genes. Such inhibitors can be formulated into drug compositions for
CC prevention or treatment of HIV infection, with inhibition of expression
CC of CXCR4 or/and CCR5 gene. Sequences AAZ31307-362 represent antisense
CC oligonucleotides to the CXCR4 gene
CC
SQ Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1367 GGCTTACCAAGACGCTG 1385
Db 2 GGCTTACCAAGAAACTG 20

RESULT 182
AAZ06182
ID AAZ06182 standard; DNA; 20 BP.
XX
AC AAZ06182;
XX
DT 07-OCT-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW Vaccine; eye disease; conventional trachoma; nongendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; perihhepatitis;
KW nongonococcal urethritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS Synthetic.
OS Chlamydia trachomatis.
XX

PN WO9928475-A2.
XX
PD 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
XX
PF 28-NOV-1997; 97FR-00015041.
XX
PR 17-DEC-1997; 97FR-00016034.
XX
PR 04-NOV-1998; 98US-0107077P.
XX
PA (GEST) GENSET.
XX
PI Grifffais R;
XX
DR WPI; 1999-371125/31.
XX
XX Genome sequence of Chlamydia trachomatis.
PT Disclosure; Page 1831; 1755pp; English.
XX
XX PCR primers AAZ01426-Z06209 were used to amplify open reading frames
XX (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
XX encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
XX against Chlamydia trachomatis. Antisense and ribozyme sequences can also
XX be used to control growth of the microorganism. Chlamydia trachomatis is
XX responsible for a large number of diseases, e.g. eye diseases such as
XX conventional trachoma, nongendemic trachoma, paratrachoma, and inclusion
XX conjunctivitis; genital diseases such as nongonococcal urethritis;
XX epidymitis, cervicitis, salpingitis, perihhepatitis, bartholinitis;
XX pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
CC
SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1363 CTGAGCTTACCAAGACA 1381
Db 2 CTGAGCTTACCAAGACA 20

RESULT 183
AAZ36856/C
ID AAZ36856 standard; DNA; 20 BP.
XX
AC AAZ36856;
XX
DT 14-JUL-1999 (first entry)
XX
DE Human XLIS gene fragment PCR primer Comr.
XX
XX XLIS gene; human; detection; diagnosis; prenatal diagnosis; therapy;
KW lissencephaly; LIS; agyria-pachygyria; subcortical laminar heterocopia;
KW SCH; cortical dysgenesis; cryptogenic epilepsy; neurological disorder;
KW neurodegenerative disease; Alzheimer's disease; X-linked disorder;
KW genetic counselling; PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
PN EP18091-A1.
XX
PD 26-MAY-1999.
XX
XX 21-NOV-1997; 97EP-00402811.
XX
PR 21-NOV-1997; 97EP-00402811.
XX
XX (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
XX

PI Chelly J, Kahn A, Des Portes V, Pinard J;
XX WPI, 1999-290318/25.
XX
PT New gene and its gene product expressed in the brain, useful for
PT diagnosing and treating disorders such as lissencephaly and subcortical
PT lamnar heterotopia.
XX
PS Claim 9, Page 40; 71pp; English.
XX
CC This sequence is a primer for the human XLIS gene of the invention. The
CC XLIS fragments may be used to detect abnormalities in the expression of
CC the XLIS gene transcripts or to compare their sequence with that of the
CC XLIS transcripts from patients for in vitro especially prenatal diagnosis
CC of lissencephaly (LIS) (or agyria-pachygyria), subcortical lamnar
CC heterotopia (SCLH), cortical dysgenesis, cryptogenic epilepsies or
CC neurodegenerative diseases such as Alzheimer's disease. These disorders
CC mainly affect females as the XLIS gene is X-linked. The XLIS fragments
CC may also be used to administer to patients to prevent or treat the above
CC disorders and may be used as a tool in genetic counselling.
CC Oligonucleotides which bind to the fragments may be used to amplify the
CC XLIS gene from a sample for comparison to normal samples in the in vitro
CC diagnosis regime. This may also be performed by amplifying XLIS cDNA from
CC the mRNA in the sample. Antibodies to XLIS may be used to detect XLIS in
CC a biological sample or can be administered to patients to prevent or
CC treat the above disorders. They may also be used to purify XLIS from a
CC biological sample. XLIS may also be administered to patients to prevent
CC or treat the above neurological disorders. In addition XLIS may be used
CC as a marker of neuronal cells at an early stage of development; its
CC discovery increases understanding of both the neuronal movement which
CC leads to development of the cortical region of the brain and of the
CC pathogenesis of the group of neuronal disorders mentioned above
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
DY 1333 GGGGACCTCTTCCACAG 1341
DB 19 GGGGACCGCTACTCAAG 1
RESULT 184
AAZ86920/C
ID AAZ86920 standard; DNA; 20 BP.
XX
AC AAZ86920;
XX
XX 04-MAY-2000 (first entry)
DT
XX
XX Probe for mouse MC26 gene.
DE
XX
KM MC26 gene; structural gene; regulatory region; lactation-specific gene;
KM mammary gland-specific expression; leukocyte CM; cell adhesion molecule;
KM G1YCAM-1; glycosylation-dependent cell adhesion molecule-1; B1P; milk;
KM bone inducing protein; transgenic animal; protein production; probe; ss.
XX
XX Mus sp.
OS
XX
XX US6018039-A.
PN
XX
XX 25-JAN-2000.
PD
XX
XX 30-JUL-1996; 96US-00688376.
PF
XX
XX 30-JUL-1996; 96US-00688376.
PR
XX
XX (SATO/) SATOW H.
PA
XX
XX Satow H;
PI

DR WPI; 2000-136709/12.
XX
XX Nucleic acids encoding and regulating the MC26 structural gene, useful
PT for the lactation/mammary gland specific expression of heterologous
PT proteins in transgenic animals.
XX
XX
PS Disclosure; Col 5; 23pp; English.
XX
CC This sequence is a probe for the MC26 gene. The invention relates to
CC nucleic acids encoding the MC26 structural gene and its regulatory
CC region, which is expressed in a large amounts in a lactation-specific or
CC tissue (mammary gland)-specific manner. The protein product of MC26 has
CC been identified as a leukocyte CM (cell adhesion molecule) designated
CC G1YCAM-1 (glycosylation-dependent cell adhesion molecule-1). The nucleic
CC acids may be used for the production of transgenic cells and organisms
CC containing heterologous DNA molecules (which are expressed in a tissue
CC specific manner) according to standard recombinant DNA methodologies. The
CC heterologous protein produced is the bone inducing protein (BIP). The
CC nucleic acids direct the expression of the heterologous DNA in a
CC lactation-specific or tissue (mammary gland)-specific manner (i.e. the
CC heterologous protein is expressed in the milk of the transgenic animal
CC from where it can be recovered)
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
DY 1349 CTTTCCGAGGCGACCTGAG 1367
DB 19 CTTTCCCTGGGAGCAGAG 1
RESULT 185
ABN74835
ID ABN74835 standard; DNA; 20 BP.
XX
XX
AC ABN74835;
XX
DT 26-JUL-2002 (first entry)
XX
DE Human and mouse caspase 2 antisense inhibitor oligonucleotide #9.
XX
KM Caspase 2; antisense; cytostatic; osteopathic; cerebroprotective;
KM neuroprotective; antilipemic; antiinflammatory; antitubercular;
KM haematopoietic disorder; bone metabolism disorder; cholesterol disorder;
KM hyperproliferative disorder; cancer; blood disorder; stroke;
KM brain injury; neurodegenerative disease; infection; inflammation; tumour;
KM ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= m5C, OTHER
XX FT /note= "Nucleotides 1-5 and 16-20 are five-nucleotide
XX FT wings consisting 2'methoxyethyl (2'-MOE) nucleotides, 6-
XX FT 15 are 2'deoxy nucleotides, backbone linkages are
XX FT phosphodiester, all cytosines are 5-methylcytidines"
XX
XX WO200224720-A1.
PN
XX
XX 28-MAR-2002.
PD
XX
XX 14-SEP-2001; 2001WO-US028631.
PF
XX
XX 20-SEP-2000; 2000US-00667018.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Zhang H, Watt AT;
PI

[illegible][illegible]

XX WO200179548-A2.
 XX
 PD 25-OCT-2001.
 XX
 XX 04-APR-2001; 2001WO-US010958.
 XX
 PF 14-APR-2000; 2000US-0197271P.
 PR
 PA (CORR) CORNELL RES FOUND INC.
 XX
 PI Barany F, Zivvi M, Gerry NP, Favis R, Kilman R;
 XX WPI: 2002-034366/04.
 XX
 PS Designing capture oligonucleotide probes for use on a support to which
 XX complementary oligonucleotides hybridize with little mismatch.
 XX
 PS Example 5; Fig 29; 300pp; English.
 XX
 XX The present invention describes a method (M1) for designing capture
 CC oligonucleotide probes (I) for use on a support to which complementary
 CC oligonucleotide probes (II) will hybridize with little mismatch, where
 CC (I) have melting temperatures within a narrow range. The method is useful
 CC for detecting infectious diseases caused by bacterial infectious agents
 CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
 CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
 CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
 CC Epstein-Barr virus and polio virus, and parasitic infectious agents
 CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
 CC medicine. The method is also useful for detecting genetic diseases such
 CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
 CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
 CC involved in DNA amplification, replication, recombination or repair, the
 CC cancer is specifically associated with a gene selected from BRCA1 gene,
 CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
 CC method is also used for environmental monitoring, forensics and the food
 CC and feed industry, detecting comprised scanning (using e.g. a scanning
 CC election microscope and infrared microscope) the support at the
 CC particular sites and identifying if ligation of the oligonucleotide probe
 CC sets occurred and correlating (using a computer) identified ligation to a
 CC presence or absence of the target nucleotide sequences. AB182074 to
 CC AB197546 represent oligonucleotide sequences used in the exemplification
 CC of the present invention
 XX
 XX Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 5.6%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0.
 OY 1318 AGCTAGGGACCTTCTC 1336
 Db 1 AGCCAGAGAGACTCTCTC 19
 RESULT 188
 ABX97662
 ID ABX97662 standard; DNA; 20 BP.
 AC ABX97662;
 XX
 DT 16-MAY-2003 (first entry)
 XX
 DE Novel human protein NOVX associated reverse PCR primer #9.
 XX
 KW Human; NOV; adrenoleukodystrophy; congenital adrenal hyperplasia;
 KW haemophilia; hypercoagulation; autoimmune disease; allergy;
 KW immunodeficiency; transplantation; Von Hippel-Lindau syndrome;
 KW Alzheimer's disease; stroke; tubercous sclerosis; hypercalcaemia;
 KW Parkinson's disease; Huntington's disease; cancer; fertility; diabetes;
 KW adult respiratory distress syndrome; infection; tissue typing;
 KW forensic identification; gene; PCR; primer; ss.

```

XX OS Homo sapiens.
XX XX +...+...+...+...
XX PN WO20029500-A2.
XX XX
XX PD 14-NOV-2002.
XX XX
PF 02-MAY-2002; 2002WO-US014256.
XX XX
PR 03-MAY-2001; 2001US-0288395P.
PR 07-MAY-2001; 2001US-0289087P.
PR 08-MAY-2001; 2001US-0289619P.
PR 09-MAY-2001; 2001US-0289817P.
PR 09-MAY-2001; 2001US-0289818P.
PR 11-MAY-2001; 2001US-0290194P.
PR 14-MAY-2001; 2001US-0290753P.
PR 15-MAY-2001; 2001US-0291189P.
PR 21-MAY-2001; 2001US-0292374P.
PR 23-MAY-2001; 2001US-0293107P.
PR 25-MAY-2001; 2001US-0293747P.
PR 29-MAY-2001; 2001US-0294110P.
PR 30-MAY-2001; 2001US-0294434P.
PR 10-SEP-2001; 2001US-0318346P.
PR 17-SEP-2001; 2001US-0322646P.
PR 01-MAY-2002; 2002US-00136728.
XX XX
PA (CURAGEN) CURAGEN CORP.
XX XX
PI SPYCEK KA, Li L, Edinger SR, Stone DU, Guo X, Anderson DW;
PI Paturujan M, Gerlach VL, Taupier RJ, Pena CE, Padigar M;
PI PI Kekuda R, Gorman L, Zehusen BD, Smithson G, MacDougall JR;
PI Mezes PS, Peyman JA, Zhong M;
XX XX
DR WPI; 2003-103511/09.
XX XX
PT New NOVX polypeptides and polynucleotides useful for treating or
PT preventing e.g. congenital adrenal hyperplasia, hemophilia,
PT hypercoagulation, autoimmune disease, allergies, immunodeficiencies,
PT transplantation.
XX XX
PS Example H; Page 239; 300pp; English.
XX XX
CC The invention describes an isolated polypeptide, NOVX, comprising a
CC sequence or a mature form of one of 21 51-1543 residue amino acid
CC sequences (PI-P21), given in the specification. The NOVX polypeptides,
CC polynucleotides and antibodies are useful in the manufacture of a
CC medicament for treating or preventing e.g. adrenoleukodystrophy,
CC congenital adrenal hyperplasia, haemophilia, hypercoagulation, autoimmune
CC disease, allergies, immunodeficiencies, transplantation, Von Hippel-
CC Lindau syndrome, Alzheimer's disease, stroke, tuberculous sclerosis,
CC hypercalcaemia, Parkinson's disease, Huntington's disease, cancer,
CC fertility, diabetes, adult respiratory distress syndrome, viral,
CC bacterial and parasitic infections. The nucleic acid sequences may be
CC used in chromosome mapping, identifying individual from minute biological
CC samples (tissue typing), and in forensic identification of a biological
CC sample. This sequence represents a primer used to isolate DNA encoding a
CC novel human protein (NOV)
XX XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX XX
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Beat Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1219 GTCGACCTCCAGCATGT 1237
Db 1 GTCGACCATCCAGCATGT 19
XX XX
RESULT 189
ABZ23825
ID ABZ23825 standard; DNA; 20 BP.
XX XX

```

```
AC AB223825;
XX
XX 18-MAR-2003 (first entry)
XX
DE EGFR mRNA inhibiting antisense oligonucleotide AS15.
XX
XX Epidermal growth factor receptor; EGFR; cytosstatic; cancer; EGF;
XX antisense; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX WO200290514-A2.
XX
XX 14-NOV-2002.
XX
XX 07-MAY-2002; 2002WO-US014557.
XX
XX 07-MAY-2001; 2001US-0289055P.
XX
XX 07-MAY-2001; 2001US-0289149P.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX Agrawal S, Kandimala ER;
XX
XX WPI; 2003-120540/11.
XX
XX New synthetic oligonucleotide complementary to nucleic acids encoding
XX PT epidermal growth factor receptor (EGFR), useful for inhibiting the EGFR
XX PT gene or mRNA expression, and reducing cancer cell proliferation.
XX
XX Claim 10; Page 13; 36pp; English.
XX
XX The invention relates to synthetic antisense oligonucleotides
XX CC complementary to a region of nucleic acid encoding epidermal growth
XX CC factor receptor (EGFR) with location 245-1117, 2407-3201, 3786-4102 or
XX CC 4574-45633. The methods and compositions of the invention are useful for
XX CC enhancing inhibition of EGFR gene or mRNA expression, and reducing cancer
XX CC cell proliferation, in particular cancer cells of the colon, ovarian or
XX CC breast. Sequences AB223811-832 represent specific examples of such
XX CC antisense oligonucleotides that inhibit the EGFR mRNA expression
XX
XX Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 5.6%; Score 14.2; DB 1; Length 20;
XX Best Local Similarity 84.2%; Pred. No. 2.1e+02;
XX Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
OY 1390 TTGCTGAGCTGCTGACAG 1408
XX ||||| ||||| |||||
XX 1 TTGCTCAGATGCTGCGCAG 19
XX
RESULT 190
XX AB222817/c
XX ID AB222817 standard; DNA; 20 BP.
XX
XX AB222817;
XX
XX 02-APR-2003 (first entry)
XX
XX Salmomella s1pb-s1pc region PCR primer SEQ ID NO:1.
XX
XX Salmomella; Escherichia coli; Listeria monocytogenes; detection;
XX KW food service industry; PCR primer; ss.
XX
XX Salmomella sp.
XX
XX WO2003000935-A1.
XX
XX 03-JAN-2003.
XX
XX 21-JUN-2002; 2002WO-US021181.
```

```
XX
XX 22-JUN-2001; 2001US-0300199P.
XX
XX 18-APR-2002; 2002US-0373588P.
XX
XX 18-APR-2002; 2002US-0373589P.
XX
XX (MARS-) MARSHFIELD CLINIC.
XX
XX Ellingson JLE, Veeva DN;
XX
XX WPI; 2003-184059/18.
XX
XX Detecting Salmomella species, Escherichia coli O157:H7 or Listeria
XX PT monocytogenes, for testing of bacteria in the food service industry,
XX PT comprises amplifying a genomic nucleotide sequence and detecting the
XX PT amplification product.
XX
XX Claim 1; Page 6; 23pp; English.
XX
XX The present invention describes a method (M1) for detecting Salmomella
XX CC species, Escherichia coli O157:H7, or Listeria monocytogenes comprising
XX CC amplifying a genomic nucleotide sequence of a corresponding species and
XX CC detecting the amplification product. The method comprises amplifying a
XX CC genomic nucleotide sequence comprising nucleotides 9-243 of a fully
XX CC defined sequence of 251 base pairs (see AB222829), nucleotides 7-354 of a
XX CC fully defined sequence of 361 base pairs (see AB222830), or nucleotides 9
XX CC -210 of a fully defined sequence of 217 base pairs (see AB222831), and
XX CC detecting an amplification product that contains the genomic nucleotide
XX CC sequence. Detecting Salmomella species, E. coli O157:H7, or L.
XX CC monocytogenes is useful for industrial testing of bacteria in the food
XX CC service industry. The present method provides an inexpensive testing
XX CC technology with a rapid turn-around time, and a high degree of accuracy
XX CC and reproducibility resulting in safer food manufacturing and
XX CC preparation. The present sequence represents a PCR primer used for
XX CC detecting the s1pb-s1pc region of the Salmomella genome, which is used in
XX CC the exemplification of the present invention
XX
XX Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 5.6%; Score 14.2; DB 1; Length 20;
XX Best Local Similarity 84.2%; Pred. No. 2.1e+02;
XX Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
OY 1377 AAGCAGCTGCGTTTGCTG 1395
XX ||||| ||||| |||||
XX 20 AAGCATCGCATTTTGCTG 2
XX
RESULT 191
XX AAL62392
XX ID AAL62392 standard; DNA; 20 BP.
XX
XX AAL62392;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206573.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosstatic;
XX KW hyperproliferative; autoimmune disorder; antisense gene therapy;
XX KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX KW phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX FT 1..20
XX FT /*cag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidines are 5-
XX FT methylcytidines"
XX FT 1..5
XX FT /*cag= b
XX
XX modified_base
```

FT	/mod_base= OTHER
PT	/note= "2'methoxyethyl nucleotides"
FT	modified_base
FT	16..20
FT	/*tag= C
FT	/mod_base= OTHER
XX	/note= "2'methoxyethyl nucleotides"
PN	WO2003051309-A2.
XX	
PD	26-JUN-2003.
PF	12-DEC-2002; 2002MO-US040101.
PR	17-DEC-2001; 2001US-00024369.
PA	(ISIS-) ISIS PHARM INC.
PI	Borchers AH, Ward DT, Freiler SM;
DR	WPI; 2003-577305/54.
XX	
PT	New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.
XX	
PS	Claim 3; Page 80; 112pp; English.
CC	The invention relates to a compound targeted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridises with the nucleic acid molecule and inhibits expression of ATM or specifically hybridises with at least a portion of an active site on the nucleic acid molecule. The invention is useful for inhibiting the expression of ATM in cells or tissues. The invention is useful for treating an animal with hyperproliferative or autoimmune disorder. The invention is useful for diagnostics,
CC	therapeutics, prophylaxis, as research reagents and kits, for distinguishing functions of various members of a biological pathway and in anti-sense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation.
CC	The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention
SQ	Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match	5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity	84.2%; Pred.No.2.le+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0	
OY	1344 GGAGACTTTCACGCGCAG 1362
DB	 2 GGTGA CTTC CC CA GT CG AG 20
RESULT 192	
AAL61584	AAL61584 standard; DNA; 20 BP.
AAI61584;	
DJ	22-SEP-2003 (first entry)
DE	Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130509.
KX	Human, inhibitor-kappa B-R, I-kappaBR, IKR, I-kappa-B-related, NFKBIL2, ikapgab r; antisense; immune response; infection; inflammation; therapy; tumour; prophylaxis; phosphorothioate; ss.
OS	Homo sapiens.
SS	Synthetic.
XH	Key Location/Qualifiers

FT	modified_base	1..20	/*tag= a	
FT			/mod_base= OTHER	
FT			/note= "Phosphorothioate backbone; All cytidine residues	
FT			are 5-methylcytidines"	
FT	modified_base	1..5	/*tag= b	
FT			/mod_base= OTHER	
FT	modified_base	16..20	/note= "2'-methoxyethyl (2'-MOE) nucleotides"	
FT			16..20	
FT			/*tag= c	
FT			/mod_base= OTHER	
FT			/note= "2'-methoxyethyl (2'-MOE) nucleotides"	
XX				
PN	WO2003042360-A2.			
XX				
PD	22-MAY-2003.			
XX				
PE	05-NOV-2002; 2002WO-US035597.			
XX				
PR	13-NOV-2001; 2001US-00993731.			
XX				
PA	(ISIS-) ISIS PHARM INC.			
XX				
PI	Monia BP, Watt AT;			
DR	WPI; 2003-468635/44.			
XX				
PT	New antisense oligonucleotides targeted to nucleic acids encoding			
PT	inhibitor-kappa B-R, useful for diagnosing or treating diseases			
PT	associated with expression of inhibitor-kappa B-R, e.g., a heightened			
PT	immune response or infection.			
XX				
PS	Claim 3; Page 75; 108pp; English.			
XX				
CC	The invention relates to antisense compounds targeted to a nucleic acid			
CC	molecule encoding human inhibitor-kappa B-R (also known as I-kappaB α ,			
CC	IKB α , I-kappa-B-related, ikappab r, nuclear factor of kappa light			
CC	polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to			
CC	inhibit its expression. Antisense compounds of the invention are useful			
CC	for treating diseases or conditions associated with the expression of			
CC	inhibitor-kappa B-R such as a heightened immune response involving			
CC	increased cytokine expression, or a result of infection (e.g. bacterial,			
CC	viral or parasitic). They are useful for diagnostics, therapeutic,			
CC	prophylaxis e.g. to prevent or delay infection, inflammation or tumour			
CC	formation, as research reagents and kits and in distinguishing between			
CC	functions of various members of a biological pathway. They are also			
CC	useful in antisense therapy. The present sequence is an oligonucleotide			
CC	targeted to human inhibitor-kappa B-R DNA			
XX				
SQ	Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;			
	Query Match	5.6%;	Score 14.2;	DB 1; Length 20;
	Best Local Similarity	84.2%;	Pred. No. 2.1e+02;	
	Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;			
Qy	1252 GGCTCAGCAACAGCTGGA 1270			
Db	2 GGCTCAGCCTCAGCTGCA 20			
	RESULT 193			
	ADF87711			
XX	ADF87711 standard; DNA; 20 BP.			
XX				
XX	ADF87711;			
XX				
DE	26-FEB-2004 (first entry)			
XX				
XX	Single nucleotide polymorphism detection primer, SEQ ID No 1294.			
XX	human; single nucleotide polymorphism; microarray; side effect; sb;			
XX	primer; PCR.			

XX	Synthetic.
OS	Homo sapiens.
XX	
PN	JP2003235571-A.
XX	
PD	26-AUG-2003.
XX	
PF	12-FEB-2002; 2002JP-00034717.
XX	
PR	12-FEB-2002; 2002JP-00034717.
XX	
PA	(KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX	
DR	WPI; 2003-820454/77.
XX	
PT	Novel polynucleotide useful for detecting single nucleotide polymorphisms
XX	in human gene.
XX	
PS	Claim 2; SEQ ID NO 1294; 704bp; Japanese.
XX	
CC	The invention relates to a novel polynucleotide isolated and purified
CC	from a human gene having any one of 935 fully defined sequences as given
CC	in specification, or a sequence having a base substitution. The invention
CC	further relates to: an oligonucleotide containing single nucleotide
CC	polymorphisms; a PCR primer set chosen from the combination of two DNA
CC	fragments from any one of 1220 fully defined sequences as given in
CC	specification; a labelling probe containing the SNP containing oligo; and
CC	a microarray equipped with the SNP containing oligo. The isolated human
CC	gene of the invention is useful for detecting the single nucleotide
CC	polymorphisms in human gene. The isolated human gene is also useful for
CC	diagnosis of disease and determination of side effect to a medical agent.
CC	The isolated human gene is also effective in detecting single nucleotide
CC	polymorphisms in a human gene. This polynucleotide sequence represents
CC	one of the PCR primers used in the single nucleotide polymorphism
CC	detection method of the invention.
SQ	Sequence 20 BP; 5 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
	Query Match 5.6%; Score 14.2; DB 1; Length 20;
	Best Local Similarity 84.2%; Pred. No. 2.1e+02;
	Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0
QY	1264 ACCTGAGAGGCTGAGGG 1282
DB	2 ACCTGAGAGGCTGAGGG 20
RESULT 194	
ADH93689/c	
ID	ADH93689 strand; DNA; 20 BP.
XX	
AC	ADH93689;
XX	
DT	22-APR-2004 (first entry)
XX	
DE	Human gene PCR primer #534.
XX	
KW	human; gene sequence; single nucleotide polymorphism; SNP;
XX	disease diagnosis; ss; PCR; primer.
XX	
OS	Homo sapiens.
XX	
PN	JP2003174883-A.
XX	
PD	24-JUN-2003.
XX	
PF	11-DEC-2001; 2001JP-00377637.
XX	
PR	11-DEC-2001; 2001JP-00377637.
XX	
PA	(KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX	

[illegible]

CC immunosuppressive, and cyostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1367 GGCTTACGAGAGCAGCTG 1385
Db 20 GGCAATCCAGCAGCAGCTG 2
RESULT 196
ABZ85937
ID ABZ85937 standard; DNA; 20 BP.
AC ABZ85937;
XX
XX 17-OCT-2003 (first entry)
DT
XX
XX Human oligonucleotide sequence.
DE
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cyostatic; gene therapy;
KW adenosine gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX WO200285308-A2.
PN
XX 31-OCT-2002.
PD
XX 23-APR-2002; 2002WO-US013135.
PF
XX 24-APR-2001; 2001US-0286137P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Claim 15; SEQ ID NO 1179; 872pp; English.
PS
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cyostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1243 CAGTGTCCGCGCTCAGCA 1261
Db 1 CAGTGTCTGTCTCAGCA 19
RESULT 197
ABD22167
ID ABD22167 standard; DNA; 20 BP.
AC ABD22167;
XX
XX 29-JUL-2004 (first entry)
DT
XX
XX Human stannocalcin-derived oligo SEQ ID 1179.
DE
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX 31-OCT-2002.
PD
XX 23-APR-2002; 2002WO-US013143.
PF
XX 24-APR-2001; 2001US-0286036P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
DR
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 1179; 763pp; English.
PS
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating

XX (ISIS-) ISIS PHARM INC.
PA Freier SM, Baker BF, Dobie KW;
XX WPI; 2004-022079/02.
XX
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding sterol regulatory element-binding protein-1, useful
PT for treating diabetes, atherosclerosis or hyperlipidemia.
XX
XX Example 16; SEQ ID NO 222; 112pp; English.
XX
XX The invention relates to a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridises with a nucleic acid molecule
CC encoding sterol regulatory element-binding protein-1 (SREBP-1, also known
CC as sterol regulatory element-binding transcription factor, SREBF), and
CC inhibits the expression of SREBP-1, i.e. is an antisense oligonucleotide.
CC Also included are a compound 8-80 nucleobases in length that specifically
CC hybridises with at least an 8-nucleobase portion of an active site on a
CC nucleic acid molecule encoding sterol regulatory element-binding protein-
CC 1, a composition comprising the compound and a carrier or diluent,
CC inhibiting the expression of sterol regulatory element-binding protein-1
CC in cells or tissues (by contacting the cells or tissues with the compound
CC so that expression of sterol regulatory element-binding protein-1 is
CC inhibited) and treating an animal having a disease or condition
CC associated with sterol regulatory element-binding protein-1 by
CC administering to the animal a therapeutic or prophylactic amount of the
CC compound so that expression of sterol regulatory element-binding protein-
CC 1 is inhibited. The antisense oligonucleotide comprises at least one
CC modified internucleoside linkage (preferably 2'-O-methoxyethyl sugar
CC at least one modified sugar moiety (preferably 2'-O-methoxyethyl sugar
CC moiety) or at least one modified nucleobase (preferably 5-
CC methylcytosine). The compound, composition and methods are useful for
CC treating a disease or condition associated with sterol regulatory element
CC -binding protein-1, such as a metabolic disorder e.g. diabetes, or a
CC cardiovascular disorder, e.g. atherosclerosis or hyperlipidemia. They
CC are also useful in research and diagnostics for modulating the expression
CC of sterol regulatory element-binding protein-1. The present sequence is a
CC human SREBP-1 target region for the antisense oligonucleotides.
XX
XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1197 CCTGTGAGAGGAGGCCA 1215
Db 2 CCTGTGCTGACGAGGCCA 20
RESULT 200
ADG72098/C
ID ADG72098 standard; DNA; 20 BP.
XX
XX ADG72098;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human SREBP-1 antisense oligonucleotide ISIS 220111.
DE
XX
XX Sterol regulatory element-binding protein-1; SREBP-1; ss; human;
KW antisense gene therapy;
KW sterol regulatory element-binding transcription factor; SREBF;
KW metabolic disorder; diabetes; cardiovascular disorder; atherosclerosis;
KW hyperlipidemia.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b

FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residues"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residues"
XX
XX US2003224515-A1.
XX
XX 04-DEC-2003.
XX
XX 04-JUN-2002; 2002US-00161996.
XX
XX 04-JUN-2002; 2002US-00161996.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Baker BF, Dobie KW;
XX WPI; 2004-022079/02.
XX
XX New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding sterol regulatory element-binding protein-1, useful
PT for treating diabetes, atherosclerosis or hyperlipidemia.
XX
XX Example 15; SEQ ID NO 93; 112pp; English.
XX
XX The invention relates to a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridises with a nucleic acid molecule
CC encoding sterol regulatory element-binding protein-1 (SREBP-1, also known
CC as sterol regulatory element-binding transcription factor, SREBF), and
CC inhibits the expression of SREBP-1, i.e. is an antisense oligonucleotide.
CC Also included are a compound 8-80 nucleobases in length that specifically
CC hybridises with at least an 8-nucleobase portion of an active site on a
CC nucleic acid molecule encoding sterol regulatory element-binding protein-
CC 1, a composition comprising the compound and a carrier or diluent,
CC inhibiting the expression of sterol regulatory element-binding protein-1
CC in cells or tissues (by contacting the cells or tissues with the compound
CC so that expression of sterol regulatory element-binding protein-1 is
CC inhibited) and treating an animal having a disease or condition
CC associated with sterol regulatory element-binding protein-1 by
CC administering to the animal a therapeutic or prophylactic amount of the
CC compound so that expression of sterol regulatory element-binding protein-
CC 1 is inhibited. The antisense oligonucleotide comprises at least one
CC modified internucleoside linkage (preferably 2'-O-methoxyethyl sugar
CC at least one modified sugar moiety (preferably 2'-O-methoxyethyl sugar
CC moiety) or at least one modified nucleobase (preferably 5-
CC methylcytosine). The compound, composition and methods are useful for
CC treating a disease or condition associated with sterol regulatory element
CC -binding protein-1, such as a metabolic disorder e.g. diabetes, or a
CC cardiovascular disorder, e.g. atherosclerosis or hyperlipidemia. They
CC are also useful in research and diagnostics for modulating the expression
CC of sterol regulatory element-binding protein-1. The present sequence is
CC an antisense oligonucleotide targeting human SREBP-1.
XX
XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1197 CCTGTGAGAGGAGGCCA 1215
Db 19 CCTGTGCTGACGAGGCCA 1
RESULT 201
ADN03131

ID ADN03131 standard; DNA; 20 BP.
XX
AC ADN03131;
XX
DT 29-JUN-2004 (first entry)
XX
DE Human P1M-1 DNA antisense oligonucleotide target region #10.
XX
KW Human; P1M-1; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; cytostatic.
XX
OS Homo sapiens.
XX
PN US2004092463-A1.
XX
PD 13-MAY-2004.
XX
PF 11-NOV-2002; 2002US-00292849.
XX
PR 11-NOV-2002; 2002US-00292849.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Wact AT;
XX
DR WPI; 2004-374981/35.
XX
PT New compound that modulates P1M-1 expression, useful in treating an
PT animal having a disease or condition, i.e. hyperproliferative disorder.
XX
PS Example 15; SEQ ID NO 100; 51pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding the human P1M-1 polypeptide. The compound is an antisense
CC oligonucleotide that specifically hybridizes with the nucleic acid and
CC inhibits expression of the polypeptide. The antisense oligonucleotide
CC comprises at least one modified internucleoside linkage i.e. a
CC phosphorothioate linkage, at least one modified sugar moiety, preferably
CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC comprising a 5-methylcytosine. The antisense compounds are useful for
CC modulating the expression of the human P1M-1 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents a human P1M-1 DNA antisense
CC oligonucleotide target region of the invention.
XX
SQ Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match 5.6%; Score 14.2; DB 1; length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1240 TGGCAGTGTGTCGGCTGCA 1258
Db 2 TGGAAGTGTCTCTGCTGAA 20
XX
RESULT 202
ADN03059/C
ID ADN03059 standard; DNA; 20 BP.
XX
AC ADN03059;
XX
DT 29-JUN-2004 (first entry)
XX
DE Human P1M-1 DNA antisense oligonucleotide #16.
XX
KW Human; P1M-1; ss; antisense oligonucleotide; phosphorothioate linkage;
KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW hyperproliferative disorder; cancer; cytostatic.
XX
OS Homo sapiens.
XX

PN US2004092463-A1.
XX
PD 13-MAY-2004.
XX
PF 11-NOV-2002; 2002US-00292849.
XX
PR 11-NOV-2002; 2002US-00292849.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Wact AT;
XX
DR WPI; 2004-374981/35.
XX
PT New compound that modulates P1M-1 expression, useful in treating an
PT animal having a disease or condition, i.e. hyperproliferative disorder.
XX
PS Example 15; SEQ ID NO 28; 51pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding the human P1M-1 polypeptide. The compound is an antisense
CC oligonucleotide that specifically hybridizes with the nucleic acid and
CC inhibits expression of the polypeptide. The antisense oligonucleotide
CC comprises at least one modified internucleoside linkage i.e. a
CC phosphorothioate linkage, at least one modified sugar moiety, preferably
CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC comprising a 5-methylcytosine. The antisense compounds are useful for
CC modulating the expression of the human P1M-1 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents a human P1M-1 DNA antisense
CC oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 5.6%; Score 14.2; DB 1; length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1240 TGGCAGTGTGTCGGCTGCA 1258
Db 19 TGGAAGTGTCTCTGCTGAA 1
XX
RESULT 203
ADO48125
ID ADO48125 standard; DNA; 20 BP.
XX
AC ADO48125;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human HIP-1 target sequence ISIS 168230.
XX
KW ss; Huntingtin interacting protein 1; HIP-1; HIP-1 protein interactor;
KW apoptosis dysregulation.
XX
OS Homo sapiens.
XX
PN US2004096834-A1.
XX
PD 20-MAY-2004.
XX
PF 19-NOV-2002; 2002US-00300263.
XX
PR 19-NOV-2002; 2002US-00300263.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Dobie KW;
XX
DR WPI; 2004-389149/36.
XX
PT New compounds targeted to a nucleic acid molecule encoding HIP-1 protein
XX

PT Interactor, useful for treating an animal having a disease or condition
PT associated with HIP-1 protein interactor, such as dysregulation of
PT apoptosis.
XX
XX Example 15; SEQ ID NO 135; 76pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding Huntingtin interacting protein 1 (HIP-1) protein interactor. The
CC compound is useful for treating an animal having a disease or condition
CC associated with HIP-1 protein interactor, such as dysregulation of
CC apoptosis. The compound may also be used for diagnostics, therapeutics,
CC prophylaxis and as research agents and kits; or to elucidate the function
CC of particular genes or to distinguish between functions of various
CC members of a biological pathway. The present sequence represents a human
CC HIP-1 antisense oligonucleotide target sequence.
XX
SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1339 AGGCAGGAGACTTCCCG 1357
DB 1 AGGCAGGAGACTTCCCG 19
RESULT 204
ADO48059/C
ID ADO48059 standard; DNA; 20 BP.
XX
XX ADO48059;
AC
XX
XX 12-AUG-2004 (first entry)
DT
XX
XX Human HIP-1 antisense oligonucleotide ISIS 251714.
DE
XX
XX ss: Huntingtin interacting protein 1; HIP-1; HIP-1 protein interactor;
KW apoptosis dysregulation; antisense.
KM
XX
XX Homo sapiens.
OS
OS Synthetic.
OS
XX
XX US2004096834-A1.
PN
XX
XX 20-MAY-2004.
PD
XX
XX 19-NOV-2002; 2002US-00300263.
PF
XX
XX 19-NOV-2002; 2002US-00300263.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Dobie KM;
PI
XX
XX WPI; 2004-389149/36.
DR
XX
XX New compounds targeted to a nucleic acid molecule encoding HIP-1 protein
PT interactor, useful for treating an animal having a disease or condition
PT associated with HIP-1 protein interactor, such as dysregulation of
PT apoptosis.
XX
XX Example 15; SEQ ID NO 69; 76pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding Huntingtin interacting protein 1 (HIP-1) protein interactor. The
CC compound is useful for treating an animal having a disease or condition
CC associated with HIP-1 protein interactor, such as dysregulation of
CC apoptosis. The compound may also be used for diagnostics, therapeutics,
CC prophylaxis and as research agents and kits; or to elucidate the function
CC of particular genes or to distinguish between functions of various
CC members of a biological pathway. The present sequence represents a human
CC HIP-1 antisense oligonucleotide.

XX
SQ Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 5.6%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1339 AGGCAGGAGACTTCCCG 1357
DB 20 AGGCAGGAGACTTCCCG 2
RESULT 205
AAF52821
ID AAF52821 standard; DNA; 15 BP.
XX
XX AAF52821;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGF-I oligonucleotide #3781.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cyostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborthoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX
XX WPI; 2001-041421/05.
DR
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 85; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC P45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, ptyriasis, ruba, pilaris, serborthoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.6%; Score 14; DB 1; Length 15;

Db 17 AACAGCTGGAGAG 4

RESULT 208
ABD31209/C
ID ABD31209 standard; DNA; 18 BP.

AC ABD31209;

DT 29-JUL-2004 (first entry)

DE Human CD23-derived oligonucleotide SEQ ID 13420.

XX Human; antisease; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX MO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JM, Li Y, Sandraaagra A, Katz E, Pabalan J, Aguilar D,
PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisease
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15, SEQ ID NO 13420; 763bp; English.

XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX Sequence 18 BP; 1 A; 7 C; 2 G; 8 T; 0 U; 0 Other;

XX Query Match

5.6%; Score 14; DB 1; Length 18;

XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1261 AACAGCTGGAGAG 1274

Db 17 AACAGCTGGAGAG 4

RESULT 209
ADJ60043/C
ID ADJ60043 standard; DNA; 18 BP.

XX ADJ60043;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to CD23-X04772 #37.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JM, Tang L, Sandraaagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 899; 85bp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.,
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

Seq Sequence 18 BP; 1 A; 7 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 5.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1261 AACAGCTGGAAGAG 1274
Db 17 AACAGCTGGAAGAG 4
RESULT 210
AD045533/c
ID AD045533 standard; DNA; 18 BP.
XX AC AD045533;
XX AC
XX AD045533;
XX AC
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #899.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KM CCR1; CCR3; Botaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KM tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KM lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KM asthma; lung allergy; inflammation; inflammatory disease;
KM airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KM chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KM acute respiratory distress syndrome; pulmonary hypertension;
KM lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
XX Homo sapiens.
XX OS
XX US2004049022-A1.
XX PN
XX 11-MAR-2004.
XX PD
XX 25-JUL-2003; 2003US-00627930.
XX PF
XX 23-APR-2002; 2002WO-US013135.
XX PR 23-APR-2002; 2002WO-US013143.
XX BR
XX (NYCE/) NYCE J W.
XX PA (SAND/) SANDRASAGRA A.
XX PA (TANG/) TANG L.
XX PA (AGUI/) AGUILAR D.
XX PA (MILL/) MILLER S.
XX PA (SHAH/) SHAHABUDDIN S.
XX PA (LUHM/) LU H.
XX PA (CONG/) CONG H.
XX
XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-293804/27.
XX DR
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 899; 174bp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Seq Sequence 18 BP; 1 A; 7 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 5.6%; Score 14; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1261 AACAGCTGGAAGAG 1274
Db 17 AACAGCTGGAAGAG 4
RESULT 211
AB143943/c
ID AB143943 standard; DNA; 19 BP.
XX AC AB143943;
XX AC
XX 11-APR-2002 (first entry)
XX DT
XX Human chromosome 1p36-35 PCR primer SEQ ID NO:987.
XX DE
XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KM PCR primer; ss.
XX KM
XX Homo sapiens.
XX OS
XX JP2001321190-A.
XX PN
XX 20-NOV-2001.
XX PD
XX 12-MAR-2001; 2001JP-00068285.
XX PF
XX 10-MAR-2000; 2000JP-00066716.
XX PR
XX (RIKA) RIKAGAKU KENKYUSHO.
XX PA (GENO-) GENOTEX YG.
XX PA
XX WPI; 2002-144136/19.
XX DR
XX Arraying genome clones.
XX PT
XX
XX Claim 4; Page 24; 528bp; Japanese.
XX PS
XX The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell

CC plates are specified from the detected result; and (1) the clones are
CC reconstructed as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
CC
SQ Sequence 19 BP; 2 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 5.6%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1370 TTACCAAGAGCAGC 1383
DB 16 TTACCAAGAGCAGC 3
RESULT 212
ADP31546
ID ADP31546 standard; RNA; 19 BP.
AC ADP31546;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human IGF-1R transcript target sequence/siNA upper strand, SEQ ID NO:211.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW proliferative disease; restenosis; polycystic kidney disease;
KW inflammatory disease; allergic disease; autoimmune disease;
KW transplant rejection; cytostatic; vasotrophic; nephrotropic;
KW antiinflammatory; antiallergic; immunosuppressive; human;
KW insulin-like growth factor 1 receptor; IGF-1R; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070911-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005044.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0366782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwiggan J, Beigelman L, Chowrira B,
XX
DR WPI; 2003-721691/68.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the insulin-like growth
PT factor-1 receptor gene.
XX
XX Example 3; SEQ ID NO 211; 147bp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human insulin-like growth factor 1
CC receptor (IGF-1R) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.

CC Specifically, the siNAs include short interfering RNA (siRNA), double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the IGF-1R gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC cancer and other proliferative diseases (e.g., restenosis and polycystic
CC kidney disease), inflammatory and/or allergic diseases and autoimmune
CC diseases and transplant rejection. The siNAs are also useful for drug
CC screening, diagnosis, therapeutic target identification and validation,
CC genetic engineering, pharmacogenomics, studying gene function, and gene
CC mapping (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the upper strand of a human IGF-1R-targeted double-stranded
CC siNA, which is identical to the IGF-1R transcript target sequence.
XX
SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 5.6%; Score 14; DB 1; Length 19;
Best Local Similarity 71.4%; Pred. No. 2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
OY 1233 CATGCGTGGCAGT 1246
DB 1 CAUGGCGTGGCAGU 14
RESULT 213
ADP31823/C
ID ADP31823 standard; RNA; 19 BP.
AC ADP31823;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human IGF-1R siNA lower strand, SEQ ID NO:488.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; cancer;
KW proliferative disease; restenosis; polycystic kidney disease;
KW inflammatory disease; allergic disease; autoimmune disease;
KW transplant rejection; cytostatic; vasotrophic; nephrotropic;
KW antiinflammatory; antiallergic; immunosuppressive; human;
KW insulin-like growth factor 1 receptor; IGF-1R; ss.
XX
OS Homo sapiens.
XX
PN WO2003070911-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005044.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0366782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwiggan J, Beigelman L, Chowrira B,
XX
DR WPI; 2003-721691/68.
XX

PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer , downregulates expression of the insulin-like growth
PT factor-1 receptor gene.
XX
PS Example 3; SEQ ID NO 486; 147bp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human insulin-like growth factor 1
CC receptor (IGF-1R) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA), double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the IGF-1R gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC cancer and other proliferative diseases (e.g., restenosis and polycystic
CC kidney diseases), inflammatory and/or allergic diseases, autoimmune
CC diseases and transplant rejection. The siNAs are also useful for drug
CC screening, diagnosis, therapeutic target identification and validation,
CC genetic engineering, pharmacogenomics, studying gene function, and gene
CC mapping (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the lower strand of a human IGF-1R-targeted double-stranded
CC siNA.
XX
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 5.6%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1233 CATGTGCTGCAGT 1246
DB 19 CATGTGCTGCAGT 6
RESULT 214
ABX17840/C
ID ABX17840 standard; DNA; 20 BP.
XX
AC ABX17840;
XX
DT 05-FEB-2003 (first entry)
XX
DE Mouse urokinase plasminogen activator antisense oligonucleotide #72.
XX
KM Urokinase plasminogen activator; gene therapy; cancer;
KM hyperproliferative disorder; cancer; breast cancer; colon cancer;
KM bone cancer; brain cancer; ovary cancer; cervix cancer;
KM endometrium cancer; stomach cancer; kidney cancer; tumour metastasis;
KM antisense oligonucleotide; ss.
XX
OS Synthetic.
XX
PN WO200279515-A1.
XX
PD 10-OCT-2002.
XX
PP 18-MAR-2002; 2002WO-US008112.
XX
PR 30-MAR-2001; 2001US-00821972.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Baker BF, Freier SM, Watt AT;
XX
DR WPI; 2003-058441/05.

XX
XX New antisense compound, useful for preparing a composition for treating
PT hyperproliferative disorders, cancer e.g., breast, colon, bone, brain,
PT ovary, cervix, endometrium, stomach or kidney cancer, or tumor
PT metastasis.
XX
PS Example 16; Page 94; 153bp; English.
XX
XX
CC A new compound, which is 8-50 nucleobases in length targeted to a nucleic
CC acid molecule encoding urokinase plasminogen activator, specifically
CC hybridises with and inhibits the expression of urokinase plasminogen
CC activator. The compound is useful for preparing a composition for
CC treating (e.g. by gene therapy) hyperproliferative disorder, cancer e.g.,
CC breast, colon, bone, brain, ovary, cervix, endometrium, stomach or kidney
CC cancer, or tumour metastasis. This sequence represents an antisense
CC oligonucleotide used to modulate expression of urokinase plasminogen
CC activator
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 5.6%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1351 TTCCGAGGCGAGCT 1364
DB 17 TTCCGAGGCGAGCT 4
RESULT 215
ADU66929/C
ID ADU66929 standard; DNA; 20 BP.
XX
AC ADU66929;
XX
DT 06-MAY-2004 (first entry)
XX
DE RET oligonucleotide microchip-related oligonucleotide SeqID32.
XX
KM RET oligonucleotide microchip; mis-sense mutation; mutation hot spot;
KM RET gene; immobilised; automatic microarray; hereditary cancer;
KM multiple internal secretion adenomatosis type 2 syndrome; ss.
XX
OS Unidentified.
XX
PN JP2003156492-A.
XX
PD 30-MAY-2003.
XX
PP 19-APR-2002; 2002JP-00117713.
XX
PR 19-NOV-2001; 2001KR-00071774.
XX
PA (NACA-) NAT CANCER CENT.
XX
XX WPI; 2003-692502/66.
XX
PT RET oligonucleotide microchip contains oligonucleotide that can identify
PT misense mutation of mutation hot spot in a RET gene, immobilized to
PT surface of solid substrate by automatic microarrayer.
XX
PS Claim 4; SEQ ID NO 32; 25bp; Japanese.
XX
CC This invention relates to a novel RET oligonucleotide microchip which
CC contains an oligonucleotide that can identify mis-sense mutation of a
CC mutation hot spot in a RET gene, immobilised to the surface of a solid
CC substrate by automatic microarrayer. The RET oligonucleotide microchip is
CC useful for identifying mis-sense mutations in a RET gene, and thus for
CC diagnosing hereditary cancers, where the RET gene is a causative gene of
CC multiple internal secretion adenomatosis type 2 syndromes. The RET
CC oligonucleotide chip enables diagnosis of hereditary cancers accurately
CC and economically. The present sequence is that of an oligonucleotide
CC which is related to the RET oligonucleotide microchip of the invention.

```
XX SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 5.6%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1184 GGGCTCCGAGAGC 1197
DB 18 GGGCTCCGAGAGC 5

RESULT 216
ADK95533
ID ADK95533 standard; DNA; 20 BP.
AC ADK95533;
XX
XX 06-MAY-2004 (first entry)
XX DE Primer of the invention #1253.
XX CC human; single nucleotide polymorphism; SNP; ss; primer.
XX KW human; single nucleotide polymorphism; SNP; ss; primer.
XX OS Synthetic.
XX PN JP2003259875-A.
XX PD 16-SEP-2003.
XX PF 08-MAR-2002; 2002JP-00064373.
XX PR 08-MAR-2002; 2002JP-00064373.
XX PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX DR WPI; 2004-093977/10.
XX PT Novel polynucleotide useful for PCR amplification along with two DNA
XX PT fragment from another set of sequences, or for detecting single
XX PT nucleotide polymorphism in human gene.
XX PS Claim 2; SEQ ID NO 4562; 2627pp; Japanese.
XX CC The present invention relates to a polynucleotide isolated from a human
XX CC gene and is useful for detecting a single nucleotide polymorphism in a
XX CC human gene or for diagnosing of disease. The invention enables the
XX CC detection of a single nucleotide polymorphism in a human gene. The
XX CC present sequence represents a primer of the invention.
XX SQ Sequence 20 BP; 7 A; 3 C; 9 G; 1 T; 0 U; 0 Other;
Query Match 5.6%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1273 AGGCTGAGGCGAGA 1286
DB 3 AGGCTGAGGCGAGA 16

RESULT 217
ADK94306/C
ID ADK94306 standard; DNA; 20 BP.
AC ADK94306;
XX
XX 06-MAY-2004 (first entry)
XX DT Primer of the invention #26.
XX DE human; single nucleotide polymorphism; SNP; ss; primer.
XX KW human; single nucleotide polymorphism; SNP; ss; primer.
XX PT
```

```
OS Synthetic.
XX JP2003259875-A.
XX PD 16-SEP-2003.
XX PF 08-MAR-2002; 2002JP-00064373.
XX PR 08-MAR-2002; 2002JP-00064373.
XX PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX DR WPI; 2004-093977/10.
XX PT Novel polynucleotide useful for PCR amplification along with two DNA
XX PT fragment from another set of sequences, or for detecting single
XX PT nucleotide polymorphism in human gene.
XX PS Claim 2; SEQ ID NO 3335; 2627pp; Japanese.
XX CC The present invention relates to a polynucleotide isolated from a human
XX CC gene and is useful for detecting a single nucleotide polymorphism in a
XX CC human gene or for diagnosing of disease. The invention enables the
XX CC detection of a single nucleotide polymorphism in a human gene. The
XX CC present sequence represents a primer of the invention.
XX SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 5.6%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1265 GCTGGAAGAGGCTG 1278
DB 14 GCTGGAAGAGGCTG 1

RESULT 218
AAK72691
ID AAK72691 standard; RNA; 17 BP.
AC AAK72691;
XX
XX 28-JUL-1999 (first entry)
XX DT Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #124.
XX DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #124.
XX KW KDR; hammetthead ribozyme; hairpin ribozyme; cleavage;
XX KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX KW foetal liver kinase 1; ss.
XX OS Mus sp.
XX PN W09715662-A2.
XX PD 01-MAY-1997.
XX PF 25-OCT-1996; 96WO-US017480.
XX PR 26-OCT-1995; 95US-0005974P.
XX PR 11-JAN-1996; 96US-00584040.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (CHIR-) CHIRON CORP.
XX PT Payco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX PT
```

PT rheumatoid arthritis, etc., in a human patient.

P8 Claim 4; Page 126; 218pp; English.

XX

PS The present invention describes nucleic acid molecules which modulate the

CC synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), Kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX67275 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention

XX

SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0

Oy 1299 GCCATGTCATCTGTGA 1315
| | | : | : | : | : |
Db 1 GGCAUGUCUUCUCUGA 17

RESULT 219
AAX71090
ID AAX71090 standard; RNA; 17 BP.
XX
XX AAX71090;
AC
XX
DT 28-JUL-1999 (first entry)
DE
XX
XX Human KDR VEGF receptor hammerhead ribozyme substrate #102.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KM KDR; hammethead ribozyme; hairpin ribozyme; cleavage;
KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Homo sapiens.
OS
XX
XX WO9715662-A2.
PN
XX
PD 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US017480.
PF
XX
XX 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
PR
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
PI Pavco P, Mcswigen J, Stinchcomb D, Escobedo J;
PI WPI, 1997-259017/23.
XX
DR Nucleic acid molecule modulattng VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 100; 218pp; English.

PS The present invention describes nucleic acid molecules which modulate the

CC synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), Kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC anglogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC	treated by administering the nucleic acid molecule or the expression vector to the patient. AAX67275 to AAX75152 represent specific examples of nucleic acid molecules from the present invention
CC	
XX	
SQ	Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
Qy	1299 GCCATGTCATCTGTGA 1315 ::: ::
Dd	1 GGCAUGGUCUUCUGA 17
Query Match	5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity	58.8%; Pred. No. 1.6e+02;
Matches 10; Conservative	5; Mismatches 2; Indels 0; Gaps 0
RESULT 220	
AAB78082/C	
ID	AAB78082 standard; DNA; 17 BP.
XX	
AC	AAB78082;
XX	
DT	
XX	24-JAN-2002 (first entry)
DE	BRCA1 mutation correcting oligonucleotide SEQ ID NO: 928.
KW	Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BRCA1; BRCA2; CPTF; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; mismatch repair; MSH2; MSH6; hypervidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytosstatic; antisticking; antanaemic; haemostatic; antiipemic; ss.
KX	
OS	Homo sapiens.
PN	WO200173002-A2.
XX	
PD	04-OCT-2001.
XX	
Pf	27-MAR-2001; 2001WO-US009761.
XX	
PR	27-MAR-2000; 2000US-0192176P.
PR	27-MAR-2000; 2000US-0192179P.
PR	01-JUN-2000; 2000US-0208538P.
PR	30-OCT-2000; 2000US-0244989P.
XX	
PA	(UYDE) UNIV DELAMARE.
XX	
PI	Kmlec EB, Gamper HB, Rice MC;
XX	
WPt	2001-639230/73.
PT	Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.
PS	
XX	
PS	Claim 7; Page 100; 294dp; English.
XX	
CC	The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CPTF, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis,

CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention

XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGAAGAGCTGAG 1280

Db 17 AGCTGAAGAGCTGCGG 1

RESULT 221

ABAT78081
ID ABA78081 standard; DNA; 17 BP.

XX ABA78081;

AC 24-JAN-2002 (first entry)

DE BRCA1 mutation correcting oligonucleotide SEQ ID NO: 927.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KM retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; factor V;
KM cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KM adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KM haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
KM mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KM familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KM UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KM Alzheimer's disease; cytoskeletal; antisticking; antinaeumatic; haemostatic;
KM antileptic; ss.

XX Homo sapiens.

OS WO200173002-A2.

PN 04-OCT-2001.

PD 27-MAR-2001; 2001WO-US009761.

XX 27-MAR-2000; 2000US-0192176P.

PR 27-MAR-2000; 2000US-0192179P.

PR 01-JUN-2000; 2000US-0208538P.

PR 30-OCT-2000; 2000US-0244989P.

XX (UYDE) UNIV DELAMARE.

XX Kmlec EB, Gampier HB, Rice MC;

XX WPI; 2001-639230/73.

PT Oligonucleotide for targeted alterations of genetic sequences and for
PT creating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.

PS Claim 7; Page 100; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention

XX Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1264 AGCTGAAGAGCTGAG 1280

Db 1 AGCTGAAGAGCTGCGG 17

RESULT 222

ABN06620/c
ID ABN06620 standard; DNA; 17 BP.

XX ABN06620;

AC 29-MAY-2002 (first entry)

DE Human GDMMP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6612.

XX Human; genome-derived myosin-like protein 1; GDMMP-1, hGDMMP-1, heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

OS WO200192524-A2.

PN 06-DEC-2001.

PD 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

PT New polypeptide, for raising antibodies that recognize hGDMMP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMMP-1.

PS Disclosure; SEQ ID NO 6612; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMMP-1). The protein and polynucleotide sequences of hGDMMP-
CC 1 can be used in gene therapy and vaccine production. The hGDMMP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMMP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMMP-1

CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

CC Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1221 CAGAACTCTCAGCATGT 1237
||| ||||| |||||
Db 17 CAGAGCTCTCAGCATGT 1

RESULT 223

ABN02601
ID ABN02601 standard; DNA; 17 BP.

AC ABN02601;

XX 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2593.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KM skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

OS WO200192524-A2.

PN 06-DEC-2001.

PD 25-MAY-2001; 2001WO-US016981.

PF 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-023687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.

XX Disclosure; SEQ ID NO 2593; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and vaccine production. The hGDMLP-1

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1293 CAGGTCCTCAGCAT 1309
||||| ||||| |||||
Db 1 CAGGTCCTCAGCAT 17

RESULT 224

ABN06619/c

ID ABN06619 standard; DNA; 17 BP.

AC ABN06619;

XX 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6611.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KM skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

OS WO200192524-A2.

PN 06-DEC-2001.

PD 25-MAY-2001; 2001WO-US016981.

PF 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-023687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 6611; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CY 1222 AGAACCTCCAGCATGTG 1238
DB 17 AGAGCTCCAGGATGTG 1
RESULT 225
ABN08656
ID ABN08656 standard; DNA; 17 BP.
XX
AC ABN08656;
XX
DT 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8648.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; 88.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR

PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 8648; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CY 1254 CTGACGACAGCTGGA 1270
DB 1 CTGACGCTGACGCTGGA 17
RESULT 226
ABN0935
ID ABN0935 standard; DNA; 17 BP.
XX
XX ABN0935;
XX
DT 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:927.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX

XX	skeletal muscle disorder; amplicon; screening; ss.
OS	Homo sapiens.
XX	
PN	WO200192524-A2.
XX	
PD	06-DEC-2001.
XX	
PF	25-MAY-2001; 2001WO-US016981.
XX	
PR	26-MAY-2000; 2000US-0207456P.
PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	05-FEB-2001; 2001US-0266860P.
XX	
PA	(AECOM-) AECOMICA INC.
XX	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX	
DR	WPI, 2002-179446/23.
XX	
PT	New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX	
PS	Disclosure; SEQ ID NO 927; 21app; English.
XX	
CC	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGMDLP-1). The protein and polynucleotide sequences of hGMDLP-
CC	1 can be used in gene therapy and vaccine production. The hGMDLP-1
CC	nucleic acids can be used as probes to detect, characterise and quantify
CC	hGMDLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering of hGMDLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGMDLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGMDLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGMDLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption/ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGMDLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGMDLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGMDLP-1, in particular heart
CC	and skeletal muscle disorders. hGMDLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGMDLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	
SQ	Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
XX	
Query Match	5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
OY	1262 ACAGCTGGAAGAAGCGTG 1278
DB	 1 AGAGCTGAAGAAGCGCTG 17

RESULT 227

ID	ABZ64880/C	ABZ64880 standard; RNA; 17 BP.
XX	AC	ABZ64880;
XX	DT	21-MAR-2003 (first entry)
XX	DE	Human HER2 DNAzyme substrate #337.
XX	KW	Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW	KW	enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX	KW	anti-rheumatic; cancer; AIDS; ss.
XX	OS	Homo sapiens.
XX	PN	WO200297114-A2.
XX	PD	05-DEC-2002.
XX	PF	29-MAY-2002; 2002WO-US016840.
XX	PR	29-MAY-2001; 2001US-0294140P.
XX	PR	06-JUN-2001; 2001US-0296249P.
XX	PR	10-SEP-2001; 2001US-0318471P.
XX	PA	(RIBO-) RIBOZYME PHARM INC.
XX	PI	Mcsw1ngen J;
DR	WI	WI; 2003-140484/13.
XX	PT	Novel short interfering RNA and enzymatic nucleic acid useful for
XX	PT	treating cancer, modulates the expression of a nucleic acid encoding
XX	PT	HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX	PS	Claim 4; Page 139; 185pp; English.
XX	CC	The invention relates to a novel short interfering RNA (siRNA) nucleic
XX	CC	acid molecule or an enzymatic nucleic acid molecule, that modulates
CC	CC	expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC	CC	human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC	CC	acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC	CC	rheumatic activity. The nucleic acid molecules are useful for reducing
CC	CC	HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC	CC	also useful for treating breast, ovarian, colorectal, lung, prostate,
CC	CC	bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC	CC	shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC	CC	ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC	CC	ribozymes of the invention
XX	SO	Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
XX	SQ	
XX	Query Match	5.5%; Score 13.8; DB 1; Length 17;
XX	Best Local Similarity	88.2%; Pred. No. 1.6e+02;
XX	Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
OY	1268 GGAAGAGGCTGAGGCA 1284	
DB	17 GGAAGACGCTGAGTCA 1	
RESULT 228		
ACCS8685/C		
ID	ACCS8685 standard; DNA; 17 BP.	
AC	ACCS8685;	
XX	DT	26-AUG-2003 (first entry)
XX	DE	Human ADAMTS14 gene exon 13 3' acceptor splice site.
XX	KW	A disintegrin and metalloproteinase with thrombospondin repeats;
KW	KW	ADAMTS14; human; enzyme; neuroprotective; immunosuppressive; mototropic;

KW		antifibrotic; osteopathic; antirachitic; antineumatic;
KV		antiinflammatory; antiasthmatic; immunomodulator; antiallergic;
KW		antitumoural; anticancer; vasotropic; antarteriosclerotic; cardiant;
KX		cycostatic; anticler; vasotrophic; antarteriosclerotic; cardiant;
KW		anticomvulsant; antiparkinsonian; cerebroprotective; antimigraine;
KV		antidepressant; analgesic; ophthalmological; vulnery; antidiabetic;
KX		dermatological; transgenic; chromosome 10q21.3; gene; ds.
OS	Homo sapiens.	
FH	Key	Location/Qualifiers
FT	intron	1..12
FT		/*tag= a
FT	exon	/partial
FT		13..17
FT		/*tag= b
FT		/partial
PN	WO2003042379-A2.	
PD	22-MAY-2003.	
PP	08-NOV-2002; 2002WO-EP012534.	
PR	13-NOV-2001; 2001EP-00204335.	
XX	(UYLI-) UNIV LIEGE.	
PI	Collige A, Lapierre C, Nussens B;	
DR	WPI; 2003-482347/45.	
XX		
PT	New isolated and purified A disintegrin and metalloproteinase with	
PT	thrombospondin type I repeats polynucleotide, useful for manufacturing a	
PT	medicament for the treatment of e.g. neurodegenerative, autoimmune, and	
PT	cell proliferation diseases.	
PS	Disclosure; Page 39; 67pp; English.	
XX		
CC	The present sequence is that of the 3' acceptor splice site of exon 13 of	
CC	a novel human A Disintegrin and Metalloproteinase with Thrombospondin	
CC	type I repeat (ADAMTS) gene, denoted ADAMTS14, on chromosome 10q21.3. A	
CC	CDNA sequence for ADAMTS14 is given in ACC58643. ADAMTS14 (see AB42736)	
CC	is an aminoproteoglycan peptidase that functions in procollagen	
CC	processing. ADAMTS14 polynucleotides, polypeptides, vectors, cells	
CC	transfected by the vectors, and inhibitors directed against ADAMTS14 are	
CC	used in the treatment and/or prevention of a range of diseases	
XX		
SQ	Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;	
OY	Query Match	5.5%; Score 13.8; DB 1; Length 17;
OY	Best Local Similarity	88.2%; Pred. No. 1.6e+02;
OY	Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0
DB	1271 AGAGGCTGAGGCCAGAG 1287	
DB	17 ACAGGCTGAGGCCAGAG 1	
ID	ACC53896 standard; DNA; 17 BP.	
XX	ACC53896;	
XX		
DT	27-JUN-2003 (first entry)	
DE	Human tumour suppressor sequence #2663.	
XX		
KW	ss; tumour suppressor; antitumour; cytosstatic; tumour suppression;	
KV	tumour regression; apoptosis; virus resistance; diagnosis;	
KW	cellular degeneration.	
XX		
OS	Homo sapiens	

XX	FR2826373-A1.
PN	" "
XX	27-DEC-2002.
PD	
XX	20-JUN-2001; 2001FR-00008139.
XX	
PF	20-JUN-2001; 2001FR-00008139.
PR	(MOLE-) MOLECULAR ENGINES LAB SA.
XX	
PA	Tuijnder M, Telerman A, Amson R;
XX	
PI	WPI; 2003-2504998/25.
XX	
DR	New nucleic acid sequences associated with tumor suppression, regression,
PT	apoptosis or virus resistance are useful to diagnose and treat viral
PT	disease, development of tumor cells and cell degeneration.
XX	
PS	Claim 1; Page 655; 798pp; French.
XX	
CC	This sequence represents an isolated nucleic acid sequence associated
CC	with tumour suppression or regression, apoptosis or virus resistance. The
CC	invention relates to these sequences or sequences having at least 80%
CC	identity to them, and polypeptides encoded by the sequences or
CC	polypeptides having 80% identity to the polypeptide sequences. The
CC	invention is used to diagnose or treat viral disease or disease
CC	characterized by development of tumour cells or cellular degeneration
CC	
SQ	Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match	5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
Oy	1210 CAGCCATCTGCAGAAC 1226
Db	17 CAGCCTCTGTGAGATC 1
RESULT 230	
ADL48354	
ID	ADL48354 standard; RNA; 17 BP.
XX	
AC	ADL48354;
XX	
DT	20-MAY-2004 (first entry)
XX	
DE	Human IKK-gamma substrate sequence #864.
XX	
KV	antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KV	proteoglycan D2 receptor; PRCGR; IkappaB kinase; IKK;
KV	protein kinase PKR; cerebrovascular accident;
KV	central nervous system injury; CNS injury; spinal cord injury; cancer;
KV	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KV	retenoblast; asthma; Crohn's disease; diabetes; obesity;
KV	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KV	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KV	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KV	substrate; de.
XX	
OS	Unidentified.
XX	
PN	WO200281628-A2.
XX	
PD	17-OCT-2002.
XX	
PF	03-APR-2002; 2002WO-USO10512.
XX	
PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0284412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	

PA (RIBO-) RIBOZYME PHARM INC.
XX Blact L, Chowrira B, Haeblerl P, Mcswigen J, Fosnaugh K;
XX WPI; 2003-050513/05.
DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1887; 317pp; English.
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. NO. 1.6e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 1254 CTGCAGCAACGCTCGA 1270
Db 1 CUGCAGCAGCAGCUGCA 17
AAK67092/C
ID AAK67092 standard; RNA; 18 BP.
XX
AC AAK67092;
XX
DT 20-JUL-1999 (first entry)
XX
DE Human B7-2 hairpin ribozyme target SEQ ID NO:3724.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9618736-A2.
PD 20-JUN-1996.
XX
PF 22-NOV-1995; 95WO-US015516.
XX
PR 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.

PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI Mcswigen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Kapelsky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
DR
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
PS Claim 10; Page 216; 307pp; English.
CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX
SQ Sequence 18 BP; 3 A; 11 C; 2 G; 0 T; 2 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1266 CTGGAAGAGGCTGAGGG 1282
Db 18 CTGGCGAGGCTGAGGG 2
AAK71723/C
ID AAK71723 standard; RNA; 18 BP.
XX
AC AAK71723;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human KDR VEGF receptor hairpin ribozyme substrate #21.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW tmx-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.

XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
XX Pavco P, Mcawigen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 119; 219pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or fetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX57275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
XX Sequence 18 BP; 4 A; 9 C; 3 G; 0 T; 2 U; 0 Other;
SQ
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1267 TGGAGAGGCTGAGGCG 1283
Db 17 TGGAGAGGCTGAGGCG 1
RESULT 233
AAX52424
ID AAX52424 standard; DNA; 18 BP.
XX
XX AAX52424;
AC
XX 25-JUN-1999 (first entry)
DT
XX Forward PCR primer used to amplify cDNA encoding PRO295.
DE
XX Secreted protein; transmembrane protein; human; enterocolitis;
KW Zollinger-Ellison syndrome; gastrointestinal ulceration;
KW congenital microvillus atrophy; skin disease; cell growth;
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy; fibromodulin;
KW dermal scarring; Usher Syndrome; Atrophila areata; anti-thrombotic;
KW wound healing; tissue repair; PCR primer; ss.
XX
XX Synthetic.
OS
XX WO9914328-A2.
PN
XX 25-MAR-1999.
PD
XX 16-SEP-1998; 98WO-US019330.
PF
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063554P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066354P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
XX
XX (GETH) GENENTECH INC.
PA
XX Wood WI, Gurney AL, Goddard A, Pennica D, Chen J, Yuan J;
PI WPI; 1999-229533/19.
XX
XX New isolated human genes and polypeptides used in, e.g. treatment of
PT gastrointestinal ulceration.
XX
XX Example 38; Page 144; 320pp; English.
XX
XX Oligonucleotides AAX52276-532 represent PCR primers and probes used to
CC isolate and amplify cDNA encoding secreted and transmembrane human
CC proteins (see AAX52213-74 and AAX13344-403). The cDNA sequences are
CC obtained from cDNA libraries, prepared from fetal lung, fetal kidney,
CC fetal brain, fetal liver and fetal retina. The encoded polypeptides have
CC specific uses based on their homology to known polypeptides, e.g. PRO211
CC and PRO217 can be used for disorders associated with the preservation and
CC maintenance of gastrointestinal mucosa and the repair of acute and
CC chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome,
CC gastrointestinal ulceration and congenital microvillus atrophy), skin
CC diseases associated with abnormal keratinocyte differentiation (e.g.
CC psoriasis, epithelial cancers such as lung squamous cell carcinoma of the
CC vulva and gliomas), potent effects on cell growth and development,
CC diseases related to growth or survival of nerve cells including
CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies or cancer.
CC PRO265 can be used as for fibromodulin, e.g. for reducing dermal
CC scarring. PRO264 can be used as a target for anti-tumor drugs. PRO533 may
CC be used in the treatment of Usher Syndrome or Atrophila areata; PRO269 may
CC be used as an anti-thrombotic agent; PRO287 polypeptides and portions may
CC have therapeutic applications in wound healing and tissue repair; PRO317
CC can be used for treating problems of the kidney, uterus, endometrium,
CC blood vessels, or related tissue, e.g. in the heart of genital tract

```
XX SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
      Query Match 5.5%; Score 13.8; DB 1; Length 18;
      Best Local Similarity 88.2%; Pred. No. 1.8e+02;
      Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGTGCTGCAG 1245
      |||||
      2 CCAGCATGTACTGCCAG 18

RESULT 234
ID AAA52844
ID AAA52844 standard; DNA; 18 BP.
XX
AC AAA52844;
XX
DT 15-SEP-2000 (first entry)
XX
DE Human CD44 antisense oligonucleotide ISIS# 18733.
XX
KM Human; CD44; cell surface adhesion receptor; cytosratic; antirheumatic;
KM antiinflammatory; antiarthritis; CD44 antisense inhibition;
KM hyperproliferative disorder; cancer; inflammatory disorder;
KM rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO200035935-A1.
XX
PD 22-JUN-2000.
XX
PF 14-DEC-1999; 99WO-US029576.
XX
PR 17-DEC-1998; 98US-00213719.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowseert LM;
XX
DR WPI; 2000-431564/37.
XX
PT New antisense compound, that inhibits the expression of human cell
PT surface adhesion receptor CD44, for treating hyperproliferative disorders
PT and inflammatory conditions, such as cancer and rheumatoid arthritis.
XX
PS Example 15; Page 76; 105pp; English.
XX
CC The present sequence is one of a large number of antisense
CC oligonucleotides designed to target different regions of the human CD44
CC mRNA. CD44 is a multifunctional human cell surface adhesion receptor. The
CC oligonucleotides were analysed for effect on CD44 mRNA levels by
CC quantitative real-time PCR analysis. Antisense oligonucleotides that
CC inhibit CD44 expression can be used to treat CD44-associated conditions
CC including hyperproliferative disorders, such as cancer, and inflammatory
CC conditions, such as rheumatoid arthritis. The antisense compounds
CC hybridise to CD44 nucleic acids, thus allowing sandwich and other assays
CC to be easily constructed. Note: The sequence has a phosphorothioate
CC backbone and may be either an oligodeoxynucleotide or a chimeric
CC oligonucleotide containing 2'-methoxyethyl (2'-MOE) wings and a deoxy
CC gap. The ISIS number given above corresponds to the oligodeoxynucleotide
CC sequence
XX
SQ Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1401 CTGACACAGCCGGGTGC 1417
      |||||
      1 CTGACATAGCGGGTGC 17

DB
```

```
RESULT 235
ID AAC73261
ID AAC73261 standard; DNA; 18 BP.
XX
AC AAC73261;
XX
DT 02-FEB-2001 (first entry)
XX
DE Forward primer #48 used in multiplexing PCR/SBE assay.
XX
KM Oligonucleotide array; genotyping; single base extension reaction; SBE;
KM PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHEB) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
DR WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 52; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one of the primers used in
CC the method of the present invention to amplify a polymorphic sample. The
CC amplified nucleic acid product is then used as a template in a SBE
CC reaction with an extension primer. The SBE reaction products are used to
CC form the oligonucleotide array
XX
SQ Sequence 18 BP; 8 A; 5 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1258 AGCAACAGCTGGAAGAG 1274
      |||||
      1 AGCAACAGCAGAGACAG 17

DB

RESULT 236
ID ADC78694
ID ADC78694 standard; DNA; 18 BP.
XX
AC ADC78694;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO protein-related forward PCR primer SEQ ID 239.
XX
KM antiinflammatory; antiulcer; cytosratic; antipsoeiatric; antiparkinsonian;
```

KW nootropic; neuroprotective; vasotropic; chemotactic; angiogenic;
KW neurotrophic; osteopathic; antispasmodic; anticholinergic; antirheumatic;
KW antiarteriosclerotic; cardiac; antidiabetic; cerebroprotective;
KW thrombolytic; immunomodulator; enterocolitis; Zollinger-Ellison syndrome;
KW gastrointestinal ulceration; psoriasis; cancer; Parkinson's disease;
KW Alzheimer's; ALS; neuropathy; dermal scarring; wound healing;
KW nerve repair; thrombosis; bone; cartilage formation; angiogenesis;
KW asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disorder;
KW atherosclerosis; cardiac injury; infertility; premature aging; AIDS;
KW diabetes; stroke; gene therapy; transgenic; PRO; human; ss; primer; PCR.
XX
XX Homo sapiens.
OS
XX WO20015796-A2.
PN
XX 23-MAR-2000.
PD
XX 15-SEP-1999; 99WO-US021090.
PF
XX 16-SEP-1999; 98WO-US019330.
PR
XX (GETH) GENENTECH INC.
PA
XX Chen J, Goddard A, Gurney AL, Hillan K, Pennica D, Wood WI;
PI Yuan J;
PI
XX WPI; 2000-271434/23.
DR
XX Novel nucleic acids encoding secreted and transmembrane polypeptides with
PT homology, e.g. to growth and cancer-associated antigens.
PT
XX Example 38; SEQ ID NO 239; 355bp; English.
PS
XX The invention relates to a novel nucleic acid encoding a PRO polypeptide.
CC The polypeptides and polynucleotides of the invention may be useful as
CC research tools and as therapeutics for treating enterocolitis, Zollinger-
CC Ellison syndrome, gastrointestinal ulceration, psoriasis, cancer,
CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies, dermal
CC scarring and wound healing, nerve repair, thrombosis, bone and/or
CC cartilage formation, angiogenesis, asthma, rheumatoid arthritis, multiple
CC sclerosis, inflammatory disorders, atherosclerosis, cardiac injury,
CC infertility, premature aging, AIDS, diabetes complications and stroke.
CC The molecules may also be utilised during gene therapy procedures and
CC transgenic animal production. The current sequence is that of the PCR
CC primer of the invention which was used to analyse the human PRO DNA of
CC the invention.
CC
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1229 CCAGCATGCTGTCGACG 1245
DB 2 CCAGCATGCTGTCGACG 18
RESULT 237
AAAF72582
ID AAF72582 standard; DNA; 18 BP.
XX
AC AAF72582;
XX
DT 24-APR-2001 (first entry)
XX
DE Human PRO polypeptide gene PCR primer SEQ ID NO: 240.
XX
KW Human; PRO; dermatological; antipruritic; cytostatic; antiinflammatory;
KW antiparkinsonian nootropic; neuroprotective; vulnerary; cardiac;
KW antiangiogenic; vasotropic; antispasmodic; antirheumatic; cancer;
KW anticholinergic; antidiabetic; antidiabetic; antiviral; diabetes;
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;

KW ischaemia; inflammation; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200104311-A1.
PN
XX 18-JAN-2001.
PD
XX 22-FEB-2000; 2000WO-US004414.
PF
XX 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020954.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
XX
XX (GETH) GENENTECH INC.
PA
XX Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TH, Tunas D;
PI Williams FM, Wood WI;
PI
XX WPI; 2001-081051/09.
DR
XX Sixty one nucleic acids encoding PRO polypeptides which are useful in the
PT treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous
PT cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's
PT disease).
PT
XX
PS Example 38; Page 182; 393bp; English.
XX
CC The present sequence is a primer which was used in the isolation of one
CC of sixty one nucleic acids encoding novel secreted and transmembrane PRO
CC polypeptides. The PRO polypeptides are useful for treating skin diseases
CC (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma),
CC gastrointestinal disorders (e.g. enterocolitis), neurodegenerative
CC diseases (e.g. Alzheimer's disease, Parkinson's disease), wound repair,
CC cardiovascular disorders (e.g. endometrial bleeding angiogenesis,
CC ischaemia such as coronary ischaemia, atherosclerosis), inflammatory
CC disorders (e.g. asthma, rheumatoid arthritis, multiple sclerosis),
CC infertility, AIDS and diabetes and retinal disorders such as retinitis
CC pigmentosa. The PRO nucleic acids have applications in molecular
CC biology, including use as hybridization probes, and in chromosome and
CC gene mapping
CC
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1229 CCAGCATGCTGTCGACG 1245
DB 2 CCAGCATGCTGTCGACG 18
RESULT 238
ADH59543
ID ADH59543 standard; DNA; 18 BP.
XX

AC	ADHS9543;
XX	
DT	25-MAR-2004 (first entry)
XX	
DE	Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX	
KM	Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KM	tissue typing; immunohistochemical staining; gene therapy;
KM	neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KM	endothelial cell; stimulated T-lymphocyte; retinal neuron;
KM	rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KM	cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KM	retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KM	hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KM	arthritis; candida; vulvare; cystostatic; ophthalmological;
XX	osteopathic; antiarthritic; anorectic.
OS	Homo sapiens.
XX	
PN	US2003039972-A1.
XX	
PD	27-FEB-2003.
XX	
PF	16-JUL-2001; 2001US-00906700.
XX	
XX	
PR	17-SEP-1997; 97US-0059113P.
PR	17-SEP-1997; 97US-0059115P.
PR	17-SEP-1997; 97US-0059117P.
PR	17-SEP-1997; 97US-0059119P.
PR	17-SEP-1997; 97US-0059121P.
PR	17-SEP-1997; 97US-0059122P.
PR	17-SEP-1997; 97US-0059184P.
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	15-OCT-1997; 97US-0062125P.
PR	17-OCT-1997; 97US-0062285P.
PR	17-OCT-1997; 97US-0062287P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0062814P.
PR	24-OCT-1997; 97US-0062816P.
PR	24-OCT-1997; 97US-0063045P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	24-OCT-1997; 97US-0063127P.
PR	27-OCT-1997; 97US-0063327P.
PR	27-OCT-1997; 97US-0063329P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063542P.
PR	28-OCT-1997; 97US-0063544P.
PR	28-OCT-1997; 97US-0063549P.
PR	28-OCT-1997; 97US-0063550P.
PR	28-OCT-1997; 97US-0063564P.
PR	29-OCT-1997; 97US-0063435P.
PR	29-OCT-1997; 97US-0063704P.
PR	29-OCT-1997; 97US-0063732P.
PR	29-OCT-1997; 97US-0063734P.
PR	29-OCT-1997; 97US-0063735P.
PR	29-OCT-1997; 97US-0063738P.
PR	29-OCT-1997; 97US-0064215P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	03-NOV-1997; 97US-0064248P.
PR	07-NOV-1997; 97US-0064809P.
PR	12-NOV-1997; 97US-0065186P.
PR	17-NOV-1997; 97US-0065846P.
PR	18-NOV-1997; 97US-0065933P.
PR	21-NOV-1997; 97US-0066120P.
PR	24-NOV-1997; 97US-0066364P.
PR	24-NOV-1997; 97US-0066435P.
PR	24-NOV-1997; 97US-0066466P.
PR	24-NOV-1997; 97US-0066511P.
PR	24-NOV-1997; 97US-0066570P.

24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-008026P.
PR 10-SEP-1998; 98US-0098030P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 13-OCT-1998; 98WO-US019437.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98WO-US02510P.
PR 01-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146223P.
PR 08-SEP-1999; 99WO-US020524.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030944.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030991.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US010432.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX
XX (GENTH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,
PI Filvarski E, Fong S, Gao W, Gerdler H, Gerritsen ME, Goddard A,
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavitt IJ,
PI Mather JP, Pan Y, Paoni NF, Roy MA, Stewart TA, Tumas D,
PI Williams PM, Wood WI;
XX WPI; 2003-503393/47.
XX
XX
XX New isolated PRO polypeptides e.g. PRO211, PRO217 and PRO230, useful for
PT treating Parkinson's disease, Alzheimer's disease, amyotrophic lateral
PT sclerosis, cancer, neuropathies and psoriasis.
XX
XX
XX Example 38; Page 106; 476pp. English.
XX
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of

CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence of the invention is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1229 CCAGCATGTCTGGCAG 1245

Db 2 CCAGCATGTACTGCCAG 18

RESURF 239

AD18322 AD18322 standard; DNA; 18 BP.

XX AC AD18322;

DT 22-APR-2004 (first entry)

XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.

KM Human: PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KM tissue typing; immunohistochemical staining; gene therapy; proliferation;
KM neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KM endothelial cell; stimulated T-lymphocyte; retinal neuron;
KM rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KM cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KM retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KM hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KM arthritis; cardiac; vulnery; cytoskeletal; ophthalmological;
KM osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.

XX PN US2003054352-A1.

XX PD 20-MAR-2003.

XX PF 17-JUL-2001; 2001US-00907925.

XX

PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059123P.
PR 17-SEP-1997; 97US-0059125P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059265P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 21-OCT-1997; 97US-0062287P.
PR 24-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063122P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063546P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0064215P.
PR 29-OCT-1997; 97US-0064216P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066164P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099802P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US005655.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Borstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Pilvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
PI Macher JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI: 2003-695899/66.
XX
PT Novel isolated native PRO polypeptide useful for treating Parkinson's
PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal
PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usner
PT syndrome.
XX
XX Example 38; Page 105; 471pp: English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or PPA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO

CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the sequence listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1229 CACGATGCTGCGCAG 1245
Db 2 CACGATGCTGCGCAG 18
RESULT 240
ADJ26590
ID ADJ26590 standard; DNA, 18 BP.
XX
XX ADJ26590;
AC
AC
XX 20-MAY-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
DE
XX Human; PCR; primer; 59; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; PPA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytosatic; ophthalmological;
KW osteopathic; antiarthritis; anorectic.
OS Homo sapiens.
XX
XX US2003054349-A1.
XX
XX 20-MAR-2003.
PD
XX 11-JUL-2001; 2001US-00903943.
XX
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063337P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-00669425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113266P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145686P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,
PI Filvarsoff E, Fong S, Gao W, Gerber H, Gerltzen M, Goddard A,
PI Godowski PJ, Grimaldi JC, Gurney JA, Hillan KJ, Kijavyn IJ,
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumala D,

PI Williams PM, Wood WI;
XX WPI-2003-708341/67.
DR
XX
XX Novel isolated native PRO polypeptide useful for tissue typing.
PT modulating biological activity of cell, as molecular weight markers in
PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison
PI syndrome.
XX
XX
PS Example 38; Page 111; 483pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re-
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX

XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1229 CCAGCATGTGCTGGCAG 1245
DB 2 CCAGCATGTACTGCCAG 18
|||||
|||||

RESULT 241
ADE99693
ID ADE99693 standard; DNA; 18 BP.
XX
AC ADE99693;

PR	24-OCT-1997	97US-0063121P
PR	24-OCT-1997	97US-0063127P
PR	24-OCT-1997	97US-0063118P
PR	27-OCT-1997	97US-0063337P
PR	27-OCT-1997	97US-0063332P
PR	28-OCT-1997	97US-0063541P
PR	28-OCT-1997	97US-0063542P
PR	28-OCT-1997	97US-0063544P
PR	28-OCT-1997	97US-0063549P
PR	28-OCT-1997	97US-0063550P
PR	28-OCT-1997	97US-0063564P
PR	29-OCT-1997	97US-0063435P
PR	29-OCT-1997	97US-0063704P
PR	29-OCT-1997	97US-0063722P
PR	29-OCT-1997	97US-0063734P
PR	29-OCT-1997	97US-0063735P
PR	29-OCT-1997	97US-0063738P
PR	29-OCT-1997	97US-0064215P
PR	31-OCT-1997	97US-00643870P
PR	31-OCT-1997	97US-0064103P
PR	03-NOV-1997	97US-0064248P
PR	07-NOV-1997	97US-0064809P
PR	12-NOV-1997	97US-0065186P
PR	17-NOV-1997	97US-0065846P
PR	18-NOV-1997	97US-0065693P
PR	21-NOV-1997	97US-0066120P
PR	21-NOV-1997	97US-0066364P
PR	24-NOV-1997	97US-0066453P
PR	24-NOV-1997	97US-0066466P
PR	24-NOV-1997	97US-0066511P
PR	24-NOV-1997	97US-0066770P
PR	24-NOV-1997	97US-0066772P
PR	25-NOV-1997	97US-0066840P
PR	12-DEC-1997	97US-0069425P
PR	14-SEP-1998	98US-0008026P
PR	14-SEP-1998	98US-0009803P
PR	14-SEP-1998	98US-0010824P
PR	16-SEP-1998	98US-00100262P
PR	16-SEP-1998	98US-0019177P
PR	17-SEP-1998	98US-0019330P
PR	17-SEP-1998	98US-00100858P
PR	17-SEP-1998	98US-00019437P
PR	13-OCT-1998	98US-0104080P
PR	20-NOV-1998	98US-0109304P
PR	01-DEC-1998	98US-00525108P
PR	22-DEC-1998	98US-0113266P
PR	07-JUL-1999	99US-0143068P
PR	26-JUL-1999	99US-0145628P
PR	26-JUL-1999	99US-0146222P
PR	08-SEP-1999	99US-0020594P
PR	13-SEP-1999	99US-0020944P
PR	15-SEP-1999	99US-0021930P
PR	15-SEP-1999	99US-002021547P
PR	05-OCT-1999	99US-00203089P
PR	30-NOV-1999	99US-0028214P
PR	20-NOV-1999	99US-00283113P
PR	01-DEC-1999	99US-0028301P
PR	02-DEC-1999	99US-0028564P
PR	02-DEC-1999	99US-0028565P
PR	16-DEC-1999	99US-0030095P
PR	16-DEC-1999	99US-0030911P
PR	20-DEC-1999	99US-0030999P
PR	05-JAN-2000	2000US-0000219P
PR	11-FEB-2000	2000US-00003565
PR	22-FEB-2000	2000US-00004414P
PR	22-FEB-2000	2000US-00005004P
PR	02-MAR-2000	2000US-00005841P
PR	20-MAR-2000	2000US-00007377P
PR	30-MAR-2000	2000US-00008439P
PR	22-MAY-2000	2000US-00014042P
PR	02-JUN-2000	2000US-00015364P
PR	28-JUL-2000	2000US-00020710P
PR	24-AUG-2000	2000US-00023328P

PR 18-SEP-2000; 2000US-00665350.

PA (GETH) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;
PI Fildes R, Fong S, Gao W, Gertler H, Gerritsen ME, Goddard A,
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
PI Maher JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;

DR WPI; 2004-021576/02

PT New isolated native PRO polypeptide useful for treating Parkinson's
PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestlnal
PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, or Usher
PT syndrome.

PS Example 38; Page 99; 469pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinemia, hypoinsulinemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a DNA probe which was used to detect a PRO polynucleotide of the invention. NOTE: This sequence is described as SEQ ID NO 239 in Example 36 of the disclosure but is different from SEQ ID NO 239 represented in the Sequence Listing.

SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match	5.5%;	Score 13.8;	DB 1;	Length 18;
-------------	-------	-------------	-------	------------

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

[illegible][illegible]

Db 2 CCAGCATGTACTGCCAG 18

RESULT 243
ADE99240
ID ADE99240 standard; DNA; 18 BP.

AC ADE99240;
XX
XX 12-FEB-2004 (first entry)

DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

KM Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KM tissue typing; immunohistochemical staining; gene therapy; VEGF; proliferation;
KM neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KM endothelial cell; stimulated T-lymphocyte; retinal neuron;
KM rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KM cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KM retinitis pigmentosum; obesity; diabetes; hyperinsulinaemia;
KM hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KM arthritis; cardiac; vulnary; cytostatic; ophthalmological;
KM osteopathic; antiarthritic; anorectic.

OS Homo sapiens.
XX
XX US2003211568-A1.

PN 13-NOV-2003.
XX
XX 12-JUL-2001; 2001US-00904805.

PF 27-OCT-1997; 97US-0063327P.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 18-SEP-2000; 2000US-00665350.

PA (GETH) GENENTECH INC.

XX Ashkenazi A, Boetstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavyn IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PW, Wood WI;
XX WPI; 2004-021575/02.

DR New secreted and transmembrane nucleic acids and polypeptides, designated
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,
XX cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.

PS Example 38; Page 99; 473pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XX and the nucleic acid encoding them. The polypeptides can be used to raise
XX antibodies that specifically bind to the PRO polypeptide, for linking a
XX bioactive molecule to a cell expressing a PRO protein and for modulating
XX at least one biological activity of a cell. PRO polypeptides are useful
XX for detecting other PRO polypeptides in a sample and for linking a
XX bioactive molecule to a cell expressing a PRO polypeptide. The PRO
XX polypeptide antibodies are useful for modulating the biological activity
XX of a cell expressing PRO polypeptides. The PRO polypeptides or
XX polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
XX bioeffectors. These are useful for stimulating hypertrophy of neonatal
XX heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
XX proliferation of endothelial cells, modulating the proliferation of
XX stimulated T-lymphocytes, enhancing the survival or proliferation of
XX retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
XX cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
XX -differentiation of chondrocytes. In particular, these are useful for
XX detecting or treating cardiac insufficiency disorders, wounds, cancerous
XX tumours, retinal disorders or injuries (e.g. loss of sight due to

CC retinitis pigmentosum), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 36 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX
XX
XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

QY Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1229 CCAGCATGTACTGCCAG 1245
2 CCAGCATGTACTGCCAG 18

RESULT 244
ADG40710
ID ADG40710 standard; DNA; 18 BP.

AC ADG40710;
XX
XX 26-FEB-2004 (first entry)

DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosum; obesity; diabetes; hyperinsulinaemia;
XX hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiac; vulnary; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.

OS Homo sapiens.
XX
XX US2003225253-A1.

PN 04-DEC-2003.
XX
XX 29-MAY-2003; 2003US-00448923.

PF 24-OCT-1997; 97US-0063128P.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 22-FEB-2000; 2000WO-US004414.
XX PR 18-SEP-2000; 2000US-00665350.
XX PR 12-JUL-2001; 2001US-00905125.

XX (DESN/) DESNOYERS L.
PA (GODD/) GODDARD A.
PA (GODO/) GODOSKI P J.
PA (GURN/) GURNEY A L.
PA (MATH/) MATHER J P.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
XX Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP,
P1 Williams PM, Wood WI;
XX
XX WPI, 2004-022084/02.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Example 38; Page 106; 463pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
XX
XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
SQ

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1229 CCAGCATGTGCTGCAG 1245

DB ||||| ||| |||
CCAGCATGTGCTGCAG 18
RESULT 245
ADG92523
ID ADG92523 standard; DNA, 18 BP.
XX
XX
XX ADG92523;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
DE
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypoparathyroidism; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiac; valvular; cytosolic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
OS
XX Homo sapiens.
FN
XX US2003027145-A1.
PD
XX 06-FEB-2003.
XX
XX 17-JUL-2001; 2001US-00907613.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063127P.
XX 24-OCT-1997; 97US-0063128P.
XX 27-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063542P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063546P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063705P.
XX 29-OCT-1997; 97US-0063732P.
XX 29-OCT-1997; 97US-0063734P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 29-OCT-1997; 97US-0064215P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.

CC	at least one biological activity of a cell. PRO polypeptides are useful
CC	for detecting other PRO polypeptides in a sample and for linking a
CC	bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC	polypeptide antibodies are useful for modulating the biological activity
CC	of a cell expressing PRO polypeptides. The PRO polypeptides or
CC	polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC	bioreactors. These are useful for stimulating hypertrophy of neonatal
CC	heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC	proliferation of endothelial cells, modulating the proliferation of
CC	differentiated T-lymphocytes, enhancing the survival or proliferation of
CC	retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC	cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC	-differentiation of chondrocytes. In particular, these are useful for
CC	detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC	tumours, retinal disorders or injuries (e.g. loss of sight due to
CC	retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC	hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC	arthritis) in mammals. PRO polypeptides and their portions affect the
CC	expression of genes which have a role in cell death. The polynucleotides
CC	are useful in molecular biology including uses as hybridisation probes
CC	for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC	cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC	and DNA, for preparing PRO polypeptides, for generating transgenic
CC	animals or knockout animals which are useful in the development and
CC	screening of therapeutically useful reagents, as probes and for the
CC	genetic analysis of individuals with genetic disorders as well as for
CC	recombinantly expressing the protein and for chromosome identification.
CC	The proteins are useful as molecular marker for protein electrophoresis
CC	purposes, as therapeutic agents, for screening compounds to identify
CC	those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC	the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC	useful for tissue typing. PRO antibodies are useful for
CC	immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC	antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC	expression in specific cells, tissues or serum and for affinity
CC	purification of PRO from recombinant cell culture or natural sources. The
CC	PRO genes may also be used in gene therapy, particularly for replacing a
CC	defective gene. The sequence presented is a DNA probe which was used to
CC	detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC	described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC	different from SEQ ID NO 239 represented in the Sequence Listing.
XX	
XX	Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
XX	
XX	Query Match 5.5%; Score 13.8; DB 1; Length 18;
XX	Best Local Similarity 88.2%; Pred. No. 1.8e+02;
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0
XX	
XX	1229 CGACGATGCTGCGCAG 1245
XX	
XX	
XX	
XX	
XX	2 CGACGATGCTGCGCAG 18
XX	
XX	RESULT 246
XX	ADG92950
XX	ADG92950 standard; DNA; 18 BP.
XX	ADG92950;
XX	11-MAR-2004 (first entry)
XX	

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

KM osteoarthritis; osteoporosis; obesity
KM retinitis pigmentosa; obesity; diabete; hyperinsulinaemia;
KM hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KM arthritis; cardiact; vulnery; cytostatic; ophthalmological;
KM osteopathic; antiarthritic; anorectic.

XX Homo sapiens.
OS
XX US2003027146-A1.
PN
XX 06-FEB-2003.
FD
XX 17-JUL-2001; 2001US-00907942.
PF
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063481P.
PR 24-OCT-1997; 97US-0063481P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US0188234.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US01917.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030995.
PR 20-DEC-1999; 99WO-US030991.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
PA
XX Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gertlsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Klijavin IU,
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
DR WPI; 2004-106404/11.
XX
XX Isolated nucleic acid encoding a polypeptide useful for various
PT applications e.g. hybridization probes.
PS
XX Example 38; Page 103; 474pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide and for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorder, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinemia,
CC hypothyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for

CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: this sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1229 CCAGCATGCTGCGAG 1245
Db 2 CCAGCATGCTGCGAG 18

RESULT 247
ADH20739
ID ADH20739 standard; DNA; 18 BP.
XX
AC ADH20739;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnery; cytostatic; ophthalmological;
KW osteopathic; antarthritic; anorectic.
XX
OS Homo sapiens.
XX
XX US2004005553-A1.
XX
XX
PD 08-JAN-2004.
XX
PF 18-JUL-2001; 2001US-00908576.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062815P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063706P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065933P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003355.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.

18-SEP-2000; 2000US-00655350.

(GETH) GENENTECH INC.

Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N; Flivaroff B, Fong S, Gao W, Gerdler H, Gerritsen ME, Goddard A; Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavitt IJ; Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumala D; Williams PM, Wood WI;

WPI, 2004-081703/08.

New PRO nucleic acid, useful for manufacturing a medicament for diagnosing or treating tumor, for chromosome mapping or for tissue typing.

Example 38; Page 106; 126pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a DNA probe which was used to detect a PRO polynucleotide of the invention. NOTE: This sequence is described as SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ ID NO 239 represented in the sequence listing.

Seq

Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.8e-02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0

1229 CCAGCATGTCTGCGCAG 1245

|||||

2 CCAGCATGTACTGCGCAG 18

RESULT 248
 ADH07594
 ID ADH07594 standard; DNA; 18 BP.
 XX
 AC ADH07594;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
 XX
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
 KW tissue typing; immunohistochemical staining; gene therapy;
 XX
 OS Homo sapiens.
 XX
 UN US2004006211-A1.
 XX
 PD 08-JAN-2004.
 XX
 PF 29-MAY-2003; 2003US-00448713.
 XX
 PR 24-OCT-1997; 97US-0063128P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 30-NOV-1999; 99WO-US028313.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 18-SEP-2000; 2000US-00665350.
 PR 12-JUL-2001; 2001US-00905125.
 XX
 PA (DESN/) DESNOYERS L.
 PA (GODO/) GODDARD A.
 PA (GODO/) GODOWSKI P J.
 PA (GURN/) GURNEY A L.
 PA (MATH/) MATHER J P.
 PA (WILL/) WILLIAMS P M.
 PA (WOOD/) WOOD W I.
 XX
 PI Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP,
 PI Williams PM, Wood WI;
 XX
 DR WPI; 2004-081748/08.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, as molecular weight markers for protein electrophoresis,
 PT as hybridization probes or as therapeutic agents.
 PR
 PS Example 38; Page 99; 466pp; English.
 XX
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioactuators. The PRO sequences can be used in gene and protein therapy.
 CC The PRO polypeptide, the agonist or antagonist or the anti-PRO antibody
 CC can be used in the preparation of a medicament for the treatment of a
 CC condition which is responsive to the PRO polypeptide, the agonist or
 CC antagonist or the anti-PRO antibody. The nucleic acids encoding PRO
 CC polypeptides are used as hybridization probes for gene mapping,
 CC generating transgenic animals useful in the development and screening of
 CC useful reagents, in chromosome identification or for tissue typing. The
 CC PRO polypeptides are also useful in gene therapy, may be employed as
 CC molecular weight markers for protein electrophoresis or as therapeutic
 CC agents. Anti-PRO antibodies are useful in diagnostic assays or for the
 CC affinity purification of PRO for recombinant cell culture or natural
 CC sources. The sequence presented is a DNA probe which was used to detect a

CC PRO polynucleotide of the invention. NOTE: This sequence is described as
CC SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ
CC ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best local similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1229 CCAGCATGCTGGCAG 1245
Db 2 CCAGCATGCTGGCAG 18
RESULT 249
ADH60139
ID ADH60139 standard; DNA; 18 BP.
XX
AC ADH60139;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnery; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
PN US2003215904-A1.
XX
PD 20-NOV-2003.
XX
PF 16-JUL-2001; 2001US-00906722.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145688P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US030095.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030919.
PR 05-JAN-2000; 2000WO-US003219.
PR 11-FEB-2000; 2000WO-US003365.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
PA (GERTH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen WE, Goddard A;
PI Godowski PJ, Grimaldi JC, Guirney AL, Hillan KJ, Kijavlin IU;
PI Maher JP, Pan Y, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2004-141684/14.

PT Novel isolated native PRO polypeptide useful for tissue typing, as
PT molecular weight markers in protein electrophoresis, for treating
PT enterocolitis, Zollinger-Ellison syndrome, congenital microvillus
atrophy.

XX Example 38; Page 99; 470pp; English.

CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hypothyroidism,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

SO Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1229 CCAGCATGTCGTGCGAG 1245

Db 2 CCAGCATGTCGTGCGAG 18

RESULT 250
ADH07167
ID ADH07167 standard; DNA; 18 BP.

XX ADH07167;

XX 25-WAR-2004 (first entry)

DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW protein therapy.

XX Homo sapiens.

PN US2004005665-A1.

PD 08-JAN-2004.

PF 29-MAY-2003; 2003US-00449656.

PR 24-OCT-1997; 97US-0063128P.

PR 16-SEP-1998; 98MO-US019330.

PR 30-NOV-1999; 99MO-US028313.

PR 22-FEB-2000; 2000WO-US004414.

PR 18-SEP-2000; 2000US-00665350.

PR 17-JUL-2001; 2001US-00907794.

PA (DESN/) DESNOYERS L.

PA (GODO/) GODDARD A.

PA (GODO/) GODDOWSKI P J.

PA (GURN/) GURNEY A L.

PA (MATH/) MATHER J P.

PA (WILL/) WILLIAMS P M.

PA (WOOD/) WOOD W I.

PI Desnoyers L., Goddard A., Godowski PJ, Gurney AL, Mather JP;

PI Williams PM, Wood WI;

DR WPI, 2004-081725/08.

PT New PRO polypeptides and nucleic acid molecules, useful in gene therapy,
PT or preparing a medicament for treating a condition that is responsive to
PT the PRO polypeptide or anti-PRO antibody, e.g. inflammatory diseases,
PT cancer or AIDS.

XX Example 38; Page 93; 462pp; English.

CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hypothyroidism,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural
CC sources. The sequence presented is a DNA probe which was used to detect a
CC PRO polynucleotide of the invention. NOTE: This sequence is described as
CC SEQ ID NO 239 in Example 38 of the disclosure but is different from SEQ
CC ID NO 239 represented in the Sequence Listing.

SO Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affecting its
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1229 CCAGCATGCTGCTGCAG 1245
Db 2 CCAGCATGCTGCTGCAG 18
RESULT 252
AD165629
ID AD165629 standard; DNA; 18 BP.
XX
AC AD165629;
XX
DT 22-APR-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypotension; bone disorder; cartilage disorder; sports injury;
XX arthritis; cardiac; vulnary; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.
XX *homo sapiens*
XX US2001148419-A1.
XX
XX PD 07-AUG-2003.
XX
XX PF 11-JUL-2001; 2001US-00903603.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059124P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063172P.
XX 24-OCT-1997; 97US-0063178P.
XX 27-OCT-1997; 97US-0063377P.
XX 27-OCT-1997; 97US-0063379P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063542P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063549P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063705P.
XX 29-OCT-1997; 97US-0063732P.
XX 29-OCT-1997; 97US-0063734P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0064218P.
XX 29-OCT-1997; 97US-0064219P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 18-NOV-1997; 97US-0065853P.
XX 21-NOV-1997; 97US-0066120P.
XX 21-NOV-1997; 97US-0066344P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066465P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066770P.
XX 24-NOV-1997; 97US-0066772P.
XX 25-NOV-1997; 97US-0066840P.
XX 12-DEC-1997; 97US-0069425P.
XX 04-JUN-1998; 97US-0088026P.
XX 10-SEP-1998; 97US-0099803P.
XX 10-SEP-1998; 97US-0099803P.
XX 14-SEP-1998; 97US-0100262P.
XX 14-SEP-1998; 97US-0100262P.
XX 16-SEP-1998; 97US-0100262P.
XX 16-SEP-1998; 97US-0100262P.
XX 17-SEP-1998; 97US-0100858P.
XX 17-SEP-1998; 97US-0100858P.
XX 13-OCT-1998; 97US-0104080P.
XX 20-NOV-1998; 97US-0109304P.
XX 01-DEC-1998; 97US-0109304P.
XX 22-DEC-1998; 97US-0113296P.
XX 07-JUL-1999; 99US-0143048P.

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 15-OCT-1999; 99WO-US023099.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028310.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030055.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US0000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Deanoysers L, Eaton DL, Ferrara N,
XX Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A,
XX Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU,
XX Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tunas D,
XX Williams PM, Wood WI;
XX
XX WPI; 2004-020444/02.
XX
XX New isolated secreted and transmembrane PRO nucleic acids and
XX polypeptides, useful for preventing, diagnosing and treating disorders
XX associated with their aberrant expression and activity.
XX
XX Example 38; Page 106; 476pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XX and the nucleic acid encoding them. The polypeptides can be used to raise
XX antibodies that specifically bind to the PRO polypeptide, for linking a
XX bioactive molecule to a cell expressing a PRO protein and for modulating
XX at least one biological activity of a cell. PRO polypeptides are useful
XX for detecting other PRO polypeptides in a sample and for linking a
XX bioactive molecule to a cell expressing a PRO polypeptide. The PRO
XX polypeptide antibodies are useful for modulating the biological activity
XX of a cell expressing PRO polypeptides. The PRO polypeptides or
XX polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
XX bioeffectors. These are useful for stimulating hypertrophy of neonatal
XX heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
XX proliferation of endothelial cells, modulating the proliferation of
XX stimulated T-lymphocytes, enhancing the survival or proliferation of
XX retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
XX cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
XX -differentiation of chondrocytes. In particular, these are useful for
XX detecting or treating cardiac insufficiency disorders, wounds, cancerous
XX tumours, retinal disorders or injuries (e.g. loss of sight due to
XX retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
XX hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
XX arthritis) in mammals. PRO polypeptides and their portions affect the
XX expression of genes which have a role in cell death. The polynucleotides
XX are useful in molecular biology including uses as hybridisation probes
XX for cDNA library to isolate the full-length PRO cDNA or to isolate other
XX cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
XX and DNA, for preparing PRO polypeptides, for generating transgenic
XX animals or knockout animals which are useful in the development and
XX screening of therapeutically useful reagents, as probes and for the

CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the sequence listing.
XX
XX Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other:
SQ
Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1229 CCAGCATGTGCTGCGCAG 1245
Db 2 CCAGCATGTACTGTCCAG 18
AD137888
AD137888 standard; DNA; 18 BP.
AC AD137888;
XX
DT 22-APR-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
DE
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnery; cyrostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX
XX Homo sapiens.
XX
XX US2003096340-A1.
PN
XX
PD 22-MAY-2003.
XX
XX 16-JUL-2001; 2001US-00906760.
PF
XX
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059253P.
PR 18-SEP-1997; 97US-0059266P.
PR 18-SEP-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.

CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
CC differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

SO Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1229 CCAGCATGTCTGCGCAG 1245
Db 2 CCAGCATGTCTGCGCAG 18
|||||
|||

RESULT 255

AD166056
AD166056 standard; DNA; 18 BP.

XX AD166056;

DT 22-APR-2004 (first entry)

XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiant; vulnary; cyrostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

OS

XX

PN US2003148371-A1.

XX 07-AUG-2003.

XX 16-JUL-2001; 2001US-00906777.

XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059124P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063127P.
XX 24-OCT-1997; 97US-0063128P.
XX 27-OCT-1997; 97US-0063337P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063542P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063549P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063554P.
XX 29-OCT-1997; 97US-0063435P.
XX 29-OCT-1997; 97US-0063702P.
XX 29-OCT-1997; 97US-0063732P.
XX 29-OCT-1997; 97US-0063734P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 29-OCT-1997; 97US-0064215P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 18-NOV-1997; 97US-0065693P.
XX 21-NOV-1997; 97US-0066120P.
XX 21-NOV-1997; 97US-0066364P.
XX 24-NOV-1997; 97US-0066453P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066511P.
XX 24-NOV-1997; 97US-0066770P.
XX 24-NOV-1997; 97US-0066772P.
XX 25-NOV-1997; 97US-0066840P.
XX 12-DEC-1997; 97US-0069425P.
XX 04-JUN-1998; 98US-0088026P.
XX 10-SEP-1998; 98US-0099803P.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98US-0100262P.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98US-0100858P.
XX 17-SEP-1998; 98WO-US019437.
XX 13-OCT-1998; 98US-0104080P.
XX 20-NOV-1998; 98US-0109304P.
XX 01-DEC-1998; 98WO-US025108.
XX 22-DEC-1998; 98US-0113296P.
XX 07-JUL-1999; 99US-0143048P.
XX 26-JUL-1999; 99US-0145698P.
XX 28-JUL-1999; 99US-0146222P.
XX 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Boetstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvarski E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AU, Hillan KJ, Kijavitt IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-020441/02.
XX
XX Isolated secreted and transmembrane PRO nucleic acids and the proteins
XX they encode, e.g. PRO245, PRO269 and PRO1868, useful for preventing,
XX diagnosing and treating e.g. disorders relating to blood coagulation.
XX
XX Example 38; Page 102; 478pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XX and the nucleic acid encoding them. The polypeptides can be used to raise
XX antibodies that specifically bind to the PRO polypeptide, for linking a
XX bioactive molecule to a cell expressing a PRO protein and for modulating
XX at least one biological activity of a cell. PRO polypeptides are useful
XX for detecting other PRO polypeptides in a sample and for linking a
XX bioactive molecule to a cell expressing a PRO polypeptide. The PRO
XX polypeptide antibodies are useful for modulating the biological activity
XX of a cell expressing PRO polypeptides. The PRO polypeptides or
XX polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
XX bioreactors. These are useful for stimulating hypertrophy of neonatal
XX heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
XX proliferation of endothelial cells, modulating the proliferation of
XX stimulated T-lymphocytes, enhancing the survival or proliferation of
XX retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
XX cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
XX differentiation of chondrocytes. In particular, these are useful for
XX detecting or treating cardiac insufficiency disorders, wounds, cancerous
XX tumours, retinal disorders or injuries (e.g. loss of sight due to
XX retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
XX hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
XX arthritis) in mammals. PRO polypeptides and their portions affect the
XX expression of genes which have a role in cell death. The polynucleotides
XX are useful in molecular biology including uses as hybridisation probes
XX for cDNA library to isolate the full-length PRO cDNA or to isolate other
XX cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
XX and DNA, for preparing PRO polypeptides, for generating transgenic
XX animals or knockout animals which are useful in the development and
XX screening of therapeutically useful reagents, as probes and for the
XX genetic analysis of individuals with genetic disorders as well as for
XX recombinantly expressing the protein and for chromosome identification.
XX The proteins are useful as molecular marker for protein electrophoresis

CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.
XX
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query March 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 86.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1229 CCAGCATGCTGCGCAG 1245
Db 2 CCAGCATGCTGCGCAG 18
XX
XX
XX RESULT 256
XX ADM25390
XX ID ADM25390 standard; DNA; 18 BP.
XX AC ADM25390;
XX XX
XX 20-MAY-2004 (first entry)
XX
XX
XX Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiac; vulnary; cytoslatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
XX
XX
XX Homo sapiens.
XX
XX US2003096233-A1.
XX
XX 22-MAY-2003.
XX
XX 11-JUL-2001; 2001US-00903925.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059119P.
XX 17-SEP-1997; 97US-0059121P.
XX 17-SEP-1997; 97US-0059122P.
XX 17-SEP-1997; 97US-0059144P.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 15-OCT-1997; 97US-0062125P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 21-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.
 PR 27-OCT-1997; 97US-0063327P.
 PR 27-OCT-1997; 97US-0063329P.
 PR 28-OCT-1997; 97US-0063541P.
 PR 28-OCT-1997; 97US-0063542P.
 PR 28-OCT-1997; 97US-0063544P.
 PR 28-OCT-1997; 97US-0063549P.
 PR 28-OCT-1997; 97US-0063550P.
 PR 28-OCT-1997; 97US-0063564P.
 PR 29-OCT-1997; 97US-0063435P.
 PR 29-OCT-1997; 97US-0063704P.
 PR 29-OCT-1997; 97US-0063732P.
 PR 29-OCT-1997; 97US-0063734P.
 PR 29-OCT-1997; 97US-0063735P.
 PR 29-OCT-1997; 97US-0063738P.
 PR 29-OCT-1997; 97US-0064215P.
 PR 31-OCT-1997; 97US-0063870P.
 PR 31-OCT-1997; 97US-0064103P.
 PR 03-NOV-1997; 97US-0064248P.
 PR 07-NOV-1997; 97US-0064809P.
 PR 12-NOV-1997; 97US-0065186P.
 PR 17-NOV-1997; 97US-0065846P.
 PR 18-NOV-1997; 97US-0065693P.
 PR 21-NOV-1997; 97US-0065120P.
 PR 21-NOV-1997; 97US-0065364P.
 PR 24-NOV-1997; 97US-0064553P.
 PR 24-NOV-1997; 97US-0064665P.
 PR 24-NOV-1997; 97US-0065116P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 24-NOV-1997; 97US-0066772P.
 PR 25-NOV-1997; 97US-0066840P.
 PR 12-DEC-1997; 97US-00669425P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 10-SEP-1998; 98US-0098803P.
 PR 10-SEP-1998; 98US-0098803P.
 PR 14-SEP-1998; 98US-0100262P.
 PR 14-SEP-1998; 98US-0100262P.
 PR 16-SEP-1998; 98US-0100262P.
 PR 17-SEP-1998; 98US-0100858P.
 PR 17-SEP-1998; 98US-0100858P.
 PR 13-OCT-1998; 98US-0104080P.
 PR 20-NOV-1998; 98US-0109304P.
 PR 01-DEC-1998; 98US-0109304P.
 PR 22-DEC-1998; 98US-0113266P.
 PR 07-JUL-1999; 98US-0143048P.
 PR 26-JUL-1999; 98US-0145698P.
 PR 28-JUL-1999; 98US-0146222P.
 PR 08-SEP-1999; 98US-0146222P.
 PR 13-SEP-1999; 98US-0146222P.
 PR 15-SEP-1999; 98US-0146222P.
 PR 05-OCT-1999; 98US-0146222P.
 PR 29-NOV-1999; 98US-0146222P.
 PR 30-NOV-1999; 98US-0146222P.
 PR 01-DEC-1999; 98US-0146222P.
 PR 02-DEC-1999; 98US-0146222P.
 PR 02-DEC-1999; 98US-0146222P.
 PR 16-DEC-1999; 98US-0146222P.
 PR 20-DEC-1999; 98US-0146222P.
 PR 05-JAN-2000; 98US-0146222P.
 PR 11-FEB-2000; 98US-0146222P.
 PR 22-FEB-2000; 98US-0146222P.
 PR 24-FEB-2000; 98US-0146222P.
 PR 02-MAR-2000; 98US-0146222P.
 PR 20-MAR-2000; 98US-0146222P.
 PR 30-MAR-2000; 98US-0146222P.
 PR 22-MAY-2000; 98US-0146222P.
 PR 02-JUN-2000; 98US-0146222P.
 PR 28-JUL-2000; 98US-0146222P.
 PR 24-AUG-2000; 98US-0146222P.
 PR 18-SEP-2000; 98US-0146222P.

PA (GETH) GENENTECH INC.
 XX Ashkenazi A, Botstein D, Desnoves L, Eaton DL, Ferrara N;
 PI Flvavoff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
 PI Macher JP, Pan J, Paoni NF, Roy MA, Stewart VA, Tumas D;
 PI Williams PM, Wood WI;
 DR WPI, 2004-096547/10.
 XX Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245
 PT or PRO1868, useful in chromosome and gene mapping, in generating
 PT antisense RNA and DNA, and in treating cancer and Alzheimer's disease.
 XX Example 38; Page 112; 483pp; English.
 PS
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to raise
 CC antibodies that specifically bind to the PRO polypeptide, for linking a
 CC bioactive molecule to a cell expressing a PRO protein and for modulating
 CC at least one biological activity of a cell. PRO polypeptides are useful
 CC for detecting other PRO polypeptides in a sample and for linking a
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
 CC polypeptide antibodies are useful for modulating the biological activity
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or
 CC polypeptides are useful as pharmaceuticals, diagnostics, biosensors or
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
 CC proliferation of endothelial cells, modulating the proliferation of
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-
 CC differentiation of chondrocytes. In particular, these are useful for
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
 CC hyponatremia, or bone or cartilage disorders (e.g. sports injuries or
 CC arthritis) in mammals. PRO polypeptides and their portions affect the
 CC expression of genes which have a role in cell death. The polynucleotides
 CC are useful in molecular biology including uses as hybridisation probes
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
 CC and DNA, for preparing PRO polypeptides, for generating transgenic
 CC animals or knockout animals which are useful in the development and
 CC screening of therapeutically useful reagents, as probes and for the
 CC genetic analysis of individuals with genetic disorders as well as for
 CC recombinantly expressing the protein and for chromosome identification.
 CC The proteins are useful as molecular marker for protein electrophoresis
 CC purposes, as therapeutic agents, for screening compounds to identify
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
 CC useful for tissue typing. PRO antibodies are useful for
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
 CC expression in specific cells, tissues or serum and for affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequence presented is a PCR primer which was used to
 CC amplify a PRO polynucleotide of the invention.
 XX
 SO Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 5.5%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 GY 1229 CCAGCATGTGCTGGCAG 1245
 DB 2 CCAGCATGTGCTGGCAG 18
 RESULT 257
 ADM30140

ID ADM30140 standard; DNA; 18 BP.
XX
AC ADM30140;
XX
XX 20-MAY-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #45, PCR primer 2 #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy; VEGF; proliferation;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiac; vulnery; cytostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
XX
OS Homo sapiens.
XX
XX US2003190611-A1.
PN
XX 09-OCT-2003.
PD
XX
XX 17-JUL-2001; 2001US-00907728.
PF
XX
XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065933P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-020978/02.
DR
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
PI
XX
XX Example 38; Page 101; 472pp; English.
PS
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated

CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re-
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancers
CC tumors, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence is presented as a DNA probe which was used to
CC detect a PRO polynucleotide of the invention. NOTE: This sequence is
CC described as SEQ ID NO 239 in Example 38 of the disclosure but is
CC different from SEQ ID NO 239 represented in the Sequence Listing.

XX SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1229 CCAGCATGTGCTGCAG 1245

DB 2 CCAGCATGTACTGCCAG 18

RESULT 258

AD006462 ID ADO06462 standard; DNA; 18 BP.

XX AC ADO06462;

XX DT 01-JUL-2004 (first entry)

XX DE Human PRO PCR primer #198.

XX KM Human; PRO; ss; affinity purification; PCR; primer.

XX OS Homo sapiens.

XX PN US6686451-B1.

XX PD 03-FEB-2004.

XX PF 10-JUL-2001; 2001US-00902775.

XX PR 24-OCT-1997; 97US-0063128P.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 22-FEB-2000; 2000WO-US004414.

XX PR 18-SEP-2000; 2000US-00665350.

XX PA (GETH) GENENTECH INC.

PI Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;
PI Williams PM, Wood WI;
XX "Geth"
DR WPI; 2004-106364/11.

XX PT New antibodies binding PRO polypeptides, useful in gene therapy, or in
XX PT diagnostic assays for the PRO polypeptides, or for the affinity
XX PT purification of PRO polypeptides from recombinant cell culture or natural
XX PT sources.

XX PS Example 38; Col 183; 445pp; English.

XX CC The invention relates to an antibody that binds to a human PRO
XX CC polypeptide. The invention also relates to human PRO polynucleotides
XX CC encoding the PRO polypeptides of the invention. The antibody is a
XX CC monoclonal or humanised antibody, or is an antibody fragment, and is
XX CC preferably labelled. The anti-PRO antibodies may be used in diagnostic
XX CC assays for PRO, or for the affinity purification of PRO from recombinant
XX CC cell culture or natural sources. This sequence represents a PCR primer
XX CC used in isolation of a human PRO polynucleotide of the invention.

XX SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1229 CCAGCATGTGCTGCAG 1245

DB 2 CCAGCATGTACTGCCAG 18

RESULT 259

AAT00610 ID AAT00610 standard; DNA; 19 BP.

XX AC AAT00610;

XX DT 04-JUN-1996 (first entry)

XX DE 21-hydroxylase B gene amplification primer #4.

XX KM Polymerase chain reaction; PCR; primer; amplify; resolvas; endo X1;

XX KM 21-hydroxylase B; T4 endonuclease VII; T7 endonuclease I; endo X2;

XX KM endo X3; fragile X syndrome; myotonic dystrophy;

XX KM spinal muscular dystrophy; bulbar muscular dystrophy; ss.

XX OS Synthetic.

XX PN WO9529251-A1.

XX PD 02-NOV-1995.

XX PF 21-APR-1995; 95WO-US004852.

XX PR 25-APR-1994; 94US-00232530.

XX PA (TECH-) APPLIED TECHNOLOGY GENETICS CORP.

XX PI Cotton RGH, Youil R, Kemper BW;

XX DR WPI; 1995-382996/49.

XX PT Detecting single base pair mutation(s) in isolated nucleic acid - by
XX PT using a resolvas to break a hetero.duplex of test and control DNA at the
XX PT mismatch position.

XX PS Disclosure; Page 16; 60pp; English.

XX CC AAT00609 and AAT00610 represent amplification primers for a 178 bp
XX CC fragment of the wild type and mutant 21-hydroxylase B genes. The
XX CC amplified fragment (and the fragments amplified by AAT00604-T00608,
XX CC AAT00611 and AAT00612) is used as control DNA in the method of the

CC invention. The method of the invention is to identify single base pair
CC mutations in an isolated nucleic acid. In order to detect the mutations,
CC the isolated nucleic acid is denatured to give single stranded DNA. A
CC control DNA sequence is also denatured. The two sets of single stranded
CC DNA sequences are then annealed together to form heteroduplexes. The
CC heteroduplexes are then treated with a resolvase (preferably T4
CC endonuclease VII) that recognises mismatches and causes a break on the
CC heteroduplex chain. Mutations are then indicated by detecting the chain
CC breaks. This method can be used for the diagnosis of inherited diseases,
CC including fragile X syndrome, spinal and bulbar muscular dystrophy, and
CC myotonic dystrophy. Mutations produced during the manipulation of cloned
CC DNA can also be detected. The method can also be used to type bacteria,
CC viruses and other pathogens
CC
XX

SQ Sequence 19 BP; 3 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1245 GTGTCGCGCTGCAGCA 1261
| ||||| ||||| |||||
DB 3 GAGTCGGGCTGCAGCA 19

RESULT 260

AA11965
ID AA11965 standard; DNA; 19 BP.

XX
AC AA11965;

DT 01-AUG-2000 (first entry)

DE Human truncated platelet integrin tr-alpha11b PCR primer #1.

XX Platelet integrin; tr-alpha11b; alpha11b; truncated; soluble; detection;
KW tr-beta3; tumor cell; PCR primer; ss.

XX
OS Homo sapiens.

XX
PN US6046316-A.

XX
PD 04-APR-2000.

XX
PF 09-DEC-1997; 97US-00987418.

XX
PR 09-DEC-1997; 97US-00987418.

XX
PA (UYWA-) UNIV WAYNE STATE.

XX
PI Trikha M, Honn KV;

XX
DR WPI; 2000-282709/24.

PT New isolated, soluble, truncated integrin for identifying the presence of
PT tumor cells in a sample.

XX
PS Example 1; Col 17-18; 24pp; English.

XX
XX This invention describes a novel isolated nucleic acid encoding a
CC soluble, truncated integrin, known as tr-alpha11b. The product of the
CC invention is used for detecting tr-alpha11b and tr-beta3 to identify the
CC presence of tumor cells in a sample. The DNA sequence information
CC provided allows for the preparation of short DNA (or RNA) sequences or
CC probes that are identical to or hybridize to the nucleotide sequence
CC disclosed. This sequence represents a PCR primer used in the isolation of
CC the truncated platelet integrin tr-alpha11b which is described in the
CC invention
CC
XX

SQ Sequence 19 BP; 4 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 19;

Best Local Similarity 88.2%; Pred. No. 2.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1266 CTGGAGAGGCTGAGG 1282
| ||||| ||||| |||||
DB 1 CTGGAGAGGCTGAGG 17

RESULT 261

AA184795
ID AA184795 standard; DNA; 19 BP.

XX
AC AA184795;

XX
DT 04-DEC-2000 (first entry)

DE Cyclin F ribozyme binding site #63.

XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.

KW Mammalia.

XX
OS WO200032765-A2.

XX
PN 08-JUN-2000.

XX
PF 06-DEC-1999; 99WO-US028772.

XX
PR 04-DEC-1998; 98US-0110954P.

XX
PA (IMMU-) IMMUSOL INC.

XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;

XX
DR WPI; 2000-412314/35.

DE New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.

XX
XX

PS Disclosure; Page 82; 109pp; English.

XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
CC
XX

SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1271 AGAGGCTGAGGCGAG 1287
| ||||| ||||| |||||
DB 3 AGAGCTCAGGCGAG 19

RESULT 262

AA177488
ID AA177488 standard; DNA; 19 BP.

XX
AC AA177488;

XX
DT 20-JUN-2001 (first entry)

DE Sense PCR primer specific for alpha11b integrin gene.

XX
XX Human, truncated alpha11b; integrin; tumour; tr-alpha11b; antibody;
KW cancer; PCR primer; ss.

```
XX OS Homo sapiens.
XX XX
XX PN US6218514-B1.
XX XX
XX PD 17-APR-2001.
XX XX
XX PF 29-JUN-1999; 99US-00343062.
XX XX
XX PR 09-DEC-1997; 97US-00987418.
XX XX
XX PA (UYWA-) UNIV WAYNE STATE.
XX XX
XX PI Trikha M, Honn KV;
XX XX
XX DR WPI; 2001-289847/30.
XX XX
XX PT New antibodies specific for soluble truncated integrins, useful in
XX PT diagnostic assays for detecting the presence of truncated alpha IIB or
XX PT truncated beta 3 integrins, and hence useful for identifying tumor cells
XX PT in a biological sample.
XX PS
XX PS Example 1; Col 10; 24pp; English.
XX CC
XX CC This invention relates to a purified antibody which is specific for a
XX CC soluble truncated alphaIIb integrin. Truncated alphaIIb integrin (tr-
XX CC alphaIIb) is an alternatively spliced version of wild-type alphaIIb
XX CC integrin. Tr-alphaIIb differs from the wild type version with exons 27-30
XX CC replaced by a partial sequence from intcon 26 and a poly A tail. Tr-
XX CC alphaIIb is exclusively expressed in tumor cells, and the antibody does
XX CC not bind to the wild-type protein. The antibody can therefore be used to
XX CC detect tumor cells in biological samples. Additionally a truncated
XX CC version of integrin beta3 (tr-beta3) has also been identified as being
XX CC expressed exclusively in tumor cells. The invention also relates to
XX CC antibodies specific for tr-beta3. The present sequence represents a sense
XX CC PCR primer used in the amplification of cDNA encoding alphaIIb integrin
XX CC
XX SQ Sequence 19 BP; 4 A; 3 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 5.5%; Score 13.8; DB 1; Length 19;
XX Best Local Similarity 88.2%; Pred. No. 2.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1266 CTGGAAGAGGCTGAGG 1282
DB 1 CTGGAAGAGGCTGAGG 17
RESULT 263
AAH59957
ID AAH59957 standard; DNA; 19 BP.
XX
XX AC AAH59957;
XX XX
XX DT 10-SEP-2001 (first entry)
XX XX
XX DE Cyclin F ribozyme binding site SEQ ID NO:2381.
XX XX
XX KM Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX KM recognition site; target; ribozyme binding site; eye disease; vulnery;
XX KM proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX KM cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX KM matrix metalloproteinase; growth factor; redutcase; scarring; cytoabatic;
XX KM antiproliferic; dermatological; antiseborrheic; antidiabetic; vitucide;
XX KM anti-bleking; ophthalmological; keratolytic; gene therapy; viral wart;
XX KM atopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX KM basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
XX KM sickle cell retinopathy; ss.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX PN WO200130362-A2.
```

```
XX XX
XX PD 03-MAY-2001.
XX XX
XX PF 26-OCT-2000; 2000MO-US029500.
XX XX
XX PR 26-OCT-1999; 99US-0161532P.
XX XX
XX PA (IMMU-) IMMUSOL INC.
XX XX
XX PI Robbins JM, Tritz R;
XX XX
XX DR WPI; 2001-300427/31.
XX XX
XX PT Treating proliferative skin or eye diseases and scarring, using ribozymes
XX PT that cleave RNA encoding cytokines involved in inflammation, matrix
XX PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX PS
XX PS Example 1; Page 245; 408pp; English.
XX CC
XX CC The present invention describes a method for treating a proliferative
XX CC skin or eye disease and scarring. The method involves administering a
XX CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX CC dependent kinase, growth factor or a redutcase, or administering a
XX CC nucleic acid molecule (II) comprising a promoter operably linked to a
XX CC nucleic acid segment encoding (I). (I) can have antiproliferic,
XX CC dermatological, cytoabatic, antiseborrheic, antidiabetic, anti-bleking,
XX CC ophthalmological, vulnery, keratolytic and vitucide activities, and
XX CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX CC in gene therapy. (I) and (II) are useful for treating proliferative skin
XX CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
XX CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
XX CC also be used for treating proliferative eye diseases such as diabetic
XX CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX CC prematurity and retinal detachment, and for treating and preventing
XX CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
XX CC scar. AAH57577 to AAH62099 represent sequences used in the
XX CC exemplification of the present invention
XX CC
XX SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 5.5%; Score 13.8; DB 1; Length 19;
XX Best Local Similarity 88.2%; Pred. No. 2.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1271 AGAGCTGAGGCGAGG 1287
DB 3 AGAGCTGAGGCGAGG 19
RESULT 264
ADF53941
ID ADF53941 standard; RNA; 19 BP.
XX
XX AC ADF53941;
XX XX
XX DT 12-FEB-2004 (first entry)
XX XX
XX DE Human GAB2 short interfering nucleic acid upper sequence SEQ ID NO:14.
XX XX
XX KM RNA interference; short interfering nucleic acid; siNA;
XX KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX KM short hairpin RNA; shRNA; expression modulation; gene therapy;
XX KM drug screening; diagnosis; therapeutic target identification;
XX KM pharmacogenomics; gene function analysis; gene mapping; human;
XX KM GRB2-associated binding protein; GAB2; cancer; inflammation; allergy;
XX KM chromosome 11; cytoabatic; anti-inflammatory; anti-bleking;
XX KM target sequence; ss.
XX XX
XX OS Synthetic.
XX OS Homo sapiens.
XX XX
XX PN WO2003070903-A2.
```

[illegible]

KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
 KW short hairpin RNA; shRNA; expression modulation; gene therapy;
 KW drug screening; diagnosis; therapeutic target identification;
 KW pharmacogenomics; gene function analysis; gene mapping; human;
 KW GRB2-associated binding protein; GAB2; cancer; inflammation; allergy;
 KW chromosome 11; cytostatic; antiinflammatory; antiallergic; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 PN WO2003070903-A2.
 PD 28-AUG-2003.
 PF 18-FEB-2003; 2003WO-US004909.
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Belgelman L, Uman N;
 XX WPI; 2003-697611/66.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of the GRB2-associated
 PT binding protein gene.
 XX
 PT
 XX
 XX Example 3; SEQ ID NO 350; 140bp; English.
 XX
 CC The present invention relates to short interfering nucleic acids (siNA)
 CC which downregulate expression of the human GRB2-associated binding
 CC protein (GAB2) gene by RNA interference. The siNA may or may not
 CC comprise ribonucleotides and may be double or single stranded. They
 CC further comprise sense and antisense regions, or alternatively are
 CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
 CC Specifically, the siNA include short interfering RNA (siRNA) 'double-
 CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA)'. The siNA
 CC can be unmodified or chemically modified, can contain
 CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
 CC vector or enzymatically synthesised. The invention also relates to kits
 CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
 CC of siNA; and vectors that express siNA. The siNA are used to modulate
 CC expression of the GAB2 gene in cells, tissue explants or organisms (e.g.,
 CC by ex vivo gene therapy), or in grafts and transplants for the treatment
 CC of a variety of conditions. They may be used for treating cancer,
 CC inflammation and allergies. The siNA are also useful for drug screening,
 CC diagnosis, therapeutic target identification and validation, genetic
 CC engineering, pharmacogenomics, studying gene function, and gene mapping
 CC (e.g., of single nucleotide polymorphisms). The human GAB2 gene is
 CC located on chromosome 11, more specifically to region 11q13.4. The human
 CC GAB2 siNA have cytostatic, antiinflammatory and antiallergic activities.
 CC The present sequence represents the lower strand of a human GAB2-targeted
 CC double-stranded siNA.
 CC
 XX
 XX Sequence 19 BP; 5 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 5.5%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No.2,1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1307 CATCTGTGAGCAGCTAG 1323
 |||||||||
 Db 18 CTTCTGTGAGCAGGTAG 2

ADH16704/c
ID ADH16704 strand; RNA; 19 BP.
XX
AC ADH16704;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE siNA lower strand, SEQ ID NO:149.
XX
KM RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping;
KM Alzheimer's disease; dementia; stroke; cardiovascular accident;
KM beta-secretase; BACE; human; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwiggan J, Beigelman L;
XX
DR WPI; 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 494; 144bp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised.
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA, conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the BACE gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating Alzheimer's disease or other degenerative conditions such as
CC dementia and stroke/cardiovascular accident. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human BACE-targeted
CC double-stranded siNA.
XX
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1338 AGCTAGGACCTCTTC 1334
Db 17 AGTtagGAGACCTCTTC 1
RESULT 267
ADH16379
ID ADH16379 strand; RNA; 19 BP.
XX
AC ADH16379;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE transcript target sequence/siNA upper strand, SEQ ID NO:169.
XX
KM RNA interference; short interfering nucleic acid; siNA;
KM short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KM short hairpin RNA; shRNA; expression modulation; gene therapy;
KM drug screening; diagnosis; therapeutic target identification;
KM pharmacogenomics; gene function analysis; gene mapping;
KM Alzheimer's disease; dementia; stroke; cardiovascular accident;
KM beta-secretase; BACE; human; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcwiggan J, Beigelman L;
XX
DR WPI; 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 169; 144bp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siNA, conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the BACE gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating Alzheimer's disease or other degenerative conditions such as
CC dementia and stroke/cardiovascular accident. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene

CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human BACE-targeted
CC double-stranded siRNA, which is identical to the BACE transcript target
CC sequence.
XX
SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 1318 AGTAGGGGACCTCTTC 1314
||:|||||:|:
3 AGUAGAGAGACCUUC 19
Db
RESULT 268
ADH1638
ID ADH1638 standard; RNA; 19 BP.
XX
AC ADH1638;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE siRNA lower strand, SEQ ID NO:428.
XX
KW RNA interference; short interfering nucleic acid; siRNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW beta-secretase; BACE; human; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswigen J, Beigelman L;
XX
DR WPI; 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 428; 144pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised.
CC expressed from a vector or enzymatically synthesised. The invention also

CC relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the BACE gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating Alzheimer's disease or other degenerative conditions such as
CC dementia and stroke/cardiovascular accident. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human BACE-targeted
CC double-stranded siNA.
XX
SQ Sequence 19 BP; 4 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 5.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1200 GTGCAGAGCGCAGCCAT 1216
|||:|||||:
2 GCGCAGAGCGCAGCCAU 18
Db
RESULT 269
ADH16313/C
ID ADH16313 standard; RNA; 19 BP.
XX
AC ADH16313;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human BACE transcript target sequence/siNA upper strand, SEQ ID NO:103.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW Alzheimer's disease; dementia; stroke; cardiovascular accident;
KW beta-secretase; BACE; human; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070895-A2.
XX
PD 28-AUG-2003.
XX
PF 18-FEB-2003; 2003WO-US004710.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 25-JUL-2002; 2002US-00205309.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswigen J, Beigelman L;
XX
DR WPI; 2003-697608/66.
XX
PT New short interfering nucleic acids, useful e.g. for treatment and
PT diagnosis of Alzheimer's disease, which down regulates expression of the
PT beta-secretase gene.
XX
PS Example 3; SEQ ID NO 103; 144pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human beta-secretase (BACE) gene by RNA


```
SQ Sequence 15 BP; 2 A; 7 C; 2 G; 0 T; 4 U; 0 Other;
Query Match 5.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1267 TGAAGAGCTGAGG 1281
    |||||
    15 TGAAGAGCTGAGG 1
Db

RESULT 272
ACD82534
ID ACD82534 standard; DNA; 15 BP.
XX
XX ACD82534;
AC
XX 19-SEP-2003 (first entry)
DT
XX Nucleic acid cloning associated adaptor molecule #235.
DE
XX Adaptor molecule; nucleic acid cloning; nucleic acid ligating;
KM Internal deletion mutagenesis analysis; cloning vehicle; ss.
XX
XX Synthetic.
OS
XX US2003044791-A1.
XX
XX 06-MAR-2003.
PD
XX 13-JUN-2001; 2001US-00880313.
XX
XX 13-JUN-2001; 2001US-00880313.
PR
XX (FLEM/) FLEMINGTON E K.
PA
XX
XX Flemington EK;
PI
XX
XX WPI; 2003-521745/49.
DR
XX
XX New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
XX Claim 12; Fig 5; 100pp; English.
PS
XX
XX The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion
CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
CC
XX
XX Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
SQ

Query Match 5.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1247 GATCGGCTGCAGCA 1261
    |||||
    1 GATCGGCTGCAGCA 15
Db

RESULT 273
AAx71091
ID AAX71091 standard; RNA; 17 BP.
XX
XX AAX71091;
AC
XX 28-JUL-1999 (first entry)
DT
XX Human KDR VEGF receptor hammerhead ribozyme substrate #103.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KM KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KM foetal liver kinase 1; ss.
XX
XX Homo sapiens.
OS
XX
XX MO9715662-A2.
XX
XX 01-MAY-1997.
PD
XX
XX 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
PI
XX
XX WPI; 1997-259017/23.
DR
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT synthesis - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 100; 218pp; English.
PS
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
CC
XX
XX Sequence 17 BP; 3 A; 3 C; 5 G; 0 T; 6 U; 0 Other;
SQ

Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 1301 CATGTCATCTGTGA 1315
    ||:||||:|:|:|
    1 CAUGGUCUUCUGUCA 15
Db

RESULT 274
AAX72693
ID AAX72693 standard; RNA; 17 BP.
XX
XX AAX72693;
AC
XX 28-JUN-1999 (first entry)
DT
XX Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #126.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KM KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KM
```

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
OS Mus sp.
XX WO9715662-A2.
XX 01-MAY-1997.
PD 25-OCT-1996; 96WO-US017480.
XX 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
PI Pavco P, Mcswiggen J, Stinchcomb D, Jacobedo J;
XX WPI, 1997-259017/23.
DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 126; 218pp; English.
CC The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX57275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
Gy 1302 ATGCTCATCTGTGAG 1316
Db 1 AUGGUCUCUCUGAG 15
RESULT 275
ABN00939
ID ABN00939 standard; DNA; 17 BP.
XX
AC ABN00939;
XX
DT 29-MAY-2002 (first entry)
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:931.
XX
KW Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; gammac; heart disease;
KW skeletal muscle disorder; amplicon; screening; 88.
XX
OS Homo sapiens.
XX
AC WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016991.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI, 2002-179446/23.
DR
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 931; 214pp; English.
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Gy 1266 CTGGAAGAGGCTGAG 1280
Db 1 CTGAAGAAGGCTGAG 15
RESULT 276
ACD59616/c
ID ACD59616 standard; RNA; 17 BP.
XX
AC ACD59616;
XX
DT 24-SEP-2003 (first entry)
DE HCV DNAzyme substrate sequence #1418.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;

KM	anberryrme; G-cleaver ribozyme; decoy molecule; aptamer;
KM	HBV reverse transcriptase; Enhancer I region; viral replication;
KM	degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM	virucide; antiinflammatory; substrate; ss.
XX	
OS	Hepatitis C virus.
XX	
PN	WO200281494-A1.
XX	
PD	17-OCT-2002.
XX	
PF	26-MAR-2002; 2002WO-US009187.
XX	
PR	26-MAR-2001; 2001US-00817879.
PR	08-JUN-2001; 2001US-00877478.
PR	08-JUN-2001; 2001US-0296876P.
PR	24-OCT-2001; 2001US-0335059P.
PR	05-DEC-2001; 2001US-0337055P.
XX	
XX	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT) BLATT L.
PA	(MACE) MACEJAK D.
PA	(MCSW) MCSWIGGEN J.
PA	(MORR) MORRISSEY D.
PA	(PAVC) PAVCO P.
PA	(LEEP) LEE P.
PA	(DRAV) DRAPER K.
PA	(ROBE) ROBERTS E.
XX	
PI	Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI	Draper K, Roberts E;
DR	WPI; 2003-229207/22.

PS Claim 1, Page 259, 387pp: English.

XX The present invention relates to nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or

CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense

CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,

CC inozymes, zincymes, amberzymes, and G-claver ribozymes. Also disclosed

CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse

CC transcriptase and/or HBV reverse transcriptase primer sequences, as well

CC as oligonucleotides that specifically bind the Enhancer I region of HBV

CC DNA. The nucleic acids may be used to modulate the expression of HBV

CC genes and HBV viral replication. Also disclosed is a method for screening

CC compounds and/or potential therapies directed against HBV, and compounds

CC that modulate the expression and/or replication of HCV. The compounds and

CC methods of the invention are useful for the treatment of degenerative and

CC disease states related to HBV and HCV infection, replication and gene

CC expression such as cirrhosis, liver failure, and hepatocellular

CC carcinoma. The present sequence represents a substrate for one of the HCV

CC DNzyme or minus strand DNzyme sequences disclosed in the present

CC invention

SQ Sequence 17 BP, 4 A; 10 C; 2 G; 0 T; 1 U; 0 Other;

Query Match	5.3%	Score 13.4	DB 1	Length 17
Best local Similarity	93.3%	Pred. No. 1.9e+02		
Matches 14; Conservative	0	Mismatches 1	Indels 0	Gaps 0

Qy	1412	GGGTGCTGAGCCGGC	1426
Dy	15	GGGTGCTGAGCCGGC	1

RESULT 277
ADIS0114

ID	AD150114 standard; DNA; 17 BP.
XX	
AC	AD150114;
XX	
DT	15-APR-2004 (first entry)

DE Human tumour suppression/reversion-related DNA sequence SegId2617.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytosolic; vinculin; neuroprotective; nontoxic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX Homo sapiens.
DS

PN WO2003025177-A2.

PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004523.

PR 17-SEP-2001; 2001FR-00011980.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-313354/30.

PT New isolated nucleic acid, useful for treating viral diseases associated

PT and transfected cells.

PS Disclosure; SEQ ID NO 2617; 30pp; French.

This invention relates to novel isolated nucleic acid sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses. The invention may be useful for the development of compounds with a cytosaratic, vinctide, neuroprotective, neurotropic or neuroleptic activity. The DNA sequences may be useful as probes and primers for detecting, identifying, quantifying and/or amplifying nucleic acid, for example as one component of a gene chip, in vitro as antisense reagents and for production of recombinant polypeptides. The invention may therefore be useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrenia. The present sequence is that of a nucleic acid sequence of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at [ftp.wipo.int/pub/publicshepct](http://wipo.int/pub/publicshepct) sequences

Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

Query Match	5.3%	Score 13.4;	DB 1;	Length 17;
Best Local Similarity	93.3%;	Pred. No. 1.9e+02;		
Matches 14; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

```

QY      1395 GAGCTGCTGGACAGA 1409
          ||| ||||| |||
Db      1 GATCTGCTGGACAGA 15

```

RESULT 278
ACC53109/c
ID ACC53109 standard; DNA; 17 BP.

AC ACC53109;

DT 27-JUN-2003 (first entry)

Human tumour suppressor sequence #1876.

XX 5

KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
XX Homo sapiens.
XX
XX FR2826373-A1.
XX
XX 27-DEC-2002.
XX
XX 20-JUN-2001; 2001FR-00008139.
XX
XX 20-JUN-2001; 2001FR-00008139.
XX
XX (MOLE-) MOLECULAR ENGINES LAB SA.
XX
XX Tuijnder M, Telerman A, Amson R;
XX
XX WPI; 2003-250498/25.
XX
XX New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT diseases, development of tumor cells and cell degeneration.
XX
XX Claim 1; Page 473; 798pp; French.
XX
XX This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1332 TTCTCCAGCGCAGCA 1346
Db 17 TTCTCCAGCGCAGCA 3
RESULT 279
AD184172/C
ID AD184172 standard; RNA; 17 BP.
XX
XX AD184172;
AC
XX 03-JUN-2004 (first entry)
DT
XX HCV DNAzyme substrate sequence #1418.
DE
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNAzyme.
XX
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX 03-JUL-2003.
PD
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVCO/) PAVCO P A.
PA (MACE/) MACEJACK D.

XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1418; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNAzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 10 C; 2 G; 0 T; 1 U; 0 Other;
SQ
Query Match 5.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1412 GCGTGTGAGCGGCGC 1426
Db 15 GCGTGTGAGCGGCGC 1
RESULT 280
AA244760/C
ID AA244760 standard; DNA; 18 BP.
XX
XX AA244760;
AC
XX 19-APR-2000 (first entry)
DT
XX Human FADD primer ISIS #23860.
DE
XX FADD; human; antisense; inhibitor; Fas-associated death domain; primer;
KW probe; ss.
XX
XX Homo sapiens.
OS
XX US6015712-A.
PN
XX 18-JAN-2000.
PD
XX 19-JUL-1999; 99US-00357072.
PE
XX 19-JUL-1999; 99US-00357072.
XX
XX 19-JUL-1999; 99US-00357072.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Cowseert LM, Baker BF, Zhang H;
PI
XX WPI; 2000-126316/11.
DR
XX Antisense oligonucleotides, useful for inhibiting human Fas-associated
PT death domain (FADD) expression are targeted to the 3' untranslated region
PT of the FADD gene.
XX
XX Claim 16; Col 49-50; 37pp; English.
XX
XX This invention describes novel antisense oligonucleotides (OGNs) (I) 8-20
CC nucleotides in length that specifically hybridize with and inhibit
CC nucleic acids encoding human Fas-associated death domain (FADD), targeted
CC to the 3' untranslated region (3' UTR). (I) can be used to treat animals,
CC especially humans, suspected of having or being prone to a disease or
CC condition associated with FADD expression. AA244746-244831 represent
CC primers and probes used in the method of the invention

XX S0 Sequence 18 BP; 6 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 5.3%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1326 GACCTCTTCTCCAG 1340
|||
DB 15 GACCTCTTCTCCAG 1
|||
RESULT 281
ID AAA92573/C
AC AAA92573 standard; DNA; 18 BP.
XX
AC AAA92573;
XX
DT 04-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide ISIS# 30283.
XX
KW Human; SRA; steroid receptor RNA activator; cytosolic; antiinflammatory;
KM SRA inhibitor; cancer; infection; antisense oligonucleotide; ss.
XX
OS Synthetic.
XX
PN US6107092-A.
XX
PD 22-AUG-2000.
XX
PF 29-MAR-1999; 99US-00280409.
XX
PR 29-MAR-1999; 99US-00280409.
XX
PA (ISIS-) ISIS PHARM INC.
XX (BAYU) BAYLOR COLLEGE MEDICINE.
XX
PI Cowseart LM, Bennett CF, O'malley BW,
XX WPI; 2000-586211/55.
XX
XX Antisense compounds targeted to steroid receptor RNA activator useful for
PT diagnosis, prophylaxis and treatment of diseases associated with the
PT steroid activator, such as infection, inflammation or tumor formation.
XX
PS Claim 3; Col 41; 47pp; English.
XX
CC The present sequence is one of a large number of antisense
CC oligonucleotides which is directed against one of four human steroid
CC receptor RNA activator (SRA) nucleic acid sequences. Two series of
CC antisense oligonucleotides were synthesised. The first series comprised 8
CC -30 oligodeoxynucleotides with a phosphorothioate backbone. The second
CC series comprised chimeric oligonucleotides composed of a central gap
CC region, consisting of ten 2'-deoxynucleotides, which was flanked on both
CC sides by four-nucleotide wings. The wings were composed of 2'-
CC methoxyethyl (2'-MOE) nucleotides. Both series contained the same
CC nucleotide sequences. The antisense compounds are useful for research,
CC diagnosis, treatment and prophylaxis to prevent or delay infection,
CC inflammation or tumour formation. Therapeutically the oligonucleotides
CC are highly safe and are effectively administered to humans
XX
XX Sequence 18 BP; 3 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
QY
Query Match 5.3%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1254 CTGCAGCAACAGCTG 1268
|||
DB 17 CTGCAGCAACAGCTG 3
|||

RESULT 282
ID AAA82748/C
AC AAA82748 standard; DNA; 19 BP.
XX
AC AAA82748;
XX
DT 04-DEC-2000 (first entry)
XX
DE cdk3 ribozyme binding site #33.
XX
DE cdk3 ribozyme binding site #33.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 51; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
XX Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
S0
Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1261 AACAGCTGGAAGAG 1275
|||
DB 19 AGCAGCTGGAAGAG 5
|||
RESULT 283
ID AAF90372
AC AAF90372 standard; mRNA; 19 BP.
XX
AC AAF90372;
XX
DT 06-AUG-2001 (first entry)
XX
DE Human FADD mRNA targeted by ribozyme FADD-Rz4.
XX
DE Ribozyme; FADD; Fas-associated death domain; human; apoptosis;
KM antiapoptotic; gene therapy; ss.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FT misc_binding 1..9
FT /*tag= a
FT /bound_moiety= "ribozyme FADD-Rz4"


```
FT FT /note= "forms double-stranded region with bases 32-40 of
FT FT sequence in AAF90371"
FT FT misc_feature
FT FT /tag= b
FT FT /note= "cleavage site"
FT FT misc_binding
FT FT 11..19
FT FT /tag= c
FT FT /bound moiety= "ribozyme FADD-Rz4"
FT FT /note= "forms double-stranded region with bases 1-9 of
FT FT sequence in AAF90371"
XX XX
XX XX EP1097993-A2.
XX XX
XX XX 09-MAY-2001.
XX XX
XX XX 03-NOV-2000; 2000EP-00250368.
XX XX
XX XX 05-NOV-1999; 99JP-00316133.
XX XX
XX XX (INSC-) SEC AGENCY IND SCI & TECHNOLOGY.
XX XX (TAIR/) TAIRA K.
XX XX
XX XX Taïra K, Warashina M, Kuwabara T, Kawasaki H;
XX XX
XX XX WPI; 2001-357832/38.
XX XX
XX XX Novel chimeric molecule useful for clarifying biological function of
XX XX target nucleic acid and for treating viral diseases, and Alzheimer's
XX XX disease, comprises region with binding affinity for molecule capable of
XX XX sliding.
XX XX
XX XX Example 3; Fig 13D; 76pp; English.
XX XX
XX XX The present sequence is that of mRNA targeted by ribozyme FADD-Rz4 (see
XX XX AAF90371). The mRNA is located within the 5' region (see AAF90364) of
XX XX human pro-apoptotic protein FADD (Fas-associated death domain) mRNA. The
XX XX invention provides 4 polyA-linked and polyA-nonlinked ribozymes aimed at
XX XX specific sites in the human FADD mRNA. Ribozyme FADD-Rz1, ribozyme FADD-
XX XX Rz2 and ribozyme FADD-Rz3 were designed to target inaccessible sites
XX XX located in a stable stem structure, while ribozyme FADD-Rz4 was designed,
XX XX as a control, to target a relatively accessible site located in a loop
XX XX region of the FADD mRNA. The ribozymes were cloned into parental RNAval-
XX XX expression vector pUCdt. Addition of a polyA sequence to the ribozymes
XX XX allowed recruitment of eIF4A1 RNA helicase, which coupled the unwinding
XX XX activity of the helicase to the cleavage activity of the ribozymes. This
XX XX facilitated cleavage of RNA previously refractory to cleavage because of
XX XX a high-order structure. Chimeric molecules of the invention, including
XX XX polyA-linked ribozymes, or expression vectors, are used to prevent or
XX XX treat viral diseases, diseases associated with apoptosis or diseases
XX XX associated with abnormal gene expression (claimed). They are also used in
XX XX a claimed method of specifically cleaving a target nucleic acid,
XX XX especially a viral gene, protooncogene or a gene associated with
XX XX apoptosis
XX XX
XX XX Sequence 19 BP; 3 A; 8 C; 2 G; 0 T; 6 U; 0 Other;
XX XX
XX XX Query Match 5.3%; Score 13.4; DB 1; Length 19;
XX XX Best Local Similarity 66.7%; Pred. No. 2.5e+02;
XX XX Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
XX XX
XX XX 1326 GACCTCTCTCGAAG 1340
XX XX |||||:|||||
XX XX Db 5 GACCCUCUCCCAUG 19
XX XX
XX XX RESULT 284
XX XX AAS15289/C
XX XX ID AAS15289 standard; DNA; 19 BP.
XX XX
XX XX AAS15289;
XX XX
XX XX 16-JAN-2002 (first entry)
XX XX
```

```
DE DE Mouse IL-10 PCR primer #2-365R.
XX XX
XX XX Mouse; ss; PCR primer; neuroprotective; #2-365R;
XX XX antiinflammatory; interleukin-1beta; IL-1b; tumour necrosis factoralpha;
XX XX TNFalpha; macrophage inflammatory protein-1alpha; MIP-1alpha;
XX XX fractalkane; glial fibrillar associated protein; GFAP; MHC; CX3CR1; CD86;
XX XX major histocompatibility complex; Alzheimer's disease; cerebral ischaemia;
XX XX neurodegenerative disease; VLDL3-24OHase; MCP-1; IL-10; IL-12 p40;
XX XX IFN-gamma; CD3 epsilon; CD4; Igg-1; Ig K; osteopontin.
XX XX
XX XX Mus sp.
XX XX
XX XX WO200175165-A2.
XX XX
XX XX 11-OCT-2001.
XX XX
XX XX 30-MAR-2001; 2001WO-US010247.
XX XX
XX XX 30-MAR-2000; 2000US-0193847P.
XX XX
XX XX (ELAN-) ELAN PHARM INC.
XX XX
XX XX Mcconlogue LC, Games KD, Yednock TA, Hua T, Messersmith E;
XX XX Bard F;
XX XX
XX XX WPI; 2001-639367/73.
XX XX
XX XX Example 5; Page 23; 36pp; English.
XX XX
XX XX The invention relates selecting compounds that reduce symptoms of
XX XX Alzheimer's disease using a non-human mammal that has been subjected to
XX XX cerebral ischaemia or lesion of a nerve so as to produce, in the affected
XX XX region, increased levels of specific markers of Alzheimer's disease-
XX XX associated inflammation. Test compounds are selected if they reduce
XX XX levels of these markers significantly, in the affected region, relative
XX XX to controls. The markers are interleukin-1beta (IL-1b), tumour necrosis
XX XX factoralpha (TNFalpha), macrophage inflammatory protein-1alpha (MIP-
XX XX 1alpha), glial fibrillar associated protein (GFAP), MHC (major
XX XX histocompatibility complex) Iralpha or IL 1, CD86, fractalkane or CX3CR1
XX XX (a receptor for fractalkane). The method is used to identify compounds
XX XX useful in treatment or prevention of Alzheimer's disease or other
XX XX neurodegenerative diseases that have an inflammatory component. The
XX XX method provides fast, accurate and quantitative drug screens. The present
XX XX sequence is a PCR primer used to determine the level of a transcript for
XX XX an efficacy marker in a transgenic mouse which overexpresses APP and
XX XX displays Alzheimer's like neuropathology. The efficacy markers are VLDL3-
XX XX 24OHase, MCP-1, IL-10, IL-12 p40, #1/#2, IFN-gamma #1/#2, CD3 epsilon,
XX XX CD4 #1/#2, Igg-1, Ig K (light chain)
XX XX
XX XX Sequence 19 BP; 3 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX XX
XX XX Query Match 5.3%; Score 13.4; DB 1; Length 19;
XX XX Best Local Similarity 93.3%; Pred. No. 2.5e+02;
XX XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
XX XX 1286 AGACCTCAGCGTC 1300
XX XX |||||:|||||
XX XX Db 16 AGACCTCAGCATGC 2
XX XX
XX XX RESULT 285
XX XX AAH57910/C
XX XX ID AAH57910 standard; DNA; 19 BP.
XX XX
XX XX AAH57910;
XX XX
XX XX 10-SEP-2001 (first entry)
XX XX
XX XX Cell-cycle dependent kinase cdk3 ribozyme binding site SEQ ID NO:334.
XX XX
```

XX Human, ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytoskeletal;
 KW antisticking; ophthalmological; antiseborrheic; antidiabetic; virucide;
 KW antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 XX 03-MAY-2001.
 XX 26-OCT-2000; 2000WO-US029500.
 XX 26-OCT-1999; 99US-0161532P.
 XX (IMMU-) IMMUSOL INC.
 XX Robbins JM, Trletz R;
 DR WPI; 2001-300427/31.
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes
 PT that cleave RNA encoding cytokines involved in inflammation, matrix
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX
 XX Example 1; Page 96; 408pp; English.
 XX The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antiporiatic,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisticking,
 CC ophthalmological, vulnary, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH51577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention
 XX
 XX Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
 SQ
 XX Query Match 5.3%; Score 13.4; DB 1; Length 19;
 XX Best Local Similarity 93.3%; Pred No. 2.5e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1261 AACAGCTGGAGAGAG 1275
 DB 19 AGCAGCTGGAGAGAG 5
 RESULT 286
 AAS18881/C
 ID AAS18881 standard; DNA; 19 BP.
 XX AAS18881;
 AC
 XX 12-MAR-2002 (first entry)
 DT

XX Growth hormone 1 gene (GH1), PCR primer GH1R3.
 DE
 XX Growth hormone 1; GH1; osteopathic; gene therapy; protein therapy;
 KW diabetes; obesity; infection; acromegaly; gigantism; sodium retention;
 KW water retention; metabolic syndrome; mood disorder; sleep disorder;
 KW Growth hormone dysfunction; familial growth hormone deficiency;
 KW short stature; pituitary storage defect; human; PCR primer; GH1R3; ss.
 XX
 OS Homo sapiens.
 XX WO200185993-A2.
 XX 15-NOV-2001.
 XX 14-MAY-2001; 2001WO-GB002126.
 XX 12-MAY-2000; 2000GB-00011459.
 XX 14-JUL-2000; 2000EP-0036004.
 XX (UYWA-) UNIV WALES COLLEGE OF MEDICINE.
 XX Cooper DN, Procter AM, Gregory J, Millar DS;
 PI WPI; 2002-089798/12.
 DR
 XX Detecting growth hormone variants (GH1), useful in screening patients for
 PT growth hormone irregularities, comprises comparing the nucleotide
 PT sequence of a GH1 gene from a test sample with that of a standard
 PT sequence of the human GH1.
 XX
 XX Claim 11; Page 77; 95pp; English.
 XX The invention described a method of detecting variation in growth hormone
 CC 1 (GH1), and therefore GH dysfunction in an individual. The method
 CC comprises comparing the nucleotide sequence of GH1 gene obtained from the
 CC test sample with a standard human GH1 gene sequence, in order to identify
 CC variation (GH1 variant). The method is useful in screening patients for
 CC growth hormone irregularities or producing variant proteins for treating
 CC irregularities, and for the early detection and appropriate clinical
 CC management of familial GH deficiency. The GH1 variants are useful in
 CC therapeutic, diagnostic or detection method, particularly for determining
 CC binding defects and susceptibility to a disease such as diabetes, obesity
 CC or infection; for treating acromegaly or gigantism conditions associated
 CC with lactogenic, diabetogenic, lipolytic and protein anabolic effects,
 CC conditions associated with sodium and water retention, metabolic
 CC syndromes, mood and sleep disorders; diagnosing GH dysfunction and
 CC determining pituitary storage defects. The GH1 variants are especially
 CC useful in gene therapy or protein therapy. The GH1 or GH variant may also
 CC be used in the preparation of a medicament, diagnostics composition or
 CC kit, or detection kit. The method has the advantage of: expanding the
 CC know spectrum of GH1 gene mutations; evaluating the role of GH1 gene
 CC mutations in the etiology of short stature; identifying of the mode of
 CC inheritance of novel lesions; evaluation the effects of GH1 mutations on
 CC the structure and function of the GH molecule and development of rapid
 CC diagnostic tests for inherited GH deficiency. This sequence is the GH1
 CC gene specific primer, GH1R5, used with GH1R5 (AAS18880) to amplify the
 CC reverse transcribed GH1 RNA in an in vitro splicing assay described in
 CC the method of the invention
 XX
 XX Sequence 19 BP; 5 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 XX Query Match 5.3%; Score 13.4; DB 1; Length 19;
 XX Best Local Similarity 93.3%; Pred. No. 2.5e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1357 GGGCAGCTGAGGCTT 1371
 DB 19 GGGCAGCTGTGGCTT 5
 RESULT 287
 ABL44697/C

ID	ABL44697	standard; DNA; 19 BP.
XX		
AC	ABL44697;	
XX		
DT	11-APR-2002	(first entry)
XX		
DE	Human chromosome 1p36-35	PCR primer SEQ ID NO:1741.
XX		
KW	Human; chromosome 1p36-35;	chromosome 21q22.1; genetic analysis; genome;
OS	PCR primer; ss.	
XX	Homo sapiens.	
XX		
PN	JP2001321190-A.	
XX		
PD	20-NOV-2001.	
XX		
PF	12-MAR-2001; 2001JP-00068285.	
XX		
PR	10-MAR-2000; 2000JP-00066716.	
XX		
PA	(RIKA) RIKAGAKU KENKYUSHO.	
XX	(GENO-) GENOTEX YG.	
DR	WPI; 2002-144136/19.	
XX		
PT	Arraying genome clones.	
PS	Claim 4; Page 39; 528pp; Japanese.	
XX		
CC	The present invention describes a method of arraying genome clones. The	
CC	method comprises: (a) clones of the genomic libraries contained in	
CC	multitwell plates numbered for discrimination are mixed in each of the	
CC	multitwell plates; (b) a primer designed based on the chromosome marker	
CC	sequence is added to the mixture to carry out an amplification reaction;	
CC	(c) a signal corresponding to the marker is detected from the resultant	
CC	amplified product to specify the discrimination Nos. of the multitwell	
CC	plates containing the clones having said marker sequence; (d) the order of	
CC	the markers is changed so that the same discrimination Nos. succeed to	
CC	the maximum in the specified discrimination Nos. to array the multitwell	
CC	plates; (e) the clones in the multitwell plates of the specified	
CC	discrimination Nos. are mixed respectively in each wells of longitudinal	
CC	and lateral directions; (f) the mixed clones are cultured and the	
CC	resultant cultures are amplified by using the above primer; (g) signals	
CC	are detected from the amplified products; (h) the clones in the multitwell	
CC	plates are specified from the detected result; and (i) the clones are	
CC	reconstituted as the positions on the chromosome and arrayed. The	
CC	microarray is useful for gene analysis. ABL42957 to ABL45322 represent	
CC	PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634	
CC	represent PCR primers for human chromosome 21q22.1, which are	
CC	specifically claimed for use in the present invention	
XX		
SO	Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;	
XX		
Query Match	5.3%;	Score 13.4; DB 1; Length 19;
Best Local Similarity	93.3%;	Pred. No. 2.5e+02;
Matches 14; Conservative	0;	Mismatches 1; Indels 0; Gaps 0
QY	1199	TGTGCAGAGGCAGC 1213
DB	15	TGTGCAGAGGCAGC 1
XX		
RESULT 288		
ADCC61330/C		
ID	ADCC61330	standard; DNA; 19 BP.
XX		
AC	ADCC61330;	
XX		
DT	18-DEC-2003	(first entry)
XX		
DE	Human Growth Hormone 1, GH1,	PCR primer GH1R3.
XX		

KW	Growth Hormone; GH1; human; PCR; primer; ss.
XX	Homo sapiens.
OS	
PN	WO2003042408-A2.
XX	
PD	22-MAY-2003.
XX	
PF	12-NOV-2002; 2002WO-GB005103.
XX	
PR	12-NOV-2001; 2001GB-00027213.
XX	
PA	(UYMA-) UNIV MALES COLLEGE OF MEDICINE.
PI	Cooper DN, Procter AM, Gregory J, Miliar DS;
DR	WI; 2003-449578/42.
PT	Detecting a variation in pituitary-expressed growth hormone (GH1), useful
PT	as an indicator of growth hormone (GH) dysfunction comprises comparing
PT	the sequence obtained from the test sample with a standard sequence of
XX	the human GH1 gene.
PS	Claim 18; Page 58; 70pp; English.
CC	The present invention relates to a method for detecting a variation in
CC	pituitary-expressed Growth Hormone (GH1) effective to act as an indicator
CC	of Growth Hormone (GH) dysfunction in an individual. The method comprises
CC	comparing the sequence obtained from the test sample with a standard
CC	sequence of the human GH1 gene. The detection comprises PCR amplification
CC	of the GH1 gene of the individual using a GH1 gene-specific fragment that
CC	is unique to the GH1 gene whose sequence is not found in the four
CC	paralogous (non-GH1) genes in the GH cluster, and one or more GH1-gene
CC	specific primers that cannot bind to the homologous flanking regions in
CC	the other paralogous (non-GH1) genes in the GH cluster (ADC61308-
XX	ADC61343).
SQ	Sequence 19 BP; 5 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
OY	Query Match 5.3%; Score 13.4; DB 1; Length 19;
DB	Best Local Similarity 93.3%; Pred.No. 2.5e+02;
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
	1357 GGGCACTGAGCCTT 1371
	19 GGGCAGCTGTGGCTT 5
RESULT 289	
ADK95577/C	ADK95577 standard; DNA; 19 BP.
AC	ADK95577;
XX	
DT	06-MAY-2004 (first entry)
DE	Primer of the invention #1297.
XX	
KW	human; single nucleotide polymorphism; SNP; ss; primer.
OS	Synthetic.
XX	
PN	JP2003259875-A.
XX	
PD	16-SEP-2003.
XX	
PF	08-MAR-2002; 2002JP-00064373.
XX	
PR	08-MAR-2002; 2002JP-00064373.
XX	
PA	(KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
DR	WI; 2004-093977/10.

XX Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 4606; 2627pp; Japanese.
XX
CC The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
SQ Sequence 19 BP; 1 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 5.3%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1200 GTGCAAGGGCAGCC 1214
DB 16 GTACAGAGGGCAGCC 2
RESULT 290
AA057975/C
ID AA057975 standard; cDNA; 18 BP.
XX
AC AA057975;
XX
DT 02-SEP-1994 (first entry)
XX
DE Sequence of portion of wild-type murine erythropoietin receptor (nEPOR).
XX
KW Erythropoietin receptor; EPO; ss.
XX
OS Mus musculus.
XX
FH Key Location/Qualifiers
FT misc_difference 1..8
FT /*tag= C
FT /note= "deleted to form tEPOR"
XX
PN US5292654-A.
XX
PD 08-MAR-1994.
XX
PF 13-DEC-1990; 90US-00626923.
XX
PR 13-DEC-1990; 90US-00626923.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Yoshimura A, Longmore GD, Lodish H;
XX
DR WPI; 1994-082328/10.
XX
PT Mutant erythropoietin (EPO) receptor gene - hypersensitive to EPO, useful
PT in assay for identifying compounds, mimicking EPO action.
XX
PS Disclosure; Fig 1B; 13pp; English.
XX
CC nEPOR is wild-type EPOR. tEPOR is a hypersensitive mutant which has a 193
CC bp deletion which spans the 3' coding and noncoding region (from 1242G to
CC 1616G) which results in replacement of the normal C-terminal 42 AAs with
CC alanine and lysine
XX
SQ Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1291 CTCAGGTCCTCATGTCA 1308
DB 18 CTCAGAGGGCCAGGTCA 1
RESULT 291
AA066982/C
ID AA066982 standard; RNA; 18 BP.
XX
AC AA066982;
XX
DT 20-JUL-1999 (first entry)
XX
DE Human B7 hairpin ribozyme target SEQ ID NO:3614.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
diagnosis; ss.
XX
OS Homo sapiens.
XX
PN MO9618736-A2.
XX
PD 20-JUN-1996.
XX
PF 22-NOV-1995; 95WO-US015516.
XX
PR 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P,
PI Mcswigen J, Gustofson J, Usman N, Wincoff F, Matulic-Adamic J,
PI Karpelsky A, Thompson JD, Modak A, Burgin A;
XX
DR WPI; 1996-300653/30.
XX
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
PS Claim 10; Page 214; 307pp; English.
XX
CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC (iii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention

XX	Sequence	18 BP; 1 A; 5 C; 4 G; 0 T; 8 U; 0 Other;
XX	Query Match	5.2%; Score 13.2; DB 1; Length 18;
XX	Best Local Similarity	83.3%; Pred. No. 2.4e+02;
XX	Matches 15; Conservative	0; Mismatches 3; Indels 0; Gaps 0
QY	1256 GCAGCAACAGCTGGAGA 1273	
DB	18 GCACCAAGAGCTGAAAGA 1	
RESULT 292		
ID	AAZ40927/C	
XX	AAZ40927 standard; DNA; 18 BP.	
XX	AAZ40927;	
XX	26-JAN-2000 (first entry)	
DE	Human CD40 phosphorothioate antisense oligonucleotide SEQ ID NO:76.	
XX	Identification: genetic target; gene modulation; human; probe;	
KW	antisense oligonucleotide; phosphorothioate; PCR primer;	
KW	nucleotide sequence-based technology; antisense drug discovery;	
XX	target validation; ss.	
XX	Synthetic.	
OS	Homo sapiens.	
XX	MO9953101-A1.	
XX	21-OCT-1999.	
PF	13-APR-1999; 99MO-US008268.	
PR	13-APR-1998; 98US-0081483P.	
XX	28-APR-1998; 98US-00067638.	
PA	(ISIS-) ISIS PHARM INC.	
PI	Cowser LM, Baker BF, McNeil J, Freier SM, Sasmor HM, Brooks DG;	
PI	Ohsei C, Wyatt JR, Borchers AH, Vickers TA;	
XX	WPI; 1999-620446/53.	
DR		
XX	Identifying compounds which modulate expression of nucleic acids, used to	
PT	provide compounds having defined physical, chemical or bioactive	
PT	properties, e.g. antisense activity.	
XX		
PS	Example 8; Page 78; 264pp; English.	
XX		
CC	A method has been developed of defining a set of compounds that modulate	
CC	the expression of a target nucleic acid (tNA) sequence via binding of the	
CC	compounds with the tNA sequence. The method comprises generating a	
CC	library of virtual compounds in silico according to defined criteria, and	
CC	evaluating in silico the binding of the virtual compounds with the tNA	
CC	according to defined criteria. Also described are: (1) a method of	
CC	defining a set of oligonucleotides (ONs) that modulate the expression of	
CC	a tNA sequence via binding of the ONs with the tNA sequence comprising	
CC	generating a library of virtual compounds in silico according to defined	
CC	criteria, and evaluating in silico the binding of the virtual ONs with	
CC	the tNA according to defined criteria; and (2) a method of defining a set	
CC	of compounds that modulate the expression of a tNA sequence via binding	
CC	of the compounds with the tNA. The methods can be used for the generation	
CC	and identification of synthetic compounds having defined physical,	
CC	chemical or bioactive properties. Information gathered from assays of	
CC	such compounds is used to identify nucleic acid sequences that are	
CC	tractable to a variety of nucleotide sequence-based technologies, e.g.	
CC	antisense drug discovery and target validation. AAZ40852 to AAZ41220, and	
CC	AAZ52701 to AAZ52706, represent sequences used in the exemplification of	
XX	the present invention	
XX		

Query Match	5.2%	Score 13.2	DB 1	Length 18
Best Local Similarity	83.3%	Pred. No. 2.4e+02		
Matches 15	Conservative 0	Mismatches 3	Indels 0	Gaps 0
QY	1337	CAAGCAGAGACTTCC 1354		
DB	18	CAGTCGAGACACTTAC 1		
RESULT 293				
ID	AAA52898	standard; DNA; 18 BP.		
AC	AAA52898;			
XX	15-SEP-2000	(first entry)		
DE	Human CD4 antisense oligonucleotide ISIS# 18787.			
XX	Human; CD4; cell surface adhesion receptor; cytostatic; antirheumatic;			
KW	antiinflammatory; antiarthritic; CD4 antisense inhibition;			
KM	hyperproliferative disorder; cancer; inflammatory disorder;			
XX	rheumatoid arthritis; ss.			
OS	Homo sapiens.			
XX	WO200035935-A1.			
PN	22-JUN-2000.			
XX	14-DEC-1999;	99WO-US029576.		
PE	17-DEC-1998;	98US-00213719.		
XX	(ISIS-) ISIS PHARM INC.			
PA	Bennett CF, Cowsett LM;			
PI	WPI; 2000-431564/37.			
XX	New antisense compound, that inhibits the expression of human cell			
PT	surface adhesion receptor CD4, for treating hyperproliferative disorders			
PT	and inflammatory conditions, such as cancer and rheumatoid arthritis.			
XX	Example 15; Page 78; 105pp; English.			
PS	The present sequence is one of a large number of antisense			
XX	oligonucleotides designed to target different regions of the human CD4			
CC	mRNA. CD4 is a multifunctional human cell surface adhesion receptor. The			
CC	oligonucleotides were analysed for effect on CD4 mRNA levels by			
CC	quantitative real-time PCR analysis. Antisense oligonucleotides that			
CC	inhibit CD4 expression can be used to treat CD4-associated conditions			
CC	including hyperproliferative disorders, such as cancer, and inflammatory			
CC	conditions, such as rheumatoid arthritis. The antisense compounds			
CC	hybridise to CD4 nucleic acids, thus allowing sandwich and other assays			
CC	to be easily constructed. Note: The sequence has a phosphorothioate			
CC	backbone and may be either an oligodeoxynucleotide or a chimeric			
CC	oligonucleotide containing 2'-methoxyethyl (2'-MOE) wings and a deoxy			
CC	gap. The ISIS number given above corresponds to the oligodeoxynucleotide			
CC	sequence			
XX	Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 0 Other;			
XX	Query Match	5.2%; Score 13.2; DB 1; Length 18;		
XX	Best Local Similarity	83.3%; Pred. No. 2.4e+02;		
XX	Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;			
QY	1185	GGCTCCGAGAGCCTMG 1202		
DB	1	GTCCTCCAGAGCACTTG 18		

RESULT 294
AAZ47760/C
ID AAZ47760 standard; DNA; 18 BP.
XX
AC AAZ47760;
XX
DT 02-MAR-2000 (first entry)
XX
DE Human CD40 antisense oligonucleotide SEQ ID NO:76.
XX
KW Human; CD40; antisense oligonucleotide; phosphorothioate; modulation;
expression; immune disease; inflammatory disease; immunomodulatory;
anti-inflammatory; anti-arthritic; anti-asthmatic; antiproliferative;
anticancer; immuno-suppressive; anti-psoriatic; allograft rejection;
hyperproliferative disease; autoimmune disease; rheumatoid arthritis;
inflammatory bowel disease; asthma; psoriasis; cancer; tumour; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO9557320-A1.
XX
PD 11-NOV-1999.
XX
PF 22-APR-1999; 99WO-US008765.
XX
PR 01-MAY-1998; 98US-00071433.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowseert LM;
XX
DR WPI; 2000-062158/05.
XX
PT Antisense molecules directed against nucleic acid encoding human CD40,
for treating e.g. immune, inflammatory or hyperproliferative diseases.
XX
PS Example 9; Page 45; 102pp; English.
XX
CC AAZ47665 to AAZ47768 represent phosphorothioate antisense
oligonucleotides targeted to human CD40, which can be used to inhibit the
expression of human CD40. CD40 is involved in lymphocyte activation,
tumour growth and/or angiogenesis. Inhibition of CD40 is used to treat or
prevent immune-associated diseases (specifically guest vs. host disease,
allograft rejection or autoimmune diseases); inflammation (specifically
asthma, rheumatoid arthritis, allograft rejection, inflammatory bowel
disease or psoriasis) or hyperproliferation (specifically cancer and
tumours). the antisense oligonucleotides are also useful as diagnostic
and research reagents. AAZ47769 represents the human CD40 nucleotide
sequence. AAZ47770 to AAZ47772 represent human CD40 forward and reverse
PCR primers, and a human CD40 PCR probe, respectively. AAZ47773 to
CC AAZ47775 represent other PCR primers and a probe used in the
exemplification of the present invention
CC
SQ Sequence 18 BP; 4 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1337 CAAGCGAGAGACTTCC 1354
DB 18 CAGTCGAGAGACTTAC 1
XX
RESULT 295
AAZ57670
ID AAZ57670 standard; DNA; 18 BP.
XX
AC AAZ57670;
XX
DT 05-APR-2000 (first entry)

XX
DE Human G-alpha-12 antisense inhibitor ISIS# 20658.
XX
KW G-alpha-12 inhibitor; antisense compound; cell differentiation; cancer;
cell growth; metastatic growth; ss; ISIS# 20658.
XX
XX
OS Homo sapiens.
XX
PN US598206-A.
XX
PD 07-DEC-1999.
XX
PF 23-FEB-1999; 99US-00256496.
XX
PR 23-FEB-1999; 99US-00256496.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowseert LM;
XX
DR WPI; 2000-095920/08.
XX
PT Antisense inhibition of human G-alpha-12 expression.
XX
PS Example 15; Col 38; 36pp; English.
XX
CC This is a human G-alpha-12 antisense nucleotide sequence. G-alpha-12 is a
member of the G12/13 subfamily of G-proteins. The primary function of G-
alpha-12 is in cell differentiation and growth. The invention relates to
antisense compounds which are 8-30 nucleotides long (see AAZ57668-
CC 257746). The antisense molecules are targeted to the human G-alpha-12
nucleic acid molecule, and inhibit the expression of G-alpha-12. The
CC molecules preferably have a modified internucleotide linkage, and at
least one modified sugar moiety. The compounds target different regions
of the human G-alpha-12 RNA. The expression of human G-alpha 12 is
inhibited by contacting human cells or tissues in vitro with the
CC antisense molecules. The oligonucleotides are used in modulating the
function of nucleic acid molecules encoding G-alpha-12, ultimately
CC modulating the amount of G-alpha-12 produced. The antisense compounds can
be utilized for diagnostics, therapeutics, prophylaxis and as research
agents and kits. They may be useful in the treatment of cancer, and
CC metastatic growth
CC
SQ Sequence 18 BP; 4 A; 4 C; 9 G; 1 T; 0 U; 0 Other;
XX
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1264 AGCTGGAAGAGCTGAGG 1281
DB 1 AGCAGGACGGCGTGAAG 18
XX
RESULT 296
AAF22265
ID AAF22265 standard; DNA; 18 BP.
XX
AC AAF22265;
XX
DT 20-MAR-2001 (first entry)
XX
DE Arabidopsis thaliana chromosome centromere associated primer #149.
XX
KM Centromere; microsome; vector; ds.
XX
OS Arabidopsis thaliana.
XX
PN WO200055325-A2.
XX
PD 21-SEP-2000.
XX
PF 17-MAR-2000; 2000WO-US007392.

```
XX 18-MAR-1999; 99US-0125219P.
PR 01-APR-1999; 99US-0127409P.
PR 18-MAY-1999; 99US-0134770P.
PR 13-SEP-1999; 99US-0153584P.
PR 17-SEP-1999; 99US-0154603P.
PR 16-DEC-1999; 99US-0172493P.
XX (UNICH-) UNIV CHICAGO.
PA
XX Preuss D, Copenhagen G, Keith K;
XX WPI, 2000-587529/55.
XX
XX Recombinant DNA construct comprising a plant centromere, useful for
PT producing stably inherited microsome which can serve as vectors for the
PT construction of transgenic plant and animal cells.
XX
XX Disclosure; Page 308; 1449pp; English.
XX
XX The present invention relates to a recombinant DNA construct of a plant
CC (Arabidopsis thaliana) centromere. The constructs are useful for
CC producing stably inherited microsome which can serve as vectors for the
CC construction of transgenic plant and animal cells expressing selected
CC proteins such as hormones, enzymes, interleukins, clotting factors,
CC cytokines, antibodies, and growth factors
XX
XX Sequence 18 BP; 6 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1279 AGGCGACGACCCCTCAGG 1296
DB 1 AGGCGACGACGCTCAGG 18
RESULT 297
AA92620/C
ID AAA92620 standard; DNA; 18 BP.
XX
XX AAA92620;
AC
XX
XX 04-JAN-2001 (first entry)
DT
XX
XX Antisense oligonucleotide ISIS# 30439.
DE
XX
XX Human; SRA; steroid receptor RNA activator; cytosolic; antiinflammatory;
KW SRA inhibitor; cancer; infection; antisense oligonucleotide; ss.
XX
XX Synthetic.
OS
XX
XX US6107092-A.
PN
XX
XX 22-AUG-2000.
PD
XX
XX 29-MAR-1999; 99US-00280409.
PF
XX
XX 29-MAR-1999; 99US-00280409.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA (BATU) BAYLOR COLLEGE MEDICINE.
XX
XX Cowsett LM, Bennett CF, O'malley BW;
PI
XX
XX WPI, 2000-586211/55.
DR
XX
XX Antisense compounds targeted to steroid receptor RNA activator useful for
PT diagnosis, prophylaxis and treatment of diseases associated with the
PT steroid activator, such as infection, inflammation or tumor formation.
XX
XX Claim 3; Col 42; 47pp; English.
PS
```

```
XX
XX The present sequence is one of a large number of antisense
CC oligonucleotides which is directed against one of four human steroid
CC receptor RNA activator (SRA) nucleic acid sequences. Two series of
CC antisense oligonucleotides were synthesized. The first series comprised 8
CC -30 oligodeoxynucleotides with a phosphorothioate backbone. The second
CC series comprised chimeric oligonucleotides composed of a central gap
CC region, consisting of ten 2'-deoxynucleotides, which was flanked on both
CC sides by four-nucleotide wings. The wings were composed of 2'-
CC methoxyethyl (2'-MOE) nucleotides. Both series contained the same
CC nucleotide sequences. The antisense compounds are useful for research,
CC diagnosis, treatment and prophylaxis to prevent or delay infection,
CC inflammation or tumor formation. Therapeutically the oligonucleotides
CC are highly safe and are effectively administered to humans
XX
XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1378 AGCAGCTGCTGTTGGCTG 1395
DB 18 AGCAGCTGCTGTTGGATG 1
RESULT 298
AAF26687/C
ID AAF26687 standard; DNA; 18 BP.
XX
XX AAF26687;
AC
XX
XX 09-SEP-2004 (revised)
DT
XX
XX 02-APR-2001 (first entry)
DT
XX
XX Human Smad7 phosphorothioate antisense oligonucleotide SEQ ID NO:30.
DE
XX
XX Human; Smad7; antisense oligonucleotide; phosphorothioate; inhibition;
KW antiinflammatory; cytosolic; infection; inflammation; tumour formation;
KW ss.
XX
XX Homo sapiens.
OS
XX
XX Unidentified.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..18
FT /*tag= a
FT /mod base
FT /note= "phosphorothioate linkages"
XX
XX US6159697-A.
PN
XX
XX 12-DEC-2000.
PD
XX
XX 09-JAN-2000; 2000US-00487444.
PF
XX
XX 09-JAN-2000; 2000US-00487444.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Monla BP, Cowsett LM;
PI
XX
XX WPI, 2001-070108/08.
DR
XX
XX Antisense compound capable of inhibiting the expression of human Smad7,
PT useful for preventing or delaying infection, inflammation or tumor
PT formation.
XX
XX Claim 1; Col 41; 33pp; English.
PS
XX
XX The present invention describes an antisense compound (1) of up to 30
CC nucleobases in length capable of inhibiting the expression of human
CC Smad7. (1) has antiinflammatory and cytostatic, and is a modulator of
```

CC Smad7 expression. (1) can be useful for inhibiting the expression of
CC human Smad7 in human cells or tissues, in vitro. (1) is commonly used as
CC a research reagent in human cells or tissues, in vitro. (1) is commonly used as
CC function of particular genes. (1) is also useful for distinguishing
CC between functions of various members of a biological pathway and for
CC research use. (1) is also utilized for diagnostic, therapeutic,
CC prophylaxis and in kits. (1) is also useful prophylactically, e.g. to
CC prevent or delay infection, inflammation or tumour formation. AAF26667 to
CC AAF26706 represent human Smad7 antisense oligonucleotides from the
CC present invention
CC
CC Revised record issued on 09-SEP-2004 : Correction to feature table key
XX
SQ Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1405 ACAGACCGGCTGCTGAGC 1422
DB 18 ACAGAGCGCTGAGCTGAGC 1
XX
RESULT 299
AAH63040
ID AAH63040 standard; DNA; 18 BP.
XX
AC AAH63040;
XX
DT 06-AUG-2003 (revised)
DT 11-SEP-2001 (first entry)
XX
DE Shrimp white spot Bacilliform virus (WSBV) oligonucleotide 201.
XX
KM Shrimp white spot Bacilliform virus; WSBV; diagnosis; viral infection;
KM antiviral agent; gene expression; antisense construct; probe; primer;
KM transgenic viral resistant shrimp; ss.
XX
OS Shrimp white spot syndrome virus.
XX
PN WO200138351-A2.
XX
PD 31-MAY-2001.
XX
PF 08-NOV-2000; 2000WO-US028888.
XX
PR 24-NOV-1999; 99CN-00124717.
XX
PA (PENY-) PE CORP NY.
PA (THIR-) THIRD INST OCEANOGRAPHY STATE OCEANIC C A.
PA (SINO-) SINOGENOMAX CO LTD.
XX
PI Xu X, Yang F, He J, Pham L, He M, Ye Y, Shen Y, Kodira C;
XX WPI; 2001-355877/37.
XX
DR Primary nucleotide sequence of the shrimp white spot Bacilliform virus
XX (WSBV), useful for producing viral polypeptides that can be used to
PT screen for agents that are useful for treating WSBV infection.
XX
XX
XX Disclosure; Fig 3; 626bp; English.
XX
XX The invention provides the primary nucleotide sequence of the WSBV genome
CC (AAH62689), predicted transcript sequences (AAH62689-AAH62839) and
CC encoded proteins (AAH64910-AAH65051) and oligonucleotide sequences
CC (AAH62840-63160) suitable for use as primers or probes. The nucleic acid
CC molecules and proteins of the invention are useful for diagnosis and
CC monitoring viral infection, in screens for antiviral agents and for
CC monitoring viral gene expression or activity during a treatment regimen.
CC The nucleic acid molecules are also useful as antisense constructs to
CC control viral gene expression in infected cells and tissues and to create
CC transgenic viral resistant shrimp. (Updated on 06-AUG-2003 to correct OS

CC field.)
XX
SQ Sequence 18 BP; 10 A; 3 C; 5 G; 0 T; 0 U; 0 Other;
XX
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1258 AGCAACGCTGGAAGAGC 1275
DB 1 AACCAACACAGGAAGAGC 18
XX
RESULT 300
ABZ81780
ID ABZ81780 standard; DNA; 18 BP.
XX
AC ABZ81780;
XX
DT 11-JUN-2003 (first entry)
DT
XX
DE Huntington's disease gene mutated exon 1 region.
XX
KM Huntington's disease; neurotropic; anticonvulsant; huntingtin; human;
KM gene therapy; mutant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mutation replace(5,A)
FT /*tag= a
XX
PN WO2003013437-A2.
XX
PD 20-FEB-2003.
XX
PE 07-AUG-2002; 2002WO-US025352.
XX
PR 07-AUG-2001; 2001US-0310757P.
PR 08-AUG-2001; 2001US-0310770P.
PR 08-AUG-2001; 2001US-0310889P.
PR 04-DEC-2001; 2001US-0317219P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmlec EB, Parekh-Olmedo H;
XX WPI; 2003-256478/25.
XX
DR
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
XX Example 7; Fig 20; 133bp; English.
XX
XX The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also ABZ81780). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD3S/52 (see ABZ81756). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD3S/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 5.2%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
SQ Sequence 15 BP; 2 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1232 GCATGTGCTGGCA 1244
Db 3 GCATGTGCTGGCA 15
RESULT 306
AAC73225/C
ID AAC73225 standard; DNA; 17 BP.
XX AAC73225;
XX
DT 02-FEB-2001 (first entry)
XX
XX Forward primer #39 used in multiplexing PCR/SBE assay.
XX
XX Oligonucleotide array; genotyping; single base extension reaction; SBE;
XX PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
XX Unidentified.
XX
XX WO200058516-A2.
XX
XX 05-OCT-2000.
XX
XX 27-MAR-2000; 2000WO-US0080659.
XX
XX 26-MAR-1999; 99US-0126473P.
XX
XX 23-JUN-1999; 99US-0140359P.
XX
XX (MHED) WHITEHEAD INST BIOMEDICAL RES.
XX (AFFY-) AFFYMETRIX INC.
XX
XX Fan Y, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
XX Ryder T, Sklar P;
XX
XX WPI; 2000-656171/63.
XX
XX Universal array of oligonucleotides tags attached to a solid substrate
XX along with locus-specific tagged oligonucleotides useful in genotyping
XX using single base extension reactions.
XX
XX Example 7; Page 51; 70pp; English.
XX
XX The present invention relates to an oligonucleotide array comprising
XX oligonucleotide tags fixed to a solid substrate. The oligonucleotide
XX array is useful for genotyping a nucleic acid sample at one or more loci
XX via single base extension (SBE) reactions. A pair of primers is used to
XX amplify a polymorphic locus in a sample e.g. a single nucleotide
XX polymorphism (SNP). The present sequence is one of the primers used in
XX the method of the present invention to amplify a polymorphic sample. The
XX amplified nucleic acid product is then used as a template in a SBE
XX reaction with an extension primer. The SBE reaction products are used to
XX form the oligonucleotide array

XX
SQ Sequence 17 BP; 1 A; 9 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1200 GTGCAGAGGCGCAG 1212
Db 14 GTGCAGAGGCGCAG 2
RESULT 307
ABN02597
ID ABN02597 standard; DNA; 17 BP.
XX
XX ABN02597;
XX
DT 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2589.
XX
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure; SEQ ID NO 2589; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the protein. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI: 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure: SEQ ID NO 2591; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and vaccine production. The hGDMLP-1
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1293 CAGGGTGCATGG 1305
Db 3 CAGGGTGCATGG 15
RESULT 310
ABN02600
ID ABN02600 standard; DNA; 17 BP.
XX
XX
AC ABN02600;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2592.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
PN
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
XX

PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI: 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure: SEQ ID NO 2592; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and vaccine production. The hGDMLP-1
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1293 CAGGGTGCATGG 1305
Db 2 CAGGGTGCATGG 14
RESULT 311
ABT38605
ID ABT38605 standard; DNA; 17 BP.
XX
XX
AC ABT38605;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID NO 4242.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
OS
XX

XX	PN	MO2003025175-A2.
XX	PD	27-MAR-2003.
XX	PF	17-SEP-2002; 2002WO-IB004208.
XX	PR	17-SEP-2001; 2001FR-00011978.
XX	PA	(MOLE-) MOLECULAR ENGINES LAB.
XX	PI	Telerman A, Amson R, Tuijnder M;
XX	PT	WPI, 2003-313353/30.
XX	DR	
XX	PT	New isolated nucleic acid, useful for treating viral diseases associated
XX	PT	with tumors and cell degeneration, also related polypeptides, antibodies
XX	PT	and transfected cells.
XX	PS	Disclosure, Page 529; 720pp; French.
XX	CC	
XX	CC	The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX	CC	given in the specification, a sequence containing at least 15 consecutive
XX	CC	nucleotides from the 17 mer sequence, a sequence with, after optimal
XX	CC	alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX	CC	hybridizes to them under highly stringent conditions, or the complement
XX	CC	of any of them, or the corresponding RNA. The novel isolated nucleic
XX	CC	acids of the invention are useful as probes and primers for detecting,
XX	CC	identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX	CC	component of a gene chip, in vitro as (anti)sense reagents, and for
XX	CC	production of recombinant polypeptides. Any of the nucleic acids,
XX	CC	polypeptides, vectors containing the nucleic acids, cells containing the
XX	CC	vector or antibodies directed against the polypeptides are useful for
XX	CC	preparation of pharmaceuticals for prevention and/or treatment of viral
XX	CC	diseases that are characterized by development of tumours or cell
XX	CC	degeneration, specifically cancer but also Alzheimer's disease and
XX	CC	schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX	CC	patient samples is useful for diagnosis and/or prognosis of these
XX	CC	diseases. The polypeptides can also be used to generate antibodies, and
XX	CC	both the polypeptide and antibodies are useful as components of protein
XX	CC	chips. The nucleic acid sequences of the invention can be used in gene
XX	CC	therapy. This polynucleotide sequence represents a tumour suppression
XX	CC	related human fukutin oligonucleotide of the invention
XX	CC	
XX	SO	Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
XX		
XX	Query Match	5.2%; Score 13; DB 1; Length 17;
XX	Best Local Similarity	100.0%; Pred. No. 2,2e+02;
XX	Matches 13; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
XX		
XX	QY	1215 ATCTGTCTGAGAACCC 1227
XX		
XX	DB	2 ATCTGTCTGAGAACCC 14
XX		
XX	RESULT 312	
XX	ADBA42641	
XX	ID	ADBA42641 standard; DNA; 17 BP.
XX	AC	ADBA42641;
XX	DT	18-DEC-2003 (revised)
XX	DT	04-DEC-2003 (first entry)
XX	DE	Tumour suppression/reversion associated nucleotide #2964.
XX	XX	cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX	XX	primer; probe; tumour suppression; tumour reversion; apoptosis;
XX	XX	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX	XX	diagnosis.
XX	OS	Homo sapiens.
XX	XX	MO2003040369-A2.

[illegible]

PR 15-JUN-1993; 93US-00078471.
PR 07-SEP-1993; 93US-00117952.
XX
XX (SALK) SALK INST BIOLOGICAL STUDIES.
PA
XX Evans GA, Smith MW;
XX
XX WPI, 1995-036508/05.
DR
XX
XX Sequencing complex genomes, present as fragments in a cosmid library - by
PT sequencing end-specific nucleotides of each clone then correlating with
PT spatial relationship of cosmid, esp. for mammalian chromosomes.
XX
XX Example 4; Page 81, 128pp; English.
PS
XX Sequences were determined from the ends of chromosome 11-specific cosmids
CC by automated sequencing without intermediate subcloning. A sample of 371
CC DNA sequence fragments were determined and of these, 277 were suitable
CC for STS primer prediction by computer analysis (using the "Primer"
CC program available from B.Lander, MIT). The STS and cosmids were mapped
CC by in situ hybridisation, somatic cell hybrid analysis or both. Using
CC this method, 370 STS specific for human chromosome 11 were generated and
CC most of them were regionally mapped. This procedure illustrates a novel
CC method for sequencing complex genomes, designated "sequence sampled
CC mapping". The sequence sampled mapping method is useful for the
CC completion of high density sequence-based maps, and ultimately, for the
CC complete sequencing of genomic DNA directly from cosmid clones. See
CC AA082001-082706 for STS primers. (Also see AA091325-58). (Updated on 25-
CC MAR-2003 to correct PN field.)
XX
SQ Sequence 18 BP; 2 A; 10 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred.No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1200 GTGCAGAGGCGAG 1212
Db 18 GTGCAGAGGCGAG 6
RESULT 314
AAT56700/C
ID AAT56700 standard; RNA; 18 BP.
XX
AC AAT56700;
XX
DT 25-MAR-2003 (revised)
DT 02-APR-1997 (first entry)
XX
DE Human TNF-alpha hairpin ribozyme target sequence (nt position 185).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumor necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmunity disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW 88.
XX
XX Homo sapiens.
OS
XX
XX WO9523225-A2.
PN
XX
XX 31-AUG-1995.
PD
XX
XX 23-FEB-1995; 95WO-IB000156.
PF
XX
XX 23-FEB-1994; 94US-00201109.
PR

PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357517.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpelsky A, Kisich K, Matulic-Adamic J, McSwiggan JA;
PI Modak A, Pavco P, Bejlegian L, Sullivan SM, Svedler D, Thompson JD;
PI Traetz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI, 1995-351090/45.
DR
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
PT
PS Claim 2; Page 259; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha mRNA at
CC the nucleotide base position indicated in the DE line. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesised with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit TNF-alpha expression, making them
CC potentially useful for treating rheumatoid arthritis, septic shock and
CC other inflammatory disorders including psoriasis, as well as for
CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 18 BP; 1 A; 9 C; 1 G; 0 T; 7 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred.No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1269 GAAGAGGCTGAGG 1281
Db 15 GAAGAGGCTGAGG 3
RESULT 315
AAT50730/C
ID AAT50730 standard; RNA; 18 BP.
XX
XX
XX AAT50730;
AC
XX
XX 07-MAR-1997 (first entry)
DT
XX
XX Rabbit CERP hairpin ribozyme target sequence #1198.
DE

XX Hairpin ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atrectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CERP;
KW familial hypercholesterolaemia; dyslipidaemia; hypolipidoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; ss.
XX
OS Oryctolagus cuniculus.
XX
PN W09620279-A1.
XX
PD 04-JUL-1996.
XX
PF 11-DEC-1995; 95WO-US016000.
XX
PR 23-DEC-1994; 94US-00363240.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX (WARN) WARNER LAMBERT CO.
XX
PI Couture L, Stinchcomb D, Mcswiggen J, Biegaler C, Pape M,
XX WPI; 1996-321852/32.
XX
PT New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -
XX useful for preventing or treating initial development, progression or
XX regression of vascular diseases, esp. familial hypercholesterolaemia.
XX
PS Claim 4, Page 56; 72pp; English.
XX
XX AAT50699-T50754 represent target sequences for the rabbit cholesterol
XX ester transfer protein (CERP) hairpin ribozymes (see AAT50643-T50688).
XX CERP is a 74 kD glycoprotein that facilitates neutral lipid transfer
XX between plasma lipoproteins. The numbering of the targets refers to the
XX position of the cleavage site in full length CERP. The ribozyme then
XX binds to 4-6 nucleotides 5', and a variable number 3' of this site. The
XX ribozymes are able to cleave mRNA from the gene encoding CERP, thereby
XX blocking synthesis and/or expression of the mRNA. By inhibiting CERP, the
XX reverse cholesterol transport (RCT) pathway can be inhibited (or
XX eliminated) thereby preventing the reduction in size density of the high
XX density lipoproteins (HDL), prolonging HDL half life, and therefore
XX increasing HDL levels. The ribozymes can be used to treat conditions
XX associated with abnormal levels of CERP, specifically atherosclerosis,
XX peripheral vascular disease, hyperbetalipoproteinaemia, dyslipidaemia,
XX familial hypercholesterolaemia, hypolipidoproteinaemia, vascular
XX complications of diabetes, transplant, atrectomy and angioplastic
XX restenosis. By inhibiting CERP, the levels of HDL and low density
XX lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a
XX decrease in LDL levels, and a corresponding increase in HDL levels). The
XX ribozymes can also be used diagnostically to study genetic drift and
XX mutations in diseased cells, and to detect CERP mRNA. As the ribozymes
XX target specific regions of the CERP gene, they have low non-specific
XX activity
XX
SQ Sequence 18 BP; 6 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
XX
XX
XX Query Match 5.2%; Score 13; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1389 TTTGCTGAGCTGC 1401
DB 17 TTTGCTGAGCTGC 5

RESULT 316
AAZ41106/C
ID AAZ41106 standard; DNA; 18 BP.
XX
AC AAZ41106;
XX

DT 26-JAN-2000 (first entry)
XX
XX Human G-alpha-11 phosphorothioate antisense oligonucleotide #10.
DE
XX Identification; genetic target; gene modulation; human; probe;
KW antisense oligonucleotide; phosphorothioate; PCR primer;
KW nucleotide sequence-based technology; antisense drug discovery;
KW target validation; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
PN W09953101-A1.
XX
PD 21-OCT-1999.
XX
PF 13-APR-1999; 99WO-US008268.
XX
PR 13-APR-1998; 98US-0081483P.
XX 28-APR-1998; 98US-00067638.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowser LM, Baker BF, Mcneil J, Freier SM, Sasnor HM, Brooks DG;
XX Ohasi C, Wyatt JR, Borchers AH, Vickers TA;
XX WPI; 1999-620446/53.
XX
XX
XX Identifying compounds which modulate expression of nucleic acids, used to
XX provide compounds having defined physical, chemical or bioactive
XX properties, e.g. antisense activity.
XX
XX Example 27; Page 108; 264pp; English.
XX
XX A method has been developed of defining a set of compounds that modulate
XX the expression of a target nucleic acid (tNA) sequence via binding of the
XX compounds with the tNA sequence. The method comprises generating a
XX library of virtual compounds in silico according to defined criteria, and
XX evaluating in silico the binding of the virtual compounds with the tNA
XX according to defined criteria. Also described are: (1) a method of
XX defining a set of oligonucleotides (ONs) that modulate the expression of
XX a tNA sequence via binding of the ONs with the tNA sequence comprising
XX generating a library of virtual compounds in silico according to defined
XX criteria, and evaluating in silico the binding of the virtual ONs with
XX the tNA according to defined criteria; and (2) a method of defining a set
XX of compounds that modulate the expression of a tNA sequence via binding
XX of the compounds with the tNA. The methods can be used for the generation
XX and identification of synthetic compounds having defined physical,
XX chemical or bioactive properties. Information gathered from assays of
XX such compounds is used to identify nucleic acid sequences that are
XX tractable to a variety of nucleotide sequence-based technologies, e.g.
XX antisense drug discovery and target validation. AAZ40852 to AAZ41220, and
XX AAZ52701 to AAZ52706, represent sequences used in the exemplification of
XX the present invention
XX
XX
SQ Sequence 18 BP; 1 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX
XX Query Match 5.2%; Score 13; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred. No. 2.6e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1375 AGAAGCAGCTCG 1387
DB 18 AGAAGCAGCTCG 6

RESULT 317
AAZ19477/C
ID AAZ19477 standard; DNA; 18 BP.
XX
AC AAZ19477;
XX
DT 15-NOV-1999 (first entry)


```
XX Human G-alpha-11 phosphorothioate antisense oligonucleotide SEQ ID NO:17.
DE Human; G-alpha-11; antisense oligonucleotide; inhibition; expression;
XX phosphorothioate; ss.
KM Synthetic.
XX Homo sapiens.
OS Homo sapiens.
XX US9551455-A.
XX 14-SEP-1999.
PD 14-SEP-1999.
XX 04-DEC-1998; 98US-00205922.
PF 04-DEC-1998; 98US-00205922.
XX 04-DEC-1998; 98US-00205922.
PR 04-DEC-1998; 98US-00205922.
XX (ISIS-) ISIS PHARM INC.
PA Cowest LM;
XX WPI; 1999-539140/45.
DR WPI; 1999-539140/45.
XX Inhibitory antisense compounds useful for the treatment of diseases
PT associated with G-alpha-11.
PS Claim 3; Col 40; 38pp; English.
XX The present invention describes inhibitory antisense compounds of 8-30
CC nucleotides, targeted to a nucleic acid molecule encoding human G-alpha-
CC 11. AA219468 to AA219547 represent human G-alpha-11 phosphorothioate
CC antisense oligonucleotides given in the present invention. The
CC oligonucleotides may be useful for the treatment of diseases associated
CC with G-alpha-11
XX Sequence 18 BP; 1 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1375 AGAAGCAGCTGCG 1387
Db 18 AGAAGCAGCTGCG 6
RESULT 318
AAZ70371/C
ID AAZ70371 standard; DNA; 18 BP.
XX AAZ70371;
AC 10-SEP-2001 (first entry)
XX 10-SEP-2001 (first entry)
DE Human biallelic marker upstream amplification primer SEQ ID NO:4727.
XX Human genome; biallelic marker; high density disequilibrium map;
KM genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KM diagnosis; ss.
XX Homo sapiens.
OS Homo sapiens.
XX WO9954500-A2.
PN WO9954500-A2.
XX 28-OCT-1999.
PD 28-OCT-1999.
XX 21-APR-1999; 99WO-1B000822.
PF 21-APR-1999; 99WO-1B000822.
XX 21-APR-1998; 98US-0082614P.
PR 21-APR-1998; 98US-0082614P.
XX 23-NOV-1998; 98US-0109732P.
PR 23-NOV-1998; 98US-0109732P.
XX
```

```
PA (GEST ) GENSET.
XX Cohen D, Blumentfeld M, Chumakov I;
XX WPI; 2000-013267/01.
DR WPI; 2000-013267/01.
XX Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX Claim 8; Page 1239; 2745pp; English.
XX AA265654 to AA269578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AA269579 to AA277440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX Sequence 18 BP; 4 A; 0 C; 8 G; 6 T; 0 U; 0 Other;
SQ
Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1327 ACCTCTTCTCCAA 1339
Db 13 ACCTCTTCTCCAA 1
RESULT 319
AAZ89196/C
ID AAZ89196 standard; DNA; 18 BP.
XX AAZ89196;
AC 09-JUN-2000 (first entry)
XX 09-JUN-2000 (first entry)
DE Human riboprotein L21 reverse PCR primer.
XX Human; expression profile; Three Prime End Amplification; TPEA;
KW riboprotein L21; RPL21; PCR primer; ss.
XX Homo sapiens.
OS Homo sapiens.
XX WO200008208-A2.
PN WO200008208-A2.
XX 17-FEB-2000.
PD 17-FEB-2000.
XX 05-AUG-1999; 99WO-GB002579.
PF 05-AUG-1999; 99WO-GB002579.
XX 05-AUG-1998; 98GB-00017055.
PR 05-AUG-1998; 98GB-00017055.
XX (MEDI-) MEDICAL RES COUNCIL.
PA Freeman TC, Richardson PJ, Dixon AK;
XX WPI; 2000-224033/19.
DR WPI; 2000-224033/19.
XX Reverse transcription of mRNA species used for expression profiling of
PT single cells by employing a first heeled primer to provide first strand
PT cDNA species and then a second heeled primer population to generate
PT second strand cDNAs.
XX Example 1; Page 29; 50pp; English.
PS
```

XX This invention describes a novel process (M1) of reverse transcribing
CC mRNA species present in a sample from an organism by: (a) reverse
CC transcribing the mRNA species using a first healed primer, to provide a
CC first strand cDNA species; and (b) synthesizing second cDNA species using
CC a second healed primer population, the nucleotide sequences of the non-
CC heal portions of the second healed primers being such that the reverse
CC transcribed first strand cDNA species are capable of hybridizing to at
CC least one second primer. The processes can be used for expression
CC profiling of single cells. The polynucleotide comprising an oligo d(T)
CC sequence and a heal sequence 5' can be used for the reverse transcription
CC of mRNA species in a sample. The polynucleotide primer population of
CC claim (4) can be used for the synthesis of second strand cDNA from a
CC population of first strand cDNA species. Single cell cDNA libraries can
CC be made for subsequent detailed analysis of gene expression and the
CC discovery of novel genes. Small samples can be used and allow the
CC utilization of the large amount of sequence data available for further
CC understanding of disease processes and the cellular physiology of complex
CC issues. The invention provides a rapid, robust and reproducible procedure
CC called Three Prime End Amplification (TPEA), optionally with PCR (TPEA-
CC PCR). Prior art methods for the analysis of gene expression within single
CC cells or small tissue samples are limiting. whilst in situ hybridization
CC techniques provide detailed information about the cellular expression
CC pattern of a gene in intact tissue the technique is laborious and unable
CC to analyze multiple transcripts in a single preparation. The methods
CC presented in the disclosure provide a more straightforward, reproducible
CC and reliable cDNA amplification procedure for small mRNA samples where
CC expression profiling can be conducted. The amplification technique can be
CC carried out in a single tube with a need for only limited manual
CC intervention and large numbers of samples can be analyzed. There is a
CC bias towards more uniform length cDNA molecules ensuring that even
CC relatively low abundance mRNA species are transcribed and optionally
CC amplified at the same level of efficiency as more abundant mRNA species.
CC AAZ9191-289253 represent the primers described in the method of the
CC invention
CC XX
SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1393 CTGAGCTGCTGGA 1405
DB 14 CTGAGCTGCTGGA 2
RESULT 320
ABT06162/C
ID ABT06162 standard; DNA; 18 BP.
XX
AC ABT06162;
XX
DT 28-OCT-2002 (first entry)
XX
DE Human light chain lambda gene related PCR primer SPQ ID No 176.
XX
KM Single Primer Amplification; nested oligonucleotide extension reaction;
KM hairpin; SPA; library; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200248401-A2.
XX
PD 20-JUN-2002.
XX
PF 10-DEC-2001; 2001WO-US047727.
XX
PR 11-DEC-2000; 2000US-0254669P.
XX
PR 19-SEP-2001; 2001US-0323400P.
XX
PA (ALEX-) ALEXION PHARM INC.
XX

PI Bowdish KS, Barbas-Fredrickson S, Lin Y, Mcwhirter J, Maruyama T;
XX
XX WPI; 2002-500537/53.
DR
XX
PT Amplifying nucleic acid by synthesizing template nucleic acid containing
PT a predetermined sequence and hairpin structure and using the template for
PT target amplification by Single Primer Amplification.
XX
PS Example 6; Page 36; 54pp; English.
XX
XX The invention relates to a method for amplifying a nucleic acid using
CC Single Primer Amplification (SPA). The method comprises synthesising a
CC template nucleic acid containing a predetermined sequence and hairpin
CC structure with the nested oligonucleotide extension reaction. The method
CC is useful for amplifying a nucleic acid, preferably for amplifying a
CC family of related nucleic acid sequences to build a complex library of
CC polypeptides encoded by the sequences. The engineered nucleic acid strand
CC is useful for amplifying a nucleic acid strand by providing a nucleic
CC acid with a predetermined sequence engineered onto its first end, a
CC sequence complementary to the predetermined sequence and a hairpin
CC structure between them and contacting the engineered nucleic acid strand
CC with a primer containing at least a portion of the predetermined
CC sequence. This process is done in the presence of a polymerase and
CC nucleotides under conditions suitable for polymerisation to produce a
CC complementary nucleic acid strand. The method of the invention is useful
CC for producing large amounts of a target nucleic acid sequence and for
CC amplifying simultaneously more than one different target nucleic acid
CC sequence located on the same or different nucleic acid molecules. This
CC polynucleotide sequence represents a PCR primer of the invention
CC XX
SQ Sequence 18 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 5.2%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1195 AGCCTGTGCAGAG 1207
DB 13 AGCCTGTGCAGAG 1
RESULT 321
AAX09676/C
ID AAX09676 standard; DNA; 16 BP.
XX
AC AAX09676;
XX
DT 24-MAR-1999 (first entry)
XX
DE Human biallelic polymorphic marker upstream primer #556.
XX
KM Polymorphism; biallelic; human; forensic; paternity testing; disease;
KM detection; phenotypic typing; characteristic; infection; hereditary;
KM autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KM treatment; marker; primer; ss.
XX
OS Synthetic.
XX
PN WO9820165-A2.
XX
PD 14-MAY-1998.
XX
PF 05-NOV-1997; 97WO-US020313.
XX
PR 06-NOV-1996; 96US-0030455P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Lander ES, Wang D, Hudson T;
XX
DR WPI; 1998-286974/25.
XX

PT New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
XX testing or phenotypic typing for disease.
PS Claim 15, Page 219, 310pp; English.
XX
CC AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X12937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC forensics, paternity testing or for phenotypic typing for diseases such
CC as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Minkot-Aldrich syndrome, Fabry's disease, familial
CC hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases
XX
SQ Sequence 16 BP; 1 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1354 CCAGGCGAGCTGAGGC 1369
DB 16 CCAATGGCAGCAGAGGC 1
RESULT 322
AAS56903/C
ID AAS56903 standard; DNA; 16 BP.
XX
AC AAS56903;
XX
DT 16-JAN-2002 (first entry)
XX
DE Validation ribozyme DNA sequence #77.
XX
XX Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
KW cytoskeletal; RNA cleavage; tumour suppressor; PCR primer; CHIR2; Afe; BR2;
KW inhibitor dominant negative 4; breast basic conserved protein 1; BR1;
KW BR1; ID4; cancer; proliferative disorder; tumour proliferation; ss.
XX
OS Homo sapiens.
XX
PN WO200170982-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US009559.
XX
PR 23-MAR-2000; 2000US-00536058.
XX
PA (IMMU-) IMMUSOL INC.
PA (BEGE/) BEGER C.
PI Beger C, Barber J, Wong-Staal F;
PI WPI, 2001-611503/70.
XX
PT Novel polypeptides that are the regulators of BRCA-1, useful for treating
PT cancer and diagnosing the presence of neoplastic cells in biological
XX sample.
PS Disclosure; Fig 8; 97pp; English.

XX
CC Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,
CC ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
CC and primers used in the methods of the invention. Hybridisation of
CC ribozymes can be used to cleave targets results in cleavage of the RNA target. The
CC 1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
CC mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor
CC dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),
CC CHIR2, Afe, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
CC diagnosing cancer and other proliferative disorders. The severity of an
CC incidence of cancer can be lessened by regulating tumour proliferation
CC through modulation of BRCA-1 expression. The sequences of the invention
CC are useful in the development of anti-cancer drugs
XX
SQ Sequence 16 BP; 1 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1197 CCTGTGAGAGCGCAG 1212
DB 16 CCTGCGAGAGCGCAG 1
RESULT 323
ABS98338/C
ID ABS98338 standard; DNA; 16 BP.
XX
AC ABS98338;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human multidrug resistance associated protein 3 PCR primer #4.
XX
XX Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDRI; PCR;
KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTR;
KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW aryl hydrocarbon receptor nuclear translocator; AKR1; cathepsin S; CTSS;
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW HMMT; kallikrein 2; KXK2; nicotinamide-N-methyl transferase; NMNT;
KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
KW UGT2B7; UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; UPA;
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW multidrug resistance associated protein 3; cancer; prostate;
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW altered drug metabolism; cardiovascular function; colorectal tumour;
KW central nervous system; pulmonary; immunological.
XX
OS Homo sapiens.
XX
PN WO200257410-A2.
XX
PD 25-JUL-2002.
XX
PF 28-NOV-2001; 2001WO-US044838.
XX
PR 28-NOV-2000; 2000US-00724389.
XX
PA (DNAS-) DNA SCI LAB INC.
PI Guida M, Hall J;
PI WPI, 2002-698522/75.
XX
PT Isolated nucleic acid molecules having polymorphisms in known human genes
PT e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
PT for locating, identifying and characterizing the genes responsible for
PT disorder-related traits.

XX Example 24; Page 150; 714pp; English.

PS CC This invention relates to the sequence of an isolated nucleic acid

XX CC molecule comprising at least one base variation from that of a known

CC human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),

CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),

CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator

CC (ARNT), catepsin S (CTSS), cyclooxygenase 2 (COX2), diasepan binding

CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating

CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl

CC transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl

CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),

CC sulfoxyltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4

CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl

CC transferase (UGT2B15), uridine kinase receptor (uPR), multidrug resistance 1

CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3

CC (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic

CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.

CC The polymorphisms in the human genes cited in the invention are useful as

CC genetic linkage markers for locating and characterising the genes that

CC are responsible for specific traits within the genome and eventually

CC identifying the genes responsible for a variety of disorder-related

CC traits as a result of their e.g., overexpression, constitutive

CC expression, mutation or underexpression, which may be used in diagnosing

CC and/or treating the disorders. The nucleic acid molecules comprising the

CC polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1,

CC AHR1, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,

CC MDR1 and/or MDR3 are useful for screening individuals for altered drug

CC metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,

CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for

CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are

CC used to screen for altered cardiovascular function, in COX2 for altered

CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central

CC nervous system function, in FLAP and HNMT for altered pulmonary,

CC immunological or haematological function, in KLK2 for altered serine

CC protease activity in the prostate, in LTF for altered immunological or

CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and

CC peripheral nervous system function. The present sequence represents a PCR

CC primer used to amplify the sequences of the invention

XX

SQ Sequence 16 BP; 1 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1353 CCCAGGCGCAGCTGAGG 1368

Db 16 CACAGCGCAGCATGAGG 1

RESULT 324

AAK74502/C

ID AAK74502 standard; RNA; 17 BP.

XX

AC AAK74502;

XX

DT 28-JUL-1999 (first entry)

XX

DE Mouse flt-1 VEGF receptor hammerhead ribozyme substructure #30.

XX

KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;

KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW tm6-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.

XX

OS Mus sp.

XX

PN MO9715662-A2.

XX

PD 01-MAY-1997.

XX

PF 25-OCT-1996; 96MO-US017480.

XX

PR 26-OCT-1995; 95US-0005974P.

PR 11-JAN-1996; 96US-00584040.

XX

PA (RIBO-) RIBOZYME PHARM INC.

PA (CHIR) CHIRON CORP.

XX

PI Payco P, Mcswigen J, Slinchcomb D, Escobedo J;

XX

DR WPI; 1997-259017/23.

XX

PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA

PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,

PT rheumatoid arthritis, etc., in a human patient.

XX

PS Claim 4; Page 156; 218pp; English.

XX

XX The present invention describes nucleic acid molecules which modulate the

CC synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC tm6-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAK67275 to AAK75752 represent specific examples

CC of nucleic acid molecules from the present invention

XX

SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.4e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1280 GGGCAGAGACCTCAG 1295

Db 16 GGGCAGAGACCATGAG 1

RESULT 325

AAV96518/C

ID AAV96518 standard; RNA; 17 BP.

XX

AC AAV96518;

XX

DT 01-MAR-1999 (first entry)

XX

DE Potato citrate synthase target sequence position 729.

XX

KW Solanidine; glucosyltransferase; potato; citrate synthase; target;

KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;

KW flower formation; cleavage; solanaceous plant; ss.

XX

OS Solanum tuberosum.

XX

PN MO9832843-A2.

XX

PD 30-JUL-1998.

XX

PF 14-JAN-1998; 98WO-US000738.

XX

PR 28-JAN-1997; 97US-0036545P.

PR 28-JAN-1997; 97US-0036599P.

PR 24-NOV-1997; 97US-00979416.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Zwick MG, Mcswigen JA;

XX

DR WPI; 1998-427939/36.

PR 05-NOV-1997; 97US-0064866P.
PR 19-DEC-1997; 97US-0068212P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Jarvis T, Metulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI Parry T, Beigelman L, Mcswiggen JA, Karpelisy A, Burgin A;
PI Thompson J, Workman CT, Beaudry A, Sweedler D;
XX
DR WPI; 1999-009494/01.
XX
XX Identifying new catalytic nucleic acid that modulates selected processes
PT - especially ribozymes that cleave Raf RNA for treating cancer,
PT restenosis, and also new ribozymes and modified nucleoside triphosphates
PT used as antiviral agents and synthons.
XX
XX Claim 177; Page 147; 259pp; English.
XX
XX A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules with
CC endonuclease activity and catalytic activity, from the present invention,
CC are used to modulate gene expression in plant and mammalian cells and to
CC cleave target nucleic acid, particularly for treating systemic diseases
CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC ascites and infection. They may also be used to detect genetic drift and
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC with RNA-cleaving activity that modulate expression of the Raf gene, are
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC generally any condition associated with the level of c-raf. Introduction
CC of sugar/phosphate modifications increases stability against nuclease and
CC activity. AA990922 to AA993877 represent NACs that can be used in the
CC method, specifically for modulating the expression of a Raf gene
XX
XX Sequence 17 BP; 6 A; 4 C; 2 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 62.5%; Pred. No. 2.4e+02;
XX Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
OY 1214 CATCTGTCGAGAACCTC 1229
DB 2 CAUCUGUCAGAAUUC 17
RESULT 328
AAFO2687
ID AAFO2687 standard; DNA; 17 BP.
XX
AC AAFO2687;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #982.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
XX Homo sapiens.
XX
XX OS
XX PN WO200061729-A2.
XX
XX PD 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US009721.
XX
XX 12-APR-1999; 99US-0123390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA

XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
DR
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
XX Claim 37; Page 78; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/CODP-TR-1, the GATA transcription
CC factor gene, IRE-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 1 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1182 CTGGGCTCCGAGAGC 1197
DB 2 CTGGGCTCCAGGGGC 17
RESULT 329
ABK00539/C
ID ABK00539 standard; RNA; 17 BP.
XX
AC ABK00539;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Hammerhead Ribozyme #539.
XX
XX Human; ss; antiense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiParkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberyzyme; zinzyne; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
XX
XX OS
XX PN WO200159103-A2.
XX
XX PD 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX
XX 28-FEB-2000; 2000US-0185516P.
XX
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLAT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
PI

XX WPI: 2001-607195/69.

DR Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense

XX constructs, which down regulate expression of a CD20 gene or neurite

PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and

PT central nervous system injury.

XX Claim 86; Page 74; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates

XX expression of a CD20 gene and a nucleic acid molecule which down

XX regulates expression of a neurite growth inhibitor gene (NOCO). The

XX nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a

XX DNzyme) an NCH motif, a G-cleaver (cleaving RNA with a NN motif) or

XX an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA

XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA

XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.

XX Furthermore, it may be contacted with a cell to reduce CD20 activity of

XX the cell and treat a patient having a condition associated with the level

XX of CD20. The treatment may further comprise the use of one or more

XX therapies. In particular, the CD20 targeting nucleic acid may be used to

XX treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-

XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell

XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,

XX immune thrombocytopenia, and inflammatory arthropathy. The NOCO-

XX targeting nucleic acid is used to cleave RNA of the NOCO gene in the

XX presence of a divalent cation that is preferably Mg²⁺. Furthermore, the

XX nucleic acid may be contacted with a cell to reduce NOCO activity of the

XX cell and treat a patient having a condition associated with the level of

XX NOCO. The treatment may further comprise the use of one or more

XX therapies. In particular, the NOCO-targeting nucleic acid may be used to

XX treat central nervous system (CNS) injury and cerebrovascular accident

XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),

XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob

XX disease, muscular dystrophy, and/or other neurodegenerative disease

XX states which respond to the modulation of NOCO expression. The present

XX sequence is a hammerhead ribozyme of the invention

SO Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

QY Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.4e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1263 CAGCTGAAGAGCGTG 1278

16 CAGCAGAAATGAGCTG 1

RESULT 330

ABK02178/c

ID ABK02178 standard; RNA; 17 BP.

AC ABK02178;

XX 12-MAR-2002 (first entry)

DT

XX Human NOCO DNzyme #90.

DE

XX Human; 89; antisense therapy; cytostatic; antiinflammatory; haemostatic;

XX cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;

XX muscular; CD20; neurite growth inhibitor gene; NOCO; hammerhead ribozyme;

XX DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukemia;

XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;

XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;

XX MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;

XX inflammatory arthropathy; central nervous system injury;

XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;

XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;

KW Parkinson's disease; ataxia; Huntington's disease;

KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX Homo-sapiens.

OS Synthetic.

OS WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.

XX 28-FEB-2000; 2000US-0185516P.

XX 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGEN J.

XX (CHOW/) CHOWRIRA B M.

XX Blatt L, Mcswigen J, Chowrira BM,

XX WPI: 2001-607195/69.

DR Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense

PT constructs, which down regulate expression of a CD20 gene or neurite

PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and

PT central nervous system injury.

XX Claim 86; Page 114; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates

XX expression of a CD20 gene and a nucleic acid molecule which down

XX regulates expression of a neurite growth inhibitor gene (NOCO). The

XX nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a

XX DNzyme) an inozyme, an endolytic nucleic acid cleaving a an RNA molecule

XX possessing an NCH motif, a G-cleaver (cleaving RNA with a NVN motif) or

XX an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA

XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA

XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.

XX Furthermore, it may be contacted with a cell to reduce CD20 activity of

XX the cell and treat a patient having a condition associated with the level

XX of CD20. The treatment may further comprise the use of one or more

XX therapies. In particular, the CD20 targeting nucleic acid may be used to

XX treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-

XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell

XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,

XX immune thrombocytopenia, and inflammatory arthropathy. The NOCO-

XX targeting nucleic acid is used to cleave RNA of the NOCO gene in the

XX presence of a divalent cation that is preferably Mg²⁺. Furthermore, the

XX nucleic acid may be contacted with a cell to reduce NOCO activity of the

XX cell and treat a patient having a condition associated with the level of

XX NOCO. The treatment may further comprise the use of one or more

XX therapies. In particular, the NOCO-targeting nucleic acid may be used to

XX treat central nervous system (CNS) injury and cerebrovascular accident

XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),

XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob

XX disease, muscular dystrophy, and/or other neurodegenerative disease

XX states which respond to the modulation of NOCO expression. The present

XX sequence is a DNzyme molecule of the invention

SO Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

QY Query Match 5.1%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.4e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1188 TCCGAGAAGCTGTGC 1203

17 TCTCAGAAATCTGTGC 2

RESULT 331
ID ABN01971 standard; DNA; 17 BP.
AC ABN01971;
DT 29-MAY-2002 (first entry)
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1963.
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PR 30-JAN-2001; 2001WO-US000662.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 1963; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1392 GCTGAGCTGCTGACACA 1407
Db 1 GCTCAGCTGCTGACACA 16
RESULT 332
ID ABN06618/c
ID ABN06618 standard; DNA; 17 BP.
AC ABN06618;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6610.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PR 30-JAN-2001; 2001WO-US000661.
XX
PR 30-JAN-2001; 2001WO-US000662.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 05-FEB-2001; 2001US-0266860P.
XX
XX
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 6610; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionization, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed WIPO
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC XX
SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1223 GAACCTCCAGCATGTG 1238
DB 17 GAGCTCCGAGTGTG 2
RESULT 333
ABN07805
ID ABN07805 standard; DNA; 17 BP.
AC ABN07805;
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7797.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KV skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
FN
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABCM-1) ABCMICA INC.
PA
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 7797; 214pp; English.

XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
CC XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1253 GCTGCAGCAGCATGTG 1268
DB 2 GCTTCAGCAGCATGTG 17
RESULT 334
ABN01970
ID ABN01970 standard; DNA; 17 BP.
AC ABN01970;
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1962.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KV skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
FN
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX

PA (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 1962; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
QY
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Db 1392 GCTGAGCTGCTGGACA 1407
2 GCTCAGCTGCTGCACA 17
OY
RESULT 335
ABN07355
ID ABN07355 standard; DNA; 17 BP.
XX
AC ABN07355;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7347.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 7347; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 7 A; 3 C; 5 G; 2 T; 0 U; 0 Other;
QY
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Db 1261 AACAGCTGAAGAGAGC 1276
1 AACAGTTGAAGAGAGC 16
OY
RESULT 336
ABN06621/C
ID ABN06621 standard; DNA; 17 BP.
XX
AC ABN06621;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6613.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX

PN WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024253.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AECOM-) AECOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX
XX Disclosure; SEQ ID NO 6613; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-
XX 1 can be used in gene therapy and vaccine production. The hGDMRP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMRP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMRP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMRP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMRP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMRP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionization, as
XX therapeutic supplement in patients having specific deficiency in hGDMRP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMRP-1, in particular heart
XX and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMRP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMRP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7798.
XX
XX Human; genome-derived myosin-like protein 1; GDMRP-1; hGDMRP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024253.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AECOM-) AECOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMRP-1.
XX
XX Disclosure; SEQ ID NO 7798; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-
XX 1 can be used in gene therapy and vaccine production. The hGDMRP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMRP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMRP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMRP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMRP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMRP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionization, as
XX therapeutic supplement in patients having specific deficiency in hGDMRP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMRP-1, in particular heart
XX and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMRP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1253 GCTGAGCAGACTGG 1268
 |||||
 DB 1 GCTTCAGCAGCAGCTG 16

RESULT 338
 ABN08655
 ID ABN08655 standard; DNA, 17 BP.
 XX
 AC ABN08655;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8647.
 XX
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 8647; 214pp; English.

CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 XX

Query Match 5.1%; Score 12.0; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1254 CTGAGCAGCAGCTGG 1269
 |||||
 DB 2 CTGAGCAGCAGCTGG 17

RESULT 339
 ABN07354
 ID ABN07354 standard; DNA, 17 BP.
 XX
 AC ABN07354;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7346.
 XX
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 7346; 214pp; English.

CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 8 A; 2 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1261 AACAGCTGGAAGAGCG 1276
Db 2 AACAGTTGGAAGAGAC 17
RESULT 340
ABN08657
ID ABN08657 standard; DNA, 17 BP.
XX
AC ABN08657;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8649.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 8649; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1255 TGACGACACAGCTGGA 1270
Db 1 TGACGCTGACAGCTGGA 16
RESULT 341
ABN09355
ID ABN09355 standard; DNA, 17 BP.
XX
AC ABN09355;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9347.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure; SEQ ID NO 9347; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser description ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX
SQ Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CY 1269 GAAGAGGCTGAGGGCA 1284
DB 1 GAAGAGGCTGGGACA 16
RESULT 342
ABN02602
ID ABN02602 standard; DNA; 17 BP.
AC ABN02602;
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2594.
DE
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX 25-MAY-2001; 2001WO-US016981.
PF
XX 26-MAY-2000; 2000US-0207456P.
PR

PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure; SEQ ID NO 2594; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser description ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX
SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CY 1294 AGGCTGCCATGTCAT 1309
DB 1 AGGCTGCCATGAGAT 16
RESULT 343
ABN09354
ID ABN09354 standard; DNA; 17 BP.
AC ABN09354;
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9346.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW

XX skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AECOM-) AECOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-1794446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 9346; 21pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleotide acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX 1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0
XX
XX 1269 GAAGAGCGTGAAGGACA 1284
XX |||||
XX 2 GAAGAGCGCTGGGACACA 17

ID AEN00934 standard; DNA; 17 BP.
 AC AEN00934;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:926.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-FEB-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEMO-) AEMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 926; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

```
Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1262 ACAGCTGGAAGAGGCT 1277
      |||||
Db       2 AGAGCTGAAGAGGCT 17

RESULT 345
AB064096
ID      AB064096 standard; DNA; 17 BP.
XX
AC      AB064096;
XX
DT      20-AUG-2002 (first entry)
XX
DE      Human KTOM1a portion (AB063232) probe # 809.
XX
KW      Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytosstatic;
KW      gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW      kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS      Homo sapiens.
XX
PN      WO200224750-A2.
XX
PD      28-MAR-2002.
XX
PF      21-SEP-2001; 2001WO-US029656.
XX
PR      21-SEP-2000; 2000US-0234687P.
PR      27-SEP-2000; 2000US-0236359P.
PR      04-OCT-2000; 2000GB-00024263.
PR      30-JAN-2001; 2001WO-US000661.
PR      30-JAN-2001; 2001WO-US000662.
PR      30-JAN-2001; 2001WO-US000663.
PR      30-JAN-2001; 2001WO-US000664.
PR      30-JAN-2001; 2001WO-US000665.
PR      30-JAN-2001; 2001WO-US000666.
PR      30-JAN-2001; 2001WO-US000667.
PR      30-JAN-2001; 2001WO-US000668.
PR      30-JAN-2001; 2001WO-US000669.
PR      30-JAN-2001; 2001WO-US000670.
PR      23-MAY-2001; 2001US-00864761.
PR      28-AUG-2001; 2001US-0315676P.
XX
PA      (AEOM-) AEOMICA INC.
XX
PI      Zhang J;
XX
DR      WPI; 2002-479509/51.
XX
PT      New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT      acids encoding the protein, useful for treating subjects having defects
PT      in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT      e.g., liver or bone.
XX
PS      Example 2; Page 263; 418bp; English.
XX
SS      The invention relates to a novel isolated nucleic acid encoding human
XX      KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX      invention has cytosstatic activity. The nucleotide may have a use in gene
XX      therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX      monitor a disease caused by altered expression of human KTOM1.
XX      Compositions comprising the nucleic acids, proteins or antibodies may be
XX      used to treat subjects having defects in KTOM1 which can manifest as
XX      cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX      heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX      function. The sequence represents a probe used in the invention to scan
XX      the nt 1-1001 portion of human KTOM1a (AB063232)
```

```
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match          5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1353 CCCAGGCGCAGCTGAGG 1368
      |||||
Db       1 CCTAGACGACGCTGAGG 16

RESULT 346
AB064095
ID      AB064095 standard; DNA; 17 BP.
XX
AC      AB064095;
XX
DT      20-AUG-2002 (first entry)
XX
DE      Human KTOM1a portion (AB063232) probe # 808.
XX
KW      Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytosstatic;
KW      gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW      kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS      Homo sapiens.
XX
PN      WO200224750-A2.
XX
PD      28-MAR-2002.
XX
PF      21-SEP-2001; 2001WO-US029656.
XX
PR      21-SEP-2000; 2000US-0234687P.
PR      27-SEP-2000; 2000US-0236359P.
PR      04-OCT-2000; 2000GB-00024263.
PR      30-JAN-2001; 2001WO-US000661.
PR      30-JAN-2001; 2001WO-US000662.
PR      30-JAN-2001; 2001WO-US000663.
PR      30-JAN-2001; 2001WO-US000664.
PR      30-JAN-2001; 2001WO-US000665.
PR      30-JAN-2001; 2001WO-US000666.
PR      30-JAN-2001; 2001WO-US000667.
PR      30-JAN-2001; 2001WO-US000668.
PR      30-JAN-2001; 2001WO-US000669.
PR      30-JAN-2001; 2001WO-US000670.
PR      23-MAY-2001; 2001US-00864761.
PR      28-AUG-2001; 2001US-0315676P.
XX
PA      (AEOM-) AEOMICA INC.
XX
PI      Zhang J;
XX
DR      WPI; 2002-479509/51.
XX
PT      New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT      acids encoding the protein, useful for treating subjects having defects
PT      in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT      e.g., liver or bone.
XX
PS      Example 2; Page 263; 418bp; English.
XX
SS      The invention relates to a novel isolated nucleic acid encoding human
XX      KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX      invention has cytosstatic activity. The nucleotide may have a use in gene
XX      therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX      monitor a disease caused by altered expression of human KTOM1.
XX      Compositions comprising the nucleic acids, proteins or antibodies may be
XX      used to treat subjects having defects in KTOM1 which can manifest as
XX      cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX      heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX      function. The sequence represents a probe used in the invention to scan
XX      the nt 1-1001 portion of human KTOM1a (AB063232)
```


CC skeletal muscle or colon function. HTPPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention

XX Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1297 GTGCCATGTCATCTCG 1312

DB 16 GTTCATGTCATCTCG 1

RESULT 349
ABV80571/c
ID ABV80571 standard; DNA; 17 BP.

XX ABV80571;

XX 03-JAN-2003 (first entry)

DE Human HTPL scanning oligonucleotide SEQ ID 1817.

XX Human; gene therapy; tumour suppressor; HTPPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.

XX Homo sapiens.

OS Homo sapiens.

PN EPI229046-A2.

XX EPI229046-A2.

PD 07-AUG-2002.

XX 07-AUG-2002.

XX 28-JAN-2002; 2002EP-00001167.

PF 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 23-MAY-2001; 2001US-00864761.

PR 09-OCT-2001; 2001US-0327898P.

XX 09-OCT-2001; 2001US-0327898P.

XX (AEOM-) AEOMICA INC.

XX (AEOM-) AEOMICA INC.

XX Zhan J;

PI Zhan J;

XX WPI; 2002-676582/73.

XX WPI; 2002-676582/73.

XX Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.

XX Example 2; Page 302; 718pp; English.

XX The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPPL-S (S for short) compared to HTPPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human

CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention

XX Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1300 CCATGTCATCTCGA 1315

DB 17 CCATGTCATCTCGA 2

RESULT 350
ABV80572/c
ID ABV80572 standard; DNA; 17 BP.

XX ABV80572;

XX 03-JAN-2003 (first entry)

DE Human HTPL scanning oligonucleotide SEQ ID 1818.

XX Human; gene therapy; tumour suppressor; HTPPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.

XX Homo sapiens.

OS Homo sapiens.

PN EPI229046-A2.

XX EPI229046-A2.

PD 07-AUG-2002.

XX 07-AUG-2002.

XX 28-JAN-2002; 2002EP-00001167.

PF 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 23-MAY-2001; 2001US-00864761.

PR 09-OCT-2001; 2001US-0327898P.

XX 09-OCT-2001; 2001US-0327898P.

XX (AEOM-) AEOMICA INC.

XX (AEOM-) AEOMICA INC.

XX Zhan J;

PI Zhan J;

XX WPI; 2002-676582/73.

XX WPI; 2002-676582/73.

XX Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.

XX Example 2; Page 302; 718pp; English.

XX The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPPL-S (S for short) compared to HTPPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in

CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPV. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPV proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention

XX
SQ Sequence 17 BP; 6 A; 4 C; 3 T; 0 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1300 CCATGTCATCTGTGA 1315
DB 16 CCATGTCATCTGTGA 1

RESULT 351
ACN04605/C
ID ACN04605 standard; RNA; 17 BP.
XX
AC ACN04605;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV Zinzyme substrate SEQ ID NO 4608.
XX
XX MNV, West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
XX viruside; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (BLAT/) BLATT L.
XX
PA (MCSW/) MCSWIGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 4608; 495bp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX
SQ Sequence 17 BP; 4 A; 1 C; 8 G; 0 T; 4 U; 0 Other;

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1225 ACCTCCAGCATGTGCT 1240
DB 17 ACCTCCAGCATGTGCT 2

RESULT 352
ACN13660
ID ACN13660 standard; RNA; 17 BP.
XX
AC ACN13660;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV minus strand DNAzyme substrate SEQ ID NO 13663.
XX
XX MNV, West Nile Virus; antiinflammatory; cytosolic; hepatotropic;
XX viruside; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (BLAT/) BLATT L.
XX
PA (MCSW/) MCSWIGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 13663; 495bp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid

Query Match 5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.4e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1225 ACCTCCAGCATGTGCT 1240
|||:|||||:|:
DB 2 ACCUCCACACAUUCU 17

RESULT 353
ACN12142/C

ID ACN12142 standard; RNA; 17 BP.

ACN12142;

22-APR-2004 (first entry)

WNV minus strand Inozyme substrate SEQ ID NO 12145.

XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; meningitis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (MNV), useful for treating a condition related to MNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 12145; 495pp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 2 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

XX Query Match 5.1%; Score 12.8; DB 1; Length 17;

XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;

XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1396 AGCTGCTGACAGACC 1411
|||||
DB 16 AGCTGCTGAAAGAAC 1

RESULT 354

ACN09390/C
ID ACN09390 standard; RNA; 17 BP.

ACN09390;

22-APR-2004 (first entry)

WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9393.

XX MNV; West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; meningitis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (MNV), useful for treating a condition related to MNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 9393; 495pp; English.

CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 2 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

XX Query Match 5.1%; Score 12.8; DB 1; Length 17;

XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;

XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1396 AGCTGCTGACAGACC 1411
|||||
DB 17 AGCTGCTGAAAGAAC 2

RESULT 355

ACN05546
ID ACN05546 standard; RNA; 17 BP.

ACN05546;

22-APR-2004 (first entry)

```

DE MNV Amberzyme substrate SEQ ID NO 5549.
XX
XX MNV: West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
KM viricide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; meningitis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KM Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blact L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 5549; 495bp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 2.4e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1396 AGCTGCTGACAGACC 1411
XX |||||:|||||
XX 1 AGCTGCTGACAGAAC 16
XX
XX RESULT 356
XX ACON05545
XX ID ACON05545 standard; RNA; 17 BP.
XX
XX ACON05545;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV Amberzyme substrate SEQ ID NO 5548.
XX
XX MNV: West Nile Virus; antiinflammatory; cyostatic; hepatotropic;
XX viricide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.

```

XX	West Nile Virus.
OS	
XX	WO200268637-A2.
PN	
XX	
PD	06-SEP-2002.
XX	
PF	19-OCT-2001; 2001WO-US048350.
PR	
XX	20-OCT-2000; 2000US-0242411P.
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
XX	(MCSW/) MCSWIGGEN J A.
PI	
DR	Blatt L, Mcswiggen JA;
XX	
WP	WI, 2002-706994/76.
PT	
XX	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(MNV), useful for treating a condition related to MNV infection e.g. pancreatitis,
XX	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PS	
XX	Claim 23; SEQ ID NO 5548; 495bp; English.
CC	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inosyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
SQ	
XX	Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match	5.1%; Score 12.8; DB 1; Length 17;
Best Local Similarity	75.0%; Pred. No. 2.4e+02;
Matches 12; Conservative	2; Mismatches 2; Indels 0; Gaps 0;
OY	1396 AGCTGCTGCACAGACC 1411 : DB 2 AGCTCGGAAAGAAC 17
RESULT 357	
ACA99695	
ID	ACA99695 standard; DNA; 17 BP.
XX	
AC	ACA99695;
XX	
DT	28-JUL-2003 (first entry)
XX	
G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #188.	
Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour; G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss. Homo sapiens. MO2003031621-A2. 17-APR-2003. 11-OCT-2002; 2002MO-US032599. 12-OCT-2001; 2001US-0329000P.	

```
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
PA
PI Zhang J;
XX WPI; 2003-381720/36.
DR
XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
XX Example 2; SEQ ID NO 212; 156bp; English.
PS
XX The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
XX Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1315 AGCAGCTAGGGGACCT 1330
Db 1 AGCTGTAGGGGACCT 16
RESULT 358
ACA99694
ID ACA99694 standard; DNA; 17 BP.
XX
XX ACA99694;
AC
XX 28-JUL-2003 (first entry)
DT
XX
XX G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #187.
DE
XX
XX Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2003031621-A2.
PN
XX
XX 17-APR-2003.
PD
XX
XX 11-OCT-2002; 2002WO-US032599.
PF
XX
XX 12-OCT-2001; 2001US-0329000P.
PR
XX
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
PA
XX Zhang J;
PI
XX WPI; 2003-381720/36.
DR
XX
XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
XX Example 2; SEQ ID NO 211; 156bp; English.
PS
XX
XX The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
```

```
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 5.1%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.4e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1315 AGCAGCTAGGGGACCT 1330
Db 2 AGCTGTAGGGGACCT 17
RESULT 359
ADA99495/C
ID ADA99495 standard; DNA; 17 BP.
XX
XX ADA99495;
AC
XX 20-NOV-2003 (first entry)
DT
XX
XX Human MD23 scanning oligonucleotide SEQ ID 484.
DE
XX
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM developmental disorder; ss.
XX
XX Homo sapiens.
OS
XX
XX EPI281758-A2.
PN
XX
XX 05-FEB-2003.
PD
XX
XX 30-JUL-2002; 2002EP-00016874.
PF
XX
XX 02-AUG-2001; 2001US-00922181.
PR
XX
XX (AEOM- ) AEOMICA INC.
PA
XX Shannon M, Gu Y, Nguyen C;
PI
XX
XX WPI; 2003-423107/40.
DR
XX
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
XX Example 8; SEQ ID NO 484; 103bp; English.
PS
XX
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 7q22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
```